FN Thomson Reuters Web of Science™ VR 1.0 PT J AU HIBBS, ED HAMBURGER, SD KRUESI, MJP LENANE, M AF HIBBS, ED HAMBURGER, SD KRUESI, MJP LENANE, M TI FACTORS AFFECTING EXPRESSED EMOTION IN PARENTS OF ILL AND NORMAL-CHILDREN SO AMERICAN JOURNAL OF ORTHOPSYCHIATRY LA English DT Article ID OBSESSIVE-COMPULSIVE DISORDER; FOLLOW-UP; SCHIZOPHRENIC-PATIENTS; DISRUPTIVE BEHAVIOR; DEPRESSED-PATIENTS; FAMILY FACTORS; RELAPSE; ADOLESCENTS; RELATIVES; MAINTENANCE AB In order to examine their relationship to Expressed Emotion, family environment and marital relationships were measured in the parents of disruptive, obsessive-compulsive, and normal children. Satisfactory family and marital environment were found to be related to low Expressed Emotion, while achievement orientation in mothers and greater family conflict were found to be significantly related to high Expressed Emotion. C1 NIMH,CHILD PSYCHIAT BRANCH,BETHESDA,MD 20892. NR 54 TC 50 Z9 51 U1 4 U2 6 PU AMER ORTHOPSYCHIATRIC ASSN PI NEW YORK PA 19 W 44TH ST, NEW YORK, NY 10036 SN 0002-9432 J9 AM J ORTHOPSYCHIAT JI Am. J. Orthopsychiatr. PD JAN PY 1993 VL 63 IS 1 BP 103 EP 112 DI 10.1037/h0079395 PG 10 WC Psychiatry; Social Work SC Psychiatry; Social Work GA KJ472 UT WOS:A1993KJ47200011 PM 8427300 ER PT J AU MCCUNE, BK PATTERSON, K CHANDRA, RS KAPUR, S SPORN, MB TSOKOS, M AF MCCUNE, BK PATTERSON, K CHANDRA, RS KAPUR, S SPORN, MB TSOKOS, M TI EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA ISOFORMS IN SMALL ROUND CELL TUMORS OF CHILDHOOD - AN IMMUNOHISTOCHEMICAL STUDY SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID MYOGENIC DIFFERENTIATION; PROMOTER REGION; HUMAN-PLATELETS; TGF BETA-1; PROLIFERATION; RECEPTOR; GENE; RHABDOMYOSARCOMA; NEUROBLASTOMA; TGF-BETA-3 AB The transforming growth factor (TGF)-betas are a highly conserved group of potent multifunctional cell regulatory proteins with variable effects on cell growth and differentiation. Most of the small round cell group of childhood tumors are thought to arise from either primitive mesenchyme or neuroectoderm and show evidence of skeletal muscle or neural differentiation, and rarely both. To investigate the possibility that the TGF-betas have a role in the growth or differentiation of these neoplasms, we used antibodies specific for peptide sequences of the three known mammalian TGF-beta isoforms (TGF-betas 1, 2, and 3) to probe for TGF-beta protein expression in a total of 49 cases. TGF-beta1 immunoreactivity was present in 16/17 (94%) of rhabdomyosarcomas, and the staining intensity was usually strong. TGF-beta1 was also present in three of three ectomesenchymomas. In contrast, TGF-beta1 was absent in all but one out of nine poorly differentiated neuroblastomas. Differentiating neuronal cells of ganglioneuroblastomas, however, were strongly positive for TGF-beta1. Ewing's sarcomas and peripheral primitive neuroectodermal tumors had a less consistent, but usually positive, staining pattern. TGF-beta3 staining patterns were very similar to those of TGF-beta1. TGF-beta2 immunoreactivity was only rarely detected in this group of tumors. The results suggest different roles for TGF-betas 1 and 3 in neuroblastoma and rhabdomyosarcoma. Expression of TGF-betas 1 and 3 is associated with neuronal differentiation of neuroblastoma. In contrast, these proteins may promote the growth of rhabdomyosarcoma by suppressing differentiation. C1 NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892. NCI,PATHOL LAB,BETHESDA,MD 20892. CHILDRENS HOSP,NATL MED CTR,MED CTR,DEPT PATHOL,WASHINGTON,DC 20010. RP MCCUNE, BK (reprint author), FRANCIS SCOTT KEY MED CTR,DEPT PATHOL,BALTIMORE,MD 21224, USA. NR 44 TC 31 Z9 35 U1 0 U2 0 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BALTIMORE PA 428 EAST PRESTON ST, BALTIMORE, MD 21202-3993 SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD JAN PY 1993 VL 142 IS 1 BP 49 EP 59 PG 11 WC Pathology SC Pathology GA KG953 UT WOS:A1993KG95300008 PM 8380955 ER PT J AU RESCAN, PY LOREAL, O HASSELL, JR YAMADA, Y GUILLOUZO, A CLEMENT, B AF RESCAN, PY LOREAL, O HASSELL, JR YAMADA, Y GUILLOUZO, A CLEMENT, B TI DISTRIBUTION AND ORIGIN OF THE BASEMENT-MEMBRANE COMPONENT PERLECAN IN RAT-LIVER AND PRIMARY HEPATOCYTE CULTURE SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID HEPARAN-SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; MESSENGER-RNA; IV COLLAGEN; DIFFERENTIAL EXPRESSION; LAMININ RECEPTOR; EPITHELIAL-CELLS; CORE PROTEIN; FIBRONECTIN AB Basement membranes contain three major components (ie collagen IV, laminin, and the heparan sulfate proteoglycan termed perlecan). Although the distribution and origin of both collagen IV and laminin have been well documented in the liver, perlecan has been poorly investigated, so far. We have studied the distribution and cellular origin of perlecan in rat livers in various conditions as well as in hepatocyte primary culture. By immunolocalization in both adult and 18-day-old fetal liver, perlecan was found in portal spaces, around central veins, and throughout the lobule. Immunoelectron microscopy revealed its presence at the level of basement membranes surrounding bile ducts and blood vessels, and in the space of Disse discontinuously interacting with hepatocyte microvilli. Precursors of perlecan were detected in the rough endoplasmic reticulum of bile duct cells and both vascular and sinusoidal endothelial cells. Both hepatocytes and Ito cells were negative. Northern-blot analysis confirmed the lack of appreciable expression of perlecan in hepatocytes isolated from either fetal or adult livers. In 18-month-diethylnitrosamine-treated rat liver, perlecan was abundant in neoplastic nodules. Electron microscopic investigation revealed an almost continuous layer of perlecan in the space of Disse and intracellular staining in sinusoidal endothelial cells, only. Perlecan mRNAs were detectable in malignant nodules, and absent in hepatocytes from nontumorous areas. Hepatocytes expressed high levels of perlecan mRNAs only when put in culture. This expression was reduced in conditions that allow improvement of hepatocyte survival and function (ie addition of corticoids, dimethylsulfoxide or nicotinamide to the medium, or in coculture with liver epithelial cells from biliary origin). Immunolocalization by light and electron microscopy showed that deposition of the proteoglycan occurred in coculture, in basement membranelike structures located around hepatocyte cords. In vitro attachment assay of hepatocytes on purified perlecan substrate indicated that these cells may interact with the proteoglycan through integrins which belong to the beta1 family. These data suggest that deposition of perlecan in the space of Disse requires cellular cooperation. This article on perlecan, the third major component of hepatic basement membranes, shows a unique cellular origin in the liver and, as found for both collagen IV and laminin, an expression in adult hepatocytes when placed in culture. C1 HOP PONTCHAILLOU,INSERM,U49,UNITE RECH HEPATOL,F-35033 RENNES,FRANCE. UNIV PITTSBURGH,DEPT OPHTALMOL,PITTSBURGH,PA 15260. NIDR,DEV BIOL LAB,BETHESDA,MD 20892. RI Loreal, Olivier/G-3366-2013; Clement, Bruno/E-5546-2016 NR 54 TC 53 Z9 54 U1 0 U2 1 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BALTIMORE PA 428 EAST PRESTON ST, BALTIMORE, MD 21202-3993 SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD JAN PY 1993 VL 142 IS 1 BP 199 EP 208 PG 10 WC Pathology SC Pathology GA KG953 UT WOS:A1993KG95300022 PM 7678718 ER PT J AU RASMUSSON, RL DAVIS, DG LIEBERMAN, M AF RASMUSSON, RL DAVIS, DG LIEBERMAN, M TI AMINO-ACID LOSS DURING VOLUME REGULATORY DECREASE IN CULTURED CHICK HEART-CELLS SO AMERICAN JOURNAL OF PHYSIOLOGY LA English DT Article DE TAURINE; CHLORIDE; OSMOLYTES; OSMOREGULATION; CARDIAC; HYPOSMOTIC ID VENTRICULAR MYOCYTES; MEMBRANE INTEGRITY; TAURINE; INVITRO; INJURY AB Mechanisms of volume regulation in hyposmotically treated cultured chick heart cell preparations were studied using optical, biochemical, and nuclear magnetic resonance methods. This approach afforded the resolution of time-dependent responses that might ordinarily be obscured by the complex morphology of intact cardiac muscle preparations. In hyposmotic solutions, cells swelled to a peak volume within 3 min and slowly regulated toward original volume (regulatory volume decrease, RVD). Upon return of the cells to isosmotic solution following hyposmotic treatment, the cells shrank to a steady-state volume that was substantially less than the initial volume in control solution. A vigorous RVD could also be elicited by hyposmotic swelling under Cl--free conditions. Measurement of both inorganic cation loss via atomic absorption spectroscopy and organic solute loss via H-1-nuclear magnetic resonance and high-pressure liquid chromatographic techniques revealed that the RVD observed following exposure to hyposmotic solutions was mediated in part by a substantial loss of taurine, glutamate, aspartate, and glycine as well as loss of inorganic ions (Na+, K+). The hyposmotically activated transport of amino acids was also associated with the production of glutamate and aspartate. The volume regulatory release and production of amino acids have significant implications for the metabolic and functional integrity of cardiac cells. C1 DUKE UNIV,MED CTR,DEPT CELL BIOL,DIV PHYSIOL,BOX 3709,DURHAM,NC 27710. NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709. FU NHLBI NIH HHS [HL-07063, HL-27105] NR 43 TC 92 Z9 92 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0002-9513 J9 AM J PHYSIOL JI Am. J. Physiol. PD JAN PY 1993 VL 264 IS 1 BP C136 EP C145 PN 1 PG 10 WC Physiology SC Physiology GA KK291 UT WOS:A1993KK29100016 PM 8430762 ER PT J AU LEE, SI TURNER, RJ AF LEE, SI TURNER, RJ TI SECRETAGOGUE-INDUCED RB-86(+) EFFLUX FROM BOVINE PAROTID IS HCO3- DEPENDENT SO AMERICAN JOURNAL OF PHYSIOLOGY LA English DT Article DE ANION CHANNEL; BICARBONATE SECRETION; FLUID SECRETION; MUSCARINIC STIMULATION; EXOCRINE GLAND; SALIVA ID MANDIBULAR SALIVARY-GLAND; ACTIVATED POTASSIUM CHANNELS; ACINAR-CELLS; FLUID SECRETION; ELECTROLYTE TRANSPORT; INTRACELLULAR PH; RAT; CALCIUM AB Muscarinic agonist (carbachol)-induced K+ loss from a bovine parotid mince was studied using Rb-86+ as a K+ marker. In contrast to our previous studies with the rat parotid [Am. J. Physiol. 261 (Gastrointest Liver Physiol. 24): G111-G118, 1991] in which both Cl--dependent and HCO3- dependent components of carbachol-induced Rb-86+ efflux were observed, no significant evidence for Cl--dependent Rb-86+ loss was detected in the bovine parotid. HCO3--dependent agonist-induced Rb-86+ loss was blunted by K+ and Cl- channel blockers and by removal of extracellular Ca2+, consistent with the hypothesis that this Rb-86+ loss occurs via a Ca2+-activated K+ channel and that this cation loss serves to electrically balance the concomitant loss of HCO3- via an electrically conductive pathway, presumably an apical anion channel. Acetate, formate, and propionate could substitute for HCO3-. Interpreted in terms of current models of salivary fluid secretion, which hypothesize that the production of fluid is secondary to anion secretion accompanied by an electrically coupled K+ loss, these results indicate that salivary production in the bovine parotid is driven almost exclusively by acinar HCO3- secretion. C1 YONSEI UNIV,COLL DENT,DEPT ORAL BIOL,SEOUL 8044,SOUTH KOREA. NIDR,CLIN INVEST & PATIENT CARE BRANCH,BLDG 10,RM 1AO6,BETHESDA,MD 20892. NR 34 TC 16 Z9 17 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0002-9513 J9 AM J PHYSIOL JI Am. J. Physiol. PD JAN PY 1993 VL 264 IS 1 BP R162 EP R168 PN 2 PG 7 WC Physiology SC Physiology GA KK292 UT WOS:A1993KK29200066 PM 8430877 ER PT J AU NORCROSS, JL NEWMAN, JD AF NORCROSS, JL NEWMAN, JD TI CONTEXT AND GENDER-SPECIFIC DIFFERENCES IN THE ACOUSTIC STRUCTURE OF COMMON MARMOSET (CALLITHRIX-JACCHUS) PHEE CALLS SO AMERICAN JOURNAL OF PRIMATOLOGY LA English DT Article DE MARMOSETS; CALLITHRIX-JACCHUS; VOCALIZATIONS; SOUND LOCALIZATION; SEX DIFFERENCES ID COTTON-TOP TAMARIN; LONG CALLS; SOCIAL-ORGANIZATION; VOCAL COMMUNICATION; WORLD MONKEYS; BEHAVIOR; CALLITRICHIDAE; REPERTOIRE; PRIMATE; BRAZIL AB Captive adult common marmosets (Callithrix jacchus) produce whistle-like ''phee'' calls in two contexts; in the home cage environment, phee calls may function as part of territorial marking behavior, and when animals are separated from social companions, phee calls may serve to reunite the group. Isolation phee calls tend to have more syllables than calls produced in the home cage by the same animals, and as a result, are longer in duration. The durations of isolation call syllables are shorter than in home cage calls, and isolation calls have lower start and end frequencies, higher peak frequencies, and increased frequency range compared to phee calls produced by the same animals in their home cages. The modifications made to the general structure of the phee call by isolated animals result in more information that may indicate context or location of an isolated caller. When the vocalizations were analyzed by sex, between-sex differences in call structure appeared consistently in both contexts. Males tended to exhibit higher call frequencies and greater variability between syllables than females. C1 NICHHD,COMPARAT ETHOL LAB,POOLESVILLE,MD 20837. NR 49 TC 48 Z9 48 U1 1 U2 9 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0275-2565 J9 AM J PRIMATOL JI Am. J. Primatol. PY 1993 VL 30 IS 1 BP 37 EP 54 DI 10.1002/ajp.1350300104 PG 18 WC Zoology SC Zoology GA KZ262 UT WOS:A1993KZ26200003 ER PT J AU BOINSKI, S AF BOINSKI, S TI VOCAL COORDINATION OF TROOP MOVEMENT AMONG WHITE-FACED CAPUCHIN MONKEYS, CEBUS-CAPUCINUS SO AMERICAN JOURNAL OF PRIMATOLOGY LA English DT Article DE VOCAL COMMUNICATION; CAPUCHIN MONKEY; SOCIAL MANIPULATION; FOOD-ASSOCIATED CALL ID SQUIRREL-MONKEYS; VOCALIZATIONS; BEHAVIOR; RANGE AB Coordinated travel by social groups is well documented, often with evidence that cognitive spatial maps are employed. Yet the mechanisms by which movement decisions are made and implemented within social groups are poorly known. In a field study of white-faced capuchin monkeys in Costa Rica it was demonstrated that a specific call, the ''trill,'' is used by adults in the initiation and directing of troop movement. The trills of subadults were restricted to vocal exchanges with other subadults. Continuous vocal recordings were collected of the vocalizations of the 14 members of the study troop. A cumulative 33.7 h of continuous samples and 1,892 sonagrams were analyzed. In addition to vocalizations clearly associated with alarm, distress, or agonistic contexts, two distinct call types were identified, trills and huhs. Age-sex classes differed in the rate at which both types of calls were produced in different spatial positions within the troop. Adult females and males produced higher rates of trills when in the leading edge compared to all other spatial positions in a traveling troop. Trills at the edge of a stationary troop represented 36 ''successful'' and 3 ''unsuccessful'' start attempts; the troop usually moved in the trajectory predicted by a trilling adult's location on the troop periphery within 10 min of the initiation of trilling. Adults also altered the trajectory of traveling troops by trilling at the side and back of the troop (10 ''successful'' and 4 ''unsuccessful'' attempts). Huh vocalizations were most predictably produced when a capuchin is in a dense fruit patch. These results emphasize the role vocalizations serve in the coordination and trajectory of group movement in nonhuman primates, especially those populations that are arboreal or in which visual contact is otherwise impeded. C1 NIH,CTR ANIM,COMPARAT ETHOL LAB,POOLESVILLE,MD. RP BOINSKI, S (reprint author), UNIV FLORIDA,DEPT ANTHROPOL,1350 TURLINGTON,GAINESVILLE,FL 32611, USA. NR 44 TC 77 Z9 79 U1 0 U2 18 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0275-2565 J9 AM J PRIMATOL JI Am. J. Primatol. PY 1993 VL 30 IS 2 BP 85 EP 100 DI 10.1002/ajp.1350300202 PG 16 WC Zoology SC Zoology GA LD160 UT WOS:A1993LD16000001 ER PT J AU SEUANEZ, HN ALVES, G OBRIEN, SJ AF SEUANEZ, HN ALVES, G OBRIEN, SJ TI GENETIC-CHARACTERIZATION OF PARENTAL CELL-LINES AND BIOCHEMICAL-ANALYSIS OF SOMATIC-CELL HYBRIDS BETWEEN MOUSE (RAG) CELLS AND FIBROBLASTS OF ATELES-PANISCUS-CHAMEK (PRIMATES, PLATYRRHINI) SO AMERICAN JOURNAL OF PRIMATOLOGY LA English DT Article DE ATELES; HYBRID CELL LINES; CHROMOSOMES; BIOCHEMICAL MARKERS AB Mouse (RAG) cells, (deficient in hypoxanthine-phosphoribosyl-transferase), and Ateles paniscus chamek primary fibroblasts were used in fusion experiments to generate somatic cell hybrids. Both parental cell lines were genetically characterized by karyological and biochemical analyses with 27 isozyme systems. These procedures were useful for monitoring primate chromosome segregation in somatic cell hybrids, for detecting chromosome rearrangements of primate chromosomes, and for identifying individual primate chromosomes. These characterizations are necessary to distinguish between different hybrid cell lines and to generate a panel for gene mapping studies. This is achieved by selecting cell lines that segregate different sets of relatively few primate isozymes and chromosomes. Conversely, we eliminated hybrid cell lines either showing: (1) rearrangements between primate and mouse chromosomes, (2) extensive rearrangements of primate chromosomes, or (3) a large number of primate biochemical markers. C1 NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701. RP SEUANEZ, HN (reprint author), UNIV FED RIO DE JANEIRO,DEPT GENET,INST NACL CANC,GENET SECT,RIO JANEIRO,BRAZIL. NR 26 TC 8 Z9 8 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0275-2565 J9 AM J PRIMATOL JI Am. J. Primatol. PY 1993 VL 30 IS 3 BP 181 EP 194 DI 10.1002/ajp.1350300304 PG 14 WC Zoology SC Zoology GA LH431 UT WOS:A1993LH43100002 ER PT J AU BIBEN, M AF BIBEN, M TI RECOGNITION OF ORDER EFFECTS IN SQUIRREL-MONKEY ANTIPHONAL CALL SEQUENCES SO AMERICAN JOURNAL OF PRIMATOLOGY LA English DT Article DE SAIMIRI-SCIUREUS; SQUIRREL MONKEY; COMMUNICATION; PLAYBACK EXPERIMENTS ID AFFILIATIVE VOCAL EXCHANGES; SAIMIRI-SCIUREUS; ISOLATION PEEPS; PLAYBACK; VOCALIZATIONS; FAMILIARITY; BEHAVIOR; SCREAMS AB Squirrel monkeys exchange chuck vocalizations in antiphonal sequences that suggest a request for information, and a response to that request. Chucks are characterized by measurable acoustic differences, notably in peak frequency, related to their position in a sequence. To determine the cues by which animals might identify a chuck that is a request for information from one that is a response, first-in-sequence (alpha) and second-insequence (beta) chucks, differing in peak frequency, were recorded from familiar individuals and strangers. These chucks, and a sham control, were played back, in the temporal context of a first-in-sequence call, to a target group of socially housed captive squirrel monkeys. Animals responded more strongly to a chucks than to beta chucks for calls originating from familiar individuals. No distinction was made between the alpha and beta chucks of strangers, and all strangers' chucks got a weaker response than did familiar alpha chucks. Squirrel monkeys probably use acoustic differences, rather than context, to discriminate the ordinal significance of a chuck, but cannot do so unless they are familiar with the caller. RP BIBEN, M (reprint author), NICHHD,COMPARAT ETHOL LAB,BLDG 112,ROOM 205,BETHESDA,MD 20892, USA. NR 26 TC 23 Z9 23 U1 2 U2 3 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0275-2565 J9 AM J PRIMATOL JI Am. J. Primatol. PY 1993 VL 29 IS 2 BP 109 EP 124 DI 10.1002/ajp.1350290204 PG 16 WC Zoology SC Zoology GA KJ740 UT WOS:A1993KJ74000003 ER PT J AU OVERPECK, MD HOFFMAN, HJ PRAGER, K AF OVERPECK, MD HOFFMAN, HJ PRAGER, K TI ITALIAN INFANT-MORTALITY ATTRIBUTABLE TO LOW-BIRTH-WEIGHT - RESPONSE SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter ID BIRTH-WEIGHT C1 NIDOCD,BETHESDA,MD. NATL CTR HLTH STAT,HYATTSVILLE,MD 20782. RP OVERPECK, MD (reprint author), NICHHD,DIV PREVENT RES,6100 EXECUT BLVD,ROOM 7B03,BETHESDA,MD 20892, USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 1993 VL 83 IS 1 BP 117 EP 118 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA KW272 UT WOS:A1993KW27200029 ER PT J AU OVERPECK, MD HOFFMAN, HJ PRAGER, K AF OVERPECK, MD HOFFMAN, HJ PRAGER, K TI ADDRESSING LOW-BIRTH-WEIGHT AND INFANT-MORTALITY - REPLY SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter ID BIRTH-WEIGHT; PREGNANCY; WOMEN C1 NATL CTR HLTH STAT,HYATTSVILLE,MD 20782. NIDOCD,BETHESDA,MD. RP OVERPECK, MD (reprint author), NICHHD,DIV PREVENT RES,6100 EXECUT BLVD,ROOM 7B03,BETHESDA,MD 20892, USA. NR 14 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 1993 VL 83 IS 1 BP 119 EP 120 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA KW272 UT WOS:A1993KW27200031 ER PT J AU SINDELAR, WF KINSELLA, TJ TEPPER, JE DELANEY, TF MAHER, MM SMITH, R ROSENBERG, SA GLATSTEIN, E AF SINDELAR, WF KINSELLA, TJ TEPPER, JE DELANEY, TF MAHER, MM SMITH, R ROSENBERG, SA GLATSTEIN, E TI RANDOMIZED TRIAL OF INTRAOPERATIVE RADIOTHERAPY IN CARCINOMA OF THE STOMACH SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 33RD ANNUAL MEETING OF THE SOC FOR SURGERY OF THE ALIMENTARY TRACT CY MAY 11-13, 1992 CL SAN FRANCISCO, CA SP SOC SURG ALIMENTARY TRACT ID ADVANCED CANCERS; GASTRIC-CANCER; ADENOCARCINOMA AB A prospectively randomized controlled clinical trial was performed comparing surgical resection and intraoperative radiotherapy (IORT) with conventional therapy in adenocarcinoma of the stomach. Patients in the experimental group underwent gastrectomy, and IORT was administered to their gastric bed (20 Gy using 11 to 15 MeV electrons). Patients in the control group underwent gastrectomy alone for early-stage lesions confined to the stomach (stages I to II) or resection and postoperative external beam radiotherapy to the upper abdomen (50 Gy using 6 to 10 mV photons) for advanced-stage lesions extending beyond the gastric wall (stages III to IV). One hundred patients were screened for the study, of whom 60 were randomized and underwent exploratory surgery. Nineteen patients were excluded intraoperatively because of unresectability or metastatic disease, leaving 41 patients in the study. Seven patients (17%) died of complications. The median survival for patients with tumors of all stages was 25 months for the IORT group and 21 months for the control group (p = 0.99). Locoregional disease failures occurred in 7 of 16 (44%) IORT patients and in 23 of 25 (92%) control patients (p <0.001). Complication rates were similar between IORT and control patients. Although IORT failed to afford a significant advantage over conventional therapy in overall survival, IORT did significantly improve control of locoregional disease. C1 NCI,RADIAT ONCOL BRANCH,BETHESDA,MD 20892. NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT NURSING,BETHESDA,MD 20892. RP SINDELAR, WF (reprint author), NCI,SURG BRANCH,BETHESDA,MD 20892, USA. NR 15 TC 65 Z9 66 U1 0 U2 2 PU CAHNERS PUBL CO PI NEW YORK PA 249 WEST 17 STREET, NEW YORK, NY 10011 SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD JAN PY 1993 VL 165 IS 1 BP 178 EP 187 DI 10.1016/S0002-9610(05)80423-4 PG 10 WC Surgery SC Surgery GA KF374 UT WOS:A1993KF37400028 PM 8418695 ER PT J AU HOLLINGSWORTH, HC LONGO, DL JAFFE, ES AF HOLLINGSWORTH, HC LONGO, DL JAFFE, ES TI SMALL NONCLEAVED CELL LYMPHOMA ASSOCIATED WITH FLORID EPITHELIOID GRANULOMATOUS RESPONSE - A CLINICOPATHOLOGICAL STUDY OF 7 PATIENTS SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE MALIGNANT LYMPHOMA; SMALL NONCLEAVED CELL; BURKITTS LYMPHOMA; GRANULOMA; EPITHELIOID HISTIOCYTIC RESPONSE ID MALIGNANT-LYMPHOMA; HODGKINS-DISEASE; UNTREATED PATIENTS; SARCOID REACTIONS; LENNERTS LYMPHOMA; LAPAROTOMY; FEATURES AB The finding of epithelioid granulomas has been widely reported in solid tumors and in hematologic malignancies. This phenomenon has been especially well studied in Hodgkin's disease, where its presence has been shown to confer a favorable prognosis. Such granulomas have not, however, been as extensively studied in other forms of hematologic malignancy, particularly in small noncleaved cell lymphoma. We report seven cases of small noncleaved cell lymphoma that were associated with a marked epithelioid granulomatous response. Detailed clinical data, including follow-up, were available in five of the seven patients. Three had localized disease (stage I), whereas two had advanced disease (stages III-A and IV-B, respectively). All five patients achieved a complete remission and are alive without evidence of disease (median follow-up, 6 years). These findings suggest that the epithelioid granulomas may be a manifestation of a host response that confers an improved prognosis in this subtype of non-Hodgkin's lymphoma. C1 NCI,BIOL RESPONSE MODIFIERS PROGRAM,BETHESDA,MD 20892. RP HOLLINGSWORTH, HC (reprint author), NCI,PATHOL LAB,BLDG 10,ROOM 2N212,BETHESDA,MD 20892, USA. NR 30 TC 29 Z9 29 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0147-5185 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD JAN PY 1993 VL 17 IS 1 BP 51 EP 59 DI 10.1097/00000478-199301000-00006 PG 9 WC Pathology; Surgery SC Pathology; Surgery GA KE623 UT WOS:A1993KE62300006 PM 8447509 ER PT J AU ELTOUM, IA SAAD, AM ISMAIL, BM ALI, MM SULIAMAN, S BENNETT, JL HOMEIDA, MAA AF ELTOUM, IA SAAD, AM ISMAIL, BM ALI, MM SULIAMAN, S BENNETT, JL HOMEIDA, MAA TI LIVER SONOGRAPHY IN AN AREA ENDEMIC FOR SCHISTOSOMIASIS-HAEMATOBIUM SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID MANSONI INFECTION; SUDAN; EGYPT AB Through the use of portable ultrasonography, eight cases (2%) of periportal fibrosis were identified in a random sample of 400 subjects selected from a village with a high prevalence and morbidity due to schistosomiasis haematobium in the White Nile Province of Sudan. In contrast, 36 cases (15%) of fibrosis were seen in an area with a similar prevalence and morbidity due to schistosomiasis mansoni in the Gezira Managil region of Sudan. Although there was only one case of Schistosoma mansoni as determined by repeated stool examination of the entire sample population in the first village, the majority of those with fibrosis and age-matched controls showed serologic evidence of active S. mansoni infection. This led to the conclusion that the cases of periportal fibrosis seen in the White Nile Province are most probably due to S. mansoni rather than to S. haematobium. C1 FAC MED KHARTOUM,DEPT PATHOL,KHARTOUM,SUDAN. FAC MED KHARTOUM,DEPT SURG,KHARTOUM,SUDAN. FAC MED KHARTOUM,DEPT MED,KHARTOUM,SUDAN. NATL HLTH LAB,BILHARZIA RES UNIT,KHARTOUM,SUDAN. MICHIGAN STATE UNIV,DEPT PHARMACOL & TOXICOL,E LANSING,MI 48824. RP ELTOUM, IA (reprint author), NIAID,BETHESDA,MD 20892, USA. NR 14 TC 8 Z9 8 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101 SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 1993 VL 48 IS 1 BP 77 EP 81 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA KL730 UT WOS:A1993KL73000011 PM 8427391 ER PT J AU GREENE, CE MARKS, MA LAPPIN, MR BREITSCHWERDT, EB WOLSKI, NA BURGDORFER, W AF GREENE, CE MARKS, MA LAPPIN, MR BREITSCHWERDT, EB WOLSKI, NA BURGDORFER, W TI COMPARISON OF LATEX AGGLUTINATION, INDIRECT IMMUNOFLUORESCENT ANTIBODY, AND ENZYME-IMMUNOASSAY METHODS FOR SERODIAGNOSIS OF ROCKY-MOUNTAIN-SPOTTED-FEVER IN DOGS SO AMERICAN JOURNAL OF VETERINARY RESEARCH LA English DT Article ID INDIRECT FLUORESCENT-ANTIBODY; RICKETTSIA-RICKETTSII TEST; DIAGNOSIS; IGM AB Indirect immunofluorescent antibody (IFA), latex agglutination (LA), and enzyme immunoassay (EIA) methods were compared for evaluation of the serum antibody responses of dogs experimentally and naturally exposed to spotted fever-group rickettsiae. Selected sera (obtained on days 1, 42, 53, 124, 145, 236, 255, 264, and 292) were examined from three 8-month-old female Beagles inoculated with Rickettsia rickettsii on days 34 and 250 of the study. A second group of dogs comprised three 8-month-old female Beagles inoculated with R montana on days 34 and 102. Subsequently, these dogs were inoculated with R rickettsii on day 250. Serum samples were obtained from the second group of dogs on days 1, 96, 103, 132, 180, 215, 292, and 494. A third group consisted of 21 naturally exposed dogs, from which sequentially obtained serum samples were available, and which had clinical signs compatible with Rocky Mountain spotted fever. Clinical signs of disease in dogs of the third group resolved after treatment with tetracycline (22 mg/kg of body weight, PO, q 8 h) was instituted. At least 2 sequentially obtained serum samples from each dog were tested. In general, the first sample was obtained just prior to treatment and the convalescent serum samples were obtained at weekly or greater intervals thereafter. For correlation and reactivity data, an IFA test for IgG/IgM (using heavy and light chains-specific conjugate) was used as the reference standard for comparison of results with those of the other tests. For analyzing sensitivity and specificity data in naturally exposed dogs, the assumption was made that fourfold change in the IFA IgG/IgM titer for R rickettsii or titer greater-than-or-equal-to 1,024 identified infected dogs. Threshold titer indicative of specific rickettsial antibody was determined for each test: IFA IgG/IgM, 64; IFA IgM, 8; LA, 16; EIA IgG, 64; and EIA IgM, 64. Marked cross-reactivity of sera with R rickettsii, R rhipicephali, and R montana was apparent for the IFA method using these antigens; lesser cross-reactivity was observed for R bellii. Although the IFA test for IgM, using R rickettsii as antigen, had high specificity (88.2%), it had low sensitivity (21.7%), limiting its use as a sole diagnostic test. The LA test had a higher sensitivity (58.5%) than did any of the IgM IFA tests. The LA test results correlated best with IgM IFA test results, and the closest agreement was obtained when R bellii was used as antigen. Because of its relatively high sensitivity (58.5%) and specificity (83.6%), the LA procedure may be a valuable screening test for diagnosis of Rocky Mountain spotted fever in dogs. The IgG and IgM EIA methods had high sensitivity-90.6 and 83.1%, respectively. The IgM EIA performed by us had low specificity; it detected infection with R montana in inoculated dogs, Comparing results of all test methods in naturally exposed dogs, the IgM EIA results were positive for the greatest number of samples with corresponding negative results by the reference IgG/IgM IFA test. This low specificity may preclude its routine use as a diagnostic test. No single serologic method correctly identified all affected dogs. On the basis of comparison with results obtained for the other serologic procedures and antigen-detection methods in 1 dog, the IgG/IgM IFA test used as a reference test may not have detected some infected dogs. Combination of a test that detects predominantly IgG, with either the LA or IgM IFA test, would help to identify most infected dogs. C1 N CAROLINA STATE UNIV,SCH VET MED,DEPT COMPAN & SPECIAL SPECIES MED,RALEIGH,NC 27606. NIAID,ROCKY MTN LABS,HAMILTON,MT 59840. RP GREENE, CE (reprint author), UNIV GEORGIA,COLL VET MED,DEPT SMALL ANIM MED,ATHENS,GA 30602, USA. NR 20 TC 3 Z9 3 U1 0 U2 2 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 SN 0002-9645 J9 AM J VET RES JI Am. J. Vet. Res. PD JAN PY 1993 VL 54 IS 1 BP 20 EP 28 PG 9 WC Veterinary Sciences SC Veterinary Sciences GA KH568 UT WOS:A1993KH56800003 PM 8427468 ER PT J AU COHEN, AH KIEMEL, T AF COHEN, AH KIEMEL, T TI INTERSEGMENTAL COORDINATION - LESSONS FROM MODELING SYSTEMS OF COUPLED NONLINEAR OSCILLATORS SO AMERICAN ZOOLOGIST LA English DT Article; Proceedings Paper CT SYMP ON COMPUTATIONAL APPROACHES TO COMPARATIVE NEUROBIOLOGY, AT THE 1990 ANNUAL MEETING OF THE AMERICAN-SOC-OF-ZOOLOGISTS CY DEC 27-30, 1990 CL SAN ANTONIO, TX SP AMER SOC ZOOLOGISTS ID LAMPREY SPINAL-CORD; CENTRAL PATTERN GENERATOR; LEECH SWIMMING RHYTHM; FICTIVE LOCOMOTION; INTERNEURONS; MECHANISMS; NEURONS; INVITRO; ACTIVATION; RECEPTORS AB Intersegmental coordination of both vertebrates and invertebrates is poorly understood primarily because so little is known about the substrate of the neural underpinnings and how the elements interact to produce the complex timing relationships required by the organism. We describe here a systems approach combining experimental and theoretical treatment of the lamprey locomotor central pattern generator. The central pattern generator is viewed as a chain of coupled non-linear oscillators corresponding to segmental burst generators. We analyze various coupling schemes in terms of their ability to produce a stable traveling wave similar to that seen in the isolated spinal cord and the intact animal. The role of long coordinating neurons is particularly discussed. C1 CORNELL UNIV,NEUROBIOL & BEHAV SECT,ITHACA,NY 14853. NIDDK,MATH RES BRANCH,BETHESDA,MD 20892. NR 46 TC 15 Z9 15 U1 0 U2 3 PU AMER SOC ZOOLOGISTS PI LAWRENCE PA 1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 SN 0003-1569 J9 AM ZOOL JI Am. Zool. PY 1993 VL 33 IS 1 BP 54 EP 65 PG 12 WC Zoology SC Zoology GA LW580 UT WOS:A1993LW58000006 ER PT J AU BUTLER, JD LEVIN, SW FACCHIANO, A MUKHERJEE, AB AF BUTLER, JD LEVIN, SW FACCHIANO, A MUKHERJEE, AB TI A HISTIDINE BINDING-PROTEIN OF ESCHERICHIA-COLI - A COMPONENT OF CYSTINE BINDING-PROTEIN OF ESCHERICHIA-COLI SO AMINO ACIDS LA English DT Article DE AMINO ACIDS; HISTIDINE; CYSTINE; AMINO ACID BINDING PROTEINS ID TRANSPORT; ACID AB Commercially obtained cystine binding protein (CBP), an osmotic shock protein of Escherichia coli, was studied in an effort to determine its binding characteristics. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE) analysis of commercially obtained CBP showed three protein bands. N-terminal amino acid microsequencing and subsequent computer search revealed that the sequence of one of these proteins (25-kDa) was nearly identical to histidine binding protein (HisJ) of Salmonella typhimurium. Purification of CBP by HPLC yielded four protein peaks, of which one bound histidine exclusively. Binding was maximal at pH 5.0 to 6.0, at 4-degrees-C, did not require calcium or magnesium ions and was not inhibited by reduction of CBP disulfide bonds. Amino acids other than histidine or cystine did not bind to CBP. These data show that commercially available CBP is not a homogenous protein; it contains a histidine as well as a cystine binding component. C1 WALTER REED ARMY MED CTR,DEPT PEDIAT,EXCEPT FAMILY MEMBER PROGRAM,WASHINGTON,DC 20307. NICHHD,HUMAN GENET BRANCH,DEV GENET SECT,BETHESDA,MD 20892. RP BUTLER, JD (reprint author), NICHHD,HUMAN GENET BRANCH,GENET DIS INVOLVING SULFUR METAB UNIT,BLDG 10,ROOM 10N308,BETHESDA,MD 20892, USA. RI Facchiano, Antonio/K-5984-2016 OI Facchiano, Antonio/0000-0002-4243-2392 NR 8 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0939-4451 J9 AMINO ACIDS JI Amino Acids PY 1993 VL 5 IS 1 BP 39 EP 50 DI 10.1007/BF00806191 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA LU104 UT WOS:A1993LU10400005 PM 24190643 ER PT J AU SAROFF, HA AF SAROFF, HA TI LINKED FUNCTIONS AND THE ANALYSIS OF INDIVIDUAL-SITE BINDING DATA SO ANALYTICAL BIOCHEMISTRY LA English DT Article ID IONIZATION RP SAROFF, HA (reprint author), NIDDKD,BIOCHEM PHARMACOL LAB,BLDG 8,ROOM 227,BETHESDA,MD 20892, USA. NR 11 TC 1 Z9 1 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0003-2697 J9 ANAL BIOCHEM JI Anal. Biochem. PD JAN PY 1993 VL 208 IS 1 BP 88 EP 95 DI 10.1006/abio.1993.1012 PG 8 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA KF518 UT WOS:A1993KF51800012 PM 8434800 ER PT J AU JANINI, GM FOX, SD CITRO, ML MUSCHIK, GM ISSAQ, HJ AF JANINI, GM FOX, SD CITRO, ML MUSCHIK, GM ISSAQ, HJ TI DETERMINATION OF TOTAL N-NITROSO COMPOUNDS IN BIOLOGICAL-FLUIDS BY PHOTOLYTIC DENITROSATION AND THERMAL-ENERGY ANALYSIS SO ANALYTICAL INSTRUMENTATION LA English DT Article ID LIQUID-CHROMATOGRAPHY; GASTRIC-JUICE; URINE; NITRATE AB Quantification of total N-nitroso compounds (NOC) in urine and gastric juice is achieved by combining photolytic denitrosation with thermal energy analysis. The minimum mass detection limit of the technique is about 10 pmole NO. Urine samples with NOC concentration as low as 200 nmolL-1 can be analyzed with a precision of approximately 5-10%. The minimum concentration detection limit for gastric juice samples is about 1 mumolL-1. Except for nitrite, no interference is observed from nitrogenous compounds present in urine and gastric juice. The nitrite interference is effectively eliminated with sulphamic acid. RP JANINI, GM (reprint author), NCI,FREDERICK CANC RES & DEV CTR,DYNCORP,PROGRAM RESOURCES INC,POB B,FREDERICK,MD 21702, USA. NR 14 TC 8 Z9 8 U1 1 U2 2 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0743-5797 J9 ANAL INSTRUM PY 1993 VL 21 IS 1-2 BP 1 EP 9 PG 9 WC Chemistry, Analytical; Instruments & Instrumentation SC Chemistry; Instruments & Instrumentation GA LC822 UT WOS:A1993LC82200001 ER PT S AU HOFFMAN, GS AF HOFFMAN, GS BE Gross, WL TI TREATMENT OF CHRONIC IDIOPATHIC SYSTEMIC VASCULITIDES SO ANCA-ASSOCIATED VASCULITIDES: IMMUNOLOGICAL AND CLINICAL ASPECTS SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 4TH International Workshop on ANCA (Antineutrophil Cytoplasmic Antibodies) and 2nd International Colloquium on Wegeners Granulomatosis and Vasculitic Disorders CY MAY 28-30, 1992 CL LUBECK, GERMANY C1 NIAID,IMMUNOREGULAT LAB,VASCULITIS & RELATED DIS SECT,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44573-5 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1993 VL 336 BP 227 EP 234 PG 8 WC Immunology SC Immunology GA BZ51J UT WOS:A1993BZ51J00033 PM 7905231 ER PT S AU KERR, GS FLEISHER, TA HALLAHAN, CW LEAVITT, RY FAUCI, AS HOFFMAN, GS AF KERR, GS FLEISHER, TA HALLAHAN, CW LEAVITT, RY FAUCI, AS HOFFMAN, GS BE Gross, WL TI LIMITED PROGNOSTIC VALUE OF CHANGES IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-TITERS IN PATIENTS WITH WEGENERS GRANULOMATOSIS SO ANCA-ASSOCIATED VASCULITIDES: IMMUNOLOGICAL AND CLINICAL ASPECTS SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 4TH International Workshop on ANCA (Antineutrophil Cytoplasmic Antibodies) and 2nd International Colloquium on Wegeners Granulomatosis and Vasculitic Disorders CY MAY 28-30, 1992 CL LUBECK, GERMANY C1 NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892. NR 0 TC 22 Z9 22 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44573-5 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1993 VL 336 BP 411 EP 414 PG 4 WC Immunology SC Immunology GA BZ51J UT WOS:A1993BZ51J00071 PM 8296645 ER PT J AU PAWLOSKY, RJ SALEM, N AF PAWLOSKY, RJ SALEM, N TI THE METABOLISM OF ESSENTIAL FATTY-ACIDS IN HUMANS - GC-MS STUDIES ON THE EFFECTS OF DIETARY FATS ON THE CONVERSION OF DEUTERIUM-LABELED 18/3(N-3) AND 18/2(N-6) TO LONG-CHAIN POLYUNSATURATES SO ANNALES DE BIOLOGIE CLINIQUE LA English DT Article; Proceedings Paper CT 10TH EUROPEAN CONGRESS OF CLINICAL CHEMISTRY / 12TH NATIONAL MEETING OF THE SOC-FRANCAISE-DE-BIOLOGIE-CLINIQUE ( EUROLAB 93 ) CY APR 25-29, 1993 CL NICE, FRANCE SP INT FEDERAT CLIN CHEM, SOC FRANCAISE BIOL CLIN RP PAWLOSKY, RJ (reprint author), NIAAA,DICBR,MEMBRANE BIOCHEM & BIOPHYS LAB,BETHESDA,MD 20892, USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU JOHN LIBBEY EUROTEXT LTD PI MONTROUGE PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE SN 0003-3898 J9 ANN BIOL CLIN-PARIS JI Ann. Biol. Clin. PY 1993 VL 51 IS 3-5 BP 303 EP 303 PG 1 WC Medical Laboratory Technology; Medicine, Research & Experimental SC Medical Laboratory Technology; Research & Experimental Medicine GA LR555 UT WOS:A1993LR55500084 ER PT J AU ZURLO, JJ ONEILL, D POLIS, MA MANISCHEWITZ, J YARCHOAN, R BASELER, M LANE, HC MASUR, H AF ZURLO, JJ ONEILL, D POLIS, MA MANISCHEWITZ, J YARCHOAN, R BASELER, M LANE, HC MASUR, H TI LACK OF CLINICAL UTILITY OF CYTOMEGALOVIRUS BLOOD AND URINE CULTURES IN PATIENTS WITH HIV-INFECTION SO ANNALS OF INTERNAL MEDICINE LA English DT Article DE CYTOMEGALOVIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; VIRUS CULTIVATION; VIREMIA; VIRURIA; ACQUIRED IMMUNODEFICIENCY SYNDROME ID IMMUNE-DEFICIENCY SYNDROME; ACQUIRED IMMUNODEFICIENCY SYNDROME; HOMOSEXUAL MEN; VIRUS INFECTION; SYNDROME AIDS; RETINITIS; MANIFESTATION; DISEASE; GUANINE AB Objective: To determine the clinical significance of cytomegalovirus (CMV) blood and urine cultures in patients with human immunodeficiency virus (HIV) infection. Design: Inception cohort of patients with HIV infection and CMV culture data. Setting: Government referral-based research hospital. Patients: A total of 322 HIV-infected patients who had a CMV blood culture and 293 HIV-infected patients who had a CMV urine culture within 7 days of a CD4 determination. Measurements: Cytomegalovirus blood and urine culture results; circulating CD4 lymphocyte counts; pathologic or retinopathic findings of CMV disease. Results: Nine of 26 patients (34.6%) with CMV viremia subsequently developed CMV end-organ disease compared with 11 of 74 (14.9%) patients without viremia, (difference, 19.7%; 95% CI, -0.3% to 39.7%). Fifteen of 47 patients (31.9%) with CMV viruria developed end-organ disease compared with 4 of 43 (9.3%) patients without viruria, (difference, 22.6%; CI, 6.7% to 38.5%). Cytomegalovirus culture positivity had poor predictive value for the subsequent development of end-organ disease (35% for viremia and 28% for viruria). Further, patients with proven end-organ disease were often not viremic (45%), but most were viruric (88%). Cytomegalovirus viremia did not correlate with the presence of either fever or weight loss in this patient group. Both blood culture positivity and urine culture positivity varied inversely with the CD4 count (P = 0.0001 for both associations). Conclusions: The likelihood that a blood or urine culture will be positive in a patient with HIV infection correlates better with immunologic status than with current or future clinical status. Although the absence of CMV viruria may suggest that CMV disease is not present, CMV blood and urine cultures have poor diagnostic and predictive value and therefore should be used primarily for research purposes or drug susceptibility testing and not for making clinical decisions. C1 NIH,WARREN GRANT MAGNUSON CLIN CTR,BETHESDA,MD 20892. US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892. NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21702. NIAID,BETHESDA,MD 20892. NCI,BETHESDA,MD 20892. OI Polis, Michael/0000-0002-9151-2268 FU NCI NIH HHS [N01-CO-74102] NR 16 TC 79 Z9 82 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 1 PY 1993 VL 118 IS 1 BP 12 EP 17 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA KE605 UT WOS:A1993KE60500003 PM 8093214 ER PT J AU QUEZADO, ZMN WILSON, WH CUNNION, RE PARKER, MM REDA, D BRYANT, G OGNIBENE, FP AF QUEZADO, ZMN WILSON, WH CUNNION, RE PARKER, MM REDA, D BRYANT, G OGNIBENE, FP TI HIGH-DOSE IFOSFAMIDE IS ASSOCIATED WITH SEVERE, REVERSIBLE CARDIAC DYSFUNCTION SO ANNALS OF INTERNAL MEDICINE LA English DT Article DE IFOSFAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE, CONGESTIVE; SHOCK CARDIOGENIC; ARRHYTHMIA ID ISOPHOSPHAMIDE NSC-109724; CYCLOPHOSPHAMIDE; CARDIOTOXICITY; NEPHROTOXICITY; PHARMACOKINETICS; GLUTATHIONE; THERAPY; CANCER; MESNA AB Objective: To determine the incidence and characterize the occurrence of cardiac toxicity with high-dose ifosfamide. Design: Retrospective chart review. Setting: Biomedical research referral center. Patients: Fifty-two consecutive patients with advanced lymphoma or carcinoma enrolled in phase I trials of high-dose ifosfamide as part of combination chemotherapy with autologous bone marrow transplantation. Interventions: Patients were given escalating doses (10 to 18 g/m2) of ifosfamide in combination with carboplatin and etoposide or with lomustine and vinblastine. Measurements: The chart review focused on clinical, radiographic, or electrocardiographic evidence of cardiovascular dysfunction. Data from invasive hemodynamic monitoring, radionuclide cineangiography, and echocardiography were also reviewed. Results: Nine of the patients treated with ifosfamide developed congestive heart failure (17%; 95% CI, 8% to 30%). Eight of these patients, experiencing dyspnea, tachycardia, weight gain, and signs of pulmonary edema, required admission to an intensive care unit. Left ventricular contractility was found to be depressed when evaluated by radionuclide cineangiography, echocardiography, or both. Most patients responded to diuretic, vasodilator, and inotropic therapies. Two patients developed malignant ventricular arrhythmias. One patient died of intractable cardiogenic shock. Five patients died of multiorgan failure, despite showing improvement in left ventricular ejection fraction. Three patients survived and regained baseline left ventricular ejection fraction. Conclusions: High-dose ifosfamide is associated with severe but usually reversible myocardial depression and malignant arrhythmias. C1 NCI,BETHESDA,MD 20892. WARREN G MAGNUSON CLIN CTR,BETHESDA,MD. RI Quezado, Zenaide/O-4860-2016 OI Quezado, Zenaide/0000-0001-9793-4368 NR 34 TC 73 Z9 76 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 1 PY 1993 VL 118 IS 1 BP 31 EP 36 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA KE605 UT WOS:A1993KE60500006 PM 8416155 ER PT J AU STRAUS, SE COHEN, JI TOSATO, G MEIER, J AF STRAUS, SE COHEN, JI TOSATO, G MEIER, J TI EPSTEIN-BARR-VIRUS INFECTIONS - BIOLOGY, PATHOGENESIS, AND MANAGEMENT SO ANNALS OF INTERNAL MEDICINE LA English DT Discussion DE EPSTEIN-BARR VIRUS; B-LYMPHOCYTES; INFECTIOUS MONONUCLEOSIS; BURKITTS LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS ID LINKED LYMPHOPROLIFERATIVE SYNDROME; BONE-MARROW TRANSPLANTATION; LATENT MEMBRANE-PROTEIN; ORAL HAIRY LEUKOPLAKIA; T-CELL EPITOPE; B-CELLS; APLASTIC-ANEMIA; EPITHELIAL-CELLS; HODGKINS-DISEASE; VIRAL LATENCY AB Epstein-Barr virus (EBV) encodes genes that ensure its persistence in human B lymphocytes. Some of the genes encourage B-cell proliferation; others are poised to evade or defeat immune recognition. Immune restraints on the virus, however, are typically so effective that most infections are never symptomatic. In contrast, acute infectious mononucleosis, a self-limited lymphoproliferative illness, is common in adolescents and young adults. Unbridled proliferative illnesses arise when cellular immunity is grossly defective. Treatment of EBV-associated syndromes is largely supportive. Antiviral drugs have no proven role except in patients with oral hairy leukoplakia. Vaccine development is technically feasible but is not considered a high priority for developed nations. C1 US FDA,CTR BIOL EVALUAT & RES,IMMUNOL LAB,BETHESDA,MD 20014. RP STRAUS, SE (reprint author), NIAID,MED VIROL SECT,CLIN INVEST LAB,BLDG 10,ROOM 11N228,BETHESDA,MD 20892, USA. NR 107 TC 270 Z9 281 U1 1 U2 6 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 1 PY 1993 VL 118 IS 1 BP 45 EP 58 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA KE605 UT WOS:A1993KE60500009 PM 8380053 ER PT J AU HARRIS, KA OYLER, GA DOOLITTLE, GM VINCENT, I LEHMAN, RAW KINCAID, RL BILLINGSLEY, ML AF HARRIS, KA OYLER, GA DOOLITTLE, GM VINCENT, I LEHMAN, RAW KINCAID, RL BILLINGSLEY, ML TI OKADAIC ACID INDUCES HYPERPHOSPHORYLATED FORMS OF TAU PROTEIN IN HUMAN BRAIN-SLICES SO ANNALS OF NEUROLOGY LA English DT Article ID PAIRED HELICAL FILAMENTS; MICROTUBULE-ASSOCIATED PROTEIN-2; ALZHEIMERS-DISEASE; DEPENDENT KINASE; PHOSPHORYLATION; GLUTAMATE; DEPHOSPHORYLATION; PHOSPHATASE-2A; BINDING; A68 AB Hyperphosphorylated forms of the microtubule-associated protein tau are components of the paired helical filaments (PHFs) seen in patients with Alzheimer's disease. Slices of human lateral temporal cortex were obtained from tissues removed incidental to resections for intractable hippocampal epilepsy. Tau phosphorylation in temporal lobe slices was determined using mobility shifts after sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunodetection with the monoclonal antibodies Alz-50, 5E2, and Tau-1. The results indicate that tau phosphorylation was altered in a dose-dependent manner by the phosphatase inhibitor okadaic acid, but not by N-methyl-D-aspartate, quisqualate, or kainate. The slowest mobility forms of tau, termed ''PHF-like tau,'' produced by okadaic acid treatment were dephosphorylated by purified protein phosphatase 2B (calcineurin). Formation of PHF-like tau peptides was blocked by KN-62, 1[N,O-bis(1,5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]4-phenylpiperazine, an inhibitor of Ca2+/calmodulin-dependent protein kinase II. The protein kinase inhibitor staurosporine also prevented formation of PHF-like tau. These data suggest that phosphorylation of tau is regulated by Ca2+-dependent protein kinases and okadaic acid-sensitive protein phosphatases, alterations of which may be implicated in the pathogenesis of Alzheimer's disease. C1 PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PHARMACOL,POB 850,HERSHEY,PA 17033. PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT ANESTHESIOL,HERSHEY,PA 17033. YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461. NIAAA,IMMUNOL SECT,ROCKVILLE,MD 20852. FU NIEHS NIH HHS [ES-5450]; PHS HHS [R818002-01-0] NR 48 TC 93 Z9 93 U1 0 U2 0 PU LITTLE BROWN CO PI BOSTON PA 34 BEACON STREET, BOSTON, MA 02108-1493 SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD JAN PY 1993 VL 33 IS 1 BP 77 EP 87 DI 10.1002/ana.410330113 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA KG088 UT WOS:A1993KG08800011 PM 8494335 ER PT J AU HANSEN, HH EISENHAUER, EA HANSEN, M NEIJT, JP PICCART, MJ SESSA, C THIGPEN, JT AF HANSEN, HH EISENHAUER, EA HANSEN, M NEIJT, JP PICCART, MJ SESSA, C THIGPEN, JT TI NEW CYTOSTATIC DRUGS IN OVARIAN-CANCER SO ANNALS OF ONCOLOGY LA English DT Article; Proceedings Paper CT International Workshop on Advanced Ovarian Cancer: where Do We Stand and Where Do We Go CY JUN 15-19, 1993 CL HELSINGOR, DENMARK DE OVARIAN CANCER; NEW DRUGS; PHASE II ID PHASE-II; THERAPY; TAXOL; CHEMOTHERAPY; CARCINOMA; SYSTEMS; TRIAL; AGENT AB Background: Many ovarian cancer patients will after treatment of the recurrence with cisplatin based therapy enter phase I or II studies with new drugs. Lately, some new agents have shown activity. Materials and methods: The review is based on phase II studies mainly and focuses on paclitaxel (taxol). Results: A Canadian/European study of high (175 mg/m(2)) versus low dose (135 mg/m(2)), and short (3 hours) versus long (24 hours) infusion confirms the reported activity of paclitaxel in previously treated patients. The preliminary overall response rate in 286 evaluable patients is 18.5%. A dose effect exists regarding neuropathy and neutropenia, and a longer infusion duration results in a higher frequency of grade 4 neutropenia. In a phase III study comparing cisplatin 75 mg/m(2) plus cyclophosphamide (750 mg/m(2)) or plus paclitaxel 135 mg/m(2) over 24 hours, the paclitaxel-based combination gave a superior response rate (54% versus 33%) and statistically significant longer progression-free interval. The semisynthetic docetaxel (taxotere) gives an overall response rate of 32% (95% confidence interval 23%-43%). Skin toxicity and edema are dose-limiting factors. Gemcita-bine has also shown activity in platinum-resistant patients with an overall response rate of 23% (95% CI 10%-40%). Conclusions: The role of new drugs in first-line therapy remains to be seen. Further development of experimental work for screening and evaluation of new agents is needed. C1 QUEENS UNIV,NCI,CANADA TRIALS GRP,KINGSTON,ON,CANADA. FAC HILLEROD,DEPT MED,HILLEROD,DENMARK. UNIV HOSP UTRECHT,UTRECHT,NETHERLANDS. JULES BORDET INST,BRUSSELS,BELGIUM. OSPED SAN GIOVANNI BELLINZONA,DIV ONCOL,BELLINZONA,SWITZERLAND. UNIV MISSISSIPPI,SCH MED,JACKSON,MS. RP HANSEN, HH (reprint author), RIGSHOSP,DEPT ONCOL 5074,DK-2100 COPENHAGEN,DENMARK. NR 36 TC 15 Z9 15 U1 1 U2 4 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PY 1993 VL 4 SU 4 BP 63 EP 70 PG 8 WC Oncology SC Oncology GA MP747 UT WOS:A1993MP74700010 PM 7906138 ER PT S AU ROBEY, PG AF ROBEY, PG BE Bristol, JA Hagmann, WK McCall, JM Plattner, JJ Robertson, DW Seamon, KB Venuti, MC TI RGD-CONTAINING PROTEINS AND BONE SO ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 28 SE Annual Reports in Medicinal Chemistry LA English DT Review ID OSTEO-SARCOMA CELLS; MONOCLONAL-ANTIBODIES; VITRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; FIBRONECTIN RECEPTOR; SIALOPROTEIN BSP; RAT OSTEOCLASTS; RESORPTION; OSTEOPONTIN; EXPRESSION RP NIDR, BONE RES BRANCH, BETHESDA, MD 20892 USA. RI Robey, Pamela/H-1429-2011 OI Robey, Pamela/0000-0002-5316-5576 NR 68 TC 10 Z9 10 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0065-7743 BN 0-12-040528-8 J9 ANNU REP MED CHEM JI Annu. Rep. Med. Chem. PY 1993 VL 28 BP 227 EP 236 PG 10 WC Chemistry, Applied; Pharmacology & Pharmacy SC Chemistry; Pharmacology & Pharmacy GA BA26B UT WOS:A1993BA26B00024 ER PT J AU SUFFNESS, M AF SUFFNESS, M TI TAXOL - FROM DISCOVERY TO THERAPEUTIC USE SO ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 28 SE ANNUAL REPORTS IN MEDICINAL CHEMISTRY LA English DT Review ID WATER-SOLUBLE PRODRUGS; HAMSTER OVARY CELLS; SIDE-CHAIN; ANTITUMOR-ACTIVITY; PHASE-I; TAXUS-BREVIFOLIA; BIOLOGICAL-ACTIVITY; PRACTICAL APPROACH; RESISTANT MUTANTS; TAXOTERE RP-56976 RP SUFFNESS, M (reprint author), NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892, USA. NR 111 TC 153 Z9 156 U1 0 U2 6 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0065-7743 J9 ANNU REP MED CHEM PY 1993 VL 28 BP 305 EP 314 PG 10 WC Chemistry, Applied; Pharmacology & Pharmacy SC Chemistry; Pharmacology & Pharmacy GA BA26B UT WOS:A1993BA26B00032 ER PT J AU LONG, JC AF LONG, JC TI HUMAN MOLECULAR PHYLOGENETICS SO ANNUAL REVIEW OF ANTHROPOLOGY LA English DT Review DE PHYLOGENETICS; GENETICS; EVOLUTION; MTDNA; NDNA ID HUMAN MITOCHONDRIAL-DNA; ENDONUCLEASE CLEAVAGE PATTERNS; BETA-GLOBIN HAPLOTYPES; HUMAN Y-CHROMOSOME; HUMAN-EVOLUTION; POPULATION-GENETICS; HUMAN ORIGINS; AFRICAN ORIGIN; HOMO-SAPIENS; SEQUENCES C1 UNIV NEW MEXICO,DEPT ANTHROPOL,ALBUQUERQUE,NM 87131. RP LONG, JC (reprint author), NIAAA,NEUROGENET LAB,BETHESDA,MD 20892, USA. NR 121 TC 5 Z9 5 U1 1 U2 2 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0084-6570 J9 ANNU REV ANTHROPOL JI Annu. Rev. Anthropol. PY 1993 VL 22 BP 251 EP 272 PG 22 WC Anthropology SC Anthropology GA ME244 UT WOS:A1993ME24400011 ER PT J AU MORGAN, RA ANDERSON, WF AF MORGAN, RA ANDERSON, WF TI HUMAN GENE-THERAPY SO ANNUAL REVIEW OF BIOCHEMISTRY LA English DT Review DE GENE TRANSFER; VIRAL VECTORS; GENETIC DISEASE ID HEMATOPOIETIC STEM-CELLS; HUMAN ADENOSINE-DEAMINASE; BETA-GLOBIN GENE; TUMOR-INFILTRATING LYMPHOCYTES; MODIFIED SKIN FIBROBLASTS; VECTOR-MEDIATED TRANSFER; LONG-TERM EXPRESSION; HEPATITIS-B VIRUS; HUMAN FACTOR-IX; RETROVIRAL-VECTOR C1 UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033. RP MORGAN, RA (reprint author), NHLBI,MOLEC HEMATOL BRANCH,BETHESDA,MD 20892, USA. NR 205 TC 275 Z9 281 U1 1 U2 10 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0066-4154 J9 ANNU REV BIOCHEM JI Annu. Rev. Biochem. PY 1993 VL 62 BP 191 EP 217 PG 27 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA LK687 UT WOS:A1993LK68700008 PM 8352589 ER PT J AU GOTTESMAN, MM PASTAN, I AF GOTTESMAN, MM PASTAN, I TI BIOCHEMISTRY OF MULTIDRUG-RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER SO ANNUAL REVIEW OF BIOCHEMISTRY LA English DT Review DE CHEMOTHERAPY; CANCER; ATPASE; GENE THERAPY ID P-GLYCOPROTEIN GENE; CHINESE-HAMSTER CELLS; ASCITES TUMOR-CELLS; KB CARCINOMA-CELLS; HUMAN MDR1 GENE; INTRINSIC DRUG-RESISTANCE; POLYMERASE CHAIN-REACTION; CALCIUM-CHANNEL BLOCKERS; REGENERATING RAT-LIVER; HUMAN-BREAST CANCER C1 NCI,MOLEC BIOL LAB,BETHESDA,MD 20892. RP GOTTESMAN, MM (reprint author), NCI,CELL BIOL LAB,BETHESDA,MD 20892, USA. RI Ain, Kenneth/A-5179-2012 OI Ain, Kenneth/0000-0002-2668-934X NR 268 TC 3309 Z9 3375 U1 14 U2 175 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0066-4154 J9 ANNU REV BIOCHEM JI Annu. Rev. Biochem. PY 1993 VL 62 BP 385 EP 427 DI 10.1146/annurev.bi.62.070193.002125 PG 43 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA LK687 UT WOS:A1993LK68700014 PM 8102521 ER PT J AU WLODAWER, A ERICKSON, JW AF WLODAWER, A ERICKSON, JW TI STRUCTURE-BASED INHIBITORS OF HIV-1 PROTEASE SO ANNUAL REVIEW OF BIOCHEMISTRY LA English DT Review DE AIDS; DRUG DESIGN; PROTEOLYTIC ENZYME; X-RAY CRYSTALLOGRAPHY; ANTIVIRAL DRUGS ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUBSTRATE-ANALOG INHIBITORS; C2 SYMMETRICAL INHIBITORS; TYPE-1 PROTEASE; ASPARTIC PROTEINASES; CRYSTAL-STRUCTURE; RATIONAL DESIGN; 3-DIMENSIONAL STRUCTURE; RETROVIRAL PROTEASES; RHIZOPUS-CHINENSIS C1 NCI, FREDERICK CANC RES & DEV CTR,PRI,DYNCORP, STRUCT BIOCHEM PROGRAM, FREDERICK, MD 21702 USA. RP WLODAWER, A (reprint author), NCI, FREDERICK CANC RES & DEV CTR, ABL, BASIC RES PROGRAM, MACROMOLEC STRUCT LAB, FREDERICK, MD 21702 USA. FU NCI NIH HHS [N01-CO-741O1, N01-CO-741O2] NR 93 TC 698 Z9 706 U1 11 U2 128 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA SN 0066-4154 EI 1545-4509 J9 ANNU REV BIOCHEM JI Annu. Rev. Biochem. PY 1993 VL 62 BP 543 EP 585 DI 10.1146/annurev.bi.62.070193.002551 PG 43 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA LK687 UT WOS:A1993LK68700019 PM 8352596 ER PT J AU KOLB, A BUSBY, S BUC, H GARGES, S ADHYA, S AF KOLB, A BUSBY, S BUC, H GARGES, S ADHYA, S TI TRANSCRIPTIONAL REGULATION BY CAMP AND ITS RECEPTOR PROTEIN SO ANNUAL REVIEW OF BIOCHEMISTRY LA English DT Review DE TRANSCRIPTIONAL ACTIVATION; PROKARYOTIC TRANSCRIPTION; CRP; CAP ID CYCLIC-AMP RECEPTOR; GENE ACTIVATOR PROTEIN; ESCHERICHIA-COLI K-12; DNA-SEQUENCE-RECOGNITION; ADENOSINE-MONOPHOSPHATE RECEPTOR; ADENYLATE-CYCLASE SYNTHESIS; LAC OPERON TRANSCRIPTION; OUTER-MEMBRANE PROTEIN; L-ASPARAGINASE-II; RNA-POLYMERASE C1 UNIV BIRMINGHAM, SCH BIOCHEM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND. NCI, MOLEC BIOL LAB, BETHESDA, MD 20892 USA. RP KOLB, A (reprint author), INST PASTEUR, CNRS, URA 1149, F-75724 PARIS 15, FRANCE. NR 329 TC 612 Z9 619 U1 9 U2 39 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA SN 0066-4154 EI 1545-4509 J9 ANNU REV BIOCHEM JI Annu. Rev. Biochem. PY 1993 VL 62 BP 749 EP 795 DI 10.1146/annurev.bi.62.070193.003533 PG 47 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA LK687 UT WOS:A1993LK68700025 PM 8394684 ER PT J AU STADTMAN, ER AF STADTMAN, ER TI OXIDATION OF FREE AMINO-ACIDS AND AMINO-ACID-RESIDUES IN PROTEINS BY RADIOLYSIS AND BY METAL-CATALYZED REACTIONS SO ANNUAL REVIEW OF BIOCHEMISTRY LA English DT Review DE AMINO ACID OXIDATION; OXYGEN-FREE RADICALS; FENTON REAGENT; RADICAL SCAVENGERS; CHELATORS ID MIXED-FUNCTION OXIDATION; COLI GLUTAMINE-SYNTHETASE; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; OXYGEN RADICALS; LIMITED DEGRADATION; MUCUS GLYCOPROTEINS; CYSTEINE PROTEINASE; HISTIDINE-RESIDUES RP STADTMAN, ER (reprint author), NHLBI,BIOCHEM LAB,BETHESDA,MD 20892, USA. NR 116 TC 1042 Z9 1081 U1 12 U2 102 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0066-4154 J9 ANNU REV BIOCHEM JI Annu. Rev. Biochem. PY 1993 VL 62 BP 797 EP 821 DI 10.1146/annurev.bi.62.070193.004053 PG 25 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA LK687 UT WOS:A1993LK68700026 PM 8352601 ER PT J AU LOWY, DR WILLUMSEN, BM AF LOWY, DR WILLUMSEN, BM TI FUNCTION AND REGULATION OF RAS SO ANNUAL REVIEW OF BIOCHEMISTRY LA English DT Review DE ONCOGENES; SMALL G-PROTEINS; GUANINE NUCLEOTIDE BINDING PROTEINS; CELL TRANSFORMATION; CELL SIGNALING ID GTPASE-ACTIVATING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; NEUROFIBROMATOSIS TYPE-1 GENE; ONCOGENE PRODUCT P21; HUMAN N-RAS; BLADDER-CARCINOMA ONCOGENE; ADENYLYL CYCLASE COMPLEX; EPIDERMAL GROWTH-FACTOR; MURINE SARCOMA-VIRUS; C-KI-RAS C1 UNIV COPENHAGEN,DEPT MOLEC CELL BIOL,DK-1168 COPENHAGEN,DENMARK. RP LOWY, DR (reprint author), NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892, USA. RI Willumsen, Berthe/H-1903-2012; Tang, Amy/L-3226-2016 OI Willumsen, Berthe/0000-0002-2277-6999; Tang, Amy/0000-0002-5772-2878 NR 314 TC 944 Z9 965 U1 9 U2 29 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0066-4154 J9 ANNU REV BIOCHEM JI Annu. Rev. Biochem. PY 1993 VL 62 BP 851 EP 891 DI 10.1146/annurev.bi.62.070193.004223 PG 41 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA LK687 UT WOS:A1993LK68700028 PM 8352603 ER PT J AU ZIMMERMAN, SB MINTON, AP AF ZIMMERMAN, SB MINTON, AP TI MACROMOLECULAR CROWDING - BIOCHEMICAL, BIOPHYSICAL, AND PHYSIOLOGICAL CONSEQUENCES SO ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE LA English DT Review DE EXCLUDED VOLUME; CYTOPLASM; CELL VOLUME; DIFFUSION; INTERMOLECULAR INTERACTIONS; PROTEINS; DNA, NUCLEIC ACIDS; ENZYMES ID REPRESSOR-OPERATOR INTERACTION; POLYMER-PROTEIN INTERACTIONS; ESCHERICHIA-COLI CHROMOSOME; EXCLUDED-VOLUME THEORY; BOVINE SERUM-ALBUMIN; MONO-VALENT CATIONS; SINGLE-STRANDED-DNA; HARD PARTICLE MODEL; LAMBDA-PR PROMOTER; BLUNT-END LIGATION C1 NIDDKD,BIOCHEM PHARMACOL LAB,PHYS BIOCHEM SECT,BLDG 8,ROOM 226,BETHESDA,MD 20892. RP ZIMMERMAN, SB (reprint author), NIDDKD,MOLEC BIOL LAB,PHYS CHEM SECT,BLDG 5,ROOM 330,BETHESDA,MD 20892, USA. NR 176 TC 913 Z9 926 U1 11 U2 126 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 1056-8700 J9 ANNU REV BIOPH BIOM JI Annu. Rev. Biophys. Biomolec. Struct. PY 1993 VL 22 BP 27 EP 65 DI 10.1146/annurev.bb.22.060193.000331 PG 39 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA LH454 UT WOS:A1993LH45400002 PM 7688609 ER PT J AU ZIMMERBERG, J VOGEL, SS CHERNOMORDIK, LV AF ZIMMERBERG, J VOGEL, SS CHERNOMORDIK, LV TI MECHANISMS OF MEMBRANE-FUSION SO ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE LA English DT Review DE EXOCYTOSIS; VIRAL INFECTION; INFLUENZA; SYNCYTIA; LIPIDS ID INFLUENZA-VIRUS HEMAGGLUTININ; PHOSPHOLIPID-BILAYER MEMBRANES; PH-DEPENDENT FUSION; VIDEO FLUORESCENCE MICROSCOPY; INDUCED CONFORMATIONAL CHANGE; SYNAPTIC VESICLE EXOCYTOSIS; ADRENAL CHROMAFFIN CELLS; SEMLIKI-FOREST VIRUS; CESIUM-INDUCED DELAY; MOUSE MAST-CELLS RP ZIMMERBERG, J (reprint author), NICHHD,THEORET & PHYS BIOL,BETHESDA,MD 20892, USA. RI Vogel, Steven/A-3585-2012; OI Vogel, Steven/0000-0002-3005-2667 NR 192 TC 182 Z9 183 U1 1 U2 14 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 1056-8700 J9 ANNU REV BIOPH BIOM JI Annu. Rev. Biophys. Biomolec. Struct. PY 1993 VL 22 BP 433 EP 466 DI 10.1146/annurev.bb.22.060193.002245 PG 34 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA LH454 UT WOS:A1993LH45400017 PM 8347997 ER PT J AU STETLERSTEVENSON, WG AZNAVOORIAN, S LIOTTA, LA AF STETLERSTEVENSON, WG AZNAVOORIAN, S LIOTTA, LA TI TUMOR-CELL INTERACTIONS WITH THE EXTRACELLULAR-MATRIX DURING INVASION AND METASTASIS SO ANNUAL REVIEW OF CELL BIOLOGY LA English DT Review DE CELL ADHESION; INTEGRINS; LAMININ RECEPTOR; CADHERINS; METALLOPROTEINASES; COLLAGENASES; GELATINASES; TISSUE INHIBITORS OF METALLOPROTEINASES; CELL MOTILITY; AUTOCRINE MOTILITY ID HUMAN-MELANOMA CELLS; FIBROBLAST COLLAGENASE INHIBITOR; BASEMENT-MEMBRANE MATRIGEL; HUMAN 72-KDA GELATINASE; HUMAN PROSTATE-CANCER; IV COLLAGENASE; TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; EPITHELIAL-CELLS; METALLOPROTEINASE INHIBITOR RP STETLERSTEVENSON, WG (reprint author), NCI,DIV CANC BIOL DIAG & CTR,PATHOL LAB,BETHESDA,MD 20892, USA. RI Stetler-Stevenson, William/H-6956-2012 OI Stetler-Stevenson, William/0000-0002-5500-5808 NR 191 TC 1287 Z9 1313 U1 7 U2 85 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0743-4634 J9 ANNU REV CELL BIOL JI Annu. Rev. Cell Biol. PY 1993 VL 9 BP 541 EP 573 DI 10.1146/annurev.cb.09.110193.002545 PG 33 WC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology SC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology GA MJ366 UT WOS:A1993MJ36600017 PM 8280471 ER PT J AU NAPARSTEK, Y PLOTZ, PH AF NAPARSTEK, Y PLOTZ, PH TI THE ROLE OF AUTOANTIBODIES IN AUTOIMMUNE-DISEASE SO ANNUAL REVIEW OF IMMUNOLOGY LA English DT Review DE AUTOANTIBODY; AUTOIMMUNITY; IMMUNOPATHOGENESIS; MEMBRANE; AUTOANTIGEN ID SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTI-DNA ANTIBODIES; PRIMARY BILIARY-CIRRHOSIS; CULTURED HUMAN KERATINOCYTES; TRANSFER RNA-SYNTHETASE; ANTIACETYLCHOLINE RECEPTOR ANTIBODIES; IDIOPATHIC INFLAMMATORY MYOPATHY; GUILLAIN-BARRE-SYNDROME; ISLET-CELL ANTIBODIES; MOTOR-NEURON DISEASE AB In autoimmune diseases, autoantibodies may be the actual pathogenetic agents of the disease, the secondary consequence of tissue damage, or the harmless footprints of an etiologic agent. Establishing a pathogenetic role for autoantibodies requires that they meet stringent criteria. It appears that the location of the presumptive target antigen most critically influences the pathogenetic potential of autoantibodies. Autoantibodies directed against cell surface targets, such as hormone receptors, are clearly pathogenetic; those directed against extracellular targets, such as circulating molecules or extracellular matrix, may or may not cause any damage. Those apparently directed against intracellular targets are usually not pathogenetic unless it can be clearly demonstrated (a) that the antigen is released from within the cell so that it can bind onto a cell surface receptor or other extracellular location, such as proteinase 3; (b) that the antigen moves to an aberrant site on the cell surface, such as, perhaps, the small ribonucleoprotein antigen Ro; or (c) that a cross-reactive molecule, the actual target, such as the membrane ribosomal P-like protein, is at an accessible location. C1 NIAMSD,ARTHRITIS & RHEUMATISM BRANCH,BETHESDA,MD. RP NAPARSTEK, Y (reprint author), HADASSAH UNIV HOSP,DEPT MED,CLIN IMMUNOL & ALLERGY UNIT,JERUSALEM,ISRAEL. NR 129 TC 123 Z9 128 U1 2 U2 4 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0732-0582 J9 ANNU REV IMMUNOL JI Annu. Rev. Immunol. PY 1993 VL 11 BP 79 EP 104 DI 10.1146/annurev.immunol.11.1.79 PG 26 WC Immunology SC Immunology GA KX306 UT WOS:A1993KX30600004 PM 8476578 ER PT J AU GERMAIN, RN MARGULIES, DH AF GERMAIN, RN MARGULIES, DH TI THE BIOCHEMISTRY AND CELL BIOLOGY OF ANTIGEN PROCESSING AND PRESENTATION SO ANNUAL REVIEW OF IMMUNOLOGY LA English DT Review DE MHC CLASS-I; MHC CLASS-II; PEPTIDES; INVARIANT CHAIN ID MAJOR HISTOCOMPATIBILITY COMPLEX; MHC CLASS-II; SHOCK SYNDROME TOXIN-1; RESTRICTED T-CELLS; PEPTIDE-BINDING-PROTEIN; HLA-DR MOLECULES; BETA-2-MICROGLOBULIN TRANSLATED INVITRO; MATERNALLY TRANSMITTED ANTIGEN; STAPHYLOCOCCAL ENTEROTOXIN-A; INVARIANT CHAIN INFLUENCES AB T lymphocytes with alphabeta receptors recognize antigen in association with the polymorphic products of the class I and class II loci of the major histocompatibility complex (MHC). This presentation of antigen results from the intracellular generation of protein fragments, and the binding and transport to the cell surface of these peptides in stable association with the MHC class I and class II molecules. Each class of MHC molecule appears specialized for capture of peptides present in a particular intracellular compartment. We describe here the structural basis of peptide-MHC molecule interaction, the differences in biochemical behavior that focus the two classes of MHC molecules on peptides of distinct size and location, and the cell biology of MHC molecule transport, peptide generation, and intracellular movement. The importance of conformational changes accompanying peptide binding that affect subunit stability of MHC molecules, and the relationship between these changes and the handling of proteins by intracellular chaperones, are emphasized as key features in the operation of the class I and class II presentation pathways. C1 NIAID,IMMUNOL LAB,MOLEC BIOL SECT,BETHESDA,MD 20892. RP GERMAIN, RN (reprint author), NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BLDG 10,ROOM 11N311,BETHESDA,MD 20892, USA. RI Margulies, David/H-7089-2013; OI Margulies, David/0000-0001-8530-7375 NR 289 TC 897 Z9 903 U1 4 U2 26 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0732-0582 J9 ANNU REV IMMUNOL JI Annu. Rev. Immunol. PY 1993 VL 11 BP 403 EP 450 DI 10.1146/annurev.immunol.11.1.403 PG 48 WC Immunology SC Immunology GA KX306 UT WOS:A1993KX30600016 PM 8476568 ER PT J AU MARTIN, GR DANNER, DB HOLBROOK, NJ AF MARTIN, GR DANNER, DB HOLBROOK, NJ TI AGING - CAUSES AND DEFENSES SO ANNUAL REVIEW OF MEDICINE LA English DT Review DE SENESCENCE; TELOMERES; MITOCHONDRIAL DNA; HEAT SHOCK RESPONSE ID SENESCENT HUMAN-FIBROBLASTS; MITOCHONDRIAL-DNA; INDEFINITE DIVISION; GENETIC-ANALYSIS; HUMAN-CELLS; EXPRESSION; PROTEIN; PHOSPHORYLATE; INDUCTION; TELOMERES AB Recent studies have shown that chromosomes shorten as cells divide and become senescent. Also, deletions in mitochondrial DNA increase markedly with advancing age, presumably secondary to damage from oxygen radicals. Since host defenses against environmental factors also become attenuated, the molecular damage associated with aging may increasingly perturb normal homeostasis and increase the susceptibility to disease and disability. Such age-associated dysfunctions can be targeted and interrupted. RP MARTIN, GR (reprint author), NIA,GERONTOL RES CTR,BALTIMORE,MD 21224, USA. NR 45 TC 36 Z9 39 U1 1 U2 4 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0066-4219 J9 ANNU REV MED JI Annu. Rev. Med. PY 1993 VL 44 BP 419 EP 429 DI 10.1146/annurev.med.44.1.419 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA KW478 UT WOS:A1993KW47800037 PM 8476261 ER PT J AU AMARA, SG KUHAR, MJ AF AMARA, SG KUHAR, MJ TI NEUROTRANSMITTER TRANSPORTERS - RECENT PROGRESS SO ANNUAL REVIEW OF NEUROSCIENCE LA English DT Review DE NEUROTRANSMITTER REUPTAKE; SYNAPTIC SIGNAL TERMINATION; UPTAKE ID GAMMA-AMINOBUTYRIC-ACID; AFFINITY CHOLINE UPTAKE; PRIMARY ASTROCYTE CULTURES; SENSITIVE DOPAMINE TRANSPORTER; SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC-RECEPTOR; XENOPUS-LAEVIS OOCYTES; BRAIN GABA TRANSPORTER; EXCITATORY AMINO-ACIDS; RAT-BRAIN C1 NIDA,NEUROSCI BRANCH,ADDICT RES CTR,BALTIMORE,MD. RP AMARA, SG (reprint author), OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201, USA. NR 112 TC 876 Z9 894 U1 7 U2 29 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0147-006X J9 ANNU REV NEUROSCI JI Annu. Rev. Neurosci. PY 1993 VL 16 BP 73 EP 93 DI 10.1146/annurev.ne.16.030193.000445 PG 21 WC Neurosciences SC Neurosciences & Neurology GA KR724 UT WOS:A1993KR72400005 PM 8096377 ER PT J AU KAUFMAN, S AF KAUFMAN, S TI NEW TETRAHYDROBIOPTERIN-DEPENDENT SYSTEMS SO ANNUAL REVIEW OF NUTRITION LA English DT Review DE TETRAHYDROBIOPTERIN; NITRIC OXIDE; INDOLEAMINE DIOXYGENASE; NEOPTERIN; PHENYL-KETONURIA ID NITRIC-OXIDE SYNTHASE; BLOOD MONONUCLEAR-CELLS; HEPATIC PHENYLALANINE-HYDROXYLASE; AMINO-ACID HYDROXYLASES; TUMOR-NECROSIS-FACTOR; GTP-CYCLOHYDROLASE-I; INTERFERON-GAMMA; L-ARGININE; INDOLEAMINE 2,3-DIOXYGENASE; 7-SUBSTITUTED PTERINS RP KAUFMAN, S (reprint author), NIMH, NEUROCHIM LAB, BETHESDA, MD 20892 USA. NR 121 TC 150 Z9 154 U1 2 U2 4 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA SN 0199-9885 EI 1545-4312 J9 ANNU REV NUTR JI Annu. Rev. Nutr. PY 1993 VL 13 BP 261 EP 286 PG 26 WC Nutrition & Dietetics SC Nutrition & Dietetics GA LQ758 UT WOS:A1993LQ75800012 PM 8103664 ER PT J AU LEIKIN, S PARSEGIAN, VA RAU, DC RAND, RP AF LEIKIN, S PARSEGIAN, VA RAU, DC RAND, RP TI HYDRATION FORCES SO ANNUAL REVIEW OF PHYSICAL CHEMISTRY LA English DT Review DE MOLECULAR INTERACTIONS; MOLECULAR SOLVATION; SURFACE FORCES; WATER STRUCTURE ID DNA DOUBLE HELICES; AQUEOUS-ELECTROLYTE SOLUTIONS; THERMAL-MECHANICAL FLUCTUATIONS; PHOSPHOLIPID-BILAYER MEMBRANES; ELECTROSTATIC DOUBLE-LAYER; X-RAY-DIFFRACTION; MICA SURFACES; PHOSPHATIDYLCHOLINE BILAYERS; LECITHIN BILAYERS; LIPID BILAYERS C1 NIDDICD,BETHESDA,MD 20892. BROCK UNIV,DEPT BIOL SCI,ST CATHARINES L2S 3A1,ONTARIO,CANADA. RP LEIKIN, S (reprint author), NIH,DIV COMP RES & TECHNOL,BETHESDA,MD 20892, USA. RI Leikin, Sergey/A-5518-2008 OI Leikin, Sergey/0000-0001-7095-0739 NR 164 TC 377 Z9 380 U1 7 U2 74 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0066-426X J9 ANNU REV PHYS CHEM JI Annu. Rev. Phys. Chem. PY 1993 VL 44 BP 369 EP 395 DI 10.1146/annurev.physchem.44.1.369 PG 27 WC Chemistry, Physical SC Chemistry GA MH337 UT WOS:A1993MH33700014 PM 8257560 ER PT J AU WEISS, KB GERGEN, PJ WAGENER, DK AF WEISS, KB GERGEN, PJ WAGENER, DK TI BREATHING BETTER OR WHEEZING WORSE - THE CHANGING EPIDEMIOLOGY OF ASTHMA MORBIDITY AND MORTALITY SO ANNUAL REVIEW OF PUBLIC HEALTH LA English DT Review DE SURVEILLANCE; PREVALENCE; HOSPITALIZATION ID HOUSE-DUST MITE; LOW BIRTH-WEIGHT; CHILDHOOD ASTHMA; UNITED-STATES; RESPIRATORY SYMPTOMS; INTERNATIONAL TRENDS; PULMONARY-FUNCTION; BRONCHIAL HYPERREACTIVITY; ALLERGIC RHINITIS; MATERNAL SMOKING C1 GEORGE WASHINGTON UNIV,DEPT MED,WASHINGTON,DC 20037. GEORGE WASHINGTON UNIV,CTR HLTH POLICY RES,WASHINGTON,DC 20037. NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,OFF EPIDEMIOL & CLIN TRIALS,ROCKVILLE,MD 20892. CTR DIS CONTROL,OFF ANAL & EPIDEMIOL,ENVIRONM STUDIES BRANCH,HYATTSVILLE,MD 20782. RP WEISS, KB (reprint author), GEORGE WASHINGTON UNIV,DEPT HLTH CARE SCI,WASHINGTON,DC 20037, USA. NR 118 TC 209 Z9 210 U1 1 U2 6 PU ANNUAL REVIEWS INC PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 SN 0163-7525 J9 ANNU REV PUBL HEALTH JI Annu. Rev. Public Health PY 1993 VL 14 BP 491 EP 513 DI 10.1146/annurev.pu.14.050193.002423 PG 23 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA LE091 UT WOS:A1993LE09100022 PM 8323600 ER PT J AU GRUBBS, CJ JULIANA, MM ETO, I CASEBOLT, T WHITAKER, LM CANFIELD, GJ MANCZAK, M STEELE, VE KELLOFF, GJ AF GRUBBS, CJ JULIANA, MM ETO, I CASEBOLT, T WHITAKER, LM CANFIELD, GJ MANCZAK, M STEELE, VE KELLOFF, GJ TI CHEMOPREVENTION BY INDOMETHACIN OF N-BUTYL-N-(4-HYDROXYBUTYL)-NITROSAMINE-INDUCED URINARY-BLADDER TUMORS SO ANTICANCER RESEARCH LA English DT Article DE N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE (OH-BBN); INDOMETHACIN; URINARY BLADDER; MICE; CANCER; CHEMOPREVENTION ID ORNITHINE DECARBOXYLASE ACTIVITY; RAT MAMMARY CARCINOGENESIS; INHIBITION; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; PROSTAGLANDIN-E2; PROMOTION; INDUCTION; GROWTH; CELLS; ACID AB The effects of indomethacin on the development of N-butyl-N-(4-hydroxybutyl) nitrosamine (OH-BBN)-induced urinary bladder tumors were evaluated in male BDF mice. Preliminary feeding studies revealed that the highest non-toxic dose of indomethacin was 15 mg/kg of AIN-76A diet; thus, dose levels of 15 and 7.5 mg/kg of diet were selected to determine the chemopreventive efficacy of this agent. Diet supplementation with indomethacin was initiated when the mice were 49 days old and continued for the duration of the study. Starting one week after indomethacin treatment, OH-BBN was administered 1x/week for eight weeks. Upon termination of the study (180 days after the initial carcinogen administration), all tumors in the urinary bladder were removed and classified histologically. Mice receiving carcinogen and no indomethacin supplementation had a 24% incidence of urinary bladder tumors; mice receiving 7.5 mg/kg and 15 mg of indomethacin had a 5% and 0% incidence of urinary bladder tumors, respectively. The significant reduction of OH-BBN-induced urinary bladder tumors by indomethacin is consistent with previous suggestions that prostaglandin synthesis inhibitors are effective inhibitors of carcinogenesis. C1 NCI,CHEMOPREVENT BRANCH,BETHESDA,MD 20892. RP GRUBBS, CJ (reprint author), UNIV ALABAMA,DEPT NUTR SCI,1675 UNIV BLVD,BIRMINGHAM,AL 35294, USA. FU NCI NIH HHS [N01-CN-95156-01, CA28103] NR 21 TC 25 Z9 25 U1 0 U2 2 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDNTIOU-KALAMOU RD KAPANDRITI, POB 22, ATHENS 19014, GREECE SN 0250-7005 J9 ANTICANCER RES JI Anticancer Res. PD JAN-FEB PY 1993 VL 13 IS 1 BP 33 EP 36 PG 4 WC Oncology SC Oncology GA KX843 UT WOS:A1993KX84300007 PM 8476227 ER PT J AU SAMUELS, DS GARON, CF AF SAMUELS, DS GARON, CF TI COUMERMYCIN-A(1) INHIBITS GROWTH AND INDUCES RELAXATION OF SUPERCOILED PLASMIDS IN BORRELIA-BURGDORFERI, THE LYME-DISEASE AGENT SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID DNA TOPOISOMERASES; LINEAR PLASMIDS; GYRASE; TRANSCRIPTION; NOVOBIOCIN AB Coumermycin A1 is an inhibitor of DNA gyrase, an enzyme that catalyzes supercoiling of DNA and is required for bacterial DNA replication. We have investigated the activity of this coumarin antibiotic on Borrelia burgdorferi, a spirochete and the causative agent of Lyme disease. B. burgdorferi was more susceptible than many other eubacteria to coumermycin as well as novobiocin, another coumarin antibiotic; this contrasted with its relative resistance to the DNA gyrase inhibitors nalidixic acid, oxolinic acid, and ciprofloxacin. Coumermycin at 0.2 mug/ml inhibited the growth of B. burgdorferi B31 in BSK II medium. A 100-fold-lower concentration induced the relaxation of two negatively supercoiled circular plasmids within 2 h. Plasmid supercoiling was restored within 2 h of removal of coumermycin. These results suggest that B. burgdorferi has a DNA gyrase and that this enzyme's activity is required for growth. Furthermore, structural analogs of coumermycin may be considered as treatments for Lyme disease. RP SAMUELS, DS (reprint author), NIAID,ROCKY MT LABS,VECTORS & PATHOGENS LAB,HAMILTON,MT 59840, USA. RI Samuels, D Scott/B-7549-2012 OI Samuels, D Scott/0000-0001-8352-7593 NR 32 TC 42 Z9 43 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 1993 VL 37 IS 1 BP 46 EP 50 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA KF247 UT WOS:A1993KF24700008 PM 8381639 ER PT S AU DELUCA, LM AF DELUCA, LM BE Bronzetti, G Hayatsu, H DeFlora, S Waters, MD Shankel, DM TI MULTIPLE MECHANISMS - THE EXAMPLE OF VITAMIN-A SO ANTIMUTAGENESIS AND ANTICARCINOGENESIS MECHANISMS III SE BASIC LIFE SCIENCES LA English DT Proceedings Paper CT 3rd International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis CY MAY 05-10, 1991 CL LUCCA, ITALY SP COMMISS EUROPEAN COMMUNITIES, INT AGCY RES CANC, US EPA, US DOE, NIH, NCI, US DEPT AGR C1 NATL CANC CTR INST,BETHESDA,MD 20892. NR 0 TC 8 Z9 8 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0090-5542 BN 0-306-44577-8 J9 BASIC LIFE SCI PY 1993 VL 61 BP 17 EP 25 PG 9 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BZ52U UT WOS:A1993BZ52U00002 PM 8304928 ER PT S AU DIPAOLO, JA WOODWORTH, CD AF DIPAOLO, JA WOODWORTH, CD BE Bronzetti, G Hayatsu, H DeFlora, S Waters, MD Shankel, DM TI MOLECULAR CONTROL OF HUMAN PAPILLOMAVIRUS RNA EXPRESSION IN NEOPLASIA SO ANTIMUTAGENESIS AND ANTICARCINOGENESIS MECHANISMS III SE BASIC LIFE SCIENCES LA English DT Proceedings Paper CT 3rd International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis CY MAY 05-10, 1991 CL LUCCA, ITALY SP COMMISS EUROPEAN COMMUNITIES, INT AGCY RES CANC, US EPA, US DOE, NIH, NCI, US DEPT AGR C1 NCI,BIOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0090-5542 BN 0-306-44577-8 J9 BASIC LIFE SCI PY 1993 VL 61 BP 239 EP 246 PG 8 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BZ52U UT WOS:A1993BZ52U00021 PM 8304934 ER PT S AU BOONE, CW KELLOFF, GJ STEELE, VE AF BOONE, CW KELLOFF, GJ STEELE, VE BE Bronzetti, G Hayatsu, H DeFlora, S Waters, MD Shankel, DM TI HISTOPATHOLOGY OF HUMAN INTRAEPITHELIAL NEOPLASIA WITH IMPLICATIONS FOR CHEMOPREVENTION STRATEGY SO ANTIMUTAGENESIS AND ANTICARCINOGENESIS MECHANISMS III SE BASIC LIFE SCIENCES LA English DT Proceedings Paper CT 3rd International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis CY MAY 05-10, 1991 CL LUCCA, ITALY SP COMMISS EUROPEAN COMMUNITIES, INT AGCY RES CANC, US EPA, US DOE, NIH, NCI, US DEPT AGR C1 NCI,DIV CANC PREVENT & CONTROL,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0090-5542 BN 0-306-44577-8 J9 BASIC LIFE SCI PY 1993 VL 61 BP 291 EP 300 PG 10 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BZ52U UT WOS:A1993BZ52U00027 PM 8304941 ER PT S AU KELLOFF, GJ BOONE, CW MALONE, W STEELE, V AF KELLOFF, GJ BOONE, CW MALONE, W STEELE, V BE Bronzetti, G Hayatsu, H DeFlora, S Waters, MD Shankel, DM TI RECENT RESULTS IN PRECLINICAL AND CLINICAL DRUG DEVELOPMENT OF CHEMOPREVENTIVE AGENTS AT THE NATIONAL-CANCER-INSTITUTE SO ANTIMUTAGENESIS AND ANTICARCINOGENESIS MECHANISMS III SE BASIC LIFE SCIENCES LA English DT Proceedings Paper CT 3rd International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis CY MAY 05-10, 1991 CL LUCCA, ITALY SP COMMISS EUROPEAN COMMUNITIES, INT AGCY RES CANC, US EPA, US DOE, NIH, NCI, US DEPT AGR C1 NIH,DIV CANC PREVENT & CONTROL,CHEMOPREVENT BRANCH,BETHESDA,MD 20892. NR 0 TC 6 Z9 6 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0090-5542 BN 0-306-44577-8 J9 BASIC LIFE SCI PY 1993 VL 61 BP 373 EP 386 PG 14 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BZ52U UT WOS:A1993BZ52U00035 PM 8304948 ER PT J AU PITHA, J ANAND, R AF PITHA, J ANAND, R TI ALPHA-CYCLODEXTRIN SULFATE, AN ANTI-HIV AGENT, RETAINS ITS ANTIVIRAL EFFECT IN THE PRESENCE OF HYDROCORTISOL PHOSPHATE SO ANTIVIRAL CHEMISTRY & CHEMOTHERAPY LA English DT Note AB Cyclodextrin sulphates alpha (a) and beta (b) were found to be inhibitors of replication of human immunodeficiency virus (HIV-1) in phytohaemagglutinin (PHA)-stimulated human peripheral blood mononuclear cells (PBMC); the same cells were also stimulated to proliferate (Anand et al., 1990). B-Cyclodextrin sulphate was also found to stimulate another, more complex, cell proliferation-neovascularization process in rabbit cornea (Folkman et al., 1989). Since the process of neovascularization is generally associated with progression of tumour growth and other pathologies, it is obvious that its stimulation by an antiviral compound may be a serious side effect. Nevertheless endotoxin-induced neovascularization can be suppressed by simultaneous treatment with b-cyclodextrin sulphate and glucocorticoids (Folkman et al., 1989). The same co-treatment may possibly be used to improve antiviral action of cyclodextrin sulphates, but such a combination therapy may not be free of complications. Glucocorticoids also affect the stability of various cellular membranes. Treatment of cells in vitro by glucocorticoids is known to stabilize their lysozymes. Glucocorticoids affect both the proliferative capacity of the cells (Cristofalo, 1972) and cytopathic effects of rabies viral infection. Furthermore, it has been reported that the cytopathic effects of rabies and of yellow fever viruses were inhibited while those of the polio virus were only mildly affected (Hannoun et al., 1965). Consequently, in this work we evaluated effects of a glucocorticoid and of glucocorticoid-a-cyclodextrin sulphate combination on HIV-1 replication. C1 NIA,GERONTOL RES CTR,BALTIMORE,MD 21224. US FDA,CTR BIOL EVALUAT & RES,RETROVIROL LAB,BETHESDA,MD 20892. NR 4 TC 1 Z9 1 U1 0 U2 2 PU BLACKWELL SCIENCE LTD PI OXFORD PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL SN 0956-3202 J9 ANTIVIR CHEM CHEMOTH JI Antivir. Chem. Chemother. PY 1993 VL 4 IS 1 BP 65 EP 66 PG 2 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology GA KG792 UT WOS:A1993KG79200008 ER PT J AU BEUTLER, JA MCKEE, TC FULLER, RW TISCHLER, M CARDELLINA, JH SNADER, KM MCCLOUD, TG BOYD, MR AF BEUTLER, JA MCKEE, TC FULLER, RW TISCHLER, M CARDELLINA, JH SNADER, KM MCCLOUD, TG BOYD, MR TI FREQUENT OCCURRENCE OF HIV-INHIBITORY SULFATED POLYSACCHARIDES IN MARINE-INVERTEBRATES SO ANTIVIRAL CHEMISTRY & CHEMOTHERAPY LA English DT Article ID HUMAN IMMUNODEFICIENCY VIRUS; SULFATED HOMOPOLYSACCHARIDES; GLYCANS; POTENT; AGENTS; ALGAE AB Aqueous extracts of many marine invertebrates have exhibited some activity in the National Cancer Institute's primary screen for anti-HIV cytopathicity. Using a variety of techniques, including gel permeation, size exclusion and ion exchange chromatography, toluidine blue metachromicity, C-13-NMR spectroscopy and combustion analyses, we have determined that this activity is largely due to sulphated polysaccharides. Because of the wide occurrence of this class of compounds in these organisms we sought a method for the rapid dereplication of sulphated polysaccharides. It was critical that the method selected for dereplication allow differentiation of anionic polysaccharides from other AIDS-antiviral chemotypes. After evaluating a variety of methods, we found that the most efficient strategy appeared to be precipitation of the polysaccharide fraction from aqueous ethanolic solutions of the crude aqueous extracts. C1 NCI,DRUG DISCOVERY RES & DEV LAB,BLDG 1052,RM 121,FREDERICK,MD 21702. NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,NAT PROD BRANCH,FREDERICK,MD 21702. NCI,FREDERICK CANC RES CTR,PROGRAM RESOURCES INC,FREDERICK,MD 21702. RI Beutler, John/B-1141-2009 OI Beutler, John/0000-0002-4646-1924 NR 19 TC 46 Z9 50 U1 0 U2 3 PU BLACKWELL SCIENCE LTD PI OXFORD PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL SN 0956-3202 J9 ANTIVIR CHEM CHEMOTH JI Antivir. Chem. Chemother. PY 1993 VL 4 IS 3 BP 167 EP 172 PG 6 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology GA LB655 UT WOS:A1993LB65500006 ER PT B AU MCKENZIE, R STRAUSS, SE AF MCKENZIE, R STRAUSS, SE BE Mills, J Corey, L TI IMMUNOPROPHYLAXIS AND IMMUNOTHERAPY OF HERPES SIMPLEX VIRUS INFECTIONS SO ANTIVIRAL CHEMOTHERAPY: NEW DIRECTIONS FOR CLINICAL APPLICATIONS AND RESEARCH, VOLUME 3 LA English DT Proceedings Paper CT 3rd Triennial Conference on Antiviral Chemotherapy CY NOV, 1991 CL SAN FRANCISCO, CA RP MCKENZIE, R (reprint author), NIH,CLIN INVEST LAB,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PRENTICE HALL PI ENGLEWOOD CLIFFS PA ENGLEWOOD CLIFFS, NJ 07632 BN 0-13-050717-2 PY 1993 BP 63 EP 82 PG 20 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA BB87Z UT WOS:A1993BB87Z00007 ER PT B AU HADAR, M MCGOWAN, JJ AF HADAR, M MCGOWAN, JJ BE Mills, J Corey, L TI PROMISING DRUGS IN PRECLINICAL DEVELOPMENT FOR THERAPY OF HIV INFECTION SO ANTIVIRAL CHEMOTHERAPY: NEW DIRECTIONS FOR CLINICAL APPLICATIONS AND RESEARCH, VOLUME 3 LA English DT Proceedings Paper CT 3rd Triennial Conference on Antiviral Chemotherapy CY NOV, 1991 CL SAN FRANCISCO, CA RP HADAR, M (reprint author), NIAID,DIV EXTRAMURAL ACTIVITIES,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PRENTICE HALL PI ENGLEWOOD CLIFFS PA ENGLEWOOD CLIFFS, NJ 07632 BN 0-13-050717-2 PY 1993 BP 275 EP 288 PG 14 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA BB87Z UT WOS:A1993BB87Z00024 ER PT B AU NIENHUIS, AW BODINE, DM DONAHUE, R MCDONAGH, KT SORRENTINO, B AF NIENHUIS, AW BODINE, DM DONAHUE, R MCDONAGH, KT SORRENTINO, B BE Thomas, ED TI PROGRESS TOWARD GENE INSERTION INTO HEMATOPOIETIC STEM-CELLS SO APPLICATION OF BASIC SCIENCE TO HEMATOPOIESIS AND TREATMENT OF DISEASE SE BRISTOL-MYERS SQUIBB CANCER SYMPOSIA LA English DT Proceedings Paper CT 15TH BRISTOL-MYERS SQUIBB SYMP ON CANCER RESEARCH : APPLICATION OF BASIC SCIENCE TO HEMATOPOIESIS AND TREATMENT OF DISEASE CY NOV 04-05, 1991 CL SEATTLE, WA SP BRISTOL MYERS SQUIBB RP NIENHUIS, AW (reprint author), NHLBI,CLIN HEMATOL BRANCH,9000 ROCKVILLE PIKE,BLDG 10,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU RAVEN PRESS PI NEW YORK PA NEW YORK BN 0-88167-999-2 J9 BRIS MYER C PY 1993 VL 15 BP 213 EP 229 PG 17 WC Hematology; Pathology; Physiology SC Hematology; Pathology; Physiology GA BY70B UT WOS:A1993BY70B00014 ER PT B AU HAUSER, SE COOKSON, TJ THOMA, GR AF HAUSER, SE COOKSON, TJ THOMA, GR BE Rogers, SK TI USING BACK ERROR PROPAGATION NETWORKS FOR AUTOMATIC DOCUMENT IMAGE CLASSIFICATION SO APPLICATIONS OF ARTIFICIAL NEURAL NETWORKS IV SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT 4th International Conference on Applications of Artificial Neural Networks CY APR 13-16, 1993 CL ORLANDO, FL SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS C1 NATL LIB MED,LISTER HILL NATL CTR BIOMED COMMUN,BETHESDA,MD 20894. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE - INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA PO BOX 10, BELLINGHAM, WA 98227-0010 BN 0-8194-1201-5 J9 P SOC PHOTO-OPT INS PY 1993 VL 1965 BP 142 EP 150 DI 10.1117/12.152534 PG 9 WC Computer Science, Artificial Intelligence; Engineering, Electrical & Electronic; Optics SC Computer Science; Engineering; Optics GA BZ45G UT WOS:A1993BZ45G00010 ER PT B AU HAUSER, SE HSU, W THOMA, GR AF HAUSER, SE HSU, W THOMA, GR BE Rogers, SK TI REQUEST ROUTING WITH A BACK ERROR PROPAGATION NETWORK SO APPLICATIONS OF ARTIFICIAL NEURAL NETWORKS IV SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT 4th International Conference on Applications of Artificial Neural Networks CY APR 13-16, 1993 CL ORLANDO, FL SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS C1 NATL LIB MED,LISTER HILL NATL CTR BIOMED COMMUN,BETHESDA,MD 20894. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE - INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA PO BOX 10, BELLINGHAM, WA 98227-0010 BN 0-8194-1201-5 J9 P SOC PHOTO-OPT INS PY 1993 VL 1965 BP 689 EP 695 DI 10.1117/12.152572 PG 7 WC Computer Science, Artificial Intelligence; Engineering, Electrical & Electronic; Optics SC Computer Science; Engineering; Optics GA BZ45G UT WOS:A1993BZ45G00064 ER PT J AU DINSE, GE PIEGORSCH, WW BOOS, DD AF DINSE, GE PIEGORSCH, WW BOOS, DD TI CONFIDENCE-STATEMENTS ABOUT THE TIME RANGE OVER WHICH SURVIVAL CURVES DIFFER SO APPLIED STATISTICS-JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C LA English DT Article DE ANIMAL EXPERIMENT, CENSORED SURVIVAL DATA; INTERSECTION UNION PRINCIPLE; KAPLAN-MEIER SURVIVAL ESTIMATE; NONPARAMETRIC CONFIDENCE SET; SURVIVAL SACRIFICE STUDY ID LIFE AB Statistical tests can indicate that two groups have different survival experiences without the associated survival curves being stochastically ordered. Often the two survival curves are similar at early times, even though eventually one curve might dominate the other. This paper addresses the problem of making confidence statements about the range of time over which survival curves differ. In particular, the data are subjected to right censoring and we focus on estimating an upper confidence bound for the earliest time at which the survival curves diverge and remain different. C1 N CAROLINA STATE UNIV,RALEIGH,NC 27695. RP DINSE, GE (reprint author), NIEHS,DIV BIOMETRY & RISK ASSESSMENT,MAIL DROP B3-02,POB 12233,RES TRIANGLE PK,NC 27709, USA. NR 5 TC 6 Z9 6 U1 0 U2 0 PU BLACKWELL PUBL LTD PI OXFORD PA 108 COWLEY RD, OXFORD, OXON, ENGLAND OX4 1JF SN 0035-9254 J9 APPL STAT-J ROY ST C JI Appl. Stat.-J. R. Stat. Soc. PY 1993 VL 42 IS 1 BP 21 EP 30 DI 10.2307/2347406 PG 10 WC Statistics & Probability SC Mathematics GA KJ085 UT WOS:A1993KJ08500002 ER PT J AU WAX, Y BAKER, SG PATTERSON, BH AF WAX, Y BAKER, SG PATTERSON, BH TI A SCORE TEST FOR NONINFORMATIVE CENSORING USING DOUBLY SAMPLED GROUPED SURVIVAL-DATA SO APPLIED STATISTICS-JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C LA English DT Article DE INFORMATIVE CENSORING; LOGISTIC MODEL; POSTSURGICAL INFECTION; STRATIFIED ANALYSIS ID PROPORTIONAL HAZARDS MODEL; LIFE AB A closed form Score statistic for testing the assumption of non-informative censoring is proposed for situations in which a random subsample of the censored subjects is followed to determine failure times. The test is derived for grouped survival data under the assumption of a proportional odds model for the hazard rates of censoring. Extensions to a stratified sample are provided. An example is given in which the possible association of discharge time with post-surgical infection rates was investigated by using data from an Israeli study of hernia patients. The test showed that longer hospital stays were associated with higher infection rates. C1 NCI,EXECUT PLAZA N,SUITE 344,BETHESDA,MD 20892. HEBREW UNIV JERUSALEM,JERUSALEM,ISRAEL. NR 25 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL PUBL LTD PI OXFORD PA 108 COWLEY RD, OXFORD, OXON, ENGLAND OX4 1JF SN 0035-9254 J9 APPL STAT-J ROY ST C JI Appl. Stat.-J. R. Stat. Soc. PY 1993 VL 42 IS 1 BP 159 EP 172 DI 10.2307/2347418 PG 14 WC Statistics & Probability SC Mathematics GA KJ085 UT WOS:A1993KJ08500014 ER PT J AU BOOS, DD AF BOOS, DD TI ANALYSIS OF DOSE-RESPONSE DATA IN THE PRESENCE OF EXTRABINOMIAL VARIATION SO APPLIED STATISTICS-JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C LA English DT Article DE EMPIRICAL VARIANCE; GOODNESS OF FIT; LOGISTIC REGRESSION; PROBIT ANALYSIS; SCORE TESTS; TERATOLOGY ID GENERALIZED LINEAR-MODELS; C57BL/6N MICE; REGRESSION; GOODNESS; LITTER; TESTS; FIT AB Binary dose-response data often exhibit extrabinomial variation when the responses arise naturally in groups or litters. This paper investigates the use of generalized Wald and score statistics for robustifying the standard inference methods based on the binomial likelihood. Special attention is given to the probit analysis of a parallel assay of the teratogenic effects on mice of several dioxins. C1 NIEHS,RES TRIANGLE PK,NC 27709. RP BOOS, DD (reprint author), N CAROLINA STATE UNIV,DEPT STAT,RALEIGH,NC 27695, USA. NR 26 TC 8 Z9 8 U1 0 U2 1 PU BLACKWELL PUBL LTD PI OXFORD PA 108 COWLEY RD, OXFORD, OXON, ENGLAND OX4 1JF SN 0035-9254 J9 APPL STAT-J ROY ST C JI Appl. Stat.-J. R. Stat. Soc. PY 1993 VL 42 IS 1 BP 173 EP 183 DI 10.2307/2347419 PG 11 WC Statistics & Probability SC Mathematics GA KJ085 UT WOS:A1993KJ08500015 ER PT J AU WINK, DA OSAWA, Y DARBYSHIRE, JF JONES, CR ESHENAUR, SC NIMS, RW AF WINK, DA OSAWA, Y DARBYSHIRE, JF JONES, CR ESHENAUR, SC NIMS, RW TI INHIBITION OF CYTOCHROMES-P450 BY NITRIC-OXIDE AND A NITRIC OXIDE-RELEASING AGENT SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article ID NITROGEN-DIOXIDE; OXIDATION; REDUCTION; COMPLEXES; CYTOCHROME-P-450; DEALKYLATION; INDUCTION; MECHANISM; PROTEINS; BINDING C1 NCI,FCRDC,PROGRAM RESOURCES INC DYN CORP,FREDERICK,MD 21702. NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892. RP WINK, DA (reprint author), NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,CHEM SECT,FREDERICK,MD 21702, USA. FU ODCDC CDC HHS [N01-CD-74102] NR 44 TC 327 Z9 330 U1 0 U2 7 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD JAN PY 1993 VL 300 IS 1 BP 115 EP 123 DI 10.1006/abbi.1993.1016 PG 9 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA KG984 UT WOS:A1993KG98400016 PM 8424643 ER PT J AU LASSMANN, G CURTIS, J LIERMANN, B MASON, RP ELING, TE AF LASSMANN, G CURTIS, J LIERMANN, B MASON, RP ELING, TE TI ESR STUDIES ON REACTIVITY OF PROTEIN-DERIVED TYROSYL RADICALS FORMED BY PROSTAGLANDIN-H SYNTHASE AND RIBONUCLEOTIDE REDUCTASE SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article ID SPIN RESONANCE-SPECTRUM; HIGHER OXIDATION-STATES; TUMOR-CELLS; BIOLOGICAL CATALYSIS; PEROXIDASE REACTION; SPECTROSCOPY; EPR; HYDROPEROXIDE; ENZYME C1 MAX DELBRUCK CTR MOLEC MED,O-1115 BERLIN,GERMANY. RP LASSMANN, G (reprint author), NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709, USA. NR 25 TC 14 Z9 14 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD JAN PY 1993 VL 300 IS 1 BP 132 EP 136 DI 10.1006/abbi.1993.1018 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA KG984 UT WOS:A1993KG98400018 PM 8380961 ER PT J AU GUNDIMEDA, U HARA, SK ANDERSON, WB GOPALAKRISHNA, R AF GUNDIMEDA, U HARA, SK ANDERSON, WB GOPALAKRISHNA, R TI RETINOIDS INHIBIT THE OXIDATIVE MODIFICATION OF PROTEIN-KINASE-C INDUCED BY OXIDANT TUMOR PROMOTERS SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article ID LIPID-PEROXIDATION; VITAMIN-A; ASCORBIC-ACID; RECEPTOR; BINDING; BRAIN; CELLS; DIFFERENTIATION; TRANSFORMATION; IDENTIFICATION C1 UNIV SO CALIF,SCH MED,DEPT PHARMACOL & NUTR,LOS ANGELES,CA 90033. NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892. FU NCI NIH HHS [CA 47142] NR 35 TC 27 Z9 27 U1 0 U2 1 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD JAN PY 1993 VL 300 IS 1 BP 526 EP 530 DI 10.1006/abbi.1993.1072 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA KG984 UT WOS:A1993KG98400072 PM 8424690 ER PT J AU KRAEMER, KH DIGIOVANNA, JJ PECK, GL AF KRAEMER, KH DIGIOVANNA, JJ PECK, GL TI ISOTRETINOIN DOES PREVENT SKIN-CANCER SO ARCHIVES OF DERMATOLOGY LA English DT Letter ID BASAL-CELL CARCINOMA; XERODERMA-PIGMENTOSUM; ORAL ISOTRETINOIN C1 UNIV MARYLAND,SCH MED,DEPT DERMATOL,BALTIMORE,MD 21201. RP KRAEMER, KH (reprint author), NCI,BETHESDA,MD 20892, USA. NR 7 TC 4 Z9 4 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD JAN PY 1993 VL 129 IS 1 BP 43 EP 43 PG 1 WC Dermatology SC Dermatology GA KH228 UT WOS:A1993KH22800008 PM 8420486 ER PT J AU MANJI, HK HSIAO, JK POTTER, WZ RISBY, ED AF MANJI, HK HSIAO, JK POTTER, WZ RISBY, ED TI LITHIUM TREATMENT INCREASES NOREPINEPHRINE TURNOVER IN THE PLASMA OF HEALTHY-SUBJECTS - REPLY SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Letter RP MANJI, HK (reprint author), NIMH,EXPTL THERAPEUT BRANCH,CLIN PHARMACOL SECT,ROOM 2D46,BLDG 10,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 2 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD JAN PY 1993 VL 50 IS 1 BP 73 EP 73 PG 1 WC Psychiatry SC Psychiatry GA KG777 UT WOS:A1993KG77700014 ER PT J AU SPERDUTO, RD AF SPERDUTO, RD TI ANTIOXIDANT STATUS AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION SO ARCHIVES OF OPHTHALMOLOGY LA English DT Article ID BETA-CAROTENE; MACULOPATHY; HEALTH AB We evaluated the hypothesis that higher serum levels of micronutrients with antioxidant capabilities may be associated with a decreased risk of neovascular age-related macular degeneration by comparing serum levels of carotenoids, vitamins C and E, and selenium in 421 patients with neovascular age-related macular degeneration and 615 controls. Subjects were classified by blood level of the micronutrient (low, medium, and high). Persons with carotenoid levels in the medium and high groups, compared with those in the low group, had markedly reduced risks of neovascular age-related macular degeneration, with levels of risk reduced to one half and one third, respectively. Although no statistically significant protective effect was found for vitamin C or E or selenium individually, an antioxidant index that combined all four micronutrient measurements showed statistically significant reductions of risk with increasing levels of the index. Although these results suggest that higher blood levels of micronutrients with antioxidant potential, in particular, carotenoids, may be associated with a decreased risk of the most visually disabling form of age-related macular degeneration, it would be premature to translate these findings into nutritional recommendations. RP SPERDUTO, RD (reprint author), NEI,BIOMETRY & EPIDEMIOL PROGRAM,BLDG 31,ROOM 6A24,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 25 TC 239 Z9 247 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD JAN PY 1993 VL 111 IS 1 BP 104 EP 109 PG 6 WC Ophthalmology SC Ophthalmology GA KG782 UT WOS:A1993KG78200030 ER PT J AU MUSHEGIAN, AR KOONIN, EV AF MUSHEGIAN, AR KOONIN, EV TI CELL-TO-CELL MOVEMENT OF PLANT-VIRUSES - INSIGHTS FROM AMINO-ACID-SEQUENCE COMPARISONS OF MOVEMENT PROTEINS AND FROM ANALOGIES WITH CELLULAR-TRANSPORT SYSTEMS SO ARCHIVES OF VIROLOGY LA English DT Review ID CAULIFLOWER MOSAIC-VIRUS; STRANDED NUCLEIC-ACIDS; BINDING-PROTEIN; RNA REPLICATION; GENE-I; SPREAD; EXPRESSION; INFECTION; FRACTION; PRODUCT AB Cell-to-cell movement is a crucial step in plant virus infection. In many viruses, the movement function is secured by specific virus-encoded proteins. Amino acid sequence comparisons of these proteins revealed a vast superfamily containing a conserved sequence motif that may comprise a hydrophobic interaction domain. This superfamily combines proteins of viruses belonging to all principal groups of positive-strand RNA viruses, as well as single-stranded DNA containing geminiviruses, double-stranded DNA-containing pararetroviruses (caulimoviruses and badnaviruses), and tospoviruses that have negative-strand RNA genomes with two ambisense segments. In several groups of positive-strand RNA viruses, the movement function is provided by the proteins encoded by the so-called triple gene block including two putative small membrane-associated proteins and a putative RNA helicase. A distinct type of movement proteins with very high content of proline is found in tymoviruses. It is concluded that classification of movement proteins based on comparison of their amino acid sequences does not correlate with the type of genome nucleic acid or with grouping of viruses based on phylogenetic analysis of replicative proteins or with the virus host range. Recombination between unrelated or distantly related viruses could have played a major role in the evolution of the movement function. Limited sequence similarities were observed between i) movement proteins of dianthoviruses and the MIP family of cellular integral membrane proteins, and ii) between movement proteins of bromoviruses and cucumoviruses and M1 protein of influenza viruses which is involved in nuclear export of viral ribonucleoproteins. It is hypothesized that all movement proteins of plant viruses may mediate hydrophobic interactions between viral and cellular macromolecules. C1 NIH,NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20892. RP MUSHEGIAN, AR (reprint author), UNIV KENTUCKY,DEPT PLANT PATHOL,LEXINGTON,KY 40546, USA. OI Mushegian, Arcady/0000-0002-6809-9225 NR 65 TC 106 Z9 111 U1 0 U2 5 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA SN 0304-8608 J9 ARCH VIROL JI Arch. Virol. PY 1993 VL 133 IS 3-4 BP 239 EP 257 DI 10.1007/BF01313766 PG 19 WC Virology SC Virology GA MJ633 UT WOS:A1993MJ63300001 PM 8257287 ER PT J AU KURACHI, R DAIKOKU, T TSURUMI, T MAENO, K NISHIYAMA, Y KURATA, T AF KURACHI, R DAIKOKU, T TSURUMI, T MAENO, K NISHIYAMA, Y KURATA, T TI THE PATHOGENICITY OF A US-3-PROTEIN KINASE-DEFICIENT MUTANT OF HERPES-SIMPLEX VIRUS TYPE-2 IN MICE SO ARCHIVES OF VIROLOGY LA English DT Article ID REPLICATION; NEUROVIRULENCE; CELLS; GENE; NEUROINVASIVENESS; MACROPHAGES; INFECTION; INVIVO; HSV-1 AB We have investigated the pathogenicity of a US 3 protein kinase-deficient mutant (L1 BR1) of herpes simplex virus type 2 (HSV-2) for 4-week-old ICR mice to define the role of the viral protein kinase in virus-host interaction. When mice were intraperitoneally infected with 10(5) PFU of L1 BR1, the virus disappeared from the peritoneal cavity by 2 days postinfection and failed to induce any significant histopathological changes in the liver and spleen although viral antigens were occasionally detected in the epithelial cells of small bile ducts and small vascular wall. The parental virus (HSV-2 186) and a revertant of the mutant (L1 B- 11) both caused severe hepatitis, and viral antigens were clearly detected in the hepatocytes and Kupffer cells in the focal necrotic areas. Both of the virulent viruses, unlike L1 BR1, could produce infectious progeny and cytopathic effects in freshly harvested peritoneal macrophages. The growth of L1 BR1 in peritoneal macrophages was restricted at a stage of or prior to viral DNA synthesis but after the induction of viral DNA polymerase. In addition, the production and/or the spread of the mutant in mouse embryo fibroblasts (MEF) was found to be much more effectively suppressed by cocultivation of peritoneal macrophages than that of 186. An almost complete inhibition of L1 BR1-plaque formation was observed at a macrophage-to-MEF ratio of 4:1. These results suggest that the attenuation of L1 BR1 following intraperitoneal infection is primarily due to its high sensitivity to intrinsic and extrinsic inhibition of peritoneal macrophages and that the US 3 protein kinase may play a role in viral DNA replication in peritoneal macrophages. C1 NAGOYA UNIV,SCH MED,DIS MECH & CONTROL RES INST,VIROL LAB,NAGOYA,AICHI 466,JAPAN. NIH,DEPT PATHOL,BETHESDA,MD 20892. NR 24 TC 41 Z9 41 U1 0 U2 0 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA SN 0304-8608 J9 ARCH VIROL JI Arch. Virol. PY 1993 VL 133 IS 3-4 BP 259 EP 273 DI 10.1007/BF01313767 PG 15 WC Virology SC Virology GA MJ633 UT WOS:A1993MJ63300002 PM 8257288 ER PT J AU RASOOL, NBG LARRALDE, G GORZIGLIA, MI AF RASOOL, NBG LARRALDE, G GORZIGLIA, MI TI DETERMINATION OF HUMAN ROTAVIRUS VP4 USING SEROTYPE-SPECIFIC CDNA PROBES SO ARCHIVES OF VIROLOGY LA English DT Article ID POLYMERASE CHAIN-REACTION; SUBGROUP-I SPECIFICITY; AMINO-ACID-SEQUENCE; NEUTRALIZATION EPITOPES; NUCLEOTIDE-SEQUENCE; UNIQUE VP4; IDENTIFICATION; GENE; INFECTIVITY AB The VP4 genetic groups of 151 field strains of human rotaviruses obtained from infants and young children with diarrhea from four locations in Malaysia were analyzed. The strains were adapted to growth in tissue culture and studied further by molecular hybridization of northern blotted RNA to PCR-generated cDNA probes representing amino acids 84-180 of the KU strain VP4, 83-181 of the DS-1 strain VP4, and 83-180 of either the 1076 or K8 strain VP4, representing VP4 genetic groups 1-4 (P1A, P1B, P2, and P3), respectively. The majority (79% of the field strains hybridized with the KU VP4 genetic group 1 probe and were associated with G1, G3, G4, untypable, or mixed G serotypes. VP4 genetic group 1 (P1A) strains were the most common in all locations in Malaysia between 1978-1988. Three strains which exhibited G3 and subgroup I specificity hybridized with the K8 VP4 genetic group 4 probe. These three VP4 genetic group 4 (P3) strains were detected in two different years and locations, extending the initial detection of this VP4 genetic group (the K8 strain) in Japan to a larger geographical area of Asia. C1 NIAID,INFECT DIS LAB,EPIDEMIOL SECT,BETHESDA,MD 20892. CENT UNIV VENEZUELA,NEUROCHIM SECT,CARACAS,VENEZUELA. UNIV MALAYA,DEPT GENET & CELLULAR BIOL,KUALA LUMPUR 2211,MALAYSIA. NR 23 TC 21 Z9 21 U1 0 U2 2 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA SN 0304-8608 J9 ARCH VIROL JI Arch. Virol. PY 1993 VL 133 IS 3-4 BP 275 EP 282 DI 10.1007/BF01313768 PG 8 WC Virology SC Virology GA MJ633 UT WOS:A1993MJ63300003 PM 8257289 ER PT J AU SANDERS, RC WAIIN, PM ALEXANDER, SS LEVIN, AG BLATTNER, WA ALPERS, MP AF SANDERS, RC WAIIN, PM ALEXANDER, SS LEVIN, AG BLATTNER, WA ALPERS, MP TI THE PREVALENCE OF ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN DIFFERENT POPULATION GROUPS IN PAPUA-NEW-GUINEA SO ARCHIVES OF VIROLOGY LA English DT Article ID EAST-SEPIK PROVINCE; CELL LEUKEMIA; HTLV-I; SOLOMON-ISLANDS; INFECTION; MEMBER AB Isolation and partial sequencing of human T-lymphotropic virus type I (HTLV-I) variants from inhabitants of Papua New Guinea (PNG) and the Solomon Islands has confirmed the existence of virus infection in Melanesian populations. To determine the geographical distribution of seropositivity to HTLV-1 in PNG we have tested 2907 serum and plasma samples collected between 1972 to 1991 from 16 different population groups. Samples were screened using a particle agglutination assay and confirmed by p21e-enhanced Western immunoblot (WB). From a total of 94 screen positive samples run on WB, 56 (60%) were confirmed positive (positive for both env and gag products) and 38 (40%) were WB-indeterminate (gag products only). The prevalence of WB-confirmed antibodies to HTLV-1 in lowland and island populations ranged from 0 to 5.4%. There were no confirmed antibody positives in the highland populations surveyed. Geographically isolated populations living on the fringes of the highlands ranged in seropositivity from 0.2 to 5.8%. Two of the subjects surveyed gave WB antibody patterns characteristic of HTLV-II rather than HTLV-1 infection. C1 BIOTECH RES LABS INC,ROCKVILLE,MD. CLIN RES CTR,RES TRIANGLE INST UNIT,HARROW HA1 3UJ,MIDDX,ENGLAND. NCI,BETHESDA,MD 20892. RP SANDERS, RC (reprint author), PAPUA NEW GUINEA INST MED RES,POB 60,GOROKA,PAPUA N GUINEA. FU NCI NIH HHS [N01-CP-85603] NR 18 TC 6 Z9 6 U1 0 U2 0 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA SN 0304-8608 J9 ARCH VIROL JI Arch. Virol. PY 1993 VL 130 IS 3-4 BP 327 EP 334 DI 10.1007/BF01309664 PG 8 WC Virology SC Virology GA LK029 UT WOS:A1993LK02900009 PM 8517792 ER PT J AU TANG, Y HUGIN, AW HARTLEY, JW FREDRICKSON, TN MORSE, HC CHATTOPADHYAY, SK AF TANG, Y HUGIN, AW HARTLEY, JW FREDRICKSON, TN MORSE, HC CHATTOPADHYAY, SK TI EFFECTS OF IMMUNIZATION WITH THE P12 PROTEINS OF LP-BM5 DEFECTIVE AND ECOTROPIC VIRUSES ON DEVELOPMENT OF MAIDS SO ARCHIVES OF VIROLOGY LA English DT Article ID INDUCED IMMUNODEFICIENCY SYNDROME; MURINE LEUKEMIA VIRUSES; C57BL/6 MICE; RETROVIRUS; PURIFICATION; INDUCTION; LYMPHOMAS; DISEASE; STRAINS; CELLS AB Among murine leukemia viruses (MuLV) present in the LP-BM5 virus mixture, the agent etiologic for an acquired immunodeficiency syndrome (MAIDS) is replication defective, containing only a single open reading frame which includes all of gag. The Gag polyprotein encoded by the defective virus, termed BM5def, differs most in p12 from that of nonpathogenic ecotropic virus (BM5eco). As one approach to examining the role of p12 in disease, the ecotropic and defective virus forms of the protein, synthesized in bacteria, were used to immunize three strains of mice differing in their sensitivity to MAIDS. In each strain, both proteins elicited substantial antibody responses that were cross-reactive with either p12 and recognized the proteins as part of intact viral Gag polyproteins. Immunization with either p12 before infection with LP-BM5 viruses had no effect on the sensitivity or resistance of mice to MAIDS or on the extent of helper virus spread. The variant p12 of BM5def, when presented on its own, is thus not a crucial antigenic determinant of disease. Alternative mechanisms by which BM5def may contribute to MAIDS are discussed. C1 NIAID,IMMUNOPATHOL LAB,BETHESDA,MD 20892. NCI,EXPTL PATHOL LAB,BETHESDA,MD 20892. OI Morse, Herbert/0000-0002-9331-3705 FU NIAID NIH HHS [N01-AI-72622] NR 24 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA SN 0304-8608 J9 ARCH VIROL JI Arch. Virol. PY 1993 VL 129 IS 1-4 BP 155 EP 166 DI 10.1007/BF01316892 PG 12 WC Virology SC Virology GA KT986 UT WOS:A1993KT98600013 PM 8385912 ER PT J AU ABLASHI, D AGUT, H BERNEMAN, Z CAMPADELLIFIUME, G CARRIGAN, D CECCERININELLI, L CHANDRAN, B CHOU, S COLLANDRE, H CONE, R DAMBAUGH, T DEWHURST, S DILUCA, D FOATOMASI, L FLECKENSTEIN, B FRENKEL, N GALLO, R GOMPELS, U HALL, C JONES, M LAWRENCE, G MARTIN, M MONTAGNIER, L NEIPEL, F NICHOLAS, J PELLETT, P RAZZAQUE, A TORRELLI, G THOMSON, B SALAHUDDIN, S WYATT, L YAMANISHI, K AF ABLASHI, D AGUT, H BERNEMAN, Z CAMPADELLIFIUME, G CARRIGAN, D CECCERININELLI, L CHANDRAN, B CHOU, S COLLANDRE, H CONE, R DAMBAUGH, T DEWHURST, S DILUCA, D FOATOMASI, L FLECKENSTEIN, B FRENKEL, N GALLO, R GOMPELS, U HALL, C JONES, M LAWRENCE, G MARTIN, M MONTAGNIER, L NEIPEL, F NICHOLAS, J PELLETT, P RAZZAQUE, A TORRELLI, G THOMSON, B SALAHUDDIN, S WYATT, L YAMANISHI, K TI HUMAN HERPESVIRUS-6 STRAIN GROUPS - A NOMENCLATURE SO ARCHIVES OF VIROLOGY LA English DT Editorial Material C1 NCI,BETHESDA,MD 20892. HOP LA PITIE SALPETRIERE,PARIS,FRANCE. CHILDRENS HOSP,SEATTLE,WA. DUPONT MERCK PHARMACEUT CO,WILMINGTON,PA. IST MICROBIOL,FERRARA,ITALY. MAQUARIE UNIV,SYDNEY,NSW,AUSTRALIA. UNIV PISA,I-56100 PISA,ITALY. VET ADM MED CTR,PORTLAND,OR 97207. TEL AVIV UNIV,IL-69978 TEL AVIV,ISRAEL. JOHNS HOPKINS UNIV,BALTIMORE,MD 21218. US FDA,BETHESDA,MD 20014. NIH,BETHESDA,MD 20892. UNIV BOLOGNA,I-40126 BOLOGNA,ITALY. UNIV KANSAS,LAWRENCE,KS 66045. UNIV ROCHESTER,ROCHESTER,NY 14627. UNIV CAMBRIDGE,CAMBRIDGE,ENGLAND. CTR DIS CONTROL,DIV VIRAL & RICKETTSIAL DIS,VIRAL EXANTHEMS & HERPESVIRUS BRANCH,ATLANTA,GA 30333. UNIV MODENA,I-41100 MODENA,ITALY. OSAKA UNIV,OSAKA,JAPAN. MED COLL WISCONSIN,MILWAUKEE,WI 53226. INST PASTEUR,F-75724 PARIS 15,FRANCE. UNIV ERLANGEN NURNBERG,W-8520 ERLANGEN,GERMANY. HAMMERSMITH HOSP,LONDON W12 0HS,ENGLAND. NATL INST MED RES,LONDON NW7 1AA,ENGLAND. UNIV SO CALIF,LOS ANGELES,CA 90089. RI Di Luca, Dario/M-9781-2014 OI Di Luca, Dario/0000-0001-9643-9170 NR 18 TC 143 Z9 145 U1 1 U2 4 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA SN 0304-8608 J9 ARCH VIROL JI Arch. Virol. PY 1993 VL 129 IS 1-4 BP 363 EP 366 DI 10.1007/BF01316913 PG 4 WC Virology SC Virology GA KT986 UT WOS:A1993KT98600034 ER PT J AU CRISMAN, JM JACKWOOD, RJ LANA, DP JACKWOOD, DJ AF CRISMAN, JM JACKWOOD, RJ LANA, DP JACKWOOD, DJ TI EVALUATION OF VP-2 EPITOPES OF INFECTIOUS BURSAL DISEASE VIRUS USING INVITRO EXPRESSION AND RADIOIMMUNOPRECIPITATION SO ARCHIVES OF VIROLOGY LA English DT Article ID ESCHERICHIA-COLI; 2 SEROTYPES; PLASMID DNA; SEGMENT-A; RNA; BIRNAVIRUS; ANTIBODIES; CHICKENS; ANTIGENS; TURKEYS AB A clone (pV 17-7) spanning a portion of the VP 2 gene of infectious bursal disease virus (IBDV) was selected from a cDNA library produced using the variant A virus strain. This clone was expressed in vitro and the protein products were immunoprecipitated with various virus-neutralizing antisera made against 6 different strains of IBDV. The antisera made against 4 variant strains immunoprecipitated the translation products from the pV 17-7 clone, but the antisera to the classic STC virus and the serotype 2 OH virus did not immunoprecipitate the pV 17-7 translation products. C1 OHIO STATE UNIV,OHIO AGR RES & DEV CTR,DEPT VET PREVENT MED,FOOD ANIM HLTH RES PROGRAM,WOOSTER,OH 44691. NCI,FREDERICK CANC RES FACIL,FREDERICK,MD 21701. RI Jackwood, Daral/B-8948-2013 NR 38 TC 9 Z9 9 U1 0 U2 0 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA SN 0304-8608 J9 ARCH VIROL JI Arch. Virol. PY 1993 VL 128 IS 3-4 BP 333 EP 344 DI 10.1007/BF01309443 PG 12 WC Virology SC Virology GA KK740 UT WOS:A1993KK74000010 PM 7679573 ER PT J AU BUYON, JP YARON, M LOCKSHIN, MD AF BUYON, JP YARON, M LOCKSHIN, MD TI 1ST INTERNATIONAL-CONFERENCE ON RHEUMATIC DISEASES IN PREGNANCY SO ARTHRITIS AND RHEUMATISM LA English DT Article C1 NIAMSD,BLDG 31,ROOM 4C-32,BETHESDA,MD 20892. TEL AVIV UNIV,SCH MED,IL-69978 TEL AVIV,ISRAEL. NR 0 TC 14 Z9 15 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD JAN PY 1993 VL 36 IS 1 BP 59 EP 64 DI 10.1002/art.1780360110 PG 6 WC Rheumatology SC Rheumatology GA KK746 UT WOS:A1993KK74600009 PM 8424837 ER PT B AU SEDER, RA AF SEDER, RA BE Holgate, ST Austen, KF Lichtenstein, LM Kay, AB TI CYTOKINE PRODUCTION BY FC epsilon R+ CELLS SO ASTHMA: PHYSIOLOGY, IMMUNOPHARMACOLOGY, AND TREATMENT LA English DT Proceedings Paper CT 4th International Conference on Asthma CY SEP 15-18, 1992 CL SOUTHAMPTON, BERMUDA C1 NIAID,IMMUNOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS LTD PI LONDON PA 24-28 OVAL ROAD, LONDON, ENGLAND NW1 7DX BN 0-12-352330-3 PY 1993 BP 187 EP 196 PG 10 WC Respiratory System SC Respiratory System GA BC59H UT WOS:A1993BC59H00015 ER PT J AU CLASSEN, JB SHEVACH, EM AF CLASSEN, JB SHEVACH, EM TI POST-THYMECTOMY ORGAN-SPECIFIC AUTOIMMUNITY - ENHANCEMENT BY CYCLOSPORINE-A AND INHIBITION BY IL-2 SO AUTOIMMUNITY LA English DT Article DE GASTRITIS; DIABETES; IL-2; THYMECTOMY; CYCLOSPORINE-A AB It has previously been shown that the administration of cyclosporine A to newborn mice results in the development of autoimmunity later in life. It has been proposed that the neonatal administration of cyclosporine A results in altered thymic selection or inhibition of the development of suppressor cells. In the present study, treatment of day 3 thymectomized C3H/HeN mice with cyclosporine A (20 mg/kg/day) for 9 d post surgery increased the prevalence of antigastric autoantibodies. In contrast, the administration of IL-2 (300-600 Units/g/day) for 7 days after thymectomy inhibited the development of antigastric antibodies. We hypothesize that CsA may act by causing transient lymphokine abnormalities in the extrathymic environment during the first few weeks of life which lead to the development of antigastric antibodies. In contrast to the inhibition of development of antigastric antibodies, the administration of a similar course of IL-2 produced only a transient suppression of diabetes in NOD mice. These results and other data suggest that diabetes in NOD mice is probably due to a different immunologic defect. C1 NIAID,IMMUNOL LAB,BLG 10,RM 11N315,BETHESDA,MD 20892. NR 0 TC 11 Z9 11 U1 0 U2 0 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 0891-6934 J9 AUTOIMMUNITY JI Autoimmunity PY 1993 VL 15 IS 1 BP 55 EP 59 DI 10.3109/08916939309004839 PG 5 WC Immunology SC Immunology GA LR716 UT WOS:A1993LR71600007 PM 8218831 ER PT J AU LAKATTA, EG AF LAKATTA, EG TI MYOCARDIAL ADAPTATIONS IN ADVANCED AGE SO BASIC RESEARCH IN CARDIOLOGY LA English DT Article; Proceedings Paper CT Vth Symposium of the International-Institute-for-Theoretical-Cardiology ( IIFTC ) CY SEP 14-16, 1990 CL KARL FRANZENS UNIV GRAZ, GRAZ, AUSTRIA HO KARL FRANZENS UNIV GRAZ DE AGING; ARTERIAL STIFFENING; CATECHOLAMINES; CALCIUM; EXCITATION-CONTRACTION COUPLING; HYPERTENSION ID SARCOPLASMIC-RETICULUM; ELECTRICAL PERFORMANCE; MESSENGER-RNA; RAT-HEART; HYPERTENSION; CA-2+-ATPASE; EXPRESSION; YOUNG; GENES AB Arterial stiffening and an increase in arterial pressure, particularly systolic, occur with advancing age in humans. The heart manifests left ventricular wall thickening and myocardial cell enlargement, which may be adaptations to these arterial changes. At the cellular level, studies in animal models indicate that the excitation-contraction coupling cycle is prolonged with aging. Specifically, a prolonged cystolic calcium transient enables prolonged force bearing capacity, an adaption permitting normal ejection of blood by the older heart into a stiff arterial tree. The changes in cellular Ca2+ cycling are regulated, in part at least, at the transcriptional level. Specifically, the density of Ca2+ pump sites of the sarcoplasmic reticulum is reduced, due to a down regulation of the gene coding for the sarcoplasmic reticulum Ca2+ pump, resulting in slower Ca2+ removal from the cytosole following excitation. During stress, a diminution in the increased heart rate and myocardial contractility occurs in healthy older humans, due in large measure to a postsynaptic reduction in the efficacy of beta adrenergic stimulation. At the cellular level in animal models, this is manifest by a relative failure of beta 1 adrenergic receptor stimulation to augment Ca2+ influx via L-type sarcolemmal Ca2+ channels and to augment the amplitude of the cytosolic Ca2+ transient. However, in situ a cardiac adaptation, i.e., cardiac dilatation, occurs during stress and maintains the stroke volume of the older heart. The above cardiovascular adaptations that occur in older healthy humans and animals occur at a younger age in the presence of chronic pressure overload. RP LAKATTA, EG (reprint author), NIA,GERONTOL RES CTR,BEHAV SCI LAB,BALTIMORE,MD 21224, USA. NR 19 TC 19 Z9 20 U1 0 U2 1 PU DR DIETRICH STEINKOPFF VERLAG PI BERLIN 33 PA C/O SPRINGER-VERLAG, HEIDELBERGER PLATZ 3, 1000 BERLIN 33, GERMANY SN 0300-8428 J9 BASIC RES CARDIOL JI Basic Res. Cardiol. PY 1993 VL 88 SU 2 BP 125 EP 133 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA MN674 UT WOS:A1993MN67400014 PM 8147829 ER PT S AU NUSSENBLATT, RB DESMET, MD WEINER, HL GERY, I AF NUSSENBLATT, RB DESMET, MD WEINER, HL GERY, I BE Wechsler, B Godeau, P TI THE TREATMENT OF THE OCULAR COMPLICATIONS OF BEHCETS-DISEASE WITH ORAL TOLERIZATION SO BEHCETS DISEASE SE INTERNATIONAL CONGRESS SERIES LA English DT Proceedings Paper CT 6th International Conference on Bechcets Disease CY JUN 30-JUL 01, 1993 CL PARIS, FRANCE RP NUSSENBLATT, RB (reprint author), NEI,IMMUNOL LAB,BLDG 10,RM 10N202,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0531-5131 BN 0-444-81615-1 J9 INT CONGR SER PY 1993 VL 1037 BP 641 EP 646 PG 6 WC Dermatology; Medicine, General & Internal; Respiratory System; Rheumatology SC Dermatology; General & Internal Medicine; Respiratory System; Rheumatology GA BZ91R UT WOS:A1993BZ91R00136 ER PT J AU ROSOLEN, A KYLE, E CHAVANY, C BERGAN, R KALMAN, ET CROUCH, R NECKERS, L AF ROSOLEN, A KYLE, E CHAVANY, C BERGAN, R KALMAN, ET CROUCH, R NECKERS, L TI EFFECT OF OVER-EXPRESSION OF BACTERIAL RIBONUCLEASE-H ON THE UTILITY OF ANTISENSE MYC OLIGODEOXYNUCLEOTIDES IN THE MONOCYTIC LEUKEMIA-CELL LINE-U937 SO BIOCHIMIE LA English DT Article DE RNASE-H; ANTISENSE OLIGONUCLEOTIDES; MYC ID RNASE-H; OLIGONUCLEOTIDES; DEGRADATION AB RNase H has been clearly implicated in vitro in mediating some antisense effects. In vivo evidence is limited to experiments performed in Xenopus oocytes in which antisense oligonucleotides are microinjected. In other mammalian cell systems scant data have been obtained to support or deny a role for RNase H as an antisense mediator in vivo. These experiments were designed to test the hypothesis that RNase H mediates the MYC antisense-induced reduction in MYC protein observed in the human monocytic leukemia cell line U937. A bacterial RNase H-containing episomal replicon was constructed and stable transfectants were obtained which expressed E coli RNase H in their cytoplasm at a 10-fold higher level than endogenous RNase H. These cells failed to demonstrate hightened sensitivity to MYC antisense (phosphorothioate, end capped and phosphodiester) compared with untransfected or E coli RNase H antisense transfected cells. PCR analysis of each transfectant treated and untreated with MYC antisense failed to demonstrate the appearance of truncated MYC mRNA. These results do not support a role for RNase H in the mediation of MYC antisense-induced MYC protein reduction and growth inhibition in U937 cells. C1 NCI,CLIN PHARMACOL BRANCH,BETHESDA,MD 20892. NICHHD,MOLEC GENET LAB,BETHESDA,MD. NR 14 TC 14 Z9 14 U1 1 U2 1 PU EDITIONS SCIENTIFIQUES ELSEVIER PI PARIS CEDEX 15 PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE SN 0300-9084 J9 BIOCHIMIE JI Biochimie PY 1993 VL 75 IS 1-2 BP 79 EP 87 DI 10.1016/0300-9084(93)90028-Q PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA KX036 UT WOS:A1993KX03600012 PM 8389212 ER PT J AU ENNIS, DG CROUCH, RJ AF ENNIS, DG CROUCH, RJ TI ANALYSIS OF MUTAGENESIS INDUCED BY EXPRESSION OF RETROVIRAL REVERSE-TRANSCRIPTASE IN ESCHERICHIA-COLI SO BIOCHIMIE LA English DT Article DE HIV; MULV; REPLICATION; REPAIR ID RNASE-H; INVIVO; MUTATIONS; DEFICIENT; PROTEINS; CLONING; PLASMID; RECA; RNH AB We showed that expression of reverse transcriptase from HIV or MuLV resulted in exceptionally high levels of mutagenesis in E coli. We observed high rates of mutagenesis in plasmid genes when reverse transcriptase was expressed off that plasmid. Although very high rates were observed in cis, our experiments could not detect mutagenic events in markers in other replicons (ie in trans). These results suggest mutagenic events occur preferentially on the same replicon in which the reverse transcriptase is encoded. RP ENNIS, DG (reprint author), NICHHD,MOLEC GENET LAB,BLDG 6B,ROOM 2B-231,BETHESDA,MD 20892, USA. NR 23 TC 0 Z9 0 U1 0 U2 0 PU EDITIONS SCIENTIFIQUES ELSEVIER PI PARIS CEDEX 15 PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE SN 0300-9084 J9 BIOCHIMIE JI Biochimie PY 1993 VL 75 IS 1-2 BP 101 EP 105 DI 10.1016/0300-9084(93)90030-V PG 5 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA KX036 UT WOS:A1993KX03600014 PM 7684931 ER PT J AU CERRITELLI, SM SHIN, DY CHEN, HC GONZALES, M CROUCH, RJ AF CERRITELLI, SM SHIN, DY CHEN, HC GONZALES, M CROUCH, RJ TI PROTEOLYSIS OF SACCHAROMYCES-CEREVISIAE RNASE-H1 IN ESCHERICHIA-COLI SO BIOCHIMIE LA English DT Article ID ESCHERICHIA-COLI; RIBONUCLEASE-H; RNA-POLYMERASE; GENES; EXPRESSION; CLONING; MUTANT AB Expression of S cerevisiae RNase H1 in E coli leads to the formation of a proteolytic product with a molecular mass of 30 kDa that is derived from the 39-kDa full length protein. The 30-kDa form retains RNase H1 activity, as determined by renaturation gel assay. The amount of proteolysis observed depends on the procedure used in preparing the cell extracts for protein analysis. The cleavage site on the amino acid sequence of the 39-kDa RNase H1 was determined by N-terminal sequence analysis of the 30-kDa proteolytic form. The cut occurs between two arginines located at the amino terminus region of the protein. The pattern of proteolysis was examined for both the wild-type RNase H1 and a mutant RNase H1 that was constructed in this work. In the mutant the second arginine of the cleavage site was changed to a lysine. Comparisons of the expression of the wild-type and altered protein in two different E coli strains demonstrate that the protease responsible for the degradation has a specificity very similar to that of the OmpT protease. However, the proteolysis observed in an OmpT background in extracts, prepared by boiling the cells in SDS containing buffer, indicates that the protease may, unlike OH108. C1 NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892. NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892. NR 14 TC 8 Z9 8 U1 0 U2 0 PU EDITIONS SCIENTIFIQUES ELSEVIER PI PARIS CEDEX 15 PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE SN 0300-9084 J9 BIOCHIMIE JI Biochimie PY 1993 VL 75 IS 1-2 BP 107 EP 111 DI 10.1016/0300-9084(93)90031-M PG 5 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA KX036 UT WOS:A1993KX03600015 PM 8389209 ER PT J AU SPENCE, C NACHMAN, M GATELY, MK KREITMAN, RJ PASTAN, I BAILON, P AF SPENCE, C NACHMAN, M GATELY, MK KREITMAN, RJ PASTAN, I BAILON, P TI AFFINITY PURIFICATION AND CHARACTERIZATION OF ANTI-TAC(FV)-C3-PE38KDEL - A HIGHLY POTENT CYTOTOXIC AGENT SPECIFIC TO CELLS BEARING IL-2 RECEPTORS SO BIOCONJUGATE CHEMISTRY LA English DT Article ID PSEUDOMONAS EXOTOXIN; IL-2-PE40 AB A chimeric, single chain antibody fused immunotoxin, denoted anti-Tac(Fv)-C3-PE38KDEL, was engineered and expressed in Escherichia coli. The microbially expressed anti-Tac(Fv)-C3-PE38KDEL was solubilized from inclusion bodies using guanidine hydrochloride, and subsequently refolded in a redox buffer via thiol/disulfide exchange. The recombinant immunotoxin from the crude extract was purified employing receptor-affinity chromatography, which is based upon biological function and involved the immobilized p55 subunit of human IL-2 receptor. The cytotoxic activity of this immunotoxin was measured by the IL-2 dependent phytohemagglutinin (PHA) blast proliferation inhibition and HUT-102 protein synthesis inhibition assays, in which the IC50 values were 41.5 and 0.8 pM, respectively. The biochemical homogeneity and authenticity of the purified material were determined by gel permeation chromatography, amino acid composition and N-terminal sequence analyses, SDS-PAGE, isoelectric focusing, and Western blotting. The receptor-affinity-purified immunotoxin was shown to be highly effective in specifically killing cells bearing IL-2 receptors. Anti-Tac(Fv)-C3-PE38KDEL is a powerful immunosuppressant which may be a potentially useful therapeutic agent in the prevention of allograft rejection and in the treatment of autoimmune diseases. Another anticipated application of this fusion protein is as a chemotoxin in the treatment of some forms of cancer. C1 HOFFMANN LA ROCHE INC,DEPT PROT BIOCHEM,NUTLEY,NJ 07110. HOFFMANN LA ROCHE INC,DEPT IMMUNOPHARMACOL,NUTLEY,NJ 07110. NIH,MOLEC BIOL LAB,BETHESDA,MD 20892. NR 22 TC 7 Z9 7 U1 0 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD JAN-FEB PY 1993 VL 4 IS 1 BP 63 EP 68 DI 10.1021/bc00019a009 PG 6 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA KK599 UT WOS:A1993KK59900009 PM 8431514 ER PT J AU GOLDSTEIN, DS GROSSMAN, E ARMANDO, I WOLFOVITZ, E FOLIO, CJ HOLMES, C KEISER, HR AF GOLDSTEIN, DS GROSSMAN, E ARMANDO, I WOLFOVITZ, E FOLIO, CJ HOLMES, C KEISER, HR TI CORRELATES OF URINARY-EXCRETION OF CATECHOLS IN HUMANS SO BIOGENIC AMINES LA English DT Article DE NOREPINEPHRINE; SODIUM; DIHYDROXYPHENYLGLYCOL; DIHYDROXYPHENYLACETIC ACID ID SYMPATHETIC-NERVE ACTIVITY; PLASMA DOPA; SODIUM-EXCRETION; SALT INTAKE; NOREPINEPHRINE; HYPERTENSION; RATS; 3,4-DIHYDROXYPHENYLALANINE; DIHYDROXYPHENYLALANINE; METABOLITES AB An endogenous system involving renal uptake of dihydroxyphenylalanine (DOPA) and conversion to the natriuretic catecholamine, dopamine (DA), may participate in sodium homeostasis. Normal values for and correlates of urinary excretion of free (unconjugated) catechols in humans are incompletely understood. Daily excretion rates of DOPA, DA, the DA metabolite dihydroxyphenylacetic acid (DOPAC), the sympathetic neurotransmitter norepinephrine (NE), the NE metabolite dihydroxyphenylglycol (DHPG), and the adrenomedullary hormone epinephrine (EPI) were measured in 70 American normotensive volunteers of different ages, sex, and race, and 35 Israeli Caucasian males in their sixth decade, with no dietary or activity restrictions. In both groups, the excretion rate of DOPAC (overall mean 12.53 +/- 1.08 (SEM) mu moles/day) exceeded by far those of all other catechols combined. Catechol excretion rates were positively inter-correlated in both subject groups-especially DA with DOPA (r=0.71 across all subjects, p<0.001). Excretion rates of catechols were also positively correlated with the excretion rate of sodium in both groups (for DOPA r=0.70 across all subjects, p<0.001; for DA r-0.54, p<0.001; for DOPAC r=0.46, p<0.001; for NE r=0.47, p<0.001; and for EPI r=0.29, p<0.01), but not with urine volume. DA and DOPA excretion rates were higher in Black Americans than in Caucasian Americans (2.50 +/- (SEM) 0.19 vs 1.86 +/- 0.10 mu moles/d, p<0.01; 0.21 +/- 0.02 vs 0.16 +/- 0.01 mu moles/d, p<0.01); DA excretion decreased with increasing subject age (r=-0.24); and excretion rates of DOPA were negatively correlated with MAP (r=0.33, p<0.01). The high rate of urinary excretion of DOPAC probably mainly reflects glomerular filtration or tubular secretion of plasma DOPAC. The multiple positive correlations among excretion rates of catechols indicate a common source, such as coupled synthesis and turnover of catecholamines in the sympathoadrenal system. Positive correlations of excretion rates of DOPA, DA, and DOPAC with ad libitum dietary salt intake are consistent with salt-induced activation of a renal DOPA-DA natriuretic system. C1 CHAIM SHEBA MED CTR,HYPERTENS UNIT,TEL HASHOMER,ISRAEL. NHLBI,HYPERTENS ENDOCRINE BRANCH,BETHESDA,MD 20892. RP GOLDSTEIN, DS (reprint author), NINCDS,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892, USA. NR 53 TC 54 Z9 54 U1 0 U2 0 PU VSP BV PI ZEIST PA PO BOX 346, 3700 AH ZEIST, NETHERLANDS SN 0168-8561 J9 BIOGENIC AMINES JI Biog. Amines PY 1993 VL 10 IS 1 BP 3 EP 17 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA MN821 UT WOS:A1993MN82100002 ER PT J AU INOUE, K CREVELING, CR AF INOUE, K CREVELING, CR TI THE MACROPHAGE AS A SITE OF EXTRANEURONAL UPTAKE AND O-METHYLATION OF NOREPINEPHRINE SO BIOGENIC AMINES LA English DT Article DE MACROPHAGE; LYMPH NODE; CATECHOL-O-METHYLTRANSFERASE; NOREPINEPHRINE, UPTAKE ID RAT; METHYLTRANSFERASE; LOCALIZATION AB Macrophages present in cervical lymph nodes are shown to be the cellular site of both the extraneuronal uptake of norepinephrine (NE) and catechol-O-methyltransferase (COMT). The localization of COMT was determined by immunocytochemical methods showing COMT-specific immunoreactive deposits in macrophages. The extraneuronal site of NE uptake was determined by histochemical fluorescence. A pronounced granular green fluorescence was present in the cytoplasm of macrophages following NE uptake. Our results suggest that macrophages may provide a model system for the study of both the extraneuronal transport and O-methylation of NE. C1 NIDDK,BIOORGAN CHEM LAB,BETHESDA,MD 20892. RP INOUE, K (reprint author), MATSUMOTO DENT COLL,INST DENT SCI,SHIOJIRI 39907,JAPAN. NR 17 TC 6 Z9 6 U1 0 U2 0 PU VSP BV PI ZEIST PA PO BOX 346, 3700 AH ZEIST, NETHERLANDS SN 0168-8561 J9 BIOGENIC AMINES JI Biog. Amines PY 1993 VL 9 IS 4 BP 291 EP 294 PG 4 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA LC540 UT WOS:A1993LC54000005 ER PT J AU VICCHIO, D YERGEY, A OBRIEN, K ALLEN, L RAY, R HOLICK, M AF VICCHIO, D YERGEY, A OBRIEN, K ALLEN, L RAY, R HOLICK, M TI QUANTIFICATION AND KINETICS OF 25-HYDROXYVITAMIN-D3 BY ISOTOPE-DILUTION LIQUID-CHROMATOGRAPHY THERMOSPRAY MASS-SPECTROMETRY SO BIOLOGICAL MASS SPECTROMETRY LA English DT Article ID VITAMIN-D METABOLITES; PLASMA; IDENTIFICATION; 1,25-DIHYDROXYVITAMIN-D; CARTRIDGES AB A liquid chromatography/thermospray mass spectrometry method has been developed and used to measure the plasma levels and half-life of 25-hydroxyvitamin D3 in adults. The mean plasma levels of 25-hydroxyvitamin D3 averaged 40 ng ml-1 (n = 4) in summer and 30 ng ml-1 (n = 6) in winter. The method was also used to determine the half-life of serum 25-hydroxyvitamin D3 in subjects maintained on either high or low-fiber diets who had been given an intravenous infusion of (6,19,19-H-2(3))25-hydroxyvitamin D3 sufficient to label 5% of their estimated body pools. The half-life was determined to be 10.4 days (n = 4), which is approximately 50% of the currently accepted value of 19 days, determined using radiolabeled methods. This difference may be due to kinetic isotope effects arising as a result of the tritiated compounds being labeled at sites that undergo Cyt-P450-catalyzed oxidations. C1 UNIV CONNECTICUT,DEPT NUTR SCI,STORRS,CT 06269. BOSTON UNIV,SCH MED,VITAMIN D SKIN & BONE LAB,BOSTON,MA 02118. NIH,METAB ANAL & MASS SPECTROMETRY SECT,BETHESDA,MD 20892. NR 38 TC 25 Z9 25 U1 0 U2 5 PU JOHN WILEY & SONS LTD PI W SUSSEX PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD SN 1052-9306 J9 BIOL MASS SPECTROM JI Biol. Mass Spectrom. PD JAN PY 1993 VL 22 IS 1 BP 53 EP 58 DI 10.1002/bms.1200220107 PG 6 WC Biophysics; Spectroscopy SC Biophysics; Spectroscopy GA KE826 UT WOS:A1993KE82600006 PM 8431502 ER PT B AU GORDON, SL AF GORDON, SL BE Morrey, BF TI FEDERAL-SUPPORT FOR RESEARCH ON JOINT REPLACEMENTS SO BIOLOGICAL, MATERIAL, AND MECHANICAL CONSIDERATIONS OF JOINT REPLACEMENT SE BRISTOL-MYERS SQUIBB / ZIMMER ORTHOPAEDIC SYMPOSIUM SERIES LA English DT Proceedings Paper CT 7TH ANNUAL BRISTOL-MYERS SQUIBB / ZIMMER ORTHOPAEDIC RESEARCH SYMP : BIOLOGICAL, MATERIAL, AND MECHANICAL CONSIDERATIONS OF JOINT REPLACEMENT CY OCT 29-31, 1992 CL SAN ANTONIO, TX SP BRISTOL MYERS, SQUIBB, ZIMMER RP GORDON, SL (reprint author), NIAMSD,MUSCULOSKELETAL DIS BRANCH,WESTWOOD BLVD,ROOM 407,BETHESDA,MD 20814, USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU RAVEN PRESS PI NEW YORK PA NEW YORK BN 0-7817-0008-6 J9 BRIS MYER Z PY 1993 BP 393 EP 395 PG 3 WC Engineering, Biomedical; Materials Science, Multidisciplinary; Orthopedics SC Engineering; Materials Science; Orthopedics GA BY98W UT WOS:A1993BY98W00038 ER PT J AU PIGOTT, TA HILL, JL GRADY, TA LHEUREUX, F BERNSTEIN, S RUBENSTEIN, CS MURPHY, DL AF PIGOTT, TA HILL, JL GRADY, TA LHEUREUX, F BERNSTEIN, S RUBENSTEIN, CS MURPHY, DL TI A COMPARISON OF THE BEHAVIORAL-EFFECTS OF ORAL VERSUS INTRAVENOUS MCPP ADMINISTRATION IN OCD PATIENTS AND THE EFFECT OF METERGOLINE PRIOR TO IV-MCPP SO BIOLOGICAL PSYCHIATRY LA English DT Article ID OBSESSIVE-COMPULSIVE DISORDER; META-CHLOROPHENYLPIPERAZINE; SEROTONERGIC RESPONSIVITY; CLOMIPRAMINE TREATMENT; RECOGNITION SITES; 5-HT1C RECEPTORS; HUMAN-BRAIN; NEUROENDOCRINE; ANTAGONISTS; RITANSERIN AB In prior studies from three centers, an exacerbation of obsessive-compulsive disorder (OCD) symptoms was reported in some (55%-83%) patients with OCD receiving the serotonergic agonist m-chlorophenylpiperazine (m-CPP) orally, whereas intravenously administered mCPP produced anxiety but no OCD symptom exacerbation. In the present replication attempt, 27 OCD patients were given mCPP either orally (n = 17) or intravenously (n = 10) under double-blind conditions, using identical behavioral rating measures. OCD symptoms were significantly increased after intravenous mCPP (0.1 mg/kg), but not after oral mCPP (0.5 mg/kg). Anxiety and other ratings were markedly elevated after intravenous mCPP administration. After oral mCPP administration, anxiety and most other self-ratings were only slightly elevated in comparison to placebo administration, and behavioral rating increases were no different for the OCD patients compared to age-matched healthy controls. Pretreatment with the potent serotonin (5-HT) antagonist, metergoline, prior to intravenous mCPP was associated with essentially complete blockade of the exacerbation in OCD symptoms and the other behavioral responses in the OCD patients. These results suggest that the behavioral response of OCD patients to mCPP are variable and depend on the route and dose of mCPP. In addition, the ability of metergoline to antagonize the behavioral effects of intravenous mCPP suggests that these responses are mediated by 5-HT1/5-HT2 receptors. C1 DUKE UNIV,MED CTR,DEPT PSYCHIAT,DURHAM,NC 27710. NIMH,CLIN SCI LAB,BETHESDA,MD 20892. RP PIGOTT, TA (reprint author), GEORGETOWN UNIV,MED CTR,DEPT PSYCHIAT,DIV CLIN PSYCHOPHARMACOL,KOBER COGAN BLDG,RM 316,WASHINGTON,DC 20007, USA. NR 41 TC 80 Z9 80 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD JAN 1 PY 1993 VL 33 IS 1 BP 3 EP 14 DI 10.1016/0006-3223(93)90272-F PG 12 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA KJ648 UT WOS:A1993KJ64800002 PM 8420593 ER PT S AU SZU, SC WATSON, D HINOJOSA, M SCHNEERSON, R ROBBINS, JB TAYLOR, DN TROFA, A AF SZU, SC WATSON, D HINOJOSA, M SCHNEERSON, R ROBBINS, JB TAYLOR, DN TROFA, A BE Cabello, F Hormaeche, C Mastroeni, P Bonina, L TI VACCINES FOR PREVENTION OF ENTERIC BACTERIAL-INFECTIONS CAUSED BY SALMONELLAE SO BIOLOGY OF SALMONELLA SE NATO ADVANCED SCIENCE INSTITUTES SERIES, SERIES A, LIFE SCIENCES LA English DT Proceedings Paper CT NATO Advanced Research Workshop on Biology of Salmonella CY MAY 11-15, 1992 CL PORTOROSA, ITALY SP NATO, ADV SCI INST, UNIV MESSINA, MEDEVA GRP RES UK, SWISS SERUM & VACCINE RES INST C1 NICHHD,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0258-1213 BN 0-306-44492-5 J9 NATO ADV SCI INST SE PY 1993 VL 245 BP 361 EP 371 PG 11 WC Public, Environmental & Occupational Health; Microbiology SC Public, Environmental & Occupational Health; Microbiology GA BZ50X UT WOS:A1993BZ50X00039 ER PT J AU BENCHIMOL, M KACHAR, B DESOUZA, W AF BENCHIMOL, M KACHAR, B DESOUZA, W TI THE STRUCTURAL ORGANIZATION OF THE PATHOGENIC PROTOZOAN TRITRICHOMONAS-FETUS AS SEEN IN REPLICAS OF QUICK FROZEN, FREEZE-FRACTURED AND DEEP ETCHED CELLS SO BIOLOGY OF THE CELL LA English DT Article DE CYTOSKELETON; PROTOZOA; TRITRICHOMONAS; FREEZE-ETCHING ID ENDOPLASMIC-RETICULUM; FINE-STRUCTURE; TRICHOMONAS; RIEDMULLER; FILAMENTS; ACTIN AB The quick-freezing and freeze-etching technique was used to analyse the cytoskeleton of Tritrichomonas foetus, a pathogenic protozoan of the urogenital tract of cattle. The cytoplasm presented a network of filamentous structures interacting with each other, with the surface of the hydrogenosomes and the nuclear membrane. Two nm wide filamentous structures were found in the luminal space of the Golgi complex, connecting the two faces of each cisterna. The microtubules of the pelta-axostyle system were connected by bridges 30-40 nm long and 10 nm wide, regularly spaced with an interval of 25 nm. The costa is a structure formed by a complex array of filaments and globous structures. It seems to be connected to the recurrent flagellum through a complex network formed by 15 and 10 nm wide filaments which emerge from the peripheral region of the costa and penetrate into the surface projections of the protozoan body to which the recurrent flagellum is attached. Other filaments were seen connecting the surface of these projections with the surface of the flagellum. C1 UNIV FED RIO DE JANEIRO,INST BIOFIS CARLOS CHAGAS FILHO,DEPT PARASITOL & BIOFIS CELULAR,BR-21949-900 RIO JANEIRO,BRAZIL. UNIV SAO PAULO,ICB,DEPT HISTOL,BR-01051 SAO PAULO,BRAZIL. NIDCD,MOLEC OTOL LAB,BETHESDA,MD 20892. NR 30 TC 21 Z9 21 U1 0 U2 3 PU EDITIONS SCIENTIFIQUES ELSEVIER PI PARIS CEDEX 15 PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE SN 0248-4900 J9 BIOL CELL JI Biol. Cell PY 1993 VL 77 IS 3 BP 289 EP 295 DI 10.1016/S0248-4900(05)80200-X PG 7 WC Cell Biology SC Cell Biology GA LR180 UT WOS:A1993LR18000008 PM 8401293 ER PT S AU FIORELLI, V BARILLARI, G GALLO, RC ENSOLI, B AF FIORELLI, V BARILLARI, G GALLO, RC ENSOLI, B BE Preissner, KT Rosenblatt, S Kost, C Wegerhoff, J Mosher, DF TI BIOLOGICAL PROPERTIES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TAT PROTEIN - ANGIOGENIC EFFECTS AND ADHESIVE INTERACTIONS OF EXTRACELLULAR TAT SO BIOLOGY OF VITRONECTINS AND THEIR RECEPTORS SE INTERNATIONAL CONGRESS SERIES LA English DT Proceedings Paper CT 1st International Vitronectin Workshop on the Biology of Vitronectins and Their Receptors CY AUG 25-28, 1993 CL RAUISCHHOLZHAUSEN CASTLE, MARBURG, GERMANY HO RAUISCHHOLZHAUSEN CASTLE ID LONG-TERM CULTURE; SARCOMA-DERIVED CELLS; KAPOSIS-SARCOMA; AIDS; GROWTH; PATHOGENESIS; CYTOKINES; LESIONS; EXPRESS; ALPHA RP FIORELLI, V (reprint author), NCI,TUMOR CELL BIOL LAB,BLDG 37,BETHESDA,MD 20902, USA. RI Ensoli, Barbara/J-9169-2016 OI Ensoli, Barbara/0000-0002-0545-8737 NR 22 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0531-5131 BN 0-444-81680-1 J9 INT CONGR SER PY 1993 VL 1042 BP 351 EP 360 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BZ68S UT WOS:A1993BZ68S00047 ER PT J AU RECANZONE, GH AF RECANZONE, GH TI DYNAMIC CHANGES IN THE FUNCTIONAL-ORGANIZATION OF THE CEREBRAL-CORTEX ARE CORRELATED WITH CHANGES IN PSYCHOPHYSICALLY MEASURED PERCEPTUAL ACUITY SO BIOMEDICAL RESEARCH-TOKYO LA English DT Article; Proceedings Paper CT 3rd International Symposium on Dynamics of Perception CY JAN 27-29, 1993 CL NATL INST PHYSIOL SCI, OKAZAKI, JAPAN HO NATL INST PHYSIOL SCI ID FREQUENCY-DISCRIMINATION TASK; ADULT OWL MONKEYS; SOMATOSENSORY CORTEX; PROJECTION NEURONS; SENSORY INPUTS; REORGANIZATION; CONVERGENCE; PLASTICITY; MOTOR AB The functional organization of the cerebral cortex in adult owl monkeys has recently been investigated with respect to the psychophysically measured perceptual acuity in the same individual. Monkeys trained at a tactile discrimination task over a restricted skin surface showed a progressive improvement in performance with training. The representation of the trained skin surface was larger in both cortical areas 3a and 3b when compared to equivalent untrained skin of the same or contralateral hand, or on hands of monkeys stimulated in the same way while performing an unrelated behavioral task. The time-locked responses to the tactile stimulus was strongly correlated with the discrimination abilities of these skin surfaces. Monkeys trained at an acoustic frequency discrimination task showed an equivalent improvement in performance with training. The representation of the frequency range of stimuli used in the behavioral task was larger in trained monkeys than in untrained monkeys or in monkeys exposed to the same stimuli while performing an unrelated task. The cortical area of representation of these frequency ranges was strongly correlated with the psychophysically measured acuity. These studies suggest that the functional organization of the neocortex is continuously changing to account for the changes of an individual's perceptual abilities. RP RECANZONE, GH (reprint author), NEI,SENSORIMOTOR RES LAB,BLDG 49,RM 2A50,BETHESDA,MD 20892, USA. NR 26 TC 0 Z9 0 U1 0 U2 0 PU BIOMED RES FOUND PI TOKYO PA KANDA PO BOX 182 CHIYODAKU, TOKYO 101-91, JAPAN SN 0388-6107 J9 BIOMED RES-TOKYO JI Biomed. Res. PY 1993 VL 14 SU 4 BP 61 EP 69 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA MW685 UT WOS:A1993MW68500011 ER PT J AU MUNOZ, DP WURTZ, RH AF MUNOZ, DP WURTZ, RH TI SUPERIOR COLLICULUS AND VISUAL FIXATION SO BIOMEDICAL RESEARCH-TOKYO LA English DT Article; Proceedings Paper CT 2ND INTERNATIONAL SYMP ON STUDIES ON THE DYNAMICS OF PHYSIOLOGICAL FUNCTIONS CY JAN 28-30, 1992 CL NATL INST PHYSIOL SCI, OKAZAKI, JAPAN SP MINIST EDUC SCI & CULTURE JAPAN HO NATL INST PHYSIOL SCI ID SACCADIC EYE-MOVEMENTS; ORIENTING GAZE SHIFTS; HEAD-FREE CAT; TECTORETICULOSPINAL SYSTEM; DISCHARGES; NEURONS AB Saccadic eye movements and the intervening periods of visual fixation represent one of the simplest behavioral systems that have been studied in the primate. The superior colliculus (SC) is a key structure in controlling this behavior. Here we describe recent experimental evidence demonstrating that the rostral pole of the primate SC is critical in controlling visual fixation. A subset of neurons (fixation cells), located in the rostral SC, discharge tonically when a monkey actively fixates a target spot and pause during the execution of saccadic eye movements. Following injection of muscimol, a GABA agonist, into the rostral pole of one SC, the monkey was less able to suppress the initiation of saccades. We propose that fixation cells in the rostral SC form part of a fixation system that facilitates active visual fixation and suppresses the initiation of unwanted saccadic eye movements. C1 QUEENS UNIV,MRC,SENSORY MOTOR PHYSIOL GRP,KINGSTON K7L 3N6,ONTARIO,CANADA. RP MUNOZ, DP (reprint author), NEI,SENSORIMOTOR RES LAB,BLDG 10,ROOM 10C101,BETHESDA,MD 20892, USA. NR 13 TC 1 Z9 1 U1 2 U2 3 PU BIOMED RES FOUND PI TOKYO PA KANDA PO BOX 182 CHIYODAKU, TOKYO 101-91, JAPAN SN 0388-6107 J9 BIOMED RES-TOKYO JI Biomed. Res. PY 1993 VL 14 SU 1 BP 75 EP 79 PG 5 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA LL646 UT WOS:A1993LL64600018 ER PT J AU BEZRUKOV, SM VODYANOY, I AF BEZRUKOV, SM VODYANOY, I TI PROBING ALAMETHICIN CHANNELS WITH WATER-SOLUBLE POLYMERS - EFFECT ON CONDUCTANCE OF CHANNEL STATES SO BIOPHYSICAL JOURNAL LA English DT Article ID BLACK LIPID-MEMBRANES; VOLUME CHANGES AB Channel access resistance has been measured to estimate the characteristic size of a single ion channel. We compare channel conductance in the presence of nonpenetrating water-soluble polymers with that obtained for polymer-free electrolyte solution. The contribution of the access resistance to the total alamethicin channel resistance is approximately 10% for first three open channel levels. The open alamethicin channel radii inferred for these first three levels from the access resistance are 6.3, 10.3, and 11.4 angstrom. The dependence of channel conductance on polymer molecular weight also allows evaluation of the channel dimensions from polymer exclusion. Despite varying conductance, it was shown that steric radii of the alamethicin channel at different conductance levels remain approximately unchanged. These results support a model of the alamethicin channel as an array of closely packed parallel pores of nearly uniform diameter. C1 OFF NAVAL RES,800 N QUINCY ST,ARLINGTON,VA 22217. UNIV MARYLAND,COLL PK,MD 20742. NIDDKD,BIOPHYS UNIT,BIOCHEM & METAB LAB,BETHESDA,MD 20892. UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717. NR 33 TC 165 Z9 167 U1 1 U2 15 PU BIOPHYSICAL SOCIETY PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 SN 0006-3495 J9 BIOPHYS J JI Biophys. J. PD JAN PY 1993 VL 64 IS 1 BP 16 EP 25 PG 10 WC Biophysics SC Biophysics GA KJ839 UT WOS:A1993KJ83900006 PM 7679295 ER PT J AU KOONIN, EV ILYINA, TV AF KOONIN, EV ILYINA, TV TI COMPUTER-ASSISTED DISSECTION OF ROLLING CIRCLE DNA-REPLICATION SO BIOSYSTEMS LA English DT Article ID SINGLE-STRANDED-DNA; COMPLETE NUCLEOTIDE-SEQUENCE; PHAGE-PLASMID HYBRID; GOLDEN MOSAIC-VIRUS; ESCHERICHIA-COLI; HELICASE-I; STRUCTURAL ORGANIZATION; ENDONUCLEASE ACTIVITY; CONSERVED SEQUENCE; PROTEIN SEQUENCES AB A comparative analysis of the proteins involved in initiation and termination of rolling circle replication (RCR) was performed using computer-assisted methods of data based screening, motif search and multiple amino acid sequence alignmnent. Two vast classes of such proteins were delineated, one of these being associated with RCR proper, and the other with mobilization (conjugal transfer) of plasmid DNA. The common denominator of the two classes was found to be a conserved amino acid motif that consists of the sequence HisUHisUUU (U - bulky hydrophobic residue; hereafter HUH motif). Based on analogies with metalloenzymes, it is hypothesized that the two conserved His residues this motif may be involved in metal ion coordination required for the activity of the RCR and mobilization proteins. The proteins of the replication (Rep) class contained two additional conserved motifs, with the motif around the Tyr residue(s) forming the covalent link with nicked DNA being located C-proximally of the HUH motif. This class further split into two large superfamilies and several smaller families, with the proteins belonging to a single but not to different (super)families demonstrating, statistically significant similarity to each other. Superfamily I, prototyped by the gene A proteins of small isometric single-stranded (ss) DNA bacteriophages, included also Rep proteins of P2-related double-stranded (ds) DNA bacteriophages, the small phage-plasmid hybrid phasyl, and several cyanobacterial and archaebacterial plasmids. These proteins contained two invariant Tyr residues separated by three partially conserved amino acids, suggesting that they all may share the cleavage-ligation mechanism proposed for phiX174 A protein and involving alternate covalent binding of both tyrosines to DNA (Van Mansfeld, A.D., Van Teeffelen, H.A., Baas, P.D., Jansz, H.S., 1986. Nucl. Acids Res. 14, 4229-4238). Superfamily II included Rep proteins of a number of ssDNA plasmids replicating mainly in gram-positive bacteria that unexpectedly were shown to be related to the Rep proteins of plant geminiviruses. Conservation of the ''HUH'' motif and a motif around the putative DNA-linking Tyr residue was observed also in the Rep proteins of animal parvoviruses containing linear ssDNA with a terminal hairpin and replicating via the rolling hairpin mechanism. The class of plasmid mobilization (Mob) proteins was characterized by the opposite orientation of the conserved motifs, with the (putative) DNA-linking Tyr being located N-proximally of the ''HUH'' motif. This class also separated into several distinct families, the largest of which was comprised by the Mob (TraI) proteins of promiscuous IncP and IncI plasmids, VirD2 endonucleases of Agrobacterium TI plasmids, and Mob proteins of a group of gram-positive bacterial ssDNA plasmids. The majority of ssDNA plasmid Mob proteins constituted another family, whereas the Mob domains of TraI proteins of F factor and related plasmids formed a separate group that was only distantly related to the former two families. Additionally, a family of plasmid Rep proteins was analyzed that are unrelated to the above two classes and do not contain the HUH motif but possess instead several distinct conserved motifs. A protein encoded by an archaebacterial virus gene was shown to be distantly related to this family, with significant sequence conservation observed around the putative DNA-linked tyrosine residue. This analysis allowed the prediction of the amino acid residues involved in DNA nicking, which is required for the initiation of RCR or conjugational transfer of ssDNA, in the Rep and Mob proteins encoded by a number of replicons of highly diverse size, structure and origin. It is conjectured that recombination has played a major part in the dissemination of genes encoding related Rep or Mob proteins among these replicons. It is speculated that the eukaryotic replicons encoding proteins with the conserved RCR motifs and replicating via RCR-related mechanisms, such as geminiviruses and parvoviruses, may have evolved from eubacterial ssDNA replicons. Analysis of the nucleotide sequences of the replication and transfer origins (ori) of various replicons allowed identification of several previously uncharacterized ori sites but showed that only partial correlation exists between the sequence conservation in the replication (transfer) initiation proteins, and in ori sites. C1 ACAD SCI MOSCOW, INST MICROBIOL, MOSCOW 117811, RUSSIA. RP NIH, NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, 8600 ROCKVILLE PIKE, BETHESDA, MD 20894 USA. NR 84 TC 132 Z9 136 U1 2 U2 15 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0303-2647 EI 1872-8324 J9 BIOSYSTEMS JI Biosystems PY 1993 VL 30 IS 1-3 BP 241 EP 268 DI 10.1016/0303-2647(93)90074-M PG 28 WC Biology; Mathematical & Computational Biology SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology GA LN564 UT WOS:A1993LN56400018 PM 8374079 ER PT J AU KOONIN, EV AF KOONIN, EV TI GENOME SEQUENCING - A GLIMPSE OF THE AREA AT THE BRINK OF THE VIRUS ERA SO BIOSYSTEMS LA English DT Article ID RNA PLANT-VIRUSES; COMPLETE DNA-SEQUENCE; NUCLEOTIDE-SEQUENCE; CAPSID PROTEINS; VACCINIA VIRUS; POLYMERASES; PHYLOGENY; IDENTIFICATION; ELEMENTS; REPEAT RP KOONIN, EV (reprint author), NIH,NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,8600 ROCKVILLE PIKE,BETHESDA,MD 20894, USA. NR 32 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0303-2647 J9 BIOSYSTEMS JI Biosystems PY 1993 VL 30 IS 1-3 BP 269 EP 276 DI 10.1016/0303-2647(93)90075-N PG 8 WC Biology; Mathematical & Computational Biology SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology GA LN564 UT WOS:A1993LN56400019 PM 8374080 ER PT J AU TSCHACHLER, E BOHNLEIN, E FELZMANN, S REITZ, MS AF TSCHACHLER, E BOHNLEIN, E FELZMANN, S REITZ, MS TI HUMAN T-LYMPHOTROPIC VIRUS TYPE-I TAX REGULATES THE EXPRESSION OF THE HUMAN LYMPHOTOXIN GENE SO BLOOD LA English DT Article ID TUMOR-NECROSIS-FACTOR; CELL LEUKEMIA-VIRUS; TROPICAL SPASTIC PARAPARESIS; LONG TERMINAL REPEAT; CHLORAMPHENICOL ACETYLTRANSFERASE; CEREBROSPINAL-FLUID; BONE-RESORPTION; TNF LOCUS; BETA; LINES C1 UNIV VIENNA,SCH MED,DEPT DERMATOL,DIV IMMUNOL ALLERGY & INFECT DIS,A-1090 VIENNA,AUSTRIA. NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892. NR 45 TC 27 Z9 27 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD JAN 1 PY 1993 VL 81 IS 1 BP 95 EP 100 PG 6 WC Hematology SC Hematology GA KF548 UT WOS:A1993KF54800014 PM 8417807 ER PT J AU BEUTLER, E BRECHER, G BESSIS, M CRONKITE, E PALLAVICINI, M ORLIC, D AF BEUTLER, E BRECHER, G BESSIS, M CRONKITE, E PALLAVICINI, M ORLIC, D TI COMPETITIVE REPOPULATION IN LEUKEMIC AND NORMAL BONE-MARROW - DISCUSSION SO BLOOD CELLS LA English DT Discussion ID STEM-CELLS C1 ASSOCIATED UNIV INC,BROOKHAVEN NATL LAB,DEPT MED,UPTON,NY 11973. UNIV CALIF SAN FRANCISCO,DIV MOLEC CYTOMETRY,SAN FRANCISCO,CA 94143. NHLBI,CLIN HEMATOL BRANCH,BETHESDA,MD 20892. LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,BERKELEY,CA 94720. RP BEUTLER, E (reprint author), SCRIPPS CLIN,DIV HEMATOL,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0340-4684 J9 BLOOD CELLS JI Blood Cells PY 1993 VL 19 IS 3 BP 701 EP 707 PG 7 WC Hematology SC Hematology GA MU576 UT WOS:A1993MU57600033 ER PT B AU WURTZ, RH DUFFY, CJ ROY, JP AF WURTZ, RH DUFFY, CJ ROY, JP BE Ono, T Squire, LR Raichle, ME Perrett, DI Fukuda, M TI MOTION PROCESSING FOR GUIDING SELF-MOTION SO BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR LA English DT Proceedings Paper CT International Symposium on Brain Mechanisms of Perception and Memory: From Neuron to Behavior CY OCT 06-11, 1991 CL TOYAMA, JAPAN SP TOYAMA MED & PHARM UNIV C1 NEI,SENSORIMOTOR RES LAB,BETHESDA,MD 20892. NR 0 TC 6 Z9 6 U1 0 U2 0 PU OXFORD UNIV PRESS PI NEW YORK PA 198 MADISON AVENUE, NEW YORK, NY 10016 BN 0-19-507770-9 PY 1993 BP 141 EP 165 PG 25 WC Neurosciences SC Neurosciences & Neurology GA BA75C UT WOS:A1993BA75C00009 ER PT J AU REN, K RUDA, MA JACOBOWITZ, DM AF REN, K RUDA, MA JACOBOWITZ, DM TI IMMUNOHISTOCHEMICAL LOCALIZATION OF CALRETININ IN THE DORSAL-ROOT GANGLION AND SPINAL-CORD OF THE RAT SO BRAIN RESEARCH BULLETIN LA English DT Article DE CALRETININ; SPINAL CORD; DORSAL ROOT GANGLION; DORSAL COLUMN; GANGLIONECTOMY; IMMUNOCYTOCHEMISTRY; CALCIUM-BINDING PROTEINS; RAT ID CALCIUM-BINDING PROTEIN; CYTOARCHITECTONIC ORGANIZATION; SUBSTANTIA GELATINOSA; NEURONS; NUCLEUS; HORN; PARVALBUMIN; CALBINDIN; LAYERS; CORTEX AB Calretinin (CR), a recently identified calcium-binding protein, is present in nervous tissue, including sensory pathways, where it may play an important role in regulation of cellular activity. Using immunocytochemistry, we examined the cellular localization of CR in dorsal root ganglia (DRG) and spinal cord of normal rats and after multiple unilateral dorsal root ganglionectomies. In DRG, CR-immunoreactive cell bodies and axons were a small subpopulation (10%) of medium- to large-sized neurons. In the spinal cord, CR-like immunoreactivity (LI) in neurons and fibers was found in all laminae except motoneurons. Dense fiber networks were also found in Clarke's column. The densest staining of both cell bodies and fibers was in the superficial laminae, especially lamina II, and in the lateral spinal and lateral cervical nuclei. CR-immunoreactive fibers were also observed in the fasciculi cuneatus and gracilis. Fasciculus gracilis exhibited the greatest number of labeled axons at the lumbosacral levels, but few labeled axons were found at the rostral thoracic and cervical levels. In contrast, the corticospinal tract at the base of the dorsal column was devoid of CR-immunoreactive fibers. Unilateral multiple lumbar ganglionectomies resulted in a loss of CR-LI in the dorsal columns ipsilateral to the surgery. In the spinal gray matter ipsilateral to the ganglionectomies, CR-LI was reduced in Clarke's column and slightly enhanced in the medial third of lamina II. Our observations demonstrate a unique distribution pattern of CR-LI compared to other calcium-binding proteins in the spinal cord, and suggest a role for CR in nociceptive and proprioceptive pathways. C1 NIMH,CLIN SCI LAB,BETHESDA,MD 20892. RP REN, K (reprint author), NIDR,NEUROBIOL & ANESTHESIOL BRANCH,BLDG 30,ROOM B-20,BETHESDA,MD 20892, USA. NR 27 TC 48 Z9 48 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0361-9230 J9 BRAIN RES BULL JI Brain Res. Bull. PY 1993 VL 31 IS 1-2 BP 13 EP 22 DI 10.1016/0361-9230(93)90004-U PG 10 WC Neurosciences SC Neurosciences & Neurology GA KN899 UT WOS:A1993KN89900003 PM 7680942 ER PT J AU BARNES, MI MITCHELL, CL AF BARNES, MI MITCHELL, CL TI DECREASED SEIZURE THRESHOLD AFTER INTRAHIPPOCAMPAL COLCHICINE INJECTION IN RATS SO BRAIN RESEARCH BULLETIN LA English DT Article DE DENTATE GRANULE CELLS; VENTRAL HIPPOCAMPUS; DORSAL HIPPOCAMPUS; WET DOG SHAKES; SEIZURES; PERFORANT PATH STIMULATION; COLCHICINE ID DENTATE GRANULE CELLS; WET DOG SHAKES; STIMULATION; HIPPOCAMPUS; LESIONS AB Wet dog shaking elicited by perforant path stimulation is little affected by bilateral injection of colchicine into the dorsal hippocampal formation but virtually eliminated by bilateral injection into the ventral hippocampal formation. Injection of colchicine into either dorsal or ventral hippocampal formation lowers the threshold for eliciting forelimb clonus with rearing. This effect is more pronounced 8 weeks postinjection than 2 weeks postinjection when colchicine is injected in the ventral hippocampal formation. This suggests that inappropriate reactive synaptogenesis and/or neuronal degeneration continues for an extended period after intrahippocampal injection of colchicine, especially in the ventral hippocampal formation. C1 NIEHS,MOLEC & INTEGRAT NEUROSCI LAB,POB 12233,RES TRIANGLE PK,NC 27709. NR 12 TC 5 Z9 5 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0361-9230 J9 BRAIN RES BULL JI Brain Res. Bull. PY 1993 VL 31 IS 6 BP 733 EP 736 DI 10.1016/0361-9230(93)90149-6 PG 4 WC Neurosciences SC Neurosciences & Neurology GA LB231 UT WOS:A1993LB23100017 PM 8518963 ER PT S AU CALLAHAN, R GALLAHAN, D SMITH, G CROPP, C MERLO, G DIELLA, F LISCIA, D LIDEREAU, R AF CALLAHAN, R GALLAHAN, D SMITH, G CROPP, C MERLO, G DIELLA, F LISCIA, D LIDEREAU, R BE Squartini, F Bevilacqua, G Conte, PF Surbone, A TI FREQUENT MUTATIONS IN BREAST-CANCER SO BREAST CANCER: FROM BIOLOGY TO THERAPY SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Pisa Symposia in Oncology, to Celebrate the 650th Anniversary of the Founding of the University of Pisa CY OCT 19-21, 1992 CL PISA, ITALY SP UNIV PISA, NATL INST CANC RES, SANTA CHIARA HOSP, ASSOC ITALIANA ONCOL MEDICA ID MAMMARY-TUMOR VIRUS; CELL-CYCLE CONTROL; TRANSGENIC MICE; DROSOPHILA-NOTCH; TGF-ALPHA; RETINOBLASTOMA GENE; PROVIRAL INSERTION; TRANSFORMING GENE; CONTROL PROTEINS; BINDING-PROTEIN C1 SAN GIOVANNI VECCHIO HOSP,USSL 1,PATHOL SECT,I-10123 TURIN,ITALY. CTR RENE HUGUENIN,ST CLOUD,FRANCE. RP CALLAHAN, R (reprint author), NCI,BLDG 10,ROOM 5B50,BETHESDA,MD 20892, USA. NR 95 TC 5 Z9 5 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-803-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 698 BP 21 EP 30 DI 10.1111/j.1749-6632.1993.tb17188.x PG 10 WC Oncology; Medicine, Research & Experimental; Multidisciplinary Sciences; Pathology; Pharmacology & Pharmacy SC Oncology; Research & Experimental Medicine; Science & Technology - Other Topics; Pathology; Pharmacology & Pharmacy GA BZ51X UT WOS:A1993BZ51X00002 PM 8279759 ER PT S AU MERLO, GR VENESIO, T TAVERNA, D CALLAHAN, R HYNES, NE AF MERLO, GR VENESIO, T TAVERNA, D CALLAHAN, R HYNES, NE BE Squartini, F Bevilacqua, G Conte, PF Surbone, A TI GROWTH SUPPRESSION OF NORMAL MAMMARY EPITHELIAL-CELLS BY WILD-TYPE P53 SO BREAST CANCER: FROM BIOLOGY TO THERAPY SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Pisa Symposia in Oncology, to Celebrate the 650th Anniversary of the Founding of the University of Pisa CY OCT 19-21, 1992 CL PISA, ITALY SP UNIV PISA, NATL INST CANC RES, SANTA CHIARA HOSP, ASSOC ITALIANA ONCOL MEDICA ID HUMAN BREAST-CANCER; GENE; PROLIFERATION; MUTATIONS; IMMORTALIZATION; TRANSFORMATION; FIBROBLASTS; PROTEIN C1 S GIOVANNI HOSP,USL 1,I-10123 TURIN,ITALY. NCI,ONCOGENET SECT,BETHESDA,MD 20892. RP MERLO, GR (reprint author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND. RI taverna, daniela/J-8358-2016 OI taverna, daniela/0000-0002-6365-527X NR 25 TC 4 Z9 4 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-803-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 698 BP 108 EP 113 DI 10.1111/j.1749-6632.1993.tb17195.x PG 6 WC Oncology; Medicine, Research & Experimental; Multidisciplinary Sciences; Pathology; Pharmacology & Pharmacy SC Oncology; Research & Experimental Medicine; Science & Technology - Other Topics; Pathology; Pharmacology & Pharmacy GA BZ51X UT WOS:A1993BZ51X00009 PM 8279747 ER PT S AU MARCHETTI, A BUTTITTA, F PELLEGRINI, S DIELLA, F CAMPANI, D CECCHETTI, D SQUARTINI, F CALLAHAN, R BISTOCCHI, M AF MARCHETTI, A BUTTITTA, F PELLEGRINI, S DIELLA, F CAMPANI, D CECCHETTI, D SQUARTINI, F CALLAHAN, R BISTOCCHI, M BE Squartini, F Bevilacqua, G Conte, PF Surbone, A TI P53 MUTATIONS AND HISTOLOGIC TYPE OF INVASIVE BREAST-CARCINOMA - A POLYMERASE CHAIN-REACTION SINGLE-STRAND CONFORMATION POLYMORPHISM AND IMMUNOHISTOCHEMICAL ANALYSIS SO BREAST CANCER: FROM BIOLOGY TO THERAPY SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Pisa Symposia in Oncology, to Celebrate the 650th Anniversary of the Founding of the University of Pisa CY OCT 19-21, 1992 CL PISA, ITALY SP UNIV PISA, NATL INST CANC RES, SANTA CHIARA HOSP, ASSOC ITALIANA ONCOL MEDICA ID TUMOR-ANTIGEN; GENE; TRANSFORMATION; SUPPRESSOR C1 UNIV PISA,INST PATHOL ANAT & HISTOL,PISA,ITALY. NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892. RI Pellegrini, Silvia/C-3770-2011 NR 12 TC 6 Z9 6 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-803-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 698 BP 114 EP 119 DI 10.1111/j.1749-6632.1993.tb17196.x PG 6 WC Oncology; Medicine, Research & Experimental; Multidisciplinary Sciences; Pathology; Pharmacology & Pharmacy SC Oncology; Research & Experimental Medicine; Science & Technology - Other Topics; Pathology; Pharmacology & Pharmacy GA BZ51X UT WOS:A1993BZ51X00010 PM 7904136 ER PT S AU LISCIA, DS VENESIO, T DIELLA, F BERNARDI, A CAPPA, APM CALLAHAN, R MERLO, GR AF LISCIA, DS VENESIO, T DIELLA, F BERNARDI, A CAPPA, APM CALLAHAN, R MERLO, GR BE Squartini, F Bevilacqua, G Conte, PF Surbone, A TI A LOCUS ON CHROMOSOME 17P13.3, ASSOCIATED WITH A HIGH S-PHASE INDEX IS DISTINCT FROM THE P53 GENE IN BREAST-CANCER SO BREAST CANCER: FROM BIOLOGY TO THERAPY SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Pisa Symposia in Oncology, to Celebrate the 650th Anniversary of the Founding of the University of Pisa CY OCT 19-21, 1992 CL PISA, ITALY SP UNIV PISA, NATL INST CANC RES, SANTA CHIARA HOSP, ASSOC ITALIANA ONCOL MEDICA ID MAMMALIAN-CELLS C1 NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892. RP LISCIA, DS (reprint author), S GIOVANNI VECCHIO HOSP,USL 1,ANAT PATHOL SECT,VIA CAVOUR 31,I-10123 TURIN,ITALY. NR 6 TC 2 Z9 2 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-803-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 698 BP 120 EP 125 DI 10.1111/j.1749-6632.1993.tb17197.x PG 6 WC Oncology; Medicine, Research & Experimental; Multidisciplinary Sciences; Pathology; Pharmacology & Pharmacy SC Oncology; Research & Experimental Medicine; Science & Technology - Other Topics; Pathology; Pharmacology & Pharmacy GA BZ51X UT WOS:A1993BZ51X00011 PM 8279748 ER PT S AU DORIONBONNET, F QUENEL, N COINDRE, JM MAURIAC, L BONICHON, F DURAND, M WAFFLART, J MOSCOW, JA COWAN, KH GUALDE, N AF DORIONBONNET, F QUENEL, N COINDRE, JM MAURIAC, L BONICHON, F DURAND, M WAFFLART, J MOSCOW, JA COWAN, KH GUALDE, N BE Squartini, F Bevilacqua, G Conte, PF Surbone, A TI EXPRESSION OF THE GST-PI GENE AND RESPONSE TO TAMOXIFEN THERAPY IN LOCALLY ADVANCED BREAST CARCONOMAS SO BREAST CANCER: FROM BIOLOGY TO THERAPY SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Pisa Symposia in Oncology, to Celebrate the 650th Anniversary of the Founding of the University of Pisa CY OCT 19-21, 1992 CL PISA, ITALY SP UNIV PISA, NATL INST CANC RES, SANTA CHIARA HOSP, ASSOC ITALIANA ONCOL MEDICA ID CANCER CELL-LINE; PROGESTERONE RECEPTORS; ESTROGEN; SEQUENCES; CLONING; MCF-7; CDNA C1 NCI,BETHESDA,MD 20892. RP DORIONBONNET, F (reprint author), FDN BERGONIE,REG COMPREHENS CANC CTR,BORDEAUX,FRANCE. NR 14 TC 1 Z9 1 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-803-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 698 BP 182 EP 185 DI 10.1111/j.1749-6632.1993.tb17207.x PG 4 WC Oncology; Medicine, Research & Experimental; Multidisciplinary Sciences; Pathology; Pharmacology & Pharmacy SC Oncology; Research & Experimental Medicine; Science & Technology - Other Topics; Pathology; Pharmacology & Pharmacy GA BZ51X UT WOS:A1993BZ51X00021 PM 7904139 ER PT S AU MARIANI, G COLLECCHI, P GIULIANI, L BARANOWSKAKORTYLEWICZ, J DILUCA, L VANDENABBEELE, AD SALVADORI, PA DISACCO, S ADELSTEIN, SJ BEVILACQUA, G KASSIS, AI MEUCCI, G VIACAVA, P AF MARIANI, G COLLECCHI, P GIULIANI, L BARANOWSKAKORTYLEWICZ, J DILUCA, L VANDENABBEELE, AD SALVADORI, PA DISACCO, S ADELSTEIN, SJ BEVILACQUA, G KASSIS, AI MEUCCI, G VIACAVA, P BE Squartini, F Bevilacqua, G Conte, PF Surbone, A TI TUMOR TARGETING POTENTIAL AND METABOLISM OF 5-[I-125]IODO-2'-DEOXYURIDINE INJECTED INTRATUMORALLY IN PATIENTS WITH BREAST-CANCER SO BREAST CANCER: FROM BIOLOGY TO THERAPY SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Pisa Symposia in Oncology, to Celebrate the 650th Anniversary of the Founding of the University of Pisa CY OCT 19-21, 1992 CL PISA, ITALY SP UNIV PISA, NATL INST CANC RES, SANTA CHIARA HOSP, ASSOC ITALIANA ONCOL MEDICA C1 UNIV PISA,SCH MED,CTR NUCL MED,PISA,ITALY. UNIV PISA,SCH MED,INST SURG,PISA,ITALY. UNIV PISA,SCH MED,INST PATHOL ANAT,PISA,ITALY. NATL CANC INST,GENOA,ITALY. HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115. RP MARIANI, G (reprint author), UNIV PISA,SCH MED,CNR,INST CLIN PHYSIOL,VIA SAVI 8,I-56126 PISA,ITALY. RI Salvadori, Piero/B-2342-2012 OI Salvadori, Piero/0000-0001-6114-1059 NR 7 TC 17 Z9 17 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-803-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 698 BP 204 EP 211 DI 10.1111/j.1749-6632.1993.tb17210.x PG 8 WC Oncology; Medicine, Research & Experimental; Multidisciplinary Sciences; Pathology; Pharmacology & Pharmacy SC Oncology; Research & Experimental Medicine; Science & Technology - Other Topics; Pathology; Pharmacology & Pharmacy GA BZ51X UT WOS:A1993BZ51X00024 PM 8279758 ER PT S AU MORROW, CS COWAN, KH AF MORROW, CS COWAN, KH BE Squartini, F Bevilacqua, G Conte, PF Surbone, A TI ANTINEOPLASTIC DRUG-RESISTANCE AND BREAST-CANCER SO BREAST CANCER: FROM BIOLOGY TO THERAPY SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Pisa Symposia in Oncology, to Celebrate the 650th Anniversary of the Founding of the University of Pisa CY OCT 19-21, 1992 CL PISA, ITALY SP UNIV PISA, NATL INST CANC RES, SANTA CHIARA HOSP, ASSOC ITALIANA ONCOL MEDICA ID S-TRANSFERASE-PI; DNA TOPOISOMERASE-II; HAMSTER OVARY CELLS; BACTERIAL TRANSPORT PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; NITROGEN MUSTARD-RESISTANT; HIGH-DOSE METHOTREXATE; HUMAN MDR1 GENE; MULTIDRUG-RESISTANCE; DIHYDROFOLATE-REDUCTASE C1 NCI,MED BRANCH,MED BREAST CANC SECT,BETHESDA,MD 20892. NR 148 TC 22 Z9 22 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-803-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 698 BP 289 EP 312 DI 10.1111/j.1749-6632.1993.tb17220.x PG 24 WC Oncology; Medicine, Research & Experimental; Multidisciplinary Sciences; Pathology; Pharmacology & Pharmacy SC Oncology; Research & Experimental Medicine; Science & Technology - Other Topics; Pathology; Pharmacology & Pharmacy GA BZ51X UT WOS:A1993BZ51X00034 PM 7904140 ER PT S AU REICHMAN, BS SEIDMAN, AD CROWN, JPA HEELAN, R YAO, TJ HAKES, TB LEBWOHL, DE GILEWSKI, TA SURBONE, A CURRIE, V HUDIS, CA QUINLIVAN, S BERKERY, R TOOMASI, F CANETTA, R FISHERMAN, J ARBUCK, S NORTON, L AF REICHMAN, BS SEIDMAN, AD CROWN, JPA HEELAN, R YAO, TJ HAKES, TB LEBWOHL, DE GILEWSKI, TA SURBONE, A CURRIE, V HUDIS, CA QUINLIVAN, S BERKERY, R TOOMASI, F CANETTA, R FISHERMAN, J ARBUCK, S NORTON, L BE Squartini, F Bevilacqua, G Conte, PF Surbone, A TI TAXOL AND RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR, AN ACTIVE REGIMEN AS INITIAL THERAPY FOR METASTATIC BREAST-CANCER - A PRELIMINARY-REPORT SO BREAST CANCER: FROM BIOLOGY TO THERAPY SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Pisa Symposia in Oncology, to Celebrate the 650th Anniversary of the Founding of the University of Pisa CY OCT 19-21, 1992 CL PISA, ITALY SP UNIV PISA, NATL INST CANC RES, SANTA CHIARA HOSP, ASSOC ITALIANA ONCOL MEDICA ID PHASE-II TRIAL; AGENT; MECHANISM C1 MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,BREAST & GYNECOL CANC MED SERV,NEW YORK,NY 10021. MEM SLOAN KETTERING CANC CTR,DEPT MED IMAGING,NEW YORK,NY 10021. MEM SLOAN KETTERING CANC CTR,DEPT EPIDEMIOL & BIOSTAT,NEW YORK,NY 10021. BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,WALLINGFORD,CT 06492. NCI,DIV CANC THERAPY,CANC THERAPY EVALUAT PROGRAM,BETHESDA,MD 20892. RP REICHMAN, BS (reprint author), STRANG CORNELL BREAST CTR,428 E 72ND ST,NEW YORK,NY 10021, USA. FU NCI NIH HHS [NCI CA-09207-14, NCI 1-CM07311] NR 14 TC 1 Z9 1 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-803-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 698 BP 398 EP 402 DI 10.1111/j.1749-6632.1993.tb17232.x PG 5 WC Oncology; Medicine, Research & Experimental; Multidisciplinary Sciences; Pathology; Pharmacology & Pharmacy SC Oncology; Research & Experimental Medicine; Science & Technology - Other Topics; Pathology; Pharmacology & Pharmacy GA BZ51X UT WOS:A1993BZ51X00046 PM 7506506 ER PT J AU BROWN, ML FINTOR, L AF BROWN, ML FINTOR, L TI COST-EFFECTIVENESS OF BREAST-CANCER SCREENING - PRELIMINARY-RESULTS OF A SYSTEMATIC REVIEW OF THE LITERATURE SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article; Proceedings Paper CT 1992 ANNUAL SAN ANTONIO BREAST CANCER SYMP CY DEC 08, 1992 CL SAN ANTONIO, TX SP AMGEN, BRISTOL MYERS, ONCOL DIV DE BREAST CANCER; COST-EFFECTIVENESS; MAMMOGRAPHY; MEDICAL RESOURCE ALLOCATION; SCREENING ID HEALTH AB There is now considerable concern that universal access to health care within realistic resource constraints requires some sort of cost-effectiveness analysis of given medical procedures and interventions. One such intervention is routine mammographic screening for breast cancer. Here, we report preliminary results from an ongoing project to conduct a systematic and comprehensive review and comparison of the published cost-effectiveness analyses of screening for the early detection of breast cancer. We examine 16 such studies, and compare two studies in detail to explain how differences in assumptions and in consideration of down-stream effects have caused the published results for apparently comparable breast cancer screening programs to span a broad range. RP BROWN, ML (reprint author), NCI,DIV CANC PREVENT & CONTROL,SURVEILLANCE PROGRAM,APPL RES BRANCH,BETHESDA,MD 20892, USA. NR 20 TC 96 Z9 96 U1 2 U2 3 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PY 1993 VL 25 IS 2 BP 113 EP 118 DI 10.1007/BF00662136 PG 6 WC Oncology SC Oncology GA LF629 UT WOS:A1993LF62900003 PM 8347843 ER PT J AU STEEG, PS DELAROSA, A FLATOW, U MACDONALD, NJ BENEDICT, M LEONE, A AF STEEG, PS DELAROSA, A FLATOW, U MACDONALD, NJ BENEDICT, M LEONE, A TI NM23 AND BREAST-CANCER METASTASIS SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article; Proceedings Paper CT 1992 ANNUAL SAN ANTONIO BREAST CANCER SYMP CY DEC 08, 1992 CL SAN ANTONIO, TX SP AMGEN, BRISTOL MYERS, ONCOL DIV DE DIFFERENTIATION; METASTASIS; NM23; NUCLEOSIDE DIPHOSPHATE KINASE; RECURRENCE; TUMOR PROGRESSION ID NUCLEOSIDE DIPHOSPHATE KINASE; TUMOR-METASTASIS; GOOD PROGNOSIS; GENE; PROTEIN; DROSOPHILA; EXPRESSION; ASSOCIATION; ANGIOGENESIS; CONVERSION AB The majority of breast cancer patients succumb to metastatic disease. We summarize published and recent research concerning the nm23 gene in breast cancer metastasis. In a murine developmental study, nm23 expression increased with the functional differentiation of the mammary gland in nulliparous and pregnant animals. In human breast cancer, five studies have now demonstrated a significant association between reduced nm23 expression, at the RNA or protein levels, and aggressive tumor behavior. Nm23-negative tumor cells have been observed in comedo ductal carcinoma in situ lesions in two independent studies, indicating that decreases in nm23 expression begin prior to actual histologically identifiable invasion. Transfection studies, in which human mm23-H1 cDNA was expressed in the metastatic human MDA-MB-435 breast carcinoma cell line, indicate that nm23-H1 suppresses in vivo metastatic potential by 50-90%. Finally, our data in melanoma and breast carcinoma transfection systems suggest that the biochemical mechanism of nm23 suppressive activity is likely not due to its nucleoside diphosphate kinase activity, association with GAP proteins, or secretion from cells. RP STEEG, PS (reprint author), NCI,PATHOL LAB,BLDG 10, ROOM 2A33,BETHESDA,MD 20892, USA. RI Leone, Alvaro/K-6410-2016 OI Leone, Alvaro/0000-0003-3815-9052 NR 52 TC 90 Z9 92 U1 0 U2 3 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PY 1993 VL 25 IS 2 BP 175 EP 187 DI 10.1007/BF00662142 PG 13 WC Oncology SC Oncology GA LF629 UT WOS:A1993LF62900009 PM 8347849 ER PT J AU MANOLIO, TA HARLAN, WR AF MANOLIO, TA HARLAN, WR TI RESEARCH ON CORONARY-DISEASE IN WOMEN - POLITICAL OR SCIENTIFIC IMPERATIVE SO BRITISH HEART JOURNAL LA English DT Editorial Material ID SEX-DIFFERENCES; ARTERY SURGERY; HEART-DISEASE; MORTALITY; BYPASS; MEN C1 NIH,OFF DIS PREVENT,BETHESDA,MD 20892. RP MANOLIO, TA (reprint author), NHLBI,DIV EPIDEMIOL & CLIN APPLICAT,BETHESDA,MD 20892, USA. NR 21 TC 15 Z9 15 U1 0 U2 0 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR SN 0007-0769 J9 BRIT HEART J JI Br. Heart J. PD JAN PY 1993 VL 69 IS 1 BP 1 EP 2 PG 2 WC Cardiac & Cardiovascular Systems; History & Philosophy Of Science SC Cardiovascular System & Cardiology; History & Philosophy of Science GA KH116 UT WOS:A1993KH11600001 PM 8457386 ER PT J AU CASTELLI, WP AF CASTELLI, WP TI THE FACT AND FICTION OF LOWERING CHOLESTEROL CONCENTRATIONS IN THE PRIMARY PREVENTION OF CORONARY HEART-DISEASE SO BRITISH HEART JOURNAL LA English DT Article ID MORTALITY RP CASTELLI, WP (reprint author), NHLBI,FRAMINGHAM HEART STUDY,5 THURBER ST,FRAMINGHAM,MA 01701, USA. NR 10 TC 9 Z9 9 U1 0 U2 0 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR SN 0007-0769 J9 BRIT HEART J JI Br. Heart J. PD JAN PY 1993 VL 69 IS 1 SU S BP S70 EP S73 PG 4 WC Cardiac & Cardiovascular Systems; History & Philosophy Of Science SC Cardiovascular System & Cardiology; History & Philosophy of Science GA KH497 UT WOS:A1993KH49700012 PM 8427768 ER PT J AU TORRI, V KORN, EL SIMON, R AF TORRI, V KORN, EL SIMON, R TI DOSE INTENSITY ANALYSIS IN ADVANCED OVARIAN-CANCER PATIENTS SO BRITISH JOURNAL OF CANCER LA English DT Article ID PROSPECTIVE RANDOMIZED TRIAL; ADRIAMYCIN PLUS CYCLOPHOSPHAMIDE; CYTO-TOXIC CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; STAGE-III; CLINICAL-TRIAL; CIS-PLATINUM; INITIAL CHEMOTHERAPY; ONCOLOGY-GROUP; SINGLE AGENT AB To determine if chemotherapy dose intensity influences treatment outcome in advanced ovarian cancer, all randomised studies of first line chemotherapy, published between 1975 and 1989, were analysed for relationships between planned dose intensity and (a) objective response and (b) median survival. Total dose intensity of each study regimen was calculated and a weighted regression model providing for systemic differences in response or survival among studies was utilised. Hence, treatment arms of different studies were never directly compared. In addition, relative dose intensities of individual drugs within combinations was similarly evaluated. The improvement in objective response rate when adding one unit of total dose intensity ranged between 12% and 16% depending on baseline response rate. The improvement in median survival when adding one unit of total dose intensity ranged between 2 and 4 months. One unit of total dose intensity corresponds to, for example, 20 mg m2 week of cisplatin, or 25 Mg M2 week of doxorubicin, or 350 mg m2 week of cyclophosphamide. The analysis of individual drugs suggested that doxorubicin and the platinum compounds were about equally effective. with cyclophosphamide being less effective. The methodological benefits and limitations of the approach used and the implication of the results are discussed. C1 NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,BIOMETR RES BRANCH,BETHESDA,MD 20892. IST RIC FARMACOL MARIO NEGRI,I-20157 MILAN,ITALY. NR 67 TC 14 Z9 14 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS SN 0007-0920 J9 BRIT J CANCER JI Br. J. Cancer PD JAN PY 1993 VL 67 IS 1 BP 190 EP 197 DI 10.1038/bjc.1993.33 PG 8 WC Oncology SC Oncology GA KH883 UT WOS:A1993KH88300033 PM 8427779 ER PT J AU LINET, MS MALKER, HSR MCLAUGHLIN, JK WEINER, JA BLOT, WJ ERICSSON, JLE FRAUMENI, JF AF LINET, MS MALKER, HSR MCLAUGHLIN, JK WEINER, JA BLOT, WJ ERICSSON, JLE FRAUMENI, JF TI NON-HODGKINS-LYMPHOMA AND OCCUPATION IN SWEDEN - A REGISTRY BASED ANALYSIS SO BRITISH JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article ID SOFT-TISSUE SARCOMA; CANCER MORTALITY; MALIGNANT-LYMPHOMA; DEATH-CERTIFICATE; ORGANIC-SOLVENTS; UNITED-STATES; WORKERS; EXPOSURE; INDUSTRY; BENZENE AB Incidence of non-Hodgkin's lymphoma in different employment categories was evaluated from the Swedish Cancer-Environment Registry, which links cancer incidence during 1961 to 1979 with occupational information from the 1960 census. New associations were found for men employed in shoemaking and shoe repair, porcelain and earthenware industries, education, and other white collar occupations. Several findings supported associations found in other countries, including excesses among woodworkers, furniture makers, electric power plant workers, farmers, dairy workers, lorry drivers, and other land transport workers. Risks were not increased among chemists, chemical or rubber manufacturing workers, or petrochemical refinery workers. Caution must be used in drawing causal inferences from these linked registry data because information on exposure and duration of employment is not available. Nevertheless, this study has suggested new clues to possible occupational determinants of non-Hodgkin's lymphoma. C1 NATL BOARD HLTH & WELF,STOCKHOLM,SWEDEN. NATL BOARD OCCUPAT SAFETY & HLTH,S-17184 SOLNA,SWEDEN. RP LINET, MS (reprint author), NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,EPN 415B,ROCKVILLE,MD 20892, USA. NR 86 TC 37 Z9 39 U1 0 U2 0 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR SN 0007-1072 J9 BRIT J IND MED PD JAN PY 1993 VL 50 IS 1 BP 79 EP 84 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA KH117 UT WOS:A1993KH11700012 PM 8431395 ER PT J AU GOLDBERG, TE GREENBERG, RD GRIFFIN, SJ GOLD, JM KLEINMAN, JE PICKAR, D SCHULZ, SC WEINBERGER, DR AF GOLDBERG, TE GREENBERG, RD GRIFFIN, SJ GOLD, JM KLEINMAN, JE PICKAR, D SCHULZ, SC WEINBERGER, DR TI THE EFFECT OF CLOZAPINE ON COGNITION AND PSYCHIATRIC-SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA SO BRITISH JOURNAL OF PSYCHIATRY LA English DT Article ID PSYCHOPATHOLOGY DIMENSIONS; PERFORMANCE; DISORDER; MEMORY; CHLORPROMAZINE; NEUROLEPTICS; HALOPERIDOL; STABILITY; RECEPTORS; AFFINITY AB Psychiatric symptoms and cognition were assessed in 13 patients with schizophrenia, one patient with schizoaffective disorder, and one patient with psychosis not otherwise specified while they received a conventional neuroleptic and again after an average of 1 5 months on clozapine. Despite improvements in psychiatric symptoms, attention, memory, and higher-level problem-solving were essentially unchanged. This suggests that certain cognitive deficits are relatively independent of psychotic symptoms in schizophrenia, and are probably central and enduring features of the disorder. Cognitive disability appeared to have been rate-limiting in the sample's rehabilitation, as patients' social and vocational adjustment remained marginal during the study. We also observed that treatment with clozapine was associated with a decline in some memory functions; the potent anticholinergic properties of the drug may have been responsible for this. C1 PSYCHIAT INST WASHINGTON DC,CLIN NEUROSCI PROGRAM,WASHINGTON,DC. CASE WESTERN RESERVE UNIV,DEPT PSYCHIAT,CLEVELAND,OH 44106. NIMH,INTRAMURAL RES PROGRAM,CLIN SERV BRANCH,WASHINGTON,DC 20032. NIMH,INTRAMURAL RES PROGRAM,CLIN NEUROSCI BRANCH,WASHINGTON,DC 20032. RP GOLDBERG, TE (reprint author), NIMH,NEUROSCI CTR ST ELIZABETHS,INTRAMURAL RES PROGRAM,WASHINGTON,DC 20032, USA. NR 50 TC 240 Z9 243 U1 1 U2 4 PU ROYAL COLLEGE OF PSYCHIATRISTS PI LONDON PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON, ENGLAND SW1X 8PG SN 0007-1250 J9 BRIT J PSYCHIAT JI Br. J. Psychiatry PD JAN PY 1993 VL 162 BP 43 EP 48 DI 10.1192/bjp.162.1.43 PG 6 WC Psychiatry SC Psychiatry GA KF950 UT WOS:A1993KF95000007 PM 8425138 ER PT J AU JONES, PB BEBBINGTON, P FOERSTER, A LEWIS, SW MURRAY, RM RUSSELL, A SHAM, PC TOONE, BK WILKINS, S AF JONES, PB BEBBINGTON, P FOERSTER, A LEWIS, SW MURRAY, RM RUSSELL, A SHAM, PC TOONE, BK WILKINS, S TI PREMORBID SOCIAL UNDERACHIEVEMENT IN SCHIZOPHRENIA - RESULTS FROM THE CAMBERWELL COLLABORATIVE PSYCHOSIS STUDY SO BRITISH JOURNAL OF PSYCHIATRY LA English DT Article ID INTELLIGENCE; DEMENTIA; SEX AB In an investigation of the timing and precursors of social decline in schizophrenia and affective psychosis, 195 subjects from the Camberwell Collaborative Psychosis Study were currently of lower social class than were their fathers. A comparison between father's occupation and proband's best premorbid occupational level indicated underachievement confined to DSM-III schizophrenia, there being no such effect in affective psychosis. Decline in social status following onset of psychosis, analysed by comparing best premorbid occupation with current occupation, was marked in both schizophrenia and affective psychosis, indicating a non-specific effect. Schizophrenic patients who failed to achieve their fathers' social status had poorer educational qualifications than those who equalled or bettered their paternal social class, despite similar premorbid IQ (NART) scores and age at onset of psychosis. These results indicate that schizophrenia may be manifest before the onset of psychosis, and lend weight to the notion of a developmental origin to this disorder. C1 KINGS COLL HOSP,LONDON SE5 8AF,ENGLAND. CHARING CROSS & WESTMINSTER MED SCH,ACAD DEPT PSYCHIAT,LONDON W6 8RP,ENGLAND. KINGS COLL HOSP,LONDON SE5 9RS,ENGLAND. INST PSYCHIAT,MRC,SOCIAL & COMMUNITY PSYCHIAT UNIT,LONDON SE5 8AF,ENGLAND. INST PSYCHIAT,GENET SECT,LONDON SE5 8AF,ENGLAND. NIMH,BETHESDA,MD 20892. MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 9RS,ENGLAND. RP JONES, PB (reprint author), INST PSYCHIAT,DEPT PSYCHOL MED,DECRESPIGNY PK,LONDON SE5 8AF,ENGLAND. RI Bebbington, Paul/C-1939-2008; Russell, Ailsa/F-2484-2010; Russell, Ailsa/J-8268-2013; Murray, Robin/F-8658-2012; OI Bebbington, Paul/0000-0002-6030-7456; Russell, Ailsa/0000-0002-8443-9381; Murray, Robin/0000-0003-0829-0519; Lewis, Shon/0000-0003-1861-4652; Jones, Peter/0000-0002-0387-880X FU Wellcome Trust NR 34 TC 145 Z9 147 U1 0 U2 6 PU ROYAL COLLEGE OF PSYCHIATRISTS PI LONDON PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON, ENGLAND SW1X 8PG SN 0007-1250 J9 BRIT J PSYCHIAT JI Br. J. Psychiatry PD JAN PY 1993 VL 162 BP 65 EP 71 DI 10.1192/bjp.162.1.65 PG 7 WC Psychiatry SC Psychiatry GA KF950 UT WOS:A1993KF95000011 PM 8425142 ER PT J AU BEBBINGTON, P WILKINS, S JONES, P FOERSTER, A MURRAY, R TOONE, B LEWIS, S AF BEBBINGTON, P WILKINS, S JONES, P FOERSTER, A MURRAY, R TOONE, B LEWIS, S TI LIFE EVENTS AND PSYCHOSIS - INITIAL RESULTS FROM THE CAMBERWELL COLLABORATIVE PSYCHOSIS STUDY SO BRITISH JOURNAL OF PSYCHIATRY LA English DT Article ID PRIMARY AFFECTIVE-DISORDER; ENDOGENOUS-DEPRESSION; PRECIPITATING FACTORS; SCHIZOPHRENIA; ONSET; RELAPSE; MANIA; STRESS AB Data from the Camberwell Collaborative Psychosis Study were used to examine the proposition that there is an excess of life events preceding the onset of psychoses of all types. Of 97 patients from the study who had episodes within the past year that were datable, 51 had developed psychotic symptoms from an essentially symptom-free state, 29 had been suffering only from neurotic symptoms, and 17 had experienced a marked exacerbation of psychotic symptoms. DSM-III diagnoses were collapsed into three major groups: 51 cases of schizophrenia; 31 cases of mania; and 14 cases of depressive psychosis. Life-event histories were taken for the six months before onset, and when these were compared with equivalent histories from a psychiatrically healthy sample from the local general population, there was a significant excess of life events, particularly in the three months before onset of psychosis. This was apparent in all groups, and remained even when events were restricted to the independent category. The excess of events began rather earlier than has been found in previous studies. In our view, this study provides some of the strongest evidence for a link between life events and the emergence of psychotic symptoms. C1 KINGS COLL HOSP,LONDON SE5 8AF,ENGLAND. KINGS COLL HOSP,LONDON SE5 9RS,ENGLAND. CHARING CROSS & WESTMINSTER MED SCH,ACAD DEPT PSYCHIAT,LONDON W6 8RP,ENGLAND. INST PSYCHIAT,GENET SECT,LONDON SE5 8AF,ENGLAND. INST PSYCHIAT,DEPT PSYCHOL MED,LONDON SE5 8AF,ENGLAND. NIMH,BETHESDA,MD 20892. MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 9RS,ENGLAND. RP BEBBINGTON, P (reprint author), INST PSYCHIAT,MRC,SOCIAL & COMMUNITY PSYCHIAT UNIT,DECRESPIGNY PK,LONDON SE5 8AF,ENGLAND. RI Bebbington, Paul/C-1939-2008; OI Bebbington, Paul/0000-0002-6030-7456; Lewis, Shon/0000-0003-1861-4652; Jones, Peter/0000-0002-0387-880X; murray, robin/0000-0003-0829-0519 NR 54 TC 160 Z9 161 U1 1 U2 15 PU ROYAL COLLEGE OF PSYCHIATRISTS PI LONDON PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON, ENGLAND SW1X 8PG SN 0007-1250 J9 BRIT J PSYCHIAT JI Br. J. Psychiatry PD JAN PY 1993 VL 162 BP 72 EP 79 DI 10.1192/bjp.162.1.72 PG 8 WC Psychiatry SC Psychiatry GA KF950 UT WOS:A1993KF95000012 PM 8425143 ER PT J AU JEKA, JJ KELSO, JAS KIEMEL, T AF JEKA, JJ KELSO, JAS KIEMEL, T TI PATTERN SWITCHING IN HUMAN MULTILIMB COORDINATION DYNAMICS SO BULLETIN OF MATHEMATICAL BIOLOGY LA English DT Article ID PHASE-TRANSITIONS; OSCILLATORS; WALKING; MODEL AB A relative phase model of four coupled oscillators is used to interpret experiments on the coordination between rhythmically moving human limbs. The pairwise coupling functions in the model are motivated by experiments on two-limb coordination. Stable patterns of coordination between the limbs are represented by fixed points in relative phase coordinates. Four invariant circles exist in the model, each containing two patterns of coordination seen experimentally. The direction of switches between two four-limb patterns on the same circle can be understood in terms of two-limb coordination. Transitions between patterns in the human four-limb system are theoretically interpreted as bifurcations in a nonlinear dynamical system. C1 FLORIDA ATLANTIC UNIV,CTR COMPLEX SYST,PROGRAM COMPLEX SYST & BRAIN SCI,BOCA RATON,FL 33431. NIDDK,MATH RES BRANCH,BETHESDA,MD 20892. FU NIMH NIH HHS [NIMH MH19116-01, NIMH MH42900-01] NR 19 TC 26 Z9 26 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0092-8240 J9 B MATH BIOL JI Bull. Math. Biol. PY 1993 VL 55 IS 4 BP 829 EP 845 DI 10.1007/BF02460675 PG 17 WC Biology; Mathematical & Computational Biology SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology GA LE384 UT WOS:A1993LE38400007 PM 8318931 ER PT J AU LINDBERG, DAB AF LINDBERG, DAB TI THE NATIONAL-LIBRARY-OF-MEDICINE AND ITS ROLE SO BULLETIN OF THE MEDICAL LIBRARY ASSOCIATION LA English DT Editorial Material RP LINDBERG, DAB (reprint author), NATL LIB MED,BETHESDA,MD 20209, USA. NR 1 TC 6 Z9 6 U1 0 U2 0 PU MED LIBRARY ASSN PI CHICAGO PA SUITE 300 6 N MICHIGAN AVE, CHICAGO, IL 60602 SN 0025-7338 J9 B MED LIBR ASSOC JI Bull. Med. Libr. Assoc. PD JAN PY 1993 VL 81 IS 1 BP 71 EP 73 PG 3 WC Information Science & Library Science SC Information Science & Library Science GA KH515 UT WOS:A1993KH51500014 PM 8428196 ER PT J AU MEHNERT, R AF MEHNERT, R TI NLM DIRECTOR TO HEAD NATIONAL OFFICE OF HIGH-PERFORMANCE COMPUTING AND COMMUNICATIONS SO BULLETIN OF THE MEDICAL LIBRARY ASSOCIATION LA English DT Editorial Material RP MEHNERT, R (reprint author), NATL LIB MED,BETHESDA,MD 20209, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MED LIBRARY ASSN PI CHICAGO PA SUITE 300 6 N MICHIGAN AVE, CHICAGO, IL 60602 SN 0025-7338 J9 B MED LIBR ASSOC JI Bull. Med. Libr. Assoc. PD JAN PY 1993 VL 81 IS 1 BP 82 EP 82 PG 1 WC Information Science & Library Science SC Information Science & Library Science GA KH515 UT WOS:A1993KH51500018 PM 16018022 ER PT J AU HARB, M FARIS, R GAD, AM HAFEZ, ON RAMZY, R BUCK, AA AF HARB, M FARIS, R GAD, AM HAFEZ, ON RAMZY, R BUCK, AA TI THE RESURGENCE OF LYMPHATIC FILARIASIS IN THE NILE DELTA SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article AB A study of 325 000 residents of 314 villages in six governorates of the Nile delta area of Egypt revealed that the prevalence of lymphatic filariasis increased from <1% in 1965 to >20% in 1991, especially in the governorates of Qalyubiya, Monufiya, Dakhaliya, and Giza. The distribution of the communities with endemic filariasis is focal. Clusters of villages with high prevalences are surrounded by others in which the disease is absent, although their environmental, social, and agricultural features appear similar. The article analyses why the significant decline in filariasis between 1945 and 1965 in Egypt has been followed by a resurgence of the disease. C1 AIN SHAMS UNIV,FAC MED,DEPT COMMUNITY MED,RAMSES ST,CAIRO,EGYPT. MINIST HLTH CAIRO,DIV MALARIA & FILARIASIS CONTROL,CAIRO,EGYPT. AIN SHAMS UNIV,REG CTR EPIDEMIOL & CONTROL VECTOR BORNE DIS,CAIRO,EGYPT. JOHNS HOPKINS UNIV,DEPT IMMUNOL & INFECT DIS,BALTIMORE,MD 21218. NIAID,BETHESDA,MD 20892. FU NIAID NIH HHS [N0I-AI-22667] NR 22 TC 43 Z9 51 U1 0 U2 0 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA DISTRIBUTION AND SALES, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PY 1993 VL 71 IS 1 BP 49 EP 54 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA KR352 UT WOS:A1993KR35200006 PM 8440037 ER PT J AU MILLER, BA FEUER, EJ HANKEY, BF AF MILLER, BA FEUER, EJ HANKEY, BF TI RECENT INCIDENCE TRENDS FOR BREAST-CANCER IN WOMEN AND THE RELEVANCE OF EARLY DETECTION - AN UPDATE SO CA-A CANCER JOURNAL FOR CLINICIANS LA English DT Article AB The incidence of breast cancer in women has been rising dramatically in the United States since 1982, based on data collected by the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute. An additional three years of incidence and mortality data are included in this update of the earlier analyses, however, the focus of this report remains on examining the steeply increasing incidence trend between 1982 and 1986. Over this period, incidence rates for in situ and localized invasive tumors increased among women age 50 and older, while rates for regional and distant tumors remained stable. The incidence of localized tumors less than 1.0, 1.0 to 1.9, and 2.0 to 2.9 cm in size increased more rapidly than that of tumors 3.0 cm and greater among women over age 50. Survival rates also improved among cases diagnosed over this time period. These descriptive data suggest that early detection may be playing a role in the recent increase in the incidence of breast cancer in women, although other factors cannot be ruled out. Conclusions regarding improved cancer control await confirmation by reduced breast cancer mortality. RP MILLER, BA (reprint author), NCI,DIV CANC PREVENT & CONTROL,SURVEILLANCE PROGRAM,CANC STAT BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 101 Z9 103 U1 0 U2 1 PU AMER CANCER SOC PI NEW YORK PA C/O JB LIPPINCOTT CO 1180 AVE OF THE AMERICAS 6TH FLOOR, NEW YORK, NY 10036 SN 0007-9235 J9 CA-CANCER J CLIN JI CA-Cancer J. Clin. PD JAN-FEB PY 1993 VL 43 IS 1 BP 27 EP 41 DI 10.3322/canjclin.43.1.27 PG 15 WC Oncology SC Oncology GA KG105 UT WOS:A1993KG10500003 PM 8422603 ER PT J AU SHERMAN, S HADLEY, EC AF SHERMAN, S HADLEY, EC TI AGING AND BONE QUALITY - AN UNDEREXPLORED FRONTIER SO CALCIFIED TISSUE INTERNATIONAL LA English DT Editorial Material RP SHERMAN, S (reprint author), NIA,GERIATR PROGRAM,7201 WISCONSIN AVE,BETHESDA,MD 20892, USA. NR 0 TC 19 Z9 19 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0171-967X J9 CALCIFIED TISSUE INT JI Calcif. Tissue Int. PY 1993 VL 53 SU 1 BP S1 EP S1 DI 10.1007/BF01673392 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA LW987 UT WOS:A1993LW98700001 PM 8275360 ER PT S AU LONGO, DL AF LONGO, DL BE Kimura, K Yamada, K Carter, SK Longo, DL TI TREATMENT OF AGGRESSIVE LYMPHOMAS - RECENT PROGRESS AND FUTURE-PROSPECTS SO CANCER CHEMOTHERAPY: CHALLENGES FOR THE FUTURE, VOL 8 SE INTERNATIONAL CONGRESS SERIES LA English DT Proceedings Paper CT 8th Nagoya International Symposium on Cancer Treatment: New Therapeutic Concepts and Their Clinical Implications CY OCT 16-17, 1992 CL NAGOYA, JAPAN RP LONGO, DL (reprint author), NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0531-5131 BN 0-444-81694-1 J9 INT CONGR SER PY 1993 VL 1048 BP 3 EP 14 PG 12 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA BZ58P UT WOS:A1993BZ58P00002 ER PT S AU KAWAKAMI, Y ROSENBERG, SA AF KAWAKAMI, Y ROSENBERG, SA BE Kimura, K Yamada, K Carter, SK Longo, DL TI IMMUNOTHERAPY AND GENE-THERAPY FOR HUMAN CANCER USING T-LYMPHOCYTES SO CANCER CHEMOTHERAPY: CHALLENGES FOR THE FUTURE, VOL 8 SE INTERNATIONAL CONGRESS SERIES LA English DT Proceedings Paper CT 8th Nagoya International Symposium on Cancer Treatment: New Therapeutic Concepts and Their Clinical Implications CY OCT 16-17, 1992 CL NAGOYA, JAPAN RP KAWAKAMI, Y (reprint author), NCI,SURG BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0531-5131 BN 0-444-81694-1 J9 INT CONGR SER PY 1993 VL 1048 BP 39 EP 44 PG 6 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA BZ58P UT WOS:A1993BZ58P00005 ER PT S AU CANETTA, R ARBUCK, S ONETTO, N ROZENCWEIG, M CARTER, SK AF CANETTA, R ARBUCK, S ONETTO, N ROZENCWEIG, M CARTER, SK BE Kimura, K Yamada, K Carter, SK Longo, DL TI OVERVIEW OF THE CLINICAL-RESULTS OF TAXOL SO CANCER CHEMOTHERAPY: CHALLENGES FOR THE FUTURE, VOL 8 SE INTERNATIONAL CONGRESS SERIES LA English DT Proceedings Paper CT 8th Nagoya International Symposium on Cancer Treatment: New Therapeutic Concepts and Their Clinical Implications CY OCT 16-17, 1992 CL NAGOYA, JAPAN C1 NCI,BETHESDA,MD 20892. RP CANETTA, R (reprint author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,WALLINGFORD,CT, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0531-5131 BN 0-444-81694-1 J9 INT CONGR SER PY 1993 VL 1048 BP 309 EP 315 PG 7 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA BZ58P UT WOS:A1993BZ58P00032 ER PT J AU PASTAN, IH AF PASTAN, IH TI RECOMBINANT IMMUNOTOXINS - NEW THERAPEUTIC AGENTS FOR CANCER-TREATMENT SO CANCER DETECTION AND PREVENTION LA English DT Article; Proceedings Paper CT INTERNATIONAL SYMP ON THE ROLE OF BIOTECHNOLOGIES IN PREVENTIVE ONCOLOGY CY JUN 11-12, 1992 CL SAN REMO, ITALY SP INT SOC PREVENT ONCOL, NATL INST CANC RES GENOA DE PSEUDOMONAS EXOTOXIN; CHEMOTHERAPY AB We have developed new agents for the treatment of cancer by genetically modifying Pseudomonas exotoxin. We have deleted the cell-binding region of Pseudomonas exotoxin and replaced it with various growth factors or the combining regions of antibodies in a single chain form. These new recombinant molecules are called recombinant toxins. Several different types of recombinant toxins have been produced. B3(Fv)-PE38KDEL is a recombinant toxin that kills many different adenocarcinomas and epidermoid carcinomas. The molecule is now undergoing preclinical development. RP PASTAN, IH (reprint author), NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 0 TC 1 Z9 2 U1 0 U2 2 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0361-090X J9 CANCER DETECT PREV JI Cancer Detect. Prev. PY 1993 VL 17 IS 2 BP 289 EP 293 PG 5 WC Oncology SC Oncology GA LR050 UT WOS:A1993LR05000007 PM 8402714 ER PT J AU FERRARI, N TOSETTI, F PFEFFER, U PROFUMO, A VIDALI, G AF FERRARI, N TOSETTI, F PFEFFER, U PROFUMO, A VIDALI, G TI EXPRESSION OF RETINOIC ACID RECEPTORS DURING RETINOIC ACID-INDUCED CELL-DIFFERENTIATION SO CANCER DETECTION AND PREVENTION LA English DT Article; Proceedings Paper CT INTERNATIONAL SYMP ON THE ROLE OF BIOTECHNOLOGIES IN PREVENTIVE ONCOLOGY CY JUN 11-12, 1992 CL SAN REMO, ITALY SP INT SOC PREVENT ONCOL, NATL INST CANC RES GENOA DE RETINOIDS; DIFFERENTIATION; RECEPTORS RP FERRARI, N (reprint author), NATL CANC INST,MOLEC BIOL LAB,VIALE BENEDETTO XV 10,I-16132 GENOA,ITALY. RI Tosetti, Francesca/I-7866-2012 NR 0 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0361-090X J9 CANCER DETECT PREV JI Cancer Detect. Prev. PY 1993 VL 17 IS 2 BP 349 EP 349 PG 1 WC Oncology SC Oncology GA LR050 UT WOS:A1993LR05000023 ER PT J AU GLYNN, TJ MANLEY, MW MILLS, SL SHOPLAND, DR AF GLYNN, TJ MANLEY, MW MILLS, SL SHOPLAND, DR TI THE UNITED-STATES NATIONAL-CANCER-INSTITUTE AND THE SCIENCE OF TOBACCO CONTROL RESEARCH SO CANCER DETECTION AND PREVENTION LA English DT Article; Proceedings Paper CT INTERNATIONAL CONF ON CANCER IN POLAND AND CURRENT PROSPECTS FOR CANCER CONTROL CY NOV 17-19, 1992 CL WARSAW, POLAND SP INT SOC PREVENT ONCOL DE SMOKING PREVENTION; SMOKING CESSATION; TOBACCO USE CONTROL AB U.S. efforts to control tobacco use and tobacco-related morbidity and mortality have been reasonably successful over the past 3 decades, during which there has been a 34% reduction in adult smoking. Nevertheless, tobacco use remains a significant public health problem in the U.S., with more than 430,000 tobacco-related deaths per year and over one fourth of the population continuing to smoke. Many organizations are involved in tobacco-use control activities, the most broadly focused of which is that of the National Cancer Institute (NCI). The NCI's program is described and its emphasis on a data-based decision matrix in its approach to tobacco and cancer control research and applications of research is discussed. Finally, future approaches to tobacco-use control in the U.S. are suggested. RP GLYNN, TJ (reprint author), NCI,EPN 243,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0361-090X J9 CANCER DETECT PREV JI Cancer Detect. Prev. PY 1993 VL 17 IS 4-5 BP 507 EP 512 PG 6 WC Oncology SC Oncology GA MB001 UT WOS:A1993MB00100008 PM 8242650 ER PT J AU SANTI, L AF SANTI, L TI ROLE OF BIOTECHNOLOGY IN PREVENTIVE ONCOLOGY - INTRODUCTION SO CANCER DETECTION AND PREVENTION LA English DT Editorial Material RP SANTI, L (reprint author), NATL CANC INST,GENOA,ITALY. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0361-090X J9 CANCER DETECT PREV JI Cancer Detect. Prev. PY 1993 VL 17 IS 2 BP U261 EP U261 PG 1 WC Oncology SC Oncology GA LR050 UT WOS:A1993LR05000002 ER PT J AU HSING, AW COMSTOCK, GW AF HSING, AW COMSTOCK, GW TI SEROLOGICAL PRECURSORS OF CANCER - SERUM HORMONES AND RISK OF SUBSEQUENT PROSTATE-CANCER SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID PLASMA STEROIDS; BLADDER-CANCER; BETA-CAROTENE; COLON CANCER; WISTAR RATS; TOBACCO USE; TESTOSTERONE; CARCINOMA; PROLACTIN; DIHYDROTESTOSTERONE AB A population-based nested case-control study was conducted to determine the relation of prediagnostic serum levels of testosterone, dihydrotestosterone, prolactin, follicle-stimulating hormone, luteinizing hormone, estrone, and estradiol to the risk of subsequent prostate cancer. Serum specimens of study subjects were available from a blood collection campaign in Washington County, Maryland, in 1974. Serum hormone levels of 98 histologically confirmed prostate cancer cases diagnosed in the subsequent 13 years were compared to those of 98 controls who were individually matched to cases on the basis of age (within weeks), sex, and race. There were no significant differences in levels of these hormones between cases and controls, although elevated levels of luteinizing hormone and of testosterone:dihydrotestosterone ratios were associated with mild increased risks of prostate cancer. C1 JOHNS HOPKINS UNIV,BALTIMORE,MD 21205. NCI,DIV CANC ETIOL,BETHESDA,MD 20892. FU NCI NIH HHS [T32CA09314-07, CA 36390]; NHLBI NIH HHS [HL21670] NR 66 TC 100 Z9 101 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106 SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JAN-FEB PY 1993 VL 2 IS 1 BP 27 EP 32 PG 6 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA KF997 UT WOS:A1993KF99700005 PM 8420607 ER PT J AU PALLI, D DECARLI, A CIPRIANI, F SITAS, F FORMAN, D AMADORI, D AVELLINI, C GIACOSA, A MANCA, P RUSSO, A SAMLOFF, IM FRAUMENI, JF BLOT, WJ BUIATTI, E AF PALLI, D DECARLI, A CIPRIANI, F SITAS, F FORMAN, D AMADORI, D AVELLINI, C GIACOSA, A MANCA, P RUSSO, A SAMLOFF, IM FRAUMENI, JF BLOT, WJ BUIATTI, E TI HELICOBACTER-PYLORI ANTIBODIES IN AREAS OF ITALY AT VARYING GASTRIC-CANCER RISK SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID CAMPYLOBACTER-PYLORI; INFECTION; ASSOCIATION; PREVALENCE; DIET; POPULATION; CARCINOMA; SERODIAGNOSIS; MUCOSA; SAMPLE AB In a survey of 930 adults aged 35-74 years randomly sampled from the general population of four areas of Italy, two at low and two at high risk for gastric cancer, plasma levels of Helicobacter pylori IgG antibodies were assayed in order to investigate associations with the geographical distribution of gastric cancer and other dietary and life-style factors, as assessed by personal interview. H. pylori positivity (antibody liter above or equal to 10 mug/ml), 45% overall, increased with age and was inversely associated with social class but showed little geographical variation or association with dietary variables and blood nutrients. H. pylori positivity was also associated with increased blood levels of pepsinogens, particularly pepsinogen II. The authors discuss these findings in relation to those from a previous case-control study of gastric cancer in the same areas. C1 UNIV MILAN,IST STAT MED & BIOMET,I-20133 MILAN,ITALY. IST NAZL TUMORI,I-20133 MILAN,ITALY. ICRF,CANC EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND. OSPED MORGAGNI PIERANTONI,SERV ONCOL,I-47010 FORLI,ITALY. OSPED IMOLA,SERV ANAT PATOL,I-40026 IMOLA,ITALY. IST NAZL RIC CANC,I-16132 GENOA,ITALY. UNIV CAGLIARI,IST MED LAVORO,I-90100 CAGLIARI,ITALY. VET ADM MED CTR,SEPULVEDA,CA 91343. NCI,BETHESDA,MD 20892. RP PALLI, D (reprint author), CTR STUDIO & PREVENZ ONCOL,EPIDEMIOL UNIT,VIALE VOLTA 171,I-50131 FLORENCE,ITALY. RI Decarli, Adriano/C-3129-2017; OI Decarli, Adriano/0000-0003-1451-8292; Sitas, Freddy/0000-0001-9679-1481; PALLI, Domenico/0000-0002-5558-2437; Russo, Antonio Giampiero/0000-0002-5681-5861 FU NCI NIH HHS [N01-CP-51019] NR 31 TC 61 Z9 63 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106 SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JAN-FEB PY 1993 VL 2 IS 1 BP 37 EP 40 PG 4 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA KF997 UT WOS:A1993KF99700007 PM 8420610 ER PT J AU PATEL, AR OBRAMS, GI AF PATEL, AR OBRAMS, GI TI EPIDEMIOLOGY OF OVARIAN-CANCER SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Editorial Material ID EUROPEAN CASE-CONTROL; POOLED ANALYSIS; RISK; DIET; DETERMINANTS; PATHOGENESIS; VEGETARIAN; INFERENCES RP PATEL, AR (reprint author), NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892, USA. NR 17 TC 8 Z9 8 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106 SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JAN-FEB PY 1993 VL 2 IS 1 BP 79 EP 83 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA KF997 UT WOS:A1993KF99700014 PM 8420616 ER PT J AU FALK, RT PICKLE, LW AF FALK, RT PICKLE, LW TI EPIDEMIOLOGY OF BRONCHIOLOALVEOLAR CARCINOMA - REPLY SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Letter C1 NATL CTR HLTH STAT,HYATTSVILLE,MD 20782. RP FALK, RT (reprint author), NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892, USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106 SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JAN-FEB PY 1993 VL 2 IS 1 BP 90 EP 90 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA KF997 UT WOS:A1993KF99700017 ER PT J AU HOM, SS ROSENBERG, SA TOPALIAN, SL AF HOM, SS ROSENBERG, SA TOPALIAN, SL TI SPECIFIC IMMUNE RECOGNITION OF AUTOLOGOUS TUMOR BY LYMPHOCYTES INFILTRATING COLON CARCINOMAS - ANALYSIS BY CYTOKINE SECRETION SO CANCER IMMUNOLOGY IMMUNOTHERAPY LA English DT Article DE COLON CARCINOMA; TUMOR-INFILTRATING LYMPHOCYTES; CYTOKINES ID NECROSIS-FACTOR-ALPHA; ACTIVATED KILLER CELLS; INTERFERON-GAMMA; COLORECTAL-CARCINOMA; STIMULATING FACTOR; IFN-GAMMA; HLA-DR; EXPRESSION; INTERLEUKIN-2; MELANOMA AB Tumor-infiltrating lymphocytes (TIL) were grown in the presence of interleukin-2 from 19 colon carcinoma specimens, including 1 primary lesion and 18 metastatic lesions. These cultures showed a median proliferation of 606-fold (range 13-fold to 28000-fold) over 49 culture days (range 26-76 days). By phenotype, mature cultures were 69% -99% CD3+ (mean 93%) and contained mixed populations of CD4+ and CD8+ cells (CD4>CD8 in 10 of 19 cultures). Fresh cryopreserved colon tumors were not lysed by autologous TIL in short-term Cr-51-release assays, and were poorly lysed by lymphokine-activated killer cells. Ten TIL cultures were assayed for cytokine secretion in response to autologous and allogeneic tumors during a 6- to 24-h coincubation. Culture supernatants were tested by ELISA for the presence of granulocyte/macrophage-colony-stimulating factor, interferon gamma, and tumor necrosis factor alpha. Of 10 TIL, 4 secreted at least two of these cytokines specifically in response to autologous and/or HLA-matched fresh allogeneic colon carcinomas, but not to melanomas or HLA-unmatched colon carcinomas. Cytokine secretion was mediated by both CD4+ and CD8+ TIL, and could be inhibited by mAb directed against the appropriate class of MHC antigen. These data provide evidence for specific, MHC-restricted immune recognition of human colon carcinomas by T lymphocytes. C1 NCI,DIV CANC TREATMENT,SURG BRANCH,BLDG 10,ROOM 2B42,BETHESDA,MD 20892. NR 24 TC 65 Z9 65 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0340-7004 J9 CANCER IMMUNOL IMMUN JI Cancer Immunol. Immunother. PD JAN PY 1993 VL 36 IS 1 BP 1 EP 8 DI 10.1007/BF01789124 PG 8 WC Oncology; Immunology SC Oncology; Immunology GA JY735 UT WOS:A1993JY73500001 PM 8422663 ER PT J AU MOURALI, N TABBANE, F MUENZ, LR BEHI, J BENMOUSSA, F JAZIRI, M LEVINE, PH AF MOURALI, N TABBANE, F MUENZ, LR BEHI, J BENMOUSSA, F JAZIRI, M LEVINE, PH TI 10-YEAR RESULTS UTILIZING CHEMOTHERAPY AS PRIMARY-TREATMENT IN NONMETASTATIC, RAPIDLY PROGRESSING BREAST-CANCER SO CANCER INVESTIGATION LA English DT Article ID REQUIRING PROLONGED OBSERVATION; COMBINED MODALITY APPROACH; INFLAMMATORY CARCINOMA; MANAGEMENT; SURGERY; PATIENT; DESIGN AB Eighty-three patients with rapidly progressing breast cancer (RPBC) were entered into a study of primary chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil) and subsequent randomization to surgery or radiotherapy for control of local/regional disease. Eighty-three of these patients with redness, warmth, and edema compatible with clinical ''inflammatory breast cancer'' served as the focus for our analysis of factors associated with improved survival. The stage-specific disease-free intervals (DFI) of 36 and 21 months were substantially longer than in the earlier series (26 and 16 months) from the same institution. The evaluation of individual prognostic indicators revealed that the initial tumor size and the initial response to chemotherapy were the two independent factors most important in predicting the DFI. The continuing unmaintained 1-year remission in at least 12 patients supports the rationale for aggressive therapy in RPBC or ''inflammatory breast cancer.'' C1 INST SALAH AZAIZ,TUNIS,TUNISIA. NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892. NCI,DIV CANC ETIOL,BIOMETRY BRANCH,CLIN TRIALS SECT,BETHESDA,MD 20892. FU NCI NIH HHS [NCI N01-CN-31009]; PHS HHS [07002-1] NR 23 TC 22 Z9 22 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0735-7907 J9 CANCER INVEST JI Cancer Invest. PY 1993 VL 11 IS 4 BP 363 EP 370 DI 10.3109/07357909309018867 PG 8 WC Oncology SC Oncology GA LN771 UT WOS:A1993LN77100001 PM 8324641 ER PT J AU MAHANTY, S NUTMAN, TB AF MAHANTY, S NUTMAN, TB TI THE BIOLOGY OF INTERLEUKIN-5 AND ITS RECEPTOR SO CANCER INVESTIGATION LA English DT Review ID COLONY-STIMULATING FACTOR; CELL-REPLACING FACTOR; EOSINOPHIL DIFFERENTIATION FACTOR; MESSENGER-RNA EXPRESSION; RECOMBINANT HUMAN INTERLEUKIN-5; TUMOR-ASSOCIATED EOSINOPHILIA; IMMUNOSPOT ELISPOT ASSAY; SPLENIC T-CELLS; FACTOR GM-CSF; BONE-MARROW RP MAHANTY, S (reprint author), NIAID,PARASIT DIS LAB,CLIN PARASITOL SECT,BLDG 4,ROOM 126,BETHESDA,MD 20892, USA. OI Mahanty, Siddhartha/0000-0003-1068-0524 NR 114 TC 14 Z9 14 U1 0 U2 1 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0735-7907 J9 CANCER INVEST JI Cancer Invest. PY 1993 VL 11 IS 5 BP 624 EP 634 DI 10.3109/07357909309011681 PG 11 WC Oncology SC Oncology GA MA214 UT WOS:A1993MA21400014 PM 8402230 ER PT J AU BASU, J DUTTAGUPTA, C VERMUND, SH AHN, C PALAN, PR ROMNEY, SL AF BASU, J DUTTAGUPTA, C VERMUND, SH AHN, C PALAN, PR ROMNEY, SL TI ALTERATIONS IN ERYTHROCYTE GLUTATHIONE METABOLISM ASSOCIATED WITH CERVICAL DYSPLASIAS AND CARCINOMA IN-SITU SO CANCER INVESTIGATION LA English DT Article ID HUMAN PAPILLOMAVIRUS INFECTION; UTERINE CERVIX; CELLS; NEOPLASIA; ACID AB The study was designed to test the hypothesis whether cervical dysplasias of the more severe grades are associated with elevated erythrocyte glutathione levels. Subjects were women who obtained Pap tests and were subsequently found (1) not to have any cervical lesions or (2) to have colposcopically visualized, biopsy-confirmed cervical abnormalities histopathologically diagnosed as mild, moderate, severe dysplasias, or carcinoma in situ (CIS). The erythrocyte levels of reduced glutathione (GSH), oxidized glutathione (GSSG), glutathione reductase (GR), glucose-6-phosphate dehydrogenase (G6PD), and 6-phosphogluconate dehydrogenase (6PGD) were analyzed from coded peripheral venous blood samples. GSH and GR concentrations increased with increasing severity of dysplasia. Exploratory data analysis and multiple pairwise comparisons suggested comparable levels of the glutathione-related variables between these histopathological pairs: (1) mild and moderate dysplasias or (2) severe dysplasia and CIS. We suggest that the changes in erythrocyte glutathione-related indices in conjunction with histopathological diagnosis may have the potential to distinguish between low- and high-grade cervical dysplastic lesions. C1 INDIAN STAT INST,BIOCHEM UNIT,CALCUTTA 700035,W BENGAL,INDIA. NIAID,DIV AIDS,EPIDEMIOL BRANCH,BETHESDA,MD 20892. CITY HOPE NATL MED CTR,DEPT BIOSTAT,DUARTE,CA 91010. RP BASU, J (reprint author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT OBSTET & GYNECOL,ULLMANN BLDG,ROOM 111,BRONX,NY 10461, USA. OI Vermund, Sten/0000-0001-7289-8698 NR 23 TC 4 Z9 4 U1 0 U2 1 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0735-7907 J9 CANCER INVEST JI Cancer Invest. PY 1993 VL 11 IS 6 BP 652 EP 659 DI 10.3109/07357909309046937 PG 8 WC Oncology SC Oncology GA MJ439 UT WOS:A1993MJ43900002 PM 8221197 ER PT J AU ZAKUT, R TOPALIAN, SL KAWAKAMI, Y MANCINI, M ELIYAHU, S ROSENBERG, SA AF ZAKUT, R TOPALIAN, SL KAWAKAMI, Y MANCINI, M ELIYAHU, S ROSENBERG, SA TI DIFFERENTIAL EXPRESSION OF MAGE-1, MAGE-2, AND MAGE-3 MESSENGER-RNA IN TRANSFORMED AND NORMAL HUMAN CELL-LINES SO CANCER RESEARCH LA English DT Note ID TUMOR-INFILTRATING LYMPHOCYTES; HUMAN-MELANOMA; ANTIGENS; RESTRICTION; RECOGNITION; IMMUNOTHERAPY; LYSIS AB The MAGE-1 gene codes for a tumor-specific antigen, MZ2-E, that elicited a cytotoxic T-lymphocyte response in the melanoma patient from whom it was derived. We have developed a simplified method, using polymerase chain reaction amplification of exon 3 followed by restriction enzyme pattern analysis, to distinguish expression of the MAGE-1 gene from MAGE-2 and MAGE-3, other members of this gene family. MAGE-1 mRNA was expressed in-53% of 17 melanoma lines, two of seven Epstein-Barr virus-transformed B-cell lines, and 2 of 5 breast cell lines including a line established from normal breast epithelium. MAGE-1 is not likely to be the common melanoma antigen recognized by the other HLA-A1- or HLA-A2-restricted cytotoxic T-lymphocytes examined in this study, but the fact that it is expressed in about 50% of melanoma cell lines makes it a reasonable target for the immunotherapy of patients bearing HLA-A1. C1 NCI,SURG BRANCH,9000 ROCKVILLE PIKE,BLDG 10,ROOM 2B47,BETHESDA,MD 20892. RI Kawakami, Yutaka /E-7429-2013 OI Kawakami, Yutaka /0000-0003-4836-2855 NR 19 TC 56 Z9 57 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106 SN 0008-5472 J9 CANCER RES JI Cancer Res. PD JAN 1 PY 1993 VL 53 IS 1 BP 5 EP 8 PG 4 WC Oncology SC Oncology GA KD719 UT WOS:A1993KD71900002 PM 8416750 ER PT J AU GROSS, AJ STEINBERG, SM REILLY, JG BLISS, DP BRENNAN, J LE, PT SIMMONS, A PHELPS, R MULSHINE, JL IHDE, DC JOHNSON, BE AF GROSS, AJ STEINBERG, SM REILLY, JG BLISS, DP BRENNAN, J LE, PT SIMMONS, A PHELPS, R MULSHINE, JL IHDE, DC JOHNSON, BE TI ATRIAL-NATRIURETIC-FACTOR AND ARGININE VASOPRESSIN PRODUCTION IN TUMOR-CELL LINES FROM PATIENTS WITH LUNG-CANCER AND THEIR RELATIONSHIP TO SERUM SODIUM SO CANCER RESEARCH LA English DT Article ID ANTIDIURETIC-HORMONE SECRETION; INAPPROPRIATE SECRETION; BRONCHOGENIC-CARCINOMA; PROGNOSTIC FACTORS; BLOOD-PRESSURE; SUBARACHNOID HEMORRHAGE; ALDOSTERONE SYSTEM; SEQUENCE-ANALYSIS; FACTOR PRECURSOR; RENAL-FUNCTION AB Patients with lung cancer (n = 263) were studied to determine the relationship among ectopic production of atrial natriuretic factors (ANF) and arginine vasopressin (AVP), serum sodium, and patient outcome. Of 133, 21 (16%) patients with small cell lung cancer (SCLC) had hyponatremia (serum sodium, <130 mmol/liter), compared to none of 130 (0%) patients with non-small cell lung cancer (P < 0.0001). Patients with extensive-stage SCLC and hyponatremia had shorter survival than patients with extensive stage SCLC and normal serum sodium values (P = 0.012). Of the 11 hyponatremic patients with SCLC and tumor cell lines available for study, 9 produced ANF mRNA, 7 of 11 produced AVP mRNA, and 5 of 11 produced both ANF mRNA and AVP mRNA. All 11 cell lines produced either ANF mRNA and ANF peptide or AVP mRNA and AVP peptide, or both. The quantity of AVP peptide in the tumor cell lines was more closely associated with hyponatremia in the patients (P = 0.0026, r2 = 0.28) than was the production of ANF peptide (P = 0.066, r2 = 0.12), although neither association was strong. All tumor cell lines studied from SCLC patients with hyponatremia produce ANF and/or AVP mRNA and peptides. C1 USN,NATL MED CTR,NCI,MED ONCOL BRANCH,BLDG 8,RM 5105,BETHESDA,MD 20889. UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20889. WASHINGTON HOSP CTR,DEPT MED,WASHINGTON,DC 20422. NCI,BIOSTAT & DATA MANAGEMENT SECT,BETHESDA,MD 20892. NR 80 TC 61 Z9 61 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106 SN 0008-5472 J9 CANCER RES JI Cancer Res. PD JAN 1 PY 1993 VL 53 IS 1 BP 67 EP 74 PG 8 WC Oncology SC Oncology GA KD719 UT WOS:A1993KD71900013 PM 8380126 ER PT J AU RAM, Z CULVER, KW WALBRIDGE, S BLAESE, RM OLDFIELD, EH AF RAM, Z CULVER, KW WALBRIDGE, S BLAESE, RM OLDFIELD, EH TI INSITU RETROVIRAL-MEDIATED GENE-TRANSFER FOR THE TREATMENT OF BRAIN-TUMORS IN RATS SO CANCER RESEARCH LA English DT Article ID THYMIDINE KINASE GENES; GLIOMA-CELLS; INVIVO; VECTOR; POTENT AB Gene transfer with vectors derived from murine retroviruses is restricted to cells which are proliferating and synthesizing DNA at the time of infection. This suggests that retroviral-mediated gene transfer might permit targeting of gene integration into malignant cells in organs composed mainly of quiescent nonproliferating cells, such as in the brain. Accordingly, selective introduction of genes encoding for susceptibility to otherwise nontoxic drugs (''suicide'' genes) into proliferating brain tumors may be used to treat this cancer. We investigated the efficacy and dynamics of in vivo transduction of growing brain tumors with the herpes simplex-thymidine kinase gene followed by administration of the antiviral drug ganciclovir. Ganciclovir is phosphorylated by thymidine kinase to toxic triphosphates that interfere with DNA synthesis, resulting in the preferential death of the transduced tumor cells. Rats inoculated with 4 X 10(4) 9L gliosarcoma cells into the frontal lobe were treated 7 days later with an intratumoral stereotaxic injection of murine fibroblasts (NIH 3T3 cells) that were producing a retroviral vector containing the herpes simplex-thymidine kinase gene. Controls received vector producer and nonproducer NIH 3T3 cell lines containing the Escherichia coli lacZ (beta-galactosidase) gene as well as nonproducer NIH 3T3 cells containing the thymidine kinase gene. The animals were rested for 7 days to allow time for in situ transduction of the proliferating tumor cells with the herpes-thymidine kinase retroviral vector. The animals were then treated with ganciclovir, 15 mg/kg i.p. twice a day for 14 days. Gliomas receiving an injection of 3-5 X 10(6) thymidine kinase producer cells regressed completely in 23 of 30 rats given ganciclovir therapy, while 25 of 26 control rats developed large tumors. Intratumoral injection of a lower concentration of thymidine kinase vector producer cells (1.8 X 10(6)) resulted in a lower frequency of tumor regression (5 of 13 rats). To estimate the efficiency of in vivo gene transfer, 9L brain tumors were given injections of 5 X 10(6) beta-galactosidase vector producer cells. 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranaside staining revealed maximal staining of beta-galactosidase within the tumor 7-14 days after injection of the vector producer cells. In vivo transduction rates in harvested tumors ranged from 10 to 70%. There was no evidence of transduction of the surrounding normal neural tissue. Occasional blood vessel endothelial cells within or adjacent to the tumor were observed to be 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranaside positive. It is probable that destruction of this local vasculature with ganciclovir therapy also contributes to the efficacy of tumor regression. Our results substantiate the feasibility of this approach for the treatment of malignant brain tumors in humans. C1 NCI,METAB BRANCH,BETHESDA,MD 20892. RP RAM, Z (reprint author), NINCDS,CTR CLIN,SURG NEUROL BRANCH,BLDG 10,ROOM 5D37,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 17 TC 487 Z9 490 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106 SN 0008-5472 J9 CANCER RES JI Cancer Res. PD JAN 1 PY 1993 VL 53 IS 1 BP 83 EP 88 PG 6 WC Oncology SC Oncology GA KD719 UT WOS:A1993KD71900015 PM 8380127 ER PT J AU SANDLUND, JT NECKERS, LM SCHNELLER, HE WOODRUFF, LS MAGRATH, IT AF SANDLUND, JT NECKERS, LM SCHNELLER, HE WOODRUFF, LS MAGRATH, IT TI THEOPHYLLINE INDUCED-DIFFERENTIATION PROVIDES DIRECT EVIDENCE FOR THE DEREGULATION OF C-MYC IN BURKITT-LYMPHOMA AND SUGGESTS PARTICIPATION OF IMMUNOGLOBULIN ENHANCER SEQUENCES SO CANCER RESEARCH LA English DT Article ID B-CELL LYMPHOMAS; LEUKEMIC-CELLS; CHAIN GENE; LOCUS; ONCOGENE; TRANSLOCATION; EXPRESSION; REARRANGEMENTS; TRANSCRIPTION; RNAS AB Most of the evidence that supports the hypothesis that the c-myc gene is abnormally regulated in Burkitt's lymphoma (BL) is indirect. The putative abnormal expression of c-myc is likely, at least in part, to be a consequence of the usurpation of its regulatory sequences by immunoglobulin enhancer elements, which are invariably juxtaposed to c-myc by the translocations associated with this tumor (C. M. Croce, J. Erikson, A. Ar-Rushdi, D. Aden, and K. Nishikura, Proc. Natl. Acad. Sci. USA, 81: 3170-3174, 1984). We have developed a differentiation induction model system to examine this issue more directly. In a variety of non-BL cell lines, differentiation induction results in the down-regulation of c-myc (G. P. Studzinski, A. K. Bhandal, and Z. S. Brelvi, Proc. Soc. Exp. Biol. Med., 179: 288-295, 1985; Y. Matsui, R. Takahasi, K. Minara, T. Nakagawa, T. Koizumi, Y. Nakao, T. Sugiyama, and T. Fugita, Cancer Res., 49: 1366-1371, 1985; T. Mitchell, E. Sariban, and D. Kufe, Mol. Pharmacol., 30: 398-402, 1986; Z. S. Brelvi, and G. P. Studzinski, J. Cell. Physiol., 128: 171-179, 1986). Since BL is of B-cell origin, differentiation is associated with persistent or increased expression of immunoglobulin genes. Therefore, if c-myc and c-mu are coregulated in BL via immunoglobulin enhancer sequences, persistent or increased expression of the c-myc gene, rather than down-regulation, should occur in differentiated BL cells. Differentiation was induced in four BL cell lines with theophylline (7 X 10(-3) M), and mRNA was examined by Northern blot analysis. In all four BL lines studied (JD38, AG876, KK124, and Daudi), there was persistent or increased expression of both c-mu and c-myc genes (detected with a third exon c-myc probe), in contrast to the decreased expression of the c-myc gene observed in the three Epstein-Barr virus transformed lines studied (A3317, TC84, and CB34). In the BL cell line, JD38, the c-myc gene is truncated (the second and third exons are translocated to chromosome 14 while the first exon remains on chromosome 8). In this line, we demonstrated that theophylline induced differentiation results in down-regulation of the first exon while the level of expression of the translocated second and third exons remains unchanged or increases. Thus, in JD38, the c-myc genes adjacent to the immunoglobulin constant region are abnormally regulated, while the first exon remaining on chromosome 8 is regulated as is the normal c-myc gene in other non-BL differentiation-induction model systems. These data directly demonstrate that c-myc is abnormally regulated in BL and strongly support the hypothesis that the translocated c-myc gene is regulated by sequences present in the juxtaposed immunoglobulin gene. Furthermore, we propose that the structural alterations present in the translocated c-myc allele are permissive for immunoglobulin enhancer usurpation of transcriptional control. C1 ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA. UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38103 USA. RP SANDLUND, JT (reprint author), NCI, DIV CANC TREATMENT, CLIN ONCOL PROGRAM, PEDIAT BRANCH, BETHESDA, MD 20892 USA. FU NCI NIH HHS [CA-21765, CA-20180] NR 31 TC 12 Z9 13 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD JAN 1 PY 1993 VL 53 IS 1 BP 127 EP 132 PG 6 WC Oncology SC Oncology GA KD719 UT WOS:A1993KD71900022 PM 8416737 ER PT J AU KRAMER, BS BRAWLEY, OW NAYFIELD, S JOHNSON, K GREENWALD, P FORD, LG AF KRAMER, BS BRAWLEY, OW NAYFIELD, S JOHNSON, K GREENWALD, P FORD, LG TI NCI STUDIES IN PRIMARY PREVENTION OF BREAST AND PROSTATE-CANCER SO CANCER RESEARCH THERAPY & CONTROL LA English DT Article; Proceedings Paper CT University of Florida Medical Oncology Grand Rounds CY 1992 CL GAINESVILLE, FL SP UNIV FLORIDA ID STEROID 5ALPHA-REDUCTASE DEFICIENCY; RANDOMIZED CLINICAL-TRIAL; TERM TAMOXIFEN THERAPY; 5-ALPHA-REDUCTASE INHIBITOR; MALE PSEUDOHERMAPHRODITISM; ADJUVANT TAMOXIFEN; ANTI-ESTROGEN; CELL-CYCLE; NORMAL MEN; GROWTH RP KRAMER, BS (reprint author), NCI,DIV CANC PREVENT & CONTROL,BETHESDA,MD 20892, USA. NR 63 TC 8 Z9 8 U1 0 U2 1 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1064-0525 J9 CANCER RES THER CONT JI Cancer Res. Ther. Control PY 1993 VL 3 IS 3 BP 203 EP 211 PG 9 WC Oncology SC Oncology GA MU467 UT WOS:A1993MU46700007 ER PT J AU CALLAHAN, R SALOMON, DS AF CALLAHAN, R SALOMON, DS TI ONCOGENES, TUMOR-SUPPRESSOR GENES AND GROWTH-FACTORS IN BREAST-CANCER - NOVEL TARGETS FOR DIAGNOSIS, PROGNOSIS AND THERAPY SO CANCER SURVEYS LA English DT Article ID CARCINOMA CELL-LINE; FACTOR-ALPHA; FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; C-ERBB-2 PROTEIN; MESSENGER-RNA; PROTOONCOGENE PRODUCT; PSEUDOMONAS EXOTOXIN; SIGNAL TRANSDUCTION; ANTITUMOR THERAPY C1 NCI,TUMOR IMMUNOL & BIOL LAB,TUMOR GROWTH FACTOR SECT,BETHESDA,MD 20892. RP CALLAHAN, R (reprint author), NCI,ONCOGENET SECT,BETHESDA,MD 20892, USA. NR 127 TC 16 Z9 16 U1 0 U2 1 PU COLD SPRING HARBOR LAB PRESS PI PLAINVIEW PA 1 BUNGTOWN RD, PLAINVIEW, NY 11724 SN 0261-2429 J9 CANCER SURV JI Cancer Surv. PY 1993 VL 18 BP 35 EP 56 PG 22 WC Oncology SC Oncology GA ND478 UT WOS:A1993ND47800003 PM 8012999 ER PT J AU MACDONALD, NJ STEEG, PS AF MACDONALD, NJ STEEG, PS TI MOLECULAR-BASIS OF TUMOR-METASTASIS SO CANCER SURVEYS LA English DT Review ID EXTRACELLULAR-MATRIX DEGRADATION; NUCLEOSIDE DIPHOSPHATE KINASE; CELL-ADHESION MOLECULES; INHIBITS EXPERIMENTAL METASTASIS; RECONSTITUTED BASEMENT-MEMBRANE; DUCTAL BREAST CARCINOMAS; MURINE MELANOMA-CELLS; E-CADHERIN EXPRESSION; LEWIS LUNG-CARCINOMA; H-RAS ONCOGENE AB The metastatic process is complex, requiring invasion, haematogenous and/or lymphatic dissemination, angiogenesis, colonization of a distant site and avoidance of host immune responses. These phenotypic changes can be accomplished by a variety of molecular pathways. Recent evidence suggests that many of the genetic events required for metastatic competence can be coordinately regulated, perhaps by regulatory cascades controlling normal development and differentiation. In addition to alterations in cellular phenotypes, metastatic cells also exhibit genomic instability, the causes of which are presently unknown. The development of therapeutic strategies to counteract metastasis may be most promising if directed towards the final angiogenesis and colonization by tumour cells at the metastatic site. Such strategies must overcome the redundancy of molecular mechanisms. RP MACDONALD, NJ (reprint author), NCI,PATHOL LAB,BETHESDA,MD 20892, USA. NR 184 TC 52 Z9 52 U1 1 U2 2 PU COLD SPRING HARBOR LAB PRESS PI PLAINVIEW PA 1 BUNGTOWN RD, PLAINVIEW, NY 11724 SN 0261-2429 J9 CANCER SURV JI Cancer Surv. PY 1993 VL 16 BP 175 EP 199 PG 25 WC Oncology SC Oncology GA LG760 UT WOS:A1993LG76000010 PM 7688661 ER PT S AU GLAUDEMANS, CPJ BENNETT, LG BHATTACHARJEE, AK NASHED, EM ZIEGLER, T AF GLAUDEMANS, CPJ BENNETT, LG BHATTACHARJEE, AK NASHED, EM ZIEGLER, T BE Garegg, PJ Lindberg, AA TI DISTINGUISHING ANTIBODIES THAT BIND INTERNAL ANTIGENIC DETERMINANTS FROM THOSE THAT BIND THE ANTIGENIC CHAIN-TERMINUS ONLY SO CARBOHYDRATE ANTIGENS SE ACS SYMPOSIUM SERIES LA English DT Review CT SYMP ON CARBOHYDRATE ANTIGENS, AT THE 4TH CHEMICAL CONGRESS OF NORTH AMERICA ( 202ND NATIONAL MEETING OF THE AMERICAN CHEMICAL SOC ) CY AUG 25-30, 1991 CL NEW YORK, NY SP AMER CHEM SOC RP GLAUDEMANS, CPJ (reprint author), NIDDKD,CARBOHYDRATES SECT,BETHESDA,MD 20892, USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA WASHINGTON SN 0097-6156 BN 0-8412-2531-1 J9 ACS SYM SER PY 1993 VL 519 BP 72 EP 79 PG 8 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA BX26T UT WOS:A1993BX26T00006 ER PT J AU TENNANT, RW RAO, GN RUSSFIELD, A SEILKOP, S BRAUN, AG AF TENNANT, RW RAO, GN RUSSFIELD, A SEILKOP, S BRAUN, AG TI CHEMICAL EFFECTS IN TRANSGENIC MICE BEARING ONCOGENES EXPRESSED IN MAMMARY TISSUE SO CARCINOGENESIS LA English DT Article ID GENE; CARCINOGENICITY; MUTAGENICITY; SEQUENCES; MODELS; TESTS AB Three transgenic mouse lines carrying v-Ha-ras (TG-SH), c-myc (TG-M) or c-neu (TG-NK) oncogenes under regulatory control of mouse mammary tumor virus long terminal repeat (LTR) sequences were evaluated for responses to two chemical carcinogens. p-Cresidine, a mutagenic urinary bladder carcinogen, increased the incidence of urinary bladder carcinomas in males and females in all three fines, and these tumors occurred at comparable incidences and grade in transgenic and non-transgenic mice. p-Cresidine did not affect the rates of mammary or salivary gland neoplasms in transgenic mice; these tumors did not occur in non-transgenic littermates. No other tumor types were observed in exposed or control animals. Reserpine, a non-mutagenic mammary gland carcinogen, was administered under the same protocol, but the high control rates of mammary gland adenocarcinomas in the TG - M and TG-NK strains made ft difficult to detect any tumor-enhancing effect of reserpine. However, the incidences of multiple mammary gland tumors were significantly increased in dosed females from both lines. The incidence of mammary gland adenocarcinomas was significantly increased in TG-SH females receiving 5 p.p.m. reserpine. Reserpine did not induce any carcinogenic effects in non-transgenic mice. These results indicate that the transcriptional regulation of these three transgenes is a major determinant in the response to p-cresidine and reserpine. The use of transgenic models for the general detection of carcinogens may require lines in which appropriate genes are targeted for expression in many tissues, or lines in which critical genes have been inactivated. C1 ANALYT SCI INC,DURHAM,NC 27713. TSI MASON LABS,WORCESTER,MA 01608. RP TENNANT, RW (reprint author), NIEHS,POB 12233,RES TRIANGLE PK,NC 27709, USA. NR 23 TC 30 Z9 30 U1 0 U2 0 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD JAN PY 1993 VL 14 IS 1 BP 29 EP 35 DI 10.1093/carcin/14.1.29 PG 7 WC Oncology SC Oncology GA KJ990 UT WOS:A1993KJ99000006 PM 8093862 ER PT J AU DAVIS, CD SCHUT, HAJ ADAMSON, RH THORGEIRSSON, UP THORGEIRSSON, SS SNYDERWINE, EG AF DAVIS, CD SCHUT, HAJ ADAMSON, RH THORGEIRSSON, UP THORGEIRSSON, SS SNYDERWINE, EG TI MUTAGENIC ACTIVATION OF IQ, PHIP AND MEIQX BY HEPATIC MICROSOMES FROM RAT, MONKEY AND MAN - LOW MUTAGENIC ACTIVATION OF MEIQX IN CYNOMOLGUS MONKEYS INVITRO REFLECTS LOW DNA ADDUCT LEVELS INVIVO SO CARCINOGENESIS LA English DT Article ID METABOLIC-ACTIVATION; HETEROCYCLIC AMINES; COVALENT BINDING; LIVER-MICROSOMES; BROILED SARDINE; BEEF EXTRACT; COOKED FOODS; CARCINOGENICITY; 2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE; MICE AB Cooked meat, poultry and fish contain a number of mutagenic and carcinogenic heterocyclic amines, including 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), 2-amino-3,8-dimethyl-imidazo[4,5-f]quinoxaline (MeIQx) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). In the present study we examined the capacity of hepatic microsomes from Fischer 344 rats, cynomolgus monkeys and humans to metabolically activate IQ, MeIQx and PhIP in vitro using the Ames Salmonella mutagenicity assay. The mutagenic activation of IQ was similar among the three species; however, there were significant differences among the species in the activation of PhIP and MeIQx. Liver microsomes from humans showed the greatest capacity to activate PhIP and MeIQx, followed by rats, and then monkeys. The largest differences between the species were observed when MeIQx was used as the mutagen. MeIQx-DNA adducts formed in vivo were then compared among rats and monkeys given MeIQx by gavage (20 mg/kg/day, 10 doses). P-32-Postlabeling analysis, carried out under intensification conditions, was used to examine MeIQx - DNA adducts in the liver, kidney, heart, colon and white blood cells. MeIQx-DNA adducts were highest in all tissues examined from male rats, followed by female rats, and much lower in monkeys. In the liver, the total MeIQx - DNA adduct levels of monkeys were approximately 19 and approximately 10 times lower than in male and female rats respectively. In extrahepatic tissues, the differences in MeIQx-DNA adduct levels between monkeys and rats were even greater. The results suggest that the low level of MeIQx - DNA adducts found in vivo in cynomolgus monkeys reflects a low capacity to activate MeIQx via the hepatic cytochrome P450 monooxygenase system. C1 NCI,DIV CANC ETIOL,OFF DIRECTOR,BETHESDA,MD 20892. MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43614. RP DAVIS, CD (reprint author), NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892, USA. FU NCI NIH HHS [N01-CP-51013, CA47484] NR 39 TC 70 Z9 70 U1 0 U2 2 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD JAN PY 1993 VL 14 IS 1 BP 61 EP 65 DI 10.1093/carcin/14.1.61 PG 5 WC Oncology SC Oncology GA KJ990 UT WOS:A1993KJ99000011 PM 8425272 ER PT J AU HEGI, ME FOX, TR BELINSKY, SA DEVEREUX, TR ANDERSON, MW AF HEGI, ME FOX, TR BELINSKY, SA DEVEREUX, TR ANDERSON, MW TI ANALYSIS OF ACTIVATED PROTOONCOGENES IN B6C3F1 MOUSE-LIVER TUMORS INDUCED BY CIPROFIBRATE, A POTENT PEROXISOME PROLIFERATOR SO CARCINOGENESIS LA English DT Article ID HA-RAS GENE; DI(2-ETHYLHEXYL) PHTHALATE; TUMORIGENICITY ASSAY; LIPID-PEROXIDATION; TRANSFORMING GENES; LUNG-TUMORS; DNA; CELLS; HEPATOCARCINOGENESIS; MUTATIONS AB Liver tumors from B6C3F1 mice induced by the potent peroxisome proliferator ciprofibrate, a hypolipidemic drug, were evaluated for the presence of transforming genes by the nude mouse tumorigenicity assay. As reported earlier, the tumors were not activated by a point mutation in codon 61 of H-ras. Two of the eight tumors examined contained a mutation in codon 13 or an H-ras gene mutated in codon 117. Screening of another 23 ciprofibrate-induced liver tumors by oligonucleotide hybridization analysis and direct DNA sequencing resulted in the identification of three tumor DNA samples with point mutations in codon 117 of the H-ras gene. In addition, another tumor sample contained a K-ras gene with a mutation in codon 61. Mutations in these codons have been seen only rarely in chemically induced liver tumors from this mouse strain. Of 15 spontaneous B6C3F1 liver tumors screened in the same manner, one exhibited a K-ras gene activated by a mutation in codon 13 and a second contained an H-ras gene activated by a mutation in codon 117. These ras gene mutations have not been reported previously from spontaneous liver tumors. The frequency and spectrum of ras oncogene mutations characterized in ciprofibrate-induced liver tumors differ significantly from the frequency and pattern identified in spontaneously occurring liver tumors. The results of this study with a limited number of samples suggest that ras protooncogene activation or activation of other protooncogenes that can be detected by the nude mouse tumorigenicity assay are not frequent events in the mechanism of carcinogenicity of the peroxisome proliferator ciprofibrate. However, the lower frequency and distinct pattern of H-ras mutations observed in these tumors disprove the assumption of promotion of spontaneous hepatocarcinogenesis by ciprofibrate. C1 CHEM IND INST TOXICOL,RES TRIANGLE PK,NC 27709. LOVELACE BIOCHEM & RES INST,INHALAT TOXICOL RES INST,ALBUQUERQUE,NM 87185. RP HEGI, ME (reprint author), NIEHS,MOLEC TOXICOL LAB,POB 12233,RES TRIANGLE PK,NC 27709, USA. RI Hegi, Monika/O-4796-2015 OI Hegi, Monika/0000-0003-0855-6495 NR 43 TC 27 Z9 28 U1 0 U2 1 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD JAN PY 1993 VL 14 IS 1 BP 145 EP 149 DI 10.1093/carcin/14.1.145 PG 5 WC Oncology SC Oncology GA KJ990 UT WOS:A1993KJ99000025 PM 8425263 ER PT J AU SHOUKRY, S ANDERSON, MW GLICKMAN, BW AF SHOUKRY, S ANDERSON, MW GLICKMAN, BW TI USE OF FLUORESCENTLY TAGGED DNA AND AN AUTOMATED DNA SEQUENCER FOR THE COMPARISON OF THE SEQUENCE SELECTIVITY OF SN1 AND SN2 ALKYLATING-AGENTS SO CARCINOGENESIS LA English DT Note ID METHYL-N-NITROSOUREA; MECHANISM; N7-METHYLGUANINE; DEPURINATION; MUTAGENESIS AB This paper describes the application of the novel non-radioactive technique for studying the sequence selectivity of selected alkylating agents. N-Nitroso-N-methylurea (MNU) and N-methyl-N-nitro-nitrosoguanidine (MNNG) were chosen from the S(N)1 group of alkylating agents. Dimethyl sulphate (DMS) was used to represent alkylation profile produced by the S(N)2 compounds. Results of S(N)1 compounds indicated that in a run (G)3 the latter two Gs are more susceptible to alkylation than the most 5' G. Moreover, in a GG sequence the 3' G seems to be more alkylated. This effect is more evident when the GG site was preceded by a 5' pyrimidine. These findings suggest that a regio-selective mechanism, rather than the formation of diazonium ions, accounts for DNA alkylation by SN1 compounds. On the other hand, DMS showed preferential alkylation of the 5' end in a (G)3 run. However, at GG sequences no clear preferred site of alkylation could be distinguished. Lack of specificity of S(N)2 compound would seem to suggest that other factors as well as the primary DNA structure may play a role in determining the extent of alkylation at a certain site. C1 NIEHS,MOLEC TOXICOL LAB,RES TRIANGLE PK,NC 27709. RP SHOUKRY, S (reprint author), YORK UNIV,DEPT BIOL,4700 KEELE ST,N YORK M3J 1P3,ON,CANADA. NR 26 TC 9 Z9 9 U1 0 U2 1 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD JAN PY 1993 VL 14 IS 1 BP 155 EP 157 DI 10.1093/carcin/14.1.155 PG 3 WC Oncology SC Oncology GA KJ990 UT WOS:A1993KJ99000027 PM 8425265 ER PT J AU KANNEL, WB LARSON, M AF KANNEL, WB LARSON, M TI LONG-TERM EPIDEMIOLOGIC PREDICTION OF CORONARY-DISEASE - THE FRAMINGHAM EXPERIENCE SO CARDIOLOGY LA English DT Article DE FRAMINGHAM STUDY; PREVENTIVE MANAGEMENT; RISK FACTORS, ATHEROGENIC; PREDICTABILITY ID HEART-DISEASE; RISK; CHOLESTEROL AB Atherosclerotic cardiovascular disease is a complex problem involving lipid deposition, pressure, rheologic forces, carbohydrate tolerance and thrombogenesis. The major contributors identified through epidemiologic research include atherogenic personal attributes, living habits which promote them, signs of a compromised coronary circulation and host susceptibility to these risk factors. Of the atherogenic risk attributes, such as blood lipids, blood pressure, glucose tolerance and fibrinogen, each independently contributes to risk, and the risk associated with any one is compounded by the presence of the others. The risk associated with hypertension, hyperlipidemia or diabetes varies widely depending on the level of associated risk factors. Also, at a given level of total cholesterol, risk is greatly affected by the total/HDL cholesterol ratio, which provides a practical means for assessing the two-way traffic of cholesterol. In addition, living habits, such as cigarette smoking or lack of exercise, can independently affect the risk associated with any of the atherogenic traits. These living habits, obesity and diet can also affect the level of atherogenic risk factors and must be taken into account in assessing risk and implementing preventive measures. Finally, preclinical indicators of silent myocardial ischemia greatly augment the risk associated with a poor cardiovascular risk profile. Hence, ECG left ventricular hypertrophy, blocked intraventricular conduction, repolarization abnormalities and abnormal response to exercise on monitoring must be taken into consideration. Optimal risk predictions require a quantitative synthesis of risk factors into a composite estimate. Handbooks, hand calculators and PC software have been devised for office use based on multiple logistic risk formulations. These have been shown to accurately predict disease risk in a variety of American population samples, in elderly as well as young coronary candidates. Preventive management as well as risk estimation should be multifactorial if optimal results are to be achieved. Preventive strategies should include public health measures to alter the ecology so as to shift the distribution of risk factors to a more favorable level, health education to enable people to protect their own health and preventive medicine for high-risk candidates. Greater skill must be developed to carry out such interventions. In selecting drugs to correct hypertension, diabetes and lipid disorders, it is important to choose agents which do not adversely affect the composite risk profile. C1 BOSTON UNIV HOSP,SCH MED,MED CTR,EVANS MEM DEPT CLIN RES,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02218. NHLBI,FRAMINGHAM,MA. RP KANNEL, WB (reprint author), FRAMINGHAM STUDY,5 THURBER ST,FRAMINGHAM,MA 01701, USA. FU NHLBI NIH HHS [N01-HV-52971, N01-HV-92922] NR 20 TC 95 Z9 97 U1 1 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 J9 CARDIOLOGY JI Cardiology PY 1993 VL 82 IS 2-3 BP 137 EP 152 DI 10.1159/000175864 PG 16 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA LH805 UT WOS:A1993LH80500005 PM 8324776 ER PT S AU ZIEGLER, RG AF ZIEGLER, RG BE Canfield, LM Krinsky, NI Olson, JA TI CAROTENOIDS, CANCER, AND CLINICAL-TRIALS SO CAROTENOIDS IN HUMAN HEALTH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Carotenoids in Human Health CY FEB 06-09, 1993 CL SAN DIEGO, CA SP NEW YORK ACAD SCI ID EPIDEMIOLOGIC EVIDENCE; GASTRIC-CANCER; RISK; VEGETABLES; FRUIT; DIET; MEN; PREVENTION RP ZIEGLER, RG (reprint author), NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,ENVIRONM EPIDEMIOL BRANCH,NUTR EPIDEMIOL SECT,BETHESDA,MD 20892, USA. NR 21 TC 19 Z9 19 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-827-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 691 BP 110 EP 119 DI 10.1111/j.1749-6632.1993.tb26162.x PG 10 WC Biochemistry & Molecular Biology; Engineering, Civil; Multidisciplinary Sciences; Physiology SC Biochemistry & Molecular Biology; Engineering; Science & Technology - Other Topics; Physiology GA BA01B UT WOS:A1993BA01B00011 PM 8129280 ER PT S AU PITOT, HC RUBIN, J KOVACH, JS SCHUTT, AJ ADAMSON, PC AF PITOT, HC RUBIN, J KOVACH, JS SCHUTT, AJ ADAMSON, PC BE Canfield, LM Krinsky, NI Olson, JA TI ALL-TRANS-RETINOIC ACID - A DOSE-SEEKING STUDY IN SOLID TUMORS SO CAROTENOIDS IN HUMAN HEALTH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Carotenoids in Human Health CY FEB 06-09, 1993 CL SAN DIEGO, CA SP NEW YORK ACAD SCI ID ACUTE PROMYELOCYTIC LEUKEMIA; PLASMA C1 NCI,PEDIAT BRANCH,BETHESDA,MD 20892. RP PITOT, HC (reprint author), MED ONCOL MAYO CLIN,ROCHESTER,MN 55905, USA. NR 5 TC 1 Z9 1 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-827-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 691 BP 250 EP 252 PG 3 WC Biochemistry & Molecular Biology; Engineering, Civil; Multidisciplinary Sciences; Physiology SC Biochemistry & Molecular Biology; Engineering; Science & Technology - Other Topics; Physiology GA BA01B UT WOS:A1993BA01B00034 PM 8129304 ER PT J AU LEE, CC KOZAK, CA YAMADA, KM AF LEE, CC KOZAK, CA YAMADA, KM TI STRUCTURE, GENETIC-MAPPING, AND EXPRESSION OF THE MOUSE HGF SCATTER FACTOR GENE SO CELL ADHESION AND COMMUNICATION LA English DT Article DE HEPATOCYTE GROWTH FACTOR; SCATTER FACTOR; GENE MAPPING; RNASE PROTECTION ASSAY ID HEPATOCYTE GROWTH-FACTOR; C-MET; RECEPTOR; IDENTIFICATION; PURIFICATION; MITOGEN; BINDING AB The cytokine termed hepatocyte growth factor or scatter factor (HGF/SF) has been implicated in embryonic development and liver regeneration. Mouse HGF/SF cDNA clones were obtained by screening a mouse liver cDNA library with synthetic oligonucleotides, as well as by using the method of reverse transcription-polymerase chain reaction (RT-PCR) with mRNA isolated from adult mouse brain. Sequence analysis of mouse HGF/SF cDNA clones spanning the entire coding region revealed an overall amino acid identity of 90% and 98% with human and rat HGF, respectively. Using mouse HGF antisense RNA as a probe, we observed the expression of HGF/SF mRNA in the liver, kidney, whole brain and cerebellum of adult mice as well as in day 9 and day 10 mouse embryos. The mouse HGF/SF cDNA was utilized for mapping Hgf to the centromeric region of mouse Chromosome 5 in apparent close proximity to the reeler mutation by the analysis of two multilocus crosses. The relationship of Hgf to the reeler mutation is discussed. The availability of mouse HGF/SF cDNA clones should facilitate further analysis of HGF/SF function during development. C1 NIDR,DEV BIOL LAB,BLDG 30 RM 423,BETHESDA,MD 20892. NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892. OI Yamada, Kenneth/0000-0003-1512-6805 NR 27 TC 14 Z9 15 U1 0 U2 0 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1061-5385 J9 CELL ADHES COMMUN JI Cell Adhes. Commun. PY 1993 VL 1 IS 2 BP 101 EP 111 DI 10.3109/15419069309095686 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA NC903 UT WOS:A1993NC90300002 PM 8081873 ER PT J AU JOHNSON, BH GOMI, M JAKOWLEW, SB MORIWAKI, K THOMPSON, EB AF JOHNSON, BH GOMI, M JAKOWLEW, SB MORIWAKI, K THOMPSON, EB TI ACTIONS AND INTERACTIONS OF GLUCOCORTICOIDS AND TRANSFORMING GROWTH-FACTOR -BETA ON 2 RELATED HUMAN MYELOMA CELL-LINES SO CELL GROWTH & DIFFERENTIATION LA English DT Article ID BREAST CANCER-CELLS; MULTIPLE-MYELOMA; RIBONUCLEIC-ACID; MESSENGER-RNA; B-CELLS; FACTOR-BETA-1; PROLIFERATION; INHIBITION; DEXAMETHASONE; EXPRESSION AB To evaluate possible involvement of a paracrine/autocrine inhibitory growth factor in myeloma cell growth, we studied the expression and actions of two forms of transforming growth factor beta (TGF-beta1 and TGF-beta2) on two closely related myeloma cell lines, OPM-1 and OPM-2. Earlier studies showed that both cell lines contain glucocorticoid receptors, but only OPM-2 cells are growth inhibited by dexamethasone (Dex). We found that OPM-2 growth was inhibited by TGF-beta, with TGF-beta1 exerting a greater effect than TGF-beta2, and Dex plus TGF-beta1 acting synergistically. In OPM-1 (Dex insensitive), TGF-beta mRNA was not expressed, whereas it was induced by Dex in OPM-2. It was also possible to block partially the growth inhibition of Dex in OPM-2 cells by the addition of anti-TGF-beta1 antibodies. These data suggest that the glucocorticoid effect(s) on myeloma cells may be mediated at least in part through modulation of internal and/or external levels of TGF-beta1. C1 UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,F-45,GALVESTON,TX 77550. OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,OSAKA 553,JAPAN. NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892. FU NCI NIH HHS [CA41407] NR 31 TC 17 Z9 17 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106 SN 1044-9523 J9 CELL GROWTH DIFFER JI Cell Growth Differ. PD JAN PY 1993 VL 4 IS 1 BP 25 EP 30 PG 6 WC Cell Biology SC Cell Biology GA KF716 UT WOS:A1993KF71600004 PM 8424903 ER PT J AU NOVY, RE SELLERS, JR LIU, LF LIN, JJC AF NOVY, RE SELLERS, JR LIU, LF LIN, JJC TI IN-VITRO FUNCTIONAL-CHARACTERIZATION OF BACTERIALLY EXPRESSED HUMAN FIBROBLAST TROPOMYOSIN ISOFORMS AND THEIR CHIMERIC MUTANTS SO CELL MOTILITY AND THE CYTOSKELETON LA English DT Article DE HUMAN FIBROBLAST TROPOMYOSINS; ACTIN-BINDING PROTEIN; CALDESMON; ACTIN-TROPOMYOSIN-ACTIVATED HMM ATPASE; MOTILITY ID TUMORIGENIC HUMAN-FIBROBLASTS; EQUINE PLATELET TROPOMYOSIN; SMOOTH-MUSCLE; HEAVY-MEROMYOSIN; COOPERATIVE BINDING; ACANTHAMOEBA ACTIN; TRANSFORMED-CELLS; ALPHA-TROPOMYOSIN; MESSENGER-RNAS; SINGLE GENE AB At least eight tropomyosin isoforms (hTM1, hTM2, hTM3, hTM4, hTM5, hTM5a, hTM5b, and hTMsmalpha) are expressed from four distinct genes in human fibroblasts. In order to elucidate isoform properties, we have subcloned hTM3 and hTM5 full-length cDNAs, as well as their chimeric cDNAs into the bacterial expression pET8C system. Bacterially expressed tropomyosin isoforms (called PEThTM3, PEThTM5, PEThTM5/3, and PEThTM3/5) were purified and characterized. Under optimal binding conditions, the binding of PEThTM5 isoform to F-actin was stronger than the PEThTM3 isoform. However, analysis of actin-binding by the McGhee and von Hippel equation revealed that PEThTM3 exhibits higher cooperativity in binding than PEThTM5 does. Furthermore, the chimera PEThTM5/3 which possessed the N-terminal fragment of hTM5 fused to the C-terminal fragment of hTM3 had even stronger actin binding ability. The reverse chimera PEThTM3/5 which possessed the N-terminal fragment of hTM3 fused to the C-terminal fragment of hTM5 demonstrated greatly reduced affinity to actin filaments. In addition, both chimeras had different KCl requirements for optimal binding to F-actin than their parental tropomyosins. A bacterially made C-terminal fragment of human fibroblast caldesmon (PETCaD39) and native chicken gizzard caldesmon were both able to enhance the actin-binding of these bacterially expressed tropomyosins. However, PETCaD39's enhancement of binding to F-actin was greater for PEThTM5 than PEThTM3. Under 30 mM KCl and 4 mM MgCl2, the low M(r) isoform PEThTM5 appeared to be able to amplify the actin-activated HMM ATPase activity by 4.7 fold, while the high M(r) isoform PEThTM3 stimulated the activity only 1.5 fold. The higher enhancement of ATPase activity by PEThTM5 than by PEThTM3 suggested that the low M(r) isoform hTM5 may be more involved in modulating nonmuscle cell motility than hTM3. These results further suggested that different isoforms of tropomyosin might have finite differences in their specific functions (e.g., cytoskeletal vs. motile) inside the cell. (C) 1993 Wiley-Liss, Inc. C1 UNIV IOWA,DEPT BIOL SCI,IOWA CITY,IA 52242. NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892. FU NICHD NIH HHS [HD18577]; NIGMS NIH HHS [GM40580] NR 58 TC 67 Z9 68 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0886-1544 J9 CELL MOTIL CYTOSKEL JI Cell Motil. Cytoskeleton PY 1993 VL 26 IS 3 BP 248 EP 261 DI 10.1002/cm.970260308 PG 14 WC Cell Biology SC Cell Biology GA MD117 UT WOS:A1993MD11700007 PM 8293480 ER PT S AU SPIEGEL, AM WEINSTEIN, LS SHENKER, A HERMOUET, S MERENDINO, JJ AF SPIEGEL, AM WEINSTEIN, LS SHENKER, A HERMOUET, S MERENDINO, JJ BE Brown, BL Dobson, PRM TI G-PROTEINS - FROM BASIC TO CLINICAL-STUDIES SO CELL SIGNALLING : BIOLOGY AND MEDICINE OF SIGNAL TRANSDUCTION SE ADVANCES IN SECOND MESSENGER AND PHOSPHOPROTEIN RESEARCH LA English DT Proceedings Paper CT 8TH INTERNATIONAL CONF ON SECOND-MESSENGERS AND PHOSPHOPROTEINS CY AUG 03-08, 1992 CL GLASGOW, SCOTLAND SP SCOTTISH ENTERPRISE, GLASGOW CITY COUNCIL, STRATHCLYDE REG COUNCIL, GREATER GLASGOW HLTH BOARD, SOC ENDOCRINOL, WELLCOME TRUST, BIOCHEM SOC, SOC ENDOCRINOL, ABBOTT LABS, AMERSHAM INT RP SPIEGEL, AM (reprint author), NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BLDG 10,RM 8C101,BETHESDA,MD 20892, USA. RI Weinstein, Lee/I-5575-2015 NR 0 TC 6 Z9 6 U1 0 U2 0 PU RAVEN PRESS PI NEW YORK PA NEW YORK SN 1040-7952 BN 0-7817-0076-0 J9 ADV SEC MESS PHOSPH JI Adv.Second Messenger Phosphoprotein Res. PY 1993 VL 28 BP 37 EP 46 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BY68E UT WOS:A1993BY68E00005 PM 8398416 ER PT S AU RHEE, SG LEE, CW JHON, DY AF RHEE, SG LEE, CW JHON, DY BE Brown, BL Dobson, PRM TI PHOSPHOLIPASE-C ISOZYMES AND MODULATION BY CAMP-DEPENDENT PROTEIN-KINASE SO CELL SIGNALLING : BIOLOGY AND MEDICINE OF SIGNAL TRANSDUCTION SE ADVANCES IN SECOND MESSENGER AND PHOSPHOPROTEIN RESEARCH LA English DT Proceedings Paper CT 8TH INTERNATIONAL CONF ON SECOND-MESSENGERS AND PHOSPHOPROTEINS CY AUG 03-08, 1992 CL GLASGOW, SCOTLAND SP SCOTTISH ENTERPRISE, GLASGOW CITY COUNCIL, STRATHCLYDE REG COUNCIL, GREATER GLASGOW HLTH BOARD, SOC ENDOCRINOL, WELLCOME TRUST, BIOCHEM SOC, SOC ENDOCRINOL, ABBOTT LABS, AMERSHAM INT RP RHEE, SG (reprint author), NHLBI,BIOCHEM LAB,BETHESDA,MD 20892, USA. NR 0 TC 21 Z9 21 U1 0 U2 0 PU RAVEN PRESS PI NEW YORK PA NEW YORK SN 1040-7952 BN 0-7817-0076-0 J9 ADV SEC MESS PHOSPH JI Adv.Second Messenger Phosphoprotein Res. PY 1993 VL 28 BP 57 EP 64 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BY68E UT WOS:A1993BY68E00007 PM 8398418 ER PT J AU FREED, WJ AF FREED, WJ TI NEURAL TRANSPLANTATION - PROSPECTS FOR CLINICAL USE SO CELL TRANSPLANTATION LA English DT Review DE NEURAL TRANSPLANTATION; BRAIN GRAFTS; FETAL TISSUE; PARKINSONS DISEASE; NEUROSURGERY ID ADRENAL-MEDULLA GRAFTS; NERVE GROWTH-FACTOR; RAT SPINAL-CORD; ADVANCED PARKINSONS-DISEASE; FETAL STRIATAL TRANSPLANTS; RECOVERY FOLLOWING TRANSPLANTATION; INTRAVENTRICULAR SUBSTANTIA-NIGRA; PROGRESSIVE SUPRANUCLEAR PALSY; BRAIN-TISSUE TRANSPLANTATION; EMBRYONIC DOPAMINE NEURONS AB Neural transplantation has been extensively applied in Parkinson's disease, including numerous clinical studies, studies in animal models, and related basic research on cell biology. There is evidence that the clinical trials of both adrenal medulla transplantation and fetal substantia nigra transplantation have produced a detectable clinical effect, although it is not yet clear whether the clinical benefit is sufficient to justify a more widespread application of these procedures. Studies of long-term outcome and quantitative tests are important in assaying the degree of benefit produced by transplantation procedures in Parkinson's disease and for developing improved and refined procedures. Other disease-related applications of neural transplantation are beginning to be developed. These include Huntington's disease, chronic pain, epilepsy, spinal cord injury, and perhaps even demyelinating diseases and cortical ischemic injury. Although most of these applications lie in the future, it is not too soon to begin to consider the scientific justification that should be required for initiation of human clinical trials. RP ST ELIZABETH HOSP, NIMH, CTR NEUROSCI, PRECLIN NEUROSCI SECT, NEUROPSYCHIAT BRANCH, WASHINGTON, DC 20032 USA. NR 204 TC 31 Z9 31 U1 0 U2 0 PU COGNIZANT COMMUNICATION CORP PI PUTNAM VALLEY PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA SN 0963-6897 EI 1555-3892 J9 CELL TRANSPLANT JI Cell Transplant. PD JAN-FEB PY 1993 VL 2 IS 1 BP 13 EP 31 PG 19 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA KW449 UT WOS:A1993KW44900003 ER PT B AU KANEDA, K PILARO, AM SAYERS, TJ GRUYS, ME WILTROUT, TA WINE, JW NAGASHIMA, K GONDA, MA REYNOLDS, CW ORTALDO, JR WILTROUT, RH AF KANEDA, K PILARO, AM SAYERS, TJ GRUYS, ME WILTROUT, TA WINE, JW NAGASHIMA, K GONDA, MA REYNOLDS, CW ORTALDO, JR WILTROUT, RH BE Knook, DL Wisse, E TI LIVER-ASSOCIATED LARGE GRANULAR LYMPHOCYTES (PIT CELLS) AND HEPATIC RNK METASTASES EXHIBIT AN INCREASE IN ROD-CORED VESICLES SO CELLS OF THE HEPATIC SINUSOID, VOL 4 LA English DT Proceedings Paper CT 6th International Symposium on Cells of the Hepatic Sinusoid CY AUG 23-27, 1992 CL KUPFFER CELL FDN, ANTWERP, BELGIUM SP KUPFFER CELL FDN, NATL FONDS WETENSCHAPPELIJK ONDERZOEK HO KUPFFER CELL FDN RP KANEDA, K (reprint author), NCI,FREDERICK CANC RES & DEV CTR,BRMP,EXPTL IMMUNOL LAB,BETHESDA,MD 20892, USA. RI Sayers, Thomas/G-4859-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU KUPFFER CELL FOUNDATION PI LEIDEN PA PO BOX 2215, 2301 CE LEIDEN, NETHERLANDS BN 90-800079-5-1 PY 1993 BP 493 EP 495 PG 3 WC Gastroenterology & Hepatology; Immunology SC Gastroenterology & Hepatology; Immunology GA BZ42Z UT WOS:A1993BZ42Z00141 ER PT J AU MCDONALD, AH DEGRASSI, A AF MCDONALD, AH DEGRASSI, A TI PRISTANE INDUCES AN INDOMETHACIN INHIBITABLE INFLAMMATORY INFLUX OF CD4+ T-CELLS AND IFN-GAMMA PRODUCTION IN PLASMACYTOMA-SUSCEPTIBLE BALB/CANPT MICE SO CELLULAR IMMUNOLOGY LA English DT Article ID PERITONEAL PLASMACYTOMAGENESIS; DOSE REGIMENS; GROWTH; LYMPHOCYTES; MURINE; EXPRESSION; CYTOKINES; ANTIBODY; THYMUS; TRAUMA C1 UNIV UDINE,INST CLIN & EXPTL PATHOL,I-33100 UDINE,ITALY. RP MCDONALD, AH (reprint author), NCI,GENET LAB,BLDG 37,ROOM 2B10,BETHESDA,MD 20892, USA. NR 41 TC 13 Z9 13 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0008-8749 J9 CELL IMMUNOL JI Cell. Immunol. PD JAN PY 1993 VL 146 IS 1 BP 157 EP 170 DI 10.1006/cimm.1993.1014 PG 14 WC Cell Biology; Immunology SC Cell Biology; Immunology GA KK789 UT WOS:A1993KK78900014 PM 8425224 ER PT J AU LI, BQ FU, T YAN, YD BAYLOR, NW RUSCETTI, FW KUNG, HF AF LI, BQ FU, T YAN, YD BAYLOR, NW RUSCETTI, FW KUNG, HF TI INHIBITION OF HIV-INFECTION BY BAICALIN - A FLAVONOID COMPOUND PURIFIED FROM CHINESE HERBAL MEDICINE SO CELLULAR & MOLECULAR BIOLOGY RESEARCH LA English DT Article DE HIV INFECTION; BAICALIN; FLAVONOID COMPOUND; RT INHIBITOR; CHINESE HERBAL MEDICINE ID VIRUS INVITRO; QUERCETIN; PROTEIN AB Baicalin (BA), (formulated as 7-D-glucuronic acid-5,6-dihydroxy-flavone), was purified from the plant Scutellaria Baicalensis Georgi. It has been used as a traditional Chinese herbal medicine. The inhibitory effect of BA against human immunodeficiency virus (HIV-1) infection and replication has been studied in vitro. The compound inhibits HIV-1 infection and replication as measured by: (1) a quantitative focal syncytium formation on CEM-ss monolayer cells; and (2) HIV-1 specific core antigen p24 expression and retroviral reverse transcriptase (RT) activity in the HIV-1-infected H9 cells. We have further demonstrated that the enzymatic activity of purified recombinant HIV-1/RT was inhibited by BA. In addition to lymphoid cell lines, the anti-HIV-1 activity of BA was also observed in cultures of primary human peripheral blood mononuclear cells infected with HIV-1 in vitro. Neither cytotoxic nor cytostatic effects on the indicator cells were found under the assay condition. This data suggests that BA may serve as a useful drug for the treatment and prevention of HIV infections. C1 NCI,DIV CANC TREATMENT,BIOCHEM PHYSIOL LAB,BIOL RESPONSE MODIFIER PROGRAM,FREDERICK,MD 21701. JILIN ARMY AIR FORCE SCH MED,DEPT PHARM,JILIN,PEOPLES R CHINA. NCI,DIV CANC TREATMENT,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21701. RP LI, BQ (reprint author), NCI,FCRDC,DYN CORP,PROGRAM RESOURCES INC,BIOL CARCINOGENESIS & DEV PROGRAM,POB B,BLDG 560-31-76,FREDERICK,MD 21702, USA. NR 22 TC 76 Z9 87 U1 1 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0968-8773 J9 CELL MOL BIOL RES JI Cell Mol. Biol. Res. PY 1993 VL 39 IS 2 BP 119 EP 124 PG 6 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA LT649 UT WOS:A1993LT64900004 PM 7693133 ER PT J AU ALKON, DL AF ALKON, DL TI EDITORIAL SO CELLULAR & MOLECULAR BIOLOGY RESEARCH LA English DT Editorial Material RP ALKON, DL (reprint author), NIH,ADAPT SYST LAB,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0968-8773 J9 CELL MOL BIOL RES JI Cell Mol. Biol. Res. PY 1993 VL 39 IS 6 BP 545 EP 545 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA NC223 UT WOS:A1993NC22300001 ER PT J AU UMEKAWA, H CHANG, JH CORREIA, JJ WANG, DR WINGFIELD, PT OLSON, MOJ AF UMEKAWA, H CHANG, JH CORREIA, JJ WANG, DR WINGFIELD, PT OLSON, MOJ TI NUCLEOLAR PROTEIN B23 - BACTERIAL EXPRESSION, PURIFICATION, OLIGOMERIZATION AND SECONDARY STRUCTURES OF 2 ISOFORMS SO CELLULAR & MOLECULAR BIOLOGY RESEARCH LA English DT Article DE NUCLEOLUS; PROTEIN B23; PROTEIN ISOFORMS; OLIGOMERIZATION; HIV-1 REV PROTEIN ID CIRCULAR-DICHROISM; NUCLEOPHOSMIN B23; ESCHERICHIA-COLI; HELA-CELLS; REV; LOCALIZATION; RNA; PHOSPHOPROTEIN-B23; IDENTIFICATION; CONFORMATION AB Protein B23 is an abundant nucleolar phosphoprotein and putative ribosome assembly factor. Two forms of the protein, B23.1 and B23.2, contain 292 and 257 amino acids, respectively, and differ only in their C-terminal sequences. The two B23 isoforms have been Produced in Escherichia coli using the pKK223-3 expression vector and purified to near homogeneity. The purification utilized ammonium sulfate fractionation followed by chromatography on DEAE-cellulose, heparin-Sepharose and Bio-Rad Q. By combined gel filtration and sedimentation analyses, both B23.1 and B23.2 formed multimers of Mr 210 to 255 kDa (apparent hexamers), suggesting that the differences in C-terminal ends of the isoforms do not affect oligomerization. The oligomerization was not dependent on disulfide bond formation. The circular dichroism spectra of recombinant proteins B23.1 and B23.2 were similar suggesting that the carboxyl-terminal difference in the two proteins does not markedly influence overall secondary structure. Using routines for fitting the CD spectra to those of basis vectors the recombinant B23 isoforms appeared to be composed predominantly of beta-sheet and beta-turn secondary structures. Protein B23 from HeLa cell nuclei was recently shown to have a high affinity for the HIV-1 Rev protein. Using sucrose density gradient centrifugation it was shown that both recombinant proteins B23:1 and B23.2, as well as B23.1 isolated from Novikoff hepatoma nucleoli, were capable of binding the Rev protein. C1 UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216. NIH,PROT EXPRESS LAB,BETHESDA,MD 20892. FU NIGMS NIH HHS [GM28349] NR 35 TC 34 Z9 36 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0968-8773 J9 CELL MOL BIOL RES JI Cell Mol. Biol. Res. PY 1993 VL 39 IS 7 BP 635 EP 645 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA NK060 UT WOS:A1993NK06000003 PM 8054998 ER PT J AU GOLDSTEIN, M AF GOLDSTEIN, M TI STROKE PREVENTION AND HEALTH-CARE ISSUES - AN AMERICAN PERSPECTIVE SO CEREBROVASCULAR DISEASES LA English DT Article; Proceedings Paper CT SANOFI WINTHROP SYMP ON ADVANCES IN STROKE PREVENTION, AT THE 2ND EUROPEAN STROKE CONF CY JUN 26, 1992 CL LAUSANNE, SWITZERLAND SP SANOFI WINTHROP DE COST EVALUATION; COST-RISK BENEFIT; STROKE COSTS; STROKE PREVENTION AB The ultimate goal of biomedical research is the promotion of health and the prevention of disease and disability. We are indeed fortunate that preventive measures for stroke are now available and applicable; also, important additional strategies are being actively explored. Future studies of stroke prevention need to address three aspects of the stroke syndrome: (1) the prevention of the initial episode; (2) the prevention of brain cell destruction during the acute period, and (3) the prevention or reduction of cognitive and physical deficits as a consequence of cell death. The economic and social impact of stroke is difficult to evaluate. In the past, the usual economic estimates were based on the cost of long-term disability. Today, with methods of early intervention now available, the cost of acute medical and surgical care, as well as long-term consequences, need to be included. RP GOLDSTEIN, M (reprint author), NINCDS,OFF DIRECTOR,NIH BLD 31,ROOM A52,BETHESDA,MD 20892, USA. NR 4 TC 5 Z9 5 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1015-9770 J9 CEREBROVASC DIS JI Cerebrovasc. Dis. PY 1993 VL 3 SU 1 BP 29 EP 33 DI 10.1159/000108746 PG 5 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA LC676 UT WOS:A1993LC67600006 ER PT J AU WOLFS, TFW NARA, PL GOUDSMIT, J AF WOLFS, TFW NARA, PL GOUDSMIT, J TI GENOTYPIC AND PHENOTYPIC VARIATION OF HIV-1 - IMPACT ON AIDS PATHOGENESIS AND VACCINATION SO CHEMICAL IMMUNOLOGY LA English DT Review ID HUMAN-IMMUNODEFICIENCY-VIRUS; PRINCIPAL NEUTRALIZING DETERMINANT; ENVELOPE GLYCOPROTEIN GP120; IMMUNE-DEFICIENCY SYNDROME; AFRICAN-GREEN MONKEYS; EXPERIMENTALLY INFECTED CHIMPANZEES; T-LYMPHOTROPIC RETROVIRUS; DEPENDENT DNA POLYMERASE; HTLV-III INFECTION; REVERSE-TRANSCRIPTASE C1 UNIV AMSTERDAM,ACAD MED CTR,DEPT VIROL,MEIBERGDREEF 15,1105 AZ AMSTERDAM,NETHERLANDS. NCI,FCRDC,DCE,BCP,LTCB,VIRUS BIOL UNIT,FREDERICK,MD 21701. NR 207 TC 19 Z9 19 U1 1 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1015-0145 J9 CHEM IMMUNOL JI Chem. Immunol. PY 1993 VL 56 BP 1 EP 33 PG 33 WC Immunology SC Immunology GA KN658 UT WOS:A1993KN65800001 PM 8383980 ER PT J AU WINK, DA DARBYSHIRE, JF NIMS, RW SAAVEDRA, JE FORD, PC AF WINK, DA DARBYSHIRE, JF NIMS, RW SAAVEDRA, JE FORD, PC TI REACTIONS OF THE BIOREGULATORY AGENT NITRIC-OXIDE IN OXYGENATED AQUEOUS-MEDIA - DETERMINATION OF THE KINETICS FOR OXIDATION AND NITROSATION BY INTERMEDIATES GENERATED IN THE NO/O2 REACTION SO CHEMICAL RESEARCH IN TOXICOLOGY LA English DT Note ID RELAXING FACTOR; RELEASE; SUPEROXIDE AB The reaction kinetics of nitric oxide autoxidation in aerobic solutions were investigated by direct observation of the nitrite ion product and by trapping the strongly oxidizing and nitrosating intermediates formed in this reaction. The rate behavior observed for nitrite formation [rate = k3[O2][NO]2, k3 = (6 +/- 1.5) X 10(6) M-2 s-1 at 22-degrees-C] was the same as found for oxidation of Fe(CN)64- and of 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) and as for the nitrosation of sulfanilamide. There was a slight decrease in k3 to (3.5 +/- 0.7) X 10(6) M-2 s-1 at 37-degrees-C. The second-order dependency for NO was observed at NO concentrations as low as 3 muM. The results of the competitive kinetics studies suggest that the key oxidizing intermediates, species which are both strong oxidants and nitrosating agents, are not one of those commonly proposed (NO2, N2O3, NO+, or O2NO-) but are one or more as yet uncharacterized NO(x) species. C1 NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892. UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106. RP WINK, DA (reprint author), NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,CHEM SECT,FREDERICK,MD 21702, USA. RI Ford, Peter/D-1826-2011 OI Ford, Peter/0000-0002-5509-9912 NR 32 TC 436 Z9 444 U1 1 U2 19 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 SN 0893-228X J9 CHEM RES TOXICOL JI Chem. Res. Toxicol. PD JAN-FEB PY 1993 VL 6 IS 1 BP 23 EP 27 DI 10.1021/tx00031a003 PG 5 WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology SC Pharmacology & Pharmacy; Chemistry; Toxicology GA KH789 UT WOS:A1993KH78900003 PM 8448345 ER PT J AU MISRA, M OLINSKI, R DIZDAROGLU, M KASPRZAK, KS AF MISRA, M OLINSKI, R DIZDAROGLU, M KASPRZAK, KS TI ENHANCEMENT BY L-HISTIDINE OF NICKEL(II)-INDUCED DNA PROTEIN CROSS-LINKING AND OXIDATIVE DNA-BASE DAMAGE IN THE RAT-KIDNEY SO CHEMICAL RESEARCH IN TOXICOLOGY LA English DT Note ID CARCINOGENIC NICKEL COMPOUNDS; ASCITES TUMOR-CELLS; DEOXYRIBONUCLEIC-ACID; IONIZING-RADIATION; LIPID-PEROXIDATION; THYMINE GLYCOL; METAL; CHROMATIN; SITE; MUTAGENESIS AB Formation of DNA-protein cross-links and oxidatively damaged DNA bases was investigated with the use of alkaline elution and gas chromatography/mass spectrometry techniques in the nuclei from kidneys of rats 3 and 18 h after a single iv injection of the Ni(II)(His)2 complex (NiHis), nickel(II) acetate (NiAcet), or L-histidine (His). Administration of 20 mumol of NiHis/kg body wt caused the formation of DNA-protein cross-links and significantly increased levels of oxidatively damaged DNA bases, including 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyGua; 3.5-fold vs the control value) 3 h postinjection and 8-oxoguanine (2.6-fold), cytosine glycol (2.5-fold), 8-oxoadenine (2-fold), and FapyGua (1.9-fold) 18 h postinjection. Injection of 20 mumol of NiAcet/kg body wt enhanced the cross-linking to a lesser extent than NiHis and did not significantly increase the amounts of modified DNA bases over the control levels. Forty micromoles of His per kilogram body wt alone caused a marked DNA-protein cross-linking effect and increased the amount of 4,6-diamino-5-formamidopyrimidine (2-fold vs the control) 3 h, but not 18 h, after treatment. The DNA base derivatives found were typical products of hydroxyl radical (.OH) attack on DNA. Formation of the cross-links may also be attributed to .OH, although other mechanisms, e.g., formation of ternary complexes of Ni(II), cannot be excluded. The present in vivo study confirms the conclusion of our former in vitro experiments that His enhances Ni(II)-mediated oxidative damage to DNA and chromatin. Since His is the major low molecular weight tissue carrier of Ni(II), this enhancement may be responsible, at least in part, for nickel genotoxicity and carcinogenicity. C1 NCI,FCRDC,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702. NATL INST STAND & TECHNOL,CHEM SCI & TECHNOL LAB,GAITHERSBURG,MD 20899. RI Olinski, Ryszard/E-9607-2014 NR 48 TC 53 Z9 57 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 SN 0893-228X J9 CHEM RES TOXICOL JI Chem. Res. Toxicol. PD JAN-FEB PY 1993 VL 6 IS 1 BP 33 EP 37 DI 10.1021/tx00031a005 PG 5 WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology SC Pharmacology & Pharmacy; Chemistry; Toxicology GA KH789 UT WOS:A1993KH78900005 PM 8448347 ER PT J AU GRAFSTROM, RC HSU, IC HARRIS, CC AF GRAFSTROM, RC HSU, IC HARRIS, CC TI MUTAGENICITY OF FORMALDEHYDE IN CHINESE-HAMSTER LUNG FIBROBLASTS - SYNERGY WITH IONIZING-RADIATION AND N-NITROSO-N-METHYLUREA SO CHEMICO-BIOLOGICAL INTERACTIONS LA English DT Article DE ALKYLATING AGENTS; CHINESE HAMSTER V79 CELLS; FORMALDEHYDE; IONIZING RADIATION; MUTAGENICITY; TOXICITY ID HUMAN BRONCHIAL FIBROBLASTS; DNA-REPAIR; CELLS; INHIBITION; CARCINOGENESIS; GENOTOXICITY; PERSISTENCE; TOXICITY; PRODUCT; DAMAGE AB Cultured Chinese hamster V79 cells, a widely utilized model system in risk assessment of environmental agents, have been utilized to measure toxicity and mutagenicity of formaldehyde with or without previous exposure to either the alkylating agent N-nitroso-N-methylurea or to ionizing radiation. Each of these agents caused a dose-dependent decrease in colony forming efficiency and a parallel increase in 6-thioguanine resistant colonies. Significant mutant frequencies were induced by 0.3 up to 1 mM formaldehyde, 2 and 4 Gy of radiation and 0.2 and 0.5 mM N-nitroso-N-methylurea. Exposure of cells to ionizing radiation or N-nitroso-N-methylurea followed by submutagenic concentrations of formaldehyde potentiated both the cytotoxicity and the mutagenicity as compared with the corresponding separate effects caused by each of these agents. Taken together, these studies clearly demonstrate genotoxic effects in vitro of three recognized carcinogens, i.e. formaldehyde, N-nitroso-N-methylurea and ionizing radiation. Moreover, the synergies now demonstrated in regards to cytopathic consequences indicate interactive effects between formaldehyde and these agents, representing both a chemical and a physical carcinogen. C1 UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201. NCI,HUMAN CARCINOGENESI S LAB,BETHESDA,MD 20892. RP GRAFSTROM, RC (reprint author), KAROLINSKA INST,DEPT TOXICOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN. RI Grafstrom, Roland/N-7217-2016 NR 26 TC 16 Z9 18 U1 0 U2 0 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0009-2797 J9 CHEM-BIOL INTERACT JI Chem.-Biol. Interact. PD JAN PY 1993 VL 86 IS 1 BP 41 EP 49 DI 10.1016/0009-2797(93)90110-K PG 9 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology GA KM254 UT WOS:A1993KM25400004 PM 8431964 ER PT S AU LEONARD, EJ SKEEL, A YOSHIMURA, T RANKIN, J AF LEONARD, EJ SKEEL, A YOSHIMURA, T RANKIN, J BE Lindley, IJD Westwick, J Kunkel, S TI SECRETION OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) BY HUMAN MONONUCLEAR PHAGOCYTES SO CHEMOKINES: BIOLOGY OF THE INFLAMMATORY PEPTIDE SUPERGENE FAMILY II SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 3rd International Symposium on Chemotactic Cytokines CY AUG 31-SEP 01, 1992 CL BADEN BEI WIEN, AUSTRIA C1 NCI,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,FREDERICK,MD 21701. NR 0 TC 24 Z9 25 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44710-X J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1993 VL 351 BP 55 EP 64 PG 10 WC Biochemistry & Molecular Biology; Genetics & Heredity; Immunology SC Biochemistry & Molecular Biology; Genetics & Heredity; Immunology GA BA56G UT WOS:A1993BA56G00007 PM 7942299 ER PT S AU TAUB, DD LLOYD, AR WANG, JM OPPENHEIM, JJ KELVIN, DJ AF TAUB, DD LLOYD, AR WANG, JM OPPENHEIM, JJ KELVIN, DJ BE Lindley, IJD Westwick, J Kunkel, S TI THE EFFECTS OF HUMAN RECOMBINANT MIP-1-ALPHA, MIP-1-BETA, AND RANTES ON THE CHEMOTAXIS AND ADHESION OF T-CELL SUBSETS SO CHEMOKINES: BIOLOGY OF THE INFLAMMATORY PEPTIDE SUPERGENE FAMILY II SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 3rd International Symposium on Chemotactic Cytokines CY AUG 31-SEP 01, 1992 CL BADEN BEI WIEN, AUSTRIA C1 NCI,FCRDC,DIV CANC RES,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702. NR 0 TC 25 Z9 26 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44710-X J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1993 VL 351 BP 139 EP 146 PG 8 WC Biochemistry & Molecular Biology; Genetics & Heredity; Immunology SC Biochemistry & Molecular Biology; Genetics & Heredity; Immunology GA BA56G UT WOS:A1993BA56G00015 PM 7524282 ER PT S AU KELVIN, DJ WANG, JM MCVICAR, D OPPENHEIM, JJ AF KELVIN, DJ WANG, JM MCVICAR, D OPPENHEIM, JJ BE Lindley, IJD Westwick, J Kunkel, S TI PROMISCUITY OF LIGAND-BINDING IN THE HUMAN CHEMOKINE BETA-RECEPTOR FAMILY SO CHEMOKINES: BIOLOGY OF THE INFLAMMATORY PEPTIDE SUPERGENE FAMILY II SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 3rd International Symposium on Chemotactic Cytokines CY AUG 31-SEP 01, 1992 CL BADEN BEI WIEN, AUSTRIA C1 NCI,FCRDC,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702. NR 0 TC 0 Z9 0 U1 0 U2 1 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44710-X J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1993 VL 351 BP 147 EP 153 PG 7 WC Biochemistry & Molecular Biology; Genetics & Heredity; Immunology SC Biochemistry & Molecular Biology; Genetics & Heredity; Immunology GA BA56G UT WOS:A1993BA56G00016 PM 7524283 ER PT S AU OPPENHEIM, JJ AF OPPENHEIM, JJ BE Lindley, IJD Westwick, J Kunkel, S TI OVERVIEW OF CHEMOKINES SO CHEMOKINES: BIOLOGY OF THE INFLAMMATORY PEPTIDE SUPERGENE FAMILY II SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 3rd International Symposium on Chemotactic Cytokines CY AUG 31-SEP 01, 1992 CL BADEN BEI WIEN, AUSTRIA C1 NCI,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21701. NR 0 TC 35 Z9 36 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44710-X J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1993 VL 351 BP 183 EP 186 PG 4 WC Biochemistry & Molecular Biology; Genetics & Heredity; Immunology SC Biochemistry & Molecular Biology; Genetics & Heredity; Immunology GA BA56G UT WOS:A1993BA56G00019 PM 7942295 ER PT J AU JOHNSON, BE KELLEY, MJ AF JOHNSON, BE KELLEY, MJ TI OVERVIEW OF GENETIC AND MOLECULAR EVENTS IN THE PATHOGENESIS OF LUNG-CANCER SO CHEST LA English DT Article; Proceedings Paper CT CONF ON INNOVATIONS IN THE MULTIMODALITY THERAPY OF LUNG CANCER CY APR 03-04, 1992 CL DENVER, CO SP UNIV COLORADO CANC CTR, LUNG CANC INST COLORADO, ROCKY MT ONCOL SOC, METRO DENVER ONCOL NURSING SOC, UNIV COLORADO SCH MED, CME OFF ID K-RAS ONCOGENE; ADENOCARCINOMA; ACTIVATION; MUTATIONS AB Research on dominant oncogenes and tumor suppressor genes has characterized differences in genetic lesions between small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) and identified associations with clinical parameters. More than one half of all lung cancers contain a mutation of the p53 tumor suppressor gene. There does not appear to be an association between the presence of this mutation and survival. A ras family oncogene was found to be mutated in approximately 20 percent of tumors and tumor cell lines from patients with NSCLC in contrast to none of 45 tumors and tumor cell lines from patients with SCLC. The presence of a K-ras mutation was determined to be an adverse prognostic factor for survival in retrospective studies of patients with NSCLC. Mutations of K-ras are more common in tumors from smokers than nonsmokers and have not been detected in lung cancers resulting from occupational exposure to radon. Mutations in both the p53 gene and K-ras oncogene are most commonly G to T transversions in lung cancer vs G to A transitions in other cancers. Prospective studies of these mutations in resected tumor specimens taken from patients with accurate follow-up may continue to provide important clues about their potential clinical and biologic significance. C1 NATL NAVAL MED CTR, BETHESDA, MD 20814 USA. RP JOHNSON, BE (reprint author), NCI, NAVY MED ONCOL BRANCH, BETHESDA, MD 20892 USA. NR 18 TC 22 Z9 22 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD JAN PY 1993 VL 103 IS 1 SU S BP S1 EP S3 DI 10.1378/chest.103.1_Supplement.1S PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA KG377 UT WOS:A1993KG37700002 PM 8380130 ER PT J AU MULSHINE, JL TRESTON, AM BROWN, PH BIRRER, MJ SHAW, GL AF MULSHINE, JL TRESTON, AM BROWN, PH BIRRER, MJ SHAW, GL TI INITIATORS AND PROMOTERS OF LUNG-CANCER SO CHEST LA English DT Article; Proceedings Paper CT CONF ON INNOVATIONS IN THE MULTIMODALITY THERAPY OF LUNG CANCER CY APR 03-04, 1992 CL DENVER, CO SP UNIV COLORADO CANC CTR, LUNG CANC INST COLORADO, ROCKY MT ONCOL SOC, METRO DENVER ONCOL NURSING SOC, UNIV COLORADO SCH MED, CME OFF ID HUMAN SMALL-CELL; K-RAS ONCOGENE; GROWTH-FACTOR RECEPTORS; MYC GENE FAMILY; RETINOBLASTOMA ANTIONCOGENE; TRANSCRIPTIONAL ACTIVATION; INCREASED EXPRESSION; MONOCLONAL-ANTIBODY; CARCINOMA-CELLS; PROTO-ONCOGENE AB As we expand our knowledge of the initiators and promoters of lung cancer, early detection and intervention strategies show great potential in individuals at high risk, especially smokers and exsmokers. Documented mutations of dominant oncogenes and tumor suppressor genes in human lung cancer cells may represent important steps in the pathogenesis of invasive cancer. The precise molecular events and their sequence that lead to tumor promotion in lung cancer, however, are less well understood. Chemointervention with agents like the retinoids may halt proliferation of cancer cells prior to the development of metastatic competence. Use of anti-growth-factor therapy and peptide hormone antagonists may also have a role in intervention approaches. This paper reviews present understanding of the initiation and promotion of lung cancer, as well as preventive strategies currently proposed for patients at risk. RP MULSHINE, JL (reprint author), NCI,BIOMARKERS & PREVENT RES BRANCH,BLDG NICHOLROOM 100,BETHESDA,MD 20892, USA. NR 96 TC 20 Z9 20 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD JAN PY 1993 VL 103 IS 1 SU S BP S4 EP S11 DI 10.1378/chest.103.1_Supplement.4S PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA KG377 UT WOS:A1993KG37700003 PM 8380133 ER PT J AU PUTNAM, FW AF PUTNAM, FW TI DISSOCIATIVE DISORDERS IN CHILDREN - BEHAVIORAL PROFILES AND PROBLEMS SO CHILD ABUSE & NEGLECT LA English DT Article DE DISSOCIATIVE DISORDER; MULTIPLE PERSONALITY DISORDER; CHILD ABUSE; TRAUMA; AMNESIA ID MULTIPLE PERSONALITY-DISORDER; CHILDHOOD; SYMPTOMS AB Transient dissociative episodes are a common and normative phenomenon during childhood that generally decrease during adolescence to relatively low levels in adults. Retrospective clinical research has firmly established a connection between childhood trauma and the development of dissociative disorders in adults. A growing number of clinicians are now identifying dissociative symptoms in abused children, and there is increasing evidence that dissociative disorders represent a significant and hitherto unrecognized form of psychopathology in traumatized children. Pathological dissociation is a complex psychobiological process that results in a failure to integrate information into the normal stream of consciousness. It produces a range of symptoms and behaviors including: (a) amnesias; (b) disturbances in sense of self, (c) trance-like states; (d) rapid shifts in mood and behavior, (e) perplexing shifts in access to knowledge, memory, and skills; (f) auditory and visual hallucinations; and (g) vivid imaginary companionship in children and adolescents. Many of these symptoms and behaviors are misdiagnosed as attention, learning or conduct problems, or even psychoses. Early identification and therapeutic intervention appear to be particularly efficacious in children in contrast to adults, although systematic studies of treatment and outcome are presently lacking. RP PUTNAM, FW (reprint author), NIMH,BLDG 15K,RM 105,9000 ROCKVILLE PIKE,BETHESDA,MD 20895, USA. NR 35 TC 72 Z9 72 U1 1 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0145-2134 J9 CHILD ABUSE NEGLECT JI Child Abuse Negl. PD JAN-FEB PY 1993 VL 17 IS 1 BP 39 EP 45 DI 10.1016/0145-2134(93)90006-Q PG 7 WC Family Studies; Psychology, Social; Social Work SC Family Studies; Psychology; Social Work GA KK638 UT WOS:A1993KK63800005 PM 8435785 ER PT B AU OBRIEN, SJ PETERS, J SEARLE, A WOMACK, J MARSHALLGRAVES, J AF OBRIEN, SJ PETERS, J SEARLE, A WOMACK, J MARSHALLGRAVES, J BE Cuticchia, AJ Pearson, PL TI REPORT OF THE COMMITTEE ON COMPARATIVE GENE-MAPPING SO CHROMOSOME COORDINATING MEETING 1992 ( CCM 92 ), VOL 1 SE GENOME PRIORITY REPORTS LA English DT Proceedings Paper CT CHROMOSOME COORDINATING MEETING 1992 ( CCM 92 ) - UPDATE TO THE 11TH INTERNATIONAL WORKSHOP ON HUMAN GENE MAPPING CY NOV 15-17, 1992 CL JOHNS HOPKINS UNIV, JOHNS HOPKINS MED SCH, BALTIMORE, MD SP NIH, NATL CTR HUMAN GENOME RES, US DOE, OFF HLTH & ENVIRONM RES, COMMISS EUROPEAN COMMUNITIES, HUMAN GENOME ORG HO JOHNS HOPKINS UNIV, JOHNS HOPKINS MED SCH RP OBRIEN, SJ (reprint author), NCI,VIRAL CARCINOGENESIS,BLDG 560,ROOM 21 105 LAB,FREDERICK,MD 21702, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA BASEL BN 3-8055-5763-9 J9 GENOME PR R PY 1993 BP 758 EP 809 PG 52 WC Genetics & Heredity SC Genetics & Heredity GA BY04A UT WOS:A1993BY04A00033 ER PT S AU STRAUS, SE AF STRAUS, SE BE Bock, GR Whelan, J TI STUDIES OF HERPESVIRUS-INFECTION IN CHRONIC FATIGUE SYNDROME SO CHRONIC FATIGUE SYNDROME SE CIBA FOUNDATION SYMPOSIA LA English DT Proceedings Paper CT SYMP ON CHRONIC FATIGUE SYNDROME CY MAY 12-14, 1992 CL CIBA FDN, LONDON, ENGLAND SP CIBA FDN HO CIBA FDN RP STRAUS, SE (reprint author), NIAID,CLIN INVEST LAB,BLDG 10,RM 11N228,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 0 TC 12 Z9 12 U1 1 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA CHICHESTER SN 0300-5208 BN 0-471-93618-9 J9 CIBA F SYMP PY 1993 VL 173 BP 132 EP 145 PG 14 WC Clinical Neurology; Physiology; Psychiatry SC Neurosciences & Neurology; Physiology; Psychiatry GA BX44K UT WOS:A1993BX44K00008 ER PT J AU FINK, G ASSENMACHER, I PLOTSKY, PM VALE, WW BERKENBOSCH, F TILDERS, FJH AGUILERA, G AF FINK, G ASSENMACHER, I PLOTSKY, PM VALE, WW BERKENBOSCH, F TILDERS, FJH AGUILERA, G TI A CONSIDERATION OF METHODOLOGY - GENERAL DISCUSSION SO CIBA FOUNDATION SYMPOSIA LA English DT Discussion ID CORTICOTROPIN-RELEASING-FACTOR; HYPOPHYSEAL PORTAL BLOOD; ARGININE VASOPRESSIN; MEDIAN-EMINENCE; RAT; SECRETION; GLUCOCORTICOIDS; OXYTOCIN; STEROIDS; AVP C1 SALK INST,CLAYTON FDN LABS PEPTIDE BIOL,SAN DIEGO,CA 92128. UNIV EDINBURGH,DEPT PHARMACOL,MRC,BRAIN METAB UNIT,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND. FREE UNIV AMSTERDAM,DEPT PHARMACOL,1081 BT AMSTERDAM,NETHERLANDS. UNIV MONTPELLIER 2,DEPT PHYSIOL,NEUROBIOL ENDOCRINOL LAB,CNRS,U1197,F-34095 MONTPELLIER 5,FRANCE. NICHHD,DEV ENDOCRINOL BRANCH,ENDOCRINE PHYSIOL SECT,BETHESDA,MD 20892. EMORY UNIV,SCH MED,DEPT PSYCHIAT,STRESS NEUROBIOL LABS,ATLANTA,GA 30322. NR 20 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI W SUSSEX PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD SN 0300-5208 J9 CIBA F SYMP JI CIBA Found. Symp. PY 1993 VL 172 BP 199 EP 203 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA KQ025 UT WOS:A1993KQ02500010 ER PT J AU DILSIZIAN, V BONOW, RO AF DILSIZIAN, V BONOW, RO TI CURRENT DIAGNOSTIC-TECHNIQUES OF ASSESSING MYOCARDIAL VIABILITY IN PATIENTS WITH HIBERNATING AND STUNNED MYOCARDIUM SO CIRCULATION LA English DT Review ID CORONARY-ARTERY DISEASE; POSITRON EMISSION TOMOGRAPHY; LEFT-VENTRICULAR FUNCTION; HEXAKIS 2-METHOXYISOBUTYL ISONITRILE; WALL-MOTION ABNORMALITIES; TC-99M METHOXYISOBUTYL ISONITRILE; REPERFUSED CANINE MYOCARDIUM; VIABLE MYOCARDIUM; MAGNETIC-RESONANCE; INFARCT SIZE C1 NHLBI,CARDIOL BRANCH,BETHESDA,MD 20892. RP DILSIZIAN, V (reprint author), NIH,DEPT NUCL MED,BLDG 10,ROOM 7B-15,BETHESDA,MD 20892, USA. NR 185 TC 365 Z9 376 U1 0 U2 1 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD JAN PY 1993 VL 87 IS 1 BP 1 EP 20 PG 20 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA KG434 UT WOS:A1993KG43400001 PM 8418996 ER PT J AU BRAUNWALD, E MULLER, JE MCCABE, CH KNATTERUD, GL THOMPSON, B PRIOR, MJ TERRIN, M CANNER, M DEPKIN, J GIRO, R KUFERA, J MONROE, WL WILKINS, P SOLOMON, R COLLING, C CHAITMAN, B SHAW, L WIENS, RD TAKASE, B STONE, PH MACCALLUM, G RUTHERFORD, J BROWN, BG DODGE, H BISSON, B WERTHEIMER, J YAZDANFAR, S ROBERTS, R KLEIMAN, NS PRATT, C RAIZNER, A ROSE, D TRAINOR, K LOCKER, D WILLIAMS, DO BIER, J DREW, T LEDLEY, G MCKENDALL, G RILEY, R SHARAF, B THOMAS, E FERREIRA, PE ROSS, AM WASSERMAN, AP VARGHESE, J KATZ, R LUNDERGAN, C CAVALLO, G DIVER, DJ BAIM, DS CARROZZA, J RODRIGUEZ, S MULLER, J TOFLER, G LEEMAN, D SENERCHIA, C SAFIAN, M ZARICH, S MCKENNA, C ANDERSON, JL KARAGOURIS, L IPSEN, S ALLEN, A SCHUMACHER, RR VALENTINE, R WENZLER, RB YEE, K KERNERSLEMONS, SB BERRON, K THEROUX, P DEGUISE, P LAM, J PELLETIER, G SEQUIN, MA CHAITMAN, B AGUIRRE, F KERN, M LEWIS, L MAJOR, M GOLDBERG, S ZALEWSKI, A SAVAGE, M WALINSKY, P WILSONDELACOURT, P ROGERS, WJ BAXLEY, WA DELLITALIA, LJ STANLEY, AWH BELENKIE, I WARNICA, JW HALL, C KNUDTSON, ML SMITH, ER LAMBERT, C PEPINE, CJ CONTI, CR HILL, J BUSCH, J HANDBERG, E BROTHERSON, C KELLS, CM HENDERSON, M FAWCETT, TM RAPAPORT, E CRAWFORD, M GERSTENBLITH, G HARKER, L SMITH, H WILLIAMS, G BRAUNWALD, E KNATTERUD, G LETENDRE, C SOLOMON, R THOMPSON, B BROWN, BG AF BRAUNWALD, E MULLER, JE MCCABE, CH KNATTERUD, GL THOMPSON, B PRIOR, MJ TERRIN, M CANNER, M DEPKIN, J GIRO, R KUFERA, J MONROE, WL WILKINS, P SOLOMON, R COLLING, C CHAITMAN, B SHAW, L WIENS, RD TAKASE, B STONE, PH MACCALLUM, G RUTHERFORD, J BROWN, BG DODGE, H BISSON, B WERTHEIMER, J YAZDANFAR, S ROBERTS, R KLEIMAN, NS PRATT, C RAIZNER, A ROSE, D TRAINOR, K LOCKER, D WILLIAMS, DO BIER, J DREW, T LEDLEY, G MCKENDALL, G RILEY, R SHARAF, B THOMAS, E FERREIRA, PE ROSS, AM WASSERMAN, AP VARGHESE, J KATZ, R LUNDERGAN, C CAVALLO, G DIVER, DJ BAIM, DS CARROZZA, J RODRIGUEZ, S MULLER, J TOFLER, G LEEMAN, D SENERCHIA, C SAFIAN, M ZARICH, S MCKENNA, C ANDERSON, JL KARAGOURIS, L IPSEN, S ALLEN, A SCHUMACHER, RR VALENTINE, R WENZLER, RB YEE, K KERNERSLEMONS, SB BERRON, K THEROUX, P DEGUISE, P LAM, J PELLETIER, G SEQUIN, MA CHAITMAN, B AGUIRRE, F KERN, M LEWIS, L MAJOR, M GOLDBERG, S ZALEWSKI, A SAVAGE, M WALINSKY, P WILSONDELACOURT, P ROGERS, WJ BAXLEY, WA DELLITALIA, LJ STANLEY, AWH BELENKIE, I WARNICA, JW HALL, C KNUDTSON, ML SMITH, ER LAMBERT, C PEPINE, CJ CONTI, CR HILL, J BUSCH, J HANDBERG, E BROTHERSON, C KELLS, CM HENDERSON, M FAWCETT, TM RAPAPORT, E CRAWFORD, M GERSTENBLITH, G HARKER, L SMITH, H WILLIAMS, G BRAUNWALD, E KNATTERUD, G LETENDRE, C SOLOMON, R THOMPSON, B BROWN, BG TI EARLY EFFECTS OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR ADDED TO CONVENTIONAL THERAPY ON THE CULPRIT CORONARY LESION IN PATIENTS PRESENTING WITH ISCHEMIC CARDIAC PAIN AT REST - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-ISCHEMIA (TIMI-IIIA) TRIAL SO CIRCULATION LA English DT Article DE PLASMINOGEN ACTIVATORS; ANGINA; NON-Q WAVE; MYOCARDIAL INFARCTION; ARTERIOGRAPHY, QUANTITATIVE ID UNSTABLE ANGINA-PECTORIS; PLACEBO-CONTROLLED TRIAL; INTRACORONARY THROMBUS; INFARCTION; ASPIRIN; ANGIOGRAPHY; MORPHOLOGY; PLATELETS; DISEASE; DEATH AB Background. The early effects of tissue-type plasminogen activator (t-PA) on the ''culprit'' coronary lesion in patients presenting with unstable angina or non-Q wave myocardial infarction were determined by quantitative arteriography. Methods and Results. Of 391 such patients, 306 satisfied clinical and arteriographic requirements for eligibility and received a 90-minute front-loaded infusion of t-PA (0.8 mg/kg iv.; maximum, 80 mg) or placebo plus conventional antianginal therapy. All patients received full heparinization and a follow-up arteriogram 18-48 hours after treatment. A non-Q wave myocardial infarction (MI) was diagnosed in 97 patients (32%) after entry. In the entire patient population, among t-PA- and placebo-treated patients, respectively, 25% versus 19% (p=0.25) of all culprit lesions achieved the primary study end point, measurable improvement (by greater-than-or-equal-to 10% reduction of stenosis or two Thrombolysis in Myocardial Infarction [TIMI] How grades) at follow-up. Substantial improvement (by greater-than-or-equal-to 20% reduction of stenosis or two TIMI grades) was seen with t-PA in 15% of all culprit lesions versus 5% with placebo (p<0.003). Arteriographically apparent thrombus was present at baseline in the culprit lesion of 107 patients (35%). Substantial improvement was more frequent with t-PA among lesions containing apparent thrombus (in 36% with t-PA versus 15% with placebo; p<0.01), as it was among patients evolving a non-Q wave MI (33% versus 8%; p<0.005). By multivariate analysis, the significant, independent predictors of substantial improvement include apparent thrombus (p=0.0001), non-Q wave MI (p=0.003), and t-PA use (p=0.01). Both non-Q wave MI status and thrombus had been specified a priori as important variables. Conclusions. Arteriographically apparent intraluminal thrombus and improvement of the culprit lesion with either of these regimens were only moderately frequent in patients with unstable angina or non-Q wave MI. Substantial improvement of culprit lesions was more frequent with t-PA than with placebo overall and in two prospectively defined subgroups. The clinical relevance of these observations is being tested in the larger, ongoing clinical TIMI IIIB study. C1 UNIV WASHINGTON,QUANTITAT ANGIOG CORE LAB,SEATTLE,WA 98195. MARYLAND MED RES INST,CTR DATA COORDINATING,BALTIMORE,MD. NHLBI,PROGRAM OFF,BETHESDA,MD 20892. VET ADM MED RES SERV,COOPERAT STUDIES PROGRAM,CTR DRUG DISTRIBUT,ALBUQUERQUE,NM. ST LOUIS UNIV,ELECTRCARDIOG CORE LAB,ST LOUIS,MO 63103. HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,HOLTER CORE LAB,BOSTON,MA 02115. ALBERT EINSTEIN MED CTR,NO DIV,PHILADELPHIA,PA 19141. BAYLOR COLL MED,HOUSTON,TX 77030. BROWN UNIV,PROVIDENCE,RI 02912. GEORGE WASHINGTON UNIV,WASHINGTON,DC 20052. UNIV UTAH,LDS HOSP,SALT LAKE CITY,UT 84112. METHODIST HOSP INDIANA,INDIANAPOLIS,IN 46202. MONTREAL HEART INST,MONTREAL H1T 1C8,QUEBEC,CANADA. ST LOUIS UNIV,ST LOUIS,MO 63103. THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107. UNIV ALABAMA,BIRMINGHAM,AL 35294. UNIV CALGARY,CALGARY T2N 1N4,ALBERTA,CANADA. UNIV FLORIDA,GAINESVILLE,FL 32611. VICTORIA GEN HOSP,HALIFAX B3H 2Y9,NS,CANADA. NR 62 TC 110 Z9 112 U1 0 U2 2 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD JAN PY 1993 VL 87 IS 1 BP 38 EP 52 PG 15 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA KG434 UT WOS:A1993KG43400004 ER PT J AU STEENBERGEN, C PERLMAN, ME LONDON, RE MURPHY, E AF STEENBERGEN, C PERLMAN, ME LONDON, RE MURPHY, E TI MECHANISM OF PRECONDITIONING - IONIC ALTERATIONS SO CIRCULATION RESEARCH LA English DT Article DE MYOCARDIAL ISCHEMIA; PRECONDITIONING; NUCLEAR MAGNETIC RESONANCE; CYTOSOLIC FREE CALCIUM CONCENTRATION; INTRACELLULAR SODIUM CONCENTRATION ID CYTOSOLIC FREE CALCIUM; PERFUSED RAT HEARTS; MYOCARDIAL-ISCHEMIA; F-19 NMR; INTRACELLULAR SODIUM; ADENOSINE RECEPTORS; NA+ ACCUMULATION; MEMBRANE INJURY; MAMMALIAN HEART; GLOBAL-ISCHEMIA AB The mechanism by which preconditioning (brief intermittent periods of ischemia and reflow) improves recovery of function and reduces enzyme release after a subsequent 30-minute period of ischemia was investigated in perfused rat hearts. Specifically, it was hypothesized that ischemia after preconditioning would result in a decreased production of H+ and therefore a smaller rise in [Na+]i and [Ca2+]i via Na+-H+ and Na+-Ca2+ exchange. To test this hypothesis we measured pH(i), [Na+]i, [Ca2+]i, and cell high-energy phosphates during ischemia and reflow, and we correlated this with recovery of contractile function and release of creatine kinase during reflow. P-31 nuclear magnetic resonance (NMR) was used to measure pH(i) and cell phosphates. [Na+]i was measured by Na-23 NMR using the shift reagent thulium 1,4,7,10-tetraazacyclododecane-N,N,'N'',N'''-tetramethylenephosphonate to distinguish intracellular from extracellular sodium. [Ca2+]i was measured by F-19 NMR using hearts loaded with 1,2-bis(2-amino-5-fluorophenoxy)ethane-N,N,N',N'-tetraacetic acid, termed 5F-BAPTA. Basal time-averaged levels of pH(i), [Na+]i, and [Ca2+]i were 7.07+/-0.08, 9.4+/-0.8 mM, and 715+/-31 nM, respectively. After 30 minutes of ischemia, in preconditioned hearts, pH(i) was 6.5+/-0.06, [Na+]i was 20.9+/-4.4 mM, [Ca2+]i was 2.1+/-0.4 muM, and ATP was negligible. In untreated hearts, after 30 minutes of ischemia, pH(i) was 6.3+/-0.08, [Na+]i was 26.7+/-3.8 mM, [Ca2+]i Was 3.2+/-0.6 muM, and ATP was undetectable. During reperfusion after 30 minutes of ischemia, preconditioned hearts had significantly better recovery of contractile function than untreated hearts (71+/-9% versus 3+/-8% initial left ventricular developed pressure), and after 60 minutes of ischemia, preconditioned hearts had significantly less release of the intracellular enzyme creatine kinase (102+/-12 versus 164+/-17 IU/g dry wt). We also found that unpreconditioned hearts arrested with 16 mM +/-MgCl2 (to inhibit calcium entry via calcium channels and Na+-Ca2+ exchange) before 30 minutes of ischemia recover function on reflow to the same extent as preconditioned hearts with or without magnesium arrest. Thus, preconditioning has no additional benefit in addition to magnesium arrest. In addition, in hearts that received 16 mM MgCl2 just before the 30-minute period of ischemia, preconditioning had no effect on the rise in [Ca2+]i during the 30-minute period of ischemia. These data support the hypothesis that preconditioning attenuates the increase in [Ca2+]i, [Na+]i, and [H+]i during ischemia, most likely because of reduced stimulation of Na+-H+ and Na+-Ca2+ exchange. The data suggest that interventions that minimize ionic derangements during ischemia are associated with improved recovery of contractility and less enzyme release on reflow. C1 NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709. RP STEENBERGEN, C (reprint author), DUKE UNIV,MED CTR,DEPT PATHOL,BOX 3712,DURHAM,NC 27710, USA. FU NHLBI NIH HHS [R01 HL039752, R29-HL-39752] NR 71 TC 361 Z9 370 U1 1 U2 5 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7330 J9 CIRC RES JI Circ.Res. PD JAN PY 1993 VL 72 IS 1 BP 112 EP 125 PG 14 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Hematology GA KC361 UT WOS:A1993KC36100013 PM 8380259 ER PT S AU JONES, EA BASILE, AS YURDAYDIN, C SKOLNICH, P AF JONES, EA BASILE, AS YURDAYDIN, C SKOLNICH, P BE Grisolia, S Felipo, V TI DO BENZODIAZEPINE LIGANDS CONTRIBUTE TO HEPATIC-ENCEPHALOPATHY SO CIRRHOSIS, HYPERAMMONEMIA, AND HEPATIC ENCEPHALOPATHY SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT International Summer Course on Cirrhosis, Hyperammonemia, and Hepatic Encephalopathy CY AUG 10-14, 1992 CL EL ESCORIAL, SPAIN SP COMPLUTENSE UNIV MADRID C1 NIDDK,NEUROSCI LAB,BETHESDA,MD 20892. RP JONES, EA (reprint author), NIDDK,LIVER DIS SECT,BETHESDA,MD, USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44595-6 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1993 VL 341 BP 57 EP 69 PG 13 WC Endocrinology & Metabolism; Gastroenterology & Hepatology; Pathology; Toxicology SC Endocrinology & Metabolism; Gastroenterology & Hepatology; Pathology; Toxicology GA BZ51R UT WOS:A1993BZ51R00006 PM 8116487 ER PT J AU CUTLER, JA AF CUTLER, JA TI COMBINATIONS OF LIFE-STYLE MODIFICATION AND DRUG-TREATMENT IN MANAGEMENT OF MILD-MODERATE HYPERTENSION - A REVIEW OF RANDOMIZED CLINICAL-TRIALS SO CLINICAL AND EXPERIMENTAL HYPERTENSION LA English DT Article DE ANTIHYPERTENSIVE TREATMENT; MILD-MODERATE HYPERTENSION; CLINICAL TRIALS ID QUALITY-OF-LIFE; CARDIOVASCULAR RISK; BLOOD-PRESSURE; DIET; TAIM AB Several randomized clinical trials have compared combined lifestyle and drug treatment of hypertension to drugs alone, lifestyle alone, or no treatment. Lifestyle interventions tested have included: weight loss, sodium reduction, potassium increase, and combinations of these and other modalities. Each trial has found combined therapy to be superior to the comparison group(s) in terms of blood pressure reduction and/or control, or to amount of drugs required, except in the U.S. TAIM study for the sodium/potassium regimen, where the lifestyle changes were small. Combined therapy has also been consistently better regarding side effects/quality of life, and there is evidence for greater reduction in cardiovascular risk. Some findings suggest variation among drugs for optimal combinations. Information on cost-effectiveness is lacking. RP CUTLER, JA (reprint author), NHLBI,DIV EPIDEMIOL & CLIN APPLICAT,BETHESDA,MD 20892, USA. NR 16 TC 8 Z9 8 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 1064-1963 J9 CLIN EXP HYPERTENS JI Clin. Exp. Hypertens. PY 1993 VL 15 IS 6 BP 1193 EP 1204 DI 10.3109/10641969309037105 PG 12 WC Pharmacology & Pharmacy; Peripheral Vascular Disease SC Pharmacology & Pharmacy; Cardiovascular System & Cardiology GA MF614 UT WOS:A1993MF61400026 PM 8268885 ER PT J AU CHOPRA, RK RAJ, NBK SCALLY, JP DONNENBERG, AD ADLER, WH SAAH, AJ MARGOLICK, JB AF CHOPRA, RK RAJ, NBK SCALLY, JP DONNENBERG, AD ADLER, WH SAAH, AJ MARGOLICK, JB TI RELATIONSHIP BETWEEN IL-2 RECEPTOR EXPRESSION AND PROLIFERATIVE RESPONSES IN LYMPHOCYTES FROM HIV-1 SEROPOSITIVE HOMOSEXUAL MEN SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY LA English DT Article DE HIV-1; IL-2; IL-2 RECEPTOR; LYMPHOCYTES; PHYTOHEMAGGLUTININ ID ACQUIRED IMMUNODEFICIENCY SYNDROME; PERIPHERAL-BLOOD LYMPHOCYTES; IMMUNE-DEFICIENCY SYNDROME; MULTICENTER AIDS COHORT; INTERLEUKIN-2 RECEPTOR; T-CELLS; MONOCLONAL-ANTIBODIES; GROWTH-FACTOR; INVITRO; BETA AB Previous studies have shown that exogenous IL-2 does not correct the reduction in phytohaemagglutinin (PHA)-induced proliferation of lymphocytes from HIV-1 infected (HIV+) individuals. We investigated the mechanism of this reduction to determine if reduced expression of the complete IL-2 receptor (IL-2R) was responsible. In a series of experiments, PHA-stimulated lymphocytes from a total of 89 HIV - and 93 HIV + homosexual men from the Baltimore Multicentre AIDS Cohort Study (MACS) were studied to determine the expression of messages for the alpha and beta subunits of the IL-2R, the binding of I-125-IL-2 to high affinity IL-2R, and the effect of IL-2 on cell proliferation. Compared to HIV- donors, PHA-stimulated lymphocytes from most HIV+ donors demonstrated (i) a reduction in high affinity IL-2R expression that correlated with the reduction in the IL-2-induced proliferative response; and (ii) a reduction in expression of both IL-2R alpha- and beta-chain mRNA which may be responsible for decreased high affinity IL-2R expression. However, lymphocytes from some HIV+ individuals had borderline low IL-2-induced proliferation despite normal or elevated expression of high affinity IL-2R. These results suggest that decreased expression of IL-2R may account, at least in part, for the lower proliferative response of cells from HIV+ donors. C1 JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205. JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205. JOHNS HOPKINS UNIV,BONE MARROW TRANSPLANT PROGRAM,BALTIMORE,MD 21205. NIA,CLIN IMMUNOL SECT,GERONTOL RES CTR,BALTIMORE,MD 21224. BALTIMORE CTR MULTICTR AIDS COHORT STUDY,BALTIMORE,MD. RP CHOPRA, RK (reprint author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI,615 N WOLFE ST,BALTIMORE,MD 21205, USA. FU NIAID NIH HHS [AI72634, AI28748, AI25326] NR 46 TC 16 Z9 16 U1 0 U2 0 PU BLACKWELL SCIENCE LTD PI OXFORD PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL SN 0009-9104 J9 CLIN EXP IMMUNOL JI Clin. Exp. Immunol. PD JAN PY 1993 VL 91 IS 1 BP 18 EP 24 PG 7 WC Immunology SC Immunology GA KG045 UT WOS:A1993KG04500003 PM 8093435 ER PT J AU LENDERS, JWM EISENHOFER, G ARMANDO, I KEISER, HR GOLDSTEIN, DS KOPIN, IJ AF LENDERS, JWM EISENHOFER, G ARMANDO, I KEISER, HR GOLDSTEIN, DS KOPIN, IJ TI DETERMINATION OF METANEPHRINES IN PLASMA BY LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION SO CLINICAL CHEMISTRY LA English DT Article DE CHROMATOGRAPHY, REVERSED-PHASE; CATECHOLAMINE; PHEOCHROMOCYTOMA ID CONJUGATED NORMETANEPHRINE; VANILLYLMANDELIC ACID; PHASE EXTRACTION; CATECHOLAMINES; METABOLITES; ASSAY; BRAIN AB Metanephrines are O-methylated metabolites of catecholamines. We report the use of liquid chromatography with electrochemical detection to determine plasma concentrations of normetanephrine (NMN) and metanephrine (MN). Plasma NMN and MN in 32 normal volunteers and inpatients were compared with concentrations in 23 patients with pheochromocytoma. Metanephrines were adsorbed from plasma onto a cation-exchange column and eluted with ammoniacal methanol. The dried residue was dissolved in mobile phase and injected onto a reversed-phase column. Recoveries of NMN and MN from 1 mL of plasma averaged 50-70%, and results varied linearly with quantity injected over a range of 0.13-55 pmol. The detection limit was 25 fmol for NMN and 50 fmol for MN. Intra-assay CVs were <5%. In normal volunteers and inpatients, plasma concentrations of NMN ranged between 0.12 and 0.73 nmol/L (mean 0.38 nmol/L), and MN between 0.06 and 0.63 nmol/L (mean 0.19 nmol/L). Plasma NMN concentrations were increased in all 23 patients with pheochromocytoma (range 1-172 nmol/L), whereas MN concentrations (range 0.10-382 nmol/L) were increased in only 9 patients. The assay method is reliable and sensitive and offers an approach to examine the extraneuronal metabolism of catecholamines. The method may also be useful in the diagnosis of pheochromocytoma. C1 NINCDS,CLIN NEUROSCI BRANCH,BLDG 10,ROOM 5N214,BETHESDA,MD 20892. NHLBI,HYPERTENS ENDOCRINE BRANCH,BETHESDA,MD 20892. NR 15 TC 150 Z9 154 U1 4 U2 8 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD JAN PY 1993 VL 39 IS 1 BP 97 EP 103 PG 7 WC Medical Laboratory Technology SC Medical Laboratory Technology GA KG571 UT WOS:A1993KG57100016 PM 8419068 ER PT J AU THOMPSON, EW BRUNNER, N TORRI, J JOHNSON, MD BOULAY, V WRIGHT, A LIPPMAN, ME STEEG, PS CLARKE, R AF THOMPSON, EW BRUNNER, N TORRI, J JOHNSON, MD BOULAY, V WRIGHT, A LIPPMAN, ME STEEG, PS CLARKE, R TI THE INVASIVE AND METASTATIC PROPERTIES OF HORMONE-INDEPENDENT BUT HORMONE-RESPONSIVE VARIANTS OF MCF-7 HUMAN BREAST-CANCER CELLS SO CLINICAL & EXPERIMENTAL METASTASIS LA English DT Article DE BREAST CANCER; ESTROGEN-INDEPENDENT; INVASION; METASTASIS; PROGRESSION ID SODIUM DODECYL-SULFATE; ATHYMIC NUDE-MICE; MAMMARY-TUMORS; MALIGNANT PROGRESSION; CARCINOMA-CELLS; RAS ONCOGENES; GROWTH; INVITRO; LINES; TUMORIGENICITY AB We have previously isolated a series of MCF-7 human breast cancer cell variants which no longer require estrogen-supplementation for tumor growth in nude mice (Clarke et al. Proc Natl Acad Sci USA 86: 3649-3653, 1989). We now report that these hormone-independent and hormone-responsive variants (MIII, MCF7/LCC1) can invade locally from solid mammary fat pad tumors, and produce primary extensions on the surface of intraperitoneal structures including liver, pancreas, and diaphragm. Both lymphatic and hematogenous dissemination are observed, resulting in the establishing of pulmonary, bone, and renal metastases. The pattern of metastasis by MIII and MCF7/LCC1 cells closely resembles that frequently observed in breast cancer patients, and provides the first evidence of metastasis from MCF-7 cells growing in vivo without supplementary estrogen. The interexperimental incidence of metastases, and the time from cell inoculation to the appearance of metastatic disease are variable. The increased metastatic potential is not associated with an increase in either the level of laminin attachment, laminin receptor mRNA expression, or secreted type IV collagenolytic activity. We also did not detect a significant decrease in the steady-state mRNA levels of the metastasis inhibitor nm23 gene. However, when growing without estrogen in vitro, MCF7/LCC1 cells produce elevated levels of the estrogen-inducible cathepsin D enzyme. C1 GEORGETOWN UNIV,SCH MED,VINCENT T LOMBARDI CANC RES CTR,3800 RESERVOIR RD NW,ROOM 5128A,WASHINGTON,DC 20007. NCI,PATHOL LAB,BETHESDA,MD 20892. GEORGETOWN UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,WASHINGTON,DC 20007. GEORGETOWN UNIV,SCH MED,DEPT ANAT & CELL BIOL,WASHINGTON,DC 20007. RI Clarke, Robert/A-6485-2008; Thompson, Erik/A-1425-2009 OI Clarke, Robert/0000-0002-9278-0854; Thompson, Erik/0000-0002-9723-4924 FU NCI NIH HHS [UO1 CA51908, 1P30-CA-51008-01]; NCRR NIH HHS [RR5360] NR 53 TC 73 Z9 74 U1 0 U2 0 PU RAPID SCIENCE PUBLISHERS PI LONDON PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH SN 0262-0898 J9 CLIN EXP METASTAS JI Clin. Exp. Metastasis PD JAN PY 1993 VL 11 IS 1 BP 15 EP 26 DI 10.1007/BF00880062 PG 12 WC Oncology SC Oncology GA KL221 UT WOS:A1993KL22100002 PM 8380760 ER PT S AU KAGAN, J GELMAN, R WAXDAL, M KIDD, P AF KAGAN, J GELMAN, R WAXDAL, M KIDD, P BE Landay, AL Ault, KT Bauer, KD Rabinovitch, PS TI NIAID DIVISION OF AIDS FLOW-CYTOMETRY QUALITY ASSESSMENT PROGRAM SO CLINICAL FLOW CYTOMETRY SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT CONF ON CLINICAL FLOW CYTOMETRY CY APR 25-28, 1992 CL BALTIMORE, MD SP NEW YORK ACAD SCI, AMAC, HOFFMANN LA ROCHE, PFIZER CENT RES, PHARMINGEN, PHOENIX FLOW SYST RP KAGAN, J (reprint author), NIAID,DIV AIDS,BETHESDA,MD 20892, USA. FU NIAID NIH HHS [N01-AI-95010, N01-AI-95030] NR 0 TC 13 Z9 13 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-767-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 677 BP 50 EP 52 DI 10.1111/j.1749-6632.1993.tb38763.x PG 3 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA BX95P UT WOS:A1993BX95P00007 PM 8494245 ER PT S AU CHREST, FJ PAULY, RR MONTICONE, R LAKATTA, EG ADLER, WH AF CHREST, FJ PAULY, RR MONTICONE, R LAKATTA, EG ADLER, WH BE Landay, AL Ault, KT Bauer, KD Rabinovitch, PS TI TGF-BETA-1 RECEPTOR EXPRESSION AND CELL-CYCLE ANALYSIS OF VASCULAR SMOOTH-MUSCLE CELLS FROM YOUNG AND AGED RATS SO CLINICAL FLOW CYTOMETRY SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT CONF ON CLINICAL FLOW CYTOMETRY CY APR 25-28, 1992 CL BALTIMORE, MD SP NEW YORK ACAD SCI, AMAC, HOFFMANN LA ROCHE, PFIZER CENT RES, PHARMINGEN, PHOENIX FLOW SYST RP CHREST, FJ (reprint author), NIA,GERONTOL RES CTR,CARDIOVASC SCI LAB,CLIN IMMUNOL SECT,BALTIMORE,MD 21224, USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-767-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 677 BP 396 EP 399 DI 10.1111/j.1749-6632.1993.tb38796.x PG 4 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA BX95P UT WOS:A1993BX95P00040 PM 8388181 ER PT S AU KIRBY, MR DONAHUE, RE AF KIRBY, MR DONAHUE, RE BE Landay, AL Ault, KT Bauer, KD Rabinovitch, PS TI RARE EVENT SORTING OF CD34+ HEMATOPOIETIC-CELLS SO CLINICAL FLOW CYTOMETRY SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT CONF ON CLINICAL FLOW CYTOMETRY CY APR 25-28, 1992 CL BALTIMORE, MD SP NEW YORK ACAD SCI, AMAC, HOFFMANN LA ROCHE, PFIZER CENT RES, PHARMINGEN, PHOENIX FLOW SYST RP KIRBY, MR (reprint author), NHLBI,CLIN HEMATOL BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-767-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 677 BP 413 EP 416 DI 10.1111/j.1749-6632.1993.tb38802.x PG 4 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA BX95P UT WOS:A1993BX95P00046 PM 7684209 ER PT J AU POST, RM AF POST, RM TI MODELS FOR THE IMPACT OF AFFECTIVE-ILLNESS ON GENE-EXPRESSION - IMPLICATIONS FOR LONG-TERM PROPHYLAXIS SO CLINICAL NEUROSCIENCE LA English DT Article DE LITHIUM; CARBAMAZEPINE; VALPROATE; KINDLING; ANTIDEPRESSANTS ID FOS MESSENGER-RNA; C-FOS; UNIPOLAR DEPRESSION; LITHIUM-CARBONATE; BIPOLAR DISORDER; MAINTENANCE THERAPIES; CONTINUATION THERAPY; RECURRENT DEPRESSION; NERVOUS-SYSTEM; DOUBLE-BLIND AB Recurrent affective illness can progress over time, with the intervals between episodes becoming progressively shorter and psychosocial stressors becoming less important in precipitating those episodes. A change, in pharmacological responsivity can also occur as the illness progresses. Behavioral sensitization to psychomotor stimulants, which is a useful model for recurrent manic and dysphoric manic syndromes and kindling, even though it is not a homologous model for affective illness, can help conceptualize the processes that underlie the progression of affective illness and the eventual emergence of autonomous episodes. Data derived from these models lead to the prediction that stresses, as well as affective episodes themselves, may have an impact on gene expression, increasing vulnerability to the recurrence of illness and, perhaps, changing pharmaacological responsivity. These theoretical formulations, in addition to a strong existing empirical data base, support the early institution and the long-term maintenance of prophylactic medication in Patients with recurrent effective disorders. (C) 1993 Wiley-Liss, Inc. * C1 NIMH,BETHESDA,MD 20892. NR 83 TC 2 Z9 2 U1 1 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 1065-6766 J9 CLIN NEUROSCI JI Clin. Neurosci. PY 1993 VL 1 IS 3 BP 129 EP 138 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA MQ776 UT WOS:A1993MQ77600004 ER PT J AU GOODWIN, FK AF GOODWIN, FK TI NEUROBIOLOGY OF MANIC-DEPRESSIVE ILLNESS - THE NEXT CHAPTER SO CLINICAL NEUROSCIENCE LA English DT Article DE MANIA; DEPRESSION; BIPOLAR ILLNESS; UNIPOLAR ILLNESS; BIOLOGICAL RHYTHMS; CYCLICITY; GENETICS ID BIPOLAR AFFECTIVE-DISORDER; LITHIUM; ABNORMALITIES; HYPOTHESIS; STRESS AB Biological hypotheses about manic-depressive illness must account for the two most fundamental characteristics of the illness-genetic vulnerability and recurrence. Because the illness is more homogeneous than th other major mental illnesses, its genetic basis should easier to characterize. Furthering and complementing the molecular genetic work are studies aimed at identifying pathophysiological correlates, or trait markers, that are unique to the illness. Neuroimaging technology should soon clarify ambiguities about structural brain abnormalities, which could serve as trait markers. Studies of intracellular changes resulting from antidepressant and mood-stabilizing drugs could also elucidate the cellular and molecular processes involved in pathogenesis. Recurrence itself could conceivably be traced to an inherited trait. Fluctuations in clinical features suggest a profound dysregulation in homeostatic processes, perhaps involving central pacemakers that normally synchronize physiological systems. Biological rhythm research is one of many areas now being explored in neurobiological studies of manic-depressive illness. (C) 1993 Wiley-Liss, Inc. * C1 NIMH,ROCKVILLE,MD 20857. NR 35 TC 0 Z9 0 U1 2 U2 6 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 1065-6766 J9 CLIN NEUROSCI JI Clin. Neurosci. PY 1993 VL 1 IS 3 BP 157 EP 162 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA MQ776 UT WOS:A1993MQ77600008 ER PT J AU ALLEN, JP LITTEN, RZ AF ALLEN, JP LITTEN, RZ TI PSYCHOMETRIC AND LABORATORY MEASURES TO ASSIST IN THE TREATMENT OF ALCOHOLISM SO CLINICAL PSYCHOLOGY REVIEW LA English DT Review ID ADDICTION SEVERITY INDEX; SCREENING-TEST SAAST; SUBSTANCE ABUSE; DEPENDENCE SCALE; DISCRIMINANT-ANALYSIS; INPATIENT ALCOHOLICS; DRINKING PATTERNS; SERUM TRANSFERRIN; WITHDRAWAL; EXPECTANCIES AB A broad range of psychological and laboratory tests have been developed to assist in identification and treatment of alcoholism. The following measures are reviewed: Self-Administered Alcoholism Screening Test, Clinical Institute Withdrawal Assessment, Alcohol Dependence Scale, Inventory of Drinking Situations, Situational Confidence Questionnaire, Alcohol Expectancy Questionnaire, and Addiction Severity Index. Currently available and promising laboratory tests for alcoholism screening are also briefly described. Finally, comments are offered on the role of assessment in treatment planning and needs for additional psychometric research. RP ALLEN, JP (reprint author), NIAAA,DIV CLIN & PREVENT RES,TREATMENT RES BRANCH,ROOM 14C-20,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA. NR 100 TC 8 Z9 8 U1 9 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0272-7358 J9 CLIN PSYCHOL REV JI Clin. Psychol. Rev. PY 1993 VL 13 IS 3 BP 223 EP 239 DI 10.1016/0272-7358(93)90021-D PG 17 WC Psychology, Clinical SC Psychology GA KZ741 UT WOS:A1993KZ74100002 ER PT J AU TURNER, ML AF TURNER, ML TI CONNECTIVE-TISSUE DISEASES SO CLINICS IN PLASTIC SURGERY LA English DT Article RP TURNER, ML (reprint author), NIH,DERMATOL BRANCH,BLDG 10,ROOM 12N238,BETHESDA,MD 20892, USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0094-1298 J9 CLIN PLAST SURG JI Clin. Plast. Surg. PD JAN PY 1993 VL 20 IS 1 BP 77 EP 90 PG 14 WC Surgery SC Surgery GA LA249 UT WOS:A1993LA24900009 PM 8420711 ER PT J AU CLARK, D REITMAN, M STUDITSKY, V CHUNG, J WESTPHAL, H LEE, E FELSENFELD, G AF CLARK, D REITMAN, M STUDITSKY, V CHUNG, J WESTPHAL, H LEE, E FELSENFELD, G TI CHROMATIN STRUCTURE OF TRANSCRIPTIONALLY ACTIVE GENES SO COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY LA English DT Article; Proceedings Paper CT 58th Annual Cold Spring Harbor Symposia on Quantitative Biology: DNA and Chromosomes CY JUN 02-09, 1993 CL COLD SPRING HARBOR, NY SP COLD SPRING HARBOR LAB ID BETA-GLOBIN GENE; DEVELOPMENTAL REGULATION; HYPERSENSITIVE SITES; TRANSGENIC MICE; CONTROL REGION; EXPRESSION; LOCUS; DNA; ENHANCER; ACTIVATION C1 NIDDKD,DIABET BRANCH,BETHESDA,MD 20892. NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892. RP CLARK, D (reprint author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA. RI Reitman, Marc/B-4448-2013 OI Reitman, Marc/0000-0002-0426-9475 NR 34 TC 11 Z9 11 U1 0 U2 1 PU COLD SPRING HARBOR LAB PRESS PI PLAINVIEW PA 1 BUNGTOWN RD, PLAINVIEW, NY 11724 SN 0091-7451 J9 COLD SPRING HARB SYM JI Cold Spring Harbor Symp. Quant. Biol. PY 1993 VL 58 BP 1 EP 6 PG 6 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA NR751 UT WOS:A1993NR75100002 PM 7956019 ER PT J AU HAGER, GL ARCHER, TK FRAGOSO, G BRESNICK, EH TSUKAGOSHI, Y JOHN, S SMITH, CL AF HAGER, GL ARCHER, TK FRAGOSO, G BRESNICK, EH TSUKAGOSHI, Y JOHN, S SMITH, CL TI INFLUENCE OF CHROMATIN STRUCTURE ON THE BINDING OF TRANSCRIPTION FACTORS TO DNA SO COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY LA English DT Article; Proceedings Paper CT 58th Annual Cold Spring Harbor Symposia on Quantitative Biology: DNA and Chromosomes CY JUN 02-09, 1993 CL COLD SPRING HARBOR, NY SP COLD SPRING HARBOR LAB ID TUMOR VIRUS PROMOTER; MMTV PROMOTER; GLUCOCORTICOID REGULATION; NUCLEOSOMES; GENE; ACTIVATION; MECHANISM; COMPLEXES; SEQUENCE; ENHANCER RP HAGER, GL (reprint author), NCI,MOLEC VIROL LAB,BETHESDA,MD 20892, USA. NR 30 TC 48 Z9 48 U1 0 U2 0 PU COLD SPRING HARBOR LAB PRESS PI PLAINVIEW PA 1 BUNGTOWN RD, PLAINVIEW, NY 11724 SN 0091-7451 J9 COLD SPRING HARB SYM JI Cold Spring Harbor Symp. Quant. Biol. PY 1993 VL 58 BP 63 EP 71 PG 9 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA NR751 UT WOS:A1993NR75100009 PM 7956078 ER PT J AU WOLFFE, AP ALMOUZNI, G URA, K PRUSS, D HAYES, JJ AF WOLFFE, AP ALMOUZNI, G URA, K PRUSS, D HAYES, JJ TI TRANSCRIPTION FACTOR ACCESS TO DNA IN THE NUCLEOSOME SO COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY LA English DT Article; Proceedings Paper CT 58th Annual Cold Spring Harbor Symposia on Quantitative Biology: DNA and Chromosomes CY JUN 02-09, 1993 CL COLD SPRING HARBOR, NY SP COLD SPRING HARBOR LAB ID 5S RNA GENE; INTERNAL CONTROL REGION; FACTOR-IIIA; HISTONE ACETYLATION; REPLICATING DNA; LINKER HISTONES; CHROMATIN; COMPLEX; CORE; REPRESSION RP WOLFFE, AP (reprint author), NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892, USA. NR 49 TC 18 Z9 18 U1 0 U2 0 PU COLD SPRING HARBOR LAB PRESS PI PLAINVIEW PA 1 BUNGTOWN RD, PLAINVIEW, NY 11724 SN 0091-7451 J9 COLD SPRING HARB SYM JI Cold Spring Harbor Symp. Quant. Biol. PY 1993 VL 58 BP 225 EP 235 PG 11 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA NR751 UT WOS:A1993NR75100026 PM 7956033 ER PT J AU SIMPSON, RT ROTH, SY MORSE, RH PATTERTON, HG COOPER, JP MURPHY, M KLADDE, MP SHIMIZU, M AF SIMPSON, RT ROTH, SY MORSE, RH PATTERTON, HG COOPER, JP MURPHY, M KLADDE, MP SHIMIZU, M TI NUCLEOSOME POSITIONING AND TRANSCRIPTION SO COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY LA English DT Article ID YEAST ALPHA-2 REPRESSOR; SACCHAROMYCES-CEREVISIAE; CHROMATIN; PROTEIN; PROMOTER; GENE; UPSTREAM; OPERATOR; INVIVO; ACTIVATION RP NIDDKD, CELLULAR & DEV BIOL LAB, BETHESDA, MD 20892 USA. OI Morse, Randall/0000-0003-0000-8718; Patterton, Hugh-George/0000-0003-2550-0493 NR 37 TC 21 Z9 22 U1 0 U2 0 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 0091-7451 J9 COLD SPRING HARB SYM JI Cold Spring Harbor Symp. Quant. Biol. PY 1993 VL 58 BP 237 EP 245 PG 9 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA NR751 UT WOS:A1993NR75100027 PM 7956034 ER PT J AU KLAR, AJS BONADUCE, MJ AF KLAR, AJS BONADUCE, MJ TI THE MECHANISM OF FISSION YEAST MATING-TYPE INTERCONVERSION - EVIDENCE FOR 2 TYPES OF EPIGENETICALLY INHERITED CHROMOSOMAL IMPRINTED EVENTS SO COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY LA English DT Article ID SCHIZOSACCHAROMYCES-POMBE; SWITCHING GENES; DNA STRANDS; CASSETTES; CELLS; SITE; TRANSPOSITION; RECOMBINATION; METHYLATION; EXPRESSION RP NCI, FREDERICK CANC RES & DEV CTR, EUKARYOT GENE EXPRESS LAB, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA. FU NCI NIH HHS [N01-CO-74101] NR 42 TC 21 Z9 21 U1 0 U2 0 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 0091-7451 J9 COLD SPRING HARB SYM JI Cold Spring Harbor Symp. Quant. Biol. PY 1993 VL 58 BP 457 EP 465 PG 9 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA NR751 UT WOS:A1993NR75100051 PM 7956060 ER PT J AU MIZUUCHI, M MIZUUCHI, K AF MIZUUCHI, M MIZUUCHI, K TI TARGET SITE SELECTION IN TRANSPOSITION OF PHAGE-MU SO COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY LA English DT Article; Proceedings Paper CT 58th Annual Cold Spring Harbor Symposia on Quantitative Biology: DNA and Chromosomes CY JUN 02-09, 1993 CL COLD SPRING HARBOR, NY SP COLD SPRING HARBOR LAB ID DNA STRAND-TRANSFER; INTEGRATION HOST FACTOR; BACTERIOPHAGE-MU; B-PROTEIN; RETROVIRAL INTEGRATION; INVITRO TRANSPOSITION; TN7 TRANSPOSITION; MALB REGION; GENETIC-MAP; SEQUENCE C1 NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892. RP MIZUUCHI, M (reprint author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA. NR 45 TC 46 Z9 47 U1 0 U2 0 PU COLD SPRING HARBOR LAB PRESS PI PLAINVIEW PA 1 BUNGTOWN RD, PLAINVIEW, NY 11724 SN 0091-7451 J9 COLD SPRING HARB SYM JI Cold Spring Harbor Symp. Quant. Biol. PY 1993 VL 58 BP 515 EP 523 PG 9 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA NR751 UT WOS:A1993NR75100057 PM 7956065 ER PT J AU DI LEONARDO, A LINKE, SP YIN, Y WAHL, GM AF DI LEONARDO, A LINKE, SP YIN, Y WAHL, GM TI CELL-CYCLE REGULATION OF GENE AMPLIFICATION SO COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY LA English DT Article ID WILD-TYPE P53; DIHYDROFOLATE-REDUCTASE GENE; TUMOR-SUPPRESSOR P53; HAMSTER OVARY CELLS; DOUBLE-MINUTE CHROMOSOMES; DNA STRAND BREAKS; 1ST 3 ENZYMES; LATE G1 PHASE; MAMMALIAN-CELLS; MOUSE CELLS C1 UNIV PALERMO, DEPT CELL & DEV BIOL, PALERMO, ITALY. UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA. NIEHS, MOLEC CARCINOGENESIS LAB, RES TRIANGLE PK, NC 27709 USA. RP SALK INST BIOL STUDIES, GENE EXPRESS LAB, LA JOLLA, CA 92037 USA. RI Di Leonardo, Aldo/F-9833-2012 OI Di Leonardo, Aldo/0000-0003-4760-7179 NR 105 TC 26 Z9 26 U1 0 U2 0 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 0091-7451 J9 COLD SPRING HARB SYM JI Cold Spring Harbor Symp. Quant. Biol. PY 1993 VL 58 BP 655 EP 667 PG 13 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA NR751 UT WOS:A1993NR75100072 PM 7956082 ER PT J AU CAMPBELL, G RATNAPARKHI, MV AF CAMPBELL, G RATNAPARKHI, MV TI AN APPLICATION OF LOMAX DISTRIBUTIONS IN RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE ANALYSIS SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS LA English DT Article DE DIAGNOSTIC TESTS; SENSITIVITY AND SPECIFICITY; RECEIVER OPERATING CHARACTERISTIC CURVE ANALYSIS; RATINGS DATA; LOMAX DISTRIBUTION; LIKELIHOOD ESTIMATION; NEUROLOGY AND TOMOGRAPHY IMAGES ID DISCRIMINATION; ACCURACY; AREA AB Receiver operating characteristic (ROC) curves are useful for studying the performance of diagnostic tests. ROC curves occur in many fields of applications including psychophysics, quality control and medical diagnostics. In practical situations, often the responses to a diagnostic test are classified into a number of ordered categories. Such data are referred to as ratings data. It is typically assumed that the underlying model is based on a continuous probability distribution. The ROC curve is then constructed from such data using this probability model. Properties of the ROC curve are inherited from the model. Therefore, understanding the role of different probability distributions in ROC modeling is an interesting and important area of research. In this paper the Lomax distribution is considered as a model for ratings data and the corresponding ROC curve is derived. The maximum likelihood estimation procedure for the related parameters is discussed. This procedure is then illustrated in the analysis of a neurological data example. C1 NIH,BETHESDA,MD 20892. WRIGHT STATE UNIV,DAYTON,OH 45435. NR 14 TC 18 Z9 19 U1 1 U2 2 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0361-0926 J9 COMMUN STAT THEORY JI Commun. Stat.-Theory Methods PY 1993 VL 22 IS 6 BP 1681 EP 1697 DI 10.1080/03610929308831110 PG 17 WC Statistics & Probability SC Mathematics GA LE109 UT WOS:A1993LE10900011 ER PT J AU WUN, LM BROWN, CC AF WUN, LM BROWN, CC TI AN ALTERNATIVE DECISION RULE FOR QUALITY-CONTROL IN SEQUENTIAL SAMPLING PLANS SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS LA English DT Article DE ACCEPTANCE SAMPLING; BAYESIAN; ONE-SIDED CONFIDENCE INTERVAL AB The conventional rule for acceptance sampling based on sequential samples is based on the rationale of hypothesis testing developed by Wald (1947). This type of decision rule tests the hypothesis of P=p1 versus P=P2 as a proxy for determining whether P>d or Pp13.3 and rat chromosome region 2q34-->q41 by fluorescence in situ hybridization. Comparative mapping data presented in this report demonstrate conservation of synteny within the region encompassing this gene in mouse (Cd53), human (CD53), and rat (CD53). C1 FOX CHASE CANC CTR,DEPT MED ONCOL,MOLEC CYTOGENET SECT,7701 BURHOLME AVE,PHILADELPHIA,PA 19111. NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21701. RI Lazo, Pedro /M-6435-2014 OI Lazo, Pedro /0000-0001-8997-3025 FU NCI NIH HHS [CA-38047, CA-45745, CA-06927] NR 30 TC 14 Z9 15 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0171 J9 CYTOGENET CELL GENET JI Cytogenet. Cell Genet. PY 1993 VL 64 IS 3-4 BP 217 EP 221 DI 10.1159/000133580 PG 5 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA LZ100 UT WOS:A1993LZ10000122 PM 8404042 ER PT J AU VAMVAKOPOULOS, NC GRIFFIN, CA HAWKINS, AL LEE, C CHROUSOS, GP JABS, EW AF VAMVAKOPOULOS, NC GRIFFIN, CA HAWKINS, AL LEE, C CHROUSOS, GP JABS, EW TI MAPPING THE INTRON-CONTAINING HUMAN HSP90-ALPHA (HSPCAL4) GENE TO CHROMOSOME BAND 14Q32 SO CYTOGENETICS AND CELL GENETICS LA English DT Article ID HEAT-SHOCK PROTEIN; INSITU HYBRIDIZATION; SEQUENCE; FAMILY AB The human heat-shock protein (hsp) 90 gene superfamily consists of two member forms, alpha and beta. We have mapped the intron-containing human hsp90alpha expressed gene (HSPCAL4) to chromosome band 14q32. C1 UNIV ALBERTA,DEPT PATHOL,EDMONTON T6G 2E1,ALBERTA,CANADA. JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT & MED,BALTIMORE,MD 21205. JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205. RP VAMVAKOPOULOS, NC (reprint author), NICHHD,DEV ENDOCRINOL BRANCH,BLDG 10,ROOM 10N-240,BETHESDA,MD 20892, USA. FU NCI NIH HHS [2P30CA06973-29]; NHGRI NIH HHS [HG00373] NR 14 TC 13 Z9 14 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0171 J9 CYTOGENET CELL GENET JI Cytogenet. Cell Genet. PY 1993 VL 64 IS 3-4 BP 224 EP 226 DI 10.1159/000133582 PG 3 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA LZ100 UT WOS:A1993LZ10000124 PM 8404044 ER PT J AU ZHA, H WILDER, RL GOLDMUNTZ, EA CASH, JM CROFFORD, LJ MATHERN, P REMMERS, EF AF ZHA, H WILDER, RL GOLDMUNTZ, EA CASH, JM CROFFORD, LJ MATHERN, P REMMERS, EF TI LINKAGE MAP OF 10 POLYMORPHIC MARKERS ON RAT CHROMOSOME-2 SO CYTOGENETICS AND CELL GENETICS LA English DT Article ID PYRUVATE-KINASE PKL; LEWIS RATS; GENE; MOUSE; DNA; SUSCEPTIBILITY; ASSIGNMENT; ARTHRITIS; BAND AB Analysis of F2 intercross progeny of inbred F344/N x LEW/N rats led to the assignment of 10 polymorphic PCR-typable markers to rat chromosome 2. The markers form a single linkage group covering 47.9 cM with the following order: D2N1R - D2N28 - FGG (gamma fibrinogen) - PKLR (liver and RBC pyruvate kinase) - ATP1A1 (the alpha-1 polypeptide of Na+/K+ transporting ATPase) - HSD3B (hydroxy-delta-5-steroid dehydrogenase) - D2N2R - D2N91 - CAMKI (calmodulin-dependent protein kinase II) - D2N35. All but two of the markers D2N1R and D2N2R) were detected using specific PCR primers flanking dinucleotide repeats. Sequences with dinucleotide repeats associated with five genes (FGG, PKLR, ATP1A1, HSD3B, and CAMKI) were identified in GenBank, and primers were designed to flank these repeats. The PCR primer pairs for three anonymous markers (D2N28, D2N91, and D2N35) were identified by sequencing cloned LEW/N rat genomic DNA containing (CA)n.(GT)n repeats. D2N1R and D2N2R were identified by PCR amplification of genomic DNA with single, nonspecific 10-base oligonucleotide primers. All of the markers were codominant except for D2N1R, D2N2R, and CAMKI, which only amplified from F344/N homozygous and heterozygous rat DNA. The seven codominant markers were highly polymorphic in 10 other inbred rat strains (SHR/N, WKY/N, MNR/N, MR/N, LOU/MN, BN/SsN, BUF/N, WBB1/N, WBB2/N, and ACI/N), suggesting that they will be useful for general mapping studies among these strains. Comparative gene mapping analysis indicated that a portion of the mapped region of rat chromosome 2 exhibits synteny conservation with regions of human chromosome 1 and mouse Chromosome 3. RP ZHA, H (reprint author), NIAMSD,ARTHRITIS & RHEUMAT BRANCH,BLDG 10,ROOM 9N240,BETHESDA,MD 20892, USA. RI Crofford, Leslie/J-8010-2013 NR 32 TC 36 Z9 36 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0171 J9 CYTOGENET CELL GENET JI Cytogenet. Cell Genet. PY 1993 VL 63 IS 2 BP 117 EP 122 DI 10.1159/000133514 PG 6 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA LA202 UT WOS:A1993LA20200007 PM 8467710 ER PT J AU LLOYD, A MODI, W SPRENGER, H CEVARIO, S OPPENHEIM, J KELVIN, D AF LLOYD, A MODI, W SPRENGER, H CEVARIO, S OPPENHEIM, J KELVIN, D TI ASSIGNMENT OF GENES FOR INTERLEUKIN-8 RECEPTORS (IL8R)-A AND (IL8R)-B TO HUMAN-CHROMOSOME BAND 2Q35 SO CYTOGENETICS AND CELL GENETICS LA English DT Article ID CLONING AB The human genes encoding the interleukin 8 receptors type A and B were assigned to chromosome 2 by polymerase chain reaction amplification and by Southern analysis of a panel of human x rodent somatic cell hybrid DNAs. The IL8R genes were further localized by in situ hybridization to band 2q35. C1 NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701. DYNCORP INC,PROGRAM RESOURCES,FREDERICK,MD. RP LLOYD, A (reprint author), NCI,MOLEC IMMUNOREGULAT LAB,BLDG 560,RM 31-19,FREDERICK,MD 21702, USA. FU PHS HHS [N01-C0-74102] NR 14 TC 20 Z9 20 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0171 J9 CYTOGENET CELL GENET JI Cytogenet. Cell Genet. PY 1993 VL 63 IS 4 BP 238 EP 240 DI 10.1159/000133541 PG 3 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA LK061 UT WOS:A1993LK06100006 PM 8500355 ER PT J AU HOEHE, M MARTINEZ, M OTTERUD, B CAENAZZO, L MODI, W EHRENREICH, H GERSHON, E LEPPERT, M AF HOEHE, M MARTINEZ, M OTTERUD, B CAENAZZO, L MODI, W EHRENREICH, H GERSHON, E LEPPERT, M TI GENETIC-MAPPING OF 2 BRAIN-EXPRESSED CANDIDATE GENES TO HUMAN CHROMOSOME-6 SO CYTOGENETICS AND CELL GENETICS LA English DT Meeting Abstract C1 NIMH,CLIN NEUROGEN BRANCH,BETHESDA,MD 20892. NIAID,IMMUNOREG LAB,BETHESDA,MD 20892. NCI,BIOL CARCINOGEN & DEV PROGRAM,FREDERICK,MD 21701. UNIV UTAH,HHMI,DEPT GENET,SALT LAKE CITY,UT 84112. RI Martinez, Maria/B-3111-2013 OI Martinez, Maria/0000-0003-2180-4537 NR 0 TC 0 Z9 0 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0171 J9 CYTOGENET CELL GENET JI Cytogenet. Cell Genet. PY 1993 VL 62 IS 2-3 BP 85 EP 85 PG 1 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA KP384 UT WOS:A1993KP38400039 ER PT J AU HOEHE, MR EHRENREICH, H OTTERUD, B CAENAZZO, L PLAETKE, R ZANDER, H LEPPERT, M AF HOEHE, MR EHRENREICH, H OTTERUD, B CAENAZZO, L PLAETKE, R ZANDER, H LEPPERT, M TI THE HUMAN ENDOTHELIN-1 GENE (EDN1) ENCODING A PEPTIDE WITH POTENT VASOACTIVE PROPERTIES MAPS DISTAL TO HLA ON CHROMOSOME ARM 6P IN CLOSE LINKAGE TO D6S89 SO CYTOGENETICS AND CELL GENETICS LA English DT Article ID FACTOR-XIIIA F13A; SPINOCEREBELLAR ATAXIA; HUMAN GENOME; IMMUNOREACTIVE ENDOTHELIN; ESSENTIAL-HYPERTENSION; DNA POLYMORPHISM; BINDING-SITES; HUMAN-BRAIN; LOCALIZATION; LOCUS AB We determined the precise genetic location of the human endothelin-1 gene (EDN1), which encodes a peptide with extremely potent vasoactive properties and is apparently involved in a spectrum of diseases ranging from hypertension to asthma. Analyzing the segregation of a four-allele EDN1 polymorphism in 40 CEPH families including 480 individuals, we detected significant linkage of EDN1 to DNA markers spanning the telomeric half of chromosome arm 6p. EDN1 was closest to the highly polymorphic nucleotide-repeat marker D6S89 at a theta = 0.06 with the highest pairwise LOD score Z(max) = 31.2. Subsequent multipoint analysis placed EDN1 at 8 cM distal to D6S89; EDN1 was flanked at its telomeric site at a 13-cM distance by the gene encoding the A subunit of blood clotting factor XIII (F13A1). Furthermore, EDN1 was located at approximately 34-36 cM distal to the HLA region defined by HLA-A, -B, and -DRB1, and 31 cM proximal to the most telomeric marker D6S7. This location of EDN1 on the primary genetic map is strongly supported with odds of 2.7 x 10(12):1 against the next best alternative. C1 UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112. UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112. UNIV UTAH,SCH MED,DEPT PSYCHIAT,SALT LAKE CITY,UT 84112. NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892. UNIV MUNICH,KINDERPOLIKLIN,IMMUNOGENET LAB,W-8000 MUNICH 2,GERMANY. RP HOEHE, MR (reprint author), NIMH,CLIN NEUROGENET BRANCH,10-3N218,BETHESDA,MD 20892, USA. NR 48 TC 19 Z9 21 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0171 J9 CYTOGENET CELL GENET JI Cytogenet. Cell Genet. PY 1993 VL 62 IS 2-3 BP 131 EP 135 DI 10.1159/000133455 PG 5 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA KP384 UT WOS:A1993KP38400086 PM 8428511 ER PT J AU MODI, WS AF MODI, WS TI COMPARATIVE ANALYSES OF HETEROCHROMATIN IN MICROTUS - SEQUENCE HETEROGENEITY AND LOCALIZED EXPANSION AND CONTRACTION OF SATELLITE DNA ARRAYS SO CYTOGENETICS AND CELL GENETICS LA English DT Article ID CHROMOSOMAL LOCALIZATION; CONCERTED EVOLUTION; GENUS MUS; AMPLIFICATION; HYBRIDIZATION; RODENTIA; INSITU AB Southern blotting, C-banding, base-specific fluorochrome staining., and fluorescence in situ hybridization were used to analyze the constitutive heterochromatin in eight species and subspecies of arvicolid rodents (genus Microtus). Autosomal centromeric regions portrayed considerable variability between species in the amount of C-band-positive material present; e.g., M. chrotorrhinus showed relatively little, whereas M. cabrerae exhibited extensive centromeric staining. Autosomal interstitial C-bands were noted in M. guentheri and two subspecies of M. ochrogaster. All Y chromosomes examined were predominately or completely heterochromatic, as were substantial portions of the giant X chromosomes in three species (M. agrestis, M. cabrerae, and M. chrotorrhinus). Hoechst 33258 staining (with its affinity for AT binding sites) showed bright fluorescence on the heterochromatin of the sex chromosomes of M. agrestis and moderate fluorescence on those of M. cabrerae and M. chrotorrhinus; however, only the heterochromatin of M. cabrerae and M. chrotorrhinus hybridized with an AT-rich satellite DNA probe (MSAT-160) isolated from M. chrotorrhinus. Hoechst 33258-bright autosomal centromeres of M. arvalis and M. cabrerae also hybridized to the probe, whereas the Hoechst 33258-bright Y chromosomes of M. arvalis and M. guentheri did not. Two pairs of autosomes in M. guentheri are comprised of six distinct regions, based upon C-banding, Hoechst 33258 staining, chromomycin A3/distamycin A staining, and in situ hybridization. The centromeric regions of acrocentric autosomes known to retain conserved G-banding patterns may exhibit variable hybridization intensity when different species or subspecies are compared. M. ochrogaster portrays considerable intersubspecific variability in the size and location of autosomal telomeric and interstitial C-bands that are also sites of hybridization. These latter two findings illustrate that dramatic differences in copy number of the tandem satellite array can exist at homologous chromosomal positions both within and between species. RP MODI, WS (reprint author), NCI,PROGRAM RESOURCES INC,DYNCORP,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702, USA. FU NCI NIH HHS [N01-CO-74102] NR 32 TC 53 Z9 54 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0171 J9 CYTOGENET CELL GENET JI Cytogenet. Cell Genet. PY 1993 VL 62 IS 2-3 BP 142 EP & DI 10.1159/000133458 PG 0 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA KP384 UT WOS:A1993KP38400089 PM 8428514 ER PT J AU BAUER, KD BAGWELL, CB GIARETTI, W MELAMED, M ZARBO, RJ WITZIG, TE RABINOVITCH, PS AF BAUER, KD BAGWELL, CB GIARETTI, W MELAMED, M ZARBO, RJ WITZIG, TE RABINOVITCH, PS TI CONSENSUS REVIEW OF THE CLINICAL UTILITY OF DNA FLOW-CYTOMETRY IN COLORECTAL-CANCER SO CYTOMETRY LA English DT Article ID LARGE-BOWEL CARCINOMAS; COLONIC ADENOCARCINOMAS; PROGNOSTIC-SIGNIFICANCE; PROLIFERATIVE ACTIVITY; MULTIVARIATE-ANALYSIS; ULCERATIVE-COLITIS; RECTAL-CANCER; DUKES STAGE; TUMOR SITE; FOLLOW-UP C1 VERITY SOFTWARE HOUSE,TOPSHAM,ME 04086. NATL CANC INST,BIOPHYS LAB,GENOA,ITALY. NEW YORK MED COLL,DEPT PATHOL,VALHALLA,NY 10595. HENRY FORD HOSP,DEPT PATHOL,DETROIT,MI 48202. MAYO CLIN & MAYO FDN,DEPT HEMATOL & INTERNAL MED,ROCHESTER,MN 55905. UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195. RP BAUER, KD (reprint author), GENENTECH INC,DEPT CELL ANAL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA. NR 53 TC 101 Z9 102 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0196-4763 J9 CYTOMETRY JI Cytometry PY 1993 VL 14 IS 5 BP 486 EP 491 DI 10.1002/cyto.990140506 PG 6 WC Biochemical Research Methods; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA LJ150 UT WOS:A1993LJ15000005 PM 8354120 ER PT J AU GERMANN, UA AF GERMANN, UA TI MOLECULAR ANALYSIS OF THE MULTIDRUG TRANSPORTER SO CYTOTECHNOLOGY LA English DT Review DE ATPASE; ATP-BINDING CASSETTE SUPERFAMILY; DRUG TRANSPORT; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN ID DEPENDENT PROTEIN-KINASE; EHRLICH ASCITES TUMOR; HAMSTER OVARY CELLS; P-GLYCOPROTEIN GENE; RESISTANT HUMAN-CELLS; EXCHANGING HOMOLOGOUS DOMAINS; CANALICULAR MEMBRANE-VESICLES; ONE SIGNAL SEQUENCE; KB CARCINOMA-CELLS; MDR-GENE AB The multidrug resistance gene product, P-glycoprotein or the multidrug transporter, confers multidrug resistance to cancer cells by maintaining intracellular levels of cytotoxic agents below a killing threshold. P-glycoprotein is located within the plasma membrane and is thought to act as an energy-dependent drug efflux pump. The multidrug transporter represents a member of the ATP-binding cassette superfamily of transporters (or traffic ATPases) and is composed of two highly homologous halves, each of which harbors a hydrophobic transmembrane domain and a hydrophilic ATP-binding fold. This review focuses on various biochemical and molecular genetic approaches used to analyze the structure, function, and mechanism of action of the multidrug transporter, whose most intriguing feature is its ability to interact with a large number of structurally and functionally different amphiphilic compounds. These studies have underscored the complexity of this membrane protein which has recently been suggested to assume alternative topological and quaternary structures, and to serve multiple functions both as a transporter and as a channel. With respect to the multidrug transporter activity of P-glycoprotein, progress has been made towards the elucidation of essential amino acid residues and/or polypeptide regions. Furthermore, the drug-stimulatable ATPase activity of P-glycoprotein has been established. The mechanism of drug transport by P-glycoprotein, however, is still unknown and its physiological role remains a matter of speculation. RP GERMANN, UA (reprint author), NCI,CELL BIOL LAB,BLDG 37,ROOM IB22,BETHESDA,MD 20892, USA. NR 187 TC 25 Z9 26 U1 0 U2 2 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0920-9069 J9 CYTOTECHNOLOGY JI Cytotechnology PY 1993 VL 12 IS 1-3 BP 33 EP 62 DI 10.1007/BF00744657 PG 30 WC Biotechnology & Applied Microbiology; Cell Biology SC Biotechnology & Applied Microbiology; Cell Biology GA MU790 UT WOS:A1993MU79000003 PM 7765331 ER PT J AU MOSCOW, JA DIXON, KH AF MOSCOW, JA DIXON, KH TI GLUTATHIONE-RELATED ENZYMES, GLUTATHIONE AND MULTIDRUG-RESISTANCE SO CYTOTECHNOLOGY LA English DT Review DE ETOPOSIDE; DOXORUBUCIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE S-TRANSFERASE; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN; VINCRISTINE ID S-TRANSFERASE-PI; BREAST-CANCER-CELLS; HYDROXYL RADICAL FORMATION; DOXORUBICIN CYTO-TOXICITY; ESTROGEN-RECEPTOR CONTENT; TUMOR-CELLS; BUTHIONINE SULFOXIMINE; GST-PI; ADRIAMYCIN RESISTANCE; DRUG SENSITIVITY AB This review examines the hypothesis that glutathione and its associated enzymes contribute to the overall drug-resistance seen in multidrug resistant cell lines. Reports of 34 cell lines independently selected for resistance to MDR drugs are compared for evidence of consistent changes in activity of glutathione-related enzymes as well as for changes in glutathione content. The role of glutathione S-transferases in MDR is further analyzed by comparing changes in sensitivity to MDR drugs in cell lines selected for resistance to non-MDR drugs that have resulting increases in glutathione S-transferase activity. In addition, results of studies in which genes for glutathione S-transferase isozymes were transfected into drug-sensitive cells are reviewed. The role of the glutathione redox cycle is examined by comparing changes in elements of this cycle in MDR cell lines as well as by analyzing reports of the effects of glutathione depletion on MDR drug sensitivity. Overall, there is no consistent or compelling evidence that glutathione and its associated enzymes augment resistance in multidrug resistant cell lines. RP MOSCOW, JA (reprint author), NIH,MED BRANCH,BLDG 10,ROOM 12N226,BETHESDA,MD 20892, USA. NR 122 TC 42 Z9 43 U1 1 U2 2 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0920-9069 J9 CYTOTECHNOLOGY JI Cytotechnology PY 1993 VL 12 IS 1-3 BP 155 EP 170 DI 10.1007/BF00744663 PG 16 WC Biotechnology & Applied Microbiology; Cell Biology SC Biotechnology & Applied Microbiology; Cell Biology GA MU790 UT WOS:A1993MU79000009 PM 7765324 ER PT J AU BROWN, JL WU, C AF BROWN, JL WU, C TI REPRESSION OF DROSOPHILA PAIR-RULE SEGMENTATION GENES BY ECTOPIC EXPRESSION OF TRAMTRACK SO DEVELOPMENT LA English DT Article DE TRAMTRACK; DROSOPHILA; PAIR-RULE GENE; SEGMENTATION GENE; ECTOPIC EXPRESSION; REPRESSOR ID ZEBRA-STRIPE EXPRESSION; FUSHI-TARAZU PROTEIN; ENHANCER ELEMENT; BINDING-SITES; HOMEO BOX; EMBRYOGENESIS; EMBRYOS; HAIRY; PATTERN; RNA AB The tramtrack (ttk) protein has been proposed as a maternally provided repressor of the fushi tarazu (ftz) gene in Drosophila embryos at the preblastoderm stage. Consistent with this hypothesis, we have detected by immunohistochemistry the presence of ttk protein in preblastoderm embryos. This is followed by a complete decay upon formation of the cellular blastoderm when ftz striped expression is at its peak. In addition, the highly complex pattern of zygotic ttk expression suggests specific functions for ttk late in development that are separate from the regulation of ftz. We have produced ttk protein ectopically in blastoderm-stage embryos transformed with a heat shock-ttk construct. Ectopic ttk caused complete or near-complete repression of the endogenous ftz gene, as well as significant repression of the pair-rule genes even skipped, odd skipped, hairy and runt. These findings suggest that specific repression by ttk (or by undiscovered repressors) may be more than an isolated phenomenon during the rapid cleavage divisions, a period when the need for genetic repression has not been generally anticipated. RP BROWN, JL (reprint author), NCI,BIOCHEM LAB,BG 37,RM 4C-09,BETHESDA,MD 20892, USA. RI Tang, Amy/L-3226-2016 OI Tang, Amy/0000-0002-5772-2878 NR 60 TC 65 Z9 66 U1 0 U2 2 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE, CAMBS, ENGLAND CB4 4DL SN 0950-1991 J9 DEVELOPMENT JI Development PD JAN PY 1993 VL 117 IS 1 BP 45 EP 58 PG 14 WC Developmental Biology SC Developmental Biology GA KP055 UT WOS:A1993KP05500004 PM 8223261 ER PT J AU TADANO, T OTANI, H TAIRA, M DAWID, IB AF TADANO, T OTANI, H TAIRA, M DAWID, IB TI DIFFERENTIAL INDUCTION OF REGULATORY GENES DURING MESODERM FORMATION IN XENOPUS-LAEVIS EMBRYOS SO DEVELOPMENTAL GENETICS LA English DT Article DE INDUCTIVE CELL INTERACTIONS; DIFFUSIBLE MOLECULES; ANIMAL EXPLANTS; GROWTH FACTORS; CYCLOHEXIMIDE ID PROTEIN-SYNTHESIS INHIBITORS; C-FOS; ACTIVIN-A; RETINOIC ACID; MIDBLASTULA TRANSITION; SPEMANN ORGANIZER; GROWTH-FACTORS; FROG EMBRYOS; 3T3 CELLS; EXPRESSION AB Mesoderm development in Xenopus laevis depends on inductive cell interactions mediated by diffusible molecules. The mesoderm inducer activin is capable of redirecting the development of animal explants both morphologically and biochemically. We have studied the induction of four regulatory genes, Mix. 1, goosecoid (gsc), Xlim-1, and Xbro in such explants by activin, and the influence of other factors on this induction. Activin induction of gsc is strongly enhanced by dorsalization of the embryo by LiCl, while expression of the other genes is only slightly enhanced. The protein synthesis inhibitor cycloheximide (CHX) inhibits the activin-dependent induction of Xbra partially, while induction of Mix. 1 and Xlim-1 is essentially unaffected. In contrast, gsc shows strong superinduction in the presence of activin and CHX, and can be induced in animal explants by CHX alone. Induction and superinduction by CHX have previously been observed for immediate early genes in a variety of systems, notably for the activation of c-fos expression by serum stimulation, but have not been reported in early amphibian embryos. C1 NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892. NR 57 TC 39 Z9 39 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0192-253X J9 DEV GENET JI Dev. Genet. PY 1993 VL 14 IS 3 BP 204 EP 211 DI 10.1002/dvg.1020140307 PG 8 WC Developmental Biology; Genetics & Heredity SC Developmental Biology; Genetics & Heredity GA LM476 UT WOS:A1993LM47600006 PM 8395366 ER PT J AU SHAW, GA GIAMBRA, L AF SHAW, GA GIAMBRA, L TI TASK-UNRELATED THOUGHTS OF COLLEGE-STUDENTS DIAGNOSED AS HYPERACTIVE IN CHILDHOOD SO DEVELOPMENTAL NEUROPSYCHOLOGY LA English DT Article ID ATTENTION AB Examined were the relationships between task-unrelated thoughts (TUTs), self-reported sensation seeking, retrospective self-reported personality characteristics, laterality, eye dominance, and allergies in college students who were diagnosed in childhood as attention deficit/hyperactive disordered (ADHD) and in four control groups (high- and low-activity males and females). Both spontaneous and deliberate TUTs were reported during a vigilance task. Left-eye dominance was related to increased childhood hyperactive behaviors and to spontaneous TUTs. Of the five groups, subjects diagnosed as ADHD had more spontaneous TUTs and false alarms, whereas those subjects reporting high-activity characteristics as children gave more deliberate TUTs and fewer false alarms, and low-activity subjects responded with the fewest TUTs and false alarms. These results are consistent with the interpretation that in a boring task ADHD children have higher levels of nonconscious processing and poor inhibitory control and that these factors produce greater frequencies of spontaneous intrusive thoughts. C1 NIA,BETHESDA,MD 20892. RP SHAW, GA (reprint author), GEORGETOWN COLL,DEPT PSYCHOL,GEORGETOWN,KY 40324, USA. NR 25 TC 75 Z9 75 U1 2 U2 22 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 SN 8756-5641 J9 DEV NEUROPSYCHOL JI Dev. Neuropsychol. PY 1993 VL 9 IS 1 BP 17 EP 30 PG 14 WC Psychology, Developmental; Psychology; Psychology, Experimental SC Psychology GA KL751 UT WOS:A1993KL75100002 ER PT J AU MEASSO, G CAVARZERAN, F ZAPPALA, G LEBOWITZ, BD CROOK, TH PIROZZOLO, FJ AMADUCCI, LA MASSARI, D GRIGOLETTO, F AF MEASSO, G CAVARZERAN, F ZAPPALA, G LEBOWITZ, BD CROOK, TH PIROZZOLO, FJ AMADUCCI, LA MASSARI, D GRIGOLETTO, F TI THE MINI-MENTAL-STATE-EXAMINATION - NORMATIVE STUDY OF AN ITALIAN RANDOM SAMPLE SO DEVELOPMENTAL NEUROPSYCHOLOGY LA English DT Article ID COGNITIVE IMPAIRMENT; COMMUNITY RESIDENTS; ALZHEIMERS-DISEASE; DEMENTIA; AGE; EDUCATION; PERFORMANCE; RELIABILITY; VALIDITY AB We provide a set of normative data on the Mini-Mental State Examination (MMSE) from a random sample of 906 normal, healthy subjects of both sexes, 20 to 79 years of age. Subjects were selected in six Italian cities and in the Republic of San Marino. Results show the significant influence of sociodemographic variables, such as age and education, on MMSE performance. We used Multiple Linear Regression Analyses to correct MMSE normative values for these demographic effects. The analyses allow us to specify cutoff scores for distinguishing ''normal'' performance from ''borderline'' and pathologic performance. C1 FIDIA RES LABS,CTR RES MEMORY,ABANO TERME,ITALY. FIDIA RES LABS,DEPT BIOSTAT & EPIDEMIOL,ABANO TERME,ITALY. NIMH,ROCKVILLE,MD 20857. MEMORY ASSESSMENT CLIN INC,BETHESDA,MD. BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030. UNIV FLORENCE,DEPT NEUROL & PSYCHIAT,I-50121 FLORENCE,ITALY. UNIV FLORENCE,ITALIAN NATL RES COUNCIL,I-50121 FLORENCE,ITALY. UNIV PADUA,DEPT STAT SCI,I-35100 PADUA,ITALY. NR 23 TC 351 Z9 352 U1 2 U2 4 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 SN 8756-5641 J9 DEV NEUROPSYCHOL JI Dev. Neuropsychol. PY 1993 VL 9 IS 2 BP 77 EP 85 PG 9 WC Psychology, Developmental; Psychology; Psychology, Experimental SC Psychology GA MQ261 UT WOS:A1993MQ26100001 ER PT J AU CROOK, TH LEBOWITZ, BD PIROZZOLO, FJ ZAPPALA, G CAVARZERAN, F MEASSO, G MASSARI, DC AF CROOK, TH LEBOWITZ, BD PIROZZOLO, FJ ZAPPALA, G CAVARZERAN, F MEASSO, G MASSARI, DC TI RECALLING NAMES AFTER INTRODUCTION - CHANGES ACROSS THE ADULT LIFE-SPAN IN 2 CULTURES SO DEVELOPMENTAL NEUROPSYCHOLOGY LA English DT Article ID MEMORY IMPAIRMENT; ALZHEIMERS-DISEASE; AGE-DIFFERENCES; EVERYDAY LIFE; IMAGERY; YOUNG AB We tested a completely randomized, cross-sectional sample of the population of the Republic of San Marino in order to examine the effects of age on the ability to recall names of persons to whom one is introduced. Findings were compared with diose from a large sample of persons tested with the same methods in the U.S. Results suggest that comparable, highly significant declines in performance occur with advancing age in both cultures. Discussion focuses on the social and clinical significance of the cross-cultural finding. C1 NIMH,ROCKVILLE,MD 20857. BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030. FIDIA RES LABS,ABANO TERME,ITALY. RP CROOK, TH (reprint author), MEMORY ASSESSMENT CLIN INC,8311 WISCONSIN AVE,BETHESDA,MD 20814, USA. NR 27 TC 9 Z9 9 U1 1 U2 2 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 SN 8756-5641 J9 DEV NEUROPSYCHOL JI Dev. Neuropsychol. PY 1993 VL 9 IS 2 BP 103 EP 113 PG 11 WC Psychology, Developmental; Psychology; Psychology, Experimental SC Psychology GA MQ261 UT WOS:A1993MQ26100003 ER PT J AU ELTOM, SE PARK, SS SCHWARK, WS AF ELTOM, SE PARK, SS SCHWARK, WS TI STUDIES ON THE ONTOGENY OF GOAT HEPATIC CYTOCHROME P-450-ASSOCIATED O-DEALKYLASE ACTIVITIES USING MONOCLONAL-ANTIBODIES - COMPARISON TO ADULT LUNG ACTIVITY SO DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS LA English DT Article DE ONTOGENY; GOAT; NEONATE; CYTOCHROME P-450; O-DEALKYLASE; IMMUNOINHIBITION ID RAT-LIVER; PULMONARY; METABOLISM; 3-METHYLINDOLE; EXPRESSION; ENZYMES; TISSUES AB The P-450-associated O-dealkylase activity towards ethoxyresorufin (EROD) and pentoxyresorufin (PROD) was measured in liver microsomes from 1-day-, 1-week-, 4-week-, 6-week-oId and adult goats in order to characterize the ontogeny of cytochrome P-450 in this species. The inhibition of these enzyme activities by monoclonal antibodies raised against 3-methylcholanthrene-induced (MAb 1-7-1) and phenobarbital-induced (MAb 2-66-3) rat hepatic cytochrome P-450 was used to measure the contribution of the MAb-defined, epitope-specific P-450 to the total activities during these ages of goat development. EROD activity was undetectable until the 1st week of life and increased more than 25-fold by 4 weeks of age. The inhibition of EROD by MAb 1-7-1 increased from 20% in 1-week-old to 70% in adult goats. PROD activity, however, was detectable in the 1-day-old and reached adult levels by 6 weeks of age. The maximal inhibition (40 %) of PROD activity by MAb 2-66-3 was demonstrated in 1-day-old goats. The measurement of these enzyme activities and their inhibition by the monoclonal antibodies demonstrated major differences in the ontogeny of these P-450 isozymes in goats. On the other hand, adult goat lung lacked detectable PROD activity, while it expressed approximately one tenth of the EROD activity exhibited by the liver. Over 70% of this activity was inhibitable by MAb 1-7-1. C1 CORNELL UNIV,NEW YORK STATE COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853. NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702. NR 24 TC 2 Z9 2 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0379-8305 J9 DEV PHARMACOL THERAP JI Dev. Pharmacol. Ther. PY 1993 VL 20 IS 1-2 BP 93 EP 99 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA NQ642 UT WOS:A1993NQ64200012 PM 7924770 ER PT J AU STERNBERG, KJ LAMB, ME GREENBAUM, C CICCHETTI, D DAWUD, S CORTES, RM KRISPIN, O LOREY, F AF STERNBERG, KJ LAMB, ME GREENBAUM, C CICCHETTI, D DAWUD, S CORTES, RM KRISPIN, O LOREY, F TI EFFECTS OF DOMESTIC VIOLENCE ON CHILDRENS BEHAVIOR PROBLEMS AND DEPRESSION SO DEVELOPMENTAL PSYCHOLOGY LA English DT Article ID FAMILY VIOLENCE; ADJUSTMENT; MALADJUSTMENT; AGGRESSION; WITNESSES; SYMPTOMS; SHELTER; PARENTS; ABUSE AB The Children's Depression Inventory, Child Behavior Checklist, and Youth Self-Report were completed by mothers, fathers, and their 8- to 12-year-old children to assess the effects of various types of domestic violence on children's behavior problems and depression. One hundred and ten Israeli children from lower-class families were identified through social service records. Thirty-three of the children had been physically abused by their parents within the last 6 months, 16 had witnessed spouse abuse, 30 had been both victims and witnesses of domestic violence, and 31 had experienced no known domestic violence. Overall. domestic violence had effects on child development that varied in magnitude and nature depending on the type of domestic violence and who reported the information about the child's adjustment. C1 HEBREW UNIV JERUSALEM,DEPT PSYCHOL,JERUSALEM,ISRAEL. UNIV ROCHESTER,DEPT PSYCHOL,ROCHESTER,NY 14627. UNIV MARYLAND,DEPT PSYCHOL,BALTIMORE,MD 21201. CATHOLIC UNIV AMER,DEPT PSYCHOL,WASHINGTON,DC 20064. JERUSALEM MUNICIPAL DEPT FAMILY SERV,JERUSALEM,ISRAEL. RP STERNBERG, KJ (reprint author), NICHHD,SOCIAL & EMOT DEV SECT,9190 ROCKVILLE PIKE,BETHESDA,MD 20814, USA. NR 45 TC 204 Z9 204 U1 2 U2 21 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 SN 0012-1649 J9 DEV PSYCHOL JI Dev. Psychol. PD JAN PY 1993 VL 29 IS 1 BP 44 EP 52 DI 10.1037//0012-1649.29.1.44 PG 9 WC Psychology, Developmental SC Psychology GA KF090 UT WOS:A1993KF09000004 ER PT J AU KNOWLER, WC SAAD, MF PETTITT, DJ NELSON, RG BENNETT, PH AF KNOWLER, WC SAAD, MF PETTITT, DJ NELSON, RG BENNETT, PH TI DETERMINANTS OF DIABETES-MELLITUS IN THE PIMA-INDIANS SO DIABETES CARE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; PLASMA-INSULIN RESPONSE; 10-YEAR FOLLOW-UP; AMERICAN-INDIANS; HIGH PREVALENCE; NATURAL-HISTORY; OBESITY; POPULATION; RESISTANCE; DIAGNOSIS AB OBJECTIVE - To review the research findings on the determinants of diabetes mellitus in Pima Indians. RESEARCH DESIGN AND METHODS - Pima Indians in Arizona have participated in a longitudinal diabetes study that has provided data on and hypotheses about the development of NIDDM. Findings from this study are reviewed and updated. RESULTS - Frequency distributions of plasma glucose and HbA1 are bimodal in Pima adults, and substantial risk of the specific vascular complications of diabetes is confined to those in the higher components of these distributions. These findings contributed to the adoption of internationally recognized criteria for classification of glucose tolerance. Diabetes in the Pimas is strongly familial, and probably of genetic origin, although the precise nature of the gene or genes involved remains unknown. Obesity, which is at least in part environmentally determined, is a major factor inter-acting with the presumed genetic susceptibility to result in diabetes. The incidence of diabetes in the Pimas has increased during the last several decades, providing further evidence for environmental- genetic interaction. Longitudinal studies suggest that the progression from normal to diabetes can be considered to involve two stages. The first, primarily attributable to insulin resistance, leads to impaired glucose tolerance, and the second, which depends on insulin secretory failure, leads to worsening hyperglycemia and overt diabetes. CONCLUSIONS - The Pimas and many other American Indian populations suffer from a high incidence of diabetes and its characteristic disabling or fatal complications, and would benefit from continued research on the pathogenesis and prevention of the disease. C1 CLEVELAND CLIN EDUC FDN,CLEVELAND,OH 44106. RP KNOWLER, WC (reprint author), NIDDKD,PHOENIX EPIDEMIOL & CLIN RES BRANCH,DIABET & ARTHRITIS EPIDEMIOL SECT,PHOENIX,AZ 85014, USA. RI Nelson, Robert/B-1470-2012 NR 92 TC 76 Z9 78 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 1993 VL 16 IS 1 BP 216 EP 227 DI 10.2337/diacare.16.1.216 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KE571 UT WOS:A1993KE57100033 PM 8422779 ER PT J AU BOGARDUS, C AF BOGARDUS, C TI INSULIN RESISTANCE IN THE PATHOGENESIS OF NIDDM IN PIMA-INDIANS SO DIABETES CARE LA English DT Article AB NIDDM in Pima Indians is characterized by obesity, abnormal insulin secretion, insulin resistance, and excess hepatic glucose output. Cross-sectional studies, and, as yet incomplete longitudinal studies of nondiabetic and diabetic Pima Indians suggest that the natural history of the disease begins with insulin resistance and, subsequently, when insulin secretion fails, increasing hepatic glucose output occurs, resulting in increasing fasting hyperglycemia. The insulin resistance that precedes the development of fasting hyperglycemia is not due solely to obesity. Insulin resistance aggregates in families and the trimodel frequency distribution of insulin action in vivo suggests it may have genetic determinants. RP BOGARDUS, C (reprint author), NATL INST DIABET & DIGEST KIDNEY DIS,CLIN DIABETES & NUTR SECT,4212 N 16TH ST,ROOM 541,PHOENIX,AZ 85016, USA. NR 8 TC 33 Z9 33 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 1993 VL 16 IS 1 BP 228 EP 231 DI 10.2337/diacare.16.1.228 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KE571 UT WOS:A1993KE57100034 PM 8422780 ER PT J AU RAVUSSIN, E AF RAVUSSIN, E TI ENERGY-METABOLISM IN OBESITY - STUDIES IN THE PRIMA INDIANS SO DIABETES CARE LA English DT Article ID HUMAN FATNESS; BODY-WEIGHT; EXPENDITURE; FAT; GENETICS; ADOPTION; BALANCE; TWINS; RATES AB OBJECTIVE - To review the major data collected over the past 8 yr regarding energy expenditure in relationship to obesity and the development of obesity in the Pima Indian population. RESEARCH DESIGN AND METHODS - The different components of 24-h energy expenditure (i.e., the RMR, the thermic effect of food, and the energy cost of spontaneous physical activity) were measured in a respiratory chamber after a few days on a weight-maintenance diet. RESULTS - Fat-free body mass, the major determinant of RMR, explains 82% of its variance. However, an extra 7% of the variance in RMR observed between people is related to family membership. The variability of RMR for a given body size and composition is of importance, because a low metabolic rate is a major risk factor for weight gain in man. Also, genetic factors seem to be the cause of the familial aggregation of metabolic rate in man. CONCLUSIONS - The high prevalence of obesity and NIDDM in the Pima Indian community might be the consequence of a ''thrifty genotype.'' The increasing evidence that obesity cannot always be attributed to gluttony and sloth forces us to consider obesity as a ''real metabolic disease'' that needs to be treated as such, using new behavioral and pharmacological therapies. RP RAVUSSIN, E (reprint author), NATL INST DIABET & DIGEST & KIDNEY DIS,CLIN DIABETES & NUTR SECT,4212 N 16TH ST,ROOM 541,PHOENIX,AZ 85016, USA. NR 49 TC 42 Z9 44 U1 0 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 1993 VL 16 IS 1 BP 232 EP 238 DI 10.2337/diacare.16.1.232 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KE571 UT WOS:A1993KE57100035 PM 8422781 ER PT J AU HOWARD, BV AF HOWARD, BV TI DIABETES AND PLASMA-LIPOPROTEINS IN NATIVE-AMERICANS - STUDIES OF THE PIMA-INDIANS SO DIABETES CARE LA English DT Article ID APOLIPOPROTEIN-B METABOLISM; CULTURED RAT HEPATOCYTES; SULFONYLUREA THERAPY; SATURATED-FAT; INSULIN; TRIGLYCERIDE; MELLITUS; CARBOHYDRATE; CHOLESTEROL; POPULATION AB OBJECTIVE - To determine the effects of diabetes on plasma lipoproteins in Pima Indians, to identify metabolic determinants of these differences, and to examine the effects of various modes of diabetes therapy. RESEARCH DESIGN AND METHODS - A series of studies was performed including a population survey of lipoprotein concentrations, kinetic studies of VLDL and LDL metabolism, and studies of die effects of weight loss, sulfonylureas, and high carbohydrate diets. RESULTS - Population data established that diabetes was consistently associated with elevations in total and VLDL TGs and decreases in HDL cholesterol. Metabolic studies indicated multiple alterations in VLDL metabolism induced by NIDDM, including overproduction of VLDL TG, impaired clearance of VLDL TG and apoB, and decreases in adipose tissue lipoprotein lipase. Although changes m LDL concentrations accompanying NIDDM were minimal, the clearance of LDL appeared to be impaired and a higher proportion of VLDL was metabolized without conversion to LDL. There were significant changes in the flux of particles to the LDL compartment. Total and VLDL TG concentrations were found to be inversely related to rates of insulin-mediated glucose disposal, and HDL cholesterol concentrations were positively related to glucose disposal. These relationships between lipoproteins and insulin action were independent of adiposity and insulin, suggesting that insulin resistance may be involved with diabetes-induced changes in VLDL and HDL. Weight loss was associated with decreases in total and VLDL TG, decreases in total and LDL cholesterol, and improvements in die ratio of HDL to LDL cholesterol. Sulfonylurea therapy was associated with lower total and VLDL TGs and lower LDL cholesterol, but little change in HDL. Substitution of complex carbohydrates for saturated fat in the diet showed consistent and significant decreases in total and LDL cholesterol, no decreases in HDL cholesterol, or elevation of total or VLDL TG. CONCLUSIONS - Studies suggest that there are multiple changes in plasma lipoproteins accompanying NIDDM in Pima Indians, but that many of these may be reversed by current modes of hypoglycemic therapy. C1 NIH,PHOENIX,AZ. RP HOWARD, BV (reprint author), MEDLANT RES INST,GEORGE HYMAN MEM RES BLDG,108 IRVING ST NW,ROOM 242,WASHINGTON,DC 20010, USA. NR 29 TC 11 Z9 11 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 1993 VL 16 IS 1 BP 284 EP 291 DI 10.2337/diacare.16.1.284 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KE571 UT WOS:A1993KE57100047 PM 8422793 ER PT J AU PETTITT, DJ NELSON, RG SAAD, MF BENNETT, PH KNOWLER, WC AF PETTITT, DJ NELSON, RG SAAD, MF BENNETT, PH KNOWLER, WC TI DIABETES AND OBESITY IN THE OFFSPRING OF PIMA INDIAN WOMEN WITH DIABETES DURING PREGNANCY SO DIABETES CARE LA English DT Article ID AMERICAN-INDIANS; PREVALENCE; MELLITUS; POPULATION AB OBJECTIVE- To review the long-term effects of the diabetic pregnancy on the offspring among die Pima Indians of Arizona. RESEARCH DESIGN AND METHODS- Studies published by the Phoenix Epidemiology and Clinical Research branch of die National Institute of Diabetes and Digestive and Kidney Diseases, since the inception of die longitudinal diabetes studies in 1965 were reviewed. In addition, pertinent studies from other centers, mentioned as references in these publications, were reviewed. As far as possible, all original articles and abstracts on this aspect of the Pima Indian studies were discussed. RESULTS- The offspring of women who had diabetes during pregnancy, on average, were more obese and had higher glucose concentrations and more diabetes than die offspring of women who developed diabetes after pregnancy or who remained nondiabetic. Although no new analyses were attempted, several of die older publications were updated by repeating the analyses on later, expanded data sets. CONCLUSIONS- The diabetic pregnancy, in addition to its effects on the newborn, has effects on the subsequent growth and glucose metabolism of the offspring. These effects are in addition to genetically determined traits. C1 CLEVELAND CLIN FDN,DEPT BIOSTAT & EPIDEMIOL,PHOENIX,AZ. RP PETTITT, DJ (reprint author), NIDDKD,DIABET & ARTHRITIS EPIDEMIOL SECT,1550 E INDIAN SCH RD,PHOENIX,AZ 85016, USA. RI Nelson, Robert/B-1470-2012 NR 39 TC 161 Z9 163 U1 0 U2 10 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 1993 VL 16 IS 1 BP 310 EP 314 DI 10.2337/diacare.16.1.310 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KE571 UT WOS:A1993KE57100052 PM 8422798 ER PT J AU FERRIS, FL AF FERRIS, FL TI DIABETIC-RETINOPATHY SO DIABETES CARE LA English DT Article ID BLOOD-GLUCOSE; PREVALENCE; DIAGNOSIS; RISK; AGE AB OBJECTIVE - To review the natural history and treatment indications for diabetic retinopathy. RESEARCH DESIGN AND METHODS - Studies of the natural history of diabetic retinopathy and major clinical trials sponsored by the National Eye Institute were reviewed. RESULTS - Diabetic retinopathy remains a leading cause of vision disability in the U.S. Vision loss results from the consequences of proliferative retinopathy or macular edema. Photocoagulation has been demonstrated to be an effective treatment for these complications of diabetes. CONCLUSIONS - All people with diabetes should be evaluated regularly to determine whether they would benefit from photocoagulation. As a referral guideline, any person with type I diabetes of > 5 yr duration and all people with type II diabetes or any retinopathy should be referred to an ophthalmologist. RP FERRIS, FL (reprint author), NEI,BLDG 31,ROOM 6A-24,BETHESDA,MD 20892, USA. NR 22 TC 16 Z9 17 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 1993 VL 16 IS 1 BP 322 EP 325 DI 10.2337/diacare.16.1.322 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KE571 UT WOS:A1993KE57100055 PM 8422802 ER PT J AU LOE, H AF LOE, H TI PERIODONTAL-DISEASE - THE 6TH COMPLICATION OF DIABETES-MELLITUS SO DIABETES CARE LA English DT Article ID PIMA-INDIANS; PREVALENCE RP LOE, H (reprint author), NIDR,BLDG 31,ROOM 2C39,BETHESDA,MD 20892, USA. NR 11 TC 447 Z9 490 U1 3 U2 23 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 1993 VL 16 IS 1 BP 329 EP 334 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KE571 UT WOS:A1993KE57100057 PM 8422804 ER PT S AU RAVUSSIN, E FONTVIEILLE, AM SWINBURN, BA BOGARDUS, C AF RAVUSSIN, E FONTVIEILLE, AM SWINBURN, BA BOGARDUS, C BE Klimes, I Howard, BV Storlien, LH Sebokova, E TI RISK-FACTORS FOR THE DEVELOPMENT OF OBESITY SO DIETARY LIPIDS AND INSULIN ACTION: SECOND INTERNATIONAL SMOLENICE INSULIN SYMPOSIUM SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 2ND INTERNATIONAL SMOLENICE INSULIN SYMP : DIETARY LIPIDS AND INSULIN ACTION CY 1992 CL SMOLENICE CASTLE, CZECHOSLOVAKIA SP SLOVAK ACAD SCI BRATISLAVA, INST EXPTL ENDOCRINOL, CZECH DIABETES ASSOC, BOEHRINGER INGELHEIM, FARMITALIA CARLO ERBA, INT OLIVE OIL COUNCIL, KAJO ERZEUGNISSE MULLER, LABS FOURNIER, LABS SERVIER, LIMCO PIESTANY, LUDWIG MERCKLE HO SMOLENICE CASTLE RP RAVUSSIN, E (reprint author), NIDDKD,CLIN DIABET & NUTR SECT,4212 N 16TH ST,PHOENIX,AZ 85016, USA. NR 0 TC 7 Z9 7 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-797-2 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 683 BP 141 EP 150 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Nutrition & Dietetics; Physiology SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Nutrition & Dietetics; Physiology GA BY56Q UT WOS:A1993BY56Q00015 ER PT S AU ZINK, S AF ZINK, S BE Hendee, WR Trueblood, JH TI FUNDING SOURCES FOR EXTRAMURAL RESEARCH - NATIONAL-INSTITUTES-OF-HEALTH AND NATIONAL-CANCER-INSTITUTE SO DIGITAL IMAGING SE MEDICAL PHYSICS MONOGRAPHS LA English DT Proceedings Paper CT 1993 Summer School on Digital Imaging of the American-Association-of-Physicists-in-Medicine CY AUG 01-06, 1993 CL UNIV VIRGINIA, CHARLOTTESVILLE, VA SP AMER ASSOC PHYSICISTS MED HO UNIV VIRGINIA C1 NCI,RADIAT RES PROGRAM,BETHESDA,MD 20892. NR 0 TC 2 Z9 2 U1 0 U2 0 PU MEDICAL PHYSICS PUBLISHING PI MADISON PA 4513 VERNON BLVD, MADISON, WI 53705 SN 0163-1802 BN 0-944838-42-1 J9 MED PHYS MG PY 1993 IS 22 BP 443 EP & PG 0 WC Engineering, Biomedical; Medical Laboratory Technology; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Medical Laboratory Technology; Radiology, Nuclear Medicine & Medical Imaging GA BA84K UT WOS:A1993BA84K00017 ER PT J AU NELSON, DR KAMATAKI, T WAXMAN, DJ GUENGERICH, FP ESTABROOK, RW FEYEREISEN, R GONZALEZ, FJ COON, MJ GUNSALUS, IC GOTOH, O OKUDA, K NEBERT, DW AF NELSON, DR KAMATAKI, T WAXMAN, DJ GUENGERICH, FP ESTABROOK, RW FEYEREISEN, R GONZALEZ, FJ COON, MJ GUNSALUS, IC GOTOH, O OKUDA, K NEBERT, DW TI THE P450 SUPERFAMILY - UPDATE ON NEW SEQUENCES, GENE-MAPPING, ACCESSION NUMBERS, EARLY TRIVIAL NAMES OF ENZYMES, AND NOMENCLATURE SO DNA AND CELL BIOLOGY LA English DT Review ID LIVER MICROSOMAL CYTOCHROME-P-450; AMINO-ACID-SEQUENCE; PHENOBARBITAL-INDUCIBLE CYTOCHROME-P-450; CHAIN CLEAVAGE ENZYME; CONGENITAL ADRENAL-HYPERPLASIA; STEROID 21-HYDROXYLASE GENES; RAT HEPATIC CYTOCHROME-P-450; CDNA-DIRECTED EXPRESSION; ENCODING HUMAN AROMATASE; OMEGA-HYDROXYLASE CYTOCHROME-P-450 AB We provide here a list of 221 P450 genes and 12 putative pseudogenes that have been characterized as of December 14, 1992. These genes have been described in 31 eukaryotes (including 11 mammalian and 3 plant species) and 11 prokaryotes. Of 36 gene families so far described, 12 families exist in all mammals examined to date. These 12 families comprise 22 mammalian subfamilies, of which 17 and 15 have been mapped in the human and mouse genome, respectively. To date, each subfamily appears to represent a cluster of tightly linked genes. This revision supersedes the previous updates [Nebert et al., DNA 6, 1-11, 1987; Nebert et al., DNA 8, 1-13, 1989; Nebert et al., DNA Cell Biol. 10, 1-14 (1991)] in which a nomenclature system, based on divergent evolution of the superfamily, has been described. For the gene and cDNA, we recommend that the italicized root symbol ''CYP'' for human (''Cyp'' for mouse), representing ''cytochrome P450,'' be followed by an Arabic number denoting the family, a letter designating the subfamily (when two or more exist), and an Arabic numeral representing the individual gene within the subfamily. A hyphen should precede the final number in mouse genes. ''P'' (''p'' in mouse) after the gene number denotes a pseudogene. If a gene is the sole member of a family, the subfamily letter and gene number need not be included. We suggest that the human nomenclature system be used for all species other than mouse. The mRNA and enzyme in all species (including mouse) should include all capital letters, without italics or hyphens. This nomenclature system is identical to that proposed in our 1991 update. Also included in this update is a listing of available data base accession numbers for P450 DNA and protein sequences. We also discuss the likelihood that this ancient gene superfamily has existed for more than 3.5 billion years, and that the rate of P450 gene evolution appears to be quite nonlinear. Finally, we describe P450 genes that have been detected by expressed sequence tags (ESTs), as well as the relationship between the P450 and the nitric oxide synthase gene superfamilies, as a likely example of convergent evolution. C1 UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267. UNIV CINCINNATI,MED CTR,CTR ENVIRONM GENET,CINCINNATI,OH 45267. UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599. HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN. HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232. VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232. UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235. UNIV ARIZONA,DEPT ENTOMOL,TUCSON,AZ 85721. NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892. UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109. UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801. SAITAMA CANC CTR,INA,SAITAMA 362,JAPAN. HIROSHIMA UNIV,SCH DENT,DEPT BIOCHEM,HIROSHIMA 734,JAPAN. RI Feyereisen, Rene/I-3140-2012; OI Feyereisen, Rene/0000-0002-9560-571X; Nelson, David/0000-0003-0583-5421 FU NIEHS NIH HHS [P30 ES06096] NR 614 TC 1557 Z9 1602 U1 10 U2 110 PU MARY ANN LIEBERT INC PUBL PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 SN 1044-5498 J9 DNA CELL BIOL JI DNA Cell Biol. PD JAN-FEB PY 1993 VL 12 IS 1 BP 1 EP 51 DI 10.1089/dna.1993.12.1 PG 51 WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity GA KL191 UT WOS:A1993KL19100001 PM 7678494 ER PT J AU THWEATT, R FLEISCHMANN, R GOLDSTEIN, S AF THWEATT, R FLEISCHMANN, R GOLDSTEIN, S TI ANALYSIS OF THE PRIMARY STRUCTURE OF INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-3 CDNA FROM WERNER SYNDROME FIBROBLASTS SO DNA SEQUENCE LA English DT Note DE AGING; IGFBP-3; SECRETED PROTEINS ID GENE AB The mRNA encoding insulin-like growth factor binding protein-3 (IGFBP-3) is equally overexpressed in late-passage (old) normal human diploid fibroblasts (HDF) and in HDF derived from individuals with the premature aging disorder Werner syndrome (WS), relative to early-passage (young) normal HDF. However, the accumulation of IGFBP-3 protein in medium conditioned by WS cells is substantially less than in medium of old cells. In an attempt to understand this disparity between mRNA levels and protein output, we determined the nucleotide sequence of IGFBP-3 cDNA isolated from a WS cDNA library derived from mRNA of WS HDF, and compared it to three published normal IGFBP-3 DNA sequences. In the open reading frame, our results differed from one of the three sequences by a glycine substitution for alanine at residue 32. Minor differences in the 3'-untranslated region between the WS cDNA sequence and all three of the normal DNA sequences were also detected as 12 individual base substitutions and one adenine insertion. Thus, dampened accumulation of IGFBP-3 in medium conditioned by WS cells is not due to significant alterations in the sequence of the cognate mRNA. C1 JOHN L MCCLELLAN MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,LITTLE ROCK,AR 72205. UNIV ARKANSAS MED SCI HOSP,DEPT MED,LITTLE ROCK,AR 72205. UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205. NCI,CELL BIOL LAB,BETHESDA,MD 20892. FU NIA NIH HHS [AG05554, AG08708] NR 16 TC 4 Z9 5 U1 0 U2 0 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1042-5179 J9 DNA SEQUENCE JI DNA Seq. PY 1993 VL 4 IS 1 BP 43 EP 46 DI 10.3109/10425179309015621 PG 4 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA PG550 UT WOS:A1993PG55000006 PM 7508771 ER PT J AU VAMVAKOPOULOS, NC CHROUSOS, GP AF VAMVAKOPOULOS, NC CHROUSOS, GP TI STRUCTURAL ORGANIZATION OF THE 5' FLANKING REGION OF THE HUMAN CORTICOTROPIN-RELEASING HORMONE GENE SO DNA SEQUENCE LA English DT Article DE CORTICOTROPIN RELEASING HORMONE; REGULATORY REGION; REPETITIVE ELEMENTS; REGULATORY ELEMENTS ID GLUCOCORTICOID RECEPTOR-BINDING; TRANSCRIPTION FACTOR; MESSENGER-RNA; DNA-SEQUENCE; CHRONIC STRESS; HUMAN-PLACENTA; CYCLIC-AMP; RAT-BRAIN; CELL-LINE; EXPRESSION AB We have determined the nucleotide sequence of the proximal 3625 nucleotides 5' flanking the major mRNA start site of the human corticotropin releasing hormone gene (hCRH) and identified several putative regulatory elements. Interestingly, we did not detect any glucocorticoid responsive elements; we did however find five interspersed perfect half palindromic estrogen responsive elements, which might confer estrogen regulatability to the hCRH gene. We have identified a segment spanning from -2835 to -2972, which has about 72% homology to the 3' terminal half of the human Alu I family of highly repetitive elements, and another one, which spans from -2213 to -2580 and has greater than 80% homology to members of human type O family of repetitive elements. These elements may confer DNA fragility, since the loci for hCRH and the human fragile site FRA8F colocalize in human chromosome 8. The structural information reported represents a first step in the study of regulation of the hCRH gene at the molecular level. RP VAMVAKOPOULOS, NC (reprint author), NICHHD,DEV ENDOCRINOL BRANCH,BLDG 10,RM 10N-260,BETHESDA,MD 20892, USA. NR 64 TC 42 Z9 42 U1 0 U2 0 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1042-5179 J9 DNA SEQUENCE JI DNA Seq. PY 1993 VL 4 IS 3 BP 197 EP 206 DI 10.3109/10425179309015632 PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA PG554 UT WOS:A1993PG55400007 PM 8161822 ER PT S AU FERGUSON, JH AF FERGUSON, JH BE Warren, KS Mosteller, F TI NIH CONSENSUS CONFERENCES - DISSEMINATION AND IMPACT SO DOING MORE GOOD THAN HARM: THE EVALUATION OF HEALTH CARE INTERVENTIONS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Doing More Good Than Harm: The Evaluation of Health Care Interventions CY MAR 22-25, 1993 CL NEW YORK, NY SP NEW YORK ACAD SCI, L W FROHLICH CHARITABLE TRUST ID CESAREAN-SECTION RATE; 2 NATIONAL SURVEYS; DEVELOPMENT PROGRAM; HEART-DISEASE; UNITED-STATES; TECHNOLOGY-ASSESSMENT; CLINICAL RESEARCH; CHOLESTEROL; COVERAGE; CARE RP FERGUSON, JH (reprint author), NIH,OFF MED APPLICAT RES,BETHESDA,MD 20892, USA. NR 109 TC 25 Z9 26 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-833-2 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 703 BP 180 EP 199 DI 10.1111/j.1749-6632.1993.tb26348.x PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BA22S UT WOS:A1993BA22S00020 PM 8192296 ER PT S AU JACOBS, JJ AF JACOBS, JJ BE Warren, KS Mosteller, F TI ALTERNATIVE MEDICINE SO DOING MORE GOOD THAN HARM: THE EVALUATION OF HEALTH CARE INTERVENTIONS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Editorial Material CT Conference on Doing More Good Than Harm: The Evaluation of Health Care Interventions CY MAR 22-25, 1993 CL NEW YORK, NY SP NEW YORK ACAD SCI, L W FROHLICH CHARITABLE TRUST RP JACOBS, JJ (reprint author), NIH,OFF ALTERNAT MED,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-833-2 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 703 BP 304 EP 309 DI 10.1111/j.1749-6632.1993.tb26367.x PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BA22S UT WOS:A1993BA22S00035 PM 8192311 ER PT J AU POTTI, GK GALLELLI, JF AKOGYERAM, CO AHMADI, B HABIB, MJ AF POTTI, GK GALLELLI, JF AKOGYERAM, CO AHMADI, B HABIB, MJ TI IMPROVED DISSOLUTION OF INDOMETHACIN IN COPRECIPITATES WITH PHOSPHOLIPIDS .2. SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY LA English DT Article ID SOLID DISPERSION; SYSTEMS AB In our previous report' we showed that coprecipitates of Indomethacin (IND)-Phospholipids (PL) improved the dissolution profiles of the drug significantly. This study was undertaken to evaluate the mechanism of such improved dissolution and their commercial aspects upon long term storage conditions and by comparing the results with existing brands of indomethacin capsules. Aging studies of IND-PL were conducted after about one year of the preparation of the coprecipitates and no significant changes in the dissolution rates were observed from the fresh formulations. Powder x-ray diffraction data showed no crystal formation of the coprecipitates. Rather indomethacin was uniformly dispersed in an amorphous state in a solid matrix of phospholipids. The coprecipitates were also formulated into capsules and compared with Indocin(R), a commercial brand of Indomethacin. Our capsule formulation yielded about 2 fold greater initial dissolution rate as well as total amount dissolved. Phospholipid formulations thus have good industrial potential to increase the dissolution of poorly water soluble drugs. C1 NIH,WARREN G MAGNUSON CLIN CTR,DEPT PHARM,BETHESDA,MD 20892. HOWARD UNIV,COLL PHARM & PHARMACEUT SCI,WASHINGTON,DC 20059. NR 10 TC 2 Z9 2 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0363-9045 J9 DRUG DEV IND PHARM JI Drug Dev. Ind. Pharm. PY 1993 VL 19 IS 10 BP 1221 EP 1229 DI 10.3109/03639049309063014 PG 9 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA KY399 UT WOS:A1993KY39900010 ER PT J AU TRANG, JM PREJEAN, JD JAMES, RH IRWIN, RD GOEHL, TJ PAGE, JG AF TRANG, JM PREJEAN, JD JAMES, RH IRWIN, RD GOEHL, TJ PAGE, JG TI ZIDOVUDINE BIOAVAILABILITY AND LINEAR PHARMACOKINETICS IN FEMALE B6C3F1 MICE SO DRUG METABOLISM AND DISPOSITION LA English DT Article ID 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; MONKEYS; AZDDU; RATS AB The bioavailability and pharmacokinetics of zidovudine (3'-azido-3'deoxythymidine) (AZT) were determined in female B6C3F1 mice after administration of 15, 30, and 60 mg/kg doses via oral gavage or intravenous injection. Three animals in each administration group were sacrificed, and blood samples were collected at each of the following times: 0, 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, and 120 min after drug administration. Plasma zidovudine concentrations were determined by HPLC. After oral administration, mean maximum plasma concentrations (C(max)) of 9.1, 18.9, and 40.3 mg/liter were observed al 18.3, 21.7, and 15.0 min (t(max)) for the 15, 30, and 60 mg/kg doses, respectively. Following intravenous administration, mean C(max) values of 15.9, 41.8, and 76.0 mg/liter were observed for the 15, 30, and 60 mg/kg doses, respectively. Nonlinear least squares regression of all data sets, using a 1/y weight, indicated that zidovudine disposition was best described by a one-compartment open model with first-order absorption, where appropriate, and first-order elimination. The mean elimination half-life values ranged from 17.3 to 19.9 min for the three intravenous doses and from 16.5 to 21.9 min for the three oral doses. The mean values for the apparent volume of distribution (V(d)) ranged from 0.8 to 1.0 liter/kg following oral and intravenous administration. There were no significant differences in Vd between the oral and intravenous groups. The mean total body clearance values ranged from 28.9 to 34.3 ml/min/kg following intravenous administration. No significant differences existed between the oral and intravenous groups in the mean area under the curve to time infinity (AUC), when this parameter was normalized for the dose (D) administered (AUC/D). The mean absolute availability estimates for zidovudine were 0.85, 0.82, and 0.92 for the 15, 30, and 60 mg/kg dose groups, respectively. The overall average absolute availability was estimated to be approximately 86%. Zidovudine exhibited linear pharmacokinetic characteristics in mice following oral and intravenous administration at the three doses studied. Following oral gavage administration in a methylcellulose vehicle, the bioavailability of zidovudine was excellent. C1 NIEHS,SO RES INST,RES TRIANGLE PK,NC 27709. NIEHS,NATL TOXICOL PROGRAM,RES TRIANGLE PK,NC 27709. RP TRANG, JM (reprint author), SAMFORD UNIV,SCH PHARM,DEPT PHARMACEUT SCI,800 LAKESHORE DR,BIRMINGHAM,AL 35229, USA. FU NIEHS NIH HHS [N01-ES-85225] NR 15 TC 10 Z9 11 U1 0 U2 2 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0090-9556 J9 DRUG METAB DISPOS JI Drug Metab. Dispos. PD JAN-FEB PY 1993 VL 21 IS 1 BP 189 EP 193 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA KR781 UT WOS:A1993KR78100031 PM 8095218 ER PT J AU ROGAN, WJ GLADEN, BC AF ROGAN, WJ GLADEN, BC TI BREAST-FEEDING AND COGNITIVE-DEVELOPMENT SO EARLY HUMAN DEVELOPMENT LA English DT Article DE INTELLIGENCE TESTS; CHILD DEVELOPMENT; INFANT FEEDING; BIRTH ORDER; MATERNAL AGE ID DICHLORODIPHENYL DICHLOROETHENE DDE; POLYCHLORINATED-BIPHENYLS PCBS; HUMAN-MILK; CHILDRENS ABILITIES; MCCARTHY-SCALES; BIRTH-ORDER; EXPOSURE; 1ST; INTELLIGENCE; ACHIEVEMENT AB Eight-hundred fifty-five newborns were enrolled in a prospective study between 1978 and 1982 and then followed through school age. To determine whether the mode of infant feeding affected developmental scores or school grades, prospective data were collected on how the children were fed; 788 of the children had Bayley tests at 6 months, 720 at 12 months, 676 at 18 months and 670 at 2 years. McCarthy testing was done on 645 children at 3 years, 628 at 4 years and 636 at 5 years. Testers were not specifically blind to feeding method. The families provided report cards from grade 3 or higher for 366 children. There were statistically significant but small increases in scores among breast-fed children on at least some subscales of the Bayley and McCarthy at all time points from 2 years through 5 years and slightly higher English grades on report cards in both crude analyses and in multivariate analyses that allowed adjustment for the most plausible confounding variables. We conclude that, in a volunteer, 95% white sample of middle class children, those breast-fed scored slightly better than those bottle fed; the effect is small but still detectable at school age. RP ROGAN, WJ (reprint author), NIEHS,DIV BIOMETRY & RISK ASSESSMENT,MAIL DROP A3-05,POB 12233,RES TRIANGLE PK,NC 27709, USA. RI Rogan, Walter/I-6034-2012 OI Rogan, Walter/0000-0002-9302-0160 NR 29 TC 165 Z9 166 U1 1 U2 3 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0378-3782 J9 EARLY HUM DEV JI Early Hum. Dev. PD JAN PY 1993 VL 31 IS 3 BP 181 EP 193 DI 10.1016/0378-3782(93)90194-Y PG 13 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA KK650 UT WOS:A1993KK65000001 PM 8444137 ER PT B AU BAKER, R SMITH, R AF BAKER, R SMITH, R GP INT DIST HEATING & COOLING ASSOC TI RELIABILITY AND DYNAMIC DEVELOPMENT OF LARGE CAMPUS COOLING SYSTEMS SO EIGHTY-FOURTH ANNUAL CONFERENCE OF THE INTERNATIONAL DISTRICT HEATING AND COOLING ASSOCIATION, OFFICIAL PROCEEDINGS LA English DT Proceedings Paper CT 84th Annual Conference of the International-District-Heating-and-Cooling-Association CY JUN 19-23, 1993 CL HARRISBURG, PA SP INT DIST HEATING & COOLING ASSOC C1 NIH,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INTERNATIONAL DISTRICT ENERGY ASSOCIATION PI WASHINGTON PA 1200 19TH STREET NW, SUITE 300, WASHINGTON, DC 20036-2401 PY 1993 BP 19 EP 33 PG 15 WC Energy & Fuels; Engineering, Mechanical SC Energy & Fuels; Engineering GA BB64M UT WOS:A1993BB64M00002 ER PT J AU CHRAMBACH, A ALDROUBI, A AF CHRAMBACH, A ALDROUBI, A TI RELATIVE EFFICIENCY OF MOLECULAR-SIEVING IN SOLUTIONS OF 4 POLYMERS SO ELECTROPHORESIS LA English DT Article ID POLYACRYLAMIDE-GEL ELECTROPHORESIS; DNA; SEPARATION; FRAGMENTS; PARTICLES; AGAROSE; RADIUS AB The efficiency of size separations of polystyrene sulfate, 120-1085 nm radius, by molecular sieving in polymer solutions, expressed by the separation efficiency function S = M(o) \ dK(R)(R)/dR \ Te(-KR(R)T) [where M(o) is the mobility in free solution, K(R) the retardation coefficient, R the geometric mean radius of the particle, K(R)(R) the retardation coeffieient as a function of R, and the polymer concentration is T] increases from methylhydroxypropyl cellulose to polyvinyl alcohol to uncrosslinked polyacrylamide to agarose above its gelling temperature. Separations of DNA, in the size range of 3-21 nm radius, are by at least one order of magnitude more efficient than those of polystyrene sulfate in the size range of 120-1085 nm radius. A plot of S vs. R in the experimental range of T is constructed for the four polymer solutions; this allows one to select optimal media and concentrations for the sieving of particles in the desired range of molecular sizes. C1 NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892. NICHHD,THEORET & PHYS BIOL LAB,BETHESDA,MD 20892. RI Aldroubi, Akram/J-7186-2012 NR 23 TC 44 Z9 44 U1 0 U2 0 PU VCH PUBLISHERS INC PI DEERFIELD BEACH PA 303 NW 12TH AVE, DEERFIELD BEACH, FL 33442-1788 SN 0173-0835 J9 ELECTROPHORESIS JI Electrophoresis PD JAN-FEB PY 1993 VL 14 IS 1-2 BP 18 EP 22 DI 10.1002/elps.1150140104 PG 5 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA KT849 UT WOS:A1993KT84900003 PM 8462511 ER PT J AU LUO, LD WIRTH, PJ AF LUO, LD WIRTH, PJ TI CONSECUTIVE SILVER STAINING AND AUTORADIOGRAPHY OF S-35 AND P-32 LABELED CELLULAR PROTEINS - APPLICATION FOR THE ANALYSIS OF SIGNAL TRANSDUCING PATHWAYS SO ELECTROPHORESIS LA English DT Article ID TRANSFORMING GROWTH FACTOR-BETA-1; LIVER EPITHELIAL-CELLS; DIMENSIONAL GEL ELECTROPHORETOGRAMS; POLYACRYLAMIDE GELS; POLYPEPTIDE EXPRESSION; COMPUTER-ANALYSIS; LABELED PROTEINS; FILM DETECTION; FACTOR-BETA; PHOSPHORYLATION AB The methodology for the simultaneous analysis of protein synthesis concomitant with protein phosphorylation/dephosphorylation is described. The technique consists of metabolic labeling of rat liver epithelial (RLE) cells with [P-32]orthophosphate and [S-35]methionine, performing two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) of the mixed samples, followed by silverstaining and subsequent autoradiography of the dried silver stained 2-D PAGE electrophoretograms using two films placed back-to-back. The first film, which is positioned in direct contact with the dried silver-stained gel, visualized both exposure to S-35 and P-32 while the second film recorded exposure to only P-32 due to the differential energy levels of the two isotopes. The juxtapositioning of the silver-stained images with the two autoradiographic film images permits the unambiguous mapping of the phosphorylated polypeptides back to their corresponding silver-stained and methionine-labeled counterparts. This strategy provides quantitative information utilizing both silver staining (measure of constitutive levels of protein expression) and metabolic labeling to measure rates of protein synthesis and/or degradation and phosphorylation and/or dephosphorylation using [S-35]methionine and [P-32]orthophosphate, respectively. We have utilized this methodology for the in vitro analysis of transforming growth factor type beta1 (TGF-beta1)-mediated signal transduction in RLE cells and have identified three nuclear polypeptides, 1 (pI 4.95/M(r) 97 kDa), 2 (5.00/85 kDa) and 3 (4.90/84 kDa) whose phosphorylation status is rapidly and transiently modulated by TGF-beta1.The methodology described should have wide applications in studies where it is desirous to measure protein synthesis and/or degradation concomitant with signal transduction pathways involving protein phosphorylation. C1 NCI,EXPTL CARCINOGENESIS,BLDG 37,ROOM 3C28,BETHESDA,MD 20892. NR 41 TC 13 Z9 13 U1 0 U2 0 PU VCH PUBLISHERS INC PI DEERFIELD BEACH PA 303 NW 12TH AVE, DEERFIELD BEACH, FL 33442-1788 SN 0173-0835 J9 ELECTROPHORESIS JI Electrophoresis PD JAN-FEB PY 1993 VL 14 IS 1-2 BP 127 EP 136 DI 10.1002/elps.1150140121 PG 10 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA KT849 UT WOS:A1993KT84900020 PM 8462506 ER PT J AU MICHELS, KM LEE, WH SELTZER, A SAAVEDRA, JM BONDY, CA AF MICHELS, KM LEE, WH SELTZER, A SAAVEDRA, JM BONDY, CA TI UP-REGULATION OF PITUITARY [I-125] INSULIN-LIKE GROWTH FACTOR-I (IGF-I) BINDING AND IGF BINDING PROTEIN-2 AND IGF-I GENE-EXPRESSION BY ESTROGEN SO ENDOCRINOLOGY LA English DT Article ID RAT ANTERIOR-PITUITARY; CELLS; HYPOTHALAMUS; PROLACTIN; BRAIN; SECRETION; GLAND; TUMOR AB To evaluate the effects of estrogen on the rat pituitary insulin-like growth factor (IGF) system, binding of [I-125]IGF-I and in situ hybridization for IGF-1, the IGF-I receptor and IGF binding protein-2 (IGFBP-2) were coupled with quantitative autoradiography. The groups included intact cycling females, intact males, and gonadectomized males and females with or without estrogen pellet implants. Binding of [I-125] IGF-I in the anterior lobe of the pituitary occurred in dense clusters over a diffuse lower density background. [I-125]IGF-I binding was significantly increased in the estrogen-treated groups and was highest at proestrus compared to the rest of the estrous cycle. IGF-I receptor messenger RNA (mRNA) was distributed diffusely through the anterior pituitarY and was not different between the respective gonadectomized and estrogen-treated groups. IGFBP-2 mRNA was clustered throughout the anterior pituitary and was significantly higher in the estrogen-treated groups as noted above for [I-125]IGF-I binding. IGF-I mRNA was diffuse throughout the anterior pituitary and was also significantly higher in the estrogen-treated groups. In the neural lobe, [I-125]IGF-I binding, IGFBP-2 mRNA, IGF-I receptor mRNA, and IGF-I mRNA were all uniformly distributed and did not differ between groups. The results show that circulating estrogen differentially regulates components of the pituitary IGF-I system in a region-specific manner and suggest that a portion of IGF binding in the anterior pituitary may be to IGFBP-2. C1 NICHHD, DEV ENDOCRINOL BRANCH, BETHESDA, MD 20892 USA. RP MICHELS, KM (reprint author), NIMH, CLIN SCI LAB, PHARMACOL SECT, BLDG 10, ROOM 2D-45, BETHESDA, MD 20892 USA. NR 28 TC 88 Z9 88 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 1993 VL 132 IS 1 BP 23 EP 29 DI 10.1210/en.132.1.23 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KH625 UT WOS:A1993KH62500004 PM 7678216 ER PT J AU AGUILERA, G LIGHTMAN, SL KISS, A AF AGUILERA, G LIGHTMAN, SL KISS, A TI REGULATION OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS DURING WATER-DEPRIVATION SO ENDOCRINOLOGY LA English DT Article ID CORTICOTROPIN-RELEASING FACTOR; FACTOR MESSENGER-RNA; MEDIAN-EMINENCE; ADRENOCORTICOTROPIN SECRETION; ARGININE VASOPRESSIN; STIMULATED ADRENOCORTICOTROPIN; PARAVENTRICULAR LESIONS; NEUROINTERMEDIATE LOBE; IMMOBILIZATION STRESS; RAT HYPOTHALAMUS AB The contribution of the magnocellular vasopressinergic system to the regulation of ACTH secretion was studied by analysis of hypothalamic-adrenal axis function in rats subjected to water deprivation for 48 h. Water deprivation resulted in marked increases in plasma osmolarity and vasopressin (VP) levels and hypothalamic VP mRNA and immunoreactive (ir) VP in magnocellular neurons. While CRH mRNA levels in the paraventricular nucleus were decreased, irCRH accumulation in paraventricular nucleus neurons after colchicine treatment was normal or increased. Similarly, the irCRH content in the median eminence and its release under stress were similar in control and water-deprived rats. While basal plasma ACTH levels were similar in both groups (34.5 +/- 3.8 and 39.8 +/- 3.3 pg/ml), levels stimulated by CRH injection (10 mug, iv) or 15-min immobilization stress were reduced by 47% (P < 0.01) and 43% (P < 0.05), respectively, in water-restricted rats. The decreased ACTH responses were not prevented by injection of CRH (7.5 mug/day, sc) during the period of water deprivation. In contrast to the ACTH responses, basal and CRH-stimulated plasma corticosterone levels were significantly elevated (P < 0.001), and the responses to acute stress were normal. The inhibition of ACTH secretion was not due to increased glucocorticoid feedback, since similar blunted ACTH responses to acute immobilization stress were observed in adrenalectomized rats receiving corticosterone replacement. Despite similar levels of pituitary POMC mRNA, pituitary ACTH content was reduced in water-deprived rats, suggesting a posttranscriptional inhibition of POMC synthesis or processing. The data demonstrate that osmotic activation of the magnocellular VP system is accompanied by reduced responsiveness of the corticotrophs, an effect that is not due to increased glucocorticoid feedback or hypothalamic CRH deficiency. These findings suggest that the magnocellular vasopressinergic system does not play an important role in the regulation of ACTH secretion during chronic osmotic stimulation. C1 CHARING CROSS & WESTMINSTER MED SCH, CHARING CROSS HOSP, NEUROENDOCRINOL UNIT, LONDON W6 8RF, ENGLAND. RP AGUILERA, G (reprint author), NICHHD, DEV ENDOCRINOL BRANCH, ENDOCRINE PHYSIOL SECT, BLDG 10, ROOM 10N262, BETHESDA, MD 20892 USA. NR 44 TC 90 Z9 90 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 1993 VL 132 IS 1 BP 241 EP 248 DI 10.1210/en.132.1.241 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KH625 UT WOS:A1993KH62500035 PM 8380375 ER PT J AU BURKHART, JG MALLING, HV AF BURKHART, JG MALLING, HV TI MUTAGENESIS AND TRANSGENIC SYSTEMS - PERSPECTIVE FROM THE MUTAGEN, N-ETHYL-N-NITROSOUREA SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Editorial Material ID ESCHERICHIA-COLI; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; DNA GLYCOSYLASE; RAT-LIVER; REPAIR; MOUSE; CELLS; METHYL; METHYLTRANSFERASE; ETHYLNITROSOUREA RP BURKHART, JG (reprint author), NIEHS,RES TRIANGLE PK,NC 27709, USA. NR 28 TC 31 Z9 31 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0893-6692 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PY 1993 VL 22 IS 1 BP 1 EP 6 DI 10.1002/em.2850220103 PG 6 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA LP831 UT WOS:A1993LP83100001 PM 8339722 ER PT J AU MULLER, J JANZ, S AF MULLER, J JANZ, S TI MODULATION OF THE H2O2-INDUCED SOS RESPONSE IN ESCHERICHIA-COLI PQ300 BY AMINO-ACIDS, METAL CHELATORS, ANTIOXIDANTS, AND SCAVENGERS OF REACTIVE OXYGEN SPECIES SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Article DE DNA REPAIR; SOS CHROMOTEST; OXIDATIVE DNA DAMAGE ID INDUCED DNA DAMAGE; CULTURED-MAMMALIAN-CELLS; HYDROGEN-PEROXIDE; STRAND BREAKS; OXIDATIVE STRESS; SALMONELLA-TYPHIMURIUM; ASCORBIC-ACID; PLASMID DNA; RADIATION; BASES AB The SOS chromotest is a simple colorimetric genotoxicity assay that monitors DNA repair by measuring the induction of the gene sfiA in Escherichia coli K-12. E. coli PQ300, a diagnostic SOS tester strain for the detection of oxidative genotoxins, carries a mutation in a key gene for antioxidative defense, oxyR. This mutation renders PQ300 more sensitive to oxidative genotoxins, particularly to H2O2. We found that induction of the SOS response by H2O2 in E. coli PQ300 is dependent on the composition of the incubation medium; a substantially reduced response was obtained in minimal phosphate buffered saline (PBS) as opposed to complex Luria broth (LB) medium. Supplementation of PBS with histidine or cysteine stimulated H2O2-induced SOS induction to levels exceeding those found in LB medium. Low concentrations of glutathione (20-70 muM) also enhanced the H2O2-induced SOS response in E. coli PQ300, whereas higher concentrations (> 150 muM) were protective. Preincubation of tester cells with the chelators o-phenanthroline, 2,2-dipyridyl, and ethylenediaminetetraacetic acid (EDTA) protected cells from the effects of H2O2, although EDTA was only partially effective. Pretreatment of PQ300 with the antioxidant ascorbic acid or the hydroxyl radical scavenger dimethyl sulfoxide also diminished the SOS response, whereas mannitol and glucose were ineffective. The results show that the net effect of H2O2-induced DNA damage is influenced by the balance of oxidative and antioxidative factors and, furthermore, can be modulated by constituents of the extracellular milieu. (C) 1993 Wiley-Liss, Inc.* C1 NCI,GENET LAB,BLDG 37,ROOM 2B09,BETHESDA,MD 20892. UNIV LEIPZIG,FAC MED,INST CLIN IMMUNOL,LEIPZIG,GERMANY. NR 55 TC 15 Z9 15 U1 1 U2 4 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0893-6692 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PY 1993 VL 22 IS 3 BP 157 EP 163 DI 10.1002/em.2850220308 PG 7 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA MD154 UT WOS:A1993MD15400007 PM 8404875 ER PT J AU ZHU, SY ZEIGER, E AF ZHU, SY ZEIGER, E TI MUTAGENICITY OF THE HUMAN CARCINOGEN TREOSULPHAN, AND ITS HYDROLYSIS PRODUCT, DL-1,2/3,4-DIEPOXYBUTANE IN MAMMALIAN-CELLS SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Article DE TREOSULPHAN; DL-1,2-3,4-DIEPOXYBUTANE; MAMMALIAN CELLS; CHO CELLS; AS52 CELLS; CYTOTOXICITY; MUTAGENICITY ID AS52 CELLS; 4-AMINOBIPHENYL; MUTATIONS AB The cytotoxicity and mutagenicity of the human carcinogen, treosulphan, and its hydrolysis product, dl-1,2:3,4-diepoxybutane (DEB), were studied in Chinese hamster ovary, AS52, cells. Treosulphan (0.1-1.0 mM) is toxic and mutagenic at the gpt locus. A strong pH dependence was noted. DEB is cytotoxic and mutagenic at a much lower dose (0.025 mM), but these effects were not affected by pH. The results suggest that the toxic and mutagenic effects of treosulphan are mediated by its hydrolysis product DEB, and that the conversion of treosulphan to DEB is highly pH-dependent. C1 NIEHS,EXPTL CARCINOGENESIS & MUTAGENESIS BRANCH,RES TRIANGLE PK,NC 27709. NR 11 TC 13 Z9 14 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0893-6692 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PY 1993 VL 21 IS 1 BP 95 EP 99 DI 10.1002/em.2850210113 PG 5 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA KJ833 UT WOS:A1993KJ83300012 PM 8419160 ER PT J AU SHELBY, MD EREXSON, GL HOOK, GJ TICE, RR AF SHELBY, MD EREXSON, GL HOOK, GJ TICE, RR TI EVALUATION OF A 3-EXPOSURE MOUSE BONE-MARROW MICRONUCLEUS PROTOCOL - RESULTS WITH 49 CHEMICALS SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Article DE CARCINOGENS; CODED CHEMICALS; NONCARCINOGENS; GENOTOXIC CHEMICALS ID PERIPHERAL-BLOOD ERYTHROCYTES; HUMAN CARCINOGENS; POLYCHROMATIC ERYTHROCYTES; MULTIPLE TREATMENTS; GENETIC TOXICITY; INVIVO; MUTAGENICITY; SALMONELLA; MICE; GENOTOXICITY AB Forty-nine chemicals were tested in a mouse bone marrow micronucleus test that employed three daily exposures by intraperitoneal injection. Bone marrow samples were obtained 24 hr following the final exposure. Twenty-five rodent carcinogens and 24 noncarcinogens were selected randomly from the 44 carcinogens and 29 noncarcinogens used by Tennant et al. (Science 236:933-941, 1987) to evaluate the performance of four in vitro genetic toxicity tests. As in that study of in vitro tests, the micronucleus tests were conducted with coded chemicals and test results (positive or negative) were determined prior to decoding. This study was conducted as part of an effort to assess the ability of the micronucleus test to discriminate between rodent carcinogens and noncarcinogens and to determine its potential role, in combination with other short-term tests, in identifying genotoxic chemicals that present a carcinogenic hazard. Nine chemicals were judged to be positive in the micronucleus test. This relatively low number of positive results, along with published and unpublished results from rodent micronucleus and chromosome aberration assays on several of these 49 chemicals, contributed to the conclusion that a single micronucleus test protocol is not adequate to detect all chemicals capable of inducing chromosomal damage in the bone marrow. However, a combination of two relatively simple assays such as the Salmonella and micronucleus tests can provide important information on the genetic toxicity of test chemicals and may provide guidance on the need for and the nature and extent of further toxicity studies. C1 EHRT INC,RES TRIANGLE PK,NC. ILS,RES TRIANGLE PK,NC. ORAU,OAK RIDGE,TN. RP SHELBY, MD (reprint author), NIEHS,POB 12233,RES TRIANGLE PK,NC 27709, USA. FU NIEHS NIH HHS [N01-ES-85208, N01-ES-85209] NR 42 TC 136 Z9 137 U1 0 U2 5 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0893-6692 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PY 1993 VL 21 IS 2 BP 160 EP 179 DI 10.1002/em.2850210210 PG 20 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA KT391 UT WOS:A1993KT39100008 PM 8444144 ER PT J AU MIRSALIS, JC STEINMETZ, KL BLAZAK, WF SPALDING, JW AF MIRSALIS, JC STEINMETZ, KL BLAZAK, WF SPALDING, JW TI EVALUATION OF THE POTENTIAL OF RIDDELLIINE TO INDUCE UNSCHEDULED DNA-SYNTHESIS, S-PHASE SYNTHESIS, OR MICRONUCLEI FOLLOWING INVIVO TREATMENT WITH MULTIPLE DOSES SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Article DE RIDDELLIINE; UNSCHEDULED DNA SYNTHESIS; S-PHASE SYNTHESIS; MICRONUCLEI; PYRROLIZIDINE ALKALOID; REPEAT-DOSE STUDIES ID PERIPHERAL-BLOOD; B6C3F1 MICE; ERYTHROCYTES; ASSAY; HEPATOTOXICITY; CHEMICALS; INVITRO; REPAIR; RAT AB Riddelliine (RID) is a pyrrolizidine alkaloid found in plants of the genera Crotalaria, Amsinckia, and Senecio in the United States. RID has been extensively studied in a wide variety of in vitro short-term genotoxicity tests and has yielded positive responses in most test systems; however, there are fewer data available on the effects of RID in in vivo assays and no data under repeat-dose regimens. We have evaluated the ability of RID to induce unscheduled DNA synthesis (UDS) in hepatocytes, S-phase synthesis (SPS) in hepatocytes, and micronuclei in bone marrow from animals dosed for 5 or 30 days in conjunction with prechronic toxicity testing conducted for the National Toxicology Program. Results of this study indicate that RID did not induce an increase in micronucleated polychromatic erythrocytes (PCE) in bone marrow of mice after 5 days of dosing or in PCE from rats or mice after 30 days of dosing. RID did not induce an increase in UDS in rat hepatocytes after 5 or 30 days of dosing, but it did induce an equivocal UDS response in male mice after both time points and a positive response in female mice after 30 days of dosing. RID induced significant elevations in SPS in rat hepatocytes after both 5 and 30 days of dosing, even at low doses. An increase in SPS was observed in male and female mouse hepatocytes, but only after 30 days of dosing. Rats and mice of both sexes showed a depression in SPS at higher doses. This effect may be a result of toxicity, which compromises the ability of the liver to regenerate. These results demonstrate that repeated administration of test chemicals may alter the genotoxic response to chemicals. C1 NIEHS,CELLULAR & GENET TOXICOL BRANCH,RES TRIANGLE PK,NC 27709. RP MIRSALIS, JC (reprint author), SRI INT,TOXICOL LAB,333 RAVENSWOOD AVE,MENLO PK,CA 94025, USA. FU NIEHS NIH HHS [N01-ES-65139] NR 23 TC 20 Z9 20 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0893-6692 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PY 1993 VL 21 IS 3 BP 265 EP 271 DI 10.1002/em.2850210310 PG 7 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA KX341 UT WOS:A1993KX34100009 PM 8462530 ER PT J AU ZEIGER, E SHELBY, MD WITT, KL AF ZEIGER, E SHELBY, MD WITT, KL TI GENETIC TOXICITY OF FLUORIDE SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Review DE FLUORIDE; MUTATION; CYTOGENIC ASSAY; DROSOPHILA ID SISTER-CHROMATID EXCHANGE; UNSCHEDULED DNA-SYNTHESIS; SYRIAN-HAMSTER EMBRYO; HUMAN ORAL KERATINOCYTES; MOUSE LYMPHOMA-CELLS; SODIUM-FLUORIDE; CHROMOSOME-ABERRATIONS; DROSOPHILA-MELANOGASTER; GENOTOXIC EVALUATION; MUTAGENICITY C1 OAK RIDGE ASSOCIATED UNIV,OAK RIDGE,TN 37830. RP ZEIGER, E (reprint author), NIEHS,EXPTL CARCINOGENESIS & MUTAGENESIS BRANCH,RES TRIANGLE PK,NC 27709, USA. NR 90 TC 37 Z9 40 U1 3 U2 3 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0893-6692 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PY 1993 VL 21 IS 4 BP 309 EP 318 DI 10.1002/em.2850210402 PG 10 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA LE439 UT WOS:A1993LE43900001 PM 8491210 ER PT J AU SCHULTZ, RJ KAPLAN, LAE SCHULTZ, ME AF SCHULTZ, RJ KAPLAN, LAE SCHULTZ, ME TI HEAT-INDUCED LIVER-CELL PROLIFERATION IN THE LIVEBEARING FISH POECILIOPSIS SO ENVIRONMENTAL BIOLOGY OF FISHES LA English DT Article DE THERMAL EFFECTS; STRESS; LIVER REGENERATION; MITOTIC INDEX; TOPMINNOW ID GROWTH-CONTROL; RAT-LIVER; HEPATOCARCINOGENESIS; 7,12-DIMETHYLBENZANTHRACENE; INHIBITION; INDUCTION; TUMORS; RIVER; CYCLE; LAKE AB Liver regeneration is induced by heat stress in the small viviparous fish, Poeciliopsis. Acute exposure to sublethal temperatures, one to two degrees below their killing temperature, damages tissue and initiates liver cell proliferation in P. lucida, P. monacha, and P. monacha-lucida hybrid clones, SYN-4 and SYN-5. Regeneration of liver cells began within 1-2 days following heat stress and proceeded over 5 days. Peak cell proliferation occurred 2-3 days after treatment in fish of all four genotypes. Cell proliferation was induced in the two all-female clones, SYN-4 and SYN-5, by exposure to 40.5-degrees-C for 60 minutes. This treatment imposed mortalities of 17.9% and 16.7%, respectively, whereas reduction of the temperature to 39.5-degrees-C and reduction of the time to 30 minutes resulted in no mortalities without significantly lowering the level of cell proliferation (p > 0.05). Liver cell proliferation induced by both heat treatments was significantly higher (p < 0.05) in the SYN-5 hybrids than in SYN-4. The induction of liver cell proliferation with sublethal temperature exposures is discussed as it may relate to chemical carcinogenesis in both feral and laboratory fish. Acute heat exposure may be used experimentally in fish as an independent stimulus for liver cell proliferation in carcinogenesis studies. In poikilothermic animals-heat exposure offers an alternative to surgical removal of approximately two-thirds of the liver, the method most frequently used in rodents to study the process of liver regeneration. C1 UNIV CONNECTICUT,DEPT ECOL & EVOLUTIONARY BIOL,STORRS,CT 06268. UNIV CONNECTICUT,DEPT PHYSIOL & NEUROPHYSIOL,STORRS,CT 06268. RP SCHULTZ, RJ (reprint author), UNIV CONNECTICUT,NIEHS MARINE & FRESHWATER BIOMED SCI CTR,STORRS,CT 06269, USA. NR 33 TC 6 Z9 6 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0378-1909 J9 ENVIRON BIOL FISH JI Environ. Biol. Fishes PD JAN PY 1993 VL 36 IS 1 BP 83 EP 91 DI 10.1007/BF00005982 PG 9 WC Ecology; Marine & Freshwater Biology SC Environmental Sciences & Ecology; Marine & Freshwater Biology GA KJ249 UT WOS:A1993KJ24900008 ER PT S AU BEEBE, LE FORNWALD, LW FOX, SD ISSAQ, HJ ANDERSON, LM AF BEEBE, LE FORNWALD, LW FOX, SD ISSAQ, HJ ANDERSON, LM BE Gorsuch, JW Dwyer, FJ Ingersoll, CG LaPoint, TW TI EFFECTS OF A SINGLE-DOSE EXPOSURE TO AROCLOR-1254 ON MOUSE HEPATIC CYTOCHROMES-P450 SO ENVIRONMENTAL TOXICOLOGY AND RISK ASSESSMENT: 2ND VOLUME SE AMERICAN SOCIETY FOR TESTING AND MATERIALS SPECIAL TECHNICAL PUBLICATION LA English DT Proceedings Paper CT Symposium on Environmental Toxicology and Risk Assessment: Aquatic, Plant, and Terrestrial CY APR 26-30, 1992 CL PITTSBURGH, PA SP AMER SOC TESTING & MAT, COMM BIOL EFFECTS & ENVIRONM FATE DE POLYCHLORINATED BIPHENYLS; AROCLOR-1254; CYTOCHROME-P450; HEPATIC ENZYME INDUCTION; BODY BURDEN C1 NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMERICAN SOCIETY TESTING AND MATERIALS PI W CONSHOHOCKEN PA 100 BARR HARBOR DRIVE, W CONSHOHOCKEN, PA 19428-2959 SN 1071-5827 BN 0-8031-1485-0 J9 AM SOC TEST MATER PY 1993 VL 1216 BP 184 EP 194 DI 10.1520/STP13154S PG 11 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA BZ53R UT WOS:A1993BZ53R00014 ER PT J AU BRINTON, LA SCHAIRER, C AF BRINTON, LA SCHAIRER, C TI ESTROGEN REPLACEMENT THERAPY AND BREAST-CANCER RISK SO EPIDEMIOLOGIC REVIEWS LA English DT Article ID MAMMOGRAPHIC PARENCHYMAL PATTERNS; POSTMENOPAUSAL HORMONE USE; EXPANDED CASE-CONTROL; EXOGENOUS ESTROGENS; RECEPTOR STATUS; UNITED-STATES; MENOPAUSAL ESTROGENS; CONJUGATED ESTROGENS; ORAL-CONTRACEPTIVES; CIGARETTE-SMOKING RP BRINTON, LA (reprint author), NCI,ENVIRONM EPIDEMIOL BRANCH,EXECUT PLAZA N,ROOM 443,BETHESDA,MD 20892, USA. RI Brinton, Louise/G-7486-2015 OI Brinton, Louise/0000-0003-3853-8562 NR 97 TC 87 Z9 88 U1 2 U2 2 PU JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH PI BALTIMORE PA 111 MARKET PLACE, STE 840, BALTIMORE, MD 21202-6709 SN 0193-936X J9 EPIDEMIOL REV JI Epidemiol. Rev. PY 1993 VL 15 IS 1 BP 66 EP 79 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA LV351 UT WOS:A1993LV35100007 PM 8405213 ER PT J AU HILDESHEIM, A LEVINE, PH AF HILDESHEIM, A LEVINE, PH TI ETIOLOGY OF NASOPHARYNGEAL CARCINOMA - A REVIEW SO EPIDEMIOLOGIC REVIEWS LA English DT Review ID EPSTEIN-BARR-VIRUS; OLFACTORY-SPECIFIC CYTOCHROME-P-450; VOLATILE NITROSAMINE LEVELS; ENVIRONMENTAL RISK-FACTORS; HIGHER CHLORINATED DIOXINS; ANTIBODY-POSITIVE PERSONS; RESPIRATORY NASAL-MUCOSA; SQUAMOUS-CELL CANCERS; NUCLEAR ANTIGEN EBNA; SALTED FISH RP HILDESHEIM, A (reprint author), NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,ENVIRONM EPIDEMIOL BRANCH,EPN ROOM 443,BETHESDA,MD 20892, USA. NR 181 TC 162 Z9 179 U1 2 U2 8 PU JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH PI BALTIMORE PA 111 MARKET PLACE, STE 840, BALTIMORE, MD 21202-6709 SN 0193-936X J9 EPIDEMIOL REV JI Epidemiol. Rev. PY 1993 VL 15 IS 2 BP 466 EP 485 PG 20 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA MY676 UT WOS:A1993MY67600010 PM 8174667 ER PT J AU KJAER, SK BRINTON, LA AF KJAER, SK BRINTON, LA TI ADENOCARCINOMAS OF THE UTERINE CERVIX - THE EPIDEMIOLOGY OF AN INCREASING PROBLEM SO EPIDEMIOLOGIC REVIEWS LA English DT Review ID HUMAN PAPILLOMAVIRUS DNA; SQUAMOUS-CELL CARCINOMA; ENDOCERVICAL GLANDULAR DYSPLASIA; ORAL-CONTRACEPTIVE USE; INSITU HYBRIDIZATION; MICROGLANDULAR HYPERPLASIA; ADENOSQUAMOUS CARCINOMA; PROGNOSTIC-SIGNIFICANCE; YOUNG-WOMEN; MICROINVASIVE ADENOCARCINOMA C1 NCI,ENVIRONM EPIDEMIOL BRANCH,BETHESDA,MD 20892. INST CANC EPIDEMIOL BRANCH,DANISH CANC REGISTRY BRANCH,COPENHAGEN,DENMARK. RI Brinton, Louise/G-7486-2015 OI Brinton, Louise/0000-0003-3853-8562 NR 75 TC 56 Z9 56 U1 0 U2 0 PU JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH PI BALTIMORE PA 111 MARKET PLACE, STE 840, BALTIMORE, MD 21202-6709 SN 0193-936X J9 EPIDEMIOL REV JI Epidemiol. Rev. PY 1993 VL 15 IS 2 BP 486 EP 498 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA MY676 UT WOS:A1993MY67600011 PM 8174668 ER PT J AU HARLAN, LC COATES, RJ BLOCK, G GREENBERG, RS ERSHOW, A FORMAN, M AUSTIN, DF CHEN, V HEYMSFIELD, SB AF HARLAN, LC COATES, RJ BLOCK, G GREENBERG, RS ERSHOW, A FORMAN, M AUSTIN, DF CHEN, V HEYMSFIELD, SB TI ESTROGEN-RECEPTOR STATUS AND DIETARY INTAKES IN BREAST-CANCER PATIENTS SO EPIDEMIOLOGY LA English DT Article DE BREAST NEOPLASMS; DIET; WOMEN; ESTROGEN RECEPTOR; RACE, BODY MASS; CARBOHYDRATES; DIETARY FAT; ORAL CONTRACEPTIVES; PARITY AB We used data from a study of racial differences in cancer patient survival to examine the association between estrogen receptor status and the intake of nutrients and food groups among 689 black and white women, ages 20-79, with breast cancer newly diagnosed in 1985 and 1986. We reviewed medical records and collected interview data, including a 34-item food frequency questionnaire. Consistent with published reports, we found positive estrogen receptor status to be positively associated with age and inversely associated with parity and oral contraceptive use. Whites were more likely than blacks to have estrogen receptor-positive tumors. We examined eight nutrients and six food groups in multivariate analyses for association with estrogen receptor status. After adjusting for age, race, usual body mass index, and parity, a high percentage of calories from fat was associated with estrogen receptor-positive cancer, and a high percentage of calories from carbohydrates was associated with estrogen receptor-negative breast cancer. These findings indicate that women with breast cancer who are on diets with a high percentage of calories from fat may be more likely to develop estrogen receptor-positive cancers. RP HARLAN, LC (reprint author), NCI,DIV CANC PREVENT & CONTROL,9000 ROCKVILLE PIKE,EPN 313,BETHESDA,MD 20892, USA. RI Block, Gladys/E-3304-2010 FU NCI NIH HHS [N01-CN-45174, N01-CN-45175, N01-CN-45176] NR 0 TC 38 Z9 38 U1 0 U2 4 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 1044-3983 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 1993 VL 4 IS 1 BP 25 EP 31 DI 10.1097/00001648-199301000-00006 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA KG840 UT WOS:A1993KG84000006 PM 8420576 ER PT J AU BLAIR, A ZAHM, SH AF BLAIR, A ZAHM, SH TI PATTERNS OF PESTICIDE USE AMONG FARMERS - IMPLICATIONS FOR EPIDEMIOLOGIC RESEARCH SO EPIDEMIOLOGY LA English DT Article DE PESTICIDES; FARMERS; INTERVIEWS; PROXY RESPONDENTS; MISCLASSIFICATION; HERBICIDES; DATA COLLECTION AB Epidemiologic studies of farmers have linked pesticides with certain cancers. Information on exposures from many of these studies was obtained by interview of farmers or their next-of-kin. The reliability and validity of data on pesticide use obtained by recall, often years after the event, have been questioned. Pesticide use, however, is an integral component in most agricultural operations, and the farmers' knowledge and recall of chemicals used may be better than for many other occupations. Contrary to general belief, many farmers typically use only a few pesticides during their lifetimes and make only a few applications per year. Data from U.S. Department of Agriculture surveys indicate that herbicides are applied to wheat, corn, soybeans, and cotton and that application of insecticides to corn averages two or fewer times per year. In epidemiologic Studies at the National Cancer Institute, the proportion of farmers ever reporting lifetime use of five or more different chemicals was 7% for insecticides and 20% for herbicides. Surrogate respondents have often been used in epidemiologic studies of cancer; they are able to recall pesticide use with less detail than the farmers themselves. The pesticides reported by surrogates were the same as reported by subjects themselves, but with less frequency. Comparison of reporting by cases and controls provided no evidence of case-response (differential) bias; thus, inaccurate recall of pesticide use by subjects or surrogates would end to diminish risk estimates and dilute exposure-response gradients. RP BLAIR, A (reprint author), NCI,OCCUPAT STUDIES SECT,EXECUT PL N,ROOM 418,BETHESDA,MD 20892, USA. RI Zahm, Shelia/B-5025-2015 NR 0 TC 111 Z9 111 U1 1 U2 8 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 1044-3983 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 1993 VL 4 IS 1 BP 55 EP 62 DI 10.1097/00001648-199301000-00011 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA KG840 UT WOS:A1993KG84000011 PM 8420582 ER PT J AU PLEDGER, GW SAHLROOT, JT AF PLEDGER, GW SAHLROOT, JT TI ALTERNATIVE ANALYSES FOR ANTIEPILEPTIC DRUG TRIALS SO EPILEPSY RESEARCH LA English DT Article ID SEIZURES C1 NIH,BETHESDA,MD 20892. RP PLEDGER, GW (reprint author), RW JOHNSON PHARMACEUT RES INST,RARITAN,NJ, USA. NR 14 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 J9 EPILEPSY RES JI Epilepsy Res. PY 1993 SU 10 BP 167 EP 174 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA LY572 UT WOS:A1993LY57200015 ER PT J AU JACOBS, MP AF JACOBS, MP TI NIH EPILEPSY BRANCH TRIALS - BUDGETARY AND PRACTICAL ISSUES SO EPILEPSY RESEARCH LA English DT Article RP JACOBS, MP (reprint author), NIH,EPILEPSY BRANCH,114 FED BLDG,7550 WISCONSIN AVE,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 J9 EPILEPSY RES JI Epilepsy Res. PY 1993 SU 10 BP 239 EP 244 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA LY572 UT WOS:A1993LY57200024 ER PT S AU MAGRATH, I JAIN, V BHATIA, K AF MAGRATH, I JAIN, V BHATIA, K BE Tursz, T Pagano, JS Ablashi, DV deThe, G Lenoir, G Pearson, GR TI MOLECULAR EPIDEMIOLOGY OF BURKITTS-LYMPHOMA SO EPSTEIN-BARR VIRUS AND ASSOCIATED DISEASES SE COLLOQUE INSERM LA English DT Proceedings Paper CT Vth International Symposium: The Epstein-Barr Virus and Associated Diseases CY SEP 13-19, 1992 CL ANNECY, FRANCE SP INT ASSOC RES EPSTEIN BARR VIRUS & ASSOC DISEASES, INSERM C1 NCI,PEDIAT BRANCH,LYMPHOMA BIOL SECT,BETHESDA,MD 20892. NR 0 TC 4 Z9 4 U1 0 U2 0 PU EDITIONS INSERM PI PARIS PA 101 RUE DE TOLBIAC, 75645 PARIS, FRANCE SN 0768-3154 BN 2-7420-0008-9 J9 COLLOQ INSE PY 1993 VL 225 BP 377 EP 396 PG 20 WC Immunology; Pathology; Virology SC Immunology; Pathology; Virology GA BZ85Q UT WOS:A1993BZ85Q00054 ER PT S AU LEVINE, PH LUBIN, JH EVANS, AS AF LEVINE, PH LUBIN, JH EVANS, AS BE Tursz, T Pagano, JS Ablashi, DV deThe, G Lenoir, G Pearson, GR TI AN EPSTEIN-BARR-VIRUS (EBV) VACCINE - CLINICAL AND EPIDEMIOLOGIC CONSIDERATIONS SO EPSTEIN-BARR VIRUS AND ASSOCIATED DISEASES SE COLLOQUE INSERM LA English DT Proceedings Paper CT Vth International Symposium: The Epstein-Barr Virus and Associated Diseases CY SEP 13-19, 1992 CL ANNECY, FRANCE SP INT ASSOC RES EPSTEIN BARR VIRUS & ASSOC DISEASES, INSERM C1 NCI,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EDITIONS INSERM PI PARIS PA 101 RUE DE TOLBIAC, 75645 PARIS, FRANCE SN 0768-3154 BN 2-7420-0008-9 J9 COLLOQ INSE PY 1993 VL 225 BP 585 EP 591 PG 7 WC Immunology; Pathology; Virology SC Immunology; Pathology; Virology GA BZ85Q UT WOS:A1993BZ85Q00081 ER PT S AU HILDESHEIM, A WEST, S DOSEMECI, M DEVEYRA, E DEGUZMAN, MF JURADO, A AF HILDESHEIM, A WEST, S DOSEMECI, M DEVEYRA, E DEGUZMAN, MF JURADO, A BE Tursz, T Pagano, JS Ablashi, DV deThe, G Lenoir, G Pearson, GR TI NASOPHARYNGEAL CARCINOMA IN THE PHILIPPINES - PRELIMINARY-RESULTS FROM A CASE-CONTROL STUDY OF MULTIPLE FACTORS SO EPSTEIN-BARR VIRUS AND ASSOCIATED DISEASES SE COLLOQUE INSERM LA English DT Proceedings Paper CT Vth International Symposium: The Epstein-Barr Virus and Associated Diseases CY SEP 13-19, 1992 CL ANNECY, FRANCE SP INT ASSOC RES EPSTEIN BARR VIRUS & ASSOC DISEASES, INSERM C1 NCI,ENVIRONM EPIDEMIOL BRANCH,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EDITIONS INSERM PI PARIS PA 101 RUE DE TOLBIAC, 75645 PARIS, FRANCE SN 0768-3154 BN 2-7420-0008-9 J9 COLLOQ INSE PY 1993 VL 225 BP 743 EP 747 PG 5 WC Immunology; Pathology; Virology SC Immunology; Pathology; Virology GA BZ85Q UT WOS:A1993BZ85Q00102 ER PT S AU LEVINE, PH HSU, MM CHENG, YJ HILDESHEIM, A YANG, CS AF LEVINE, PH HSU, MM CHENG, YJ HILDESHEIM, A YANG, CS BE Tursz, T Pagano, JS Ablashi, DV deThe, G Lenoir, G Pearson, GR TI THE APPLICATION OF CURRENT TECHNOLOGY TO COLLABORATIVE INTERNATIONAL-STUDIES ON EPSTEIN-BARR-VIRUS RELATED DISEASES SO EPSTEIN-BARR VIRUS AND ASSOCIATED DISEASES SE COLLOQUE INSERM LA English DT Proceedings Paper CT Vth International Symposium: The Epstein-Barr Virus and Associated Diseases CY SEP 13-19, 1992 CL ANNECY, FRANCE SP INT ASSOC RES EPSTEIN BARR VIRUS & ASSOC DISEASES, INSERM C1 NCI,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EDITIONS INSERM PI PARIS PA 101 RUE DE TOLBIAC, 75645 PARIS, FRANCE SN 0768-3154 BN 2-7420-0008-9 J9 COLLOQ INSE PY 1993 VL 225 BP 789 EP 793 PG 5 WC Immunology; Pathology; Virology SC Immunology; Pathology; Virology GA BZ85Q UT WOS:A1993BZ85Q00108 ER PT B AU SCHAMBRA, PE AF SCHAMBRA, PE BE Cooper, RS Muna, W AdamsCampbell, L TI PROGRAMS FOR THE SUPPORT OF AFRICAN-AMERICAN COOPERATION IN THE BIOMEDICAL SCIENCES SO ETHNICITY & DISEASE, VOL 3, SUPPLEMENT LA English DT Proceedings Paper CT American/African International Collaborative Scientists Symposium CY FEB 25-28, 1992 CL VICTORIA FALLS, ZIMBABWE SP PANAFRICAN SOC CARDIOL, INT SOC HYPERTENS BLACKS C1 NIH,FOGARTY INT CTR,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ETHNICITY & DISEASE PI LAWRENCE PA PO BOX 1897, LAWRENCE, KS 66044 PY 1993 BP S24 EP S28 PG 5 WC Criminology & Penology; Public, Environmental & Occupational Health SC Criminology & Penology; Public, Environmental & Occupational Health GA BA98N UT WOS:A1993BA98N00003 ER PT J AU INOKUCHI, A KIMMELMAN, CP SNOW, JB AF INOKUCHI, A KIMMELMAN, CP SNOW, JB TI CONVERGENCE OF OLFACTORY AND NASOTRIGEMINAL INPUTS AND POSSIBLE TRIGEMINAL CONTRIBUTIONS TO OLFACTORY RESPONSES IN THE RAT THALAMUS SO EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY LA English DT Article DE TRIGEMINAL INPUT; OLFACTORY SYSTEM; CONVERGENCE; RAT THALAMUS; ELECTROPHYSIOLOGY ID MEDIODORSAL NUCLEUS; HORSERADISH-PEROXIDASE; CORTICAL PROJECTIONS; RABBIT; NEURONS; ODOR AB To elucidate the role of trigeminal input on the olfactory system, field-evoked potentials were measured following electrical stimulation of the nasociliary branch of the trigeminal nerve in the olfactory-related structures in the rat brain. Significant potential changes were recorded in the mediodorsal nucleus of the thalamus and the lateral hypothalamic area. In the mediodorsal nucleus of the thalamus, the neurons responding to olfactory bulb electrical stimulation also responded to trigeminal nerve stimulation. Single neuronal responses of mediodorsal thalamic neurons following odorant stimulation were enhanced by blockade of the trigeminal nerve with procaine. These results suggest that olfactory and trigeminal pathways converge on the same neural elements within the mediodorsal nucleus of the thalamus and that the trigeminal input may modulate olfactory input in this nucleus. C1 NEW YORK EYE & EAR INFIRM,DEPT OTOLARYNGOL HEAD & NECK SURG,NEW YORK,NY 10003. NIDOCD,BETHESDA,MD 20892. RP INOKUCHI, A (reprint author), KYUSHU UNIV,FAC MED,DEPT OTORHINOLARYNGOL,3-1-1 MAIDASHI,HIGASHI KU,FUKUOKA 812,JAPAN. NR 20 TC 16 Z9 16 U1 2 U2 2 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0937-4477 J9 EUR ARCH OTO-RHINO-L JI Eur. Arch. Oto-Rhino-Laryn. PD JAN PY 1993 VL 249 IS 8 BP 473 EP 477 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA KL189 UT WOS:A1993KL18900008 PM 8442943 ER PT J AU LINET, MS BOICE, JD AF LINET, MS BOICE, JD TI RADIATION FROM CHERNOBYL AND RISK OF CHILDHOOD LEUKEMIA SO EUROPEAN JOURNAL OF CANCER LA English DT Editorial Material C1 NCI,RADIAT EPIDEMIOL BRANCH,EPIDEMIOLOGY & BIOSTAT PROGRAM,BETHESDA,MD 20892. RP LINET, MS (reprint author), NCI,ANALYT STUDIES SECT,BIOSTAT BRANCH,BETHESDA,MD 20892, USA. NR 10 TC 4 Z9 5 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0959-8049 J9 EUR J CANCER JI Eur. J. Cancer PY 1993 VL 29A IS 1 BP 1 EP 3 DI 10.1016/0959-8049(93)90566-X PG 3 WC Oncology SC Oncology GA JY056 UT WOS:A1993JY05600001 ER PT J AU VANRIJSWIJK, REN CVITKOVIC, E WAGSTAFF, J MYERS, CE SALMON, S ARLT, W ARMAND, JP VANOOSTEROM, A DIRIX, LY CROWTHER, D POSTMUS, PE ARDIZZONI, A LOPEZ, RL AF VANRIJSWIJK, REN CVITKOVIC, E WAGSTAFF, J MYERS, CE SALMON, S ARLT, W ARMAND, JP VANOOSTEROM, A DIRIX, LY CROWTHER, D POSTMUS, PE ARDIZZONI, A LOPEZ, RL TI WORKSHOP ON SURAMIN WITH EMPHASIS ON PROSTATE-CANCER - REEVALUATION OF RESPONSE CRITERIA SO EUROPEAN JOURNAL OF CANCER LA English DT Note ID TRIAL C1 FREE UNIV AMSTERDAM HOSP,DEPT MED ONCOL,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS. OSPITAL GEN ASTURIAS,OVIEDO,SPAIN. UNIV COLOGNE,MED KLIN 2,W-5000 COLOGNE 41,GERMANY. NCI,BETHESDA,MD 20892. ARIZONA CANC CTR,TUCSON,AZ. UNIV HOSP ANTWERP,ANTWERP,BELGIUM. INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE. CHRISTIE HOSP & HOLT RADIUM INST,MANCHESTER M20 9BX,LANCS,ENGLAND. RI Arlt, Wiebke/B-6310-2009 OI Arlt, Wiebke/0000-0001-5106-9719 NR 15 TC 7 Z9 7 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0959-8049 J9 EUR J CANCER JI Eur. J. Cancer PY 1993 VL 29A IS 3 BP 298 EP 300 DI 10.1016/0959-8049(93)90370-U PG 3 WC Oncology SC Oncology GA KG841 UT WOS:A1993KG84100003 PM 7691118 ER PT J AU YANG, JC SHLASKO, E RITCHEY, JL LANDRY, JG WHITE, DE ROSENBERG, SA AF YANG, JC SHLASKO, E RITCHEY, JL LANDRY, JG WHITE, DE ROSENBERG, SA TI COMBINATION CHEMOIMMUNOTHERAPY FOR METASTATIC COLORECTAL-CANCER USING 5-FLUOROURACIL, LEUCOVORIN AND INTERLEUKIN-2 SO EUROPEAN JOURNAL OF CANCER LA English DT Article ID RANDOMIZED TRIAL; FOLINIC ACID; FLUOROURACIL; CARCINOMA; MODULATION; CALCIUM; GROWTH; TUMOR AB 25 patients with metastatic colorectal cancer were entered into a phase II trial of combination chemoimmunotherapy using a sequential regimen of 5-fluorouracil (5-FU) and leucovorin and high-dose recombinant human interleukin-2 (rIL-2). Patients initially received three cycles of chemotherapy consisting of 500 mg/m2 of intravenous leucovorin followed by 375 mg/m2 of bolus 5-FU both given daily on days 1-5 of a 21 day cycle. Ten days after the last dose of chemotherapy in cycle 3, patients began high-dose rIL-2 at 720 000 IU kg intravenously every 8 h to the maximum tolerated number of doses. After 7-10 days of recovery, this rIL-2 treatment was repeated to complete one full course of chemoimmunotherapy. There was no grade IV toxicity associated with 183 cycles of chemotherapy. Other than slight increases in the frequency of diarrhoea, stomatitis and hyperbilirubinaemia, rIL-2 toxicity was similar to that seen in patients given rIL-2 without chemotherapy. Of 23 evaluable patients, the overall response rate (partial + complete response) was 46% with 2 complete responses. Only 3 patients showed major tumour regression during the rIL-2 phase of therapy, but these 3 patients included both complete responders and the 3 most durable responses (15, 16 and 24 months). We conclude that sequential 5-FU/leucovorin and rIL-2 can be given safely without major increases in toxicity over either therapy alone, and although nearly all responses seen are largely attributable to chemotherapy, a contribution of immunotherapy to the minority of patients achieving complete or durable responses cannot be ruled out. RP YANG, JC (reprint author), NCI,SURG BRANCH,9000 ROCKVILLE PIKE,BLDG 10,ROOM 2B42,BETHESDA,MD 20892, USA. NR 13 TC 11 Z9 11 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0959-8049 J9 EUR J CANCER JI Eur. J. Cancer PY 1993 VL 29A IS 3 BP 355 EP 359 DI 10.1016/0959-8049(93)90385-S PG 5 WC Oncology SC Oncology GA KG841 UT WOS:A1993KG84100018 PM 8398334 ER PT J AU MILLER, WR HULME, MJ CHOCHUNG, YS ELTON, RA AF MILLER, WR HULME, MJ CHOCHUNG, YS ELTON, RA TI TYPES OF CYCLIC-AMP BINDING-PROTEINS IN HUMAN BREAST CANCERS SO EUROPEAN JOURNAL OF CANCER LA English DT Article ID RECEPTOR; GROWTH AB Total level and type of cyclic AMP binding proteins have been measured in 117 breast cancers. Six major molecular species of binding proteins were detected. The pattern and relative proportion of binding proteins varied between individual tumours. However, there were highly significant correlations between the expression of different binding proteins, including positive relationships between 52 and 67 kD proteins, 43 kD and both 39 and 37 kD proteins and inverse correlations between 48 and 52 kD, 37 and 67 kD proteins. The expression of three binding proteins (48, 43 and 39 kD) was also positively related to total binding whereas that of the remaining three bindings proteins (67, 52 and 37 kD) was negatively correlated with total levels. It may be that differential expression of certain types of binding protein are the underlying rationale for our previously published finding that tumours with high levels of high binding protein are associated with poor prognosis. C1 NCI,BETHESDA,MD 20892. UNIV EDINBURGH,DEPT MED STAT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND. RP MILLER, WR (reprint author), WESTERN GEN HOSP,ICRF,MED ONCOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND. NR 12 TC 38 Z9 38 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0959-8049 J9 EUR J CANCER JI Eur. J. Cancer PY 1993 VL 29A IS 7 BP 989 EP 991 DI 10.1016/S0959-8049(05)80207-2 PG 3 WC Oncology SC Oncology GA KZ290 UT WOS:A1993KZ29000013 PM 8388698 ER PT J AU PAI, LH PASTAN, I AF PAI, LH PASTAN, I TI THE USE OF IMMUNOTOXINS FOR CANCER-THERAPY SO EUROPEAN JOURNAL OF CANCER LA English DT Article ID PSEUDOMONAS EXOTOXIN; PHASE-I; CHAIN IMMUNOTOXIN; COLON CANCER; NUDE-MICE; RICIN; TRIAL; ANTIBODIES; INFUSION; DOMAINS C1 NCI,DIV CANC BIOL,MOLEC BIOL LAB,BETHESDA,MD 20892. NR 25 TC 8 Z9 8 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0959-8049 J9 EUR J CANCER JI Eur. J. Cancer PY 1993 VL 29A IS 11 BP 1606 EP 1609 DI 10.1016/0959-8049(93)90306-Z PG 4 WC Oncology SC Oncology GA LR996 UT WOS:A1993LR99600026 PM 8217369 ER PT J AU OGAWVA, K YAMAWAKI, I MATSUSITA, YI NOMURA, N KADOR, PF KINOSHITA, JH AF OGAWVA, K YAMAWAKI, I MATSUSITA, YI NOMURA, N KADOR, PF KINOSHITA, JH TI SYNTHESES OF SUBSTITUTED 2,4-DIOXO-THIENOPYRIMIDIN-1-ACETIC ACIDS AND THEIR EVALUATION AS ALDOSE REDUCTASE INHIBITORS SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article DE 2,4-DIOXO-THIENO[2,3-D],[3,2-D] AND [3,4-D]PYRIMIDIN-1-ACETIC ACIDS; ALDOSE REDUCTASE INHIBITORY ACTIVITY; SORBITOL ACCUMULATION INHIBITION ID DIABETIC COMPLICATIONS; DERIVATIVES; AGENTS AB A series of 2,4-dioxo-thieno[2,3-d], [3,2-d] and [3,4-d]pyrimidin-1-acetic acids (2) with a benzyl moiety at the N-3 position were prepared and tested in vitro for aldose reductase inhibitory activity against partially purified enzyme from rat lens. Some of these compounds were also evaluated for inhibition of sorbitol accumulation in the sciatic nerve or lens of streptozotocin-induced diabetic rats in vivo. Among the synthesized compounds, several showed potent aldose reductase inhibitory activity with IC50s in the 10(-8) M range. Particularly, the potencies of non-substituted thieno- (2a and 2aa), 5-methylthieno- (2c), 5,6-dimethylthieno-(2g), 6-isopropylthieno- (2j and 2k), 6-chlorothienopyrimidine (2q) and benzothienopyrimidine (2ac) analogs were approximately equipotent to FK-366 (1A) and Ponalrestat (1B) as references. Although most compounds were inactive in vivo, 2 compounds, 2k and 2q, possessed moderate in vivo activity. C1 NEI,BETHESDA,MD 20892. RP OGAWVA, K (reprint author), RES INST TAIHO PHARMACEUT CO LTD,KAWAUCHI CHO,TOKUSHIMA 77101,JAPAN. NR 24 TC 20 Z9 20 U1 0 U2 0 PU EDITIONS SCIENTIFIQUES ELSEVIER PI PARIS CEDEX 15 PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE SN 0223-5234 J9 EUR J MED CHEM JI Eur. J. Med. Chem. PY 1993 VL 28 IS 10 BP 769 EP 781 DI 10.1016/0223-5234(93)90112-R PG 13 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA MG348 UT WOS:A1993MG34800003 ER PT J AU CHEN, YT BAZZARRE, CH LEE, MM SIDBURY, JB COLEMAN, RA AF CHEN, YT BAZZARRE, CH LEE, MM SIDBURY, JB COLEMAN, RA TI TYPE-I GLYCOGEN-STORAGE-DISEASE - 9 YEARS OF MANAGEMENT WITH CORNSTARCH SO EUROPEAN JOURNAL OF PEDIATRICS LA English DT Article DE GLYCOGEN STORAGE DISEASE, TYPE-I; DIETARY THERAPY; UNCOOKED CORNSTARCH; CONTINUOUS GLUCOSE FEEDINGS; PHYSICAL GROWTH AND DEVELOPMENT ID UNCOOKED CORNSTARCH; PHYSICAL GROWTH; THERAPY; SYMPTOMS; CHILDREN; STARCH AB Long-term effects of cornstarch (CS) therapy on biochemical values and physical growth in children with type I glycogen storage disease (GSD I) were compared to those of children receiving continuous nocturnal nasogastric glucose feedings (CNG). Only patients who had received more than 5 years of dietary therapy (either CS or CNG) were evaluated. Six patients (five female, age 13.5 years +/- 1.3, range 11.7-16.5 years) received CS (1.75-2.5 g/kg, four times daily) and seven patients (five female, age 9.6 +/- 2.5 years, range 7.3-14.8 years) received CNG. Blood glucose, lactate, cholesterol and triglyceride levels were not significantly different between the two methods of treatment. All patients maintained linear growth rates normal for their age. The standard deviation score of height after 6.7 +/- 1.6 years (range 5-9 years) of CS treatment was -1.29 +/- 0.59 and after 8.8 +/- 2.4 years (range 7-14 years) of CNG was -1.24 +/- 0.63. These values did not differ significantly from each other or from the target height, an estimate of genetic potential for height as determined from parental heights. With the exceptions of diarrhea, increased flatulence and excess weight gain, there were no adverse effects of CS after 9 years of treatment. Our data suggests that cornstarch is a simple, effective and safe therapy for GSD I. C1 NICHHD,HUMAN GENET BRANCH,BETHESDA,MD 20892. RP CHEN, YT (reprint author), DUKE UNIV,MED CTR,DEPT PEDIAT,BOX 3028,DURHAM,NC 27710, USA. FU FDA HHS [FD-R-000401]; NCRR NIH HHS [M01-RR-30] NR 17 TC 34 Z9 35 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0340-6199 J9 EUR J PEDIATR JI Eur. J. Pediatr. PY 1993 VL 152 SU 1 BP S56 EP S59 PG 4 WC Pediatrics SC Pediatrics GA LB153 UT WOS:A1993LB15300014 PM 8319727 ER PT B AU VANDERMEEREN, A SEDDON, MB KISPERT, J HARRIS, CC GERWIN, BI AF VANDERMEEREN, A SEDDON, MB KISPERT, J HARRIS, CC GERWIN, BI BE Jarrand, MC Bignon, J Brochard, P TI LACK OF EXPRESSION OF THE RETINOBLASTOMA GENE IS NOT FREQUENTLY INVOLVED IN THE GENESIS OF HUMAN MESOTHELIOMA SO EUROPEAN RESPIRATORY REVIEW, VOL 3, REVIEW NO 11, MARCH 1993: INTERNATIONAL CONFERENCE ON MESOTHELIAL CELL AND MESOTHELIOMA: PAST, PRESENT AND FUTURE LA English DT Proceedings Paper CT International Conference on Mesothelial Cell and Mesothelioma: Past, Present and Future CY SEP 20-OCT 02, 1991 CL PARIS, FRANCE SP SOC PNEUMOL LANGUE FRANCAISE DE MESOTHELIOMA; RETINOBLASTOMA; TUMOR SUPPRESSOR GENES C1 NCI,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MUNKSGAARD PI COPENHAGEN K PA 35 NORRE SOGADE POSTBOX 2148, DK-1016 COPENHAGEN K, DENMARK PY 1993 BP 177 EP 179 PG 3 WC Respiratory System SC Respiratory System GA BA06U UT WOS:A1993BA06U00056 ER PT B AU VANDERMEEREN, A SEDDON, MB BETSHOLTZ, CA LECHNER, JF GERWIN, BI AF VANDERMEEREN, A SEDDON, MB BETSHOLTZ, CA LECHNER, JF GERWIN, BI BE Jarrand, MC Bignon, J Brochard, P TI PLATELET-DERIVED GROWTH FACTOR-A-CHAIN OVEREXPRESSION IS ASSOCIATED WITH TUMORIGENIC CONVERSION OF HUMAN MESOTHELIAL CELLS SO EUROPEAN RESPIRATORY REVIEW, VOL 3, REVIEW NO 11, MARCH 1993: INTERNATIONAL CONFERENCE ON MESOTHELIAL CELL AND MESOTHELIOMA: PAST, PRESENT AND FUTURE LA English DT Proceedings Paper CT International Conference on Mesothelial Cell and Mesothelioma: Past, Present and Future CY SEP 20-OCT 02, 1991 CL PARIS, FRANCE SP SOC PNEUMOL LANGUE FRANCAISE DE GROWTH FACTORS; HUMAN MESOTHELIAL CELL; MESOTHELIOMA; PLATELET-DERIVED GROWTH FACTOR C1 NCI,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MUNKSGAARD PI COPENHAGEN K PA 35 NORRE SOGADE POSTBOX 2148, DK-1016 COPENHAGEN K, DENMARK PY 1993 BP 180 EP 185 PG 6 WC Respiratory System SC Respiratory System GA BA06U UT WOS:A1993BA06U00057 ER PT B AU HILTON, M AF HILTON, M BE Greenfield, TK Zimmerman, R TI TENSIONS IN COMMUNITY-ACTION RESEARCH - REFLECTIONS ON THE CONFERENCE SO EXPERIENCES WITH COMMUNITY ACTION PROJECTS: NEW RESEARCH IN THE PREVENTION OF ALCOHOL & OTHER DRUG PROBLEMS SE CSAP PREVENTION MONOGRAPH LA English DT Proceedings Paper CT 2nd International Research Symposium on Experiences with Community Action Projects for the Prevention of Alcohol and Other Drug Problems CY JAN 29-FEB 02, 1992 CL SAN DIEGO, CA SP US DEPT HHS, PUBLIC HLTH SERV, CTR SUBST ABUSE PREVENT C1 NIAAA,PREVENT RES BRANCH,ROCKVILLE,MD 20857. NR 0 TC 0 Z9 0 U1 0 U2 0 PU US DEPT HHS PUBLIC HEALTH SERVCTR SUBSTANCE ABUSE PREVENTION PI ROCKVILLE PA 5600 FISHERS LANE, ROCKWALL II, ROCKVILLE, MD 20857 J9 CSAP PREVENT MONOGR PY 1993 VL 14 BP 277 EP 281 PG 5 WC Substance Abuse; Health Policy & Services SC Substance Abuse; Health Care Sciences & Services GA BA53Z UT WOS:A1993BA53Z00033 ER PT J AU KARL, M CHROUSOS, GP AF KARL, M CHROUSOS, GP TI FAMILIAL GLUCOCORTICOID RESISTANCE - AN OVERVIEW SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY LA English DT Article DE STEROID RECEPTORS; FAMILIAL GLUCOCORTICOID RESISTANCE; GLUCOCORTICOID RECEPTOR MUTATIONS ID PRIMARY CORTISOL RESISTANCE; ACTH-SECRETION; RECEPTOR C1 NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892. RP KARL, M (reprint author), CHRISTIAN ALBRECHTS UNIV KIEL,MED KLIN 1,ALLGEMEINE INNERE MED KLIN,SCHITTENHELMSTR 12,W-2300 KIEL 1,GERMANY. NR 24 TC 7 Z9 7 U1 0 U2 1 PU JOHANN AMBROSIUS BARTH VERLAG PI HEIDELBERG PA IM WEIHER 10, D-69121 HEIDELBERG, GERMANY SN 0232-7384 J9 EXP CLIN ENDOCRINOL JI Exp. Clin. Endocrinol. PY 1993 VL 101 IS 1 BP 30 EP 35 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KX426 UT WOS:A1993KX42600006 PM 8477821 ER PT J AU MONIG, H ALI, IU OLDFIELD, EH SCHULTE, HM AF MONIG, H ALI, IU OLDFIELD, EH SCHULTE, HM TI STRUCTURE OF THE POMC PROMOTER REGION IN PITUITARY AND EXTRAPITUITARY ACTH PRODUCING TUMORS SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY LA English DT Article DE POMC; CUSHINGS DISEASE; ECTOPIC ACTH SYNDROME ID CORTICOTROPIN-RELEASING FACTOR; BETA-ENDORPHIN; GENE; TRANSCRIPTION; SECRETION; GLUCOCORTICOIDS; SEQUENCE; INVIVO; CELLS; DNA AB Proopiomelanocortin (POMC) is the common precursor of a variety of important endocrine peptides including ACTH. Transcription of the POMC gene is positively regulated by CRH through cAMP-responsive regions and is under negative feedback control by glucocorticoids which exert their inhibitory effect trough negative glucocorticoid responsive elements (nGRE). In vitro studies using the rat POMC promoter suggested that binding of the glucocorticoid receptor complex to a -63 bp binding site is correlated with repression of POMC gene transcription, and that specific mutations in this region abolish this effect. Impaired negative feedback regulation, though to a different degree, is a common feature of both corticotroph tumors (Cushing's disease) and extrapituitary ACTH producing tumors. We have analyzed the upstream promoter region of POMC gene from eleven patients with Cushing's disease, four of which had Nelson's syndrome, and from one patient with an ectopic ACTH syndrome secondary to a lung carcinoid for any possible mutations in the nGRE and/or cAMP-responsive sequences. DNA was purified from tumor tissue and was used as template for polymerase chain reaction (PCR). A segment between -371 and -19 bp of the POMC transcription start site was amplified and cloned into a plasmid vector. Sequencing was performed using the dideoxy chain termination procedure. Analysis of the 5'-flanking region revealed no defect in all tumors investigated. We conclude from our results that the defective glucocorticoid repression of POMC peptides production may be more likely due to aberrancies in other components of the complex transcriptional regulatory mechanism. C1 NIH,SURG NEUROL BRANCH,BETHESDA,MD 20892. RP MONIG, H (reprint author), UNIV KIEL,MED KLIN 1,SCHITTENHELMSTR 12,W-2300 KIEL 1,GERMANY. NR 17 TC 13 Z9 14 U1 0 U2 1 PU JOHANN AMBROSIUS BARTH VERLAG PI HEIDELBERG PA IM WEIHER 10, D-69121 HEIDELBERG, GERMANY SN 0232-7384 J9 EXP CLIN ENDOCRINOL JI Exp. Clin. Endocrinol. PY 1993 VL 101 IS 1 BP 36 EP 38 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KX426 UT WOS:A1993KX42600007 PM 8386673 ER PT J AU VIVINO, MA CHINTALAGIRI, S TRUS, B DATILES, M AF VIVINO, MA CHINTALAGIRI, S TRUS, B DATILES, M TI DEVELOPMENT OF A SCHEIMPFLUG SLIT LAMP CAMERA SYSTEM FOR QUANTITATIVE DENSITOMETRIC ANALYSIS SO EYE LA English DT Article DE CATARACT; DENSITOMETRY; IMAGE PROCESSING; OPHTHALMIC INSTRUMENTATION; SCHEIMPFLUG ID CATARACT; CLASSIFICATION; DEVICE; LENS AB We have developed a computerised video system for accurate quantification of lens opacities from Scheimpflug images. Using a modified Zeiss Scheimpflug camera and Macintosh computer, the system software can warn of improper exposure and can provide immediate results of cataract progression on individual patients. These results are obtained from a novel technique which automatically divides the lens into anatomical regions and computes regional densities in the standard optical density unit. Because of the system's speed, the operator can properly capture and analyse a cataract in seconds, compare results with past patient records and give feedback to the patient on the results of the analysis, The system provides the appropriate data integrity and formats for documenting and monitoring lens opacities. Such a system will be useful in longitudinal studies of cataracts (i.e. for natural history and anti-cataract drug trials). C1 US DEPT HLTH & HUMAN SERV,NEI,OPHTHALM GENET & CLIN SERV BRANCH,CATARACT & CORNEA SECT,BETHESDA,MD 20892. US DEPT HLTH & HUMAN SERV,NEI,DIV COMP RES & TECHNOL,COMP SYST LAB,BETHESDA,MD 20892. OI Datiles, Manuel III B./0000-0003-4660-1664 NR 28 TC 20 Z9 20 U1 0 U2 0 PU ROYAL COLL OPHTHALMOLOGISTS PI LONDON PA 17 CORNWALL TERRACE, LONDON, ENGLAND NW1 4QW SN 0950-222X J9 EYE JI Eye PY 1993 VL 7 BP 791 EP 798 PN 6 PG 8 WC Ophthalmology SC Ophthalmology GA MN334 UT WOS:A1993MN33400020 PM 8119436 ER PT B AU KELAGHAN, J AF KELAGHAN, J BE Senanayake, P Kleinman, RL TI ORAL-CONTRACEPTIVES AND ACQUISITION OF HIV-INFECTION SO FAMILY PLANNING: MEETING CHALLENGES: PROMOTING CHOICES LA English DT Proceedings Paper CT IPPF Family Planning Congress - Family Planning, Meeting Challenges: Promoting Choices CY OCT, 1992 CL NEW DELHI, INDIA SP INT PLANNED PARENTHOOD FEDERAT, FAMILY PLANNING ASSOC INDIA C1 NICHHD,CTR POPULAT RES,CONTRACEPT & REPROD EVALUAT BRANCH,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PARTHENON PUBLISHING GROUP LTD PI LANCASTER PA CASTERTON HALL, CARNFORTH, LANCASTER, ENGLAND LA6 2LA BN 1-85070-514-3 PY 1993 BP 533 EP 539 PG 7 WC Family Studies SC Family Studies GA BZ97R UT WOS:A1993BZ97R00059 ER PT J AU BASU, R GHOSH, AN DASGUPTA, S GHOSH, A AF BASU, R GHOSH, AN DASGUPTA, S GHOSH, A TI BIOPHYSICAL CHARACTERIZATION OF VIBRIO E1 TOR TYPING PHAGE-E5 SO FEMS MICROBIOLOGY LETTERS LA English DT Article DE VIBRIO-CHOLERAE; TYPING PHAGE; RESTRICTION MAP ID BACTERIOPHAGE DNA; CHOLERAE AB Vibrio cholerae typing phage e5, which can lyse only the El Tor strains of V cholerae, was characterized. The phage had a polyhedral head 51 nm in diameter and a short tail 13 nm in length. It contained 13 structural polypeptides, with the molecular mass of the major component being 50 kDa. Phage chromosome comprised a 38.5-kb linear double-stranded DNA molecule with unique termini, as determined by restriction fragment analysis and electron microscopy, and had a G+C content of 35.5%. A physical map was constructed with the restriction endonucleases HaeII and HpaII. Adsorption of the phage to its host followed a biphasic kinetics and its intracellular growth was characterized by a latent period of 15 min and a burst size of 100 particles per infected cell. The phage was found to be moderately thermotolerant. C1 INST MICROBIAL TECHNOL,SECTOR 39-A,CHANDIGARH,INDIA. INDIAN INST CHEM BIOL,CALCUTTA 700032,W BENGAL,INDIA. UNIV WISCONSIN,INST MOLEC VIROL,MADISON,WI 53706. NCI,BIOCHEM LAB,BETHESDA,MD 20892. NR 22 TC 8 Z9 8 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1097 J9 FEMS MICROBIOL LETT JI FEMS Microbiol. Lett. PD JAN 1 PY 1993 VL 106 IS 1 BP 9 EP 16 DI 10.1016/0378-1097(93)90049-8 PG 8 WC Microbiology SC Microbiology GA KH858 UT WOS:A1993KH85800002 PM 8095039 ER PT J AU WESTERGAARD, GC SUOMI, SJ AF WESTERGAARD, GC SUOMI, SJ TI HAND PREFERENCE IN THE USE OF NUT-CRACKING TOOLS BY TUFTED CAPUCHIN MONKEYS (CEBUS-APELLA) SO FOLIA PRIMATOLOGICA LA English DT Note DE CAPUCHIN MONKEY; CEBUS APELLA; HAND PREFERENCE; LATERALITY; TOOL USE ID HANDEDNESS; CHIMPANZEES; MANUFACTURE RP WESTERGAARD, GC (reprint author), NICHHD,COMPARAT ETHOL LAB,POB 529,POOLESVILLE,MD 20837, USA. NR 16 TC 30 Z9 30 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0015-5713 J9 FOLIA PRIMATOL JI Folia Primatol. PY 1993 VL 61 IS 1 BP 38 EP 42 DI 10.1159/000156726 PG 5 WC Zoology SC Zoology GA NB752 UT WOS:A1993NB75200005 PM 8144110 ER PT B AU WEISS, PJ AF WEISS, PJ BE Coyle, K TI SERIALS SO FORMAT INTEGRATION AND ITS EFFECT ON CATALOGING, TRAINING, AND SYSTEMS SE ALCTS PAPERS ON LIBRARY TECHNICAL SERVICES AND COLLECTIONS LA English DT Proceedings Paper CT ALCTS Preconference on Implementing USMARC Format Integration, before American-Library-Association Annual Conference CY JUN 26, 1992 CL SAN FRANCISCO, CA SP ASSOC LIB COLLECT & TECH SERV, LIB & INFORMAT TECHNOL ASSOC, AMER LIB ASSOC, REFERENCE & ADULT SERV DIV C1 NATL LIB MED,OFF CHIEF,DIV TECH SERV,BETHESDA,MD 20209. NR 0 TC 1 Z9 1 U1 2 U2 2 PU AMER LIBRARY ASSOC PI CHICAGO PA 50 E. HURON ST., CHICAGO, IL 60611 BN 0-8389-3432-3 J9 ALCTS P LIB TECH SER PY 1993 BP 47 EP 62 PG 16 WC Information Science & Library Science SC Information Science & Library Science GA BA36Q UT WOS:A1993BA36Q00005 ER PT J AU KUZUYA, M KUZUYA, F AF KUZUYA, M KUZUYA, F TI PROBUCOL AS AN ANTIOXIDANT AND ANTIATHEROGENIC DRUG SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Review DE PROBUCOL; ATHEROSCLEROSIS; ANTIOXIDANT; OXIDIZED LOW-DENSITY LIPOPROTEIN; DRUG THERAPY; FREE RADICALS ID LOW-DENSITY-LIPOPROTEIN; CULTURED ENDOTHELIAL-CELLS; CHOLESTERYL ESTER TRANSFER; SMOOTH-MUSCLE CELLS; HYPERCHOLESTEROLEMIC WATANABE RABBITS; HERITABLE HYPERLIPIDEMIC RABBITS; ENHANCED MACROPHAGE DEGRADATION; MURINE PERITONEAL-MACROPHAGES; ISCHEMIC HEART-DISEASE; FREE-RADICAL OXIDATION AB Recently, interest has increased in the hypothesis that low-density lipoprotein (LDL) modified by oxidation may lead to the initiation and to the development of atherosclerosis. In vitro studies of cellular interactions with LDL have revealed that various cells, including endothelial cells and smooth muscles cells, can oxidize LDL. The biochemical changes in LDL may further enhance its atherogenic potential. In addition to these in vitro studies. there is in vivo evidence for oxidized LDL in atherosclerotic lesions and for circulating antibodies against oxidized LDL. Probucol, 4,4'-(isopropylidenedithio)bis(2,6-di-tert-butylphenol), is a widely used cholesterol-lowering drug. Recently, there has been accumulating evidence for other mechanisms of probucol's antiatherogenic effects apart from cholesterol-lowering action. Attention has especially focused on probucol's antioxidant action in the mechanism of antiatherogenesis. In the present article, we will summarize the antiatherogenic and antioxidant actions of probucol. C1 NAGOYA UNIV, SCH MED, DEPT GERIATR, SHOWA KU, NAGOYA, AICHI 466, JAPAN. RP NIA, GERONTOL RES CTR, CARDIOVASC SCI LAB, MEMBRANE BIOL SECT, 4940 EASTERN AVE, BALTIMORE, MD 21224 USA. RI Kuzuya, Masafumi/I-1583-2012 NR 112 TC 79 Z9 83 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD JAN PY 1993 VL 14 IS 1 BP 67 EP 77 DI 10.1016/0891-5849(93)90510-2 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA KF442 UT WOS:A1993KF44200008 PM 8454225 ER PT J AU RESZKA, K BILSKI, P SIK, RH CHIGNELL, CF AF RESZKA, K BILSKI, P SIK, RH CHIGNELL, CF TI PHOTOSENSITIZED GENERATION OF SUPEROXIDE RADICAL IN APROTIC-SOLVENTS - AN EPR AND SPIN-TRAPPING STUDY SO FREE RADICAL RESEARCH COMMUNICATIONS LA English DT Article DE SUPEROXIDE RADICAL; PHOTOSENSITIZATION; APROTIC SOLVENT; BENZENE; TOLUENE; ACETONE; CYCLOHEXANE; N-HEPTANE; SPIN TRAPPING; 5,5-DIMETHYL-1-PYRROLINE N-OXIDE ID PHOTOLYSIS; RESONANCE; HYDROPEROXIDE; SYSTEMS AB The UV or visible irradiation of pigments such as curcumin, anthralin, benzanthrone, 1,8-dihydroxyanthraquinone, and rose bengal- or eosine-complexes with cationic surfactants in aerated aprotic solvents, such as benzene, toluene, acetone, n-heptane, cyclohexane, in the presence of 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) generates EPR spectra with hyperfine splitting constants (hfsc's) a(N) = 12.75 G, a(H)beta = 10.50 G, a(H)gamma = 1.26 G in toluene, 12.83 G, 10.64 G, 1.24 G in benzene, 12.75 G, 10. 19 G, 1.35 G in acetone and 12.54 G, 10.46 G, 1.38 G in n-heptane and cyclohexane. These spectra are similar to those observed when DMPO reacts with 18-crown-6 ether-solubilized KO2 in the respective solvents and suggests that the photoinduced EPR spectra can be safely assigned to the DMPO/superoxide radical adduct (1). A correlation between the hfsc's of 1 and solvent parameters, the solvent acceptor number AN and the Kosower Z value, has been evaluated in terms of its usefulness for the identification of the DMPO/superoxide adduct in organic media. RP RESZKA, K (reprint author), NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709, USA. NR 24 TC 14 Z9 14 U1 0 U2 2 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 8755-0199 J9 FREE RADICAL RES COM JI Free Radic. Res. Commun. PY 1993 VL 19 SU 1 BP S33 EP S44 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA MG869 UT WOS:A1993MG86900005 PM 8282230 ER PT J AU RIESZ, P KONDO, T CARMICHAEL, AJ AF RIESZ, P KONDO, T CARMICHAEL, AJ TI SONOCHEMISTRY OF ACETONE AND ACETONITRILE IN AQUEOUS-SOLUTIONS - A SPIN-TRAPPING STUDY SO FREE RADICAL RESEARCH COMMUNICATIONS LA English DT Article DE SONOCHEMISTRY; SPIN TRAPPING; ELECTRON SPIN RESONANCE; ACOUSTIC CAVITATION; ACETONE; ACETONITRILE ID ISOTOPE-EXCHANGE-REACTIONS; THERMAL-DECOMPOSITION; HYDROXYL RADICALS; WATER MIXTURES; ULTRASOUND; SONOLYSIS; VOLATILE; OH AB The 50 kHz sonolysis of argon-saturated water-acetone and water-acetonitrile mixtures was studied by EPR and spin trapping with 3,5-dibromo-4-nitrosobenzenesulfonate over a wide range of solvent composition. For both systems a single maximum was observed for the spin adduct yield of methyl radicals and of the radicals formed by H-abstraction from acetone and acetonitrile. These results combined with previous studies of water-methanol and water-ethanol mixtures indicate that the greater the vapor pressure of the volatile organic component, the lower the concentration of organic solute at which the maximum radical yield occurs. Methyl radicals from acetone are formed by C-C bond scission in the collapsing argon bubbles. For acetonitrile, C-H bond scission at high temperature is followed by H-addition to the triple bond and the decomposition of this intermediate radical to form methyl radicals. Since Anbar has shown (Science 161, 1343, 1961) that sonoluminescence and acoustic cavitation occur during the impact of liquid water on water with linear velocities similar to those of collapsing ocean waves, the sonochemistry of nitriles is of interest to chemical evolution studies. C1 KOBE UNIV,SCH MED,DEPT RADIAT BIOPHYS,CHUO KU,KOBE 650,JAPAN. ARMED FORCES RADIOBIOL RES INST,DEPT RADIAT BIOPHYS,BETHESDA,MD 20889. RP RIESZ, P (reprint author), NCI,RADIAT ONCOL BRANCH,BLDG 10,RM B1B50,BETHESDA,MD 20892, USA. NR 26 TC 16 Z9 16 U1 1 U2 7 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 8755-0199 J9 FREE RADICAL RES COM JI Free Radic. Res. Commun. PY 1993 VL 19 SU 1 BP S45 EP S53 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA MG869 UT WOS:A1993MG86900006 PM 8282231 ER PT J AU KRISHNA, MC SAMUNI, A AF KRISHNA, MC SAMUNI, A TI THE EFFECT OF OXYGEN AT PHYSIOLOGICAL LEVELS ON THE DETECTION OF FREE-RADICAL INTERMEDIATES BY ELECTRON-PARAMAGNETIC-RESONANCE SO FREE RADICAL RESEARCH COMMUNICATIONS LA English DT Article DE DMPO, 5,5-DIMETHYL-1-PYRROLINE-N-OXIDE; EPR, ELECTRON PARAMAGNETIC RESONANCE; TEMPO, 2,2,6,6-TETRAMETHYL-PIPERIDINOXYL; TEMPONE, 4-OXI-2,2,6,6-TETRAMETHYL-PIPERIDINOXY; TEMPOL, 4-HYDROXY-2,2,6,6-TETRAMETHYL-PIPERIDINOXYL ID SPIN-RESONANCE; OXIMETRY; LABEL; SPECTROSCOPY; NEUTROPHILS; MEMBRANES AB It is well known that oxygen enhances the relaxation of free radical EPR probes through spin lattice and Heisenberg spin-spin interactions with consequent effect on the line height and width. The two relaxation processes have opposing effects on the signal heights and depend on the concentration of oxygen, the incident microwave power, and the presence of other paramagnetic species. During EPR studies of chemical, biochemical, and cellular processes involving free radicals, molecular oxygen has significant magnetic influence on the EPR signal intensity of the free radical species under investigation in addition to affecting the rates of production of the primary species and the stability of the spin adduct nitroxides. These effects are often overlooked and can cause artifacts and lead to erroneous interpretation. In the present study, the effects of oxygen and ferricyanide on the EPR signal height of stable and persistent spin adduct nitroxides at commonly employed microwave powers were examined. The results show that under commonly adopted EPR spectrometer instrumental conditions, artifactual changes in the EPR signal of spin adducts occur and the best way to avoid them is by keeping the oxygen level constant using a gas-permeable cell. C1 HEBREW UNIV JERUSALEM,SCH MED,IL-91010 JERUSALEM,ISRAEL. RP KRISHNA, MC (reprint author), NCI,DIV CANC TREATMENT,RADIAT ONCOL BRANCH,CLIN ONCOL PROGRAM,ROOM B3 B69,BLDG 10,BETHESDA,MD 20892, USA. NR 13 TC 9 Z9 9 U1 0 U2 3 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 8755-0199 J9 FREE RADICAL RES COM JI Free Radic. Res. Commun. PY 1993 VL 18 IS 4 BP 239 EP 247 DI 10.3109/10715769309145873 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA LN479 UT WOS:A1993LN47900006 PM 8396553 ER PT B AU ROBEY, PG YOUNG, MF KERR, JM JUNDT, G SCHULZ, A RIFAS, L HALSTEAD, L CHENG, SL AVIOLI, LV AF ROBEY, PG YOUNG, MF KERR, JM JUNDT, G SCHULZ, A RIFAS, L HALSTEAD, L CHENG, SL AVIOLI, LV BE Novak, JF McMaster, JH TI COMPARATIVE BONE-MATRIX BIOCHEMISTRY - NORMAL AND TRANSFORMED-CELLS SO FRONTIERS OF OSTEOSARCOMA RESEARCH: INTERDISCIPLINARY SURVEY OF CLINICAL AND RESEARCH ADVANCES LA English DT Proceedings Paper CT 1st International Meeting on Interdisciplinary Research in Osteosarcoma CY OCT 16-18, 1991 CL PITTSBURGH, PA SP ALLEGHENY GEN HOSP, ALLEGHENY SINGER RES INST, DEPUY, H J HEINZ CO FDN, KRISTIN LEE MCMASTER MEM FUND, ORTHO BIOTECH, PPG IND FDN, SANDOZ PHARM CORP, SMITH & NEPHEW RICHARDS INC, SMITHKLINE BEECHAM, STUART MED INC, ROBERT & MARY WEISBROD FDN C1 NIH,BETHESDA,MD 20892. NR 0 TC 3 Z9 3 U1 0 U2 1 PU HOGREFE & HUBER PUBLISHERS PI TORONTO PA 12 BRUCE PARK AVE, TORONTO ON M4P 2S3, CANADA BN 0-88937-113-X PY 1993 BP 205 EP 214 PG 10 WC Anatomy & Morphology; Biochemistry & Molecular Biology; Oncology; Endocrinology & Metabolism; Pathology SC Anatomy & Morphology; Biochemistry & Molecular Biology; Oncology; Endocrinology & Metabolism; Pathology GA BZ52E UT WOS:A1993BZ52E00025 ER PT B AU POMPETTI, F CARBONE, M AF POMPETTI, F CARBONE, M BE Novak, JF McMaster, JH TI ONCOGENE ALTERATIONS IN GIANT-CELL TUMORS AND CHONDROSARCOMAS SO FRONTIERS OF OSTEOSARCOMA RESEARCH: INTERDISCIPLINARY SURVEY OF CLINICAL AND RESEARCH ADVANCES LA English DT Proceedings Paper CT 1st International Meeting on Interdisciplinary Research in Osteosarcoma CY OCT 16-18, 1991 CL PITTSBURGH, PA SP ALLEGHENY GEN HOSP, ALLEGHENY SINGER RES INST, DEPUY, H J HEINZ CO FDN, KRISTIN LEE MCMASTER MEM FUND, ORTHO BIOTECH, PPG IND FDN, SANDOZ PHARM CORP, SMITH & NEPHEW RICHARDS INC, SMITHKLINE BEECHAM, STUART MED INC, ROBERT & MARY WEISBROD FDN C1 NIH,VIRUSES & CELLULAR BIOL SECT,BETHESDA,MD 20892. NR 0 TC 1 Z9 1 U1 0 U2 0 PU HOGREFE & HUBER PUBLISHERS PI TORONTO PA 12 BRUCE PARK AVE, TORONTO ON M4P 2S3, CANADA BN 0-88937-113-X PY 1993 BP 443 EP 446 PG 4 WC Anatomy & Morphology; Biochemistry & Molecular Biology; Oncology; Endocrinology & Metabolism; Pathology SC Anatomy & Morphology; Biochemistry & Molecular Biology; Oncology; Endocrinology & Metabolism; Pathology GA BZ52E UT WOS:A1993BZ52E00059 ER PT J AU CHAPIN, RE GULATI, DK FAIL, PA HOPE, E RUSSELL, SR HEINDEL, JJ GEORGE, JD GRIZZLE, TB TEAGUE, JL AF CHAPIN, RE GULATI, DK FAIL, PA HOPE, E RUSSELL, SR HEINDEL, JJ GEORGE, JD GRIZZLE, TB TEAGUE, JL TI THE EFFECTS OF FEED RESTRICTION ON REPRODUCTIVE FUNCTION IN SWISS CD-1 MICE SO FUNDAMENTAL AND APPLIED TOXICOLOGY LA English DT Article ID PITUITARY-TESTICULAR FUNCTION; DIETARY RESTRICTION; RATS; STARVATION C1 ENVIRONM HLTH RES & TESTING INC,LEXINGTON,KY 40503. ANALYT SCI CORP,DURHAM,NC 27713. RES TRIANGLE INST,DIV CHEM & LIFE SCI,RES TRIANGLE PK,NC 27709. RP CHAPIN, RE (reprint author), NIEHS,NATL TOXICOL PROGRAM,DEV & REPROD TOXICOL GRP,POB 12233,RES TRIANGLE PK,NC 27709, USA. OI Chapin, Robert/0000-0002-5997-1261 FU NIEHS NIH HHS [N01-ES-65142, N01-ES-65141] NR 21 TC 43 Z9 43 U1 1 U2 2 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0272-0590 J9 FUND APPL TOXICOL JI Fundam. Appl. Toxicol. PD JAN PY 1993 VL 20 IS 1 BP 15 EP 22 DI 10.1006/faat.1993.1002 PG 8 WC Toxicology SC Toxicology GA KJ572 UT WOS:A1993KJ57200002 PM 8432424 ER PT J AU CHAPIN, RE GULATI, DK BARNES, LH TEAGUE, JL AF CHAPIN, RE GULATI, DK BARNES, LH TEAGUE, JL TI THE EFFECTS OF FEED RESTRICTION ON REPRODUCTIVE FUNCTION IN SPRAGUE-DAWLEY RATS SO FUNDAMENTAL AND APPLIED TOXICOLOGY LA English DT Article ID FOOD RESTRICTION; GONADOTROPIN-SECRETION; TESTICULAR FUNCTION; ESTROUS-CYCLE; FEMALE RAT C1 ENVIRONM HLTH RES & TESTING INC,LEXINGTON,KY 40503. ANALYT SCI CORP,DURHAM,NC 27713. RP CHAPIN, RE (reprint author), NIEHS,NATL TOXICOL PROGRAM,DEV & REPROD TOXICOL GRP,POB 12233,RES TRIANGLE PK,NC 27709, USA. OI Chapin, Robert/0000-0002-5997-1261 FU NIEHS NIH HHS [N01-ES-65142] NR 23 TC 73 Z9 74 U1 0 U2 1 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0272-0590 J9 FUND APPL TOXICOL JI Fundam. Appl. Toxicol. PD JAN PY 1993 VL 20 IS 1 BP 23 EP 29 DI 10.1006/faat.1993.1003 PG 7 WC Toxicology SC Toxicology GA KJ572 UT WOS:A1993KJ57200003 PM 8432425 ER PT J AU PORTIER, C TRITSCHER, A KOHN, M SEWALL, C CLARK, G EDLER, L HOEL, D LUCIER, G AF PORTIER, C TRITSCHER, A KOHN, M SEWALL, C CLARK, G EDLER, L HOEL, D LUCIER, G TI LIGAND RECEPTOR-BINDING FOR 2,3,7,8-TCDD - IMPLICATIONS FOR RISK ASSESSMENT SO FUNDAMENTAL AND APPLIED TOXICOLOGY LA English DT Article ID EPIDERMAL GROWTH-FACTOR; RAT-LIVER MICROSOMES; AH-RECEPTOR; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; DIOXIN; CARCINOGENESIS; MODEL; PHARMACOKINETICS; INCREASES; BIPHENYLS C1 GERMAN CANC RES CTR,W-6900 HEIDELBERG 1,GERMANY. RP PORTIER, C (reprint author), NIEHS,RES TRIANGLE PK,NC 27709, USA. RI Portier, Christopher/A-3160-2010 OI Portier, Christopher/0000-0002-0954-0279 NR 55 TC 69 Z9 70 U1 0 U2 1 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0272-0590 J9 FUND APPL TOXICOL JI Fundam. Appl. Toxicol. PD JAN PY 1993 VL 20 IS 1 BP 48 EP 56 DI 10.1006/faat.1993.1006 PG 9 WC Toxicology SC Toxicology GA KJ572 UT WOS:A1993KJ57200006 PM 8381755 ER PT J AU HAASCH, ML QUARDOKUS, EM SUTHERLAND, LA GOODRICH, MS LECH, JJ AF HAASCH, ML QUARDOKUS, EM SUTHERLAND, LA GOODRICH, MS LECH, JJ TI HEPATIC CYP1A1 INDUCTION IN RAINBOW-TROUT BY CONTINUOUS FLOWTHROUGH EXPOSURE TO BETA-NAPHTHOFLAVONE SO FUNDAMENTAL AND APPLIED TOXICOLOGY LA English DT Article ID HYDROCARBON BENZOPYRENE HYDROXYLASE; MICROSOMAL MONOOXYGENASE ACTIVITY; FUNCTION OXYGENASE ENZYMES; MESSENGER-RNA LEVELS; POLYCHLORINATED-BIPHENYLS; STENOTOMUS-CHRYSOPS; SALMO-GAIRDNERI; FISH; CYTOCHROME-P-450; LIVER C1 UNIV WISCONSIN,NIEHS,CTR MARINE & FRESHWATER BIOMED RES CORE,MILWAUKEE,WI 53204. RP HAASCH, ML (reprint author), MED COLL WISCONSIN,DEPT PHARMACOL & TOXICOL,MILWAUKEE,WI 53226, USA. FU NIEHS NIH HHS [ES01080, ES04184] NR 43 TC 87 Z9 87 U1 1 U2 7 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0272-0590 J9 FUND APPL TOXICOL JI Fundam. Appl. Toxicol. PD JAN PY 1993 VL 20 IS 1 BP 72 EP 82 DI 10.1006/faat.1993.1009 PG 11 WC Toxicology SC Toxicology GA KJ572 UT WOS:A1993KJ57200009 PM 8432429 ER PT J AU YUAN, JH DIETER, MP BUCHER, JR JAMESON, CW AF YUAN, JH DIETER, MP BUCHER, JR JAMESON, CW TI APPLICATION OF MICROENCAPSULATION FOR TOXICOLOGY STUDIES .3. BIOAVAILABILITY OF MICROENCAPSULATED CINNAMALDEHYDE SO FUNDAMENTAL AND APPLIED TOXICOLOGY LA English DT Article ID CINNAMYL ALCOHOL; HIPPURIC ACID; TRICHLOROETHYLENE; CHROMATOGRAPHY; FRAGRANCE; TOXICITY; URINE; RATS RP YUAN, JH (reprint author), NIEHS,POB 12233,RES TRIANGLE PK,NC 27709, USA. NR 23 TC 13 Z9 13 U1 1 U2 9 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0272-0590 J9 FUND APPL TOXICOL JI Fundam. Appl. Toxicol. PD JAN PY 1993 VL 20 IS 1 BP 83 EP 87 DI 10.1006/faat.1993.1010 PG 5 WC Toxicology SC Toxicology GA KJ572 UT WOS:A1993KJ57200010 PM 8432430 ER PT B AU JENSEN, RT AF JENSEN, RT BE Walsh, JH TI GASTRINOMA AS A MODEL FOR PROLONGED HYPERGASTRINEMIA IN THE HUMAN SO GASTRIN LA English DT Proceedings Paper CT MEETING ON GASTRIN CY FEB 09-12, 1992 CL DANA POINT, CA SP ASTRA HASSLE, GLAXO, SANDOZ PHARM US, MERCK SHARP & DOHME RES LABS, MARION MERRELL DOW, BYK GULDEN, CASCAN, SANDOZ GERMANY, ASTRA CHEM, DAIICHI PHARM RP JENSEN, RT (reprint author), NIDDKD,DIGEST DIS BRANCH,BLDG 10,ROOM 9C-103,BETHESDA,MD 20892, USA. NR 0 TC 48 Z9 48 U1 0 U2 0 PU RAVEN PRESS PI NEW YORK PA NEW YORK BN 0-7817-0060-4 PY 1993 BP 373 EP 393 PG 21 WC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Physiology SC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Physiology GA BY42H UT WOS:A1993BY42H00029 ER PT J AU GOLDIN, LR GERSHON, ES AF GOLDIN, LR GERSHON, ES TI LINKAGE OF ALZHEIMERS-DISEASE TO CHROMOSOME-21 AND CHROMOSOME-19 MARKERS - EFFECT OF AGE-OF-ONSET ASSUMPTIONS SO GENETIC EPIDEMIOLOGY LA English DT Article; Proceedings Paper CT Genetic Analysis Workshop 8: Issues in the Analysis of Complex Diseases and Their Risk Factors ( GAW8 ) CY NOV 08-10, 1992 CL WATSONVILLE, CA SP NIH, SANDOZ PHARM DE AGE OF ONSET; GENETIC HETEROGENEITY; LINKAGE ANALYSIS; ALZHEIMERS DISEASE ID GENETIC-LINKAGE AB Age of onset heterogeneity in Alzheimer's disease families was modelled by allowing for different liability classes for affected individuals according to their age of onset when calculating lod scores to chromosome 21 and chromosome 19 markers. Linkage to chromosome 21 was supported in the Boston data set, and the method of age correction did not greatly change the lod scores when only affected individuals were analyzed. The location of a gene on chromosome 19 for late age of onset illness was affected by the assumptions about early onset individuals. (C) 1993 Wiley-Liss, Inc.* RP GOLDIN, LR (reprint author), NIMH,CLIN NEUROGENET BRANCH,9000 ROCKVILLE PIKE,BLDG 10 3N218,BETHESDA,MD 20892, USA. NR 6 TC 4 Z9 4 U1 1 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PY 1993 VL 10 IS 6 BP 449 EP 454 DI 10.1002/gepi.1370100620 PG 6 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA MM366 UT WOS:A1993MM36600018 PM 8314042 ER PT J AU REED, T CARMELLI, D CHRISTIAN, JC SELBY, JV FABSITZ, RR AF REED, T CARMELLI, D CHRISTIAN, JC SELBY, JV FABSITZ, RR TI THE NHLBI MALE VETERAN TWIN STUDY DATA SO GENETIC EPIDEMIOLOGY LA English DT Article; Proceedings Paper CT Genetic Analysis Workshop 8: Issues in the Analysis of Complex Diseases and Their Risk Factors ( GAW8 ) CY NOV 08-10, 1992 CL WATSONVILLE, CA SP NIH, SANDOZ PHARM DE TWINS; CORONARY HEART DISEASE ID BLOOD-INSTITUTE TWIN; CHOLESTEROL AB The National Heart, Lung and Blood Institute (NHLBI) twin study is a collaborative, longitudinal study of the role of genetic risk factors on subsequent cardiovascular disease processes in 514 pairs of white, male World War II and Korean veteran twins born between 1917 and 1927. This paper describes the sampling procedures and zygosity determination at the initial examination, participation by the cohort members at later examinations, and a summary of the variables provided for Genetic Analysis Workshop 8 (GAW8). (C) 1993 Wiley-Liss, Inc. C1 SRI INT,HLTH SCI PROGRAM,MENLO PK,CA 94025. KAISER PERMANENTE MED CARE PROGRAM,DIV RES,OAKLAND,CA. NHLBI,CLIN & GENET EPIDEMIOL BRANCH,BETHESDA,MD 20892. RP REED, T (reprint author), INDIANA UNIV,SCH MED,DEPT MED & MOLEC GENET,975 W WALNUT ST,INDIANAPOLIS,IN 46202, USA. NR 10 TC 16 Z9 16 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PY 1993 VL 10 IS 6 BP 513 EP 517 DI 10.1002/gepi.1370100630 PG 5 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA MM366 UT WOS:A1993MM36600028 PM 8314052 ER PT J AU HARRIS, EL FALK, RT GOLDSTEIN, AM PARK, LP AF HARRIS, EL FALK, RT GOLDSTEIN, AM PARK, LP TI CLUSTERING OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS IN PREMENOPAUSAL AND POSTMENOPAUSAL FEMALE TWINS SO GENETIC EPIDEMIOLOGY LA English DT Article; Proceedings Paper CT Genetic Analysis Workshop 8: Issues in the Analysis of Complex Diseases and Their Risk Factors ( GAW8 ) CY NOV 08-10, 1992 CL WATSONVILLE, CA SP NIH, SANDOZ PHARM DE HIGH DENSITY LIPOPROTEIN CHOLESTEROL; FAMILIAL CLUSTERING; TWINS AB Previous family and twin studies indicate that genetic variation makes an important contribution to individual variation in high density lipoprotein cholesterol (HDL) levels, even after adjustment for covariates (such as obesity and alcohol consumption) that also cluster in families. However, most studies assume that genetic mechanisms affecting variation in HDL level are the same in all subgroups of the population (e.g., men versus women, by age). Using data from the Kaiser-Permanente Women Twins Study, we found different patterns of clustering for monozygotic (MZ) and dizygotic (DZ) twins depending on menopausal status. Premenopausal MZ twins were more similar than postmenopausal MZ twins (r(i) = 0.79 and r(i) = 0.61, respectively, after adjustment for age, alcohol consumption, smoking status, degree of obesity, and leisure-time exercise); premenopausal and postmenopausal DZ twins were alike to the same extent (r(i) = 0.31 and r(i) = 0.32, respectively, adjusted as above). These data suggest that either postmenopausal MZ twins have a greater degree of shared environment than postmenopausal DZ twins (e.g., postmenopausal female hormone use) or that genetic mechanisms that affect individual variation in HDL level differ in pre- and postmenopausal women. Data were not available on postmenopausal female hormone use. If genetic mechanisms that influence variation in HDL levels differ between pre- and postmenopausal women, genetic epidemiologic methods that assume that genetic and environmental sources of variation are the same for all groups of individuals may lead to false conclusions. (C) 1993 Wiley-Liss, Inc. C1 JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21218. NCI,ENVIRONM EPIDEMIOL BRANCH,BETHESDA,MD 20892. NR 6 TC 2 Z9 2 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PY 1993 VL 10 IS 6 BP 563 EP 567 DI 10.1002/gepi.1370100639 PG 5 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA MM366 UT WOS:A1993MM36600037 PM 8314061 ER PT J AU AMOS, CI LAING, AE AF AMOS, CI LAING, AE TI A COMPARISON OF UNIVARIATE AND MULTIVARIATE TESTS FOR GENETIC-LINKAGE SO GENETIC EPIDEMIOLOGY LA English DT Article; Proceedings Paper CT Genetic Analysis Workshop 8: Issues in the Analysis of Complex Diseases and Their Risk Factors ( GAW8 ) CY NOV 08-10, 1992 CL WATSONVILLE, CA SP NIH, SANDOZ PHARM DE GENETIC LINKAGE; MULTIVARIATE ANALYSIS; SEGREGATION ANALYSIS; SERUM LIPIDS; LIKELIHOOD AB A variety of robust and model-dependent genetic linkage methods were applied to log transformed lipid levels from a large pedigree in which the LDL receptor defect has been shown to segregate by molecular biologic techniques. Application of the Haseman-Elston and a variance-components based test for linkage identified LDL and cholesterol as cosegregating with the marker C3, which is genetically linked to the LDL receptor defect. Consideration of lipid fractions as a multivariate response identified (0.723 x cholesterol) - (0.551 x triglycerides) as most strongly supporting evidence for linkage with C3. Subsequent segregation and linkage analyses provided support for an autosomal dominant major gene influencing either LDL or the function of cholesterol and triglycerides. Genetic linkage to LDL was only mildly supported, with a maximum lod score of 0.51 at a recombination fraction of theta = 0.33. Genetic linkage of the linear function to C3 was more strongly supported, with a maximum lod score of 1.69 at theta = 0.09. Bivariate analysis of clinical affection (with either type IIa or type IIb hyperlipidemia) and quantitative measures (LDL or the linear function) generally led to decreased lod scores, indicating, in this pedigree, loss of information when using clinical affection. (C) 1993 Wiley-Liss, Inc.* C1 HOWARD UNIV,CTR CANC,DIV BIOSTAT,WASHINGTON,DC 20059. RP AMOS, CI (reprint author), NIAMS,GENET STUDIES SECT,ROOM 429,BLDG 6,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. FU NCI NIH HHS [CA55772]; NCRR NIH HHS [RR03655] NR 6 TC 35 Z9 35 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PY 1993 VL 10 IS 6 BP 671 EP 676 DI 10.1002/gepi.1370100657 PG 6 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA MM366 UT WOS:A1993MM36600055 PM 8314079 ER PT J AU ARKING, R DUDAS, SP BAKER, GT AF ARKING, R DUDAS, SP BAKER, GT TI GENETIC AND ENVIRONMENTAL-FACTORS REGULATING THE EXPRESSION OF AN EXTENDED LONGEVITY PHENOTYPE IN A LONG-LIVED STRAIN OF DROSOPHILA SO GENETICA LA English DT Article DE AGING; EXTENDED LONGEVITY; GENETICS OF AGING; DROSOPHILA; GENE-ENVIRONMENT INTERACTIONS; GENE REGULATION; ANTIOXIDANTS ID POSTPONED SENESCENCE; LIFE-SPAN; ALCOHOL-DEHYDROGENASE; CORRELATED RESPONSES; DIETARY RESTRICTION; STRESS RESISTANCE; AGING PROCESSES; MELANOGASTER; SELECTION; REPRODUCTION C1 WAYNE STATE UNIV,INST GERONTOL,DETROIT,MI 48202. NIA,GERONTOL RES CTR,BALTIMORE,MD 21224. SHOCK AGING RES FDN,SILVER SPRING,MD 20905. RP ARKING, R (reprint author), WAYNE STATE UNIV,DEPT BIOL SCI,DETROIT,MI 48202, USA. NR 50 TC 24 Z9 24 U1 0 U2 1 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0016-6707 J9 GENETICA JI Genetica PY 1993 VL 91 IS 1-3 BP 127 EP 142 DI 10.1007/BF01435993 PG 16 WC Genetics & Heredity SC Genetics & Heredity GA MT350 UT WOS:A1993MT35000012 PM 8125264 ER PT J AU CLAVERIE, JM HARDELIN, JP LEGOUIS, R LEVILLIERS, J BOUGUELERET, L MATTEI, MG PETIT, C AF CLAVERIE, JM HARDELIN, JP LEGOUIS, R LEVILLIERS, J BOUGUELERET, L MATTEI, MG PETIT, C TI CHARACTERIZATION AND CHROMOSOMAL ASSIGNMENT OF A HUMAN CDNA-ENCODING A PROTEIN RELATED TO THE MURINE 102-KDA CADHERIN-ASSOCIATED PROTEIN (ALPHA-CATENIN) SO GENOMICS LA English DT Article ID CELL-ADHESION MOLECULE; FUNCTIONAL DOMAINS; VINCULIN; SEQUENCE; IDENTIFICATION; ANCHORAGE; GENE C1 CNRS,URA 1445,UNITE GENET MOLEC HUMAINE,25 RUE DR ROUX,F-75015 PARIS,FRANCE. NIH,NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20892. CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE. HOP ENFANTS LA TIMONE,INSERM,U242,F-13385 MARSEILLE,FRANCE. RI Legouis, Renaud/G-9088-2014 NR 31 TC 32 Z9 33 U1 0 U2 2 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0888-7543 J9 GENOMICS JI Genomics PD JAN PY 1993 VL 15 IS 1 BP 13 EP 20 DI 10.1006/geno.1993.1004 PG 8 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA KK685 UT WOS:A1993KK68500004 PM 8432524 ER PT J AU VETTER, U VOGEL, W JUST, W YOUNG, MF FISHER, LW AF VETTER, U VOGEL, W JUST, W YOUNG, MF FISHER, LW TI HUMAN DECORIN GENE - INTRON EXON JUNCTIONS AND CHROMOSOMAL LOCALIZATION SO GENOMICS LA English DT Article ID SMALL PROTEOGLYCAN-I; OSTEOINDUCTIVE FACTOR; CORE PROTEIN; BONE-CELLS; BIGLYCAN; SEQUENCE; PROMOTER; COLLAGEN; DNA; PURIFICATION C1 NIDR,BONE RES BRANCH,ROOM 106,BLDG 30,BETHESDA,MD 20892. UNIV ULM,KLIN GENET ABT,W-7900 ULM,GERMANY. NR 30 TC 29 Z9 32 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0888-7543 J9 GENOMICS JI Genomics PD JAN PY 1993 VL 15 IS 1 BP 161 EP 168 DI 10.1006/geno.1993.1023 PG 8 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA KK685 UT WOS:A1993KK68500023 PM 8432527 ER PT J AU COPELAND, NG GILBERT, DJ LI, K SAWAMURA, D GIUDICE, GJ CHU, ML JENKINS, NA UITTO, J AF COPELAND, NG GILBERT, DJ LI, K SAWAMURA, D GIUDICE, GJ CHU, ML JENKINS, NA UITTO, J TI CHROMOSOMAL LOCALIZATION OF MOUSE BULLOUS PEMPHIGOID ANTIGEN-BPAG1 AND ANTIGEN-BPAG2 - IDENTIFICATION OF A NEW REGION OF HOMOLOGY BETWEEN MOUSE AND HUMAN-CHROMOSOMES SO GENOMICS LA English DT Note ID CDNA CLONING; DOMAINS; ORGANIZATION; SEQUENCES; COLLAGEN; BPAG1 C1 THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL,ROOM 450 BLSB,233 S 10TH ST,PHILADELPHIA,PA 19107. THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107. THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107. NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702. MED COLL WISCONSIN,DEPT DERMATOL,MILWAUKEE,WI 53226. FU NIAMS NIH HHS [T32-AR7561, P01-AR38923, R29-AR40410] NR 13 TC 24 Z9 24 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0888-7543 J9 GENOMICS JI Genomics PD JAN PY 1993 VL 15 IS 1 BP 180 EP 181 DI 10.1006/geno.1993.1027 PG 2 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA KK685 UT WOS:A1993KK68500027 PM 8432531 ER PT J AU POPESCU, NC SILVERMAN, JA THORGEIRSSON, SS AF POPESCU, NC SILVERMAN, JA THORGEIRSSON, SS TI MAPPING OF A RAT MULTIDRUG RESISTANCE GENE BY FLUORESCENCE INSITU HYBRIDIZATION SO GENOMICS LA English DT Note ID CYSTIC-FIBROSIS; MOUSE; CHROMOSOMES; FAMILY C1 NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892. RP POPESCU, NC (reprint author), NCI,BIOL LAB,BETHESDA,MD 20892, USA. NR 17 TC 3 Z9 3 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0888-7543 J9 GENOMICS JI Genomics PD JAN PY 1993 VL 15 IS 1 BP 182 EP 184 DI 10.1006/geno.1993.1028 PG 3 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA KK685 UT WOS:A1993KK68500028 PM 8094367 ER PT J AU MARINI, JC NELSON, KK BATTEY, J SIRACUSA, LD AF MARINI, JC NELSON, KK BATTEY, J SIRACUSA, LD TI THE PITUITARY-HORMONES ARGININE VASOPRESSIN-NEUROPHYSIN-II AND OXYTOCIN-NEUROPHYSIN-I SHOW CLOSE LINKAGE WITH INTERLEUKIN-1 ON MOUSE CHROMOSOME-2 SO GENOMICS LA English DT Note ID NUCLEOTIDE-SEQUENCE; GENES; EXPRESSION; PRECURSOR; CDNA; RAT C1 JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,233 S 10TH ST,PHILADELPHIA,PA 19107. NCI,BIOL CHEM LAB,BETHESDA,MD 20892. NR 16 TC 27 Z9 27 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0888-7543 J9 GENOMICS JI Genomics PD JAN PY 1993 VL 15 IS 1 BP 200 EP 202 DI 10.1006/geno.1993.1034 PG 3 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA KK685 UT WOS:A1993KK68500034 PM 8432536 ER PT J AU WILKIE, PJ POLYMEROPOULOS, MH TRENT, JM SMALL, KW WEBER, JL AF WILKIE, PJ POLYMEROPOULOS, MH TRENT, JM SMALL, KW WEBER, JL TI GENETIC AND PHYSICAL MAP OF 11 SHORT TANDEM REPEAT POLYMORPHISMS ON HUMAN CHROMOSOME-6 SO GENOMICS LA English DT Note C1 MARSHFIELD MED RES FDN,1000 N OAK AVE,MARSHFIELD,WI 54449. ST ELIZABETH HOSP,NIMH,CTR NEUROSCI,WASHINGTON,DC 20032. UNIV MICHIGAN,DEPT RADIAT ONCOL,ANN ARBOR,MI 48109. UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109. DUKE UNIV,MED CTR,DIV NEUROL,DURHAM,NC 27710. FU NCI NIH HHS [CA-29476]; NHGRI NIH HHS [HG-00248] NR 12 TC 10 Z9 10 U1 0 U2 1 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0888-7543 J9 GENOMICS JI Genomics PD JAN PY 1993 VL 15 IS 1 BP 225 EP 227 DI 10.1006/geno.1993.1042 PG 3 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA KK685 UT WOS:A1993KK68500042 PM 8432543 ER PT B AU MERCHENTHALER, I LIPOSITS, Z LOPEZ, FJ WETSEL, WC NEGROVILAR, A AF MERCHENTHALER, I LIPOSITS, Z LOPEZ, FJ WETSEL, WC NEGROVILAR, A BE Bouchard, P Caraty, A Bennink, HJT Pavlou, SN TI FUNCTIONAL MORPHOLOGY OF THE LHRH (GNRH) NEURONAL SYSTEM - CONNECTIVITY AND CO-LOCALIZATION SO GNRH, GNRH ANALOGS, GONADOTROPINS AND GONADAL PEPTIDES LA English DT Proceedings Paper CT 3rd Organon Round Table Conference - GnRH, GnRH Analogs, Gonadotropins and Gonadal Peptides CY 1992 CL PARIS, FRANCE C1 NIEHS,MOLEC & INTEGRAT NEUROSCI LAB,FUNCTIONAL MORPHOL SECT,RES TRIANGLE PK,NC 27709. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PARTHENON PUBLISHING GROUP LTD PI LANCASTER PA CASTERTON HALL, CARNFORTH, LANCASTER, ENGLAND LA6 2LA BN 1-85070-471-6 PY 1993 BP 23 EP 38 PG 16 WC Biochemistry & Molecular Biology; Electrochemistry SC Biochemistry & Molecular Biology; Electrochemistry GA BC44T UT WOS:A1993BC44T00003 ER PT B AU CATT, KJ REINHART, J MERTZ, LM KRSMANOVIC, LZ STOJILKOVIC, SS AF CATT, KJ REINHART, J MERTZ, LM KRSMANOVIC, LZ STOJILKOVIC, SS BE Bouchard, P Caraty, A Bennink, HJT Pavlou, SN TI THE GNRH RECEPTOR - MOLECULAR STRUCTURE AND CALCIUM SIGNALING MECHANISMS SO GNRH, GNRH ANALOGS, GONADOTROPINS AND GONADAL PEPTIDES LA English DT Proceedings Paper CT 3rd Organon Round Table Conference - GnRH, GnRH Analogs, Gonadotropins and Gonadal Peptides CY 1992 CL PARIS, FRANCE C1 NIH,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892. NR 0 TC 2 Z9 2 U1 0 U2 0 PU PARTHENON PUBLISHING GROUP LTD PI LANCASTER PA CASTERTON HALL, CARNFORTH, LANCASTER, ENGLAND LA6 2LA BN 1-85070-471-6 PY 1993 BP 95 EP 111 PG 17 WC Biochemistry & Molecular Biology; Electrochemistry SC Biochemistry & Molecular Biology; Electrochemistry GA BC44T UT WOS:A1993BC44T00008 ER PT B AU KARTEN, MJ RIVIER, C FOLKERS, K BOWERS, CY HOOK, W RIVIER, J AF KARTEN, MJ RIVIER, C FOLKERS, K BOWERS, CY HOOK, W RIVIER, J BE Bouchard, P Caraty, A Bennink, HJT Pavlou, SN TI PROGRESS IN THE DESIGN OF GNRH ANTAGONISTS SO GNRH, GNRH ANALOGS, GONADOTROPINS AND GONADAL PEPTIDES LA English DT Proceedings Paper CT 3rd Organon Round Table Conference - GnRH, GnRH Analogs, Gonadotropins and Gonadal Peptides CY 1992 CL PARIS, FRANCE C1 NIH,CO,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PARTHENON PUBLISHING GROUP LTD PI LANCASTER PA CASTERTON HALL, CARNFORTH, LANCASTER, ENGLAND LA6 2LA BN 1-85070-471-6 PY 1993 BP 205 EP 209 PG 5 WC Biochemistry & Molecular Biology; Electrochemistry SC Biochemistry & Molecular Biology; Electrochemistry GA BC44T UT WOS:A1993BC44T00016 ER PT J AU ROBERTS, AB SPORN, MB AF ROBERTS, AB SPORN, MB TI PHYSIOLOGICAL ACTIONS AND CLINICAL-APPLICATIONS OF TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) SO GROWTH FACTORS LA English DT Review DE TISSUE REPAIR; FIBROSIS; CARCINOGENESIS; IMMUNE CELLS; AUTOIMMUNE DISEASES; BONE ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MATRIX GENE-EXPRESSION; HAMSTER OVARY CELLS; EXTRACELLULAR-MATRIX; MESSENGER-RNA; EXPERIMENTAL GLOMERULONEPHRITIS; PULMONARY FIBROSIS; MOUSE EPIDERMIS; IMPAIRED WOUNDS AB In the 10 years since its definition and characterization, TGF-beta has come to be accepted as the prototypical multifunctional peptide growth factor. Attempts to understand its mechanism of action on cells have resulted in conceptual advances in knowledge of the contextual nature of growth factor activities. These have included modulatory effects both of sets of growth factors and of the cellular environment, including extracellular matrix (Sporn and Roberts, 1990; Nathan and Sporn, 1991). Because of the breadth of the cellular targets and activities of TGF-beta, it is impossible to be comprehensive in review of its physiological roles. Rather, we will cover selected aspects with emphasis on physiological roles which might ultimately find clinical application. As much as possible, we will consider in vivo roles of TGF-beta in the context of the inherent complexity of cell-matrix and cell-cell interactions characteristic of mixed cell populations, tissues, or organs. C1 NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892. NR 91 TC 691 Z9 717 U1 1 U2 8 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 0897-7194 J9 GROWTH FACTORS JI Growth Factors PY 1993 VL 8 IS 1 BP 1 EP 9 PG 9 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA LL965 UT WOS:A1993LL96500001 PM 8448037 ER PT J AU MACKAY, K AF MACKAY, K TI HOMODIMERS OF THE 60-KDA PHOSPHATIDYLINOSITOL-ANCHORED TRANSFORMING GROWTH-FACTOR-BETA-2 BINDING-PROTEINS IN FBHEC AND MG-63 CELLS SO GROWTH FACTORS LA English DT Article DE RECEPTORS; TGF-BETA; PHOSPHATIDYLINOSITOL; ENDOTHELIAL CELLS; SARCOMA; HOMODIMERS ID TGF-BETA RECEPTOR; MEMBRANE PROTEOGLYCAN; PURIFICATION; EXPRESSION; COMPONENT AB Phophatidylinositol (PI) anchored TGF-beta2 binding proteins of approximately 60 and 140 kDa were recently identified in MG-63 human osteogenic sarcoma and fetal bovine heart endothelial cells (FBHEC) (Cheifetz, S., Massague, J. (1991) J. Biol. Chem. 266, 20767-20772). The relationship between these two PI-anchored TGF-beta2 binding proteins was investigated. Specifically labeled bands of approximately 60 and 110 kDa were observed when I-125-TGF-beta2 labeled FBHEC and MG-63 cells were separated by SDS-PAGE under non-reducing conditions. Partial proteolysis of the affinity labeled 60 and 110 kDa species yielded similar peptides. The integrity of the 110 kDa species under denaturing conditions is dependent on both disulfide bonds and chemical cross-linking: reduction of the 110 kDa species yielded an affinity labeled species co-electrophoresing with the 60 kDa band; cleavage of chemical cross-links in the 110 kDa complex yielded a labeled 60 kDa component. These results indicate that the 110 kDa affinity labeled species in FBHEC and MG-63 cells is a homodimer. Within this complex the binding protein monomers can be chemically cross-linked to opposite arms of the disulfide-linked TGF-beta2 homodimer. C1 NIDDKD,METAB DIS BRANCH,KIDNEY DIS SECT,BETHESDA,MD. NR 17 TC 2 Z9 2 U1 0 U2 0 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 0897-7194 J9 GROWTH FACTORS JI Growth Factors PY 1993 VL 8 IS 3 BP 187 EP 195 DI 10.3109/08977199309011022 PG 9 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA LL967 UT WOS:A1993LL96700004 PM 8318253 ER PT B AU ROBERTS, AB SPORN, MB AF ROBERTS, AB SPORN, MB BE Cummins, P TI TRANSFORMING GROWTH-FACTOR-BETA - LOCALIZATION AND POSSIBLE FUNCTIONAL ROLES IN CARDIAC MYOCYTES SO GROWTH FACTORS AND THE CARDIOVASCULAR SYSTEM SE DEVELOPMENTS IN CARDIOVASCULAR MEDICINE LA English DT Proceedings Paper CT Symposium on the Growth Factors in the Heart, at the XIIIth Congress of the European-Society-of-Cardiology CY 1991 CL AMSTERDAM, NETHERLANDS SP EUROPEAN SOC CARDIOL, WORKING GRP PATHOPHYSIOL CARDIAC MYOCYTE C1 NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892. NR 0 TC 1 Z9 1 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 0-7923-2401-3 J9 DEV CARDIOVASC MED PY 1993 VL 147 BP 45 EP 53 PG 9 WC Cardiac & Cardiovascular Systems; Physiology SC Cardiovascular System & Cardiology; Physiology GA BZ48L UT WOS:A1993BZ48L00004 ER PT S AU LOWY, DR JOHNSON, MR DECLUE, JE CEN, H ZHANG, K PAPAGEORGE, AG VASS, WC WILLUMSEN, BM VALENTINE, MB LOOK, AT AF LOWY, DR JOHNSON, MR DECLUE, JE CEN, H ZHANG, K PAPAGEORGE, AG VASS, WC WILLUMSEN, BM VALENTINE, MB LOOK, AT BE Marsh, J Goode, J TI CELL-TRANSFORMATION BY RAS AND REGULATION OF ITS PROTEIN PRODUCT SO GTPASE SUPERFAMILY SE CIBA FOUNDATION SYMPOSIA LA English DT Article ID GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; TYPE-1 NEUROFIBROMATOSIS; CATALYTIC DOMAIN; AMINO-ACIDS; P21 GTPASE; GAP; IDENTIFICATION; GROWTH; KINASE AB We are studying the biological activity and regulation of mammalian Ras protein in tumours and in physiological signalling. We have shown that GAP (the GTPase-activating protein) is a potent negative regulator of normal Ras in cells. Reduction or loss of the NF1 gene product neurofibromin, in association with genetic abnormalities of the NF1 locus, has been identified in schwannoma cell lines from patients with neurofibromatosis and in melanoma and neuroblastoma lines from patients without neurofibromatosis. Although loss of neurofibromin in the schwannoma lines was associated with a high proportion of normal Ras protein in the active GTP-bound state, Ras-GTP appeared to be appropriately regulated in the melanoma and neuroblastoma lines, which contain normal levels of GAP. Therefore the GTPase-activating activity of neurofibromin is not essential for negative regulation of Ras in some cell types and the putative tumour suppressor function of neurofibromin in such cell types is independent of its GTPase-activating activity. Mitogen activation of Ras in fibroblasts is mediated primarily by exchange factors, which probably interact with a region on the Ras protein distinct from the region required for interaction with GAP. Multiple full-length cDNAs have identified a mouse gene whose products are related to yeast CDC25 guanine nucleotide exchange factor. C1 UNIV COPENHAGEN, INST MICROBIOL, COPENHAGEN, DENMARK. UNIV TENNESSEE, COLL MED, DEPT PEDIAT, KNOXVILLE, TN 37996 USA. ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN USA. RP LOWY, DR (reprint author), NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA. RI Willumsen, Berthe/H-1903-2012 OI Willumsen, Berthe/0000-0002-2277-6999 NR 40 TC 16 Z9 16 U1 0 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, WEST SUSSEX, ENGLAND SN 0300-5208 BN 0-471-93914-5 J9 CIBA F SYMP PY 1993 VL 176 BP 67 EP 80 PG 14 WC Biochemistry & Molecular Biology; Medicine, General & Internal SC Biochemistry & Molecular Biology; General & Internal Medicine GA BA03U UT WOS:A1993BA03U00005 PM 8299427 ER PT J AU AARONSON, SA AF AARONSON, SA TI INFLUENCES OF GROWTH-FACTORS AND THEIR SIGNALING PATHWAYS IN MALIGNANCY SO HARVEY LECTURES, VOL 87 SE HARVEY LECTURES LA English DT Review ID INTERLEUKIN-1 RECEPTOR ANTAGONIST; EXPRESSION CDNA CLONING; PROTEIN-KINASE ACTIVITY; PHOSPHOLIPASE-C-GAMMA; SIMIAN SARCOMA-VIRUS; EPITHELIAL-CELLS; TYROSINE KINASES; TRK PROTOONCOGENE; MOLECULAR-CLONING; HEPATOPOIETIN-A RP AARONSON, SA (reprint author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA. NR 121 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS, INC PI NEW YORK PA 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0073-0874 J9 HARVEY LECT PY 1993 VL 87 BP 17 EP 34 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA BB86V UT WOS:A1993BB86V00002 ER PT S AU SAFFIOTTI, U DANIEL, LN MAO, Y WILLIAMS, AO KAIGHN, ME AHMED, N KNAPTON, AD AF SAFFIOTTI, U DANIEL, LN MAO, Y WILLIAMS, AO KAIGHN, ME AHMED, N KNAPTON, AD BE Guthrie, GD Mossman, BT TI BIOLOGICAL STUDIES ON THE CARCINOGENIC MECHANISMS OF QUARTZ SO HEALTH EFFECTS OF MINERAL DUSTS SE REVIEWS IN MINERALOGY LA English DT Review CT SHORT COURSE ON HEALTH EFFECTS OF MINERAL DUSTS CY OCT 22-24, 1993 CL NANTUCKET ISLAND, MA SP MINERAL SOC AMER, GEOL SOC AMER, US DOE, OFF BASIC ENERGY SCI, DIV ENGN & GEOSCI, US DOE, OFF HLTH & ENVIRONM RES, HLTH EFFECTS & LIFE SCI, AMER COLL CHEST PHYSICIANS, US GEOL SURVEY RP SAFFIOTTI, U (reprint author), NCI,EXPTL PATHOL LAB,BETHESDA,MD 20892, USA. NR 0 TC 16 Z9 16 U1 0 U2 0 PU MINERALOGICAL SOC AMERICA PI WASHINGTON PA WASHINGTON SN 0275-0279 BN 0-939950-33-2 J9 REV MINERAL PY 1993 VL 28 BP 523 EP 544 PG 22 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BZ30X UT WOS:A1993BZ30X00018 ER PT J AU FIBACH, E AF FIBACH, E TI MEASUREMENT OF TOTAL AND FETAL HEMOGLOBIN IN CULTURED HUMAN ERYTHROID-CELLS BY A NOVEL MICROMETHOD SO HEMOGLOBIN LA English DT Article ID LIQUID CULTURE; PROGENITORS; TETRAMETHYLBENZIDINE; MATURATION; SEPARATION; BLOOD AB The present paper reports on the application of a simple micromethod for quantitation of total and fetal hemoglobin in small volumes of diluted erythroid cell hemolysates. A modified alkaline denaturation procedure was used to denature and precipitate non-fetal hemoglobins and the tetramethylbenzidine procedure was used for quantitation of the soluble hemoglobin. Using a combination of these procedures, total hemoglobin concentrations as low as 0.2 mg% (2 mug/ml) and a fetal hemoglobin proportion of 0.5% could be reliably determined. We have utilized this procedure to study two aspects of hemoglobin production in human erythroid cells grown in culture; the proportion of fetal hemoglobin of cells in culture as compared to that in the peripheral blood of the donors, and the kinetics of hemoglobin production during maturation of these cultured cells. The results show that the cultured erythroid cells have a hemoglobin phenotype similar to the individual from whom they are derived and that erythroid differentiation may be studied in vitro in these cultured cells by measurement of these and other parameters. C1 NIDDKD,CHEM BIOL LAB,BETHESDA,MD 20892. RP FIBACH, E (reprint author), HADASSAH UNIV HOSP,DEPT HEMATOL,IL-91120 JERUSALEM,ISRAEL. NR 18 TC 14 Z9 14 U1 0 U2 2 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0363-0269 J9 HEMOGLOBIN JI Hemoglobin PY 1993 VL 17 IS 1 BP 41 EP 53 DI 10.3109/03630269308998884 PG 13 WC Biochemistry & Molecular Biology; Hematology SC Biochemistry & Molecular Biology; Hematology GA KK997 UT WOS:A1993KK99700005 PM 7681049 ER PT J AU FLIPPENANDERSON, JL HE, XS BROSSI, A GREIG, NH RAPOPORT, SI AF FLIPPENANDERSON, JL HE, XS BROSSI, A GREIG, NH RAPOPORT, SI TI THIAPHYSOVENOL PHENYLCARBAMATES - X-RAY STRUCTURES OF BIOLOGICALLY-ACTIVE AND INACTIVE ANTICHOLINESTERASE AGENTS SO HETEROCYCLES LA English DT Article ID CARBAMATE; ANALOGS AB The X-ray structure of the biologically active phenylcarbamate (4), and the biologically inactive phenylcarbamate (5) of the thiaphysovenol series, reveal that the two aromatic ring systems are differently oriented towards each other. The absolute configuration of both compounds, determined by using the anomolous scattering from the sulfur atoms, was found to be (3aS-cis). C1 NIDDK,ANALYT CHEM LAB,BETHESDA,MD 20982. NIA,NEUROSCI LAB,BETHESDA,MD 20892. RP FLIPPENANDERSON, JL (reprint author), USN,RES LAB,STRUCT MATTER LAB,WASHINGTON,DC 20375, USA. NR 11 TC 5 Z9 5 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0385-5414 J9 HETEROCYCLES JI Heterocycles PD JAN 1 PY 1993 VL 36 IS 1 BP 79 EP 86 PG 8 WC Chemistry, Organic SC Chemistry GA KH275 UT WOS:A1993KH27500014 ER PT B AU FOJO, T SCALA, S ZHAN, Z MICKLEY, L AF FOJO, T SCALA, S ZHAN, Z MICKLEY, L BE Dincalci, M Mantovani, A Garattini, S TI HETEROGENEITY OF DRUG-RESISTANCE SO HETEROGENEITY OF CANCER CELLS SE SERONO SYMPOSIA PUBLICATIONS FROM RAVEN PRESS LA English DT Proceedings Paper CT International Symposium on Heterogeneity of Cancer Cells CY JUN, 1992 CL MARIO NEGRI INST, MILAN, ITALY SP SERONO SYMP HO MARIO NEGRI INST RP FOJO, T (reprint author), NIH,DEPT HLTH & HUMAN SERV CLIN ONCOL,BLDG 10,ROOM 12N226,BETHESDA,MD 20892, USA. RI Scala, Stefania/K-1380-2016 OI Scala, Stefania/0000-0001-9524-2616 NR 0 TC 0 Z9 0 U1 2 U2 2 PU RAVEN PRESS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 BN 0-88167-907-0 J9 SERONO SYM PY 1993 VL 95 BP 27 EP 39 PG 13 WC Oncology; Genetics & Heredity; Pathology SC Oncology; Genetics & Heredity; Pathology GA BZ70P UT WOS:A1993BZ70P00003 ER PT S AU RADER, DJ IKEWAKI, K SCHAEFER, JR BREWER, BH AF RADER, DJ IKEWAKI, K SCHAEFER, JR BREWER, BH BE Catapano, AL Bernini, F Corsini, A TI METABOLISM OF HDL PARTICLES LPA-I AND LPA-I,A-II IN NORMAL AND HYPERALPHALIPOPROTEINEMIC SUBJECTS SO HIGH DENSITY LIPOPROTEINS: PHYSIOPATHOLOGY AND CLINICAL RELEVANCE SE ATHEROSCLEROSIS REVIEWS LA English DT Proceedings Paper CT 2ND BELLAGIO MEETING ON HIGH DENSITY LIPOPROTEINS CY SEP 13-14, 1991 CL BELLAGIO, ITALY SP RHONE POULENC RORER RP RADER, DJ (reprint author), NIH,BLDG 10 ROOM 7N117,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU RAVEN PRESS PI NEW YORK PA NEW YORK SN 0362-1650 BN 0-88167-990-9 J9 ATHER REV PY 1993 VL 24 BP 43 EP 55 PG 13 WC Biochemistry & Molecular Biology; Cardiac & Cardiovascular Systems; Physiology SC Biochemistry & Molecular Biology; Cardiovascular System & Cardiology; Physiology GA BX72E UT WOS:A1993BX72E00003 ER PT B AU CACHAU, RE AF CACHAU, RE BE Tentner, AM TI ULTRAFAST HIGH-PRECISION MOLECULAR MECHANIC AND DYNAMIC CALCULATIONS USING A FLOATING POLYNOMIAL FORCE-FIELD (FPFF) REPRESENTATION SO HIGH PERFORMANCE COMPUTING SYMPOSIUM 1993: GRAND CHALLENGES IN COMPUTER SIMULATION LA English DT Proceedings Paper CT 1993 Simulation Multiconference features the 1st High Performance Computing Symposium: Grand Challenges in Computer Simulation CY MAR 29-APR 01, 1993 CL ARLINGTON, VA SP SOC COMP SIMULAT C1 NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,CTR BIOMED SUPERCOMP,STRUCT BIOCHEM LAB,FREDERICK,MD 21702. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC COMPUTER SIMULATION INT PI SAN DIEGO PA PO BOX 17900, SAN DIEGO, CA 92177 BN 1-56555-052-8 PY 1993 BP 90 EP 95 PG 6 WC Computer Science, Interdisciplinary Applications SC Computer Science GA BA16Z UT WOS:A1993BA16Z00014 ER PT J AU ANDERSON, DE AUSTIN, J COYLE, K AF ANDERSON, DE AUSTIN, J COYLE, K TI METABOLIC AND HEMODYNAMIC-EFFECTS OF INHIBITORY BREATHING SO HOMEOSTASIS IN HEALTH AND DISEASE LA English DT Article DE BLOOD PRESSURE; CARDIAC OUTPUT; HYPERCAPNIA; HYPOVENTILATION; PH; STROKE VOLUME; TIDAL VOLUME; TOTAL PERIPHERAL RESISTANCE ID BLOOD-PRESSURE; ESSENTIAL-HYPERTENSION; MUSCLE; STRESS AB The physiological effects of hypoxia and hypercapnia have been studied extensively, but less experimental attention has been paid to the effects of sustained shifts in blood gases within the normal breathing range which accompany ,,stressful'' interactions of the individual with the environment. Previous research has associated an ,,inhibitory'' (i.e. low frequency/normal tidal volume) breathing pattern with the development of behavioral hypertension in sodium- loaded dogs. Current studies with human subjects in our laboratory have investigated the metabolic and cardiovascular effects of ,,inhibitory'' breathing, which was enabled by a respiratory gas monitor and feedback procedure. These studies show that breathing patterns which increase CO2 in expired air are associated with (a) decreased pH and increased bicarbonate concentrations, and (b) increased total peripheral resistance and blood pressure, but not heart rate or cardiac output, which occur (c) whether breathing frequency or tidal volume are subnormal. Additional research is needed to determine whether sustained changes in acid-base balance accompanying ,,inhibitory'' breathing increase blood pressure sensitivity to high sodium intake via sodium-hydrogen exchange or other mechanisms. RP ANDERSON, DE (reprint author), NIA,GERONTOL RES CTR,BEHAV SCI LAB,4940 EASTERN AVE,BALTIMORE,MD 21224, USA. NR 27 TC 10 Z9 10 U1 0 U2 1 PU CIANS-HOMEOSTASIS PI PRAGUE 10 PA C/O NATL INST PUBLIC HEALTH, SROBAROVA 48, PRAGUE 10, CZECH REPUBLIC CZ 100 42 SN 0960-7560 J9 HOMEOSTASIS HLTH DIS JI Homeost. Health Dis. PY 1993 VL 34 IS 5-6 BP 328 EP 337 PG 10 WC Behavioral Sciences; Cardiac & Cardiovascular Systems SC Behavioral Sciences; Cardiovascular System & Cardiology GA MY690 UT WOS:A1993MY69000013 ER PT J AU TSUTSUMI, O TAKETANI, Y OKA, T AF TSUTSUMI, O TAKETANI, Y OKA, T TI EVIDENCE FOR THE INVOLVEMENT OF EPIDERMAL GROWTH-FACTOR IN FERTILITY DECLINE IN AGING FEMALE MICE SO HORMONE RESEARCH LA English DT Article; Proceedings Paper CT 1ST TOKYO CONF ON REPRODUCTIVE PHYSIOLOGY 2 : AGING OF REPRODUCTIVE ORGANS CY AUG 22, 1992 CL TOKYO, JAPAN SP JAPAN SANDOZ DE AGING; EPIDERMAL GROWTH FACTOR; FERTILITY; MOUSE; OVARY; UTERUS ID ESTROGEN; RECEPTOR; AGE AB A decline in fertility, defined as the number of implantation sites, was observed in mice as they aged; the decline started at 30 weeks of age and reached a nadir by 60 weeks when no implantation was detected. Epidermal growth factor (EGF) levels in the submandibular gland and plasma increased as the female mice aged, and sialoadenectomy (surgical removal of the submandibular glands) attenuated the rise in the plasma EGF level without affecting the overall health or survival of the animals. Uterine weight at 10-20 weeks of age was about 70 mg, and it significantly increased with age. This weight has increased more than 2-fold by 60 weeks. These changes closely followed the increase in the concentrations of EGF in the submandibular gland and the plasma. After sialoadenectomy, uterine weight decreased immediately and remained at about 50-60 mg throughout the experimental period. Interestingly, sialoadenectomized mice became pregnant at an older age than the controls. These findings suggest that elevated levels of EGF may have a physiological role in fertility decline in aging mice perhaps via uterine hypertrophy. C1 NIDDK,MOLEC & CELLULAR BIOL LAB,BETHESDA,MD. RP TSUTSUMI, O (reprint author), UNIV TOKYO,FAC MED,DEPT OBSTET & GYNECOL,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN. NR 19 TC 9 Z9 9 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 1993 VL 39 SU 1 BP 32 EP 36 DI 10.1159/000182755 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA LM561 UT WOS:A1993LM56100008 PM 8365708 ER PT J AU ROSS, JL REISS, AL FREUND, L ROELTGEN, D CUTLER, GB AF ROSS, JL REISS, AL FREUND, L ROELTGEN, D CUTLER, GB TI NEUROCOGNITIVE FUNCTION AND BRAIN IMAGING IN TURNER SYNDROME - PRELIMINARY-RESULTS SO HORMONE RESEARCH LA English DT Article DE BRAIN IMAGING; COGNITIVE FUNCTION; MAGNETIC RESONANCE IMAGING; NEUROCOGNITIVE DEFICITS; TURNER SYNDROME ID HEMISPHERIC LATERALIZATION; BEHAVIOR PROBLEMS; MENSTRUAL-CYCLE; GIRLS; ABILITY; SKILLS AB Girls with Turner syndrome were investigated in order to determine the anatomical differences in their brains compared with those of normal age-matched female controls, and to relate these differences to deficits in neurocognitive function with a view to understanding the abnormal brain development in Turner syndrome. During the 2-year study period, it is planned to evaluate 50 girls with Turner syndrome and 50 age-matched controls. A wide range of authentic neurocognitive tests will be applied to establish the neurocognitive profile, and brain anatomy will be studied by magnetic resonance imaging (MRI). Ten patients with Turner syndrome have been evaluated by neurocognitive testing to date, and 8 girls with Turner syndrome and 13 controls have had MRI scans performed. There is preliminary evidence of both specific and generalized processes affecting brain development and cognitive function in Turner syndrome. The evidence of a role for sex hormones in socio-behavioural and cognitive abilities in Turner syndrome is discussed. C1 NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD. KENNEDY KRIEGER INST,BEHAV & NEUROIMAGING RES CTR,BALTIMORE,MD. HAHNEMANN UNIV,DEPT NEUROL,PHILADELPHIA,PA 19102. RP ROSS, JL (reprint author), MED COLL PENN,DEPT PEDIAT,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA. FU NINDS NIH HHS [R01-NS29857] NR 38 TC 11 Z9 11 U1 0 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 1993 VL 39 SU 2 BP 65 EP 69 DI 10.1159/000182773 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA LN152 UT WOS:A1993LN15200016 PM 8359792 ER PT J AU FELTNER, DE HERTZMAN, M AF FELTNER, DE HERTZMAN, M TI PROGRESS IN THE TREATMENT OF TARDIVE-DYSKINESIA - THEORY AND PRACTICE SO HOSPITAL AND COMMUNITY PSYCHIATRY LA English DT Article ID CALCIUM-CHANNEL ANTAGONISTS; LONG-TERM TREATMENT; SCHIZOPHRENIC-PATIENTS; ELECTROCONVULSIVE-THERAPY; NEUROLEPTIC MEDICATION; PSYCHOSIS; PREVALENCE; CLOZAPINE; HALOPERIDOL; DRUGS AB Objective: About 20 percent of patients receiving long-term treatment with neuroleptic medications develop tardive dyskinesia. A 1988 review of treatment studies for the disorder found that 40 percent of patients showed at least 50 percent improvement in symptoms. This paper reviews studies published since 1984, including those not reviewed in 1988, to learn whether new or improved treatments for the disorder have been developed. Methods: Twenty-five open, blind, or double-blind studies (with a minimum of five patients) published between 1984 and May 1992 were examined. The studies involved neuroleptics, including clozapine, dopaminergic and dopamine-depleting agents, GABA-ergic drugs, vitamin E, calcium channel blockers, and adrenergic drugs. Results and conclusions: Overall, only 26 percent of patients who participated in the studies reviewed had a 50 percent or greater reduction in symptoms. The authors conclude that treatment of tardive dyskinesia remains a highly individual process and recommend that future studies be more carefully designed. C1 GEORGE WASHINGTON UNIV,MED CTR,INPATIENT SERV,WASHINGTON,DC 20037. RP FELTNER, DE (reprint author), ST ELIZABETH HOSP,NIMH,NEUROPSYCHIAT BRANCH,NPB,WILLIAM A WHITE BLDG,WASHINGTON,DC 20032, USA. NR 77 TC 22 Z9 22 U1 3 U2 3 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 SN 0022-1597 J9 HOSP COMMUNITY PSYCH PD JAN PY 1993 VL 44 IS 1 BP 25 EP 34 PG 10 WC Public, Environmental & Occupational Health; Psychiatry SC Public, Environmental & Occupational Health; Psychiatry GA KF278 UT WOS:A1993KF27800007 PM 8094705 ER PT J AU FLEISCHHAUER, K MCBRIDE, OW DISANTO, JP OZATO, K YANG, SY AF FLEISCHHAUER, K MCBRIDE, OW DISANTO, JP OZATO, K YANG, SY TI CLONING AND CHROMOSOME MAPPING OF HUMAN RETINOID-X RECEPTOR BETA - SELECTIVE AMINO-ACID-SEQUENCE CONSERVATION OF A NUCLEAR HORMONE RECEPTOR IN MAMMALS SO HUMAN GENETICS LA English DT Article ID CLASS-I GENES; CELLS; DIFFERENTIATION; TRANSCRIPTION; EXPRESSION AB The murine retinoid X receptor beta (mRXRbeta) is a nuclear hormone receptor that activates transcription of murine major histocompatibility complex (MHC) class I genes in response to retinoic acid. In this study, the human RXRbeta gene was mapped onto the short arm or centromeric region of chromosome 6 (6pter-q13), which also harbors the MHC. Chromosomal localization was performed by Southern hybridization of genomic DNA from human rodent cell hybrids with the mRXRbeta gene as a probe. In addition, a full-length cDNA clone encoding a human RXRbeta was isolated by nucleic acid screening of a human cDNA library with a fragment of the mRXRbeta gene as a probe. Comparison of the nucleotide-coding sequences of the human and the murine RXRbeta revealed a predominance of third base substitutions, resulting in selective conservation of the predicted amino acid sequence of the proteins. The overall sequence homology was 97.6% on the amino acid level as opposed to 91.6% on the nucleotide level. In Northern hybridization experiments with the human cDNA as a probe, RXRbeta gene transcripts were detected in a variety of human tumor cell lines, regardless of whether these cell lines expressed MHC class I genes. C1 MEM SLOAN KETTERING CANC CTR,BIOCHEM IMMUNOGENET LAB,NEW YORK,NY 10021. NCI,DIV CANC BIOL & DIAG,BIOCHEM LAB,BETHESDA,MD 20892. NICHHD,DEV & MOLEC IMMUN LAB,BETHESDA,MD 20892. MEM SLOAN KETTERING CANC CTR,CELLULAR BIOL LAB,NEW YORK,NY 10021. RI Fleischhauer, Katharina/B-6980-2009; Di Santo, James/M-4298-2014 OI Di Santo, James/0000-0002-7146-1862 NR 29 TC 11 Z9 13 U1 0 U2 1 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0340-6717 J9 HUM GENET JI Hum. Genet. PD JAN PY 1993 VL 90 IS 5 BP 505 EP 510 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA KJ350 UT WOS:A1993KJ35000006 PM 8381386 ER PT J AU GAO, X BENNETT, P SERJEANTSON, SW AF GAO, X BENNETT, P SERJEANTSON, SW TI AUSTRALIAN ABORIGINES AND AMERINDIANS - A SHARED STORY SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 ANU,JCSMR,HUMAN GENET GRP,PHOENIX,AZ. NIDDK,PHOENIX,AZ. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1993 VL 37 SU 1 BP 22 EP 22 PG 1 WC Immunology SC Immunology GA LW989 UT WOS:A1993LW98900038 ER PT J AU MARTI, D STEPHENS, C MANN, D CARRINGTON, M AF MARTI, D STEPHENS, C MANN, D CARRINGTON, M TI CHARACTERIZATION OF TAP1 AND TAP2 ALLELES AND HAPLOTYPES WITHIN THE CEPH FAMILIES SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 DYNCORP,PROGRAM RESOURCES INC,FREDERICK,MD. NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1993 VL 37 SU 1 BP 29 EP 29 PG 1 WC Immunology SC Immunology GA LW989 UT WOS:A1993LW98900051 ER PT J AU ZHAO, TM WHITAKER, SE ROBINSON, MA AF ZHAO, TM WHITAKER, SE ROBINSON, MA TI HUMAN T-CELL RECEPTOR V-BETA GENE SEGMENTS INVOLVED IN AN INSERTION DELETION-RELATED POLYMORPHISM SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 NIAID,IMMUNOGENET LAB,ROCKVILLE,MD. NR 0 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1993 VL 37 SU 1 BP 42 EP 42 PG 1 WC Immunology SC Immunology GA LW989 UT WOS:A1993LW98900075 ER PT J AU HARDING, A CARRINGTON, M ODONNELL, M MARTI, D GOEDERT, JJ MANN, DL AF HARDING, A CARRINGTON, M ODONNELL, M MARTI, D GOEDERT, JJ MANN, DL TI HLA ASSOCIATIONS IN LONG-TERM SURVIVORS OF HIV-1 INFECTION SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 DYNCORP,PROGRAM RESOURCES INC,ROCKVILLE,MD. NCI,VIRAL EPIDEMIOL BRANCH,FREDERICK,MD 21701. NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701. NR 0 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1993 VL 37 SU 1 BP 55 EP 55 PG 1 WC Immunology SC Immunology GA LW989 UT WOS:A1993LW98900100 ER PT J AU BARRON, KS DEULOFEUT, H REVEILLE, JD ROBINSON, MA AF BARRON, KS DEULOFEUT, H REVEILLE, JD ROBINSON, MA TI T-CELL RECEPTOR (TCR) V-BETA NULL ALLELES IN JUVENILE RHEUMATOID-ARTHRITIS (JRA) SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 NIAID,IMMUNOGENET LAB,ROCKVILLE,MD. UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1993 VL 37 SU 1 BP 59 EP 59 PG 1 WC Immunology SC Immunology GA LW989 UT WOS:A1993LW98900108 ER PT J AU BARRON, KS CARRINGTON, M REVEILLE, JD AF BARRON, KS CARRINGTON, M REVEILLE, JD TI POLYMORPHISM IN TAP GENES IN REITERS-SYNDROME SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 NIAID,MA ROBINSON IMMUNOGENET LAB,ROCKVILLE,MD. NCI,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21701. UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1993 VL 37 SU 1 BP 60 EP 60 PG 1 WC Immunology SC Immunology GA LW989 UT WOS:A1993LW98900109 ER PT J AU ZIMMERMAN, PA CARRINGTON, MN NUTMAN, TB AF ZIMMERMAN, PA CARRINGTON, MN NUTMAN, TB TI CHEMILUMINESCENT DIRECTED HETERODUPLEX ANALYSIS USING PSEUDO-GENEPROBES SIMPLIFIES DQA1-ASTERISK AND DQB1-ASTERISK GENOTYPING SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 NIAID,PARASIT DIS LAB,BETHESDA,MD 20892. NCI,FCRDC,DYNCORP,PROGRAM RESOURCES INC,BCDP,FREDERICK,MD 21701. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1993 VL 37 SU 1 BP 138 EP 138 PG 1 WC Immunology SC Immunology GA LW989 UT WOS:A1993LW98900263 ER PT J AU ZACHARY, AA STEINBERG, AG BIAS, WB MACHAN, CH LEFFELL, MS AF ZACHARY, AA STEINBERG, AG BIAS, WB MACHAN, CH LEFFELL, MS TI ANALYSIS OF HLA-ANTIGEN DISTRIBUTION IN DONORS AND RECIPIENTS IN THE UNOS RENAL REGISTRY SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 NIAID,BETHESDA,MD 20892. JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1993 VL 37 SU 1 BP 159 EP 159 PG 1 WC Immunology SC Immunology GA LW989 UT WOS:A1993LW98900305 ER PT S AU CRAGG, GM BOYD, MR CARDELLINA, JH GREVER, MR SCHEPARTZ, SA SNADER, KM SUFFNESS, M AF CRAGG, GM BOYD, MR CARDELLINA, JH GREVER, MR SCHEPARTZ, SA SNADER, KM SUFFNESS, M BE Kinghorn, AD Balandrin, MF TI ROLE OF PLANTS IN THE NATIONAL-CANCER-INSTITUTE DRUG DISCOVERY AND DEVELOPMENT PROGRAM SO HUMAN MEDICINAL AGENTS FROM PLANTS SE ACS SYMPOSIUM SERIES LA English DT Review CT SYMP ON HUMAN MEDICINAL AGENTS FROM PLANTS, AT THE 203RD NATIONAL MEETING OF THE AMERICAN CHEMICAL SOC CY APR 05-10, 1992 CL SAN FRANCISCO, CA SP AMER CHEM SOC, DIV AGR & FOOD CHEM, AMER SOC PHARMACOGNOSY, SOC ECON BOT, BRISTOL MYERS SQUIBB PHARM RES INST, GLAXO GRP RES, MURDOCK HEALTHCARE, PHYTOPHARM, SCHERING PLOUGH RES INST, SHAMAN PHARM, WYETH AYERST LABS RP CRAGG, GM (reprint author), NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892, USA. NR 0 TC 29 Z9 29 U1 1 U2 6 PU AMER CHEMICAL SOC PI WASHINGTON PA WASHINGTON SN 0097-6156 BN 0-8412-2705-5 J9 ACS SYM SER PY 1993 VL 534 BP 80 EP 95 PG 16 WC Plant Sciences; Pharmacology & Pharmacy SC Plant Sciences; Pharmacology & Pharmacy GA BY79A UT WOS:A1993BY79A00007 ER PT S AU CARDELLINA, JH GUSTAFSON, KR BEUTLER, JA MCKEE, TC HALLOCK, YF FULLER, RW BOYD, MR AF CARDELLINA, JH GUSTAFSON, KR BEUTLER, JA MCKEE, TC HALLOCK, YF FULLER, RW BOYD, MR BE Kinghorn, AD Balandrin, MF TI NATIONAL-CANCER-INSTITUTE INTRAMURAL RESEARCH ON HUMAN-IMMUNODEFICIENCY-VIRUS INHIBITORY AND ANTITUMOR PLANT NATURAL-PRODUCTS SO HUMAN MEDICINAL AGENTS FROM PLANTS SE ACS SYMPOSIUM SERIES LA English DT Review CT SYMP ON HUMAN MEDICINAL AGENTS FROM PLANTS, AT THE 203RD NATIONAL MEETING OF THE AMERICAN CHEMICAL SOC CY APR 05-10, 1992 CL SAN FRANCISCO, CA SP AMER CHEM SOC, DIV AGR & FOOD CHEM, AMER SOC PHARMACOGNOSY, SOC ECON BOT, BRISTOL MYERS SQUIBB PHARM RES INST, GLAXO GRP RES, MURDOCK HEALTHCARE, PHYTOPHARM, SCHERING PLOUGH RES INST, SHAMAN PHARM, WYETH AYERST LABS RP CARDELLINA, JH (reprint author), NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,DRUG DISCOVERY RES & DEV LAB,FREDERICK,MD 21702, USA. RI Beutler, John/B-1141-2009 OI Beutler, John/0000-0002-4646-1924 NR 0 TC 11 Z9 11 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA WASHINGTON SN 0097-6156 BN 0-8412-2705-5 J9 ACS SYM SER PY 1993 VL 534 BP 218 EP 227 PG 10 WC Plant Sciences; Pharmacology & Pharmacy SC Plant Sciences; Pharmacology & Pharmacy GA BY79A UT WOS:A1993BY79A00015 ER PT J AU SCHMIDT, L LI, H WEI, MH LERMAN, MI ZBAR, B TORY, K AF SCHMIDT, L LI, H WEI, MH LERMAN, MI ZBAR, B TORY, K TI A POLYMORPHIC DINUCLEOTIDE REPEAT PROBE ON CHROMOSOME 3P - LIB 44-36CA (D3S769) SO HUMAN MOLECULAR GENETICS LA English DT Note C1 NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,FREDERICK,MD 21702. RP SCHMIDT, L (reprint author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702, USA. FU NCI NIH HHS [N01-CO-74102] NR 4 TC 2 Z9 2 U1 0 U2 3 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD JAN PY 1993 VL 2 IS 1 BP 89 EP 89 DI 10.1093/hmg/2.1.89-a PG 1 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA KM980 UT WOS:A1993KM98000023 PM 8098247 ER PT J AU LATIF, F TORY, K MODI, W GEIL, L LAFORGIA, S HUEBNER, K ZBAR, B LERMAN, MI AF LATIF, F TORY, K MODI, W GEIL, L LAFORGIA, S HUEBNER, K ZBAR, B LERMAN, MI TI A MSPI POLYMORPHISM AND LINKAGE MAPPING OF THE HUMAN PROTEIN-TYROSINE PHOSPHATASE-G (PTPRG) GENE SO HUMAN MOLECULAR GENETICS LA English DT Note C1 THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107. NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21701. RP LATIF, F (reprint author), NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,FREDERICK,MD 21701, USA. FU PHS HHS [N01-C02-74102] NR 2 TC 2 Z9 2 U1 0 U2 5 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD JAN PY 1993 VL 2 IS 1 BP 91 EP 91 DI 10.1093/hmg/2.1.91 PG 1 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA KM980 UT WOS:A1993KM98000026 PM 7683956 ER PT J AU HILDESHEIM, J KINSLEY, G BISSELL, M PIERCE, J BRANTLY, M AF HILDESHEIM, J KINSLEY, G BISSELL, M PIERCE, J BRANTLY, M TI GENETIC DIVERSITY FROM A LIMITED REPERTOIRE OF MUTATIONS ON DIFFERENT COMMON ALLELIC BACKGROUNDS - ALPHA(1)-ANTITRYPSIN DEFICIENCY VARIANT-P(DUARTE) SO HUMAN MUTATION LA English DT Article DE ALPHA-ANTITRYPSIN; MUTATION; DEFICIENCY; DIVERSITY; GENE ID HUMAN ALPHA-1-ANTITRYPSIN; MOLECULAR ANALYSIS; PI; POLYMORPHISM; PHENOTYPES; VARIANTS; SEQUENCE; SUBTYPE; DNA AB Alpha1-Antitrypsin (alpha1AT) is one of the most polymorphic gene loci in the human genome. Alpha1AT variants are typically identified by their migration position in an isoelectric focusing gel at pH 4-5. Heterogeneity of the isoelectric point of alpha1AT variants, hence variant migration, most often results from amino acid substitutions which alter the net charge of the molecule. We identified an individual heterozygous for an alpha1AT variant migrating in the ''P'' variant region which differs from other known ''P'' variants. Using isoelectric focusing on an immobilized pH gradient at pH 4.50-4.85 the novel P allele, P(duarte), migrates between P(st. albans) and P(lowell). Densitometric analysis of normal ''M'' type alpha1AT and the deficiency variant P(lowell) major bands separated by isoelectric focusing demonstrates that P(duarte) con, tributes approximately 41% as much alpha1AT to the total serum alpha1AT concentration as the normal ''M'' alpha1AT, similar to P(lowell). Direct DNA sequencing of the proband's genomic DNA demonstrates that the P(duarte) allele differs from the normal M1(V213) allele by two amino acid substitutions, R101 (CGT underbar)--> H(CAT underbar) and D256 (GAT underbar)-V (GTT underbar). Individually, these amino acid substitutions characterize the normal M4 allele (R101--> H) and the deficient P(lowell) allele (D256--> V). Thus the P(duarte) allele differs from the P(lowell) allele only by the normal allelic background in which the V256 mutation occurs. Comparison of amino acid sequences among several alpha1AT variants demonstrates that Pd(duarte) is an example of a more general observation regarding diversity within the PI (protease inhibitor) system. It is apparent that the heterogeneity observed among alpha1AT variants is due in part to combinations of a limited repertoire of amino acid substitutions. These combinations may be the product of mutational hot spots and/or recombination on normal allelic backgrounds. (C) 1993 Wiley-Liss, Inc.(dagger) C1 NICHHD,HUMAN GENET BRANCH,GENET DISORDERS SECRETED PROT UNIT,BALTIMORE,MD 21224. CITY HOPE HOSP,DEPT PATHOL,DUARTE,CA 91018. WASHINGTON UNIV,SCH MED,DIV PULM,ST LOUIS,MO 63110. NR 31 TC 9 Z9 10 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PY 1993 VL 2 IS 3 BP 221 EP 228 DI 10.1002/humu.1380020311 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA LK447 UT WOS:A1993LK44700010 PM 8364590 ER PT J AU RAVNIKGLAVAC, M GLAVAC, D KOMEL, R DEAN, M AF RAVNIKGLAVAC, M GLAVAC, D KOMEL, R DEAN, M TI SINGLE-STRANDED CONFORMATION POLYMORPHISM ANALYSIS OF THE CFTR GENE IN SLOVENIAN CYSTIC-FIBROSIS PATIENTS - DETECTION OF MUTATIONS AND SEQUENCE VARIATIONS SO HUMAN MUTATION LA English DT Article DE CYSTIC FIBROSIS; SSCP; CFTR; SLOVENIAN POPULATION; MUTATION DETECTION ID POLYMERASE CHAIN-REACTION; GRADIENT GEL-ELECTROPHORESIS; NUCLEOTIDE-BINDING FOLD; POINT MUTATIONS; BASE SUBSTITUTIONS; DNA-SEQUENCE; IDENTIFICATION; GENERATION; MISMATCHES; REGIONS AB Cystic fibrosis (CF) mutations have been identified in Slovenian CF patients using single-stranded conformation polymorphism (SSCP) analysis. The entire coding region and all of the splice junction sites were screened in 24 patients. By varying the electrophoretic conditions and composition of the gel, 16 different nucleotide changes have been observed in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Three newly described mutations and four previously reported mutations were found. In addition two new polymorphisms have been identified. Of 35 non-DELTAF508 chromosomes examined, mutations were detected on 25.7%, raising the proportion of Slovenian CF alleles characterized to 67.5%. Because of the high sensitivity of the SSCP technique most of the remaining uncharacterized CF mutations probably lie in large introns, promoter sequences, or putative regulatory regions not yet analyzed. (C) 1993 Wiley-Liss, Inc. C1 NCI,FREDERICK CANC RES & DEV CTR,DYNCORP,PROGRAM RESOURCES INC,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702. NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702. UNIV LJUBLJANA,FAC MED,INST BIOCHEM,61000 LJUBLJANA,SLOVENIA. RI Dean, Michael/G-8172-2012 OI Dean, Michael/0000-0003-2234-0631 NR 43 TC 15 Z9 15 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PY 1993 VL 2 IS 4 BP 286 EP 292 DI 10.1002/humu.1380020408 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA LP784 UT WOS:A1993LP78400007 PM 7691352 ER PT J AU FILIE, JD ORRISON, BM WANG, Q LEWIS, MB MARINI, JC AF FILIE, JD ORRISON, BM WANG, Q LEWIS, MB MARINI, JC TI A DE-NOVO G+1-]A MUTATION AT THE ALPHA-2(I) EXON 16 SPLICE DONOR SITE CAUSES SKIPPING OF EXON 16 IN THE CDNA OF ONE ALLELE OF AN OI TYPE-IV PROBAND SO HUMAN MUTATION LA English DT Article DE OSTEOGENESIS IMPERFECTA; TYPE-I COLLAGEN; SPLICING DEFECTS ID ATYPICAL OSTEOGENESIS IMPERFECTA; PRO-ALPHA-2(I) GENE; COLLAGEN; RNA; CHAIN; PROCOLLAGEN; DELETION; COL1A2 AB We have investigated the procollagen, collagen, alpha2(I) mRNA, and DNA of a proband with type IV OI. The proband synthesized two alpha2(I) chains, one with normal electrophoretic migration and one more rapidly migrating. The fast alpha2(I) chain was relatively retained within the cell and was present in collagens synthesized in the presence of alpha,alpha'-dipyridyl. The alpha2(I) cyanogen bromide peptide CB 4-2 contained both normal and rapidly migrating components. Thermal stability of helices containing the rapidly migrating alpha2(I) chain was reduced 6-degrees-C. Parental fibroblast collagens were normal. RNA/RNA hybrids between proband total RNA and antisense riboprobe complementary to alpha2(I) nt 236-1390 were digested with RNase A and T1. Digestion products seen exclusively in the proband suggested a structural change in the region coding for exons 16-19. The region which hybridized to the riboprobe was amplified using RNA-PCR and subcloned. Multiple restriction enzyme digestions of the two subcloned alleles suggested a structural change localized to the region coding for exons 16-17. Sequencing revealed a deletion of the 54 bp comprising exon 16 in the cDNA of one allele. The region of the proband's genomic DNA spanning exons 15-17 was amplified by PCR. The subcloned genomic fragments of each allele were distinguished by RNAJDNA hybrid analysis using a riboprobe complementary to normal genomic DNA from this region. Sequencing revealed a G+1-->A mutation at the exon 16 donor site in one allele. The mutation eliminates a Styl site. Digestion of PCR fragments amplified from the proband and parental WBC DNA revealed that only the proband had the undigested mutant fragment. (C) 1993 Wiley-Liss, Inc.dagger C1 NICHHD,HUMAN GENET BRANCH,CONNECT TISSUE DISORDERS SECT,BETHESDA,MD 20892. NR 22 TC 11 Z9 11 U1 0 U2 4 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PY 1993 VL 2 IS 5 BP 380 EP 388 DI 10.1002/humu.1380020510 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA LZ776 UT WOS:A1993LZ77600009 PM 8257992 ER PT J AU GLAVAC, D DEAN, M AF GLAVAC, D DEAN, M TI OPTIMIZATION OF THE SINGLE-STRAND CONFORMATION POLYMORPHISM (SSCP) TECHNIQUE FOR DETECTION OF POINT MUTATIONS SO HUMAN MUTATION LA English DT Article DE SINGLE-STRANDED CONFORMATION POLYMORPHISM; BETA-GLOBIN GENE; MUTATION DETECTION ID POLYMERASE CHAIN-REACTION; GEL-ELECTROPHORESIS; DNA FRAGMENTS; GENE; PCR AB The efficiency of detection of single base substitutions by single-stranded conformation polymorphism (SSCP) analysis was tested on 86 randomly distributed point mutations in a 193-bp-long DNA fragment of the mouse beta-globin gene. Multiple parameters were varied, including electrophoresis temperature, buffer concentration, gel concentration, acrylamide-to-bis-acrylamide ratio, and/or addition of different compounds to the gel matrix. Gels with a higher concentration of acrylamide and lower crosslinking gave optimal separation, and all 86 mutations can be clearly distinguished from the wild type on a 5% or 7.5% (2.6% C) acrylamide gel at 4-degrees-C. Most of the mutations are also resolvable from wild type on gels with 5% urea or formamide, or 10% dimethylsulfoxide or sucrose. The relative position of the purine and pyrimidine-rich single strands were followed by an asymmetric PCR-SSCP technique. We found that most of the informativity comes from the purine rich strand, which appears to be much more sensitive to changes in the gel. The position or type of mutation showed no co''elation with its ability to be detected. However, the neighboring base sequence around the mutation appears to have an' effect on mobility. For example, A-->G substitutions in GC-rich regions significantly increase the mobility shift of the purine-rich strand, while most G-->A changes decrease it. We conclude that SSCP is a very efficient method for the detection of point mutations, if the parameters that effect the separation are optimized for a particular DNA fragment. (C) 1993 Wiley,Liss, Inc.dagger C1 NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702. NCI,PROGRAM RESOURCES INC DYN CORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21701. RI Dean, Michael/G-8172-2012 OI Dean, Michael/0000-0003-2234-0631 NR 21 TC 208 Z9 216 U1 0 U2 5 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PY 1993 VL 2 IS 5 BP 404 EP 414 DI 10.1002/humu.1380020513 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA LZ776 UT WOS:A1993LZ77600012 PM 8257994 ER PT J AU LAMB, ME AF LAMB, ME TI BIRTH MANAGEMENT AND PERINATAL-CARE - BIOSOCIAL PERSPECTIVES .1. SO HUMAN NATURE-AN INTERDISCIPLINARY BIOSOCIAL PERSPECTIVE LA English DT Article DE BIRTH; LABOR; NEONATES; PERINATAL CARE; EVOLUTION; CROSS-CULTURAL COMPARISON AB In the past four decades, obstetric and neonatal care practices have changed dramatically throughout the western world. As a result, humans now confront unprecedented situations for which they have no biological preparation or cultural experience. In these special issues, an integrated view of the evolving practices of birthing and infant care are discussed from a variety of perspectives. Contributors attempt to show how understanding of the biomedical and psychosocial issues can be informed by cross-cultural and cross-species evidence concerning birth management, neonatal care, and early development. The individual contributions are summarized in this introductory article. RP LAMB, ME (reprint author), NICHHD,SOCIAL & EMOT DEV SECT,BSA BLDG,ROOM 331,9190 ROCKVILLE PIKE,BETHESDA,MD 20814, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ALDINE DE GRUYTER DIVISION WALTER DE GRUYTER INC PI HAWTHORNE PA 200 SAW MILL RIVER, HAWTHORNE, NY 10532 SN 1045-6767 J9 HUM NATURE-INT BIOS JI Hum. Nat.-Interdiscip. Biosoc. Perspect. PY 1993 VL 4 IS 4 BP 323 EP 328 DI 10.1007/BF02692243 PG 6 WC Anthropology; Social Sciences, Biomedical SC Anthropology; Biomedical Social Sciences GA MU521 UT WOS:A1993MU52100001 PM 24214400 ER PT J AU TRUONG, LD KADMON, D MCCUNE, BK FLANDERS, KC SCARDINO, PT THOMPSON, TC AF TRUONG, LD KADMON, D MCCUNE, BK FLANDERS, KC SCARDINO, PT THOMPSON, TC TI ASSOCIATION OF TRANSFORMING GROWTH FACTOR-BETA-1 WITH PROSTATE-CANCER - AN IMMUNOHISTOCHEMICAL STUDY SO HUMAN PATHOLOGY LA English DT Article DE TRANSFORMING GROWTH FACTOR-BETA-1 PROSTATE CANCER; PROSTATE NODULAR HYPERPLASIA ID FACTOR-BETA; MYC PROTOONCOGENE; TRANSGENIC MICE; TGF-BETA; EXPRESSION; CARCINOMA; RAS; HYPERPLASIA; CELLS; GENE C1 BAYLOR COLL MED,SCOTT DEPT UROL,6535 FANNIN,F427A,HOUSTON,TX 77030. METHODIST HOSP,DEPT PATHOL,HOUSTON,TX 77030. BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030. VET AFFAIRS MED CTR,UROL RES LAB,HOUSTON,TX. NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892. FU NCI NIH HHS [CA50588] NR 31 TC 160 Z9 165 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0046-8177 J9 HUM PATHOL JI Hum. Pathol. PD JAN PY 1993 VL 24 IS 1 BP 4 EP 9 DI 10.1016/0046-8177(93)90055-L PG 6 WC Pathology SC Pathology GA KJ122 UT WOS:A1993KJ12200002 PM 7678092 ER PT J AU BYRD, LG AF BYRD, LG TI REGIONAL LOCALIZATION OF THE NU-MUTATION ON MOUSE CHROMOSOME-II SO IMMUNOGENETICS LA English DT Article ID GENE; CLONING; ACTIVATION; LINKAGE; GENOME; CDNA C1 UNIV MARYLAND,DEPT ZOOL,COLL PK,MD 20742. RP BYRD, LG (reprint author), NCI,BLDG 37,RM 2B08,BETHESDA,MD 20892, USA. NR 14 TC 9 Z9 9 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0093-7711 J9 IMMUNOGENETICS JI Immunogenetics PD JAN PY 1993 VL 37 IS 2 BP 157 EP 159 PG 3 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA JZ681 UT WOS:A1993JZ68100013 PM 8423056 ER PT J AU CARRINGTON, M COLONNA, M SPIES, T STEPHENS, JC MANN, DL AF CARRINGTON, M COLONNA, M SPIES, T STEPHENS, JC MANN, DL TI HAPLOTYPIC VARIATION OF THE TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING (TAP) GENES AND THEIR EXTENSION OF HLA CLASS-II REGION HAPLOTYPES SO IMMUNOGENETICS LA English DT Article ID MAJOR HISTOCOMPATIBILITY COMPLEX; MHC; MOLECULES; PROTEIN; PATHWAY; FAMILY; CELLS; SB AB Stable cell surface presentation of HLA class I molecules requires active transport of antigenic peptides across the endoplasmic reticulum by products of two genes, TAP1 and TAP2, which map in the major histocompatibility complex class II region. Alleles of each gene are derived from a combination of variable sites at each locus. In this study, TAP1 and TAP2 alleles were identified in homozygous typing cell (HTC) lines, allowing resolution of specific haplotypes in conjunction with the highly polymorphic HLA class II region haplotypes. Three alleles at each TAP locus were found from which eight haplotypes could be assigned. Determination of TAP1 and TAP2 alleles in cell lines homozygous at DR, DQ, and DP created eight additional haplotypes beyond the number observed with these class II genes alone. Complete analysis of DR, DQ, TAP, and DP genotypes in 66 HTCs resulted in the following groups: 1) 46 homozygotes; 2) nine homozygous at DR, DQ, and TAP, but heterozygous at DP; 3) four homozygous at DR, DQ, and DP, but heterozygous at one or both TAP genes; 4) four homozygous at DR and DQ, but heterozygous at TAP and DP; and 5) three complex genotypes heterozygous at DP, TAP, and at least one of DQA1, DQB1, or DRB1 loci. TAP1 and TAP2 genes map in an area of frequent recombination. TAP alleles were determined in five DQB1, DPB1 recombinant individuals, three of which were informative. Recombination was found between DQB1 and the TAP loci in two individuals and between TAP and DPB1 in the other individual. C1 NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115. RP CARRINGTON, M (reprint author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702, USA. OI Colonna, Marco/0000-0001-5222-4987 FU NCI NIH HHS [N01-CO-74102] NR 33 TC 100 Z9 100 U1 0 U2 2 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0093-7711 J9 IMMUNOGENETICS JI Immunogenetics PD JAN PY 1993 VL 37 IS 4 BP 266 EP 273 PG 8 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA KD737 UT WOS:A1993KD73700004 PM 8267790 ER PT J AU HUPPI, K SIWARSKI, D SHAUGHNESSY, J KLEMSZ, MJ SHIRAKATA, M MAKI, R SAKANO, H AF HUPPI, K SIWARSKI, D SHAUGHNESSY, J KLEMSZ, MJ SHIRAKATA, M MAKI, R SAKANO, H TI GENES ASSOCIATED WITH IMMUNOGLOBULIN V(D)J RECOMBINATION ARE LINKED ON MOUSE CHROMOSOME-2 AND HUMAN CHROMOSOME-11 SO IMMUNOGENETICS LA English DT Article ID TRANSCRIPTION FACTOR; REGION GENE; DNA; SEQUENCES; MUTATION; ONCOGENE; SITES; RAG-1; PU.1 C1 LA JOLLA CANC RES FDN,LA JOLLA,CA 92037. UNIV CALIF BERKELEY,DIV IMMUNOL,BIOL CHEM LAB,BERKELEY,CA 94720. RP HUPPI, K (reprint author), NCI,GENET LAB,MOLEC GENET SECT,BLDG 37,RM 2B-21,BETHESDA,MD 20892, USA. NR 21 TC 4 Z9 4 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0093-7711 J9 IMMUNOGENETICS JI Immunogenetics PD JAN PY 1993 VL 37 IS 4 BP 288 EP 291 PG 4 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA KD737 UT WOS:A1993KD73700008 PM 8093609 ER PT J AU HODES, RJ ABE, R GALLAHAN, D CALLAHAN, R AF HODES, RJ ABE, R GALLAHAN, D CALLAHAN, R TI T-CELL RECEPTOR B-V REPERTOIRE EXPRESSION IN THE ABSENCE OF AN ENDOGENOUS MOUSE MAMMARY-TUMOR PROVIRUS SO IMMUNOGENETICS LA English DT Article ID MAJOR HISTOCOMPATIBILITY COMPLEX; SELF-ANTIGENS; I-E; TOLERANCE; DELETION; GENE; MICE; MHC; V-BETA-11; PRODUCTS C1 NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892. RP HODES, RJ (reprint author), NCI,EXPTL IMMUNOL BRANCH,BLDG 10,RM 4B17,BETHESDA,MD 20892, USA. NR 16 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0093-7711 J9 IMMUNOGENETICS JI Immunogenetics PD JAN PY 1993 VL 37 IS 4 BP 309 EP 311 PG 3 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA KD737 UT WOS:A1993KD73700013 PM 8380566 ER PT J AU HATHCOCK, KS HIRANO, H HODES, RJ AF HATHCOCK, KS HIRANO, H HODES, RJ TI CD45 EXPRESSION BY MURINE B-CELLS AND T-CELLS - ALTERATION OF CD45 ISOFORMS IN SUBPOPULATIONS OF ACTIVATED B-CELLS SO IMMUNOLOGIC RESEARCH LA English DT Article DE CD45; B-CELL; T-CELL; THYMUS; ISOFORM; ACTIVATED B-CELLS ID LEUKOCYTE-COMMON ANTIGEN; PROTEIN TYROSINE PHOSPHATASE; ALTERNATIVELY SPLICED EXONS; DIFFERENTIATION ANTIGENS; LYMPHOCYTE-B; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; SURFACE-ANTIGENS; RECEPTOR; T200 AB The CD45 family of high molecular weight cell surface glycoproteins is abundantly expressed by virtually all hematopoietic cells. CD45 molecules exist as multiple isoforms whose extracellular portions vary in protein structure and carbohydrate content but whose intracellular portions are highly conserved and possess tyrosine phosphatase activity. In this review we summarize current studies describing CD45 isoform expression on peripheral and thymic lymphocytes. Further, we analyze changes in CD45 isoform expression by selective populations of activated B cells. RP HATHCOCK, KS (reprint author), NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892, USA. NR 61 TC 19 Z9 19 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 SN 0257-277X J9 IMMUNOL RES JI Immunol. Res. PY 1993 VL 12 IS 1 BP 21 EP 36 DI 10.1007/BF02918366 PG 16 WC Immunology SC Immunology GA LB994 UT WOS:A1993LB99400003 PM 8515182 ER PT J AU BLOCH, EF RAHBAR, M WRIGHT, AK PATTERSON, AM SOUZA, RF HAMMER, CH GAITHER, TA JOINER, KA AF BLOCH, EF RAHBAR, M WRIGHT, AK PATTERSON, AM SOUZA, RF HAMMER, CH GAITHER, TA JOINER, KA TI POTASSIUM CYANIDE PROTECTS ESCHERICHIA-COLI FROM COMPLEMENT KILLING BY THE INHIBITION OF C3-CONVERTASE ACTIVITY SO IMMUNOLOGICAL INVESTIGATIONS LA English DT Article ID COMPONENTS; MUTANT; C5B-9; C9 AB The exact mechanism by which deposited C5b-9 complexes kill Gram-negative bacteria is unclear. It has been proposed that during complement activation the membrane attack complex triggers an energy dependent process in Gram-negative bacteria that mediates destruction of the inner membrane. This observation in part resulted from the survival of Gram-negative bacteria that were incubated with an uncoupler (DNP) or an inhibitor (KCN) of oxidative phosphorylation during complement activation. In a reexamination of this issue we employed potassium cyanide (KCN) to block energy dependent pathways and observed a dose dependent inhibition of C9 uptake on E. coli J5 during serum incubation, suggesting that cyanide was interfering with complement activation. To verify the effect on complement activation we chose specifically to study the effects of KCN on the C3 convertase of the classical pathway. Sensitized sheep erythrocytes were employed as our model system. This system allowed us to construct a series of stable intermediates that were used to test the effect of cyanide on the formation and activity of precursors of the classical pathway C3 convertase. The data illustrate that the concentrations of potassium cyanide that inhibit complement killing of J5 also inhibit C3 convertase activity on sensitized sheep erythrocytes. The results of this study refute the principal observation made by other investigators, that potassium cyanide protects bacteria from complement killing by inhibiting bacterial energy dependent pathways that spark inner membrane destruction. A better scenario is that the organisms survive because cyanide inhibits complement activation. C1 NIAID,CLIN INVEST LAB,BETHESDA,MD 20892. YALE UNIV,DEPT MED,INFECT DIS SECT,NEW HAVEN,CT 06520. RP BLOCH, EF (reprint author), HOWARD UNIV,COLL MED,DEPT MICROBIOL,WASHINGTON,DC 20001, USA. NR 16 TC 3 Z9 3 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0882-0139 J9 IMMUNOL INVEST JI Immunol. Invest. PY 1993 VL 22 IS 2 BP 127 EP 149 DI 10.3109/08820139309063396 PG 23 WC Immunology SC Immunology GA KV191 UT WOS:A1993KV19100006 PM 8505069 ER PT J AU HOLLADAY, S BLAYLOCK, B SMITH, B LUSTER, M AF HOLLADAY, S BLAYLOCK, B SMITH, B LUSTER, M TI PNA LECTIN-BASED SEPARATION OF THYMOCYTES INTO MATURE AND IMMATURE SUBPOPULATIONS - CD4-8- DOUBLE-NEGATIVE CELLS DISPLAY CHARACTERISTICS OF PNA(1O) MATURE THYMOCYTES SO IMMUNOLOGICAL INVESTIGATIONS LA English DT Article ID ADULT MURINE THYMUS; PEANUT AGGLUTININ; EXTRACELLULAR-MATRIX; ANTIGEN EXPRESSION; MOUSE THYMOCYTES; DEFINED MEDIUM; GROWN-INVITRO; DIOXIN TCDD; FETAL; EXPOSURE AB Cortical (immature) thymocytes are widely reported to express intermediate to high levels of receptors for the lectin, peanut agglutinin (PNA). Light-scatter studies of murine fetal thymocytes stained with PNA or anti-mouse CD4 and CD8 monoclonal antibodies indicated, however, that the most immature CD4-8- (DN) thymocyte subpopulation binds levels of PNA commonly described as PNA(lo). Evaluation of the PNA binding characteristics of fetal thymocytes negative for the CD8 antigen confirmed the existence of a major population (approximately 20% of total cells) of CD4-8- PNA(lo) fetal thymocytes. The majority of these DN thymocytes were subsequently found to bind sub-agglutinating levels of PNA, similar to mature CD4+ or CD8+ single positive (SP) thymocytes. Given this information, an immunomodulating compound (2,3,7,8-tetrachlorodibenzo-p-dioxin; TCDD) known to produce a maturational delay in murine thymocytes was tested for a possible concurrent effect on thymocyte PNA lectin binding. A TCDD-induced increase in DN thymocytes was found to be paralleled by an increase of equal magnitude in PNA(lo) thymocytes. Taken together, these data provide evidence that acquisition of the PNA receptor may be a maturational event occurring during the DN stage of thymocyte ontogeny. Further, these results suggest that separation of thymocytes into mature (medullary) and immature (cortical) subpopulations by PNA agglutination may result in contamination of medullary cells by the most immature (DN) subpopulation of thymocytes. C1 NE LOUISIANA UNIV,DEPT BIOL,MONROE,LA 71209. NIEHS,ENVIRONMENTAL IMMUNOL & NEUROBIOL SECT,RES TRIANGLE PK,NC 27709. RP HOLLADAY, S (reprint author), VIRGINIA POLYTECH INST & STATE UNIV,VIRGINIA MARYLAND REG COLL VET MED,DEPT BIOMED SCI,BLACKSBURG,VA 24061, USA. NR 33 TC 8 Z9 8 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0882-0139 J9 IMMUNOL INVEST JI Immunol. Invest. PY 1993 VL 22 IS 8 BP 517 EP 529 DI 10.3109/08820139309084180 PG 13 WC Immunology SC Immunology GA ML432 UT WOS:A1993ML43200003 PM 8300160 ER PT B AU HOOFNAGLE, JH AF HOOFNAGLE, JH BE MeyerZumBuschenfelde, KH Hoofnagle, JH Manns, M TI INNOVATIVE THERAPIES FOR CHRONIC HEPATITIS-B SO IMMUNOLOGY AND LIVER SE FALK SYMPOSIUM LA English DT Proceedings Paper CT 70TH Falk Symposium on Immunology and Liver CY OCT 18-20, 1992 CL BASEL, SWITZERLAND C1 NIH,DEPT HLTH & HUMAN SERV,DIV DIGEST DIS & NUTR,BETHESDA,MD 20892. NR 0 TC 2 Z9 2 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 0-7923-8830-5 J9 FALK SYMP PY 1993 VL 70 BP 120 EP 130 PG 11 WC Gastroenterology & Hepatology; Immunology SC Gastroenterology & Hepatology; Immunology GA BZ95U UT WOS:A1993BZ95U00015 ER PT B AU POHL, LR AF POHL, LR BE MeyerZumBuschenfelde, KH Hoofnagle, JH Manns, M TI IDENTIFICATION AND CHARACTERIZATION OF PROTEIN ADDUCTS OF REACTIVE METABOLITES BY THE USE OF SPECIFIC ANTIBODIES SO IMMUNOLOGY AND LIVER SE FALK SYMPOSIUM LA English DT Proceedings Paper CT 70TH Falk Symposium on Immunology and Liver CY OCT 18-20, 1992 CL BASEL, SWITZERLAND C1 NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 0-7923-8830-5 J9 FALK SYMP PY 1993 VL 70 BP 284 EP 292 PG 9 WC Gastroenterology & Hepatology; Immunology SC Gastroenterology & Hepatology; Immunology GA BZ95U UT WOS:A1993BZ95U00032 ER PT J AU GOLDENBERG, DM SCHLOM, J AF GOLDENBERG, DM SCHLOM, J TI THE COMING OF AGE OF CANCER RADIOIMMUNOCONJUGATES SO IMMUNOLOGY TODAY LA English DT Article AB Great progress imaging and therapy with radioimmunoconjugates was discussed at the fourth conference on radioimmunodetection and radioimmunotherapy of cancer.* Monoclonal antibody-based cancer imaging agents are awaiting marketing approval and newer, potentially improved forms are in development. Tumor responses to radioimmunoconjugates are also being reported in increasing numbers, this is especially so with radiosensitive tumors and in regional or direct applications. C1 NCI,DCBDC,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892. RP GOLDENBERG, DM (reprint author), GARDEN STATE CANC CTR,CTR MOLEC MED & IMMUNOL,NEWARK,NJ 07103, USA. NR 1 TC 22 Z9 22 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB SN 0167-5699 J9 IMMUNOL TODAY JI Immunol. Today PD JAN PY 1993 VL 14 IS 1 BP 5 EP 7 DI 10.1016/0167-5699(93)90315-C PG 3 WC Immunology SC Immunology GA KJ589 UT WOS:A1993KJ58900003 PM 8442865 ER PT S AU STGEORGIEV, V AF STGEORGIEV, V BE Georgiev, VS Yamaguchi, H TI IMMUNOMODULATING DRUGS - MAJOR ADVANCES IN RESEARCH-AND-DEVELOPMENT SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP STGEORGIEV, V (reprint author), NIAID,SOLAR BLDG,ROOM 4C-39,BETHESDA,MD 20892, USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 1 EP 10 PG 10 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00001 PM 8363213 ER PT S AU STGEORGIEV, V AF STGEORGIEV, V BE Georgiev, VS Yamaguchi, H TI ENZYMES OF THE PURINE METABOLISM - INHIBITION AND THERAPEUTIC POTENTIAL SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP STGEORGIEV, V (reprint author), NIAID,SOLAR BLDG,ROOM 4C-39,BETHESDA,MD 20892, USA. NR 0 TC 10 Z9 10 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 207 EP 216 PG 10 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00025 PM 8103311 ER PT S AU JANIK, J KOPP, WC SMITH, JW LONGO, DL ALVORD, WG URBA, WJ AF JANIK, J KOPP, WC SMITH, JW LONGO, DL ALVORD, WG URBA, WJ BE Georgiev, VS Yamaguchi, H TI LEVAMISOLE-INDUCED NEOPTERIN SYNTHESIS SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP JANIK, J (reprint author), NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21701, USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 252 EP 258 DI 10.1111/j.1749-6632.1993.tb35873.x PG 7 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00030 PM 8363229 ER PT S AU INMAN, JK AF INMAN, JK BE Georgiev, VS Yamaguchi, H TI SYNTHESES OF MACROMOLECULAR IMMUNOMODULATORS AND CONJUGATES EMPLOYING HALOACETYL REAGENTS SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP INMAN, JK (reprint author), NIAID,IMMUNOL LAB,BLDG 10,ROOM 11N311,BETHESDA,MD 20892, USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 347 EP 350 DI 10.1111/j.1749-6632.1993.tb35887.x PG 4 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00044 PM 8363239 ER PT S AU FAUCI, AS AF FAUCI, AS BE Georgiev, VS Yamaguchi, H TI IMMUNOPATHOGENESIS OF HIV-INFECTION SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP FAUCI, AS (reprint author), NIAID,BETHESDA,MD 20892, USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 409 EP 419 DI 10.1111/j.1749-6632.1993.tb35899.x PG 11 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00054 ER PT S AU RUSCETTI, F VARESIO, L OCHOA, A ORTALDO, J AF RUSCETTI, F VARESIO, L OCHOA, A ORTALDO, J BE Georgiev, VS Yamaguchi, H TI PLEIOTROPIC EFFECTS OF TRANSFORMING GROWTH-FACTOR-BETA ON CELLS OF THE IMMUNE-SYSTEM SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP RUSCETTI, F (reprint author), NCI,FREDERICK CANC RES & DEV CTR,LEUKOCYTE BIOL MOLEC IMMUNOREGULAT & EXPTL IMMUNOL LABS,FREDERICK,MD 21702, USA. RI varesio, luigi/J-8261-2016 OI varesio, luigi/0000-0001-5659-2218 NR 0 TC 69 Z9 69 U1 0 U2 5 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 488 EP 500 DI 10.1111/j.1749-6632.1993.tb35911.x PG 13 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00064 PM 8363258 ER PT S AU PLAUT, M AF PLAUT, M BE Georgiev, VS Yamaguchi, H TI CYTOKINES AND MODULATION OF DISEASES OF IMMEDIATE HYPERSENSITIVITY SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP PLAUT, M (reprint author), NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,ASTHMA & ALLERGY BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 512 EP 520 DI 10.1111/j.1749-6632.1993.tb35913.x PG 9 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00066 PM 8363259 ER PT S AU STGEORGIEV, V ALBRIGHT, JF AF STGEORGIEV, V ALBRIGHT, JF BE Georgiev, VS Yamaguchi, H TI CYTOKINES AND THEIR ROLE AS GROWTH-FACTORS AND IN REGULATION OF IMMUNE-RESPONSES SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP STGEORGIEV, V (reprint author), NIAID,SOLAR BLDG,ROOM 4C-39,BETHESDA,MD 20892, USA. NR 0 TC 9 Z9 10 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 584 EP 602 PG 19 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00075 PM 8363268 ER PT S AU WALDMANN, TA GOLDMAN, C TOP, L GRANT, A BURTON, J BAMFORD, R ROESSLER, E HORAK, I ZAKNOEN, S KASTENSPORTES, C WHITE, J ENGLAND, R HORAK, E MARTINUCCI, J TINUBU, SA MISHRA, B JUNGHANS, R DIPRE, M CARRASQUILLO, J REYNOLDS, J GANSOW, O NELSON, D AF WALDMANN, TA GOLDMAN, C TOP, L GRANT, A BURTON, J BAMFORD, R ROESSLER, E HORAK, I ZAKNOEN, S KASTENSPORTES, C WHITE, J ENGLAND, R HORAK, E MARTINUCCI, J TINUBU, SA MISHRA, B JUNGHANS, R DIPRE, M CARRASQUILLO, J REYNOLDS, J GANSOW, O NELSON, D BE Georgiev, VS Yamaguchi, H TI THE INTERLEUKIN-2 RECEPTOR - A TARGET FOR IMMUNOTHERAPY SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP WALDMANN, TA (reprint author), NCI,METAB BRANCH,BETHESDA,MD 20892, USA. RI Carrasquillo, Jorge/E-7120-2010; OI Carrasquillo, Jorge/0000-0002-8513-5734 NR 0 TC 6 Z9 6 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 603 EP 610 DI 10.1111/j.1749-6632.1993.tb35923.x PG 8 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00076 PM 8363269 ER PT S AU ALBRIGHT, JF AF ALBRIGHT, JF BE Georgiev, VS Yamaguchi, H TI IMMUNE DYSFUNCTION RELATED TO DRUG-METABOLIZING-ENZYMES SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP ALBRIGHT, JF (reprint author), NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,SOLAR BLDG,ROOM 4A22,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 620 EP 623 DI 10.1111/j.1749-6632.1993.tb35927.x PG 4 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00080 PM 8395782 ER PT S AU SNELLER, MC LANE, HC AF SNELLER, MC LANE, HC BE Georgiev, VS Yamaguchi, H TI IMMUNOLOGICAL APPROACHES TO THE THERAPY OF HIV-1 INFECTION SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP LANE, HC (reprint author), NIAID,IMMUNOREGULAT LAB,BLDG 10,RM 11B-13,BETHESDA,MD 20892, USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 687 EP 696 DI 10.1111/j.1749-6632.1993.tb35932.x PG 10 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00085 PM 8363275 ER PT S AU ROHRBAUGH, ML MCGOWAN, JJ AF ROHRBAUGH, ML MCGOWAN, JJ BE Georgiev, VS Yamaguchi, H TI GENE-TRANSFER FOR THERAPY AND PROPHYLAXIS OF HIV-1 INFECTION SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP ROHRBAUGH, ML (reprint author), NIAID,DIV EXTRAMURAL ACTIVITIES,BETHESDA,MD 20892, USA. OI Rohrbaugh, Mark/0000-0002-6136-3337 NR 0 TC 2 Z9 2 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 697 EP 712 DI 10.1111/j.1749-6632.1993.tb35933.x PG 16 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00086 PM 8363276 ER PT S AU FITZGERALD, D PASTAN, I AF FITZGERALD, D PASTAN, I BE Georgiev, VS Yamaguchi, H TI PSEUDOMONAS EXOTOXIN AND RECOMBINANT IMMUNOTOXINS DERIVED FROM IT SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP FITZGERALD, D (reprint author), NCI,DIV CANC BIOL DIAGN & CTR,MOLEC BIOL LAB,BLDG 36,1D-32,BETHESDA,MD 20892, USA. NR 0 TC 27 Z9 27 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 740 EP 745 DI 10.1111/j.1749-6632.1993.tb35935.x PG 6 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00088 PM 8363279 ER PT S AU HOTH, DF AF HOTH, DF BE Georgiev, VS Yamaguchi, H TI ISSUES IN THE DEVELOPMENT OF A PROPHYLACTIC HIV VACCINE SO IMMUNOMODULATING DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL EVALUATION CY FEB 27-JUL 01, 1992 CL WASHINGTON, DC SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO RP HOTH, DF (reprint author), NIAID,DIV AIDS,6003 EXECUT BLVD,ROOM 2A18,BETHESDA,MD 20892, USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-771-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 685 BP 777 EP 783 DI 10.1111/j.1749-6632.1993.tb35943.x PG 7 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA BY53M UT WOS:A1993BY53M00096 PM 8363285 ER PT J AU AIELLO, FB GUSELLA, L LONGO, DL BIRCHENALLROBERTS, M TAKACS, L TAKEI, F RUSCETTI, F MUSIANI, P DURUM, SK AF AIELLO, FB GUSELLA, L LONGO, DL BIRCHENALLROBERTS, M TAKACS, L TAKEI, F RUSCETTI, F MUSIANI, P DURUM, SK TI INDUCIBLE ACCESSORY FUNCTION OF A MACROPHAGE CELL-LINE SO IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY LA English DT Article ID ANTIGEN-PRESENTING CELLS; ADHESION MOLECULE-1 ICAM-1; AUTOCRINE GROWTH-FACTOR; LYMPHOCYTE-T CLONES; MONOCLONAL-ANTIBODY; DENDRITIC CELLS; B-CELLS; PROLIFERATIVE RESPONSES; IMMUNE INTERFERON; EXPRESSION AB Costimulatory molecules in addition to occupancy of the T-cell antigen receptor, are required to induce T-cell proliferation.Previous work suggested that membrane molecules responsible for costimulatory activity were not constitutively expressed on the antigen presenting cell (APC) surface. In the present study, we have identified a cloned macrophage cell line (FLJ2) with inducible APC function. The unactivated FLJ2 line could not induce T-cell proliferation. FLJ2 could present alloantigen, and stimulate proliferation of either a T-cell clone or normal resting T cells following activation with IFN gamma or unexpectedly with lipopolysaccaride (LPS)-Activated FLJ2 cells could be fixed and APC function was preserved. The relevant inducible molecules required for APC function appeared distinct from Ia and IL1. The expression of ICAM-1 and LFA-1 was increased during activation and anti-LFA-1 antibody blocked APC function. This suggests that one important feature of the activation process may be improvement of cellular adhesion. C1 CONSORZIO MARIO NEGRI S,IST RIC FARMACOL & BIOMED MARIO NEGRI,I-66030 SANTA MARIA IMBAR,ITALY. NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21701. CANC CONTROL AGCY,VANCOUVER V5Z 3J3,BC,CANADA. RP AIELLO, FB (reprint author), NCI,FREDERICK CANC RES & DEV CTR,DYNCORP,PROGRAM RESOURCES INC,FREDERICK,MD 21701, USA. FU NCI NIH HHS [N01-CO-74102] NR 59 TC 1 Z9 1 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0892-3973 J9 IMMUNOPHARM IMMUNOT JI Immunopharmacol. Immunotoxicol. PY 1993 VL 15 IS 4 BP 327 EP 353 DI 10.3109/08923979309035232 PG 27 WC Immunology; Pharmacology & Pharmacy; Toxicology SC Immunology; Pharmacology & Pharmacy; Toxicology GA LU849 UT WOS:A1993LU84900001 PM 7901265 ER PT S AU WHITCUP, SM NUSSENBLATT, RB AF WHITCUP, SM NUSSENBLATT, RB BE Allison, AC Lafferty, KJ Fliri, H TI TREATMENT OF AUTOIMMUNE UVEITIS SO IMMUNOSUPPRESSIVE AND ANTIINFLAMMATORY DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Immunosuppressive and Antiinflammatory Drugs CY APR 12-15, 1993 CL ORLANDO, FL SP NEW YORK ACAD SCI ID INTERCELLULAR-ADHESION MOLECULE-1; INTRAOCULAR INFLAMMATORY DISEASE; LOW-DOSE CYCLOSPORINE; LYMPHOCYTE-T SUBSETS; SYMPATHETIC OPHTHALMIA; BEHCETS-DISEASE; S-ANTIGEN; RHEUMATOID-ARTHRITIS; MYCOPHENOLIC-ACID; IMMUNOSUPPRESSIVE AGENT RP WHITCUP, SM (reprint author), NEI,BLDG 10,ROOM 10N 202,BETHESDA,MD 20892, USA. NR 99 TC 12 Z9 12 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-835-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 696 BP 307 EP 318 PG 12 WC Immunology; Multidisciplinary Sciences; Pharmacology & Pharmacy SC Immunology; Science & Technology - Other Topics; Pharmacology & Pharmacy GA BZ60M UT WOS:A1993BZ60M00032 PM 8109836 ER PT S AU JONES, EA BERGASA, NV AF JONES, EA BERGASA, NV BE Allison, AC Lafferty, KJ Fliri, H TI IMMUNOSUPPRESSIVE TREATMENT OF CHRONIC LIVER-DISEASE SO IMMUNOSUPPRESSIVE AND ANTIINFLAMMATORY DRUGS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Immunosuppressive and Antiinflammatory Drugs CY APR 12-15, 1993 CL ORLANDO, FL SP NEW YORK ACAD SCI ID PRIMARY BILIARY-CIRRHOSIS; CHRONIC ACTIVE HEPATITIS; PRIMARY SCLEROSING CHOLANGITIS; CONTROLLED TRIAL; URSODEOXYCHOLIC ACID; DOUBLE-BLIND; AZATHIOPRINE; METHOTREXATE; LYMPHOCYTES; MULTICENTER C1 UNIV LONDON ROYAL FREE HOSP,DEPT MED,LONDON,ENGLAND. NIH,LIVER DIS SECT,BETHESDA,MD. NR 52 TC 4 Z9 4 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-835-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 696 BP 319 EP 327 PG 9 WC Immunology; Multidisciplinary Sciences; Pharmacology & Pharmacy SC Immunology; Science & Technology - Other Topics; Pharmacology & Pharmacy GA BZ60M UT WOS:A1993BZ60M00033 PM 8109838 ER PT B AU YUSPA, SH AF YUSPA, SH BE Goldberg, AM TI IN-VITRO MODELS TO EVALUATE AGENTS THAT CONTRIBUTE TO CUTANEOUS CARCINOGENESIS SO IN VITRO TOXICOLOGY: TENTH ANNIVERSARY SYMPOSIUM OF CAAT SE ALTERNATIVE METHODS IN TOXICOLOGY SERIES LA English DT Proceedings Paper CT 10th Anniversary Symposium of CAAT - In Vitro Toxicology CY APR 14-16, 1992 CL JOHNS HOPKINS HLTH INST, BALTIMORE, MD SP US EPA, NIH, HLTH EFFECTS RES LAB, 3M, ALBERTO CULVER CO, ARCO, AVAON PROD INC, BERNICE BARBOUR FDN INC, BRISTOL MYERS SQUIBB CO, CHARLES RIVER LABS INC, CIBA GEIGY CORP, COSMET TOILETRY & FRAGRANCE ASSOC, GERALDINE R DODGE FDN, EXXON CORP, HOFFMANN LA ROCHE INC, IBM CORP, JOHNSON & JOHNSON, L OREAL, MARY KAY COSMET INC HO JOHNS HOPKINS HLTH INST C1 NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 BN 0-913113-60-3 J9 ALTERN METH PY 1993 VL 9 BP 49 EP 53 PG 5 WC Toxicology SC Toxicology GA BB48D UT WOS:A1993BB48D00005 ER PT S AU CHADWICK, RS AZANCOTBENISTY, A OHAYON, J ITO, Y AF CHADWICK, RS AZANCOTBENISTY, A OHAYON, J ITO, Y BE Sideman, S Beyar, R TI RIGHT AND LEFT-VENTRICLE INTERACTION AND REMODELING IN CONGENITAL HEART-DISEASE SO INTERACTIVE PHENOMENA IN THE CARDIAC SYSTEM SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 8th Henry Goldberg Workshop on Interactive Phenomena in the Cardiac System CY DEC 06-10, 1992 CL BETHESDA, MD SP MR HENRY GOLDBERG, NIH, TECHNION ISRAEL INST TECHNOL, ISRAEL CARDIOL SOC C1 HOP ROBERT DEBRE,EXPLORAT FONCT LAB,F-75019 PARIS,FRANCE. UNIV PARIS 12,MECAN PHYS LAB,F-94010 CRETEIL,FRANCE. HIROSHIMA UNIV MED,DEPT INTERNAL MED 2,MINAMI KU,1-2-3 KASUMI,HIROSHIMA 734,JAPAN. RP CHADWICK, RS (reprint author), NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892, USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44637-5 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1993 VL 346 BP 373 EP 381 PG 9 WC Cardiac & Cardiovascular Systems; Medicine, General & Internal; Physiology SC Cardiovascular System & Cardiology; General & Internal Medicine; Physiology GA BZ51S UT WOS:A1993BZ51S00036 PM 8184777 ER PT S AU ADAM, DR KEMPNER, KM VIVINO, MA TUCKER, EE JONES, M AF ADAM, DR KEMPNER, KM VIVINO, MA TUCKER, EE JONES, M BE Sideman, S Beyar, R TI CARDIOVASCULAR FLOW VELOCITY-MEASUREMENTS BY 2D DOPPLER IMAGING FOR ASSESSMENT OF VASCULAR FUNCTION SO INTERACTIVE PHENOMENA IN THE CARDIAC SYSTEM SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 8th Henry Goldberg Workshop on Interactive Phenomena in the Cardiac System CY DEC 06-10, 1992 CL BETHESDA, MD SP MR HENRY GOLDBERG, NIH, TECHNION ISRAEL INST TECHNOL, ISRAEL CARDIOL SOC C1 NHLBI,DIV COMP RESOURCES & TECHNOL,CARDIOL BRANCH,BETHESDA,MD 20892. RP ADAM, DR (reprint author), TECHNION ISRAEL INST TECHNOL,CTR HEART SYST RES,JULIUS SILVER INST,DEPT BIOMED ENGN,HAIFA,ISRAEL. NR 0 TC 2 Z9 2 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44637-5 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1993 VL 346 BP 393 EP 399 PG 7 WC Cardiac & Cardiovascular Systems; Medicine, General & Internal; Physiology SC Cardiovascular System & Cardiology; General & Internal Medicine; Physiology GA BZ51S UT WOS:A1993BZ51S00038 PM 8184780 ER PT S AU SIDEMAN, S BASSINGTHWAIGHTE, J CHADWICK, R BEYAR, R RUDY, Y LANDESBERG, A RITMAN, E GOTSMAN, M WESTERHOF, N YELLIN, E FORD, LE AF SIDEMAN, S BASSINGTHWAIGHTE, J CHADWICK, R BEYAR, R RUDY, Y LANDESBERG, A RITMAN, E GOTSMAN, M WESTERHOF, N YELLIN, E FORD, LE BE Sideman, S Beyar, R TI A VIEW INTO THE FUTURE - DISCUSSION SO INTERACTIVE PHENOMENA IN THE CARDIAC SYSTEM SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Discussion CT 8th Henry Goldberg Workshop on Interactive Phenomena in the Cardiac System CY DEC 06-10, 1992 CL BETHESDA, MD SP MR HENRY GOLDBERG, NIH, TECHNION ISRAEL INST TECHNOL, ISRAEL CARDIOL SOC C1 UNIV WASHINGTON,CTR BIOENGN WD12,SEATTLE,WA 98195. NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892. CASE WESTERN RESERVE UNIV,DEPT BIOMED ENGN,CLEVELAND,OH 44106. HADASSAH UNIV HOSP,DEPT CARDIOL,IL-91120 JERUSALEM,ISRAEL. MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905. FREE UNIV AMSTERDAM,PHYSIOL LAB,1081 BT AMSTERDAM,NETHERLANDS. FREE UNIV AMSTERDAM,INST CARDIOVASC RES,AMSTERDAM,NETHERLANDS. UNIV CHICAGO,CARDIOL SECT,CHICAGO,IL 60637. RP SIDEMAN, S (reprint author), TECHNION ISRAEL INST TECHNOL,CTR HEART SYST RES,JULIUS SILVER INST,DEPT BIOMED ENGN,IL-32000 HAIFA,ISRAEL. NR 0 TC 0 Z9 0 U1 0 U2 1 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44637-5 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1993 VL 346 BP 401 EP 406 PG 6 WC Cardiac & Cardiovascular Systems; Medicine, General & Internal; Physiology SC Cardiovascular System & Cardiology; General & Internal Medicine; Physiology GA BZ51S UT WOS:A1993BZ51S00039 ER PT J AU ARORA, N MIN, KU COSTA, JJ RHIM, JS METCALFE, DD AF ARORA, N MIN, KU COSTA, JJ RHIM, JS METCALFE, DD TI IMMORTALIZATION OF MOUSE BONE MARROW-DERIVED MAST-CELLS WITH AD12-SV40 VIRUS SO INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY LA English DT Article DE MAST CELLS; TRANSFORMATION; VIRUS ID ABELSON LEUKEMIA-VIRUS; NEOPLASTIC TRANSFORMATION; MEDIATED ACTIVATION; MESSENGER-RNA; HYBRID VIRUS; IGE; GROWTH; FIBROBLASTS; SUBSETS; CULTURE AB Mast cells arise in cultures of murine bone marrow in medium supplemented with interleukin-3 (IL-3). In the present study, we report the development of long-term mast cell lines from murine bone-marrow-derived cultured mast cells (BMCMC) following inoculation with adenovirus 12-simian virus 40 (Ad12-SV40) hybrid virus. One culture of Ad12-SV40 immortalized BMCMC (designated as MCP-5) was selected for further analysis. These transformed cells appear similar in morphology and histochemistry to the primary BMCMC from which they are derived and did not shed infectious virus into the culture supernatants. In addition, these cells synthesize predominantly chondroitin sulfate proteoglycans and contain histamine which is released following a physiologic stimulus. Limiting-dilution single-cell cloning produced five independent mast cell lines (MCP-5.1 to MCP-5.5). Southern blot analysis of genomic DNA isolated from these single-cell clones demonstrates different patterns of viral integration in all the five clones. All clones retain responsiveness to an exogenous source of IL-3 for growth and proliferation. Each single-cell clone also demonstrates a unique pattern of cytokine gene expression in response to calcium ionophore A23187 and phorbol-12-myristate-13-acetate. This suggests that within a culture of BMCMC there are differences in cytokine gene expression that vary from one cell to another. The availability of immortalized mast cell lines derived from murine bone marrow which retain their growth factor responsiveness and the ability to respond to degranulating stimuli should facilitate future studies of mast cell biology. C1 NCI,DCE,BETHESDA,MD 20892. NIAID,LCI,BETHESDA,MD 20892. SEOUL NATL UNIV,COLL MED,SEOUL 151,SOUTH KOREA. BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA 02215. RP ARORA, N (reprint author), NIDR,LME,BLDG 30,ROOM 313,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. RI Min, Kyung-Up/J-5468-2012 NR 30 TC 37 Z9 37 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-2438 J9 INT ARCH ALLERGY IMM JI Int. Arch. Allergy Immunol. PY 1993 VL 100 IS 4 BP 319 EP 327 PG 9 WC Allergy; Immunology SC Allergy; Immunology GA LC597 UT WOS:A1993LC59700004 PM 7683224 ER PT J AU ASSENNATO, G FERRI, GM FOA, V STRICKLAND, P POIRIER, M POZZOLI, L COTTICA, D AF ASSENNATO, G FERRI, GM FOA, V STRICKLAND, P POIRIER, M POZZOLI, L COTTICA, D TI CORRELATION BETWEEN PAH AIRBORNE CONCENTRATION AND PAH-DNA ADDUCTS LEVELS IN COKE-OVEN WORKERS SO INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article; Proceedings Paper CT INTERNATIONAL SYMP ON BIOLOGICAL MONITORING CY NOV 12-15, 1992 CL KYOTO, JAPAN SP INT COMMISS OCCUPAT HLTH, WHO, INT LABOR OFF, SCI COUNCIL JAPAN, JAPANESE SOC HYG, JAPAN ASSOC IND HLTH, JAPANESE SOC TOXICOL SCI, MINIST HLTH & WELF JAPAN, MINIST INT TRADE & IND JAPAN, MINIST LABOR JAPAN DE COKE-OVEN WORKERS; DNA-ADDUCTS; PAHS ID FLUORESCENCE AB In order to evaluate the correlation between peripheral blood leukocyte DNA adducts as an indicator of exposure to polycyclic aromatic hydrocarbons (PAH) and the airborne contamination of PAH at the work places, a survey of a cohort of coke-oven workers has been carried out. In each workplace, total and specific PAH airborne concentrations were measured. Among the job title groups, the highest proportion of subjects with levels of adducts above the detection limit and the highest mean value were observed in the door-operators. The correlation between median values of environmental benzo(a)pyrene concentration and mean values of adducts concentration support the fact that the maintenance workers group has a higher relative risk (RR) to have detectable level of PAH-adducts, which is estimated to be 1.84 for an increase of 1 mug/m3 of benzo(a)pyrene. C1 JOHNS HOPKINS UNIV,DEPT OCCUPAT MED,BALTIMORE,MD 21218. FDN CLIN LAVORO,PAVIA,ITALY. NCI,BETHESDA,MD 20892. RP ASSENNATO, G (reprint author), UNIV BARI,INST OCCUPAT HLTH,I-70124 BARI,ITALY. NR 10 TC 13 Z9 14 U1 1 U2 2 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0340-0131 J9 INT ARCH OCC ENV HEA JI Int. Arch. Occup. Environ. Health PY 1993 VL 65 IS 1 SU S BP S143 EP S145 DI 10.1007/BF00381327 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA LR207 UT WOS:A1993LR20700029 PM 8406912 ER PT B AU CRAGG, GM BOYD, MR CARDELLINA, JH GREVER, MR SCHEPARTZ, SA SNADER, KM AF CRAGG, GM BOYD, MR CARDELLINA, JH GREVER, MR SCHEPARTZ, SA SNADER, KM BE Buxton, DR Shibles, R Forsberg, RA Blad, BL Asay, KH Paulsen, GM Wilson, RF TI THE ROLE OF PLANTS IN THE DRUG DISCOVERY PROGRAM OF THE UNITED-STATES NATIONAL-CANCER-INSTITUTE SO INTERNATIONAL CROP SCIENCE I LA English DT Proceedings Paper CT International Crop Science Congress CY JUL 14-22, 1992 CL AMES, IA SP IOWA STATE UNIV, CROP SCI SOC AMER C1 NCI,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 1 PU CROP SCIENCE SOC AMERICA PI MADISON PA 677 SOUTH SEGOE ROAD, MADISON, WI 53711 BN 0-89118-538-0 PY 1993 BP 465 EP 472 PG 8 WC Agronomy; Environmental Sciences SC Agriculture; Environmental Sciences & Ecology GA BZ67Y UT WOS:A1993BZ67Y00072 ER PT J AU UMEHARA, H TAKASHIMA, A MINAMI, Y BLOOM, ET AF UMEHARA, H TAKASHIMA, A MINAMI, Y BLOOM, ET TI SIGNAL TRANSDUCTION VIA PHOSPHORYLATED ADHESION MOLECULE, LFA-1-BETA (CD18), IS INCREASED BY CULTURE OF NATURAL-KILLER-CELLS WITH IL-2 IN THE GENERATION OF LYMPHOKINE-ACTIVATED KILLER-CELLS SO INTERNATIONAL IMMUNOLOGY LA English DT Article DE ADHESION MOLECULE; CYTOTOXICITY; HUMAN; INTEGRIN; LYMPHOKINE ACTIVATED KILLER CELLS; NATURAL KILLER CELLS; PHOSPHORYLATION ID P70-75 BETA-SUBUNIT; PROTEIN-KINASE-C; LYMPHOCYTES-T; TYROSINE PHOSPHORYLATION; INTERLEUKIN-2 RECEPTOR; MONOCLONAL-ANTIBODIES; MEDIATED CYTOLYSIS; LEUKOCYTE ADHESION; SERINE ESTERASE; PLASMA-MEMBRANE AB It is well known that IL-2 stimulates natural killer (NK) cells to express lymphokine activated killer (LAK) activity and that this stimulation prompts the acquisition of the ability to lyse previously insensitive target cells. The possible role of adhesion molecules in the IL-2 activation process was probed by focussing on a lymphocyte function-associated antigen (LFA)-1-dependent model system. A mAb to the LFA-1beta chain abrogated LAK activity, but only moderately suppressed NK activity, suggesting a differential role for LFA-1beta in LAK compared with NK mediated lysis. Orthophosphate labeling demonstrated that the LFA-1beta chain was strongly phosphorylated in LAK but not NK cells; in contrast, the alpha chain was phosphorylated similarly in both effector cell types. At least a portion of the phosphorylation of the beta chain was on tyrosine residues, as shown by Western blotting with anti-phosphotyrosine antibody of LFA-1beta immunoprecipitates. Crosslinking of the LFA-1beta chain with plastic-adhered antibody stimulated Ca2+-dependent release of cytoplasmic lytic granules and induced phosphatidyl inositol turnover in LAK but not NK cells. We conclude that the IL-2-induced phosphorylation of the beta chain of the LFA-1 adhesion molecule in LAK cells and associated alteration in signal transduction may be important in the stimulation of LAK cell activity in NK cells. C1 US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20892. US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BETHESDA,MD 20892. NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892. FU NCI NIH HHS [CA30187] NR 63 TC 25 Z9 26 U1 0 U2 0 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0953-8178 J9 INT IMMUNOL JI Int. Immunol. PD JAN PY 1993 VL 5 IS 1 BP 19 EP 27 DI 10.1093/intimm/5.1.19 PG 9 WC Immunology SC Immunology GA KJ347 UT WOS:A1993KJ34700003 PM 8095153 ER PT J AU RHOADS, AR VU, ND CARROLL, AG AF RHOADS, AR VU, ND CARROLL, AG TI SMALL MEMBRANE-ASSOCIATED GTP-BINDING PROTEINS OF CATECHOLAMINE-SECRETING CELLS SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY LA English DT Article ID PERMEABILIZED PC12 CELLS; SUBCELLULAR-DISTRIBUTION; VESICLES; BRAIN; IDENTIFICATION; LOCALIZATION; PURIFICATION; GRANULE AB 1. Four GTP-binding proteins (23-27 kDa) were identified in membranes from PC 12 cells by [alpha P-32]GTP binding to nitrocellulose blots of SDS-polyacrylamide gels. 2. The GTP-binding proteins remained associated with membranes during stimulation of intact cells by K+-depolarization or even after addition of Ca2+ to digitonin-permeabilized cells. 3. By two-dimensional gel electrophoresis, six GTP-binding proteins were resolved and based on their mobility, their phosphorylation state appeared independent of Ca2+. 4. Fractionation of PC 12 membranes showed that these GTP-binding proteins were broadly distributed in post-nuclear membranes with the plasma membranes containing the highest specific GTP-binding activity. 5. Membrane fractions from bovine adrenal medulla contain similar GTP-binding proteins with GTP-binding intensity also being highest in the plasma membrane. 6. The GTP-binding proteins could be concentrated in the detergent-rich fraction upon Triton X-114 phase separation. C1 NCI,BETHESDA,MD 20892. GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007. RP RHOADS, AR (reprint author), HOWARD UNIV,COLL MED,DEPT BIOCHEM & MOLEC BIOL,520 W STR NW,WASHINGTON,DC 20059, USA. NR 21 TC 3 Z9 3 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0020-711X J9 INT J BIOCHEM JI Int. J. Biochem. PD JAN PY 1993 VL 25 IS 1 BP 79 EP 86 DI 10.1016/0020-711X(93)90492-W PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA KH982 UT WOS:A1993KH98200011 PM 8432385 ER PT J AU HETHERINGTON, MM SPALTER, AR BERNAT, AS NELSON, ML GOLD, PW AF HETHERINGTON, MM SPALTER, AR BERNAT, AS NELSON, ML GOLD, PW TI EATING PATHOLOGY IN BULIMIA-NERVOSA SO INTERNATIONAL JOURNAL OF EATING DISORDERS LA English DT Article ID ANOREXIA-NERVOSA; DIETARY RESTRAINT; RATING-SCALE; BEHAVIOR; WOMEN; DISORDERS; PATTERNS; EPISODES; HUNGER; MEALS AB Degree of eating pathology in bulimia nervosa was assessed using the Eating Behavior Rating Scale (EBRS) across three videotaped eating sessions. Twelve bulimic and 12 non-eating disordered subjects participated in this study. All subjects were filmed during a baseline meat (ad libitum), a high-calorie meal, and a low-calorie meal (both fixed amounts). Mean EBRS scores were significantly higher for bulimics (12.6 +/- 1.7) than for controls (3.9 +/- 0.9), suggesting a higher degree of eating pathology in these patients. Affect during eating was significantly more negative in the bulimic patients. EBRS and affect scores were significantly correlated [r (11) = .813, p < .01]. Bulimics had a slower rate of eating than controls and took significantly longer to initiate eating. Scores of pathological eating correlated with scores on the Eating Attitudes Test and the Bulimic investigatory Test-Edinburgh, indicating a relationship between objective measures of pathological eating and self-report measures of eating disorder symptoms. C1 NIMH,BETHESDA,MD 20892. RP HETHERINGTON, MM (reprint author), UNIV DUNDEE,DEPT PSYCHOL,DUNDEE DD1 4HN,SCOTLAND. RI Hetherington, Marion/A-4397-2013 NR 31 TC 16 Z9 17 U1 2 U2 3 PU JOHN WILEY & SONS INC PI NEW YORK PA 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0276-3478 J9 INT J EAT DISORDER JI Int. J. Eating Disord. PD JAN PY 1993 VL 13 IS 1 BP 13 EP 24 DI 10.1002/1098-108X(199301)13:1<13::AID-EAT2260130103>3.0.CO;2-0 PG 12 WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology SC Psychology; Nutrition & Dietetics; Psychiatry GA KF153 UT WOS:A1993KF15300002 PM 8477272 ER PT J AU MARTINEZ, RA LEBOWITZ, BD COHEN, GD AF MARTINEZ, RA LEBOWITZ, BD COHEN, GD TI FUNDING RESEARCH STRUCTURES SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE FUNDING; RESEARCH; GERIATRIC PSYCHIATRY AB Research priorities established by the field of geriatric psychiatry are the principal source of ideas for investigations supported by the National Institute of Mental Health, the National Institute of Aging and a host of private organizations and foundations. Individuals, at various stages in their careers, can compete for federal stipends to pursue these research inquiries. Knowledge of the assortment of awards available is part of an overall strategy candidates need to develop in planning and maintaining productive research careers. C1 NIA,BETHESDA,MD 20892. RP MARTINEZ, RA (reprint author), NIMH,MENTAL DISORDERS AGING BRANCH,PARKLAWN BLDG,ROOM 7C-103,ROCKVILLE,MD 20857, USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI W SUSSEX PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD JAN PY 1993 VL 8 IS 1 BP 19 EP 24 DI 10.1002/gps.930080105 PG 6 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA KH525 UT WOS:A1993KH52500004 ER PT J AU SCHNEIDER, LS MARTINEZ, RA LEBOWITZ, BD AF SCHNEIDER, LS MARTINEZ, RA LEBOWITZ, BD TI CLINICAL PSYCHOPHARMACOLOGY RESEARCH IN GERIATRICS - AN AGENDA FOR RESEARCH SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE RESEARCH; GERIATRIC PSYCHIATRY; CLINICAL PSYCHOPHARMACOLOGY ID ELDERLY DEPRESSED-PATIENTS; PLASMA 10-HYDROXYNORTRIPTYLINE; ALZHEIMERS-DISEASE; PRIMARY DEMENTIA; NORTRIPTYLINE; PSYCHOSIS AB The two main areas of geriatric clinical psychopharmacology research, depression and dementia, are reviewed. The issues for depression research include pharmacokinetics in the geriatric population and the relationship to efficacy and side-effects; the treatment of the medically ill and the very old; and maintenance and continuation treatments. In particular, the recommendations from the recently convened NIH Consensus Development Conference for the Diagnosis and Treatment of Depression in Late Life are discussed. The issues in dementia research include effective treatment of behavioral symptoms as well as severe and mild cognitive impairment; the development of better cholinesterase inhibitors; the application of other drugs; and the use of appropriate clinical trials methodology. C1 NIMH,ROCKVILLE,MD 20857. RP SCHNEIDER, LS (reprint author), UNIV SO CALIF,SCH MED,DEPT PSYCHIAT & BEHAV SCI,1934 HOSP PL,LOS ANGELES,CA 90033, USA. NR 37 TC 1 Z9 1 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI W SUSSEX PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD JAN PY 1993 VL 8 IS 1 BP 89 EP 93 DI 10.1002/gps.930080113 PG 5 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA KH525 UT WOS:A1993KH52500012 ER PT J AU GREWAL, RP AF GREWAL, RP TI PSYCHIATRIC-DISORDERS IN PATIENTS WITH FABRYS-DISEASE SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE FABRYS DISEASE; DEPRESSION; CEREBROVASCULAR DISEASE; PSYCHIATRIC COMPLICATIONS; SUICIDE; CHRONIC DISEASE; CHRONIC PAIN ID SUICIDE; RISK AB Objective: To determine the frequency and etiology of psychiatric complications in patients with Fabry's disease. Method-Retrospective analysis and review of the records of thirty-three patients with confirmed Fabry's disease. Results: Six patients (18%) developed psychiatric disorders. Five patients suffered depression and two of these patients committed suicide. One patient developed an acute confusional episode with subsequent development of behavioral changes as a complication of cerebrovascular disease. Conclusions: Psychiatric disorders, most commonly depression, complicate Fabry's disease and contribute to the morbidity and mortality of this disease. C1 NIMH,BETHESDA,MD 20892. NR 13 TC 53 Z9 54 U1 0 U2 1 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, AMITYVILLE, NY 11701 SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 1993 VL 23 IS 3 BP 307 EP 312 DI 10.2190/JKFW-3WXK-QA7N-BYLN PG 6 WC Psychiatry SC Psychiatry GA MD619 UT WOS:A1993MD61900006 PM 8270359 ER PT J AU KINSELLA, TJ JOHNSTONE, P SINDELAR, WF AF KINSELLA, TJ JOHNSTONE, P SINDELAR, WF TI INTRAOPERATIVE RADIOTHERAPY - CURRENT STATUS - 1993 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 UNIV WISCONSIN,SCH MED,DEPT HUMAN ONCOL,MADISON,WI 53792. NCI,RADIAT ONCOL BRANCH,BETHESDA,MD 20892. NCI,SURG BRANCH,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1993 VL 27 SU 1 BP 115 EP 115 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA LV404 UT WOS:A1993LV40400038 ER PT J AU CHABNER, BA BATES, SE FOJO, AT WITTES, RE BRYANT, GA HERDT, JRL WILSON, WH AF CHABNER, BA BATES, SE FOJO, AT WITTES, RE BRYANT, GA HERDT, JRL WILSON, WH TI STUDIES OF DRUG-RESISTANCE IN MALIGNANT-LYMPHOMA SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 NCI,BETHESDA,MD 20892. NIH,CTR CLIN,BETHESDA,MD 20892. NR 0 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1993 VL 27 SU 1 BP 124 EP 124 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA LV404 UT WOS:A1993LV40400057 ER PT J AU JOHNSTONE, PA SPRAGUE, M DELUCA, AM BACHER, J HAMPSHIRE, V TERRILL, R KINSELLA, T SINDELAR, WF AF JOHNSTONE, PA SPRAGUE, M DELUCA, AM BACHER, J HAMPSHIRE, V TERRILL, R KINSELLA, T SINDELAR, WF TI TOLERANCE OF VASCULAR GRAFTS TO INTRAOPERATIVE RADIOTHERAPY IN A CANINE MODEL SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 NCI,RADIAT ONCOL BRANCH,BETHESDA,MD 20892. NCI,SURG BRANCH,BETHESDA,MD 20892. NCI,OFF LAB ANIM SCI,BETHESDA,MD 20892. NIH,NATL CTR RES RESOURCES,VET RESOURCES PROGRAM,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1993 VL 27 SU 1 BP 145 EP 145 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA LV404 UT WOS:A1993LV40400090 ER PT J AU SULLIVAN, FJ HERSCHER, LL COOK, JA SMITH, J STEINBERG, SM EPSTEIN, AH MITCHELL, JB GLATSTEIN, E AF SULLIVAN, FJ HERSCHER, LL COOK, JA SMITH, J STEINBERG, SM EPSTEIN, AH MITCHELL, JB GLATSTEIN, E TI HIGH-GRADE GLIOMA TREATED WITH PARTIAL BRAIN HYPERFRACTIONATED RADIATION AND IODODEOXYURIDINE SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 NCI,RADIAT ONCOL BRANCH,BETHESDA,MD 20892. NCI,BIOSTAT & DATA MANAGEMENT SECT,BETHESDA,MD 20892. SIMMONS CANC CTR,DALLAS,TX. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1993 VL 27 SU 1 BP 176 EP 176 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA LV404 UT WOS:A1993LV40400141 ER PT J AU HERSCHER, LL KRISHNA, MC COOK, J COLEMAN, CN BIAGLOW, JE GONZALEZ, FJ MITCHELL, JB AF HERSCHER, LL KRISHNA, MC COOK, J COLEMAN, CN BIAGLOW, JE GONZALEZ, FJ MITCHELL, JB TI PROTECTION AGAINST SR-4233 AEROBIC CYTOTOXICITY BY THE METAL CHELATORS DESFERRIOXAMINE AND TIRON SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 NCI,RADIAT ONCOL BRANCH,RADIAT BIOL SECT,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1993 VL 27 SU 1 BP 196 EP 196 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA LV404 UT WOS:A1993LV40400172 ER PT J AU CUSCELA, D COFFIN, D MULDOON, R GLASS, J KRISHNA, MC BERNSTEIN, E MITCHELL, JB AF CUSCELA, D COFFIN, D MULDOON, R GLASS, J KRISHNA, MC BERNSTEIN, E MITCHELL, JB TI PROTECTION FROM RADIATION-INDUCED ALOPECIA WITH TOPICAL APPLICATION OF NITROXIDES - FRACTIONATED STUDIES SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 NCI,RADIAT ONCOL BRANCH,RADIAT BIOL SECT,BETHESDA,MD 20892. NR 0 TC 2 Z9 2 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1993 VL 27 SU 1 BP 197 EP 197 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA LV404 UT WOS:A1993LV40400174 ER PT J AU MCGINN, CJ MILLER, EM PESTALOZZI, BC LINDSTROM, MJ FOWLER, JF KUNUGI, KA JOHNSTON, PG KINSELLA, TJ AF MCGINN, CJ MILLER, EM PESTALOZZI, BC LINDSTROM, MJ FOWLER, JF KUNUGI, KA JOHNSTON, PG KINSELLA, TJ TI CELL-CYCLE REDISTRIBUTION BY FLUORODEOXYURIDINE (FDURD) AS A MECHANISM OF FLUOROPYRIMIDINE RADIOSENSITIZATION SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI 53792. HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115. USN,NCI,MED ONCOL BRANCH,BETHESDA,MD 20889. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1993 VL 27 SU 1 BP 242 EP 242 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA LV404 UT WOS:A1993LV40400247 ER PT J AU GRIFFIN, TW KRALL, JM LARAMORE, GE PARKER, RG BURNISON, M PETERS, LJ MAOR, M ZINK, S DAVIS, LW RUSSELL, KJ AF GRIFFIN, TW KRALL, JM LARAMORE, GE PARKER, RG BURNISON, M PETERS, LJ MAOR, M ZINK, S DAVIS, LW RUSSELL, KJ TI FAST-NEUTRON IRRADIATION OF PROSTATE-CANCER - THE RESULTS OF A COOPERATIVE, PHASE-III RANDOMIZED STUDY SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 UNIV WASHINGTON, MED CTR, DEPT RADIAT ONCOL, SEATTLE, WA 98195 USA. AMER COLL RADIOL, STAT UNIT, PHILADELPHIA, PA 19107 USA. UNIV CALIF LOS ANGELES, DEPT RADIAT ONCOL, LOS ANGELES, CA 90024 USA. UNIV TEXAS, MD ANDERSON CANC CTR, DIV RADIOTHERAPY, HOUSTON, TX 77030 USA. NCI, RADIAT RES PROGRAM, BETHESDA, MD 20892 USA. EMORY CLIN, DEPT RADIAT ONCOL, ATLANTA, GA 30322 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1993 VL 27 SU 1 BP 247 EP 247 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA LV404 UT WOS:A1993LV40400254 ER PT J AU BARRETT, JT SCHOENLEIN, PV LIPSHULTZ, C AF BARRETT, JT SCHOENLEIN, PV LIPSHULTZ, C TI MITOCHONDRIAL-DNA DAMAGE AND CELL-SURVIVAL FOLLOWING PHOTODYNAMIC THERAPY AND IONIZING-RADIATION SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MED COLL GEORGIA,DEPT RADIOL,AUGUSTA,GA 30912. MED COLL GEORGIA,DEPT CELLULAR BIOL & ANAT,AUGUSTA,GA 30912. NCI,RADIAT ONCOL BRANCH,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1993 VL 27 SU 1 BP 308 EP 308 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA LV404 UT WOS:A1993LV40400357 ER PT J AU MEREDITH, R KHAZAELI, M PLOTT, G BUESCHEN, A WHEELER, R RUSSELL, C SCHLOM, J LOBUGLIO, A AF MEREDITH, R KHAZAELI, M PLOTT, G BUESCHEN, A WHEELER, R RUSSELL, C SCHLOM, J LOBUGLIO, A TI RADIOIMMUNOTHERAPY FOR METASTATIC PROSTATE-CANCER USING A HIGH-AFFINITY ANTIBODY SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 UNIV ALABAMA,CTR COMPREHENS CANC,BIRMINGHAM,AL 35294. NCI,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1993 VL 27 SU 1 BP 318 EP 318 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA LV404 UT WOS:A1993LV40400374 ER PT J AU VALDEZ, IH ATKINSON, JC SHIP, JA FOX, PC AF VALDEZ, IH ATKINSON, JC SHIP, JA FOX, PC TI MAJOR SALIVARY-GLAND FUNCTION IN PATIENTS WITH RADIATION-INDUCED XEROSTOMIA - FLOW-RATES AND SIALOCHEMISTRY SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE SALIVA; ORAL; RADIATION THERAPY; CANCER ID DIFFERENT AGE-GROUPS; CANCER-PATIENTS; PAROTID-SALIVA; WHOLE SALIVA; RADIOTHERAPY; IRRADIATION; LACTOFERRIN; SYMPTOM; THERAPY AB Radiation therapy for cancer of the head and neck region often causes salivary gland dysfunction and xerostomia. Several reports suggest that the submandibular/sublingual (SM/SL) glands may be less radiosensitive than the parotid. The purpose of this study was to evaluate differential radiation effects on the major salivary glands. Fifty patients with radiation-induced xerostomia were evaluated (33 males, 17 females; mean age 52.7). The average total tumor dose was 6034 cGy. Major salivary gland function was compared with that of 50 non-irradiated controls. Salivary flow rates included unstimulated and stimulated flows of both the parotid and SM/SL glands. Sialochemical analyses included total protein, lysozyme, lactoferrin, sodium, chloride, and potassium. All four measures of salivary flow were significantly reduced in patients as compared to controls (p = .0001). Like the parotid, submandibular/sublingual gland dysfunction appears to be radiation dose- and field-dependent. Patients in the lowest radiation dose quartile (less-than-or-equal-to 5000 cGy) had significantly increased salivary flow compared to those in the highest dose quartile (greater-than-or-equal-to 6800 cGy; p = .025). Glands that were partially irradiated were more likely to have some residual function than fully irradiated glands (p = .003). Lactoferrin content was increased in parotid saliva of radiation patients (p = .0001). Chloride content was significantly increased also (p = .0001). The SM/SL glands are clearly dysfunctional in post-irradiation xerostomia patients compared to controls, in terms of both flow rates and sialochemistry. RP VALDEZ, IH (reprint author), NIDR,CLIN INVEST & PATIENT CARE BRANCH,BLDG 10,RM 1N-113,BETHESDA,MD 20892, USA. NR 41 TC 150 Z9 153 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 1993 VL 25 IS 1 BP 41 EP 47 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA KF812 UT WOS:A1993KF81200007 PM 8416881 ER PT J AU FISHBEIN, DH JAFFE, JH SNYDER, FR HAERTZEN, CA HICKEY, JE AF FISHBEIN, DH JAFFE, JH SNYDER, FR HAERTZEN, CA HICKEY, JE TI DRUG-USERS SELF-REPORTS OF BEHAVIORS AND AFFECTIVE STATES UNDER THE INFLUENCE OF ALCOHOL SO INTERNATIONAL JOURNAL OF THE ADDICTIONS LA English DT Article DE ALCOHOL; SELF-REPORT; ANTISOCIAL PERSONALITY; AGGRESSION; IMPULSIVITY; DEPRESSION; DRUG USE; AFFECTIVE STATE ID DIAGNOSTIC INTERVIEW SCHEDULE; VALIDITY; MEN; PERSONALITY AB This study tested a modified version of the Alcohol-Related Behavior Questionnaire (ARBQ) to investigate the influence of alcohol on negative mood states. The ARBQ asked subjects (substance users and those not misusing drugs or alcohol) to recall various moods and behaviors under three drug conditions: sober, drinking, and drunk. Tests of the ARBQ subscales provided support for its reliability and validity. Scale scores measuring negative affect increased as levels of recalled alcohol intake increased, suggesting that larger amounts of alcohol produced more negative and aggressive feelings. Alcohol-dependent subjects reported more anger and aggression with increasing levels of alcohol intake than nonproblem drinkers. These data further indicated that, among those with alcohol dependence, a history of childhood aggression is an important predictor of negative behaviors and feelings associated with alcohol intake. Among other groups of drug users, a diagnosis of antisocial personality was relatively more important. C1 NIDA,ADDICT RES CTR,BALTIMORE,MD 21224. ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,OFF TREATMENT IMPROVEMENT,ROCKVILLE,MD 20857. RP FISHBEIN, DH (reprint author), UNIV BALTIMORE,DEPT CRIMINAL JUSTICE,1420 N CHARLES ST,BALTIMORE,MD 21201, USA. NR 29 TC 16 Z9 16 U1 0 U2 1 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0020-773X J9 INT J ADDICT JI Int. J. Addict. PY 1993 VL 28 IS 14 BP 1565 EP 1585 PG 21 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA ML427 UT WOS:A1993ML42700006 PM 8307666 ER PT J AU GALLIN, JI AF GALLIN, JI TI DELINEATION OF THE PHAGOCYTE NADPH OXIDASE THROUGH STUDIES OF CHRONIC GRANULOMATOUS DISEASES OF CHILDHOOD SO INTERNATIONAL JOURNAL OF TISSUE REACTIONS-EXPERIMENTAL AND CLINICAL ASPECTS LA English DT Article; Proceedings Paper CT 5th Interscience World Conference on Inflammation CY APR 25-28, 1993 CL GENEVA, SWITZERLAND SP WHO ID GTP-BINDING PROTEIN; COMPONENT; CYTOCHROME-B-245; P22-PHOX; P21RAC1 AB The formation of microbicidal oxidants by stimulated phagocytes is a major mechanism of host defence against infection and may also cause unwanted damage to host tissues in the setting of inappropriate inflammation. Recently, the molecular basis for oxidant production has been defined by elucidating the structure, biochemistry and regulation of the phagocyte NADPH oxidase, a multicomponent enzyme that uses NADPH to reduce molecular oxygen to superoxide anion which is then converted to hydrogen peroxide. Many of the advances resulted from the study of phagocytes obtained from patients with inherited abnormalities of the NADPH oxidase system, known as the chronic granulomatous diseases of childhood (CGD). These patients are susceptible to life-threatening infections. The NADPH oxidase is a complex enzyme system that has been shown to contain cytosolic and membrane components that assemble at the plasma membrane with cell activation. These components include a membrane NADPH-binding flavoprotein, cytochrome b(558), the cytosolic proteins p47phox, p67phox and a small ras-related guanosine triphosphatase or rac protein that confers guanosine triphosphate sensitivity to the NADPH oxidase. Clinically, the NADPH oxidase system can be stimulated with interferon-gamma, resulting in reduced infections in patients with CGD. In addition, the recent incorporation of genes for the components of the NADPH oxidase into retrovirus Vectors has resulted in successful transduction of these genes into blood stem cells from CGD patients with correction of the functional defect. This suggests that gene therapy for correction of CGD will be possible in the near future. RP GALLIN, JI (reprint author), NIAID,HOST DEF LAB,BLDG 10,ROOM 11N113,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 21 TC 3 Z9 4 U1 0 U2 0 PU BIOSCIENCE EDIPRINT INC PI CAROUGE PA RUE ALEXANDRE-GAVARD 16, 1227 CAROUGE, SWITZERLAND SN 0250-0868 J9 INT J TISSUE REACT JI Int. J. Tissue React.-Exp. Clin. Asp. PY 1993 VL 15 IS 3 BP 99 EP 103 PG 5 WC Cell Biology SC Cell Biology GA MR901 UT WOS:A1993MR90100003 PM 8188451 ER PT J AU GRILLI, M CHIU, JJS LENARDO, MJ AF GRILLI, M CHIU, JJS LENARDO, MJ TI NF-KAPPA-B AND REL - PARTICIPANTS IN A MULTIFORM TRANSCRIPTIONAL REGULATORY SYSTEM SO INTERNATIONAL REVIEW OF CYTOLOGY - A SURVEY OF CELL BIOLOGY, VOL 143 SE INTERNATIONAL REVIEW OF CYTOLOGY-A SURVEY OF CELL BIOLOGY LA English DT Review ID HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; LONG TERMINAL REPEAT; CELL LEUKEMIA-VIRUS; ENHANCER-BINDING-PROTEIN; MAJOR HISTOCOMPATIBILITY COMPLEX; RECEPTOR-ALPHA-CHAIN; COLONY-STIMULATING FACTOR; HUMAN T-CELLS; AVIAN RETICULOENDOTHELIOSIS VIRUS RP GRILLI, M (reprint author), NIAID,IMMUNOL LAB,BETHESDA,MD 20892, USA. NR 451 TC 865 Z9 872 U1 1 U2 10 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0074-7696 J9 INT REV CYTOL JI Int.Rev.Cytol. PY 1993 VL 143 BP 1 EP 62 PG 62 GA BZ69D UT WOS:A1993BZ69D00001 PM 8449662 ER PT J AU WEBSTER, RG WRIGHT, SM CASTRUCCI, MR BEAN, WJ KAWAOKA, Y AF WEBSTER, RG WRIGHT, SM CASTRUCCI, MR BEAN, WJ KAWAOKA, Y TI INFLUENZA - A MODEL OF AN EMERGING VIRUS-DISEASE SO INTERVIROLOGY LA English DT Article DE INFLUENZA VIRUS; RESERVOIRS; EVOLUTION AND HOST RANGE ID A VIRUSES; SPECIFICITY; EVOLUTION; SWINE; HEMAGGLUTININ; TRANSMISSION AB Influenza A viruses continue to emerge from the aquatic avian reservoir and cause pandemics. Phylogenetic analysis of the nucleotide sequence of all eight influenza A virus RNA segments indicates that all of the influenza viruses in mammalian hosts originate from the avian gene pool. In contrast to the rapid progressive changes in both the nucleotide and amino acid sequences of mammalian virus gene lineages, avian virus genes show far less variation and, in most cases, appear to be in evolutionary stasis. There are periodic exchanges of influenza virus genes or whole viruses between species giving rise to pandemics of diseases in humans, lower animals and birds. The periodic emergence of influenza viruses in mammalian species has been illustrated by the appearance of a new influenza virus in horses in northern China in 1989. Phylogenetic analysis of classical H1N1, avian-like H1N1 and human H3N2 viruses circulating in Italian pigs reveals that genetic reassortment is taking place between avian- and human-like viruses in the European pig population. These studies provide evidence supporting the possibility that pigs serve as a mixing vessel for reassortment between influenza viruses in mammalian and avian hosts and raise the question of whether the next pandemic of influenza will emerge in Europe! C1 IST SUPER SANITA, DEPT VIROL, I-00161 ROME, ITALY. MIDDLE TENNESSEE STATE UNIV, DEPT BIOL, MURFREESBORO, TN 37130 USA. NIAID, SCI REVIEW BRANCH, BETHESDA, MD 20892 USA. RP WEBSTER, RG (reprint author), ST JUDE CHILDRENS RES HOSP, DEPT VIROL MOLEC BIOL, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA. RI CASTRUCCI, MARIA RITA/C-2535-2016 FU NCI NIH HHS [CA-21765]; NIAID NIH HHS [AI-29599, AI-29680] NR 22 TC 47 Z9 49 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0300-5526 J9 INTERVIROLOGY JI Intervirology PY 1993 VL 35 IS 1-4 BP 16 EP 25 PG 10 WC Virology SC Virology GA LR155 UT WOS:A1993LR15500004 PM 8407243 ER PT S AU MASTORAKOS, G WEBSTER, EL CHROUSOS, GP AF MASTORAKOS, G WEBSTER, EL CHROUSOS, GP BE Tolis, G Bringer, J Chrousos, GP TI CORTICOTROPIN-RELEASING HORMONE AND ITS RECEPTORS IN THE OVARY - PHYSIOLOGICAL IMPLICATIONS SO INTRAOVARIAN REGULATORS AND POLYCYSTIC OVARIAN SYNDROME: RECENT PROGRESS ON CLINICAL AND THERAPEUTIC ASPECTS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT SYMP ON INTRAOVARIAN REGULATORS AND POLYCYSTIC OVARIAN SYNDROME: RECENT PROGRESS ON CLINICAL AND THERAPEUTIC ASPECTS, AT THE 9TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY CY AUG 24-26, 1992 CL ATHENS, GREECE SP NICHHD, HELLENIC MINIST HLTH & WELFARE, ABBOTT LABS, BIOANAL, BIOATRIKA, BIOMEDICA, ICI, FARAN LABS, LAKATSA DIAGNOST CTR, IPSEN INT RP MASTORAKOS, G (reprint author), NICHHD,DEV ENDOCRINOL BRANCH,BLDG 10,ROOM 10N244,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-779-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 687 BP 20 EP 38 PG 19 WC Endocrinology & Metabolism; Pathology; Physiology; Reproductive Biology SC Endocrinology & Metabolism; Pathology; Physiology; Reproductive Biology GA BY50K UT WOS:A1993BY50K00005 ER PT S AU BONDY, C ZHOU, JA AF BONDY, C ZHOU, JA BE Tolis, G Bringer, J Chrousos, GP TI INSULIN-LIKE GROWTH-FACTOR SYSTEM GENE-EXPRESSION IN THE POSTPUBERTAL HUMAN OVARY SO INTRAOVARIAN REGULATORS AND POLYCYSTIC OVARIAN SYNDROME: RECENT PROGRESS ON CLINICAL AND THERAPEUTIC ASPECTS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Proceedings Paper CT SYMP ON INTRAOVARIAN REGULATORS AND POLYCYSTIC OVARIAN SYNDROME: RECENT PROGRESS ON CLINICAL AND THERAPEUTIC ASPECTS, AT THE 9TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY CY AUG 24-26, 1992 CL ATHENS, GREECE SP NICHHD, HELLENIC MINIST HLTH & WELFARE, ABBOTT LABS, BIOANAL, BIOATRIKA, BIOMEDICA, ICI, FARAN LABS, LAKATSA DIAGNOST CTR, IPSEN INT RP BONDY, C (reprint author), NICHHD,DEV ENDOCRINOL BRANCH,BLDG 10,ROOM 10N262,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-779-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 687 BP 65 EP 76 PG 12 WC Endocrinology & Metabolism; Pathology; Physiology; Reproductive Biology SC Endocrinology & Metabolism; Pathology; Physiology; Reproductive Biology GA BY50K UT WOS:A1993BY50K00011 ER PT S AU CHROUSOS, GP BRINGER, J TOLIS, G AF CHROUSOS, GP BRINGER, J TOLIS, G BE Tolis, G Bringer, J Chrousos, GP TI INTRAOVARIAN REGULATORS AND POLYCYSTIC OVARIAN SYNDROME - RECENT PROGRESS ON CLINICAL AND THERAPEUTIC ASPECTS - INTRODUCTION SO INTRAOVARIAN REGULATORS AND POLYCYSTIC OVARIAN SYNDROME: RECENT PROGRESS ON CLINICAL AND THERAPEUTIC ASPECTS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Editorial Material CT SYMP ON INTRAOVARIAN REGULATORS AND POLYCYSTIC OVARIAN SYNDROME: RECENT PROGRESS ON CLINICAL AND THERAPEUTIC ASPECTS, AT THE 9TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY CY AUG 24-26, 1992 CL ATHENS, GREECE SP NICHHD, HELLENIC MINIST HLTH & WELFARE, ABBOTT LABS, BIOANAL, BIOATRIKA, BIOMEDICA, ICI, FARAN LABS, LAKATSA DIAGNOST CTR, IPSEN INT RP CHROUSOS, GP (reprint author), NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA NEW YORK SN 0077-8923 BN 0-89766-779-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1993 VL 687 BP R13 EP R15 PG 3 WC Endocrinology & Metabolism; Pathology; Physiology; Reproductive Biology SC Endocrinology & Metabolism; Pathology; Physiology; Reproductive Biology GA BY50K UT WOS:A1993BY50K00001 ER PT J AU HEIDEMAN, RL MCCULLY, C BALIS, FM POPLACK, DG AF HEIDEMAN, RL MCCULLY, C BALIS, FM POPLACK, DG TI CEREBROSPINAL-FLUID PHARMACOKINETICS AND TOXICOLOGY OF INTRAVENTRICULAR AND INTRATHECAL ARABINOSYL-5-AZACYTOSINE (FAZARABINE, NSC-281272) IN THE NONHUMAN PRIMATE SO INVESTIGATIONAL NEW DRUGS LA English DT Article DE ARABINOSYL-5-AZACYTIDINE; CEREBROSPINAL FLUID; PHARMACOKINETICS; TOXICOLOGY; NONHUMAN PRIMATE ID PRECLINICAL PHARMACOLOGY; PHASE-I; ARABINOFURANOSYL-5-AZACYTOSINE; ARABINOSIDE; CYTOSINE; TRIAL; DNA AB Arabinosyl-5-azacytosine (AAC), a new nucleoside antimetabolite, is broadly active in preclinical tumor screening evaluations. To assess the potential for intrathecal use of this drug, we studied the toxicity and pharmacokinetics of intrathecal and intraventricular administration in nonhuman primates. Four adult male rhesus monkeys were given single 10 mg intrathecal (n = 1) or intraventricular (n = 3) doses of AAC to determine its acute toxicity and pharmacokinetic parameters. An additional 3 animals were given four weekly 10 mg intrathecal doses to assess the systemic and neurologic toxicity associated with chronic administration. Disappearance from the cerebrospinal fluid (CSF) was biexponential, and CSF clearance was 0.2 ml/min, which exceeds the rate of CSF bulk flow by 5-fold. The peak CSF concentration and area under the concentration x time curve achieved with the intraventricular administration of 10 mg were one hundred, and fifty fold greater, respectively, than those achieved after an intravenous dose of 200 mg/kg (1500-2400 mg) in prior experiments. No clinically evident neurotoxicity was observed in either the single or the weekly x 4 dose groups. A slight, transient CSF pleocytosis and increased CSF protein was observed. Systemic toxicity was limited to one animal in the weekly x 4 dose group who demonstrated a mild and transient decrease in his peripheral leukocyte count unassociated with a change in his hematocrit or platelet count. These studies in nonhuman primates demonstrate a clear pharmacokinetic advantage for intrathecal vs systemic administration of AAC. This is demonstrated by a 50-fold greater CSF drug exposure with an intrathecal or intraventricular dose 1/200th of that which can be given systemically. Intrathecal AAC was found to be safe on a weekly dosing schedule. On the basis of these results, human trials evaluating intrathecal AAC are planned. C1 NCI,PEDIAT BRANCH,BETHESDA,MD 20892. NR 21 TC 3 Z9 3 U1 0 U2 1 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0167-6997 J9 INVEST NEW DRUG JI Invest. New Drugs PY 1993 VL 11 IS 2-3 BP 135 EP 140 DI 10.1007/BF00874147 PG 6 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA LZ110 UT WOS:A1993LZ11000002 PM 7505267 ER PT J AU NEWMAN, RA VIDAL, JC VISKATIS, LJ JOHNSON, J ETCHEVERRY, MA AF NEWMAN, RA VIDAL, JC VISKATIS, LJ JOHNSON, J ETCHEVERRY, MA TI VRCTC-310 - A NOVEL COMPOUND OF PURIFIED ANIMAL TOXINS SEPARATES ANTITUMOR EFFICACY FROM NEUROTOXICITY SO INVESTIGATIONAL NEW DRUGS LA English DT Article DE VRCTC-310; ANIMAL VENOM; PHOSPHOLIPASE-A(2); CARDIOTOXIN; CROTOXIN; LEWIS LUNG CARCINOMA ID TUMOR-CELL-LINES; SNAKE-VENOM; SKELETAL-MUSCLE; COBRA VENOM; CARDIOTOXINS; PHOSPHOLIPASE-A2; CROTOXIN; PURIFICATION; HEMOLYSIS; DRUGS AB Two purified animal venom toxins, crotoxin and cardiotoxin, have been combined to produce a unique natural product (VRCTC-3 1 0) currently under investigation as an antitumor agent by the National Cancer Institute. In vitro, it has demonstrated cytotoxic disease specificity and a unique mechanism of action when submitted to COMPARE analysis. In vivo, tolerance was developed to the neurotoxic properties of crotoxin which allowed comparison of several schedules of fixed and escalating daily i.m. doses to mice bearing s.c. Lewis Lung carcinoma. An 83% inhibition of tumor growth was achieved using an escalating dose schedule starting at 1.8 mg/kg and reaching 6.3 mg/kg/day on day 20. Although some irritation around the sites of i.m. injection was noted, animal weight loss was negligible and there were no other signs of adverse toxicity. This natural product represents a new, membrane interactive anticancer agent which produces a unique spectrum of cytotoxicity in vitro and which has demonstrated interesting in vivo antitumor efficacy. C1 VENTECH RES INC,CAMBRIDGE,MA. NCI,DIV CANC TREATMENT,DRUG SYNTH & CHEM BRANCH,BETHESDA,MD 20892. RP NEWMAN, RA (reprint author), UNIV TEXAS,M D ANDERSON CANC CTR,DEPT CLIN INVEST,1515 HOLCOMBE BLVD,BOX 52,HOUSTON,TX 77030, USA. FU NCI NIH HHS [NCI CA-16672] NR 35 TC 41 Z9 43 U1 0 U2 8 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0167-6997 J9 INVEST NEW DRUG JI Invest. New Drugs PY 1993 VL 11 IS 2-3 BP 151 EP 159 DI 10.1007/BF00874149 PG 9 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA LZ110 UT WOS:A1993LZ11000004 PM 8262727 ER PT J AU BERG, SL BALIS, FM GODWIN, KS POPLACK, DG AF BERG, SL BALIS, FM GODWIN, KS POPLACK, DG TI PHARMACOKINETICS, CEREBROSPINAL-FLUID PENETRATION, AND METABOLISM OF PIROXANTRONE IN THE RHESUS-MONKEY SO INVESTIGATIONAL NEW DRUGS LA English DT Article DE PIROXANTRONE; PHARMACOKINETICS; CEREBROSPINAL FLUID; RHESUS MONKEY ID PRECLINICAL PHARMACOLOGY; PHASE-I; OXANTRAZOLE; ANTHRA<1,9-CD>PYRAZOL-6(2H)-ONES; ANTHRAPYRAZOLES; NSC-349174; AGENTS; ASSAY AB Piroxantrone is an anthrapyrazole derivative with broad anti-tumor activity in vitro and less cardiac toxicity than the anthracyclines. The metabolic pathways and central nervous system penetration of piroxantrone have not been determined. In this study we examined the pharmacokinetic behavior of piroxantrone in plasma and cerebrospinal fluid in a non-human primate model. In addition, a urinary metabolite of piroxantrone was isolated and its cytotoxicity evaluated in vitro. The disappearance of piroxantrone from plasma after an intravenous dose of 150 mg/m(2) given over 60 minutes was biexponential with mean t(1/2) alpha of 1.0 minutes and a mean t(1/2) beta of 180 minutes. The mean area under the curve was 220 mu M min and the clearance was 1420 ml/min/m(2). Piroxantrone was not detectable in the cerebrospinal fluid. Piroxantrone and three other compounds not present in pre-treatment samples were detected in urine. The major urinary metabolite was isolated. Its cytotoxicity against MOLT-4 cells in vitro was at least one log less than that of piroxantrone. In addition, one of the other compounds detected in urine was determined to be a glucuronide conjugation product of the major metabolite. The results of this study may be useful in the interpretation of the activity and toxicity of piroxantrone in clinical trials. RP BERG, SL (reprint author), NCI,PEDIAT BRANCH,BLDG 10,ROOM 13N240,BETHESDA,MD 20892, USA. NR 24 TC 3 Z9 3 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0167-6997 J9 INVEST NEW DRUG JI Invest. New Drugs PY 1993 VL 11 IS 4 BP 255 EP 261 DI 10.1007/BF00874424 PG 7 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA MR907 UT WOS:A1993MR90700002 PM 8157468 ER PT J AU PIATIGORSKY, J AF PIATIGORSKY, J TI INTRODUCTION OF HORWITZ,JOSEPH FOR THE PROCTOR MEDAL SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Item About an Individual RP PIATIGORSKY, J (reprint author), NEI,MOLEC & DEV BIOL LAB,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 1993 VL 34 IS 1 BP 7 EP 8 PG 2 WC Ophthalmology SC Ophthalmology GA KJ696 UT WOS:A1993KJ69600003 ER PT J AU LI, Q WHITCUP, SM FUJINO, Y NUSSENBLATT, RB CHAN, CC AF LI, Q WHITCUP, SM FUJINO, Y NUSSENBLATT, RB CHAN, CC TI THE ROLE OF MAST-CELLS IN ENDOTOXIN-INDUCED UVEITIS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE ENDOTOXIN-INDUCED UVEITIS; INBRED RAT STRAINS; MAST CELLS ID EXPRESSION; RAT C1 NEI,IMMUNOL LAB,BLDG 10,RM 10N206,BETHESDA,MD 20892. NR 10 TC 20 Z9 20 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 1993 VL 34 IS 1 BP 256 EP 259 PG 4 WC Ophthalmology SC Ophthalmology GA KJ696 UT WOS:A1993KJ69600031 PM 8425832 ER PT J AU KASHIMA, K TRUS, BL UNSER, M EDWARDS, PA DATILES, MB AF KASHIMA, K TRUS, BL UNSER, M EDWARDS, PA DATILES, MB TI AGING STUDIES ON NORMAL LENS USING THE SCHEIMPFLUG SLIT-LAMP CAMERA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE AGE-RELATED LENS CHANGES; ANTERIOR CHAMBER DEPTH; CATARACT; LENS THICKNESS; SCHEIMPFLUG CAMERA C1 NEI,OPHTHAL GENET & CLIN SERV BRANCH,CATARACT & CORNEA SECT,BETHESDA,MD 20892. NEI,OPHTHAL GENET & CLIN SERV BRANCH,CATARACT & CORNEAL DIS SECT,BETHESDA,MD 20892. NIH,DIV COMP RES & TECHNOL,COMP SYST LAB,BETHESDA,MD 20892. NIH,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892. RI Unser, Michael/A-1550-2008; OI Datiles, Manuel III B./0000-0003-4660-1664 NR 7 TC 34 Z9 34 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 1993 VL 34 IS 1 BP 263 EP 269 PG 7 WC Ophthalmology SC Ophthalmology GA KJ696 UT WOS:A1993KJ69600033 PM 8425834 ER PT J AU STADALNIK, RC KUDO, M ECKELMAN, WC VERA, DR AF STADALNIK, RC KUDO, M ECKELMAN, WC VERA, DR TI INVIVO FUNCTIONAL IMAGING USING RECEPTOR-BINDING RADIOPHARMACEUTICALS - TECHNETIUM 99M-GALACTOSYL-NEOGLYCOALBUMIN AS A MODEL SO INVESTIGATIVE RADIOLOGY LA English DT Article ID POSITRON EMISSION TOMOGRAPHY; MUSCARINIC ACETYLCHOLINE-RECEPTORS; PRELIMINARY CLINICAL-EXPERIENCE; LIVING HUMAN-BRAIN; GALACTOSYL-NEOGLYCOALBUMIN; HEPATOCELLULAR-CARCINOMA; IDENTIFIABILITY ANALYSIS; HEPATIC-FUNCTION; CIRRHOTIC LIVER; NGA C1 KOBE CITY GEN HOSP,DEPT MED,DIV GASTROENTEROL,KOBE,JAPAN. NIH,DEPT PET,BETHESDA,MD 20892. RP STADALNIK, RC (reprint author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,DIV NUCL MED,2315 STOCKTON BLVD,SACRAMENTO,CA 95817, USA. OI Kudo, Masatoshi/0000-0002-4102-3474 FU NIADDK NIH HHS [R0I-AM34706, R0I-AM34768] NR 69 TC 21 Z9 21 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0020-9996 J9 INVEST RADIOL JI Invest. Radiol. PD JAN PY 1993 VL 28 IS 1 BP 64 EP 70 DI 10.1097/00004424-199301000-00018 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA KH740 UT WOS:A1993KH74000012 PM 8425855 ER PT J AU TASAKI, I BYRNE, PM AF TASAKI, I BYRNE, PM TI THE ORIGIN OF RAPID CHANGES IN BIREFRINGENCE, LIGHT-SCATTERING AND DYE ABSORBENCY ASSOCIATED WITH EXCITATION OF NERVE-FIBERS SO JAPANESE JOURNAL OF PHYSIOLOGY LA English DT Article; Proceedings Paper CT 17TH SEIRIKEN CONF ON FRONTIERS IN OPTICAL NEUROSCIENCES CY MAR 03-07, 1992 CL NATL INST PHYSIOL SCI, OKAZAKI, JAPAN SP INOUE SCI FDN HO NATL INST PHYSIOL SCI DE NERVE BIREFRINGENCE; LIGHT-SCATTERING; DYE ABSORBENCY ID GARFISH OLFACTORY NERVE AB By comparing the time-courses of rapid optical changes in the garfish olfactory nerve evoked by electric stimulation with those of mechanical changes observed at the site of optical recording, the origin of optical changes in the nerve has been investigated. Based on the finding that the time-course of the birefringence change accurately coincides with that of swelling of the nerve, optical changes are interpreted as being brought about by invasion of water into the superficial layer of the nerve fibers. A close relationship has also been demonstrated between nerve swelling and changes in light scattering and in dye absorbance. RP TASAKI, I (reprint author), NIMH,NEUROBIOL UNIT,CELL BIOL LAB,BETHESDA,MD 20892, USA. NR 21 TC 21 Z9 21 U1 1 U2 2 PU CENTER ACADEMIC PUBL JAPAN PI TOKYO PA 4-16 YAYOI 2-CHOME, BUNKYO-KU, TOKYO 113, JAPAN SN 0021-521X J9 JPN J PHYSIOL JI Jpn. J. Physiol. PY 1993 VL 43 SU 1 BP S67 EP S75 PG 9 WC Physiology SC Physiology GA LW994 UT WOS:A1993LW99400012 PM 7505858 ER PT J AU MASUR, H FEINBERG, J BOZZETTE, SA DEGRUTTOLA, V EDLIN, B EISINGER, R ELSADR, W ELLENBERG, S FEIGAL, D FRAME, P GOLDBERGER, M HAFNER, R HARDY, WD HARRINGTON, M HUGHES, W KERKERING, T KOVACS, J LEOUNG, G MONTANER, J MUNOZ, A PHAIR, J SATTLER, F SPECTOR, S AF MASUR, H FEINBERG, J BOZZETTE, SA DEGRUTTOLA, V EDLIN, B EISINGER, R ELSADR, W ELLENBERG, S FEIGAL, D FRAME, P GOLDBERGER, M HAFNER, R HARDY, WD HARRINGTON, M HUGHES, W KERKERING, T KOVACS, J LEOUNG, G MONTANER, J MUNOZ, A PHAIR, J SATTLER, F SPECTOR, S TI RECOMMENDATIONS FOR PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA FOR PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY LA English DT Article ID TRIMETHOPRIM-SULFAMETHOXAZOLE; AEROSOLIZED PENTAMIDINE; AIDS PATIENTS; HIV-INFECTION; PREVENTION; CHEMOPROPHYLAXIS; DIAGNOSIS; DAPSONE; COUNTS; TRIAL RP MASUR, H (reprint author), NIH,BLDG 10,ROOM 7043,BETHESDA,MD 20892, USA. OI Edlin, Brian/0000-0001-8172-8797 NR 37 TC 19 Z9 19 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 1077-9450 J9 J ACQ IMMUN DEF SYND JI J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. PD JAN PY 1993 VL 6 IS 1 BP 46 EP 55 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA KE095 UT WOS:A1993KE09500007 ER PT J AU HOOVER, DR SAAH, AJ BACELLAR, H MURPHY, R VISSCHER, B ANDERSON, R KASLOW, RA AF HOOVER, DR SAAH, AJ BACELLAR, H MURPHY, R VISSCHER, B ANDERSON, R KASLOW, RA TI SIGNS AND SYMPTOMS OF ASYMPTOMATIC HIV-1 INFECTION IN HOMOSEXUAL MEN SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY LA English DT Article DE CHRONIC IMPACT; DEPRESSION; HEALTH STATUS; HIV-1; PREAIDS; SYMPTOMS ID AIDS AB We investigated the long-term health effects of HIV-1 infection in homosexual men not close to developing AIDS by comparing 916 HIV-1-seropositive (SP) men at least 1.67-3.67 years prior to a clinical AIDS diagnosis to 2,161 HIV-1-seronegative (SN) controls. The SP group reported a higher total of 12 distinct symptoms (fatigue, shortness of breath, night sweats, rash, cough, diarrhea, headache, thrush, skin discoloration, fever, weight loss, and sore throat/mouth) than did the SN group (p < 0.0001), corresponding to at least 5.6 more days/year of such symptoms. The SP group had lower body mass index (p < 0.0001) and lower hemoglobin (p < 0.0001). The SP group was more depressed, as measured by CES-D score (p = 0.047), before knowledge of one's serostatus was likely, and became even further depressed (p = 0.038 for increase in depression) after the HIV-1 serostatus test was accessible to high-risk groups. These associations remained unchanged in multivariate models, incorporating other covariates. C1 NORTHWESTERN UNIV,SCH MED,HOWARD BROWN MEM CLIN,CHICAGO,IL 60611. UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024. UNIV PITTSBURGH,GRAD SCH PUBL HLTH,PITTSBURGH,PA 15260. UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15261. NIAID,EPIDEMIOL BRANCH,BETHESDA,MD 20892. RP HOOVER, DR (reprint author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,CTR DATA COORDINATING,CAMACS,BALTIMORE,MD 21205, USA. OI Murphy, Robert/0000-0003-3936-2052 FU NIAID NIH HHS [AI-72631, AI-72632, AI-72634] NR 16 TC 44 Z9 45 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 1077-9450 J9 J ACQ IMMUN DEF SYND JI J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. PD JAN PY 1993 VL 6 IS 1 BP 66 EP 71 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA KE095 UT WOS:A1993KE09500010 PM 8417176 ER PT J AU CASH, JM AF CASH, JM TI METHOTREXATE IN ASTHMA - AN ALTERNATIVE VIEW SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Letter ID DEPENDENT ASTHMA RP CASH, JM (reprint author), NIAMS,ARTHRITIS BRANCH,BLDG 10,ROOM 9N240,BETHESDA,MD 20892, USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1993 VL 91 IS 1 BP 140 EP 140 DI 10.1016/0091-6749(93)90307-2 PN 1 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA KK044 UT WOS:A1993KK04400013 PM 8423269 ER PT J AU EHRHARDT, RO HARRIMAN, GR STROBER, W AF EHRHARDT, RO HARRIMAN, GR STROBER, W TI FUNCTIONAL UNRESPONSIVENESS OF PP IGA+ AND IGG+ PLN B-CELLS TO THYMUS-INDEPENDENT TYPE-I AND TYPE-II ANTIGENS - INDICATION FOR A T-CELL-DEPENDENT, ANTIGEN-DRIVEN SELECTION IN SIGG+ AND SIGA+ B-CELLS SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 NIAID,MUCOSAL IMMUN SECT,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1993 VL 91 IS 1 BP 184 EP 184 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA KK431 UT WOS:A1993KK43100173 ER PT J AU BIANCHINE, PJ METCALFE, DD DIX, RK PERHACH, JL FRIEDMAN, BS AF BIANCHINE, PJ METCALFE, DD DIX, RK PERHACH, JL FRIEDMAN, BS TI THE EFFECT OF AZELASTINE (ASTELIN(TM), AZ) ON SKIN-TEST REACTIVITY IN SUBJECTS WITH MASTOCYTOSIS SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 NIAID,BETHESDA,MD 20892. WALLACE LABS,PRINCETON,NJ. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1993 VL 91 IS 1 BP 244 EP 244 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA KK431 UT WOS:A1993KK43100415 ER PT J AU BARDWELL, SA BUBB, MR HOHMAN, RJ AF BARDWELL, SA BUBB, MR HOHMAN, RJ TI PHOSPHOLIPASE-C-GAMMA(1) ASSOCIATES WITH A PROTEIN IN THE DETERGENT INSOLUBLE CYTOSKELETON OF RAT BASOPHILIC LEUKEMIA-CELLS SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 NIAID,BETHESDA,MD 20892. NHLBI,BETHESDA,MD 20892. NIH,HOWARD HUGHES MED INST,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1993 VL 91 IS 1 BP 331 EP 331 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA KK431 UT WOS:A1993KK43100761 ER PT J AU BOYD, AL SAMID, D AF BOYD, AL SAMID, D TI MOLECULAR-BIOLOGY OF TRANSGENIC ANIMALS - REVIEW SO JOURNAL OF ANIMAL SCIENCE LA English DT Article; Proceedings Paper CT SYMP ON GENETICALLY MODIFIED LIVESTOCK : PROGRESS, PROSPECTS AND ISSUES, AT THE 1992 ANNUAL MEETING OF THE AMERICAN SOC OF ANIMAL SCIENCE CY AUG 11, 1992 CL PITTSBURGH, PA SP AMER SOC ANIM SCI, USDA, EXTENS SERV, USDA, AGR RES SERV, USDA, FOOD SAFETY & INSPECT SERV DE DNA; RECOMBINANT; TRANSGENIC; MOLECULAR ID MAMMALIAN-CELLS; GENE-TRANSFER; DEOXYRIBONUCLEIC-ACID; MESSENGER-RNA; DNA; MICE; EXPRESSION; MOUSE; HYBRIDIZATION; TRANSLATION AB The amazing pace of discovery within the field of molecular biology has expanded the understanding of as well as the potential for genetic engineering in laboratory and domestic animals. Recently, specific techniques have been perfected, including recombinant DNA, genetic cloning, analysis of gene expression, and the sequencing of nucleic acids and proteins. These molecular techniques combined with methods allowing transfer of the recombinant genes into living cells and fertilized eggs advent the production of transgenic mice and other animals, the application of which is unlimited. C1 NCI,BETHESDA,MD 20892. RP BOYD, AL (reprint author), HOOD COLL,DEPT BIOL,FREDERICK,MD 21701, USA. NR 61 TC 15 Z9 15 U1 1 U2 4 PU AMER SOC ANIMAL SCIENCE PI SAVOY PA 1111 NORTH DUNLAP AVE, SAVOY, IL 61874 SN 0021-8812 J9 J ANIM SCI JI J. Anim. Sci. PY 1993 VL 71 SU S3 BP 1 EP 9 PG 9 WC Agriculture, Dairy & Animal Science SC Agriculture GA LB507 UT WOS:A1993LB50700002 PM 8505264 ER PT J AU KOLENBRANDER, PE AF KOLENBRANDER, PE TI COAGGREGATION OF HUMAN ORAL BACTERIA - POTENTIAL ROLE IN THE ACCRETION OF DENTAL PLAQUE SO JOURNAL OF APPLIED BACTERIOLOGY LA English DT Article; Proceedings Paper CT SYMP OF THE SOC FOR APPLIED BACTERIOLOGY CY JUL, 1992 CL UNIV MANCHESTER, MANCHESTER, ENGLAND SP SOC APPL BACTERIOL HO UNIV MANCHESTER ID STREPTOCOCCUS-GORDONII CHALLIS; SALIVA-COATED HYDROXYAPATITE; PROLINE-RICH PROTEINS; FUSOBACTERIUM-NUCLEATUM; APATITIC SURFACES; FILAMENTOUS MICROORGANISMS; ACTINOMYCES-NAESLUNDII; VIRIDANS STREPTOCOCCI; ADHESIVE PROPERTIES; ESCHERICHIA-COLI RP KOLENBRANDER, PE (reprint author), NIDR,MICROBIAL ECOL LAB,BLDG 30,ROOM 310,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 68 TC 34 Z9 36 U1 0 U2 2 PU BLACKWELL SCIENCE LTD PI OXFORD PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL SN 0021-8847 J9 J APPL BACTERIOL JI J. Appl. Bacteriol. PY 1993 VL 74 SU S BP S79 EP S86 DI 10.1111/j.1365-2672.1993.tb04344.x PG 8 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA LJ555 UT WOS:A1993LJ55500009 PM 8349536 ER PT J AU BARANIUK, JN OHKUBO, K KWON, OJ MAK, J ROHDE, J KALINER, MA DURHAM, SR BARNES, PJ AF BARANIUK, JN OHKUBO, K KWON, OJ MAK, J ROHDE, J KALINER, MA DURHAM, SR BARNES, PJ TI IDENTIFICATION OF NEUTRAL ENDOPEPTIDASE MESSENGER-RNA IN HUMAN NASAL-MUCOSA SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE ENKEPHALINASE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CALLA; CD10; NEUROGENIC INFLAMMATION; PROTEASE; NONISOTOPIC INSITU HYBRIDIZATION ID AMINO-ACID SEQUENCE; RAT TRACHEA; NEUROGENIC INFLAMMATION; LEUKEMIA ANTIGEN; SUBSTANCE-P; GUINEA-PIG; 24.11 ENKEPHALINASE; MOLECULAR-CLONING; NEURAL CONTROL; HYPERRESPONSIVENESS AB Neutral endopeptidase (NEP) may regulate peptide-induced inflammation in the upper respiratory tract. NEP mRNA was detected by Northern blotting in poly(A)+ mRNA prepared from human turbinates. NEP mRNA bands were detected at 3.9 and 1.8 kb. In situ hybridization identified NEP mRNA in epithelial cells, serous cells of submucosal glands, and vessel walls. The vacuoles of goblet and mucous cells were not stained, but it is likely that the cytoplasm of these cells contained some NEP mRNA. Radioactive in situ hybridization with S-35-UTP appeared to be more sensitive than nonradioactive in situ hybridization with biotin-UTP and immunogold detection. The NEP mRNA-containing cells identified by in situ hybridization were the same as those identified by immunohistochemistry to contain immunoreactive NEP. These NEP-containing cells have been previously shown to possess peptide receptors. This is consistent with the hypothesis that NEP on cells bearing peptide receptors may regulate neuropeptide-induced inflammation in human nasal mucosa. C1 NIAID,ALLERG DIS SECT,BETHESDA,MD 20892. NATL HEART & LUNG INST,DEPT THORAC MED,LONDON SW3 6LY,ENGLAND. NATL HEART & LUNG INST,DEPT CLIN IMMUNOL,LONDON SW3 6LY,ENGLAND. RP BARANIUK, JN (reprint author), GEORGETOWN UNIV,DIV RHEUMATOL IMMUNOL & ALLERGY,GLOZO GORMAN BLDG,WASHINGTON,DC 20007, USA. NR 34 TC 16 Z9 16 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD JAN PY 1993 VL 74 IS 1 BP 272 EP 279 PG 8 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA KJ480 UT WOS:A1993KJ48000037 PM 8444703 ER PT J AU WEICKERT, MJ ADHYA, S AF WEICKERT, MJ ADHYA, S TI CONTROL OF TRANSCRIPTION OF GAL REPRESSOR AND ISOREPRESSOR GENES IN ESCHERICHIA-COLI SO JOURNAL OF BACTERIOLOGY LA English DT Article ID SEQUENCE; PROMOTER; OPERON; AUTOREGULATION; ULTRAINDUCTION; COMPLEX; SYSTEM; PURR; DNA; K12 AB Two regulatory proteins, Gal repressor and isorepressor, control the expression of the gal and mgl operons in Escherichia coli. The transcription start sites for galR and galS, the genes for the repressor and isorepressor, were determined by primer extension of in vivo transcripts. Study of the promoter-lacZ gene fusions introduced into the chromosome indicated that galS expression was elevated in cells in which the normal galS gene was interrupted, but not in cells in which the galR gene was deleted. When both genes were disrupted, galS expression was further elevated. Expression from the galS promoter was stimulated by the addition of D-fucose, repressed by glucose, and dependent on cyclic AMP receptor protein (CRP). Expression of a similar gene fusion of the galR promoter to lacZ was unregulated. Both galR and galS genes contain two potential operator sites (O(E) and O(I)) and a CRP-binding site. The arrangement of O(E), O(I), and the CRP-binding site in the galS gene is analogous to the arrangement in the gal and mgl promoters, but the arrangement in galR is atypical. The increased concentration of the isorepressor when inducer is present may facilitate early shutoff of the isorepressor-regulated genes of the gal regulon when inducer (substrate) concentration falls. C1 NCI,MOLEC BIOL LAB,BETHESDA,MD 20892. NR 33 TC 39 Z9 39 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD JAN PY 1993 VL 175 IS 1 BP 251 EP 258 PG 8 WC Microbiology SC Microbiology GA KE618 UT WOS:A1993KE61800031 PM 8416900 ER PT J AU GANESHKUMAR, N ARORA, N KOLENBRANDER, PE AF GANESHKUMAR, N ARORA, N KOLENBRANDER, PE TI SALIVA-BINDING PROTEIN (SSAB) FROM STREPTOCOCCUS-SANGUIS 12 IS A LIPOPROTEIN SO JOURNAL OF BACTERIOLOGY LA English DT Article ID COATED HYDROXYAPATITE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; BACTERIA; GORDONII; ADHESIN; GENE; COAGGREGATION; ACTINOMYCES; GLYCERIDE AB Two lipoprotein consensus sequences (Leu-X-X-Cys) are found in the presumptive signal peptide region (positions 12 to 15 and 17 to 20) of saliva-binding protein (SsaB) from Streptococcus sanguis 12. Three analogs of SsaB containing Cys-->Gly mutations were constructed by site-directed mutagenesis of pSA2, the recombinant plasmid expressing SsaB. [H-3]palmitate was incorporated into SsaB only when the native Cys-20 residue was present. These data show that SsaB is a lipoprotein and that Cys-20 is the critical site for acylation. RP GANESHKUMAR, N (reprint author), NIDR,MICROBIAL ECOL LAB,BETHESDA,MD 20892, USA. NR 22 TC 25 Z9 26 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD JAN PY 1993 VL 175 IS 2 BP 572 EP 574 PG 3 WC Microbiology SC Microbiology GA KG501 UT WOS:A1993KG50100035 PM 8419308 ER PT J AU VUISTER, GW DELAGLIO, F BAX, A AF VUISTER, GW DELAGLIO, F BAX, A TI THE USE OF 1JC-ALPHA-H-ALPHA COUPLING-CONSTANTS AS A PROBE FOR PROTEIN BACKBONE CONFORMATION SO JOURNAL OF BIOMOLECULAR NMR LA English DT Article DE ONE-BOND COUPLING; PROTEIN BACKBONE; CALMODULIN; SECONDARY STRUCTURE; C-13 ENRICHMENT ID PANCREATIC TRYPSIN-INHIBITOR; 2D NMR-SPECTRA; 3-DIMENSIONAL NMR; STAPHYLOCOCCAL NUCLEASE; SECONDARY STRUCTURE; CHEMICAL-SHIFTS; SPECTROSCOPY; CALMODULIN; C-13; ASSIGNMENT AB Simple pseudo-3D modifications to the constant-time HSQC and HCACO experiments are described that allow accurate (+/- 0.5 Hz) measurement of one bond J(CalphaHalpha) coupling constants in proteins that are uniformly enriched with C-13. An empirical phi,psi-surface is calculated which describes the deviation of 1J(CalphaHalpha) from its random coil value, using 203 1J(CalphaHalpha) values measured for residues in the proteins calmodulin, staphylococcal nuclease, and basic pancreatic trypsin inhibitor, for which phi and psi are known with good precision from previous X-ray crystallographic studies. Residues in alpha-helical conformation exhibit positive deviations of 4-5 Hz, whereas deviations in beta-sheet are small and, on average, slightly negative. Data indicate that 1J(CalphaHalpha) depends primarily on psi, and that 1J(CalphaHalpha) may be useful as a qualitative pi-obe for secondary structure. Comparison of 1J(CalphaHalpha). COUPling constants measured in free calmodulin and in its complex with a 26-amino-acid peptide fragment of myosin light-chain kinase confirm that the calmodulin secondary structure is retained upon complexation but that disruption of the middle part of the 'central helix' is even more extensive than in free calmodulin. RP VUISTER, GW (reprint author), NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892, USA. NR 39 TC 71 Z9 71 U1 0 U2 3 PU ESCOM SCI PUBL BV PI LEIDEN PA PO BOX 214, 2300 AE LEIDEN, NETHERLANDS SN 0925-2738 J9 J BIOMOL NMR JI J. Biomol. NMR PD JAN PY 1993 VL 3 IS 1 BP 67 EP 80 PG 14 WC Biochemistry & Molecular Biology; Spectroscopy SC Biochemistry & Molecular Biology; Spectroscopy GA KM206 UT WOS:A1993KM20600005 PM 8448436 ER PT J AU ANGLISTER, J GRZESIEK, S REN, H KLEE, CB BAX, A AF ANGLISTER, J GRZESIEK, S REN, H KLEE, CB BAX, A TI ISOTOPE-EDITED MULTIDIMENSIONAL NMR OF CALCINEURIN-B IN THE PRESENCE OF THE NON-DEUTERATED DETERGENT CHAPS SO JOURNAL OF BIOMOLECULAR NMR LA English DT Article DE DETERGENT; CHAPS; CALCINEURIN; ISOTOPE LABELING; PROTEIN STRUCTURE DETERMINATION; MULTIDIMENSIONAL NMR ID MEMBRANE-PROTEIN; SPECTROSCOPY; DYNAMICS; BACTERIORHODOPSIN; SOLUBILIZATION; SUPPRESSION; SPECTRA AB At the concentration needed for NMR, the calcium-saturated form of calcineurin B dissolved in water shows resonance line widths that indicate aggregation of this protein. Although the line width or aggregation state can be influenced to some degree by temperature, pH, and salt concentrations, in the absence of detergent no conditions could be found where the protein behaved as a monomeric unit. In the presence of a 10- to 20-fold molar excess of the zwitterionic detergent 3-[(3-cholamidopropyl)-dimethyl-ammonio]-1-propanesulfonate (CHAPS), resonance line widths were considerably narrower and were compatible with a protein of approximately 25 kDa. The presence of the NMR signals of the non-deuterated CHAPS does not interfere with modern isotope-directed NMR studies as the signals from protons not attached to N-15 or C-13 are removed by isotope filtering and purge pulses. C1 NCI,BIOCHEM LAB,BETHESDA,MD 20892. RP ANGLISTER, J (reprint author), NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892, USA. NR 16 TC 83 Z9 83 U1 0 U2 1 PU ESCOM SCI PUBL BV PI LEIDEN PA PO BOX 214, 2300 AE LEIDEN, NETHERLANDS SN 0925-2738 J9 J BIOMOL NMR JI J. Biomol. NMR PD JAN PY 1993 VL 3 IS 1 BP 121 EP 126 PG 6 WC Biochemistry & Molecular Biology; Spectroscopy SC Biochemistry & Molecular Biology; Spectroscopy GA KM206 UT WOS:A1993KM20600009 PM 8383554 ER PT J AU IRWIN, P PFEFFER, P DONER, L FERRETTI, J AF IRWIN, P PFEFFER, P DONER, L FERRETTI, J TI NMR-STUDIES OF H2O-N-PHENYL (N-PHENYL-BETA-D-GLUCOPYRANOSYLAMINE)URONAMIDE INTERACTIONS IN DIMETHYL-SULFOXIDE AT 2 FIELDS SO JOURNAL OF CARBOHYDRATE CHEMISTRY LA English DT Article ID SPIN DIFFUSION; SPECTROSCOPY; RELAXATION; CONFORMATION; PROTEINS; RATES; DMSO AB During the course of NMR structural investigations of the title compound (N-phenyl uronamide) we noticed the presence of a strong H2O activity-dependent NOE between the small amount of H2O associated with the carbohydrate's hydroxyl protons in solutions of DMSO-d6. The -OH/H2O off-diagonal t1 slices displayed a NOESY tau(m)-dependence similar to molecules (tau(c) = 0.1-5 ns) experiencing slow exchange (1-10 s-1). From T1 data at two fields a tau(c) for the title compound was calculated to be ca. 0.54 ns at 313 K. The -OH/H2O exchange rate constant, kappa, increased from 0.32 to 11.14 s-1 as the molar ratio of [H2O] : [N-phenyl uronamide] increased from ca. 4.5 to 5.2. The latter finding indicated that the -OH/H2O proton exchange process, which is strongly affected by the translational diffusion of H2O, diminished as [H2O] approached that which was inherently a complex in the crystalline structure (e.g., C18H20O5N2.4H2O) and was, presumably, tightly hydrogen-bound to the -OH/NH funtional groups. To test this, the title compound was recrystallized from ethanol/2,2-dimethoxypropane whereupon the bound H2O was eliminated; the lack of H2O induced a significant upfield shift in the resonance frequencies of all the exchangable (-OH DELTAdelta=86.33Hz; -NH DELTAdelta-67.84Hz) functional groups relative to the methine protons (CH DELTAdelta=0.25Hz). C1 NHLBI,BIOPHYS CHEM LAB,BETHESDA,MD 20892. RP IRWIN, P (reprint author), USDA,EASTERN REG RES CTR,600 E MERMAID LANE,PHILADELPHIA,PA 19118, USA. NR 20 TC 1 Z9 1 U1 0 U2 1 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0732-8303 J9 J CARBOHYD CHEM JI J. Carbohydr. Chem. PY 1993 VL 12 IS 1 BP 63 EP 79 DI 10.1080/07328309308018541 PG 17 WC Biochemistry & Molecular Biology; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA KG644 UT WOS:A1993KG64400006 ER PT J AU LEDER, IG AF LEDER, IG TI SYNTHESIS OF THE SODIUM-SALTS OF METHYL ALPHA-L-FUCOPYRANOSIDE 2-SULFATES, 3-SULFATES, AND 4-SULFATES SO JOURNAL OF CARBOHYDRATE CHEMISTRY LA English DT Article ID SULFATED GLYCOLIPIDS; POLYSACCHARIDES; THROMBOSPONDIN AB The sodium salts of the isomeric methyl alpha-L-fucopyranoside 2-, 3- and 4- sulfates have been prepared from methyl alpha-L-fucopyranoside 1. Specific hydroxyl groups, isolated by 4-dimethylaminopyridine-catalyzed tritylation and acetylation of 1, were sulfated by the pyridine:SO3 complex. RP LEDER, IG (reprint author), NIDKD,STRUCT BIOL LAB,BETHESDA,MD 20892, USA. NR 18 TC 4 Z9 4 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0732-8303 J9 J CARBOHYD CHEM JI J. Carbohydr. Chem. PY 1993 VL 12 IS 1 BP 95 EP 103 DI 10.1080/07328309308018543 PG 9 WC Biochemistry & Molecular Biology; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA KG644 UT WOS:A1993KG64400008 ER PT J AU GOTOH, M KOVAC, P AF GOTOH, M KOVAC, P TI SYNTHESIS OF LIGANDS RELATED TO THE O-SPECIFIC ANTIGEN OF VIBRIO-CHOLERAE .1. SYNTHESIS AND CHARACTERIZATION OF THE CRYSTALLINE METHYL ALPHA-GLYCOSIDE OF THE REPEATING UNIT OF THE O-POLYSACCHARIDE OF VIBRIO-CHOLERAE O-1 SO JOURNAL OF CARBOHYDRATE CHEMISTRY LA English DT Note C1 NIDDK,BETHESDA,MD 20892. NR 7 TC 4 Z9 4 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0732-8303 J9 J CARBOHYD CHEM JI J. Carbohydr. Chem. PY 1993 VL 12 IS 7 BP 981 EP 983 DI 10.1080/07328309308020110 PG 3 WC Biochemistry & Molecular Biology; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA MB992 UT WOS:A1993MB99200015 ER PT J AU JOUNEAUX, C GOLDSMITH, P HANOUNE, J LOTERSZTAJN, S AF JOUNEAUX, C GOLDSMITH, P HANOUNE, J LOTERSZTAJN, S TI ENDOTHELIN INHIBITS THE CALCIUM-PUMP AND STIMULATES PHOSPHOINOSITIDE PHOSPHOLIPASE-C IN LIVER PLASMA-MEMBRANES VIA 2 DIFFERENT-G PROTEINS, GS AND GQ SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article; Proceedings Paper CT 3rd International Conference on Endothelin CY FEB 15-17, 1993 CL BAYLOR COLL MED, HOUSTON, TX HO BAYLOR COLL MED DE CALCIUM SIGNAL; HEPATOCYTES; PHOSPHOLIPASE-C ACTIVATION; CALCIUM PUMP INHIBITION; G-PROTEINS ID RAT-LIVER; RECEPTOR AB We have shown previously that in liver, endothelin (ET) binding to plasma membranes causes a rise in cytosolic calcium and activation of glycogenolysis. Here we show that the calcium extrusion pump in liver plasma membranes is inhibited by ET peptides, with ET-1 greater-than-or-equal-to ET-3 = sarafotoxin S6C-inhibition of the system being potentiated by GTPgammaS. Also, ET-1 stimulates PIP2 hydrolysis in liver plasma membranes in a guanine nucleotide-dependent manner, with ET-1 greater-than-or-equal-to ET-3 = sarafotoxin S6C. In order to determine the nature of G protein(s) coupling of the ET(B) receptor to both effectors, antibodies against the C-terminus of different G-protein alpha-subunits were used. Antibodies reactive with G(s)alpha blocked ET-1 inhibition of the calcium pump, but they had no effect on ET-1 stimulation of PIP2 hydrolysis. Antibodies reactive with G(q)alpha dose-dependently antagonized stimulation of PIP2 breakdown by ET-1 without affecting ET-1 inhibition of the calcium pump. Antibodies reactive with G(i1)alpha/G(i2)alpha had no effect on both systems. We conclude that the calcium signal induced by endothelins in hepatocytes may be consequent to both an activation of phospholipase C and inhibition of the calcium pump, both effectors being coupled to the ET(B) receptor by different G proteins, G(q) and G(s), respectively. C1 HOP HENRI MONDOR,INSERM,U99,F-94010 CRETEIL,FRANCE. NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BETHESDA,MD. NR 12 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0160-2446 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PY 1993 VL 22 SU 8 BP S158 EP S160 DI 10.1097/00005344-199322008-00042 PG 3 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA MN028 UT WOS:A1993MN02800042 PM 7509931 ER PT J AU MORLEY, D KEEFER, LK AF MORLEY, D KEEFER, LK TI NITRIC-OXIDE NUCLEOPHILE COMPLEXES - A UNIQUE CLASS OF NITRIC-OXIDE BASED VASODILATORS SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article; Proceedings Paper CT SYMP ON NITRIC OXIDE DONORS AND THE TREATMENT OF CARDIOVASCULAR DISEASE CY NOV 15, 1992 CL NEW ORLEANS, LA SP THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, HOECHST ROUSSEL PHARM DE NITRIC OXIDE; NUCLEOPHILES; VASODILATION; VASCULAR SMOOTH MUSCLE ID S-NITROSOTHIOLS; VASCULAR RELAXATION; CORONARY-ARTERIES; ORGANIC NITRATES; NITROPRUSSIDE; CYANIDE; INVOLVEMENT; MECHANISM AB Complexes of nitric oxide (NO) with nucleophiles. also known as nitric oxide/nucleophile adducts or NONOates, appear to offer many advantages as research tools in cardiovascular pharmacology and may have future clinical potential as well. A wide variety of NONOates can be synthesized simply by exposing various nucleophilic compounds to NO. The products are generally stable as solids and highly soluble in aqueous media. The potent vasodilator activity displayed by select members of this series is endothelium independent and is mediated by the free NO that is released on dissolution, which activates smooth-muscle guanylate cyclase with subsequent intracellular cyclic guanosine monophosphate production. NO release from the NONOate complexes is not catalyzed by exogenous thiol or albumin. The NONOates differ from other currently available nitrovasodilators in that their potency as vasorelaxants correlates closely with data on their first-order rates of spontaneous reversion to NO in simple aqueous buffers. The compounds' properties can be conveniently altered by changing the identity of the nucleophilic residue. Continued work with NONOate complexes may provide useful clinical agents as well as improved tools for probing the bioregulatory roles of NO. C1 NCI,FREDERICK CANC RES & DEV CTR,COMPARAT COMPREHENS LAB,FREDERICK,MD 21701. RP MORLEY, D (reprint author), HAHNEMANN UNIV,DIV CARDIOVASC DIS,BROAD & VINE,MAIL STOP 115,PHILADELPHIA,PA 19102, USA. RI Keefer, Larry/N-3247-2014 OI Keefer, Larry/0000-0001-7489-9555 NR 29 TC 85 Z9 86 U1 0 U2 5 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0160-2446 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PY 1993 VL 22 SU 7 BP S3 EP S9 DI 10.1097/00005344-199300221-00003 PG 7 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA MA493 UT WOS:A1993MA49300003 PM 7504766 ER PT J AU USUKI, S SAITOH, T SAITOH, M TANAKA, J KAWAKURA, Y USUKI, Y SHINJO, M KIM, SJ AF USUKI, S SAITOH, T SAITOH, M TANAKA, J KAWAKURA, Y USUKI, Y SHINJO, M KIM, SJ TI ENDOTHELIN-RENIN-ANGIOTENSIN-ATRIAL NATRIURETIC PEPTIDE SYSTEM IN OVARIES - AN INTRAOVARIAN ERAANP SYSTEM SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article; Proceedings Paper CT 3rd International Conference on Endothelin CY FEB 15-17, 1993 CL BAYLOR COLL MED, HOUSTON, TX HO BAYLOR COLL MED DE ENDOTHELIN-1; RENIN-ANGIOTENSIN SYSTEM; ATRIAL NATRIURETIC PEPTIDE (ERAANPS); OVARY; GRANULOSA CELLS ID TREATED IMMATURE RATS; PROGESTERONE SECRETION; HYPERTENSIVE RATS; RELEASE; CELLS; TOKISHAKUYAKUSAN; KEISHIBUKURYOGAN; SHAKUYAKUKANZOTO; TESTOSTERONE; INJECTION AB In a recent investigation of the ovary, high levels of endothelin-I (ET-1), the renin-angiotensin system (RAS), and atrial natriuretic peptide (ANP) were identified. It was determined that ET, RAS, and ANP, alone or together, affected ovarian function. It is important that mutual relationships of these vasoactive and hormonal peptides, which coexist in the ovary, are examined to determine their in vivo functions. This study, using immature rats treated with pregnant mare's serum gonadotropin (PMS), examined the effects of ET-1, angiotensin II (Ang II) and ANP, individually or in combination, on steroidogenesis by granulosa cells (GCs) cultured for 72 h. ET-1 Ang II, and ANP, alone or combined, also had a mutual effect on steroidogenesis. Concomitantly with previous findings on the ovary, the authors propose that the intraovarian endothelin-renin-angiotensin-ANP system (ERAANPS) functions as a novel intraovarian regulator system. C1 UNIV TSUKUBA,INST CLIN MED,DEPT SURG,TSUKUBA,IBARAKI 305,JAPAN. UNIV TSUKUBA,INST CLIN MED,DEPT OPHTHALMOL,TSUKUBA,IBARAKI 305,JAPAN. UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI,JAPAN. NCI,BETHESDA,MD 20892. RP USUKI, S (reprint author), UNIV TSUKUBA,INST CLIN MED,DEPT OBSTET & GYNECOL,KURAKAKE 7253,TSUKUBA,IBARAKI 305,JAPAN. NR 35 TC 13 Z9 13 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0160-2446 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PY 1993 VL 22 SU 8 BP S207 EP S210 DI 10.1097/00005344-199322008-00056 PG 4 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA MN028 UT WOS:A1993MN02800056 PM 7509946 ER PT J AU YUSUF, S GARG, R MCCONACHIE, D AF YUSUF, S GARG, R MCCONACHIE, D TI EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS IN LEFT-VENTRICULAR DYSFUNCTION - RESULTS OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION IN THE CONTEXT OF OTHER SIMILAR TRIALS SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article; Proceedings Paper CT Symposium on the Role of ACE Inhibition in Heart Failure and Atherosclerosis, at the XIVth European-Society-of-Cardiology Congress CY SEP 02, 1992 CL BARCELONA, SPAIN SP EUROPEAN SOC CARDIOL DE LEFT VENTRICULAR HYPERTROPHY; ANGIOTENSIN-CONVERTING ENZYME; MYOCARDIAL INFARCTION ID MYOCARDIAL-INFARCTION; HEART-FAILURE; ENALAPRIL AB Over 13,000 patients have been randomized in 35 long-term trials of the use of angiotensin-converting enzyme (ACE) inhibitors in patients with heart failure or left ventricular dysfunction. Overall, there is a clear reduction in mortality and hospitalizations for heart failure and myocardial infarction with a trend toward fewer sudden deaths. Furthermore, there is a significant reduction in myocardial infarction in three of the larger trials. These benefits have been demonstrated with several different agents and are consistently seen in various subgroups of patients defined by symptomatic status, etiology of left ventricular dysfunction, age, and gender. However, benefits were greatest among patients with the lowest ejection fraction. In conclusion, ACE inhibitors are of established value in patients with heart failure and/or left ventricular dysfunction. C1 MCMASTER UNIV,DIV CARDIOL,HAMILTON,ON,CANADA. MCMASTER UNIV,PREVENT CARDIOL & THERAPEUT PROGRAM,HAMILTON,ON,CANADA. NHLBI,CLIN TRIALS BRANCH,BETHESDA,MD. NR 15 TC 7 Z9 7 U1 1 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0160-2446 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PY 1993 VL 22 SU 9 BP S28 EP S35 PG 8 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA NA258 UT WOS:A1993NA25800007 PM 7514238 ER PT J AU DLUGOSZ, AA YUSPA, SH AF DLUGOSZ, AA YUSPA, SH TI COORDINATE CHANGES IN GENE-EXPRESSION WHICH MARK THE SPINOUS TO GRANULAR-CELL TRANSITION IN EPIDERMIS ARE REGULATED BY PROTEIN-KINASE-C SO JOURNAL OF CELL BIOLOGY LA English DT Article ID TUMOR PROMOTER 12-O-TETRADECANOYLPHORBOL-13-ACETATE; CULTURED MURINE KERATINOCYTES; TRANSCRIPTION FACTOR AP-2; MOUSE KERATINOCYTES; PHORBOL ESTER; MESSENGER-RNA; RETINOIC ACID; GROWTH-FACTOR; ULTRASTRUCTURAL-LOCALIZATION; DIFFERENTIATION AB The protective function of skin depends on successful completion of a tightly regulated multi-step differentiation program, during which the induction of markers for a specific stage in epidermal differentiation is coupled to repression of markers expressed at the preceding stage. We have explored the role of protein kinase C (PKC) in this process using an in vitro model system, in which cultures of primary mouse epidermal keratinocytes are induced to terminally differentiate by raising the Ca2+ concentration in the medium from 0.05 to 0.12 mM. At doses which activate PKC, 12-O-tetradecanoylphorbol-13-acetate (TPA) and 1-oleoyl-2-acetylglycerol block Ca2+-mediated induction of the spinous cell markers keratins K1 and K10 at both the protein and mRNA level. TPA and 1-oleoyl-2-acetylglycerol also rapidly repress K1 and K10 mRNA expression when added to differentiating keratinocyte cultures already expressing these markers. The inhibition of K1 mRNA expression by TPA is blocked in cells where PKC has been inactivated with bryostatin. TPA-mediated loss of K1 mRNA is also blocked in cells exposed to cycloheximide or actinomycin D implicating a PKC-induced protein factor in this process. The loss of K1 mRNA in TPA-treated cultures is the result of both a selective destabilization of K1 transcripts and a rapid inhibition of K1 gene transcription. In contrast to the dramatic repression of mRNAs typical for spinous cell differentiation, activation of PKC concurrently enhances expression of mRNAs and proteins for the granular cell markers loricrin and filaggrin. This response does not occur in cells pre-treated with bryostatin to inactivate PKC. Our results suggest that PKC is a fundamental regulator of the coordinate changes in keratinocyte gene expression that occur during the spinous to granular cell transition in epidermis. RP DLUGOSZ, AA (reprint author), NCI,DIV CANC ETIOL,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892, USA. NR 73 TC 222 Z9 222 U1 0 U2 0 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 SN 0021-9525 J9 J CELL BIOL JI J. Cell Biol. PD JAN PY 1993 VL 120 IS 1 BP 217 EP 225 DI 10.1083/jcb.120.1.217 PG 9 WC Cell Biology SC Cell Biology GA KE650 UT WOS:A1993KE65000022 PM 7678013 ER PT J AU ROBINSON, SD ROBERTS, AB DANIEL, CW AF ROBINSON, SD ROBERTS, AB DANIEL, CW TI TGF-BETA SUPPRESSES CASEIN SYNTHESIS IN MOUSE MAMMARY EXPLANTS AND MAY PLAY A ROLE IN CONTROLLING MILK LEVELS DURING PREGNANCY SO JOURNAL OF CELL BIOLOGY LA English DT Article ID GROWTH-FACTOR-BETA; PROTEIN GENE-EXPRESSION; EPITHELIAL-CELLS; HORMONAL-REGULATION; GLAND; INHIBITION; DIFFERENTIATION; PROGESTERONE; PROLACTIN; SECRETION AB Mammary explants from 14-15-d-pregnant mice synthesize and secrete milk proteins in culture in response to insulin, hydrocortisone, and prolactin. Here we demonstrate that transforming growth factor beta (TGFbeta) treatment suppresses, in a dose dependent and reversible manner, the ability of explants to synthesize and secrete milk caseins. TGFbeta does not affect the level of casein mRNA within explants but inhibits casein synthesis posttranscriptionally. We also show increased expression of TGFbeta2 and TGFbeta3 in intact mammary gland as pregnancy progresses, with reduced expression of all three TGFbetas at the onset of lactation. These findings suggest that endogenously produced TGFbeta may limit the accumulation of milk caseins that are produced in the mammary gland during pregnancy. C1 NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892. RP ROBINSON, SD (reprint author), UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,DEPT BIOL,SANTA CRUZ,CA 95064, USA. FU NICHD NIH HHS [HD 27845] NR 32 TC 73 Z9 74 U1 0 U2 0 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 SN 0021-9525 J9 J CELL BIOL JI J. Cell Biol. PD JAN PY 1993 VL 120 IS 1 BP 245 EP 251 DI 10.1083/jcb.120.1.245 PG 7 WC Cell Biology SC Cell Biology GA KE650 UT WOS:A1993KE65000025 PM 8416990 ER PT J AU NIELSEN, S SMITH, BL CHRISTENSEN, EI KNEPPER, MA AGRE, P AF NIELSEN, S SMITH, BL CHRISTENSEN, EI KNEPPER, MA AGRE, P TI CHIP28 WATER CHANNELS ARE LOCALIZED IN CONSTITUTIVELY WATER-PERMEABLE SEGMENTS OF THE NEPHRON SO JOURNAL OF CELL BIOLOGY LA English DT Article ID INTEGRAL MEMBRANE-PROTEIN; CORTICAL COLLECTING TUBULE; THICK ASCENDING LIMB; HENLES LOOP; TRANSPORT; PURIFICATION; ERYTHROCYTES; DUCT; IMMUNOCYTOCHEMISTRY; VASOPRESSIN AB The sites of water transport along the nephron are well characterized, but the molecular basis of renal water transport remains poorly understood. CHIP28 is a 28-kD integral protein which was proposed to mediate transmembrane water movement in red cells and kidney (Preston. G. M., T. P. Carroll, W. B. Guggino, and P. Agre. 1992. Science [Wash. DC]. 256:385-387). To determine whether CHIP28 could account for renal epithelial water transport, we used specific polyclonal antibodies to quantitate and localize CHIP28 at cellular and subcellular levels in rat kidney using light and electron microscopy. CHIP28 comprised 3.8% of isolated proximal tubule brush border protein. Except for the first few cells of the S1 segment, CHIP28 was immunolocalized throughout the convoluted and straight proximal tubules where it was observed in the microvilli of the apical brush border and in basolateral membranes. Very little CHIP28 was detected in endocytic vesicles or other intracellular structures in proximal tubules. Uninterrupted, heavy immunostaining of CHIP28 was also observed over both apical and basolateral membranes of descending thin limbs, including both short and long loops of Henle. These nephron sites have constitutively high osmotic water permeabilities. CHIP28 was not detected in ascending thin limbs, thick ascending limbs, or distal tubules, which are highly impermeable to water. Moreover, CHIP28 was not detected in collecting duct epithelia, where water permeability is regulated by antidiuretic hormone. These determinations of abundance and structural organization provide evidence that the CHIP28 water channel is the predominant pathway for constitutive transepithelial water transport in the proximal tubule and descending limb of Henle's loop. C1 JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205. JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL ANAT,BALTIMORE,MD 21205. NHLBI,KIDNEY & ELECTROLYTE METAB,BETHESDA,MD 20892. RP NIELSEN, S (reprint author), AARHUS UNIV,INST ANAT,DEPT CELL BIOL,DK-8000 AARHUS,DENMARK. NR 36 TC 438 Z9 449 U1 0 U2 8 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 SN 0021-9525 J9 J CELL BIOL JI J. Cell Biol. PD JAN PY 1993 VL 120 IS 2 BP 371 EP 383 DI 10.1083/jcb.120.2.371 PG 13 WC Cell Biology SC Cell Biology GA KH215 UT WOS:A1993KH21500009 PM 7678419 ER PT J AU FOWLER, VM SUSSMANN, MA MILLER, PG FLUCHER, BE DANIELS, MP AF FOWLER, VM SUSSMANN, MA MILLER, PG FLUCHER, BE DANIELS, MP TI TROPOMODULIN IS ASSOCIATED WITH THE FREE (POINTED) ENDS OF THE THIN-FILAMENTS IN RAT SKELETAL-MUSCLE SO JOURNAL OF CELL BIOLOGY LA English DT Article ID HUMAN-ERYTHROCYTE MEMBRANE; ACTIN-FILAMENTS; TROPOMYOSIN-BINDING; F-ACTIN; Z-LINE; PROTEIN; CELL; DEPOLYMERIZATION; POLYMERIZATION; SPECTRIN AB The length and spatial organization of thin filaments in skeletal muscle sarcomeres are precisely maintained and are essential for efficient muscle contraction. While the major structural components of skeletal muscle sarcomeres have been well characterized, the mechanisms that regulate thin filament length and spatial organization are not well understood. Tropomodulin is a new, 40.6-kD tropomyosin-binding protein from the human erythrocyte membrane skeleton that binds to one end of erythrocyte tropomyosin and blocks head-to-tail association of tropomyosin molecules along actin filaments. Here we show that rat psoas skeletal muscle contains tropomodulin based on immunoreactivity, identical apparent mobility on SDS gels, and ability to bind muscle tropomyosin. Results from immunofluorescence labeling of isolated myofibrils at resting and stretched lengths using antierythrocyte tropomodulin antibodies indicate that tropomodulin is localized at or near the free (pointed) ends of the thin filaments; this localization is not dependent on the presence of myosin thick filaments. Immunoblotting of supernatants and pellets obtained after extraction of myosin from myofibrils also indicates that tropomodulin remains associated with the thin filaments. 1.2-1.6 copies of muscle tropomodulin are present per thin filament in myofibrils, supporting the possibility that one or two tropomodulin molecules may be associated with the two terminal tropomyosin molecules at the pointed end of each thin filament. Although a number of proteins are associated with the barbed ends of the thin filaments at the Z disc, tropomodulin is the first protein to be specifically located at or near the pointed ends of the thin filaments. We propose that tropomodulin may cap the tropomyosin polymers at the pointed end of the thin filament and play a role in regulating thin filament length. C1 NIH, BIOCHEM GENET LAB, BETHESDA, MD 20892 USA. NIH, NEUROBIOL LAB, BETHESDA, MD 20892 USA. RP FOWLER, VM (reprint author), SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA. NR 54 TC 115 Z9 117 U1 0 U2 1 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 SN 0021-9525 J9 J CELL BIOL JI J. Cell Biol. PD JAN PY 1993 VL 120 IS 2 BP 411 EP 420 DI 10.1083/jcb.120.2.411 PG 10 WC Cell Biology SC Cell Biology GA KH215 UT WOS:A1993KH21500012 PM 8421055 ER PT J AU KELLOFF, GJ BOONE, CW STEELE, VE CROWELL, JA LUBET, R DOODY, LA GREENWALD, P AF KELLOFF, GJ BOONE, CW STEELE, VE CROWELL, JA LUBET, R DOODY, LA GREENWALD, P TI DEVELOPMENT OF BREAST-CANCER CHEMOPREVENTIVE DRUGS SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article; Proceedings Paper CT Workshop on Chemoprevention of Breast Cancer CY OCT 06-10, 1993 CL LAKE TAHOE, CA SP NCI, CHEMOPREVENTION INVESTIGAT DRUG UNIT, DIV CANC PREVENT & CONTROL DE BETA-CAROTENE; BREAST CANCER; CHEMOPREVENTION; CLINICAL TRIALS; DUCTAL CARCINOMA IN-SITU; 4-HPR; INTERMEDIATE BIOMARKERS; LOBULAR CARCINOMA IN-SITU; SURROGATE END-POINTS; TAMOXIFEN; VITAMIN-E ID ESTROGEN REPLACEMENT THERAPY; DUCTAL CARCINOMA INSITU; INDUCED MAMMARY-TUMORS; DIETARY-FAT; FAMILIAL BREAST; RISK-FACTORS; FOLLOW-UP; INTRADUCTAL CARCINOMA; OVARIAN-CANCER; PHASE-I AB Breast cancer is the second highest cause of cancer mortality (19%) estimated for U.S. women in 1993 and accounts for the highest proportion of new cancer cases (32%) in this population. The rate of documented cases increased during the early 1970s and again in 1980-87, probably due to early mammographic detection. Increased knowledge of personal risk may also have been a consideration; however, 60% of women diagnosed with breast cancer have no known risk factor(s), such as family history, early age at menarche, late age at menopause, nulliparity, late age at first live birth, socioeconomic status, contraceptive use, postmenopausal estrogen replacement, or high fat intake. To prevent cancer, one strategy undertaken by the NCI is cancer chemoprevention, or intervention with chemical agents at the precancer stage to halt or slow the carcinogenic process. An objective of the NCI, DCPC is to develop promising cancer chemopreventive chemical agents as drugs for human use. Briefly, the process begins with identification of potential agents (e.g., pharmaceuticals, natural products, minor dietary constituents) from surveillance and analysis of the literature and from in vitro prescreen assays. Data on both efficacy (i.e., biological activities that either directly or indirectly indicate inhibition of carcinogenesis) and toxicity are gathered these sources. Various criteria are used to select and prioritize agents for entry into the NCI, DCPC preclinical testing program. The program begins with battery of in vitro efficacy screens using both animal and human cells to select agents for further testing; agents positive in these assays are considered for further testing. In the assay used for breast cancer chemoprevention, 7,12-dimethylbenz(a)anthracene (DMBA)-induced mouse mammary organ culture, 64 chemicals have inhibited formation of hyperplastic alveolar-like nodules. A panel of organ-specific animal screening assays are then used to assess efficacy in vivo. Two assays relevant for breast cancer chemoprevention are inhibition of N-methyl-N-nitrosourea- and DMBA-induced rat mammary gland carcinogenesis. Of 89 agents tested, 29 have inhibited cancer incidence, multiplicity, or both in at least one of the mammary assays; 21 agents are currently on test. Highly promising agents are then placed in traditional preclinical toxicity tests performed in two species. Finally, the most promising and least toxic agents enter clinical trials. Phase I clinical trials are designed to investigate human dose-related safety and pharmacokinetics of the drug. Phase II trials are small scale, placebo-controlled studies designed to determine chemopreventive efficacy and optimal dosing regimens. Three Phase II trials are in progress or in the planning stage investigating tamoxifen citrate or N-(4-hydroxyphenyl)retinamide (4-HPR) as single agents; also, both Phase I and Phase II trials evaluating the combination of 4-HPR and tamoxifen are in the planning stage. Phase III trials involve a large target population, with cancer incidence reduction as the endpoint. Tamoxifen citrate is being tested as a breast cancer chemopreventive in high-risk women in a Phase III trial funded by NCI and under the direction of the National Surgical Adjuvant Breast and Bowel Project. Prevention by 4-HPR of a second primary in the contralateral breast of women surgically treated for Stage I/II breast cancer is being evaluated in a Phase III trial in Italy. Finally, the efficacy of beta-carotene or vitamin E in decreasing the incidence of breast, lung, and colon cancer is being determined in a Phase III trial involving nurses 45 years of age or older. Essential to the completion of Phase II clinical trials is the use of populations with defined, measurable biological alterations in tissue occurring prior to malignancy (i.e., intermediate biomarkers) which can serve as surrogate trial endpoints, instead of the more time-consuming and costly endpoint of cancer incidence. Intermediate biomarkers may be of several types, including histological/premalignant lesions, or those based on genetic, biochemical, proliferative, or differentiation-related properties. The only well-established premalignant lesions in the human breast are ductal and lobular carcinoma in situ (CIS). In 1993, an estimated 25,000 new cases of CIS will be diagnosed. These lesions are at high risk of progression to invasive cancer and may be amenable to modulation by a chemopreventive agent. In addition, other types of biomarkers could be identified within the lesions. The goal of this workshop is to identify and discuss the best chemopreventive agents and intermediate biomarkers for use as surrogate endpoints in short-term Phase II breast cancer chemoprevention trials, as well as to design protocols for such trials. (C) 1993 Wiley-Liss, Inc. C1 CCS ASSOCIATES,MENLO PK,CA 94025. RP KELLOFF, GJ (reprint author), NCI,DIV CANC PREVENT & CONTROL,CHEMOPREVENT INVEST STUDIES BRANCH,BETHESDA,MD 20892, USA. NR 78 TC 1 Z9 1 U1 1 U2 3 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17G BP 2 EP 13 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA NE169 UT WOS:A1993NE16900002 ER PT J AU KELLOFF, GJ BOONE, CW STEELE, VK PERLOFF, M CROWELL, J DOODY, LA AF KELLOFF, GJ BOONE, CW STEELE, VK PERLOFF, M CROWELL, J DOODY, LA TI DEVELOPMENT OF CHEMOPREVENTIVE AGENTS FOR LUNG AND UPPER AERODIGESTIVE TRACT CANCERS SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE CHEMOPREVENTION; NEOPLASMS; HEAD AND NECK; LUNG; ESOPHAGUS; ORAL CAVITY; TRACHEA; INTERMEDIATE BIOMARKERS; SURROGATE END-POINTS; CLINICAL TRIALS; HAMSTER; STRAIN-A MICE; RAT; PHARYNX; LARYNX; AERODIGESTIVE TRACT; RETINOIDS ID 2ND PRIMARY TUMORS; SERUM-VITAMIN-A; INTRAEPITHELIAL NEOPLASIA; BETA-CAROTENE; NECK-CANCER; RISK; ETIOLOGY; HEAD; ASSOCIATION; PREVENTION AB The lung and upper aerodigestive tract (oral cavity, larynx, pharynx, upper esophagus) will harbor the greatest proportion (almost-equal-to 20%) of estimated new cancer cases in 1992. The estimated mortality rate is even higher (32%), which is reflected in a 5-year survival rate of only 7% and 12% for esophageal and lung cancer, respectively. Tobacco use appears to remain the major cause of aerodigestive cancers despite efforts at primary prevention-cessation of exposure. Another strategy to decrease this public health problem is secondary prevention or chemoprevention. Cancer chemoprevention is defined as intervention with chemical agents before invasion to halt or slow the carcinogenic process; potential agents may include minor dietary constituents and pharmaceuticals. The main objective of the Division of Cancer Prevention and Control (DCPC), National Cancer Institute, is to develop promising chemopreventive drugs for use in humans. The testing of cancer chemopreventives for efficacy in the clinic differs from that of cancer treatment drugs. Chemopreventive drug trials involve healthy target populations, and the endpoints are reduced cancer incidence or mortality, or increased latency, with no to minimal toxicity. The lung and upper aerodigestive tract represent a unique opportunity for intervention in this setting. Even with cessation of tobacco exposure, the risk of cancer in the entire epithelium remains high for years due to the ''field cancerization'' effect. Some of the first chemopreventive trials made use of this system due to the availability of a study population with a tissue at demonstrably high risk for malignant progression. Much of the evidence for chemopreventive efficacy is in the oral cavity because of the well-defined epithelial neoplastic progression, the existence of well-established preclinical models, and relative ease of tissue monitoring and sampling. In one of the first randomized trials, Hong and co-workers demonstrated that 13-cis-retinoic acid prevents the appearance of second primary tumors in patients previously treated for squamous cell carcinomas of the oral cavity and upper respiratory tract. Even using a high risk population, chemoprevention trials involve large sample sizes, lengthy duration and follow-up, and high cost. To circumvent these problems, the use of intermediate biomarkers as surrogate endpoints is being explored. Intermediate biomarkers are defined as biological alterations in tissue (histological, genetic, biochemical, proliferative, differentiation-related) occurring prior to cancer development. In the oral cavity, studies using modulation of a histological intermediate biomarker, dysplastic leukoplakia, as the endpoint have demonstrated response to a retinoid. Several problems still need to be addressed in the chemoprevention of aerodigestive cancer, such as the toxicity of some of the agents which have been used (retinoids) and maintenance of remission after cessation of treatment. In addition, clinical chemoprevention trials in the other sites of the aerodigestive system, such as lung and upper esophagus, are not as well advanced. This is due to sampling and monitoring problems and less well-defined premalignant lesions. The DCPC is developing new strategies for chemopreventive trials in the aerodigestive tract. (C) 1993 Wiley-Liss, Inc.* C1 NCI,DIV CANC PREVENT & CONTROL,CHEMOPREVENT PROGRAM,BETHESDA,MD 20892. CCS ASSOCIATES,PALO ALTO,CA 94025. RP KELLOFF, GJ (reprint author), NCI,DIV CANC PREVENT & CONTROL,CHEMOPREVENT INVEST DRUG UNIT,BETHESDA,MD 20892, USA. NR 63 TC 1 Z9 1 U1 1 U2 3 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17F BP 2 EP 17 PG 16 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA LT580 UT WOS:A1993LT58000002 ER PT J AU BOONE, CW KELLOFF, GJ FREEDMAN, LS AF BOONE, CW KELLOFF, GJ FREEDMAN, LS TI INTRAEPITHELIAL AND POSTINVASIVE NEOPLASIA AS A STOCHASTIC CONTINUUM OF CLONAL EVOLUTION, AND ITS RELATIONSHIP TO MECHANISMS OF CHEMOPREVENTIVE DRUG-ACTION SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article; Proceedings Paper CT Workshop on Chemoprevention of Breast Cancer CY OCT 06-10, 1993 CL LAKE TAHOE, CA SP NCI, CHEMOPREVENTION INVESTIGAT DRUG UNIT, DIV CANC PREVENT & CONTROL DE CLONAL EVOLUTION; INTRAEPITHELIAL NEOPLASIA; MITOGENESIS; MUTAGENESIS; NEOPLASTIC PROGRESSION ID MOUSE SKIN PAPILLOMAS; TUMOR-DEVELOPMENT; NITRIC-OXIDE; CANCER; PROGRESSION; ANEUPLOIDY; PROMOTION; CARCINOMA; CARCINOGENESIS; INITIATION AB The progression of intraepithelial and postinvasive neoplasia depends on the occurrence of clonal evolution, defined as the continuous development of mutations and selective clonal expansions in the neoplastic cell population. The two continuously repeating events of clonal evolution, mutation and clonal expansion, occur at unpredictable times and locations. Therefore the neoplastic process is best characterized as a stochastic, i.e., probabilistic, continuum. The rate of intraepithelial neoplastic progression is continuously driven by the dosage level of exposure to mutagens and mitogens. For example, in chronic smokers the length of time before development of lung cancer depends on the number of cigarettes smoked per day. A commonly held misconception is that human carcinogenesis develops after an initial short period of mutation followed by a long period of stimulated proliferation (the multistage model). This incorrect idea derives from the sequential nature of the consecutive two- or three-step operational protocols imposed on experimental animal models by the experimenter. In reality, human carcinogenesis develops as the result of simultaneous and continuous exposure to mutagens and mitogens over the entire period of tumor development. A recent example is the finding that the intraepithelial neoplasia of colorectal adenomas continuously progresses through serial waves of mutation and clonal expansion. The rational design of chemopreventive agents should be based on blocking the two parameters which continuously drive neoplasia: mutagenesis and mitogenesis. In addition to blocking exposure, chemopreventive agents may act at many points during activation and DNA adduction of mutagens, or during stimulation of the proliferation signal pathway by mitogens. Based on the chemopreventive strategy of blocking mutagenesis and mitogenesis, chemopreventive agents are classed as either antimutagenic or antimitogenic. A third class, the antioxidants, are both antimutagenic and antimitogenic, and operate by the common mechanism of breaking free radical chain reactions initiated by reactive oxygen species. In the program of the Chemoprevention Investigational Studies Branch, Division of Cancer Prevention and Control, National Cancer Institute, preclinical development of antimutagens, antimitogens, and antioxidants is well under way, and some of these agents are highlighted here. (C) 1993 Wiley-Liss, Inc. C1 NCI,DIV CANC PREVENT & CONTROL,BIOMETRY BRANCH,BETHESDA,MD 20892. RP BOONE, CW (reprint author), NCI,DIV CANC PREVENT & CONTROL,CHEMOPREVENT INVEST STUDIES BRANCH,BETHESDA,MD 20892, USA. NR 44 TC 1 Z9 1 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17G BP 14 EP 25 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA NE169 UT WOS:A1993NE16900003 ER PT J AU BOONE, CW AF BOONE, CW TI PREMALIGNANT LESIONS IN THE UPPER AERODIGESTIVE TRACT SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Editorial Material RP BOONE, CW (reprint author), NCI,DIV CANC PREVENT & CONTROL,CHEMOPREVENT INVEST DRUG UNIT,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17F BP 36 EP 36 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA LT580 UT WOS:A1993LT58000005 ER PT J AU BOONE, CW KELLOFF, GJ AF BOONE, CW KELLOFF, GJ TI INTRAEPITHELIAL NEOPLASIA, SURROGATE END-POINT BIOMARKERS, AND CANCER CHEMOPREVENTION SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE INTRAEPITHELIAL NEOPLASIA; SURROGATE END-POINT BIOMARKERS; CHEMOPREVENTION; DYSPLASIA; HISTOPATHOLOGY ID PROGNOSTIC VALUE; INSITU; CARCINOMA; LESIONS; SYSTEM AB Neoplasia is a progression of molecular, cellular, and tissue changes starting with a critical cell mutation and advancing by clonal evolution, involving further multiple mutations and expanding mutated clones. This process is characterized by five general stages: latency, focal growth of normal-appearing but disorganized cells, abnormal-appearing cells (dysplasia), microinvasion, and finally, metastasis. The two driving forces of neoplastic progression in an epithelium are mutagenesis and mitogenesis. These forces frequently occur concurrently, produced by exposure of the epithelium to environmental and endogenous mutagens and mitogens. The major strategy of chemoprevention is to block the effects of both mutagens and mitogens during the early stages of predysplasia and dysplasia. Surrogate endpoint biomarkers (SEBs) are tissue, cellular, and molecular changes that correlate with the later development of cancer. Because of the savings in cost, labor, and time, SEBs are urgently needed to replace the use of cancer incidence reduction as the endpoint for chemopreventive agent clinical trials. The advent of computer-assisted cytometry allows each of the seven basic criteria of dysplasia to be individually assayed as an SEB. Since the dysplastic changes that characterize intraepithelial neoplasia are embodied in the causal pathway to invasive neoplasia, they are already validated as predictors of cancer incidence. More attention should be paid to the quality control of SEB assays, including control of variation in cell composition of tissue samples, assay protocol, instrumentation used, and observer performance. The dose-response relationship between a known chemopreventive agent and the SEB should also be evaluated. The Division of Cancer Prevention and Control, National Cancer Institute, has begun a program to test chemopreventive agents in short-term Phase II clinical trials using dysplasia-based SEBs. The SEBs are assayed, when possible, by computerized cytometry. Trials are being conducted for oral leukoplakia, cutaneous actinic keratosis, superficial bladder cancer, pulmonary metaplasia/dysplasia, cervical dysplasia (CIN III), and adenomatous colonic polyps. (C) 1993 Wiley-Liss, Inc.* RP BOONE, CW (reprint author), NCI,DIV CANC PREVENT & CONTROL,CHEMOPREVENT INVEST DRUG UNIT,BETHESDA,MD 20892, USA. NR 33 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17F BP 37 EP 48 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA LT580 UT WOS:A1993LT58000006 ER PT J AU BOONE, CW AF BOONE, CW TI PREMALIGNANT LESIONS OF THE BREAST - OVERVIEW SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Editorial Material RP BOONE, CW (reprint author), NCI,DIV CANC PREVENT & CONTROL,CHEMOPREVENT INVEST STUDIES BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17G BP 44 EP 44 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA NE169 UT WOS:A1993NE16900006 ER PT J AU CALLAHAN, R CROPP, C SHENG, ZM MERLO, G STEEG, P LISCIA, D LIDEREAU, R AF CALLAHAN, R CROPP, C SHENG, ZM MERLO, G STEEG, P LISCIA, D LIDEREAU, R TI DEFINITION OF REGIONS OF THE HUMAN GENOME AFFECTED BY LOSS OF HETEROZYGOSITY IN PRIMARY HUMAN BREAST-TUMORS SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article; Proceedings Paper CT Workshop on Chemoprevention of Breast Cancer CY OCT 06-10, 1993 CL LAKE TAHOE, CA SP NCI, CHEMOPREVENTION INVESTIGAT DRUG UNIT, DIV CANC PREVENT & CONTROL DE BREAST CANCER; LOSS OF HETEROZYGOSITY; NME1; TP53 ID LINKAGE MAP; CANCER; P53; CARCINOMA; INDEX; GENE; CHROMOSOME-17; MUTATIONS; PROTEIN; CELLS AB We have undertaken a systematic study of primary human breast tumor DNA to identify and characterize frequently occurring somatic mutations. Loss of heterozygosity (LOH) has been the most frequent mutation in our panels of primary breast tumor DNA. It is currently thought that LOH reveals recessive mutations within the affected region of the genome. One goal of our studies has been to physically define the target genes revealed by LOH in primary breast tumors. We have focused our efforts on chromosome 17, finding five regions of the chromosome which are independently affected by LOH in breast tumors. Two apparent target loci are on chromosome 17p; one is the TP53 gene. The other is an as-yet undefined locus telomeric to the TP53 gene. Loss of expression of the nme1 gene on chromosome 17q in tumors was linked to patients with a poor prognosis (p = 0.018). Although a significant trend (p = 0.05) was found between LOH of the nme1 gene and loss of nme1 expression, no point mutations were found within the coding region of the nme1 gene by single strand conformational polymorphism (SSCP) or nucleotide sequence analysis. These and other results suggest to us that there may be potential tumor suppressor genes both centromeric and telomeric to the nme1 locus on chromosome 17q. (C) 1993 Wiley-Liss, Inc. C1 NCI,PATHOL LAB,BETHESDA,MD 20892. S GIOVANNI HOSP,TURIN,ITALY. CTR RENE HUGUENIN,INSERM,ST CLOUD,FRANCE. RP CALLAHAN, R (reprint author), NCI,TUMOR IMMUNOL & BIOL LAB,BLDG 10,ROOM 5B53,900 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 28 TC 2 Z9 2 U1 0 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17G BP 167 EP 172 PG 6 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA NE169 UT WOS:A1993NE16900030 ER PT J AU SCOTT, F CUTTITTA, F TRESTON, AM AVIS, I GUPTA, P RUCKDESCHEL, J KELLY, K PIANTADOSI, S TOCKMAN, M MULSHINE, J AF SCOTT, F CUTTITTA, F TRESTON, AM AVIS, I GUPTA, P RUCKDESCHEL, J KELLY, K PIANTADOSI, S TOCKMAN, M MULSHINE, J TI PROSPECTIVE TRIAL EVALUATING IMMUNOCYTOCHEMICAL-BASED SPUTUM TECHNIQUES FOR EARLY LUNG-CANCER DETECTION - ASSAYS FOR PROMOTION FACTORS IN THE BRONCHIAL LAVAGE SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE LUNG CANCER; EARLY DETECTION; IMMUNOCYTOCHEMISTRY; BRONCHIAL LAVAGE ID ALPHA-AMIDATING MONOOXYGENASE; AUTOCRINE GROWTH; ALVEOLAR MACROPHAGES; MONOCLONAL-ANTIBODY; CELL-LINES; PEPTIDE; BOMBESIN; ENZYME; PRECURSOR; ACID AB To confirm the results of a previous report on the use of monoclonal antibodies in immunocytochemical assays of sputums for the early detection of lung cancer, we designed a new prospective trial in an independent clinical trial population. Since well-characterized Stage I resected non-small cell lung cancer patients have a low rate of tumor relapse and a high (1-3%/year) chance of developing a second primary lung cancer, they comprise a very favorable group for conducting an early lung cancer detection trial. The rate of new lung cancer is about 10-fold in excess of a standard ''high'' risk population of smokers. To optimize the chance for a favorable outcome, all of the technical components for the trial have been systematically evaluated to ensure that optimal procedure!s are employed. For example, automated immunostaining of the sputum specimens will be performed. Bronchial lavages will be analyzed in a subset of the trial participants to define additional targets for early lung cancer detection. Two markers will be quantitated, including gastrin releasing peptide and peptidyl glycine alpha-amidating monooxygenase activity. These two markers assess the epithelium's capacity to produce growth factors which may be central to the biology of tumor promotion. Since these assays have not been performed in this context before, we attempted to optimize the specimen handling to permit the receipt of the material from a range of collaborating clinical sites in a condition that permits accurate quantitation of these two biomarkers. Efforts to standardize the assay endpoint stimulated the development of computer-assisted methods of immunocytochemical analysis. An algorithm for image analysis was developed as a result of systematic analysis of a range of potentially quantifiable assay endpoints with a panel of teaching cases. When a sampling of the original immunostained material from the first monoclonal antibody-based early lung cancer detection report was reanalyzed using the image analysis algorithm, a 90% concurrence with the original immunostaining interpretation was observed. These results suggest that there was an objective basis to the first report and that image analysis can greatly refine the process of early lung cancer detection research. An update of the current trial status will be summarized emphasizing the unique challenges presented in early cancer detection research. (C) 1993 Wiley-Liss, Inc.* C1 NCI,DCPC,BIOMARKERS & PREVENT RES BRANCH,9610 MED CTR DR ROOM 300,ROCKVILLE,MD 20850. UNIV S FLORIDA,H LEE MOFFITT CANC CTR,TAMPA,FL 33620. UNIV COLORADO,DENVER,CO 80202. JOHNS HOPKINS SCH MED,BALTIMORE,MD. NR 37 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17F BP 175 EP 183 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA LT580 UT WOS:A1993LT58000024 ER PT J AU KELLOFF, GJ AF KELLOFF, GJ TI BREAST-CANCER CHEMOPREVENTION CLINICAL-TRIALS - OVERVIEW SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Editorial Material RP KELLOFF, GJ (reprint author), NCI,DIV CANC PREVENT & CONTROL,CHEMOPREVENT INVEST STUDIES BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17G BP 219 EP 219 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA NE169 UT WOS:A1993NE16900039 ER PT J AU RUFFIN, MT AUGUST, DA KELLOFF, GJ BOONE, CW WEBER, BL BRENNER, DE AF RUFFIN, MT AUGUST, DA KELLOFF, GJ BOONE, CW WEBER, BL BRENNER, DE TI SELECTION CRITERIA FOR BREAST-CANCER CHEMOPREVENTION SUBJECTS SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article; Proceedings Paper CT Workshop on Chemoprevention of Breast Cancer CY OCT 06-10, 1993 CL LAKE TAHOE, CA SP NCI, CHEMOPREVENTION INVESTIGAT DRUG UNIT, DIV CANC PREVENT & CONTROL DE BREAST CANCER RISK; CHEMOPREVENTION; INTERMEDIATE BIOMARKERS ID LOBULAR CARCINOMA INSITU; FAMILIAL BREAST; OVARIAN-CANCER; RISK-FACTORS; DISEASE; LINKAGE; WOMEN; GENE AB Early phase chemoprevention trials differ from standard therapeutic clinical trials because asymptomatic, healthy people are treated with a potentially toxic intervention for a prolonged period of time. Current subject selection protocols have relied upon epidemiological methods to identify high-risk individuals. Most available data provide risk estimates for various individual risk factors, but few have reported risk estimates for combinations of risk factors. Selection criteria for the large tamoxifen intervention trial (NSABP P1) were developed from the work of Gail et al. [1]. The Gail model takes into account non-genetic factors (e.g., nulliparity, age at menarche, preexisting pathological conditions) and genetic factors (family history). Using a lifetime risk of 10% of developing breast cancer as a standard to intervene, NSABP P1 uses the Gail algorithm to select pre- and postmenopausal women for a primary intervention trial. This approach has been criticized for being insufficiently selective (i.e., all women greater-than-or-equal-to 60 yrs), but appears to be the best available method to select subjects for a chemoprevention trial. Other approaches have been based on identification of very high-risk women with acknowledged pathologic conditions [lobular carcinoma in situ, ductal carcinoma in situ (DCIS)]. Attempting to use these proliferative lesions as pathologic endpoints for drug effect has not been attempted. DCIS as a risk factor for tamoxifen intervention was excluded because of controversies over its management and because of frequent difficulties in distinguishing microinvasive from non-invasive lesions. Women treated for early stage breast cancer (Stage I) may be subjects for early stage chemopreventive interventions. We propose the use of intermediate endpoint biomarkers and genetic markers as entry criteria for early phase chemoprevention trials. For colorectal cancer chemoprevention, we have used a two-step selection process. The first step was based on epidemiologic risk assessment. Entry into the study required that a potential intermediate biomarker be positive and quantifiable. The relationship between modulation of a pre-transformational biomarker and development of cancer ultimately needs proof in a primary interventional trial; however, this methodology may permit screening of potential chemopreventive agents at lower cost and more rapid tum-around times. In early chemopreventive agent testing for breast cancer chemoprevention, we propose a similar two-step procedure. Epidemiological and/or pathological criteria for risk would be followed by a procedure to obtain cellular material. The cellular material would be assayed for pre-transformational cellular change. Identifying predictive genes in familial breast cancer cohorts such as the modified BRCA1 gene promises to select individuals at high familial and potentially physiological or environmental risk. The identification of the abnormal gene product in individuals and families will provide another important group of subjects for chemopreventive interventions. The identification of high-risk subjects for breast cancer chemoprevention, particularly those with familial genetic risk, carries important ethical problems. Such women may have difficulties obtaining health and life insurance, deciding to have children, and obtaining work. Chemoprevention trials with genetic selection criteria will need to develop methods of dealing with these issues. (C) 1993 Wiley-Liss, Inc. C1 UNIV MICHIGAN,SCH MED,DEPT FAMILY PRACTICE,ANN ARBOR,MI 48109. UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109. UNIV MICHIGAN,MED CTR,SCH MED,DEPT SURG,ANN ARBOR,MI 48109. NCI,DIV CANC PREVENT & CONTROL,CHEMOPREVENT INVEST STUDIES BRANCH,BETHESDA,MD 20892. UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109. UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109. VET ADM MED CTR,MED SERV,ANN ARBOR,MI 48105. OI Ruffin, Mack/0000-0001-8336-478X NR 39 TC 1 Z9 1 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17G BP 234 EP 241 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA NE169 UT WOS:A1993NE16900042 ER PT J AU MCCORMICK, DL JOHNSON, WD RAO, KVN BOWMANGRAM, T MOON, RC STEELE, VE KELLOFF, GJ AF MCCORMICK, DL JOHNSON, WD RAO, KVN BOWMANGRAM, T MOON, RC STEELE, VE KELLOFF, GJ TI CHEMOPREVENTION OF RAT MAMMARY CARCINOGENESIS - EXCEPTIONAL ACTIVITY OF DIETARY DEHYDROEPIANDROSTERONE (DHEA) SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 IIT,RES INST,DEPT LIFE SCI,CHICAGO,IL 60616. NCI,BETHESDA,MD 20852. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17G BP 253 EP 253 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA NE169 UT WOS:A1993NE16900053 ER PT J AU SCHANTZ, SP HONG, WK BOONE, CW KELLOFF, GJ AF SCHANTZ, SP HONG, WK BOONE, CW KELLOFF, GJ TI STRATEGY FOR DESIGN OF CLINICAL-TRIALS OF CHEMOPREVENTIVE AGENTS SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article C1 UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77030. NCI,DIV CANC PREVENT & CONTROL,CHEMOPREVENT INVESTIGAT DRUG UNIT,BETHESDA,MD 20892. RP SCHANTZ, SP (reprint author), MEM SLOAN KETTERING CANC CTR,HEAD & NECK SERV,NEW YORK,NY 10021, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 1993 SU 17F BP 299 EP 300 PG 2 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA LT580 UT WOS:A1993LT58000042 ER PT J AU JAKLITSCH, MT BIRO, S CASSCELLS, W DICHEK, DA AF JAKLITSCH, MT BIRO, S CASSCELLS, W DICHEK, DA TI TRANSDUCED ENDOTHELIAL-CELLS EXPRESSING HIGH-LEVELS OF TISSUE PLASMINOGEN-ACTIVATOR HAVE AN UNALTERED PHENOTYPE INVITRO SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID HUMAN AMNIOTIC MEMBRANE; HUMAN-MELANOMA CELLS; HUMAN-TUMOR CELLS; GROWTH-FACTOR; FIBRINOLYTIC-ACTIVITY; UROKINASE-TYPE; GENE-TRANSFER; ANGIOGENESIS; MIGRATION; REQUIREMENT AB Elevated cellular plasminogen activator activity has been associated with significant alterations in the in vitro phenotype of both malignant cell lines and nonmalignant endothelial cells. To examine the role of elevated cellular plasminogen activator activity in the production of altered endothelial cell behavior, bovine coronary artery endothelial cells were transduced with a retroviral vector expressing large amounts of tissue plasminogen activator. Cells transduced with the tissue plasminogen activator vector were compared with both untransduced cells and cells transduced with a control vector in a series of in vitro assays of cellular attachment, proliferation, migration, and invasion. The morphology of the 2 transduced populations was unchanged. There was a small decrease (5-15%) in the horizontal migration rate of both transduced cell populations, as compared with that of untransduced cells. No significant differences were detected among the three cell populations in any of the other assays. We conclude that expression of high levels of tissue plasminogen activator does not specifically affect endothelial cell phenotype in vitro. These data lend support to the hypothesis that elevated plasminogen activator activity is necessary but not sufficient to produce alterations in endothelial cell behavior. C1 NHLBI,MOLEC HEMATOL BRANCH,BETHESDA,MD 20892. NHLBI,CARDIOL BRANCH,BETHESDA,MD 20892. NR 50 TC 12 Z9 12 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD JAN PY 1993 VL 154 IS 1 BP 207 EP 216 DI 10.1002/jcp.1041540124 PG 10 WC Cell Biology; Physiology SC Cell Biology; Physiology GA KF079 UT WOS:A1993KF07900023 PM 8419405 ER PT J AU CARSON, RE CHANNING, MA BLASBERG, RG DUNN, BB COHEN, RM RICE, KC HERSCOVITCH, P AF CARSON, RE CHANNING, MA BLASBERG, RG DUNN, BB COHEN, RM RICE, KC HERSCOVITCH, P TI COMPARISON OF BOLUS AND INFUSION METHODS FOR RECEPTOR QUANTITATION - APPLICATION TO [F-18] CYCLOFOXY AND POSITRON EMISSION TOMOGRAPHY SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE CYCLOFOXY; EQUILIBRIUM; INFUSION; MODELING; OPIATE RECEPTOR; POSITRON EMISSION TOMOGRAPHY ID LIVING HUMAN-BRAIN; MUSCARINIC CHOLINERGIC RECEPTOR; OPIATE ANTAGONIST CYCLOFOXY; CEREBRAL BLOOD-FLOW; KINETIC-ANALYSIS; RAT-BRAIN; INACTIVE ENANTIOMERS; COMPUTED-TOMOGRAPHY; INVIVO MEASUREMENT; NORMAL VALUES AB Positron emission tomography studies with the opiate antagonist [F-18]cyclofoxy ([F-18]CF) were performed in baboons. Bolus injection studies demonstrated initial uptake dependent on blood flow. The late uptake showed highest binding in caudate nuclei, amygdala, thalamus, and brainstem and the least accumulation in cerebellum. By 60 min postinjection, regional brain radioactivity cleared at the same rate as metabolite-corrected plasma, i.e., transient equilibrium was achieved. Compartmental modeling methods were applied to time-activity curves from brain and metabolite-corrected plasma. Individual rate constants were estimated with poor precision. The model estimate of the total volume of distribution (V(T)), representing the ratio of tissue radioactivity to metabolite-corrected plasma at equilibrium, was reliably determined. The apparent volume of distribution (V(a)), the concentration ratio of tissue to metabolite-corrected asma during transient equilibrium, was compared with the fitted V(T) values to determine if single-scan methods could provide accurate receptor measurements. V(a) significantly overestimated V(T) and produced artificially high image contrast. These differences were predicted by compartment model theory and were caused by a plasma clearance rate that was close to the slowest tissue clearance rate. To develop a simple method to measure V(T), an infusion protocol consisting of bolus plus continuous infusion (B/I) of CF was designed and applied in a separate set of studies. The V(a) values from the B/I studies agreed with the V(T) values from both B/I and bolus studies. This infusion approach can produce accurate receptor measurements and has the potential to shorten scan time and simplify the acquisition and processing of scan and blood data. C1 NIDDKD,MED CHEM LAB,BETHESDA,MD. NIMH,CEREBRAL METAB LAB,CLIN BRAIN IMAGING SECT,BETHESDA,MD 20892. RP CARSON, RE (reprint author), NIDDKD,CTR CLIN,DEPT PET,BLDG 10,RM 1C-401,BETHESDA,MD 20892, USA. RI Carson, Richard/H-3250-2011 OI Carson, Richard/0000-0002-9338-7966 NR 53 TC 250 Z9 252 U1 0 U2 2 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD JAN PY 1993 VL 13 IS 1 BP 24 EP 42 PG 19 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA KE730 UT WOS:A1993KE73000004 PM 8380178 ER PT J AU HENDRICKSON, MA NICKLAUS, MC MILNE, GWA ZAHAREVITZ, D AF HENDRICKSON, MA NICKLAUS, MC MILNE, GWA ZAHAREVITZ, D TI CONCORD AND CAMBRIDGE - COMPARISON OF COMPUTER-GENERATED CHEMICAL STRUCTURES WITH X-RAY CRYSTALLOGRAPHIC DATA SO JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES LA English DT Article ID 3-DIMENSIONAL MOLECULAR-STRUCTURES; INFORMATION; RETRIEVAL; SYSTEM; SEARCH; FILES AB The structures of a number of molecules as determined by X-ray crystallography have been compared with the structures for the same molecules as calculated by the 3D structure generation program, CONCORD. In 41% of the cases, the calculated structures were essentially identical to those measured by X-ray diffraction. In most of the remainder, there were significant differences arising primarily from the inability of the structure generation program to predict the correct torsion angle at one or more rotatable bonds. The implications of these findings on the process of 3D database generation are discussed. C1 NCI,DCT,DTP,MED CHEM LAB,BETHESDA,MD 20892. PRI DYNCORP INC,NCI,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702. RI Nicklaus, Marc/N-4183-2014 NR 23 TC 18 Z9 18 U1 0 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 SN 0095-2338 J9 J CHEM INF COMP SCI JI J. Chem. Inf. Comput. Sci. PD JAN-FEB PY 1993 VL 33 IS 1 BP 155 EP 163 DI 10.1021/ci00011a024 PG 9 WC Chemistry, Multidisciplinary; Computer Science, Information Systems; Computer Science, Interdisciplinary Applications SC Chemistry; Computer Science GA KJ615 UT WOS:A1993KJ61500025 ER PT J AU MOHR, E BROUWERS, P CHASE, TN AF MOHR, E BROUWERS, P CHASE, TN TI DIFFERENTIAL CLASSIFICATION OF DEMENTIA SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Meeting Abstract C1 INST MENTAL HLTH RES,OTTAWA K1Z 7K4,ON,CANADA. NCI,PEDIAT BRANCH,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JAN PY 1993 VL 15 IS 1 BP 29 EP 29 PG 1 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA KL806 UT WOS:A1993KL80600056 ER PT J AU FLEMING, K GOLDBERG, TE GOLD, JM WEINBERGER, DR AF FLEMING, K GOLDBERG, TE GOLD, JM WEINBERGER, DR TI BROWN-PETERSON PERFORMANCE IN SCHIZOPHRENIA SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Meeting Abstract C1 NIMH,NEUROSCI CTR ST ELIZABETHS,CLIN BRAIN DISORDERS BRANCH,WASHINGTON,DC 20032. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JAN PY 1993 VL 15 IS 1 BP 54 EP 54 PG 1 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA KL806 UT WOS:A1993KL80600185 ER PT J AU RANDOLPH, C BRAUN, A GOLDBERG, TE CHASE, TN AF RANDOLPH, C BRAUN, A GOLDBERG, TE CHASE, TN TI SEMANTIC FLUENCY IN DEMENTING DISORDERS - DISSOCIATION OF STORAGE AND RETRIEVAL FAILURES SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Meeting Abstract C1 NINCDS,ETB,BETHESDA,MD 20892. NIMH NEUROSCI CTR ST ELIZABETHS,WASHINGTON,DC 20032. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JAN PY 1993 VL 15 IS 1 BP 74 EP 74 PG 1 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA KL806 UT WOS:A1993KL80600281 ER PT J AU GOLDBERG, TE TORREY, EF BERMAN, KF SUDDATH, RL WEINBERGER, DR AF GOLDBERG, TE TORREY, EF BERMAN, KF SUDDATH, RL WEINBERGER, DR TI ANALYSES OF BRAIN MORPHOLOGY, BRAIN PHYSIOLOGY, AND COGNITION IN MONOZYGOTIC TWINS DISCORDANT FOR SCHIZOPHRENIA SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Meeting Abstract C1 NIMH,NEUROSCI CTR ST ELIZABETHS,WASHINGTON,DC 20032. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JAN PY 1993 VL 15 IS 1 BP 77 EP 77 PG 1 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA KL806 UT WOS:A1993KL80600298 ER PT J AU RANDOLPH, C GOLDBERG, TE HYDE, TM GOLD, JM WEINBERGER, DR AF RANDOLPH, C GOLDBERG, TE HYDE, TM GOLD, JM WEINBERGER, DR TI NEUROPSYCHOLOGICAL FUNCTIONING IN MONOZYGOTIC TWINS WITH TOURETTES-SYNDROME AND TIC DISORDER SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Meeting Abstract C1 NINCDS,ETB,BETHESDA,MD 20892. NIMH,NEUROSCI CTR ST ELIZABETHS,WASHINGTON,DC 20032. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JAN PY 1993 VL 15 IS 1 BP 77 EP 78 PG 2 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA KL806 UT WOS:A1993KL80600299 ER PT J AU BROUWERS, P WOLTERS, P MOSS, H PIZZO, P AF BROUWERS, P WOLTERS, P MOSS, H PIZZO, P TI ENCEPHALOPATHY IN VERTICALLY ACQUIRED PEDIATRIC HIV DISEASE SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Meeting Abstract C1 NCI,PEDIAT BRANCH,BETHESDA,MD 20892. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JAN PY 1993 VL 15 IS 1 BP 95 EP 95 PG 1 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA KL806 UT WOS:A1993KL80600381 ER PT J AU FANTIE, BD KOSMIDIS, MH AF FANTIE, BD KOSMIDIS, MH TI FAILURE TO FIND AN ANTICIPATORY BEHAVIOR DEFICIT (ABD) IN LEARNING TO AVOID A NOXIOUS NOISE AMONG SURVIVORS OF CLOSED-HEAD INJURY (CHI) SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Meeting Abstract C1 AMERICAN UNIV,DEPT PSYCHOL,WASHINGTON,DC 20016. NIMH,PSYCHOL & PSYCHOPATHOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JAN PY 1993 VL 15 IS 1 BP 106 EP 106 PG 1 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA KL806 UT WOS:A1993KL80600437 ER PT J AU KOSMIDIS, MH FANTIE, BD AF KOSMIDIS, MH FANTIE, BD TI DEFICIT IN AVOIDANCE-LEARNING MANIFESTED BY CLOSED-HEAD-INJURY (CHI) SURVIVORS - IMPAIRED ANTICIPATION, ATTENTION, OR ABILITY TO ASSOCIATE SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Meeting Abstract C1 AMERICAN UNIV,WASHINGTON,DC 20016. NIMH,PSYCHOL & PSYCHOPATHOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JAN PY 1993 VL 15 IS 1 BP 106 EP 106 PG 1 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA KL806 UT WOS:A1993KL80600435 ER PT J AU CORPAS, E HARMAN, SM PINEYRO, MA ROBERSON, R BLACKMAN, MR AF CORPAS, E HARMAN, SM PINEYRO, MA ROBERSON, R BLACKMAN, MR TI CONTINUOUS SUBCUTANEOUS INFUSIONS OF GROWTH-HORMONE (GH) RELEASING HORMONE-1-44 FOR 14 DAYS INCREASE GH AND INSULIN-LIKE GROWTH FACTOR-I LEVELS IN OLD MEN SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID SOMATOMEDIN-C LEVELS; AGED MEN; SECRETION; DEFICIENCY; YOUNG; RADIOIMMUNOASSAY; ESTRADIOL; ADULTS; SLEEP AB Twice daily sc injections of GHRH increase serum GH and IGF-I levels in healthy old men to values like those of untreated young men by producing high amplitude GH peaks after the injections. In the present study, we measured baseline insulin-like growth factor-I (IGF-I) 24-h profiles of GH release, and responses to GHRH stimulation tests in healthy young and old men. Old men were then given, in random order, 1 and 2 mg continuous sc GHRH 1-44 infusions daily for 14 days with an intervening 14-day treatment-free period. The study protocol was repeated on day 14 of each treatment. At baseline, mean duration of GH peaks (P < 0.005) and IGF-I levels (P < 0.0001) were lower in old men. Both doses increased (vs. old basal) mean 24-h GH, integrated area under the; GH curve, and GH peak number (P < 0.05), as well as strum IGF-I (P < 0.001). Interpeak GH levels also increased during low (P < 0.01) and high (P < 0.05) dose treatment. Significant increases in mean GH and integrated area under the GH curve occurred only during the day (0800-2000 h) during both low (P < 0.01) and high (P < 0.05) dose treatment. Treatment also decreased nocturnal peak GH amplitude and duration. GH responses to GHRH stimulation tests did not differ with age at baseline, or in old men after treatment. Thus, continuous, short-term sc administration of GHRH to healthy old men restores subnormal GH secretion and IGF-I levels by increasing GH peak frequency and interpeak secretion, particularly during the day. C1 NIA, GERONTOL RES CTR, CLIN PHYSIOL LAB, BALTIMORE, MD 21224 USA. FRANCIS SCOTT KEY MED CTR, DEPT MED, BALTIMORE, MD 21224 USA. JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21224 USA. RP CORPAS, E (reprint author), NIA, GERONTOL RES CTR, ENDOCRINOL SECT, ROOM 2B19, 4940 EASTERN AVE, BALTIMORE, MD 21224 USA. FU NCRR NIH HHS [MO1-RR02719] NR 26 TC 58 Z9 59 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 1993 VL 76 IS 1 BP 134 EP 138 DI 10.1210/jc.76.1.134 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA LB524 UT WOS:A1993LB52400025 PM 8421077 ER PT J AU FALCHETTI, A BALE, AE AMOROSI, A BORDI, C CICCHI, P BANDINI, S MARX, SJ BRANDI, ML AF FALCHETTI, A BALE, AE AMOROSI, A BORDI, C CICCHI, P BANDINI, S MARX, SJ BRANDI, ML TI PROGRESSION OF UREMIC HYPERPARATHYROIDISM INVOLVES ALLELIC LOSS ON CHROMOSOME-11 SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID ENDOCRINE NEOPLASIA TYPE-1; PARATHYROID ADENOMAS; RENAL-FAILURE; RETINOBLASTOMA; GENES; TUMORS; DNA; TUMORIGENESIS; PATHOGENESIS; CANCER AB In occasional cases of secondary hyperparathyroidism, long term stimulation of the parathyroid glands leads from compensatory to autonomous hyperfunction, and thus, hypercalcemia develops. This clinical entity, named tertiary hyperparathyroidism, is possibly due to the formation of an adenoma in one of the hyperplastic glands. Previous studies have shown that parathyroid adenomas may arise with allelic loss on chromosome 11. We tested for allelic loss at several loci on chromosome 11 in 12 enlarged parathyroid glands from 6 uremic patients and found loss of heterozygosity in 2 of the glands from 2 different patients with higher serum calcium levels (11.3 +/- 0.29 vs. 9.8 +/- 0.28 mg/dL; P < 0.004) and, therefore, ascribable to the so-called tertiary hyperparathyroidism. The 2 glands with allelic loss were significantly greater in mass than those without loss (3.42 +/- 0.37 vs. 1.60 +/- 0.54 g; P < 0.001). These data offer new evidence that autonomous parathyroid proliferation in uremic patients can develop through over-growth by a monoclonal tumor, presumably with inactivation of a tumor suppressor gene(s) on chromosome 11. C1 UNIV FLORENCE, DEPT CLIN PHYSIOPATHOL, ENDOCRINE UNIT, VIALE PIERACCINI 6, I-50139 FLORENCE, ITALY. UNIV FLORENCE, INST PATHOL, I-50139 FLORENCE, ITALY. UNIV FLORENCE, DEPT SURG PATHOL, I-50139 FLORENCE, ITALY. USL 10D, DIALYSIS UNIT, FLORENCE, ITALY. UNIV PARMA, INST PATHOL, I-43100 PARMA, ITALY. YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA. NIH, METAB DIS BRANCH, BETHESDA, MD 20892 USA. RI FALCHETTI, ALBERTO/Q-1787-2016 OI FALCHETTI, ALBERTO/0000-0002-6739-4417 FU NCI NIH HHS [R01-CA-50497] NR 33 TC 136 Z9 139 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 1993 VL 76 IS 1 BP 139 EP 144 DI 10.1210/jc.76.1.139 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA LB524 UT WOS:A1993LB52400026 PM 8421078 ER PT J AU LAUE, L JONES, J BARNES, KM CUTLER, GB AF LAUE, L JONES, J BARNES, KM CUTLER, GB TI TREATMENT OF FAMILIAL MALE PRECOCIOUS PUBERTY WITH SPIRONOLACTONE, TESTOLACTONE, AND DESLORELIN SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID HORMONE-RELEASING HORMONE; SEXUAL PRECOCITY; ULNAR GROWTH; KETOCONAZOLE; TESTOTOXICOSIS; CHILDREN; THERAPY; LEYDIG; RADIOIMMUNOASSAY; BIOSYNTHESIS AB Combined antiandrogen (spironolactone) and aromatase inhibitor (testolactone) are effective for the short term treatment of familial male precocious puberty. During this therapy, plasma testosterone levels remain in the adult range, since spironolactone blocks the testosterone receptor without significantly affecting plasma testosterone levels. After our initial 18-month pilot study, we continued to treat eight boys with the combined therapy for 2.0-4.2 yr. During this time all boys exhibited a pubertal rise in gonadotropin secretion and a diminishing response to treatment, which was manifested by the recurrence of clinical features of puberty and an increase in the bone maturation rate (P < 0.05). Addition of the LHRH agonist deslorelin (4 mug/kg. day, sc) to the combined therapy decreased peak LH, plasma testosterone, bone maturation rate, and growth velocity (P < 0.05) over the next year. We conclude that the rise in gonadotropin levels during central activation of hypothalamic LHRH secretion in boys with familial male precocious puberty causes a partial escape from the combined effect of spironolactone and testolactone. The addition of deslorelin to the combined therapy appears to restore the control of puberty in this setting. C1 NICHHD, DEV ENDOCRINOL BRANCH, BETHESDA, MD 20892 USA. RP LAUE, L (reprint author), GEORGETOWN UNIV, CHILDRENS MED CTR, DEPT PEDIAT, 3800 RESERVOIR RD NW, WASHINGTON, DC 20007 USA. NR 29 TC 45 Z9 45 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 1993 VL 76 IS 1 BP 151 EP 155 DI 10.1210/jc.76.1.151 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA LB524 UT WOS:A1993LB52400028 PM 8421081 ER PT J AU MARINI, JC BORDENICK, S HEAVNER, G ROSE, S HINTZ, R ROSENFELD, R CHROUSOS, GP AF MARINI, JC BORDENICK, S HEAVNER, G ROSE, S HINTZ, R ROSENFELD, R CHROUSOS, GP TI THE GROWTH-HORMONE AND SOMATOMEDIN AXIS IN SHORT CHILDREN WITH OSTEOGENESIS IMPERFECTA SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID SHORT STATURE; RESPONSES; GIRLS; BOYS AB Growth deficiency is a cardinal feature of severe osteogenesis imperfecta (OI) and a frequent feature of mild to moderate forms of this disease. We have investigated the status of hormones related to growth in 22 short prepubertal children, 13 males and 9 females, with various types of OI. Ten children had Sillence type III OI, 10 had type IV, and 2 had type I. Evaluation included GRH stimulation, three standard GH provocative tests (arginine-insulin tolerance test, L-dopa), 24-h sampling for measurement of unstimulated GH secretion and a somatomedin-C generation test. None of these children had GH deficiency by standard criteria. We found that 9 OI children had decreased responsiveness to GRH, similar to the GRH response of GH-deficient children. Overall, however, mean 24-h GH values and mean peak GH response to provocative agents of OI children were within the normal range. In the somatomedin generation test, the OI children as a group showed a blunted response, with 13 of 22 having less than a 2-fold stimulation of somatomedin-C by GH. This suggested resistance of the liver and other somatomedin-C secreting tissues to GH. The group with blunted insulin-like growth factor-I response did not correlate significantly with the group with decreased GRH response. To investigate the responsiveness of OI bone to growth stimulation, six OI children with less than average integrated GH secretion were enrolled in a pilot study in which one child received exogenous GH and six received clonidine for at least 6 months. The child treated with exogenous GH and three of six treated with clonidine experienced at least a 4.7 cm/yr increase over their pretreatment growth rates. Growth response could not be predicted from baseline studies. We conclude that abnormalities of the GH-somatomedin axis exist in some children with OI. Administration of GH or clonidine may augment growth rates in OI children; however, the effect of these agents on final stature is unknown. C1 NICHHD, DEV ENDOCRINOL BRANCH, BETHESDA, MD 20892 USA. STANFORD UNIV HOSP, DEPT PEDIAT, DIV ENDOCRINOL, STANFORD, CA 94305 USA. RP MARINI, JC (reprint author), NICHHD, HUMAN GENET BRANCH, CONNECT TISSUE DISORDERS SECT, BLDG 10, ROOM 9S242, BETHESDA, MD 20892 USA. FU NIDDK NIH HHS [DK-28229] NR 18 TC 35 Z9 35 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 1993 VL 76 IS 1 BP 251 EP 256 DI 10.1210/jc.76.1.251 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA LB524 UT WOS:A1993LB52400047 PM 8421094 ER PT J AU MULLOOLY, JP WIEST, WM ALEXANDER, NJ GREENLICK, MR FULGHAM, DL AF MULLOOLY, JP WIEST, WM ALEXANDER, NJ GREENLICK, MR FULGHAM, DL TI VASECTOMY, SERUM ASSAYS, AND CORONARY HEART-DISEASE SYMPTOMS AND RISK-FACTORS SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE VASECTOMY; ANTISPERM ANTIBODIES; CIRCULATING IMMUNE COMPLEXES; CARDIOVASCULAR DISEASE ID CIRCULATING IMMUNE-COMPLEXES; MYOCARDIAL-INFARCTION; SPERM ANTIBODIES; MEN; ATHEROSCLEROSIS; ANTIGENS; AGE AB We compared three serum assays (two antisperm antibody assays and one assay for circulating immune complexes) and a number of CHD-related variables in 69 vasectomized (V) and 126 non-vasectomized (NV) participants in the Portland Center for the Multiple Risk Factor Intervention Trial. Significant differences between the V and NV men were found in sperm agglutination (SA) and sperm immobilization (SI) titers, as well as in several CHD risk factors, symptoms, and treatments; men in the V group had higher titers for SA and SI, smoked more, and had lower diastolic and systolic blood pressure than men in the NV group. Differences between V and NV in SA and SI activity remained even after we controlled for any effects that CHD risk factors, symptoms, and treatments may have had on the serum assays. Antibody development tended to decrease with age-at-vasectomy and increase with time-post-vasectomy. In the case of SA the antibodies clearly increased with time-post-vasectomy. C1 NICHHD,CONTRACEPT DEV BRANCH,BETHESDA,MD 20892. REED COLL,DEPT PSYCHOL,PORTLAND,OR 97202. UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706. RP MULLOOLY, JP (reprint author), KAISER PERMANENTE CTR HLTH RES,PORTLAND,OR 97227, USA. NR 33 TC 7 Z9 7 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD JAN PY 1993 VL 46 IS 1 BP 101 EP 109 DI 10.1016/0895-4356(93)90014-R PG 9 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA KL956 UT WOS:A1993KL95600013 PM 8433106 ER PT J AU STRAUS, SE FRITZ, S DALE, JK GOULD, B STROBER, W AF STRAUS, SE FRITZ, S DALE, JK GOULD, B STROBER, W TI LYMPHOCYTE PHENOTYPE AND FUNCTION IN THE CHRONIC FATIGUE SYNDROME SO JOURNAL OF CLINICAL IMMUNOLOGY LA English DT Article DE CHRONIC FATIGUE SYNDROME; CD45RA/RO; PROLIFERATIVE RESPONSES; T-CELL SUBSETS ID EPSTEIN-BARR VIRUS; CORTICOTROPIN-RELEASING HORMONE; PLACEBO-CONTROLLED TRIAL; IMMUNOLOGICAL ABNORMALITIES; IMMUNE FUNCTION; HELPER-INDUCER; T-CELLS; INFECTION; DIFFERENTIATION; SUBPOPULATIONS AB Lymphocytes of 18 patients meeting the Centers for Disease Control (CDC) case definition for the chronic fatigue syndrome (CFS), 10 similar, chronically fatigued patients not fully conforming to the CDC case definition, and 17 matched, healthy individuals were studied to determine the presence of abnormalities of peripheral cell phenotype and function. Extensive phenotypic analyses of B- and T-cell subsets, natural killer (NK) cells, and macrophages were performed using single-, dual-, and three-color flow cytometry. Compared to controls, in CFS patients the percentage of CD4 T cells and CD4,CD45RA, or naive T cells, was reduced. The CD4,CD45RO, or memory T-cell, subset was numerically normal but expressed increased levels of adhesion markers (CD29, CD54, and CD58). CFS patient lymphocytes showed reduced proliferative responses to phytohemagglutinin, concanavalin A, and staphylococcal enterotoxin B. Lymphocytes from fatigue patients not meeting the CDC definition showed similar abnormalities. These data indicate that peripheral T cells manifest an increased state of differentiation in CFS and related conditions. This may arise as a consequence of an underlying neuropsychiatric and/or neuroendocrine disorder or because of exposure to antigens or superantigens of an infectious agent. C1 NIAID,MUCOSAL IMMUN SECT,CLIN INVEST LAB,BETHESDA,MD 20892. DYN CORP,PROGRAM RESOURCES INC,NCI,FREDERICK CANC RES & DEV CTR,CLIN IMMUNOL SERV,FREDERICK,MD. RP STRAUS, SE (reprint author), NIAID,MED VIROL SECT,CLIN INVEST LAB,BLDG 10,ROOM 11N228,BETHESDA,MD 20892, USA. FU NCI NIH HHS [N01-CO-74102] NR 54 TC 74 Z9 75 U1 0 U2 0 PU PLENUM PUBL CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0271-9142 J9 J CLIN IMMUNOL JI J. Clin. Immunol. PD JAN PY 1993 VL 13 IS 1 BP 30 EP 40 DI 10.1007/BF00920633 PG 11 WC Immunology SC Immunology GA KK782 UT WOS:A1993KK78200004 PM 8095270 ER PT J AU MASTRANGELI, A DANEL, C ROSENFELD, MA STRATFORDPERRICAUDET, L PERRICAUDET, M PAVIRANI, A LECOCQ, JP CRYSTAL, RG AF MASTRANGELI, A DANEL, C ROSENFELD, MA STRATFORDPERRICAUDET, L PERRICAUDET, M PAVIRANI, A LECOCQ, JP CRYSTAL, RG TI DIVERSITY OF AIRWAY EPITHELIAL-CELL TARGETS FOR INVIVO RECOMBINANT ADENOVIRUS-MEDIATED GENE-TRANSFER SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article DE CYSTIC FIBROSIS; GENE THERAPY; BETA-GALACTOSIDASE; COTTON RAT; LUNG ID TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; CHLORIDE CHANNELS; EXPRESSION; IDENTIFICATION; RETROVIRUS; PROMOTER; LINEAGE; VIRUS; DNA AB A variety of pulmonary disorders, including cystic fibrosis, are potentially amenable to treatment in which a therapeutic gene is directly transferred to the bronchial epithelium. This is difficult to accomplish because the majority of airway epithelial cells replicate slowly and/or are terminally differentiated. Adenovirus vectors may circumvent this problem, since they do not require target cell proliferation to express exogenous genes. To evaluate the diversity of airway epithelial cell targets for in vivo adenovirus-directed gene transfer, a replication deficient recombinant adenovirus containing the Escherichia coli lacZ (beta-galactosidase [beta-gal]) gene (Ad.RSVbetagal) was used to infect lungs of cotton rats. In contrast to uninfected animals, intratracheal Ad.RSVbetagal administration resulted in beta-gal activity in lung lysate and cytochemical staining in all cell types forming the airway epithelium. The expression of the exogenous gene was dose-dependent, and the distribution of the beta-gal positive airway epithelial cells in Ad.RSVbetagal-infected animals was similar to the normal cell differential of the control animals. Thus, a replication deficient recombinant adenovirus can transfer an exogenous gene to all major categories of airway epithelial cells in vivo, suggesting that adenovirus vectors may be an efficient strategy for in vivo gene transfer in airway disorders such as cystic fibrosis. C1 NHLBI,PULM BRANCH,BETHESDA,MD 20892. INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE. TRANSGENE SA,F-67082 STRASBOURG,FRANCE. NR 42 TC 195 Z9 196 U1 0 U2 3 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 1993 VL 91 IS 1 BP 225 EP 234 DI 10.1172/JCI116175 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KK042 UT WOS:A1993KK04200034 PM 8423221 ER PT J AU GILBERT, L ELWOOD, LJ MERINO, M MASOOD, S BARNES, R STEINBERG, SM LAZAROUS, DF PIERCE, L DANGELO, T MOSCOW, JA TOWNSEND, AJ COWAN, KH AF GILBERT, L ELWOOD, LJ MERINO, M MASOOD, S BARNES, R STEINBERG, SM LAZAROUS, DF PIERCE, L DANGELO, T MOSCOW, JA TOWNSEND, AJ COWAN, KH TI A PILOT-STUDY OF PI-CLASS GLUTATHIONE-S-TRANSFERASE EXPRESSION IN BREAST-CANCER - CORRELATION WITH ESTROGEN-RECEPTOR EXPRESSION AND PROGNOSIS IN NODE-NEGATIVE BREAST-CANCER SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID EPIDERMAL-GROWTH-FACTOR; CONFERS RESISTANCE; DRUG-RESISTANCE; CELLS; GENE; AMPLIFICATION; CHLORAMBUCIL; RECURRENCE; SURVIVAL; INT-2 C1 NCI,MED BRANCH,PATHOL LAB,BIOSTAT & DATA MANAGEMENT SECT,BETHESDA,MD 20892. UNIV FLORIDA,HLTH SCI CTR,DEPT PATHOL,JACKSONVILLE,FL. NR 42 TC 116 Z9 116 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN PY 1993 VL 11 IS 1 BP 49 EP 58 PG 10 WC Oncology SC Oncology GA KF531 UT WOS:A1993KF53100009 PM 8418241 ER PT J AU JANIK, J KOPP, WC SMITH, JW LONGO, DL ALVORD, WG SHARFMAN, WH FENTON, RG SZNOL, M STEIS, RG CREEKMORE, SP EWEL, CH HURSEY, J URBA, WJ AF JANIK, J KOPP, WC SMITH, JW LONGO, DL ALVORD, WG SHARFMAN, WH FENTON, RG SZNOL, M STEIS, RG CREEKMORE, SP EWEL, CH HURSEY, J URBA, WJ TI DOSE-RELATED IMMUNOLOGICAL EFFECTS OF LEVAMISOLE IN PATIENTS WITH CANCER SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID HUMAN LYMPHOCYTE-RESPONSE; BLOOD MONONUCLEAR-CELLS; ADJUVANT THERAPY; MALIGNANT-MELANOMA; INTERFERON-GAMMA; RANDOMIZED TRIAL; COLON-CARCINOMA; INVITRO; BIOSYNTHESIS; NEOPTERIN C1 NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,POB B,FREDERICK,MD 21702. NCI,FREDERICK CANC RES & DEV CTR,DATA MANAGEMENT SERV INC,FREDERICK,MD 21701. NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21701. FREDERICK MEM HOSP,FREDERICK,MD. NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,INVEST DRUG BRANCH,BETHESDA,MD 20892. FU NCI NIH HHS [N01-CO-74102] NR 39 TC 32 Z9 32 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN PY 1993 VL 11 IS 1 BP 125 EP 135 PG 11 WC Oncology SC Oncology GA KF531 UT WOS:A1993KF53100020 PM 8418223 ER PT J AU POCKAJ, BA TOPALIAN, SL STEINBERG, SM WHITE, DE ROSENBERG, SA AF POCKAJ, BA TOPALIAN, SL STEINBERG, SM WHITE, DE ROSENBERG, SA TI INFECTIOUS COMPLICATIONS ASSOCIATED WITH INTERLEUKIN-2 ADMINISTRATION - A RETROSPECTIVE REVIEW OF 935 TREATMENT COURSES SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID ACTIVATED KILLER-CELLS; METASTATIC MALIGNANT-MELANOMA; CONTINUOUS INFUSION INTERLEUKIN-2; CATHETER-RELATED INFECTIONS; HIGH-DOSE INTERLEUKIN-2; RECOMBINANT INTERLEUKIN-2; CANCER-PATIENTS; PHASE-II; PROPHYLACTIC ANTIBIOTICS; RECEIVING INTERLEUKIN-2 C1 NCI, DIV CANC TREATMENT,SURG BRANCH,BLDG 10,ROOM 2B-47, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA. NCI, BIOSTAT & DATA MANAGEMENT SECT, BETHESDA, MD 20892 USA. NR 60 TC 35 Z9 35 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN PY 1993 VL 11 IS 1 BP 136 EP 147 PG 12 WC Oncology SC Oncology GA KF531 UT WOS:A1993KF53100021 PM 8418224 ER PT J AU SMITH, M SIMON, R AF SMITH, M SIMON, R TI AGE EFFECTS OF RADIATION-ASSOCIATED NEUROTOXICITY IN CHILDREN SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Letter RP SMITH, M (reprint author), NCI,CANC THERAPY EVALUAT PROGRAM,BETHESDA,MD 20892, USA. NR 3 TC 8 Z9 8 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN PY 1993 VL 11 IS 1 BP 195 EP 196 PG 2 WC Oncology SC Oncology GA KF531 UT WOS:A1993KF53100034 PM 8466570 ER PT J AU POSSE, S SCHUKNECHT, B SMITH, ME VANZIJL, PCM HERSCHKOWITZ, N MOONEN, CTW AF POSSE, S SCHUKNECHT, B SMITH, ME VANZIJL, PCM HERSCHKOWITZ, N MOONEN, CTW TI SHORT ECHO TIME PROTON MR SPECTROSCOPIC IMAGING SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE MAGNETIC RESONANCE IMAGING, SPECTROSCOPY; BRAIN, NEOPLASMS; MULTIPLE SCLEROSIS ID MAGNETIC-RESONANCE SPECTROSCOPY; HUMAN-BRAIN INVIVO; MULTIPLE-SCLEROSIS; NMR-SPECTROSCOPY; INTRACRANIAL TUMORS; STIMULATED ECHOES; RAT-BRAIN; CELLS; EXCITATION; SUPPRESSION AB Proton spectroscopic imaging at short TEs (20-30 ms) in human brain requires volume preselection inside the brain to suppress overwhelming lipid and water signals from surrounding tissue. In this article we discuss limitations of conventional volume preselection using stimulated echoes that lead to spectral contamination from surrounding tissue. Improved volume preselection was obtained by adding a complete outer volume suppression (presaturation). The performance of the method is illustrated on normal volunteers and on clinical cases with brain tumors and multiple sclerosis (MS) plaques. In normal human brain, we detected resonances with short T2 values and complex J-coupling, including rather broad methyl/methylene resonances in the chemical shift range between 0 and 2 ppm. Spectroscopic images obtained on patients with intracranial tumors and on one patient with several MS plaques demonstrate the possibility of detecting regional distributions of increased methyl/methylene resonances between 0 and 2 ppm in brain lesions. C1 NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892. NIH,NCRR,BEIP,IN VIVO NMR RES CTR,BETHESDA,MD 20892. JOHNS HOPKINS UNIV,SCH MED,DEPT RADIOL,BALTIMORE,MD 21205. UNIV HOSP ZURICH,DEPT NEURORADIOL,CH-8091 ZURICH,SWITZERLAND. UNIV BERN,DEPT PEDIAT,CH-3000 BERN,SWITZERLAND. RP POSSE, S (reprint author), NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT DIAGNOST RADIOL,BLDG 10,BETHESDA,MD 20892, USA. RI van Zijl, Peter/B-8680-2008; Moonen, Chrit/K-4434-2016 OI Moonen, Chrit/0000-0001-5593-3121 NR 72 TC 85 Z9 85 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0363-8715 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD JAN-FEB PY 1993 VL 17 IS 1 BP 1 EP 14 PG 14 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA KH403 UT WOS:A1993KH40300001 PM 8380426 ER PT J AU PEARSON, JL AF PEARSON, JL TI PARENTS REACTIONS TO THEIR CHILDRENS SEPARATION AND DIVORCE AT 2 AND 4 YEARS - PARENT GENDER AND GRANDPARENT STATUS SO JOURNAL OF DIVORCE & REMARRIAGE LA English DT Article ID IMPACT; GRANDMOTHER; SUPPORT AB This study examined how parents' gender and grandparent status were related to their reactions to their children's marital dissolutions at two and four years after the initial marital separation. Fathers were just as reactive as mothers to the situation initially, and over time. Although generally similar to nongrandparents, grandparents reported increased feelings of responsibility and embarrassment over time. About half of the parents reported increased reactions of loss, surprise, and feeling upset. Older parents were initially more bitter, and became more upset over time. Implications for future research, as well as family interventions, are discussed. RP PEARSON, JL (reprint author), NIMH,MENTAL DISORDERS AGING RES BRANCH,RM 18-105,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA. NR 34 TC 1 Z9 1 U1 1 U2 1 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 SN 1050-2556 J9 J DIVORCE REMARRIAGE JI J. Divorce Remarriage PY 1993 VL 20 IS 3-4 BP 25 EP 43 PG 19 WC Family Studies SC Family Studies GA NJ998 UT WOS:A1993NJ99800003 ER PT J AU BAILEY, JJ MCAREAVEY, D AF BAILEY, JJ MCAREAVEY, D TI METHODS FOR TESTING AUTONOMIC CONTROL OF HEART-RATE - TABLE-TILT AND METRONOMIC BREATHING MANIPULATIONS SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article ID SPECTRAL-ANALYSIS RP BAILEY, JJ (reprint author), NIH,DIV COMP RES & TECHNOL,APPL STUDIES LAB,6100 EXECUT BLVD,5C01,BETHESDA,MD 20892, USA. NR 5 TC 1 Z9 1 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 SN 0022-0736 J9 J ELECTROCARDIOL JI J. Electrocardiol. PY 1993 VL 26 SU S BP 34 EP 36 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA NE170 UT WOS:A1993NE17000006 PM 8189138 ER PT J AU POTTALA, EW BAILEY, JJ GILHAM, J AF POTTALA, EW BAILEY, JJ GILHAM, J TI EFFECT OF TIMING RESOLUTION UPON RRV SPECTRA WITH A ROBUST QRS DETECTOR AFTER BANDPASS FILTERING SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article C1 NIH,9700 KENMORE DR,BETHESDA,MD 20895. SPACELABS INC,REDMOND,WA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 SN 0022-0736 J9 J ELECTROCARDIOL JI J. Electrocardiol. PY 1993 VL 26 SU S BP 38 EP 38 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA NE170 UT WOS:A1993NE17000008 PM 8189140 ER EF